

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property Organization  
International Bureau



(43) International Publication Date  
11 April 2002 (11.04.2002)

PCT

(10) International Publication Number  
WO 02/29058 A2

- (51) International Patent Classification<sup>7</sup>: C12N 15/12,  
C07K 14/47, 14/475, 14/705, C12N 15/63, 1/21, 5/10,  
C12Q 1/68, G01N 33/68
- (21) International Application Number: PCT/US01/31248
- (22) International Filing Date: 5 October 2001 (05.10.2001)
- (25) Filing Language: English
- (26) Publication Language: English
- (30) Priority Data:
- |            |                             |    |
|------------|-----------------------------|----|
| 60/238,323 | 5 October 2000 (05.10.2000) | US |
| 60/238,325 | 5 October 2000 (05.10.2000) | US |
| 60/238,372 | 6 October 2000 (06.10.2000) | US |
| 60/238,373 | 6 October 2000 (06.10.2000) | US |
| 60/238,379 | 6 October 2000 (06.10.2000) | US |
| 60/238,382 | 6 October 2000 (06.10.2000) | US |
| 60/238,383 | 6 October 2000 (06.10.2000) | US |
| 60/238,384 | 6 October 2000 (06.10.2000) | US |
| 60/238,397 | 6 October 2000 (06.10.2000) | US |
| 60/238,400 | 6 October 2000 (06.10.2000) | US |
| 60/238,401 | 6 October 2000 (06.10.2000) | US |
| 60/238,402 | 6 October 2000 (06.10.2000) | US |
| 60/275,892 | 14 March 2001 (14.03.2001)  | US |
| 60/296,860 | 8 June 2001 (08.06.2001)    | US |
- (63) Related by continuation (CON) or continuation-in-part (CIP) to earlier applications:
- |          |                             |
|----------|-----------------------------|
| US       | 60/238,323 (CIP)            |
| Filed on | 5 October 2000 (05.10.2000) |
| US       | 60/238,325 (CIP)            |
| Filed on | 5 October 2000 (05.10.2000) |
| US       | 60/238,372 (CIP)            |
| Filed on | 6 October 2000 (06.10.2000) |
| US       | 60/238,373 (CIP)            |
| Filed on | 6 October 2000 (06.10.2000) |
| US       | 60/238,379 (CIP)            |
| Filed on | 6 October 2000 (06.10.2000) |
| US       | 60/238,382 (CIP)            |
| Filed on | 6 October 2000 (06.10.2000) |
| US       | 60/238,383 (CIP)            |
| Filed on | 6 October 2000 (06.10.2000) |
| US       | 60/238,384 (CIP)            |
| Filed on | 6 October 2000 (06.10.2000) |
- (71) Applicant (for all designated States except US): CURA-  
GEN CORPORATION [US/US]; 555 Long Wharf Drive,  
11th floor, New Haven, CT 06511 (US).
- (72) Inventors; and
- (75) Inventors/Applicants (for US only): SHIMKETS,  
Richard, A. [US/US]; 191 Leete Street, West Haven, CT  
06516 (US). TAUPIER, Raymond, J., Jr. [US/US]; 34  
Pardee Place Extension, West Haven, CT 06512 (US).  
BURGESS, Catherine, E. [US/US]; 90 Carriage Hill  
Drive, Wethersfield, CT 06109 (US). ZERHUSEN;  
Bryan, D. [US/US]; 337 Monticello Drive, Branford,  
CT 06405 (US). MEZES, Peter, S. [US/US]; 7 Clark's  
Lane, Old Lyme, CT 06371 (US). RASTELLI, Luca  
[IT/US]; 52 Pepperbush Lane, Guilford, CT 06437 (US).  
MALYANKAR, Uriel, M. [IN/US]; 35 Averill Place,  
Branford, CT 06405 (US). GROSSE, William, M.  
[US/US]; 15 Rice Terrace Road, Branford, CT 06405  
(US). ALSOBROOK, John, P., II [US/US]; 60 Lake  
Drive, Madison, CT 06443 (US). LEPLEY, Denise, M.  
[US/US]; 51 Church Street, Branford, CT 06405 (US).  
SPYTEK, Kimberly, Ann [US/US]; 28 Court Street #1,  
New Haven, CT 06511 (US). LI, Li [CN/US]; 487 Oak Av-  
enue #67, Cheshire, CT 06410 (US). EDINGER, Shlomit  
[US/US]; 555 Long Wharf Drive, New Haven, CT 06511  
(US). GERLACH, Valerie [US/US]; 18 Rock Pasture  
Road, Branford, CT 06405 (US). ELLERMAN, Karen  
[US/US]; 87 Montoya Drive, Branford, CT 06405 (US).  
MACDOUGALL, John [CA/US]; 117 Russell Street,  
Hamden, CT 06517 (US). GUNTHER, Erik [US/US];  
555 Long Wharf Drive, New Haven, CT 06511 (US).  
MILLET, Isabelle [US/US]; 555 Long Wharf Drive, New  
Haven, CT 06511 (US). STONE, David [US/US]; 223  
Whitehorn Drive, Guilford, CT 06437 (US). SMITHSON,

[Continued on next page]

(54) Title: NOVEL HUMAN PROTEINS, POLYNUCLEOTIDES ENCODING THEM AND METHODS OF USING THE SAME

(57) Abstract: Disclosed herein are nucleic acid sequences that encode novel polypeptides. Also disclosed are polypeptides encoded by these nucleic acid sequences, and antibodies, which immunospecifically-bind to the polypeptide, as well as derivatives, variants, mutants, or fragments of the aforementioned polypeptide, polynucleotide, or antibody. The invention further discloses therapeutic, diagnostic and research methods for diagnosis, treatment, and prevention of disorders involving any one of these novel human nucleic acids and proteins.

WO 02/29058 A2

BEST AVAILABLE COPY



Glennnda [US/US]; 81 Main Street #32A, Branford, CT 06405 (US). SZEKERES, Edward, S., Jr. [US/US]; 130 Montoya Drive, Branford, CT 06405 (US).

(74) Agent: ELRIFI, Ivor, R.; Mintz, Levin, Cohn, Ferris, Glovsky, and Popeo, P.C., One Financial Center, Boston, MA 02111 (US).

(81) Designated States (*national*): AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW.

(84) Designated States (*regional*): ARIPO patent (GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).

**Published:**

— without international search report and to be republished upon receipt of that report

For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.



## NOVEL HUMAN PROTEINS, POLYNUCLEOTIDES ENCODING THEM AND METHODS OF USING THE SAME

### FIELD OF THE INVENTION

The invention relates to polynucleotides and the polypeptides encoded by such  
5 polynucleotides, as well as vectors, host cells, antibodies and recombinant methods for  
producing the polypeptides and polynucleotides, as well as methods for using the same.

### BACKGROUND OF THE INVENTION

The present invention is based in part on nucleic acids encoding proteins that are new  
members of the following protein families: alpha-2-macroglobulin, secreted proteins related to  
10 angiogenesis, leucine rich-like, cathepsin-L precursor-like, fatty acid-binding protein-like  
neurolysin precursor-like, gamma-aminobutyric acid (GABA) transporter-like, integrin alpha-  
7 precursor-like, TMS-2, UNC5 receptor-like, hepatocyte growth factor-like and 26S protease  
regulatory subunit-like. More particularly, the invention relates to nucleic acids encoding  
novel polypeptides, as well as vectors, host cells, antibodies, and recombinant methods for  
15 producing these nucleic acids and polypeptides.

The alpha-2-macroglobulin (A2M) fatty acid family of proteins are large glycoproteins  
found in the plasma of vertebrates, in the hemolymph of some invertebrates and in reptilian  
and avian egg white. A2M-like proteins are able to inhibit all four classes of proteins by a  
“trapping” mechanism. The A2M-like proteins have a peptide stretch, called the “bait region”,  
20 which contains specific cleavage sites for different proteinases. When a proteinase cleaves the  
bait region, a conformational change is induced in the protein, thus trapping the proteinase.  
The entrapped enzyme remains active against low molecular weight substrates, whilst its  
activity toward larger substrates is greatly reduced, due to steric hindrance. Following  
cleavage in the bait region, a thiol ester bond, formed between the side chains of a cysteine  
25 and a glutamine, is cleaved and mediates the covalent binding of the A2M-like protein to the  
proteinase. A2M is also found in association with senile plaques in Alzheimer’s disease.  
A2M has been implicated biochemically in binding and degradation of amyloid beta protein  
which accumulates in senile plaques.

The leucine rich-like proteins generally comprise leucine-rich repeats (LRRs),  
30 relatively short motifs (22-28 residues in length) found in a variety of cytoplasmic, membrane  
and extracellular proteins. Although these proteins are associated with widely different  
functions, a common property involves protein-protein interaction. Although little is known

about the 3-D structure of LRRs, it is believed that they can form amphipathic structures with hydrophilic surfaces capable of acting with membranes. In vitro studies of a synthetic LRR from *Drosophila* Toll protein have indicated that the peptides form gels by adopting beta-sheet structures that form extended filaments. These results are consistent with the idea that LRRs mediate protein-protein interactions and cellular adhesion. Other functions of LRR-containing proteins include, for example, binding to enzymes and vascular repair. The 3-D structure of ribonuclease inhibitor, a protein containing 15 LRRs, has been determined, revealing LRRs to be a new class of alpha/beta fold. LRRs form elongated non globular structures and are often flanked by cysteine-rich domains.

Cathepsins are lysosomal proteases that are distributed in many normal tissues and are primarily responsible for intracellular catabolism and turnover. Cathepsin has also been suggested to have roles in the terminal differentiation. Increased levels of cathepsins in tumors together with their ability to degrade extracellular matrix proteins has led to the hypothesis that they are involved in the process of invasion and metastasis. Cathepsin-L is a lysosomal cysteine proteinase belonging to the papain family. This proteinase is different from other members of the mammalian papain family cysteine proteinase in the following ways: (i) the cathepsin-L gene is activated by a variety of growth factors and activated oncogenes, (ii) procathepsin-L, a precursor form of cathepsin L is secreted from various cells, (iii) the mRNA level of cathepsin-L is related to the *in vivo* metastatic potential of the transformed cells. Thus, the regulation of the cathepsin-L gene and the extracellular functions of secreted procathepsin-L are tightly coupled. Cathepsin-L is induced in tumors by malignant transformation, growth factors, and tumor promoters suggesting they play an important role in tumor invasion and metastasis; additionally, cathepsin-L may be involved in bone resorption implicating possible roles in bone diseases such as osteoporosis, or bone cancers

Fatty acid metabolism in mammalian cells depends on a flux of fatty acids, between the plasma membrane and mitochondria or peroxisomes for beta-oxidation, and between other cellular organelles for lipid synthesis. The fatty acid-binding protein family consists of small, cystolic proteins believed to be involved in the uptake, transport, and solubilization of their hydrophobic ligands. Members of the fatty acid-binding family have highly conserved sequences and tertiary structure. Fatty acid-binding proteins (FABP) were first isolated in the intestine (FABP2) and later found in the liver (FABP1), striated muscle (FABP3), adipocytes (FABP4) and epithelial tissues (E-FABP).

A number of neuropeptidases share two unusual properties: they are strict oligopeptidases—that is they hydrolyze only short peptides—and they cleave at a limited set

of sites that are nonetheless diverse in sequence. One neuropeptidase that exemplifies these properties is neurolysin (EC 3.4.24.16), a zinc metalloendopeptidase that functions as a monomer of molecular mass 78 kDa (Checler, F. et al., *Methods Enzymol.* 248 (1995) 593-614; Barrett, A.J. et al., *Methods Enzymol.* 248 (1995). *In vitro*, neurolysin cleaves a number of bioactive peptides at sequences that vary widely, and its longest known substrate is only 17 residues in length. The enzyme belongs to the M3 family of metallopeptidases (Rawlings, N.D. et al., *Methods Enzymol.* 248 (1995) 183-228) along with eight other known peptidases that share extensive sequence homology, including the closely related (60% sequence identity) thimet oligopeptidase (EC3.4.24.15). Enzymes in the M3 family share with several other metallopeptidase families a common active site sequence motif, His-Glu-Xaa-Xaa-His (HEXXH), that forms part of the binding site for the metal cofactor (Matthews, B.W. et al., *J. Biol. Chem.* 249 (1974) 8030-8044). The two histidines of the motif coordinate the zinc ion, and the glutamate orients and polarizes a water molecule that is believed to act as the attacking nucleophile. Neurolysin is widely distributed in mammalian tissues (Checler, F. et al., *Methods Enzymol.* 248 (1995) 593-614) and is found in different subcellular locations that vary with cell type. Much of the enzyme is cytosolic, but it also can be secreted or associated with the plasma membrane (Vincent, B. et al., *J. Neurosci.* 16 (1996) 5049-5059), and some of the enzyme is made with a mitochondrial targeting sequence by initiation at an alternative transcription start site (Kato, A. et al., *J. Biol. Chem.* 272 (1997) 15313-15322). Although neurolysin cleaves a number of neuropeptides *in vitro*, its most established (Vincent, B. et al., *Brit. J. Pharmacol.* 115 (1995) 1053-1063; Barelli, H. et al., *Brit. J. Pharmacol.* 112 (1994) 127-132; Chabry, J. et al., *J. Neurosci.* 10 (1990) 3916-3921) role *in vivo* (along with thimet oligopeptidase) is in metabolism of neurotensin, a 13-residue neuropeptide. It hydrolyzes this peptide between residues 10 and 11, creating shorter fragments that are believed to be inactive. Neurotensin (pGlu-Leu-Tyr-Gln-Asn-Lys-Pro-Arg-Arg-Pro Tyr-Ile-Leu) is found in a variety of peripheral and central tissues where it is involved in a number of effects, including modulation of central dopaminergic and cholinergic circuits, thermoregulation, intestinal motility, and blood pressure regulation (Goedert, M., *Trends Neurosci.* 7 (1984) 3-5). Neurotensin is also one of the most potent antinocioptive substances known (Clineschmidt, B.V. et al., *Eur. J. Pharmacol.* 46 (1977) 395-396), and an inhibitor of neurolysin has been shown to produce neurotensin-induced analgesia in mice (Vincent, B. et al., *Br. J. Pharmacol.* 121 (1997) 705-710).

Proteins belonging to the gamma-aminobutyric acid (GABA) transporter family of proteins play an important role in signal transduction of different cell type such as neuronal

and muscle cells. This protein is the human ortholog of VGAT (vesicular GABA transporter) from *Rattus norvegicus* and unc-47 from *C. elegans* which are involved in packaging GABA in synaptic vesicles. This protein has a domain similar to the amino acid permease domain found in integral membrane proteins that regulate transport of amino acids. GABA is the product of a biochemical decarboxylation reaction of glutamic acid by the vitamin pyridoxal. GABA serves as a inhibitory neurotransmitter to block the transmission of an impulse from one cell to another in the central nervous system. Medically, GABA has been used to treat both epilepsy and hypertension where it is thought to induce tranquility in individuals who have a high activity of manic behavior and acute agitation.

The integrins are a family of heterodimeric membrane glycoproteins that mediate a wide spectrum of cell-cell and cell-matrix interactions. Their capacity to participate in cellular adhesive processes underlies a wide range of functions. The integrins have preeminent roles in cell migration and morphologic development, differentiation, and metastasis. To a large extent, the diversity and specificity of functions mediated by integrins rest in the structural diversity of the 16 different alpha and 8 beta chains that have been identified and in their ligand-binding and signal transduction capacity. One structural difference in the alpha chains appears to divide them into 2 subgroups. The I-integrin alpha chains have an insertion of about 180 amino acids in the extracellular region, and the non-I-integrins do not. The functional significance of the I-domain is not known. Alternate splicing increases the structural diversity in the cytoplasmic domains of several integrin alpha and beta chains, and this presumably further expands their functional repertoire. Expression of the alpha-7 integrin gene (ITGA7) is developmentally regulated during the formation of skeletal muscle. Increased levels of expression and production of isoforms containing different cytoplasmic and extracellular domains accompany myogenesis.

A family of genes encoding membrane proteins with a unique structure has been identified in DNA and cDNA clones of various eukaryotes ranging from yeast to human. The nucleotide sequences of three novel cDNAs from *Drosophila melanogaster* and mouse were determined. The amino acid sequences of the two mouse proteins have human homologs. The gene (TMS-1) encoding the yeast member of this family was disrupted, and the resulting mutant showed no significant phenotype under several stress conditions. The expression of the mouse genes TMS-1 and TMS-2 was examined by in situ hybridization of sections from brain, liver, kidney, heart and testis of an adult mouse as well as in a 1-day-old whole mouse. While the expression of TMS-2 was found to be restricted to the central nervous system, TMS-1 was also expressed in kidney and testis. The expression of TMS-1 and TMS-2 in the

brain overlapped and was localized to areas associated with glutamatergic excitatory neurons, such as the hippocampus and cerebral cortex. High-magnification analysis indicated that both mRNAs are expressed in neurons. Semiquantitative analysis of mRNA expression was performed in various parts of the brain. The conservation, unique structure and localization in the mammalian brain of this novel protein family suggest an important biological role.

The vertebrate UNC5 genes, like their *Caenorhabditis elegans* counterpart, define a family of putative netrin receptors. The netrins comprise a small phylogenetically conserved family of guidance cues important for guiding particular axonal growth cones to their targets. Migration of neurons from proliferative zones to their functional sites is fundamental to the normal development of the central nervous system. Mice homozygous for the spontaneous rostral cerebellar malformation mutation (*rcm(s)*) or a newly identified transgenic insertion allele (*rcm(tg)*) exhibit cerebellar and midbrain defects, apparently as a result of abnormal neuronal migration. Lamina structure abnormalities in lateral regions of the rostral cerebellar cortex have been described in homozygous *rcm(s)* mice. It has been demonstrated that the cerebellum of both *rcm(s)* and *rcm(tg)* homozygotes is smaller and has fewer folia than in the wild-type, ectopic cerebellar cells are present in midbrain regions by three days after birth, and there are abnormalities in postnatal cerebellar neuronal migration. The *rcm* complementary DNA which encodes a transmembrane receptor of the immunoglobulin superfamily has been cloned. The sequence of the *rcm* protein (*Rcm*) is highly similar to that of UNC-5, a *Caenorhabditis elegans* protein that is essential for dorsal guidance of pioneer axons and for the movement of cells away from the netrin ligand, which is encoded by the *unc-6* gene. As *Rcm* is a member of a newly described family of vertebrate homologues of UNC-5 which are netrin-binding proteins, our results indicate that UNC-5-like proteins may have a conserved function in mediating netrin-guided migration (PMID: 9126743, UI: 97271898).

Hepatocyte Growth Factor (HGF), also known as Scatter Factor, is a polypeptide that shows structural homology with enzymes of the blood coagulation cascade. It is a biologically inactive single chain precursor that is then cleaved by specific serine proteases to a fully active alphabeta heterodimer. All the biological responses induced by HGF/SF are elicited by binding to its receptor, a transmembrane tyrosine kinase encoded by the MET proto-oncogene. The signaling cascade triggered by HGF begins with the autophosphorylation of the receptor and is mediated by concomitant activation of different cytoplasmic effectors that bind to the same multifunctional docking site. During development, HGF function is essential: knock-out mice for both ligand and receptor show an embryonic lethal phenotype. HGF/SF displays a unique feature in inducing "branching morphogenesis", a complex program of proliferation

and motogenesis in a number of different cell types. Moreover, HGF is involved in the invasive behaviour of several tumor cells both in vivo and in vitro. The role of HGF as putative therapeutical agent in pathologies characterized by massive cell loss or deregulated cell proliferation is under investigation (PMID: 10641789, UI: 20104755). Additionally, there is increasing evidence that indicates that HGF acts as a multifunctional cytokine on different cell types (PMID: 10760078, UI: 20223576)

The 26S proteasome is the major non-lysosomal protease in eukaryotic cells. This multimeric enzyme is the integral component of the ubiquitin-mediated substrate degradation pathway. It consists of two subcomplexes, the 20S proteasome, which forms the proteolytic core, and the 19S regulator (or PA700), which confers ATP dependency and ubiquitinated substrate specificity on the enzyme. Recent biochemical and genetic studies have revealed many of the interactions between the 17 regulatory subunits, yielding an approximation of the 19S complex topology. Inspection of interactions of regulatory subunits with non-subunit proteins reveals patterns that suggest these interactions play a role in 26S proteasome regulation and localization (PMID: 10664589).

### SUMMARY OF THE INVENTION

The invention is based in part upon the discovery of nucleic acid sequences encoding novel polypeptides. The novel nucleic acids and polypeptides are referred to herein as NOVX, or NOV1, NOV2, NOV3, NOV4, NOV5, NOV6, NOV7, NOV8, NOV9, NOV10, NOV11 and NOV12 nucleic acids and polypeptides. These nucleic acids and polypeptides, as well as derivatives, homologs, analogs and fragments thereof, will hereinafter be collectively designated as "NOVX" nucleic acid or polypeptide sequences.

In one aspect, the invention provides an isolated NOVX nucleic acid molecule encoding a NOVX polypeptide that includes a nucleic acid sequence that has identity to the nucleic acids disclosed in SEQ ID NOS:1, 3, 5, 7, 9, 11, 13, 15, 17, 19, 21, 23, 25, 27, 29, 31, 33, 35, 37, 39, 41, 43, 45, 47, 49, 51, 53, 55, 57, 59, 61 and 63. In some embodiments, the NOVX nucleic acid molecule will hybridize under stringent conditions to a nucleic acid sequence complementary to a nucleic acid molecule that includes a protein-coding sequence of a NOVX nucleic acid sequence. The invention also includes an isolated nucleic acid that encodes a NOVX polypeptide, or a fragment, homolog, analog or derivative thereof. For example, the nucleic acid can encode a polypeptide at least 80% identical to a polypeptide comprising the amino acid sequences of SEQ ID NOS:2, 4, 6, 8, 10, 12, 14, 16, 18, 20, 22, 24, 26, 28, 30, 32, 34, 36, 38, 40, 42, 44, 46, 48, 50, 52, 54, 56, 58, 60, 62 and 64. The nucleic acid can be, for example, a genomic DNA fragment or a cDNA molecule that includes the

nucleic acid sequence of any of SEQ ID NOS:1, 3, 5, 7, 9, 11, 13, 15, 17, 19, 21, 23, 25, 27, 29, 31, 33, 35, 37, 39, 41, 43, 45, 47, 49, 51, 53, 55, 57, 59, 61 and 63.

Also included in the invention is an oligonucleotide, *e.g.*, an oligonucleotide which includes at least 6 contiguous nucleotides of a NOVX nucleic acid (*e.g.*, SEQ ID NOS:1, 3, 5, 7, 9, 11, 13, 15, 17, 19, 21, 23, 25, 27, 29, 31, 33, 35, 37, 39, 41, 43, 45, 47, 49, 51, 53, 55, 57, 59, 61 and 63) or a complement of said oligonucleotide. Also included in the invention are substantially purified NOVX polypeptides (SEQ ID NOS:2, 4, 6, 8, 10, 12, 14, 16, 18, 20, 22, 24, 26, 28, 30, 32, 34, 36, 38, 40, 42, 44, 46, 48, 50, 52, 54, 56, 58, 60, 62 and 64). In certain embodiments, the NOVX polypeptides include an amino acid sequence that is substantially identical to the amino acid sequence of a human NOVX polypeptide.

The invention also features antibodies that immunoselectively bind to NOVX polypeptides, or fragments, homologs, analogs or derivatives thereof.

In another aspect, the invention includes pharmaceutical compositions that include therapeutically- or prophylactically-effective amounts of a therapeutic and a pharmaceutically-acceptable carrier. The therapeutic can be, *e.g.*, a NOVX nucleic acid, a NOVX polypeptide, or an antibody specific for a NOVX polypeptide. In a further aspect, the invention includes, in one or more containers, a therapeutically- or prophylactically-effective amount of this pharmaceutical composition.

In a further aspect, the invention includes a method of producing a polypeptide by culturing a cell that includes a NOVX nucleic acid, under conditions allowing for expression of the NOVX polypeptide encoded by the DNA. If desired, the NOVX polypeptide can then be recovered.

In another aspect, the invention includes a method of detecting the presence of a NOVX polypeptide in a sample. In the method, a sample is contacted with a compound that selectively binds to the polypeptide under conditions allowing for formation of a complex between the polypeptide and the compound. The complex is detected, if present, thereby identifying the NOVX polypeptide within the sample.

The invention also includes methods to identify specific cell or tissue types based on their expression of a NOVX.

Also included in the invention is a method of detecting the presence of a NOVX nucleic acid molecule in a sample by contacting the sample with a NOVX nucleic acid probe or primer, and detecting whether the nucleic acid probe or primer bound to a NOVX nucleic acid molecule in the sample.

In a further aspect, the invention provides a method for modulating the activity of a NOVX polypeptide by contacting a cell sample that includes the NOVX polypeptide with a compound that binds to the NOVX polypeptide in an amount sufficient to modulate the activity of said polypeptide. The compound can be, *e.g.*, a small molecule, such as a nucleic acid, peptide, polypeptide, peptidomimetic, carbohydrate, lipid or other organic (carbon containing) or inorganic molecule, as further described herein.

Also within the scope of the invention is the use of a therapeutic in the manufacture of a medicament for treating or preventing disorders or syndromes including, *e.g.*, Cancer, Leukodystrophies, Breast cancer, Ovarian cancer, Prostate cancer, Uterine cancer, Hodgkin disease, Adenocarcinoma, Adrenoleukodystrophy, Cystitis, incontinence, Von Hippel-Lindau (VHL) syndrome, hypercalcaemia, Endometriosis, Hirschsprung's disease, Crohn's Disease, Appendicitis, Cirrhosis, Liver failure, Wolfram Syndrome, Smith-Lemli-Opitz syndrome, Retinitis pigmentosa, Leigh syndrome; Congenital Adrenal Hyperplasia, Xerostomia; tooth decay and other dental problems; Inflammatory bowel disease, Diverticular disease, fertility, Infertility, cardiomyopathy, atherosclerosis, hypertension, congenital heart defects, aortic stenosis, atrial septal defect (ASD), atrioventricular (A-V) canal defect, ductus arteriosus, pulmonary stenosis, subaortic stenosis, ventricular septal defect (VSD), valve diseases, tuberous sclerosis, scleroderma, Hemophilia, Hypercoagulation, Idiopathic thrombocytopenic purpura, obesity, Diabetes Insipidus and Mellitus with Optic Atrophy and Deafness, Pancreatitis, Metabolic Dysregulation, transplantation recovery, Autoimmune disease, Systemic lupus erythematosus, asthma, arthritis, psoriasis, Emphysema, Scleroderma, allergy, ARDS, Immunodeficiencies, Graft versus host, Alzheimer's disease, Stroke, Parkinson's disease, Huntington's disease, Cerebral palsy, Epilepsy, Multiple sclerosis, Ataxia-telangiectasia, Behavioral disorders, Addiction, Anxiety, Pain, Neurodegeneration, Muscular dystrophy, Lesch-Nyhan syndrome, Myasthenia gravis, schizophrenia, and other dopamine-dysfunctional states, levodopa-induced dyskinesias, alcoholic seizures and other neurological disorders, mental depression, Cerebellar ataxia, pure; Episodic ataxia, type 2; Hemiplegic migraine, Spinocerebellar ataxia-6, Tuberous sclerosis, Renal artery stenosis, Interstitial nephritis, Glomerulonephritis, Polycystic kidney disease, Renal tubular acidosis, IgA nephropathy, and/or other pathologies and disorders of the like.

The therapeutic can be, *e.g.*, a NOVX nucleic acid, a NOVX polypeptide, or a NOVX-specific antibody, or biologically-active derivatives or fragments thereof.

For example, the compositions of the present invention will have efficacy for treatment of patients suffering from the diseases and disorders disclosed above and/or other pathologies



and disorders of the like. The polypeptides can be used as immunogens to produce antibodies specific for the invention, and as vaccines. They can also be used to screen for potential agonist and antagonist compounds. For example, a cDNA encoding NOVX may be useful in gene therapy, and NOVX may be useful when administered to a subject in need thereof. By way of non-limiting example, the compositions of the present invention will have efficacy for treatment of patients suffering from the diseases and disorders disclosed above and/or other pathologies and disorders of the like.

The invention further includes a method for screening for a modulator of disorders or syndromes including, *e.g.*, the diseases and disorders disclosed above and/or other pathologies and disorders of the like. The method includes contacting a test compound with a NOVX polypeptide and determining if the test compound binds to said NOVX polypeptide. Binding of the test compound to the NOVX polypeptide indicates the test compound is a modulator of activity, or of latency or predisposition to the aforementioned disorders or syndromes.

Also within the scope of the invention is a method for screening for a modulator of activity, or of latency or predisposition to disorders or syndromes including, *e.g.*, the diseases and disorders disclosed above and/or other pathologies and disorders of the like by administering a test compound to a test animal at increased risk for the aforementioned disorders or syndromes. The test animal expresses a recombinant polypeptide encoded by a NOVX nucleic acid. Expression or activity of NOVX polypeptide is then measured in the test animal, as is expression or activity of the protein in a control animal which recombinantly-expresses NOVX polypeptide and is not at increased risk for the disorder or syndrome. Next, the expression of NOVX polypeptide in both the test animal and the control animal is compared. A change in the activity of NOVX polypeptide in the test animal relative to the control animal indicates the test compound is a modulator of latency of the disorder or syndrome.

In yet another aspect, the invention includes a method for determining the presence of or predisposition to a disease associated with altered levels of a NOVX polypeptide, a NOVX nucleic acid, or both, in a subject (*e.g.*, a human subject). The method includes measuring the amount of the NOVX polypeptide in a test sample from the subject and comparing the amount of the polypeptide in the test sample to the amount of the NOVX polypeptide present in a control sample. An alteration in the level of the NOVX polypeptide in the test sample as compared to the control sample indicates the presence of or predisposition to a disease in the subject. Preferably, the predisposition includes, *e.g.*, the diseases and disorders disclosed above and/or other pathologies and disorders of the like. Also, the expression levels of the new

polypeptides of the invention can be used in a method to screen for various cancers as well as to determine the stage of cancers.

In a further aspect, the invention includes a method of treating or preventing a pathological condition associated with a disorder in a mammal by administering to the subject  
5 a NOVX polypeptide, a NOVX nucleic acid, or a NOVX-specific antibody to a subject (*e.g.*, a human subject), in an amount sufficient to alleviate or prevent the pathological condition. In preferred embodiments, the disorder, includes, *e.g.*, the diseases and disorders disclosed above and/or other pathologies and disorders of the like.

In yet another aspect, the invention can be used in a method to identify the cellular  
10 receptors and downstream effectors of the invention by any one of a number of techniques commonly employed in the art. These include but are not limited to the two-hybrid system, affinity purification, co-precipitation with antibodies or other specific-interacting molecules.

NOVX nucleic acids and polypeptides are further useful in the generation of antibodies that bind immuno-specifically to the novel NOVX substances for use in therapeutic or  
15 diagnostic methods. These NOVX antibodies may be generated according to methods known in the art, using prediction from hydrophobicity charts, as described in the "Anti-NOVX Antibodies" section below. The disclosed NOVX proteins have multiple hydrophilic regions, each of which can be used as an immunogen. These NOVX proteins can be used in assay systems for functional analysis of various human disorders, which will help in understanding  
20 of pathology of the disease and development of new drug targets for various disorders.

The NOVX nucleic acids and proteins identified here may be useful in potential therapeutic applications implicated in (but not limited to) various pathologies and disorders as indicated below. The potential therapeutic applications for this invention include, but are not limited to: protein therapeutic, small molecule drug target, antibody target (therapeutic,  
25 diagnostic, drug targeting/cytotoxic antibody), diagnostic and/or prognostic marker, gene therapy (gene delivery/gene ablation), research tools, tissue regeneration *in vivo* and *in vitro* of all tissues and cell types composing (but not limited to) those defined here.

Unless otherwise defined, all technical and scientific terms used herein have the same meaning as commonly understood by one of ordinary skill in the art to which this invention  
30 belongs. Although methods and materials similar or equivalent to those described herein can be used in the practice or testing of the present invention, suitable methods and materials are described below. All publications, patent applications, patents, and other references mentioned herein are incorporated by reference in their entirety. In the case of conflict, the

present specification, including definitions, will control. In addition, the materials, methods, and examples are illustrative only and not intended to be limiting.

Other features and advantages of the invention will be apparent from the following detailed description and claims.

5

## DETAILED DESCRIPTION OF THE INVENTION

The present invention provides novel nucleotides and polypeptides encoded thereby. Included in the invention are the novel nucleic acid sequences and their encoded polypeptides. The sequences are collectively referred to herein as "NOVX nucleic acids" or "NOVX polynucleotides" and the corresponding encoded polypeptides are referred to as "NOVX polypeptides" or "NOVX proteins." Unless indicated otherwise, "NOVX" is meant to refer to any of the novel sequences disclosed herein. Table A provides a summary of the NOVX nucleic acids and their encoded polypeptides.

10

**TABLE A. Sequences and Corresponding SEQ ID Numbers**

NOVX Assignment	Internal Identification	SEQ ID NO (nucleic acid)	SEQ ID NO (polypeptide)	Homology
1	SC 78316254_A	1	2	ALPHA-2-MACROGLOBULIN
2	AC005799_A	3	4	Secreted Proteins Related to Angiogenesis
3	SC124141642_A	5	6	Leucine Rich-like
4	GMba39917_A/	7	8	Cathepsin-L Precursor-like
5	GMba38118_A	9	10	Fatty Acid-Binding Protein-like
6a	SC133790496_A	11	12	Neurolysin Precursor-like
6b	13375342	13	14	Neurolysin Precursor-like
6c	c99.456	15	16	Neurolysin Precursor-like
6d	c99.457	17	18	Neurolysin Precursor-like
6e	c99.458	19	20	Neurolysin Precursor-like
6f	13375341	21	22	Neurolysin Precursor-like
6g	c99.459	23	24	Neurolysin Precursor-like
6h	c99.460	25	26	Neurolysin Precursor-like
6i	c99.752	27	28	Neurolysin Precursor-like
7a	ba122o1	29	30	gamma-aminobutyric acid (GABA) transporter-like
7b	13374575	31	32	gamma-aminobutyric acid (GABA) transporter-like
7c	13374576	33	34	gamma-aminobutyric acid (GABA) transporter-like
7d	13374577	35	36	gamma-aminobutyric acid (GABA) transporter-like
7e	13374578	37	38	gamma-aminobutyric acid (GABA) transporter-like
7f	13374579	39	40	gamma-aminobutyric acid (GABA) transporter-like
8a	AC073487 da1	41	42	Integrin Alpha 7 Precursor-like
8b	CG53926-02	43	44	Integrin Alpha 7 Precursor-like
9a	124141642_EXT da1	45	46	TMS-2
9b	13375406	47	48	TMS-2

9c	13375405	49	50	TMS-2
9d	13375404	51	52	TMS-2
9e	13375403	53	54	TMS-2
10	SC121209524_A	55	56	UNC5 Receptor-like
11a	GMba446g13_A	57	58	HEPATOCYTE GROWTH FACTOR-like
11b	cg34a.348	59	60	HEPATOCYTE GROWTH FACTOR-like
11c	cg34a.349	61	62	HEPATOCYTE GROWTH FACTOR-like
12	GMAC023940_A	63	64	26S protease regulatory subunit-like

NOVX nucleic acids and their encoded polypeptides are useful in a variety of applications and contexts. The various NOVX nucleic acids and polypeptides according to the invention are useful as novel members of the protein families according to the presence of domains and sequence relatedness to previously described proteins. Additionally, NOVX nucleic acids and polypeptides can also be used to identify proteins that are members of the family to which the NOVX polypeptides belong.

NOV1 is homologous to a Alpha-2-Macroglobin-like family of proteins. Thus, the NOV1 nucleic acids, polypeptides, antibodies and related compounds according to the invention will be useful in therapeutic and diagnostic applications implicated in, for example; Alzheimer's disease, inflammation, asthma, allergy and psoriasis, emphysema, pulmonary disease, immune disorders, neurological disorders, and/or other pathologies/disorders.

NOV2 is homologous to the secreted protein related to angiogenesis family of proteins. Thus NOV2 nucleic acids, polypeptides, antibodies and related compounds according to the invention will be useful in therapeutic and diagnostic applications implicated in, for example; abnormal angiogenesis, such as cancer and more specifically, aggressive, metastatic cancer, including tumors of the lungs, kidneys, brain, liver and breasts and/or other pathologies/disorders.

NOV3 is homologous to a family of Leucine rich-like proteins. Thus, the NOV3 nucleic acids and polypeptides, antibodies and related compounds according to the invention will be useful in therapeutic and diagnostic applications implicated in, for example: Lymphatic Diseases, Skin and Connective Tissue Diseases, Diabetes and Kidney Disease, Cancers, tumors, and Brain Disorders, disorders that can be addressed by controlling and directing cell migration, Alzheimer's disease, Stroke, Tuberous sclerosis, hypercalcaemia, Parkinson's disease, Huntington's disease, Cerebral palsy, Epilepsy, Lesch-Nyhan syndrome, Multiple sclerosis, Ataxia-telangiectasia, Leukodystrophies, Behavioral disorders, Addiction, Anxiety, Pain, Neuroprotection, Inflammatory bowel disease, Diverticular disease, Crohn's Disease and/or other pathologies/disorders.

NOV4 is homologous to the Cathepsin-L precursor -like family of proteins. Thus, NOV4 nucleic acids, polypeptides, antibodies and related compounds according to the invention will be useful in therapeutic and diagnostic applications implicated in, for example: growth of soft tissue sarcomas; malignant transformation, tumor invasion and metastasis, bone diseases such as osteoporosis, or bone cancers, Cardiomyopathy, Atherosclerosis, 5 Hypertension, Congenital heart defects, Aortic stenosis, Atrial septal defect (ASD), Atrioventricular (A-V) canal defect, Ductus arteriosus, Pulmonary stenosis, Subaortic stenosis, Ventricular septal defect (VSD), valve diseases, Tuberous sclerosis, Scleroderma, Transplantation, Adrenoleukodystrophy, Congenital Adrenal Hyperplasia, Diabetes, Von 10 Hippel-Lindau (VHL) syndrome, Pancreatitis, Endometriosis, Fertility, Inflammatory bowel disease, Diverticular disease, Hirschsprung's disease, Crohn's Disease, Hemophilia, hypercoagulation, Idiopathic thrombocytopenic purpura, immunodeficiencies, Osteoporosis, Hypercalcaemia, Arthritis, Ankylosing spondylitis, Scoliosis, Endocrine dysfunctions, Diabetes, Growth and reproductive disorders, Psoriasis, Actinic keratosis, Acne, Hair growth, 15 alopecia, pigmentation disorders, endocrine disorders and/or other pathologies/disorders.

NOV5 is homologous to the fatty acid-binding protein family. Thus NOV5 nucleic acids, polypeptides, antibodies and related compounds according to the invention will be useful in therapeutic and diagnostic applications implicated in, for example: psoriasis, basal and squamous cell carcinomas, obesity, diabetes, and/or other pathologies and disorders 20 involving fatty acid transport of skin, oral mucosa as well as other organs, Cardiomyopathy, Atherosclerosis, Hypertension, Congenital heart defects, Aortic stenosis, Atrial septal defect (ASD), Atrioventricular (A-V) canal defect, Ductus arteriosus, Pulmonary stenosis, Subaortic stenosis, Ventricular septal defect (VSD), valve diseases, Tuberous sclerosis, Scleroderma, Transplantation, Adrenoleukodystrophy, Congenital Adrenal Hyperplasia, Diabetes, Von 25 Hippel-Lindau (VHL) syndrome, Pancreatitis, Endometriosis, Fertility, Inflammatory bowel disease, Diverticular disease, Hirschsprung's disease, Crohn's Disease, Hemophilia, hypercoagulation, Idiopathic thrombocytopenic purpura, immunodeficiencies, Osteoporosis, Hypercalcaemia, Arthritis, Ankylosing spondylitis, Scoliosis, Endocrine dysfunctions, Diabetes, Growth and reproductive disorders, Psoriasis, Actinic keratosis, Acne, Hair growth, 30 alopecia, pigmentation disorders, endocrine disorders and/or other pathologies/disorders.

NOV6 is homologous to the Neurolysin -like family of proteins. Thus NOV6 nucleic acids, polypeptides, antibodies and related compounds according to the invention will be useful in therapeutic and diagnostic applications implicated in, for example: behavioral neurodegenerative and neuropsychiatric disorders such as schizophrenia, anxiety disorders,

bipolar disorders, depression, eating disorders, personality disorders, or sleeping disorders, Cardiomyopathy, Atherosclerosis, Hypertension, Congenital heart defects, Aortic stenosis, Atrial septal defect (ASD), Atrioventricular (A-V) canal defect, Ductus arteriosus, Pulmonary stenosis, Subaortic stenosis, Ventricular septal defect (VSD), valve diseases, Tuberosclerosis, Scleroderma, Transplantation, Adrenoleukodystrophy, Congenital Adrenal Hyperplasia, Diabetes, Von Hippel-Lindau (VHL) syndrome, Pancreatitis, Endometriosis, Fertility, Inflammatory bowel disease, Diverticular disease, Hirschsprung's disease, Crohn's Disease, Hemophilia, hypercoagulation, Idiopathic thrombocytopenic purpura, immunodeficiencies, Osteoporosis, Hypercalcaemia, Arthritis, Ankylosing spondylitis, Scoliosis, Endocrine dysfunctions, Diabetes, Growth and reproductive disorders, Psoriasis, Actinic keratosis, Acne, Hair growth, alopecia, pigmentation disorders, endocrine disorders and/or other pathologies/disorders.

NOV7 is homologous to members of the PV-1-like family of proteins. Thus, the NOV7 nucleic acids, polypeptides, antibodies and related compounds according to the invention will be useful in therapeutic and diagnostic applications implicated in, for example; cancer, trauma, regeneration (in vitro and in vivo), viral/bacterial/parasitic infections, fertility, neurological disorders and/or other pathologies/disorders.

NOV8 is homologous to the Integrin alpha 7 precursor-like family of proteins. Thus, NOV8 nucleic acids and polypeptides, antibodies and related compounds according to the invention will be useful in therapeutic and diagnostic applications implicated in, for example; Eosinophilic myeloproliferative disorder, Pseudohypoaldosteronism, type IIC, Pseudohypoaldosteronism type I, Spastic paraplegia-10, Hemolytic anemia due to triosephosphate isomerase deficiency, Immunodeficiency with hyper-IgM, type 2, C1r/C1s deficiency, combined, C1s deficiency, isolated, Leukemia, acute lymphoblastic, Periodic fever, familial, Hypertension, Episodic ataxia/myokymia syndrome, Immunodeficiency with hyper-IgM, type 2, Muscular dystrophy, Lesch-Nyhan syndrome, Myasthenia gravis and other muscular and cellular adhesion disorders and/or other pathologies/disorders.

NOV9 is homologous to members of the TMS-2-like family of proteins. Thus, the NOV9 nucleic acids, polypeptides, antibodies and related compounds according to the invention will be useful in therapeutic and diagnostic applications implicated in, for example; Von Hippel-Lindau (VHL) syndrome, Alzheimer's disease, Stroke, Tuberosclerosis, hypercalcaemia, Parkinson's disease, Huntington's disease, Cerebral palsy, Epilepsy, Lesch-Nyhan syndrome, Multiple sclerosis, Ataxia-telangiectasia, Leukodystrophies, Behavioral disorders, Addiction, Anxiety, Pain, Neuroprotection, Endocrine dysfunctions, Diabetes,

obesity, Growth and Reproductive disorders, Multiple sclerosis, Leukodystrophies, Pain, Neuroprotection, transporter disorders and/or other pathologies/disorders.

NOV10 is homologous to members of the UNC5 receptor-like family of proteins. Thus, the NOV10 nucleic acids, polypeptides, antibodies and related compounds according to the invention will be useful in therapeutic and diagnostic applications implicated in, for example; inflammatory and infectious diseases such as AIDS, cancer therapy, Neurologic diseases, Brain and/or autoimmune disorders like encephalomyelitis, neurodegenerative disorders, Alzheimer's Disease, Parkinson's Disorder, immune disorders, and hematopoietic disorders, endocrine diseases, muscle disorders, inflammation and wound repair, bacterial, fungal, protozoal and viral infections (particularly infections caused by HIV-1 or HIV-2), pain, cancer (including but not limited to Neoplasm; adenocarcinoma; lymphoma; prostate cancer; uterus cancer), anorexia, bulimia, asthma, Parkinson's disease, acute heart failure, hypotension, hypertension, urinary retention, osteoporosis, Crohn's disease; multiple sclerosis; and Treatment of Albright Hereditary Osteodystrophy, angina pectoris, myocardial infarction, ulcers, asthma, allergies, benign prostatic hypertrophy, and psychotic and neurological disorders, including anxiety, schizophrenia, manic depression, delirium, dementia, severe mental retardation and dyskinesias, such as Huntington's disease or Gilles de la Tourette syndrome and/or other pathologies/disorders.

NOV11 is homologous to members of the hepatocyte growth factor-like family of proteins. Thus, the NOV11 nucleic acids, polypeptides, antibodies and related compounds according to the invention will be useful in therapeutic and diagnostic applications implicated in, for example; various diseases involving blood coagulation, and hepatocellular carcinoma; cancers including but not limited to lung, breast and ovarian cancer; tumor suppression, senescence, growth regulation, modulation of apoptosis, reproductive control and associated disorders of reproduction, endometrial hyperplasia and adenocarcinoma, psychotic and neurological disorders, Alzheimers disease, endocrine disorders, inflammatory disorders, gastro-intestinal disorders and disorders of the respiratory system; hematopoiesis, immunotherapy, immunodeficiency diseases, all inflammatory diseases; cancer therapy; autoimmune diseases; obesity, modulation of myofibroblast development; applications to modulation of wound healing; potential applications to control of angiogenesis muscle disorders, neurologic diseases and/or other pathologies/disorders.

NOV12 is homologous to members of the 26S protease regulatory subunit-like family of proteins. Thus, the NOV12 nucleic acids, polypeptides, antibodies and related compounds according to the invention will be useful in therapeutic and diagnostic applications implicated

in, for example; eye/lens disorders including but not limited to cataract and Aphakia, Alzheimer's disease, neurodegenerative disorders, inflammation and modulation of the immune response, viral pathogenesis, aging-related disorders, neurologic disorders, cancer and/or other pathologies/disorders.

5 The NOVX nucleic acids and polypeptides can also be used to screen for molecules, which inhibit or enhance NOVX activity or function. Specifically, the nucleic acids and polypeptides according to the invention may be used as targets for the identification of small molecules that modulate or inhibit, e.g., neurogenesis, cell differentiation, cell proliferation, hematopoiesis, wound healing and angiogenesis.

10 Additional utilities for the NOVX nucleic acids and polypeptides according to the invention are disclosed herein.

## NOV1

A disclosed NOV1 nucleic acid of 4488 nucleotides (also referred to as  
15 SC\_78316254\_A) encoding a novel alpha-2-macroglobulin precursor-like protein is shown in Table 1A. An open reading frame was identified beginning with an ATG initiation codon at nucleotides 1-3 and ending with a TGA codon at nucleotides 4477-4479. A putative untranslated region downstream from the termination codon is underlined in Table 1A. The start and stop codons are in bold letters.

20

Table 1A. NOV1 Nucleotide Sequence (SEQ ID NO:1).

ATGTGGGCTCAGCTCCTTCTAGGAATGTGGCCCTATCACCAGCCATTGCAGAAGAACTTCCAAACTACCTGGTGACATTA  
CCAGCCCGGCTAAATTTCCCTCCGTTTCAGAAGGTTTGTGGACCTGAGCCCTGGGTACAGTGATGTTAAATTCACGGTT  
ACTCTGGAGACCAAGGACAAGACCCAGAAGTTGCTAGAATACTCTGGACTGAAGAAGAGGCACCTTACATTGTATCTCCTTT  
CTTGTAACCACTCCTGCTGGTGACAGAAGAAGTGGCCACAATCCGGGTGTGGGAGTTGGAAATAACATCAGCTTTGAG  
GAGAAGAAAAGGTTCTAATTCAGAGGCAGGGGAACGGCACCTTTGTACAGACTGACAAACCTCTCTACACCCAGGGCAG  
CAAGTGTATTTCCGCATTGTACCATGGATAGCAACTTCGTTCCAGTGAATGACAAGTACTCCATGGTGAAGTACAGGAT  
CCAAATAGCAACAGGATTGCACAGTGGCTGGAAGTGGTACCTGAGCAAGGCATTGTAGACCTGTCTCTCCAACTGGCACA  
GAGGCAATGCTGGGCACCTACACTGTGGCAGTGGCTGAGGGCAAGACCTTTGGTACTTTTCAGTGTGGAGGAATATGTGCTT  
TCTCCATTCTCCTTTTACTCTCTCTCAGTGTCTGCGAAGTTTAAAGTGGAAAGTGGTGAACCCAAAGGAGTTATCAACGGTG  
CAGGAATCTTTCTTAGTAAATTTGTGTAGGTACACCTATGGAAGCCCATGTAGGGGCAGTGCAGGTATCTGTGTGT  
CAGAAGGCAAATACTTACTGGTATCGAGAGGTGGAACGGGAACAGCTTCTGACAAATGCAGGAACCTCTCTGGACAGACT  
GACAAAACAGGATGTTTCTCAGCACCTGTGGACATGGCCACCTTTGACCTCATTGGATATGCGTACAGCCATCAATCAAT  
ATTGTGGCTACTGTTGTGGAGGAAGGGACAGGTGTGGAGGCCAATGCCACTCAGAAATATCTACATTTCTCCACAATGGGA  
TCAATGACCTTTGAAGACACCAATTTTACCATCCAAATTTCCCTTTCAGTGGGAAGATGCTGCTCAAGTTTCCGCAA  
GGCGGTGTGCTCCCTTGCAGAAGCACTCTAGTGTCTGGTGATTTATGGCAAAATGGAACCTTCAACAGACCTCGGTT  
ACTGATAAATGGCCTAGCTCCCTTTACCTTGGAGACATCCGGTGGAAATGGACAGACGTTTCTCTGGAGGAAAGTTT  
CAATGGGAAGACTTAGTATATAATCCGGAACAAGTGCCACGTTACTACCAAAATGCCTACCTGCACCTGCGACCTTCTTAC  
AGCACAACCCGAGCTTCTTGGCATCCACCGGCTAAACGGCCCTTGAATGTGGCCAGCCCAAGGAAGTGTGTGGAT  
TATTACATCGACCCGGCGATGCAAGCCCTGACCAAGAGATCAGCTTCTCTACTATTTAATAGGGAAGGAAGTTGGTG  
ATGGAGGGGCAGAAACACCTGAACTCTAAGAAGAAAGGACTGAAAGCCCTCTCTCTCTCTCACTGACCTTCACTTCGAGA  
CTGGCCCTGATCCTTCCCTGGTGATCTATGCCATTTTCCAGTGGAGGTGTGTAGCTGACAAAATTCAGTTCTCAGTC  
GAGATGTGCTTTGAGACATCAGCAGCTTCCAGGAGCAGAAGTGGAGCTGAGCTGAGGCAGCTCCCGGATCCCTGTGTGCG  
CTCCGGGCGGTGGATGAGAGTGTCTTACTGCTTAGGCCAGACAGAGAGCTGAGCAACCGCTCTGTCTATGGGATGTTCCA  
TTCTGGTATGGTCACTACCCCTATCAAGTGGCTGAGTATGATCAGTGTCCAGTGTCTGGCCCATGGGACTTCTCTCAGCCCC  
CTCATTTGACCAATGCCCCAAGGCATTTCGAGCCAGCGTTCCATTATCTGGAGGCCCTCGTTCTCTGAAGGCACGGACCTT  
TTCAGCTTTTTCGGGACGTGGGCCTGAAAATACTGTCCAATGCCAAATCAAGAAGCCAGTAGATTGCAGTCACAGATCT  
CCAGAATACAGCACTGCTATGGGTGGCGGTGGTCTCCAGAGGCTTTTGAGTCATCAACTCCTTTACATCAAGCAGAGGAT  
TCTCAGGTCGGCAGTACTTCCAGAGACCTGGCTCTGGGATCTGTTTCTATTGGTAACCTCGGGGAAGGAGCGGTCCAC  
GTCACAGTTCCTGACGCCATCACCGAGTGGAAAGGCGATGAGTTTCTGCACTTCCAGTCAAGAGGCTTCGGGCTTACCCC  
ACTGTTGGACTAACTGCTTCAAGCCGTTCTTTGTGACCTGACTCTCCCTTACTCAGTAGTCCGTGGGGAATCCTTTGCT  
CTTACTGCCACCATCTCAATTACCTAAAGGATGATCAGGTTTCAAGTGTGACCTGGCTAAATCGCATGAGTACCAAGTA  
GAATCATGGGCAGATTCTCAGACCTCCAGTTGTCTCTGTGCTGATGACGCAAAACCCACCACTGGAACATCAGAGCTGTC



```

AAATTGGGTCACATTAACTTACTATTAGTACAAAGATTCTGGACAGCATGAACCATGTGGGGGCCAGAAGGGGTTTGT
CCCCAAAAGGGCCGAAGTGACACGCTCATCAAGCCAGTTCTCGTCAAACCTGAGGGAGTCTGGTGGAGAAGACACACAGC
TCATTGCTGTGCCAAAAGGAGGAAAGGTGGCATCTGAATCTGTCTCCCTGGAGCTCCAGTGGACATTGTTCTCTGACTCG
ACCAAGGCTTATGTTACGGTCTCTGGGAGACATTATGGGCACAGCCCTGCAGAACCTGGATGGTCTGGTGCAGATGCCAGT
GGCTGTGGCGAGCAGAACATGGTCTTGTCTCCCATCATCTATGTCTTGACAGTACCTGGAGAAGGCAGGGCTGCTGACG
GAGGAGATCAGGTCTCGGGCAGTGGGTTTCCTGGAAATAGGGTACCAGAAGGAGCTGATGTACAAACACAGCAATGGCTCA
TACAGTGCCTTTGGGGAGCGAGATGGAAATGGAAACACATGGCTGACAGCGTTGTACAAAAATGCTTTGGCCAAGCTCAG
AAATTCATCTTCATTGATCCCAAGAACATCCAGGATGCTCTCAAGTGGATGGCAGGAAACAGCTCCCCAGTGGCTGCTAT
GCCAAGCTGGGAAATCTCCTTCACACAGCTATGAAGGGTGGTGTGATGATGAGGTCTCCTTGACTGCGTATGTACAGCT
GCATTGCTGGAGATGGGAAAGGATGTAGATGACCCAATGGTGAGTCAGGCTCTACGGTGTCTCAAGAATTCCGCCACCTCC
ACGACCAACCTCTACACACAGGCCCTGTGGCTTACATTTCTCCCTGGCTGGGAAATGGACATCAGAAACATTCTCCTT
AAACAGTTAGATCAACAGGCTATCATCTCAGGAGAATCCATTACTGGAGCCAGAAACCTACTCCATCATCGAACGCCAGC
CCTTGGTCTGAGCCTGCGGCTGTAGATGTGGAATCAGAGCATATGCATTGTTGGCCAGCTTACCAAGCCCAGCCTGACT
CAAAAGGAGATAGCGAAGGCCACTAGCATAGTGGCTTGGTTGGCCAAAGCAACAAATGCATATGGGGGCTTCTCTTCTACT
CAGGATACTGTAGTTGCTCTCCAAGCTCTTGCCAAATATGCCACTACCGCTACATGCCATCTGAGGAGATCAACCTGGTT
GTAAATCCACTGAGAATTTCCAGCGCACATTCAACATACAGTCAGTTAACAGATTGGTATTTTCCAGGAGTACCTGGCC
AATGTCCTGGAAATGTACAGTTGGAGGCCCTCAGGCCAGGGCTGTGTCTATGTGCAGACGGTGTGAGATACAATATTCTC
CCTCCCAAAATATGAAGACCTTTAGTCTTAGTGTGGAATAGGAAAAGCTAGATGTGAGCAACCGACTTCACCTCGATCC
TTGACTCTCACTATTACACCAAGTTATGTGGGGAGCCGTAGCTCTTCCAATATGGCTATTGTGGAGTGAAGATGTATCT
GGGTTTCACTCCATGGAGGGCACCAATCAGTTACTTCTCCAGCAACCCCTGGTGAAGAAGGTGAATTGGAATGACACA
CTTAACATTACTTGGATGAGCTCATTAAGAACACTCAGACTTACACCTTCACCATCAGCCAAAGTGTGCTGGTCACCAAC
TTGAAACCGACCAACCATCAAGGTCTATGACTACTACCTACCAGGTTCTTTAAATTATCTCAGTACACAATTGTGTGGTCC
ATGAACCAATGACAGCATAGTGGACTCTGTGGCACCGCACCCAGAACCACCCCTTTCAAGACAGAAGCATTATTCTCTTCA
CTTCTCTGGGAGTGTAAACAACCTGATAGCTACCA

```

In a search of public sequence databases, the NOV1 nucleic acid sequence has 840 of 1324 bases (63 %) identical to a *Rattus norvegicus* alpha-2-macroglobulin precursor mRNA (GENBANK-ID: Rat A2M) ( $E = 1.3e^{-119}$ ). Public nucleotide databases include all GenBank databases and the GeneSeq patent database.

In all BLAST alignments herein, the "E-value" or "Expect" value is a numeric indication of the probability that the aligned sequences could have achieved their similarity to the BLAST query sequence by chance alone, within the database that was searched. For example, the probability that the subject ("Sbjct") retrieved from the NOV1 BLAST analysis, e.g., *Rattus norvegicus* alpha-2-macroglobulin precursor mRNA, matched the Query NOV1 sequence purely by chance is  $1.3e^{-119}$ . The Expect value (E) is a parameter that describes the number of hits one can "expect" to see just by chance when searching a database of a particular size. It decreases exponentially with the Score (S) that is assigned to a match between two sequences. Essentially, the E value describes the random background noise that exists for matches between sequences.

The Expect value is used as a convenient way to create a significance threshold for reporting results. The default value used for blasting is typically set to 0.0001. In BLAST 2.0, the Expect value is also used instead of the P value (probability) to report the significance of matches. For example, an E value of one assigned to a hit can be interpreted as meaning that in a database of the current size one might expect to see one match with a similar score simply by chance. An E value of zero means that one would not expect to see any matches with a similar score simply by chance. See, e.g., <http://www.ncbi.nlm.nih.gov/Education/BLASTinfo/>. Occasionally, a string of X's or N's will result from a BLAST search. This is a result of automatic filtering of the query for low-

complexity sequence that is performed to prevent artifactual hits. The filter substitutes any low-complexity sequence that it finds with the letter "N" in nucleotide sequence (e.g., "NNNNNNNN") or the letter "X" in protein sequences (e.g., "XXX"). Low-complexity regions can result in high scores that reflect compositional bias rather than significant position-by-position alignment. Wootton and Federhen, Methods Enzymol 266:554-571, 1996.

The disclosed NOV1 polypeptide (SEQ ID NO:2) encoded by SEQ ID NO:1 has 1492 amino acid residues and is presented in Table 1B using the one-letter amino acid code. Signal P, Psort and/or Hydropathy results predict that NOV1 has a signal peptide and is likely to be localized outside the cell with a certainty of 0.3703. The most likely cleavage site for a NOV1 peptide is between amino acids 17 and 18, at: AIA-EE.

**Table 1B. Encoded NOV1 protein sequence (SEQ ID NO:2).**

```
MWAQLLLGMLALSFAIAEELPNYLVTLPARLNFPSVQKVCCLDLSPGYSDVKFTVTLETQDKTKQLLEYSGLK
KRHLHCISFLVPPAGGTEEVATIRVSGVGNNISFEEKKKVLIQRQNGTFVQTDKPLYTPGQQVYFRIVTM
DSNFVPVNDKYSVMVELQDPNSNRIQWLEVVPEQQGIVDLVSFLAPEAMLGTYTVAVAEGKTFGTFSVEEYVL
SPFLLLLSSVLPKFKVEVVEPKELSTVQESFLVKICCRYTYGKPMLGAVQVSVCQKANTYWYREVEREQLPD
KCRNLSSGQTDKTGCFSAFVDMATFDLIGYAYSHQINIVATVVEEGTGVANATQNIYISPMGSMFTFEDTSN
FYHPNFPFSGKMLLKFPQGGVLPCKNHLVFLVIYGTNGTFNQTLVTDNGLAPFTLETSGWNGTDVSLGKGF
QMEDLVYNPEQVPRYYQNAYLHLRPFYSTTRSFGLGIHRLNGPLKCGQPQEVLDVYYIDPADASPDQEISFSY
YLIGKGSVMGQKHLNSKKKGLKASFSLSTFTSRLAPDPSLVIYAI FPPSGGVVADKIQFSVEMCFDNQQL
PGAEEVELQQAAPGSLCALRAVDESLLLLRPDRELSNRSVYGMFPFHYGHYPYQVAEYDQCPVSGPWFDPQP
LIDPMPOGHSSQRSIIWRPSFSEGTDLFSFFRDVGLKILSNAKIKKPVDCSHRSPEYSTAMGGGGHPEAFES
STPLHQAEDSQVRQYFPETWLWDLFPIGNSGKEAVHVTVPDAITEWKAMSFCTSQSRGFGLSPTVGLTAFKP
FFVDLTLPYSVVRGESFRLTATIFNYLKDCIRVQTDLAKSHEYQLESWADSQTSSCLCADDKTHWNITAV
KLGHINFITISTKILDSNEPCGGQKGFVPQKGRSDTLIKPVLVKPEGVLVEKTHSSLLCPKGGKVASESVSLE
LPVDIVPDSTKAYVTVLGDMGTALQNL DGLVQMPSGCGEQNMVLFAPIIYVLQYLEKAGLLTEIRSRVAG
FLEIGYQKELMYKHSNGSYSAFGERDGNNTWLTAFTKCFGQAQKFIIDPKNIQDALKWMAGNQLPSGCY
ANVGNLLHTAMKGGVDDEVSLTAYVTAALLEMGKDVPDPMVSQGLRCLKNSATSTTNLYTQALLAYIFSLAG
EMDIRNILLKQLDQQAIIISGESIYWSQKPTPSSNASPWSEPAVDVELTAYALLAQLTKPSLTQKEIAKATS
IVAWLAKQHNAYGGFSSTQDTVVALQALAKYATTAYMPSEEINLVVKSTENFORTFNISQSVNRLVFQDITLP
NVPGMYTLEASGQCQVYVQTVLRYNILLPPTNMKTFSLSVEIGKARCEQPTSPRSLTLTIHTSYVGSRSSNM
AIVEVKMLSGFSPMEGTNQLLLQQLVKKVEFGTDTLNIYLDLIKNTQTYTFTISQSVLVTNLKPATIKVY
DYYLPGSFKLSQYTIWVSMNNDISIVDSVARHPEPPPFKTEAFIPSLPGSVNN
```

The NOV1 amino acid sequence has 595 of 1450 amino acid residues (41 %) identical to, and 873 of 1450 residues (60 %) positive with, the *Homo sapiens* 1474 amino acid residue alpha-2-macroglobulin precursor protein (ptrn: SPTREMBL-ACC:P01023) ( $E = 2.0e^{-279}$ ).

The disclosed NOV1 polypeptide has homology to the amino acid sequences shown in the BLASTP data listed in Table 1C.

**Table 1C. BLAST results for NOV1**

Gene Index/ Identifier	Protein/ Organism	Length (aa)	Identity (%)	Positives (%)	Expect
gi 14765710 ref XP_006925.4	alpha 2 macroglobulin precursor [Homo sapiens]	1474	593/1486 (39%)	870/1486 (57%)	0.0

gi 4557225 ref NP 00005.1	alpha 2 macroglobulin precursor [Homo sapiens]	1474	591/1486 (39%)	869/1486 (57%)	0.0
gi 224053 prf 1009174A	macroglobulin alpha2 [Homo sapiens]	1450	585/1471 (39%)	861/1471 (57%)	0.0
gi 6978425 ref NP 036620.1	alpha-2- macroglobulin [Rattus norvegicus]	1472	578/1483 (38%)	867/1483 (57%)	0.0
gi 2144118 pir JC5143	alpha- macroglobulin precursor [Cavia porcellus]	1476	570/1495 (38%)	858/1495 (57%)	0

The homology between these and other sequences is shown graphically in the ClustalW analysis shown in Table 1D. In the ClustalW alignment of the NOV1 protein, as well as all other ClustalW analyses herein, the black outlined amino acid residues indicate regions of conserved sequence (*i.e.*, regions that may be required to preserve structural or functional properties), whereas non-highlighted amino acid residues are less conserved and can potentially be altered to a much broader extent without altering protein structure or function.

Table 1D. ClustalW Analysis of NOV1

- 1) Novel NOV1 (SEQ ID NO:2)
- 2) gi|14765710|ref|XP\_006925.4| alpha 2 macroglobulin precursor [Homo sapiens] (SEQ ID NO:65)
- 3) gi|4557225|ref|NP\_00005.1| alpha 2 macroglobulin precursor [Homo sapiens] (SEQ ID NO:66)
- 4) gi|224053|prf|1009174A macroglobulin alpha2 [Homo sapiens] (SEQ ID NO:67)
- 5) gi|6978425|ref|NP\_036620.1| alpha-2-macroglobulin [Rattus norvegicus] (SEQ ID NO:68)
- 6) gi|2144118|pir|JC5143 alpha-macroglobulin precursor [Cavia porcellus] (SEQ ID NO:69)

	10	20	30	40	50
NOV1	.....	.....	.....	.....	.....
gi 14765710	MWAO	LLGMLALSP	ATAEEL	PNYLV	TEPARLNPPSVOK
gi 4557225	MGKNKL	-----	LEPSLV	LLLLLVLL	PTDASVSGKPQYMLVPSLLHETTEK
gi 224053	MGKNKL	-----	LEPSLV	LLLLLVLL	PTDASVSGKPQYMLVPSLLHETTEK
gi 6978425	MGKHRL	RSLSL	LELLLR	LLLLLVLL	PTDASAPOKPIYVMVPSLLHAGTPEK
gi 2144118	MGKNKL	-----	LEPNP	VLLLLLVLL	LAADASISGKPQYMLVPSLLHSGTPEK
	60	70	80	90	100
NOV1	VCLDL	SPGYSDV	KFTV	LTETKDKT	QRLL EYSGLKRRHLHCISFLVPPPPAG
gi 14765710	GCVL	LSVLNETV	TVSASLES	VRGNRS	SLFTDL EABNDVLHCVAFAVPKSSS
gi 4557225	GCVL	LSVLNETV	TVSASLES	VRGNRS	SLFTDL EABNDVLHCVAFAVPKSSS
gi 224053	GCVL	LSVLNETV	TVSASLES	VRGNRS	SLFTDL EABNDVLHCVAFAVPKSSS
gi 6978425	ACFL	FSHLNETV	AVRV	SLESV	HGNOSLFTDLVVDKDLFCHCTSETVPOSSS
gi 2144118	ICLL	LTQLNETV	TVKAS	LDLTIRE	NGSLEMMVAEKDLFCQVAFVTPQSPY
	110	120	130	140	150
NOV1	GTEEV	ATIRV	SGVGN	NISFE	EKKRVLTQRQNGTFFVQTDKPLYPGQOVY
gi 14765710	-NEEV	MFLTVQ	VKGPT	OEKKR	RTVMVKNEDSLVFVQTDKSIYKPGQTVK
gi 4557225	-NEEV	MFLTVQ	VKGPT	OEKKR	RTVMVKNEDSLVFVQTDKSIYKPGQTVK
gi 224053	-NEEV	MFLTVQ	VKGPT	OEKKR	RTVMVKNEDSLVFVQTDKSIYKPGQTVK
gi 6978425	-DE	-LMEFTV	QVKGAT	HEFR	RQSTVLVKKICESLVFAQTDKPIYKPGQTVK
gi 2144118	-PEAV	MFLTV	VEGPT	HGRSR	KRTVLVSKSDSLVFVQTDKPIYKPGQTVK

```

      160      170      180      190      200
NOV1      FRIVTMDSNFVPVNDKYSMVETQDPNSNRIAQWLEVVPEQGLVDLSFOLA
gi|14765710| FRVVSMDENFHLNELIPLVYIQDPKGNRIAQWQSFQLEGGGLKQSFPLS
gi|4557225| FRVVSMDENFHLNELIPLVYIQDPKGNRIAQWQSFQLEGGGLKQSFPLS
gi|224053| FRVVSMDENFHLNELIPLVYIQDPKGNRIAQWQSFQLEGGGLKQSFPLS
gi|6978425| FRVVSMDENFHLNELIPLVYIQDPKGNRIAQWQSFQLEGGGLKQSFPLS
gi|2144118| ARVVSMDENFHLNELIPLVYIQDPKGNRIAQWQSFQLEGGGLKQSFPLS

      210      220      230      240      250
NOV1      PEAMLSITYTVAARG---KTFGLFSVEEVVLSPFLLLLSSVLPKFKVEVV
gi|14765710| SEPFQGSYKVVVQKKSGGRTEHPFTVEEFVL-----PKFEVQVT
gi|4557225| SEPFQGSYKVVVQKKSGGRTEHPFTVEEFVL-----PKFEVQVT
gi|224053| SEPFQGSYKVVVQKKSGGRTEHPFTVEEFVL-----PKFEVQVT
gi|6978425| SEPFQGSYKVVVQKKSGGRTEHPFTVEEFVL-----PKFEVQVT
gi|2144118| SEPLQGSYKVVVQKKSGGRTEHPFTVEEFVL-----PKFEVQVS

      260      270      280      290      300
NOV1      EPKELSTVOESFLVKECRYTYGKPMLCAGVSVCKANTYIWRVEREQ
gi|14765710| VPKIITILEEEMNVSVCGLYTYGKVPVPGHVTVSICRKYSQ--ASDCHGED
gi|4557225| VPKIITILEEEMNVSVCGLYTYGKVPVPGHVTVSICRKYSQ--ASDCHGED
gi|224053| VPKIITILEEEMNVSVCGLYTYGKVPVPGHVTVSICRKYSQ--ASDCHGED
gi|6978425| VPKIITILEEEMNVSVCGLYTYGKVPVPGHVTVSICRKYSN--PSNCFGE
gi|2144118| MPKIIITILEEEMNVSVCGLYTYGKVPVPGHVTVSICRKYSN--PSACLSE

      310      320      330      340      350
NOV1      LPDKCRNLSSQTEKTCGCSAPVDMATEDLIGYATSHQINIVATVVEEGTG
gi|14765710| SCAFCEKFSGQLNSHGCFYQQVTKVFKLKRKEYEMQLTEAQIQEEGTV
gi|4557225| SCAFCEKFSGQLNSHGCFYQQVTKVFKLKRKEYEMQLTEAQIQEEGTV
gi|224053| SCAFCEKFSGQLNSHGCFYQQVTKVFKLKRKEYEMQLTEAQIQEEGTV
gi|6978425| SCAFCEKFSGQLNSHGCFYQQVTKVFKLKRKEYEMQLTEAQIQEEGTG
gi|2144118| SRAFCEKFSGQLNSHGCFYQQVTKVFKLKRKEYEMQLTEAQIQEEGTG

      360      370      380      390      400
NOV1      VEANATONIVTSPOMGSMITFEDTSNFTHPNFPFSGKMLLKFPQGGVLPCK
gi|14765710| VELTGROSSEITRTITKLSFVKVDSHFROGIPFFGQVRLVDGKGVPIPK
gi|4557225| VELTGROSSEITRTITKLSFVKVDSHFROGIPFFGQVRLVDGKGVPIPK
gi|224053| VELTGROSSEITRTITKLSFVKVDSHFROGIPFFGQVRLVDGKGVPIPK
gi|6978425| VELTGROSSEITRTITKLSFVKVDSHFROGIPFFGQVRLVDGKGVPIPK
gi|2144118| VELTGROSSEITRTITKLSFVKVDSHFROGIPFFGQVRLVDGKGVPIPK

      410      420      430      440      450
NOV1      NHLVRLVIYGTNGTFNQTLVTDNGLAPFTLETSGWNGTDVSLGKFKQME
gi|14765710| ----VFIRGNEANYYSNATTDEHGLVQFSINTTNVMGTSLTVRVNYKDR
gi|4557225| ----VFIRGNEANYYSNATTDEHGLVQFSINTTNVMGTSLTVRVNYKDR
gi|224053| ----VFIRGNEANYYSNATTDEHGLVQFSINTTNVMGTSLTVRVNYKDR
gi|6978425| ----TIFIGADEANLYINTTTDKHGLARFSINTDDMGTSLTVRVNYKDS
gi|2144118| ----MTITASEANYYSNATTDEHGLVQFSINTTNVMGTSLTVRVNYKDS

      460      470      480      490      500
NOV1      DLVYNPEQVPRIYONAVLHLRPFYSTIRSFGLGTHRLNGPLKCCQPOEVLV
gi|14765710| SPCYGYQWVSEEEHAAHTAYLVFSPSKSFVHLEPMSHLPCCGHTQTVQA
gi|4557225| SPCYGYQWVSEEEHAAHTAYLVFSPSKSFVHLEPMSHLPCCGHTQTVQA
gi|224053| SPCYGYQWVSEEEHAAHTAYLVFSPSKSFVHLEPMSHLPCCGHTQTVQA
gi|6978425| NACYGFRWLTEENVEAHHTAYLVFSPSKSFVHLEPMSHLPCCGHTQTVQA
gi|2144118| TNCYDYQWVLEENVEAHHTAYLVFSPSKSFVHLEPMSHLPCCGHTQTVQA

      510      520      530      540      550
NOV1      DYYIDPADASPDQETISFSYLLTGKGSIVMEGOKHLNSKKGKASFSLSI
gi|14765710| HYILNGGTLGLKKLSFYLLIMAKGGIVRTGTHGLLVKQEDMRGHFSISI
gi|4557225| HYILNGGTLGLKKLSFYLLIMAKGGIVRTGTHGLLVKQEDMRGHFSISI
gi|224053| HYILNGGTLGLKKLSFYLLIMAKGGIVRTGTHGLLVKQEDMRGHFSISI

```

gi|6978425| HYILNGRAMQELKELVYYVIMAKGGIVRAGTHVLPKQGMRGHFSILL  
gi|2144118| HYILKG---QELKELVYYVIMAKGGIVQSGTVLVSQGNKKGHFSVSV

560 570 580 590 600  
NOV1 TFSRIADPDSLVIYATFPGSGVADKIQFSVEMCFDN-----QQL  
gi|14765710| PVKSDIAPVARLLIYAVLPAGDVIGDSAKYDVENCLANKVDLSFSPSQSL  
gi|4557225| PVKSDIAPVARLLIYAVLPAGDVIGDSAKYDVENCLANKVDLSFSPSQSL  
gi|224053| PVKSDIAPVARLLIYAVLPAGDVIGDSAKYDVENCLANKVDLSFSPSQSL  
gi|6978425| SMEIDTAPVARLVLYALPNGEVVGDYAKYETENCLANKVDLVERPNSGL  
gi|2144118| PVESDIAPVARVLIYALPSEITLADSAYNVENCLDNKVNLSFSEGSQSL

610 620 630 640 650  
NOV1 PGAEVLELQIQAAPGSLCALRAVDQSVLLLRPDRELSNRSVYGMFF-FWYG  
gi|14765710| PASHAHLRVTAAPQSVCALRAVDQSVLLMKPDAELSASSVYNLLPEKDLT  
gi|4557225| PASHAHLRVTAAPQSVCALRAVDQSVLLMKPDAELSASSVYNLLPEKDLT  
gi|224053| PASHAHLRVTAAPQSVCALRAVDQSVLLMKPDAELSASSVYNLLPEKDLT  
gi|6978425| PATRALLSVMAQPSQLCLRAVDQSVLLMKPETELASLTIYDLLEPKDLT  
gi|2144118| PASKTHLRVTASPSQSLCALRAVDQSVLLRKPEAVLSASSVYALLPEKDLT

660 670 680 690 700  
NOV1 HYPYQVAVYDQCPVSGPWDFPQPLIDPMPQGHSSQSRSTLNRPSFSEG-TD  
gi|14765710| GFPGLNDQDDED-----CINRHNVIYINGITITPVSSSTNEKD  
gi|4557225| GFPGLNDQDDED-----CINRHNVIYINGITITPVSSSTNEKD  
gi|224053| GFPGLNDQDDED-----CINRHNVIYINGITITPVSSSTNEKD  
gi|6978425| GFPQGADQRREDTNG-----CVKQNTIYINGITLYSPVONTNEED  
gi|2144118| GFPGLNGQRENDGE-----CVSLNTIYIDGITLYSPEFNINEKD

710 720 730 740 750  
NOV1 LFSFRDVGKILSNKIKKPVDCSHRSPEYST---AMGGGGHPFAFES  
gi|14765710| MYSFLEDMGLKAFTNSKIRKPKMCPQLQOYEMHGPEGRLRVGEYESDVMGR  
gi|4557225| MYSFLEDMGLKAFTNSKIRKPKMCPQLQOYEMHGPEGRLRVGEYESDVMGR  
gi|224053| MYSFLEDMGLKAFTNSKIRKPKMCPQLQOYEMHGPEGRLRVGEYESDVMGR  
gi|6978425| MYGFLKDMGLKVFTNSNIRKPKVCERLEDNKGIPAAHYLVQSQHMDFLE  
gi|2144118| MYGFLKDMGLKVFTNKKIKPKPOLCAHYVQKFEVP---TMAYSSESSSFRS

760 770 780 790 800  
NOV1 STP-----LHQAEDSQVROYFPETWIWDLFPICNSGKEAVHVTVP  
gi|14765710| GHARVHVH-----REPHTETVRKYFPETWIWDLVVVSAGVAEVGVTV  
gi|4557225| GHARVHVH-----REPHTETVRKYFPETWIWDLVVVSAGVAEVGVTV  
gi|224053| GHARVHVH-----REPHTETVRKYFPETWIWDLVVVSAGVAEVGVTV  
gi|6978425| -----S--SPPTETVRSYFPETWIWDLVVVSAGVAEVGVTV  
gi|2144118| GPRVPAVGIAATYSEPPKETVRTYSPETWIWDLKVTSSGVAEVGVTV

810 820 830 840 850  
NOV1 DAITENKAMSECTSSSRGFGLSPTVGLTAFKPFVVLTLTPYSVIRGESER  
gi|14765710| DTITENKAGAFCLSDAGLGISSTASLRAFQPFVVELTMPYSVIRGEAFT  
gi|4557225| DTITENKAGAFCLSDAGLGISSTASLRAFQPFVVELTMPYSVIRGEAFT  
gi|224053| DTITENKAGAFCLSDAGLGISSTASLRAFQPFVVELTMPYSVIRGEAFT  
gi|6978425| DTITENKAGAFCLSDTGLGSPFVVOFCATQPFVVELTMPYSVIRGEAFT  
gi|2144118| DTITENKAGAFCLSDTGLGSPFVVOFCATQPFVVELTMPYSVIRGEAFT

860 870 880 890 900  
NOV1 LTATLNYLQDCIRVOTDLAKSHYQLESWADSOTSSCLCADDARTHMNN  
gi|14765710| LKATVLNLYLPKCIKRVSVQLEASPAFLAVPVEKEQAPHICANGROTWSA  
gi|4557225| LKATVLNLYLPKCIKRVSVQLEASPAFLAVPVEKEQAPHICANGROTWSA  
gi|224053| LKATVLNLYLPKCIKRVSVQLEASPAFLAVPVEKEQAPHICANGROTWSA  
gi|6978425| LKATVLNLYLPKCIKRVAVQLEASPDFAAPEKEQORSHCICMNOREHTASWA  
gi|2144118| LKATVLNLYLPKCIKRVSVHLEASPKFLAEPKAKEQESMVCVCGNEROTWSW

910 920 930 940 950  
NOV1 ITAVKLGEDNFTISTKILDSNPECCGQKGFVPOKGRSDTLIKPVLRPEG  
gi|14765710| VTPKSLGNVNFVTSABEALESQELCGTEVPSVPEHGRKDTVIKPLLVEPEG

gi|4557225| VTPKSLGNVNFVTSAAEALSSQLCGTEVPSVPEHGRKDTVIKPLLVEPEG  
gi|224053| VTPKSLGNVNFVTSAAEALSSQLCGTEVPSVPEHGRKDTVIKPLLVEPEG  
gi|6978425| VTPKSLGNVNFVTSAAEALNSKELCGNEVPVPEHGRKDTVIKPLLVEPEG  
gi|2144118| VTPKSLGNVNFVTSAAEALSSQLCGNEKTVPTVGRKDTVIKPLLVEPEG

960 970 980 990 1000  
.....  
NOV1 VLVETTHSSLLCPKGGKVAESVSLLELPVDIVPDSIKAMVTVLGDIMGTA  
gi|14765710| LEKETTFNSLLCPSGGEVS-EELSLKLEPNVVEESARASVSVLGDILGSA  
gi|4557225| LEKETTFNSLLCPSGGEVS-EELSLKLEPNVVEESARASVSVLGDILGSA  
gi|224053| LEKETTFNSLLCPSGGEVS-EELSLKLEPNVVEESARASVSVLGDILGSA  
gi|6978425| LENEVTFNSLLCPMGAESV-EELALKLESVVEESARASVTVLGDILGSA  
gi|2144118| LEKETTFNSLLCPMGAESV-EELALKLESVVEESARASVTVLGDILGSA

1010 1020 1030 1040 1050  
.....  
NOV1 LQNTQCLVQMPYGCGBONMVLFAPIIYVLDYLNQQLTPEIKSKAIGYL  
gi|14765710| MONTQNLQMPYGCGBONMVLFAPIIYVLDYLNQQLTPEIKSKAIGYL  
gi|4557225| MONTQNLQMPYGCGBONMVLFAPIIYVLDYLNQQLTPEIKSKAIGYL  
gi|224053| MONTQNLQMPYGCGBONMVLFAPIIYVLDYLNQQLTPEIKSKAIGYL  
gi|6978425| MONTQNLQMPYGCGBONMVLFAPIIYVLDYLNQQLTPEIKSKAIGYL  
gi|2144118| MONTQNLQMPYGCGBONMVLFAPIIYVLDYLNQQLTPEIKSKAIGYL

1060 1070 1080 1090 1100  
.....  
NOV1 EIGYQKRLMYKHSNGSYSAFGERDGG--NGNTWLTAFVLTQCFGQAKKFIET  
gi|14765710| NTGYQRLNYKHMDGSYSTFGERYGRNQCNTWLTAFVLTQCFGQAKKFIET  
gi|4557225| NTGYQRLNYKHMDGSYSTFGERYGRNQCNTWLTAFVLTQCFGQAKKFIET  
gi|224053| NTGYQRLNYKHMDGSYSTFGERYGRNQCNTWLTAFVLTQCFGQAKKFIET  
gi|6978425| NTGYQRLNYKHMDGSYSTFGERYGRNQCNTWLTAFVLTQCFGQAKKFIET  
gi|2144118| NTGYQRLNYKHMDGSYSTFGERYGRNQCNTWLTAFVLTQCFGQAKKFIET

1110 1120 1130 1140 1150  
.....  
NOV1 DPKNIQDALRMAAGNQLPSGCGZANVGNLLETAMKGGVDEDEVSLTAYVITAA  
gi|14765710| DEAHITQALWLSQKQKNGCFRSGSLLNNAIKGGVEDEVSLTAYVITAA  
gi|4557225| DEAHITQALWLSQKQKNGCFRSGSLLNNAIKGGVEDEVSLTAYVITAA  
gi|224053| DEAHITQALWLSQKQKNGCFRSGSLLNNAIKGGVEDEVSLTAYVITAA  
gi|6978425| DEAHITQALWLSQKQKNGCFRSGSLLNNAIKGGVEDEVSLTAYVITAA  
gi|2144118| DEAHITQALWLSQKQKNGCFRSGSLLNNAIKGGVEDEVSLTAYVITAA

1160 1170 1180 1190 1200  
.....  
NOV1 LLEMSKDVDDPMVSQGLRCLNSATST--TNTVYTOALLAYIFSLAG  
gi|14765710| LLEMSKDVDDPMVSQGLRCLNSATST--TNTVYTOALLAYIFSLAG  
gi|4557225| LLEMSKDVDDPMVSQGLRCLNSATST--TNTVYTOALLAYIFSLAG  
gi|224053| LLEMSKDVDDPMVSQGLRCLNSATST--TNTVYTOALLAYIFSLAG  
gi|6978425| LLEMSKDVDDPMVSQGLRCLNSATST--TNTVYTOALLAYIFSLAG  
gi|2144118| LLEMSKDVDDPMVSQGLRCLNSATST--TNTVYTOALLAYIFSLAG

1210 1220 1230 1240 1250  
.....  
NOV1 EMDIRNILLKQLDQCATISGESITYWSQKPTPSSNASPWSEPA--VQVET  
gi|14765710| NQDKRKEVLKSLNEEAVKKDNSVHWRPQKPKAPVGHITYEPQAPSAEVEM  
gi|4557225| NQDKRKEVLKSLNEEAVKKDNSVHWRPQKPKAPVGHITYEPQAPSAEVEM  
gi|224053| NQDKRKEVLKSLNEEAVKKDNSVHWRPQKPKAPVGHITYEPQAPSAEVEM  
gi|6978425| NQDKRKEVLKSLNEEAVKKDNSVHWRPQKPKAPVGHITYEPQAPSAEVEM  
gi|2144118| NQDKRKEVLKSLNEEAVKKDNSVHWRPQKPKAPVGHITYEPQAPSAEVEM

1260 1270 1280 1290 1300  
.....  
NOV1 TAYVLLAYLTARPAPTSEDLTSAITNIVKWTQKQNAQGGFSSTQDTVVAL  
gi|14765710| TAYVLLAYLTARPAPTSEDLTSAITNIVKWTQKQNAQGGFSSTQDTVVAL  
gi|4557225| TAYVLLAYLTARPAPTSEDLTSAITNIVKWTQKQNAQGGFSSTQDTVVAL  
gi|224053| TAYVLLAYLTARPAPTSEDLTSAITNIVKWTQKQNAQGGFSSTQDTVVAL  
gi|6978425| TAYVLLAYLTARPAPTSEDLTSAITNIVKWTQKQNAQGGFSSTQDTVVAL  
gi|2144118| TAYVLLAYLTARPAPTSEDLTSAITNIVKWTQKQNAQGGFSSTQDTVVAL

1310 1320 1330 1340 1350  
.....

NOV1	QALAKYATTAYMPS--EEINLIVKSTENFQRTFNIQSVNRLVFOQDILPNN
gi   14765710	HALSKYGAATFTRTGKAAQVTIIOSSGTFSSKFOVDNNRLLQLQVSLPEI
gi   4557225	HALSKYGAATFTRTGKAAQVTIIOSSGTFSSKFOVDNNRLLQLQVSLPEI
gi   224053	HALSKYGAATFTRTGKAAQVTIIOSSGTFSSKFOVDNNRLLQLQVSLPEI
gi   6978425	HALSKYGAATFTRTGKAAQVTIIOSSGTFSSKFOVDNNRLLQLQVSLPEI
gi   2144118	HALSKYGAATFTRTGKAAQVTIIOSSGTFSSKFOVDNNRLLQLQVSLPEI

  

	1360	1370	1380	1390	1400
NOV1	PGMYTLKASGGQCVYVQTVLRVNLPPPTNMKTFSLSVKIGKARCQOPTSP				
gi   14765710	PGEYSMKVTGEGCVYLOQTSKYNILPEKEEFPFALGVQTLPTQCDPEKHAH				
gi   4557225	PGEYSMKVTGEGCVYLOQTSKYNILPEKEEFPFALGVQTLPTQCDPEKHAH				
gi   224053	PGEYSMKVTGEGCVYLOQTSKYNILPEKEEFPFALGVQTLPTQCDPEKHAH				
gi   6978425	PGDYTFKVTGEGCVYLOQTSKYNILPEKEEFPFALGVQTLPTQCDPEKHAH				
gi   2144118	SDSYTFKVTGEGCVYLOQTSKYNILPEKEEFPFALGVQTLPTQCDPEKHAH				

  

	1410	1420	1430	1440	1450
NOV1	RSLLTLTHTSYVGSRSSENMAIVSVKMLSGFSPLKGTNOILLQOPLVKKV				
gi   14765710	TSFQISLSVSYTGSRSAENMAIVSVKMLSGFSPLKGTNOILLQOPLVKKV				
gi   4557225	TSFQISLSVSYTGSRSAENMAIVSVKMLSGFSPLKGTNOILLQOPLVKKV				
gi   224053	TSFQISLSVSYTGSRSAENMAIVSVKMLSGFSPLKGTNOILLQOPLVKKV				
gi   6978425	TSFQISLSVSYTGSRSAENMAIVSVKMLSGFSPLKGTNOILLQOPLVKKV				
gi   2144118	TSFQISLSVSYTGSRSAENMAIVSVKMLSGFSPLKGTNOILLQOPLVKKV				

  

	1460	1470	1480	1490	1500
NOV1	DFGADTLNIYLDKVSNOTLSLSEFTVLODVPVRDLKPAIVKVYDYETGEF				
gi   14765710	EVSSNNHVLIIYLDKVSNOTLSLSEFTVLODVPVRDLKPAIVKVYDYETGEF				
gi   4557225	EVSSNNHVLIIYLDKVSNOTLSLSEFTVLODVPVRDLKPAIVKVYDYETGEF				
gi   224053	EVSSNNHVLIIYLDKVSNOTLSLSEFTVLODVPVRDLKPAIVKVYDYETGEF				
gi   6978425	EVSSNNHVLIIYLDKVSNOTLSLSEFTVLODVPVRDLKPAIVKVYDYETGEF				
gi   2144118	EVSSNNHVLIIYLDKVSNOTLSLSEFTVLODVPVRDLKPAIVKVYDYETGEF				

  

	1510	1520	1530	1540
NOV1	KLSQVTLVWSMNDIVDSVARHPEPPPFKTEAFIPSLPGSVNN			
gi   14765710	ATAEYNAPCSKDLGNA-----			
gi   4557225	ATAEYNAPCSKDLGNA-----			
gi   224053	ATAEYNAPCSKDLGNA-----			
gi   6978425	ATAEYNAPCSKDLGNA-----			
gi   2144118	ATAEYNAPCSKDLGNA-----			

The presence of identifiable domains in NOV1, as well as all other NOVX proteins, was determined by searches using software algorithms such as PROSITE, DOMAIN, Blocks, Pfam, ProDomain, and Prints, and then determining the Interpro number by crossing the domain match (or numbers) using the Interpro website (<http://www.ebi.ac.uk/interpro>). DOMAIN results for NOV1, as disclosed in Tables 1E and 1F, were collected from the Conserved Domain Database (CDD) with Reverse Position Specific BLAST analyses. This BLAST analysis software samples domains found in the Smart and Pfam collections. For Tables 1E, 1F and all successive DOMAIN sequence alignments, fully conserved single residues are indicated by black shading or by the sign (!) and "strong" semi-conserved residues are indicated by grey shading or by the sign (+). The "strong" group of conserved amino acid residues may be any one of the following groups of amino acids: STA, NEQK, NHQK, NDEQ, QHRK, MILV, MILF, HY, FYW.



Tables 1E and 1F lists the domain description from DOMAIN analysis results against NOV1. This indicates that the NOV1 sequence has properties similar to those of other proteins known to contain these domains.

**Table 1E. Domain Analysis of NOV1**

gnl|Pfam|pfam00207, A2M, Alpha-2-macroglobulin family. This family includes the C-terminal region of the alpha-2-macroglobulin family. (SEQ ID NO:70)  
Length = 751 residues, 98.5% aligned  
Score = 563 bits (1451), Expect = 2e-161

NOV1	728	EDSQVRQYPPETWLWDLFPIGNSGKEAVHVTVPDAITEWKAMSFACTSQRGFGLSPTVGL	787
		+  +     +   ++ +   ++ +      + ++   ++  ++	
Pfam00207	4	DDITIRSYFPESWLWEVEVDSPVLTVNITLPSDITTEILAVLSNTKGLCVADPVEL	63
NOV1	788	TAFKPFVFDLTLPYSVVRGESFRITATIFNYL-KDCIRVQTDLAKSHFYQLESWADSQTS	846
		+   ++              ++    +	
Pfam00207	64	TVFQDFLELRFPYSVVRGEQVELRAVLVLYNLPSPQDIKV-----VVQLEVEPLCQAG	115
NOV1	847	SCLCADDAKTHHWNITAVKLGHINFTISTKILDSNEPCGGQKGFVPQKGRSDTLIKPVLV	906
		++  ++  +     ++  ++  ++  +	
Pfam00207	116	FCSLATQTRSSQSVRPKSLSSVSFPVVVPLASGLSLVEVVASVPEFFVKDAVVKTLKV	175
NOV1	907	KPEGVLVEKTHSSLLCP---KGGKVAESVSLELPPVDIVPD-STKAYVTVLGDMGTALQ	962
		+      +          +         +  ++    +   +	
Pfam00207	176	BPFGARKEETVSSLLPPEHLGGGLEVSEVPALKLPDDVPDTEAEAVISVQGDPAQAQIQ	235
NOV1	963	N-----LDGLVQMPSCGCGQNMLVFAPIIYVLQYLEKAGLLTE---EIRSRVGFLEIG	1013
		+   ++          +     +     ++  + + + +  + +	
Pfam00207	236	NTLSGEGLNNLLRLPSGCGEQNMIIYMAPTVYVLHYLDETQWKEPGTKKKQKAIIDLKNG	295
NOV1	1014	YQKELMYKHSNGSYSAFGERDGNNGNTWLTAFVTKCFGQAQKFIFIDPKNIQDALKW-MAG	1072
		++  + + +  +    +              +  ++  ++    +  +	
Pfam00207	296	YQRQLNYRKADGSYAFLHRA--SSTWLTAFVLKVFQARNYVFIDEEHICGAVKWLILN	353
NOV1	1073	NQLPSGCYANVGNLLHTAMKGGVDD---EVSLTAYVTAALLEMGKDVPDPMVSQGLRCL	1128
		+   ++              ++  ++        +  +	
Pfam00207	354	QQKDDGVFPRESGPVIHNMKGGVDDAEVEVTLTAFITIALLEAKLVCISPVVANALSIL	413
NOV1	1129	KNSATSTTN-----LYTQALLAYIFSLAGEMDIRNILLKQLDQQAIIISGESIYWS--QK	1180
		+         +    + +     ++  + +	
Pfam00207	414	KASDYLLNENYANGQRVYTLALTAYALALAGVLHKLKEILKSLKEELYKALVKGHWERPQK	473
NOV1	1181	PTPSSNASPWSEPAADVDELTAALLAQLTKPSLTQKEIAKATSIVAWLAKQHNAVGGFS	1240
		+ +      +              ++  +	
Pfam00207	474	PKDAPGHPYSPQPQAAVEMTSYALLALIT--LLPFPKVMAPKVVKWLTEQQYYGGGFG	531
NOV1	1241	STQDTVVALQALAKYATTAYMPSE-EINLVVKSTEN-FQRTFNIQSVNRLVFPQDTLP-N	1297
		+      +    ++  ++    +    +  + +	
Pfam00207	532	STQDTVVALQALSKYGIATPTHKEKNLSVTIQSPSGSFKSHFQILNNAFLLRPVLPVLPN	591
NOV1	1298	VPGMYTLEASGQCCVYVQTVLRYNLPPTNMKTFSLSVEIGKARCEQPTSPR-SLTTLTIH	1356
		+ +      + +     +      +    +  +   +	
Pfam00207	592	EGFTVTAKVTGQGTTLTVTTYRYKVLDKKNTEFCPDLKIETVPDTCVEPKGAKNSDYLSIC	651
NOV1	1357	TSYVGSRSSSNMAIVEVKMLSGFSPMEGT--NQLLQLQPLVKKVEFGTDTLNIYLDDELK	1414
		++  +      ++      + + +      ++	
Pfam00207	652	TRYAGSRSDSGMAIADISMLTGFIPLKPDLLKLENGVDYVSKYBIDGNHVLVLYLDKVVSH	711
NOV1	1415	-NTQTYTFTISQSVLVTNLKPATIKVYDYVLP	1445
		+         +      ++	
Pfam00207	712	SETECVGFKIHQDFEVLQAPASVKVYDYVLP	743



**Table 1F. Domain Analysis of NOV1**

gnl|Pfam|pfam01835, A2M N, Alpha-2-macroglobulin family N-terminal region. This family includes the N-terminal region of the alpha-2-macroglobulin family. (SEQ ID NO:71)  
 Length = 620 residues, 98.4% aligned  
 Score = 236 bits (603), Expect = 5e-63

NOV1	5	LLLGMLALSPAIAEEL--PNYLVTLPARLNFPSPVQKVCCLDLSPGYSDVKFTVTLETDKDT	62
		+          +  +  +  +          +  +  +	
Pfam01835	2	LLWLLLLLLLLFFDSSLQKPRYMVIVPSILRTETPEKVCVQLHDLNETVTVTVSLHSFPGK	61
NOV1	63	QKLLEYSGLK---KRHLHCISFLVPPPA---GGTEEVATIRVSGVGNNISFEEKKKVLIQ	116
		+   +   +   +   +   +   +   +   +   +   +   +	
Pfam01835	62	RNLSSSLFTVLSSKDLFHCVSFTVPQPGFLFKSSKGEESFVVVQVKGPTHTEFKEKVTVLVS	121
NOV1	117	RQNGTFVQTDKPLYTPGQQVYFRIVTMDSNFVFNNDKYSMVELQDPNSNRIAQWLEVV	176
		+ +  +  +  +  +  +  +  +  +  +  +  +  +  +	
Pfam01835	122	SRRLGVFIQTDKPIYTPGQTVRYRVFSVDENLRPLNELI-LVYIEDPEGNRVDQWEVNKL	180
NOV1	177	EQGIVDLSFQLAPEAMLGTYYTAV---AEGKTFTG--FSVEEYVLSPLLLSSVLPKFK	231
		+   +   +   +   +   +   +   +   +   +	
Pfam01835	181	EGGIFQLSFPIPSEPIQGTWKIVARYESGPESNYTHYFEVKEY-----VLPSFEVS	231
NOV1	232	VEVVEPKELSTVQESFLVKICCRYTYGKPMLGAVQVSVQCQKANTYWYREVEREQLPDKCR	291
		+ +  +   +   +   +   +   +   +   +   +   +   +	
Pfam01835	232	ITPPKPFIIYDNFKEFEVTICARYTYGKPVPGVAYVRFVGK-----DEDGKKELLAGLE	285
NOV1	292	NLSGQTDKTG--CFSAPVDMATFDLIGYAY-SHQINI VATVVVEGTGVEANA-TQNIYIS	347
		+   +   +   +   +   +   +   +   +   +   +   +	
Pfam01835	286	ERAKLLDGNGEICLSQEVLLKELQLKNEDELGKSLYVAVAVIESEGDMEEAELGGIKIV	345
NOV1	348	PQMGSMTFEDTSNFIYHPNFPFSGKMLLKFPQGGVLPCKNHLVFLVIYGTNGTFNQTLVTD	407
		+   +   +   +   +   +   +   +   +   +   +   +	
Pfam01835	346	RSYKQLKFPVKTPSHFKPGIPFFLKVLVVDPDGS--PAPNVPVK--VSAQDASYYSNGITD	401
NOV1	408	NNGLAPFTLETSGWNGTDDVSLGKFMEDLVNPEQVPRYYQNAYLHLRPFYSTTRSLFG	467
		+      +  +  +  +  +  +  +  +  +  +  +  +  +	
Pfam01835	402	EDGLAQFSINTS--GISSLSITVTRTNHKELPEEVQAHAEQAATAYSTVSL--SKSYIHLS	457
NOV1	468	IHRLNGPLKCGQPQEVLDYYIDPADASPDQEISFSYYLIGKGSVMMEGQKHLNSKKKGL	527
		+   +   +   +   +   +   +   +   +   +   +	
Pfam01835	458	IER---TLPCGPGVGEQANFILRGKSLGELKILHFFYLIMSKGKIVKTGRE---PREPG	510
NOV1	528	KASPSLSLTFTSRLAPDPSLVIYAIFPSGGVADKIQFSVEMCFDN-----QQL	576
		+       +   +   +   +   +   +   +   +   +   +	
Pfam01835	511	QGLFSLSIPTVTPDLAPSFRLVAYYILPQGEVVADSVWIDVEDCCANKLDLSFSPSKDYRL	570
NOV1	577	PGAEEVLQQLQAAPGSLCALRAVDESLLLLRPDRELSNRSVY	617
		+  +  +  +  +  +  +  +  +  +  +  +  +  +	
Pfam01835	571	PAQQVKLRVEADPQSLVALRAVDQAVYLLKPKAKLSMSKVY	611

The A2M family of proteins are responsible for catalyzing the phosphorylation of the light chain of myosin during the contraction of smooth muscle. Thus, the myosin light chain kinase (MLCK) proteins serve as a key enzyme in muscle contraction and have been shown by immunohistology to be present in neurons and glia. The cDNA for human MLCK has been cloned from hippocampus and shown to encode a protein sequence 95% similar to smooth muscle MLCKs but less than 60% similar to skeletal muscle MLCKs. The cDNA clone detected two RNA transcripts in human frontal and entorhinal cortex, in hippocampus, and in jejunum, one corresponding to MLCK and the other probably to telokin, the carboxy-terminal 154 residues of MLCK expressed as an independent protein in smooth muscle. The levels of

expression has been shown to be lower in brain than in smooth muscle. The acidic C-terminus of all MLCKs from both brain and smooth muscle resembles the C-terminus of tubulins. By PCR and Southern blotting using 2 somatic cell hybrid panels, the MLCK gene has been localized to 3cen-q21. Since the MLCK disclosed herein is an MLCK, the chromosomal locus has been assigned as Chromosome 3cen-q21.

Phosphorylation of myosin II regulatory light chains (RLC) by Ca<sup>2+</sup>/calmodulin (CAM)-dependent MLCK is a critical step in the initiation of smooth muscle and non-muscle cell contraction. Post-translational modifications to MLCK down-regulate enzyme activity, suppressing RLC phosphorylation, myosin II activation and tension development.

The above defined information for NOV1 suggests that this A2M precursor-like protein may function as a member of a A2M precursor family. Therefore, the NOV1 nucleic acids and proteins of the invention are useful in potential therapeutic applications implicated in various diseases and disorders described below and/or other pathologies. For example, the NOV1 compositions of the present invention will have efficacy for treatment of patients suffering from Alzheimer's disease, inflammation, asthma, allergy and psoriasis, emphysema, pulmonary disease, immune disorders and neurological disorders. The NOV1 nucleic acid encoding A2M precursor-like protein, and the A2M precursor-like protein of the invention, or fragments thereof, may further be useful in diagnostic applications, wherein the presence or amount of the nucleic acid or the protein are to be assessed.

## NOV2

A disclosed NOV2 nucleic acid of 2021 nucleotides (also referred to as AC005799\_A) encoding a novel secreted protein related to angiogenesis is shown in Table 2A. An open reading frame was identified beginning with an ATG initiation codon at nucleotides 40-42 and ending with a TAA codon at nucleotides 1667-1669. Putative untranslated regions upstream from the initiation codon and downstream from the termination codon are underlined in Table 2A. The start and stop codons are in bold letters.

**Table 2A. NOV2 nucleotide sequence (SEQ ID NO:3).**

TTGATGGTATTAAGGGGTAGGGTCTTTGGGAGGTGCTCAATGCCGGGGCTGCGCCGGGACCGCCTACTG  
ACTCTGCTACTGCTGGGCGCGCTGCTCTCCGCCGACCTCTACTTCCACCTCTGGCCCAAGTACAGCGCC  
AGCTGCGGCCCTCGGGAGCGCCCGCGGGGTGCCGTGCACCGCGCGCCTCCTCCCTGGCGGGGACTC  
GGCCGCAGCTGCCTCGGACCCCGGCACGATCGTGCACAACTTTCCCGAACCAGCCCCGACTGAACCG  
GCTGGCGGCAGCCACAGCGGGTCGAGCTCCAAGTTGCAGGCCCTCTTCGCCACCCGCTGTACAACGTCC  
CGGAGGAGCCGCTCTCCTGGGAGCCGAGGACTCGCTCCTGGCCAGCCAGGAGGCGCTGCGGTATTACCG  
GAGGAAGGTGGCCCGCTGGAACAGGCGACACAAGATGTACAGAGAGCAGATGAACCTTACCTCCCTGGAC  
CCCCACTGCAGCTCCGACTCGAGGCCAGCTGGGTCCAGTTCACCTGGGTATTAAACCGCCATGGGCTCT  
ACTCCCGGTCCAGCCCTGTTGTGAGCAAACTTCTGCAAGACATGAGGCACCTTCCCACCATCAGTGCTGA  
TTACAGTCAAGATGAGAAAGCCTTGCTGGGGGCATGTGACTGCACCCAGATTGTGAAACCCAGTGGGGTC  
CACCTCAAGCTGGTGCTGAGGTTCTCGGATTTCCGGAAGGCCATGTTCAAACCCATGAGACAGCAGCGAG

```

ATGAGGAGACACCAGTGGACTTCTTCTACTTCATTGACTTTCAGAGACACAATGCTGAGATCGCAGCTTT
CCATCTGGACAGGATTCTGGACTTCCGACGGGTGCCGCCAACAGTGGGGAGGATAGTAAATGTCACCAAG
GAAATCCTAGAGGTACCAAGAATGAAATCCTGCAGAGTGTCTTTCTTTGTCTCTCCAGCGAGCAACGTGT
GCTTCTTCGCAAGTGTCCATACATGTGCAAGACGGAGTATGCTGTCTGTGGCAACCCACACCTGCTGGA
GGGTTCCCTCTCTGCCTTCTGCGTCCCTCAACCTGGCCCCAGGCTGTCTGTGCCCCAACCCCTGGATC
CGCTCCTACACACTGGCAGGAAAAGAGGAGTGGGAGGTCAATCCCTTTACTGTGACACAGTGAAACAGA
TCTACCCGTACAACAACAGCCAGCGGCTCCTCAATGTCATCGACATGGCCATCTTCGACTTCTTGATAGG
GAATATGACCCGGCACCATTATGAGATGTTACCAAGTTCGGGGATGATGGGTTCCTTATTACCTTGAC
AACGCCAGAGGGTTCGGACGACACTCCCATGATGAAATCTCCATCCTCTCGCCTCTCTCCAGTGTGCA
TGATAAAAAAGAAAACACTTTTGCACCTGCAGCTGCTGGCCCAAGCTGACTACAGACTCAGCGATGTGAT
GCGAGAATCACTGCTGGAAGACCAGCTCAGCCCTGTCTCACTGAACCCACCTCCTTGCCCTGGATCGA
AGGCTCCAAACCATCCTAAGGACAGTGGAGGGTGCATAGTGGCCCATGGACAGCAGAGTGTATAGTCG
ACGGCCAGTGGAAACAGTCGGCCCCAGACTCTGGCCAGGCTAACTTGACAGCTAA GGGCTGGCAGAGTC
CAGTTTCAGAAAAATACGCCTGGAGCCAGAGCAGTCACTCGAGTGGCCGACCTGCGTCTCTACTCCCACC
TGTACTGCTGGGAGTCAAGTCAGCTAGGAAGGAGCAGGACATTCTCTCAACAGCAAGTGGGGCCCAT
GGAAGTGAATCTTTACTCCTTGGTGCACCGCTTCTGTGCTGCGTTGCCTTGCTCCGTTTTTCCCAAAAG
CAGTGGCTTCATCAAGGCCACCGACGATCTCCTGAGTGCCTGGGAAATCTGGGTATAGTCAAGGCTTGG
CAGCCTTGATCCCAGGAGAGTACTAATGTTAAACAAGTCAAATAAAGGACATCAAGTGGAA

```

The disclosed NOV2 nucleic acid sequence, localized to chromosome 17, has 1378 of 1378 bases (100%) identical to *Homo sapiens* HSM801386 mRNA (GENBANK-ID: HSM801386 ( $E = 2.0e^{-305}$ )).

- 5 A NOV2 polypeptide (SEQ ID NO:4) encoded by SEQ ID NO:3 has 541 amino acid residues and is presented using the one-letter code in Table 2B. Signal P, Psort and/or Hydropathy results predict that NOV2 contains a signal peptide and is likely to be localized outside the cell with a certainty of 0.7045. The most likely cleavage site for a NOV2 peptide is between amino acids 33 and 34, at: VQR-QL.

10

**Table 2B. Encoded NOV2 protein sequence (SEQ ID NO:4).**

```

MPGLRRDRLLTLLLLGALLSADLYFHLWPQVQRQLRPRERPRGCPCTGRASSLARDSAAAAADPGTIVHN
FSRTEPRTEPAGGSHSGSSSKLQALFAHPLYNVPEEPPLLGAEDSLLASQEALRYRRKVARWNRHMY
REQMNLTSLDPLQLRLLEASWQFHLGINRHGLYSRSSPVVSKLLQDMRHFTISADYSQDEKALLGACD
CTQIVKPSGVHLKLVLRFSDFGKAMFKPMRQRDEETPVDFYFIDFQRHNAEIAAFHLDRILDPRRVP
TVGRIVNVTKIELEVTKNEILQSVFFVSPASNVCFFAKCPYMCKTEYAVCGNPHLLEGSLSAFLPSLNLA
PRLSVPNPWIRSYTLAGEEWEVNPLYCDTVKQIYPYNNSQLRLNVIDMAIFDFLIGNMDRHHYEMFTKF
GDDGFLIHLNARGFGRHSHDEISILSPLSQCCMIKKKTLHLQLLAQADYRLSDVMRESLEEDQLSPVL
TEPHLLALDRRLQTLRLTVEGCIVAHGQQSVIVDGPVEQSAPDSGQANLTS

```

The NOV2 amino acid sequence has 340 of 340 amino acid residues (100%) identical to a *Homo sapiens* CAB61412 protein (GENBANK-ID: CAB61412) ( $E = 2.9e^{-184}$ ). Essentially, the sequence constitutes a 5' extension of HSM801386.

- 15 Tissue expression data, obtained by Taqman analysis, reveals strong expression by activated endothelial cells, indicating that the NOV2 secreted protein might be involved in the angiogenic process and could be useful to identify and treat angiogenic processes. Analysis also reveals that the NOV2 gene is overexpressed by kidney tumors compared with their normal adjacent tissues and also strongly expressed by liver and liver tumors, Sage analysis  
20 also reveals NOV2 expression in ovarian tumors (Tables 21 – 23).

NOV2 also has homology to the amino acid sequences shown in the BLASTP data listed in Table 2C.

Table 2C. BLAST results for NOV2					
Gene Index/ Identifier	Protein/ Organism	Length (aa)	Identity (%)	Positives (%)	Expect
gi 11359998 pir T42684	hypothetical protein DKFZp434F2322.1 (fragment) [Homo sapiens]	340	340/340 (100%)	340/340 (100%)	0.0
gi 14776441 ref XP_045783.1	hypothetical protein DKFZp434F2322 [Homo sapiens]	307	306/307 (99%)	306/307 (99%)	1e-174
gi 9368881 emb CAB99089.1  (AL390147)	hypothetical protein [Homo sapiens]	311	176/286 (61%)	225/286 (78%)	1e-104
gi 13385516 ref NP_085042.1	hypothetical protein MGC7673 [Mus musculus]	249	132/237 (55%)	180/237 (75%)	3e-76
gi 7504833 pir T23035	hypothetical protein H03A11.1 [Caenorhabditis elegans]	512	143/381 (37%)	207/381 (53%)	4e-66

- 5 The homology of these sequences is shown graphically in the ClustalW analysis shown in Table 2D.

Table 2D. ClustalW Analysis of NOV2

- 1) NOV2 (SEQ ID NO:4)
- 2) gi|11359998|pir|T42684 hypothetical protein DKFZp434F2322.1 (fragment) [Homo sapiens] (SEQ ID NO:72)
- 2) gi|14776441|ref|XP\_045783.1| hypothetical protein DKFZp434F2322 [Homo sapiens] (SEQ ID NO:73)
- 3) gi|9368881|emb|CAB99089.1| (AL390147) hypothetical protein [Homo sapiens] (SEQ ID NO:74)
- 4) gi|13385516|ref|NP\_085042.1| hypothetical protein MGC7673 [Mus musculus] (SEQ ID NO:75)
- 5) gi|7504833|pir|T23035 hypothetical protein H03A11.1 [Caenorhabditis elegans] (SEQ ID NO:76)

	10	20	30	40	50
NOV 2	..... ..... ..... ..... ..... ..... ..... ..... ..... .....				
gi 11359998	MPGLRRDRLLTLLLLGALLSADLYFHLWFPQVQQLRPRLRPRGCPCTGRA				
gi 14776441	-----				
gi 9368881	-----				
gi 13385516	-----				
gi 7504833	---MRCNIKRLFTLAIGVFAATLVIISPSKDNRYEREWKQGPQSN---EAR-				
	60	70	80	90	100
NOV 2	..... ..... ..... ..... ..... ..... ..... ..... ..... .....				
gi 11359998	SSLARDSAAAAADPGTIVHNFSRTEPRTEPAGGSHSGSSSKLQALFAHPL				
gi 14776441	-----				
gi 9368881	-----				
gi 13385516	-----				

gi|7504833| -----AVGHQSPDLFPVQGNSLPHQPIPPSLGKDLSDPFNLFSSNK

110 120 130 140 150  
.....|.....|.....|.....|.....|.....|.....|.....|.....|.....|  
NOV 2 YNVPEEPPLGAEDSLASQALRYRRKVARWNRHMYREQMNLTSLD  
gi|11359998| -----  
gi|14776441| -----  
gi|9368881| -----  
gi|13385516| -----  
gi|7504833| ITLRKLYDLTKNVDFDQLRQNECKKNITLSKFWEK-----SEQR-----N

160 170 180 190 200  
.....|.....|.....|.....|.....|.....|.....|.....|.....|.....|  
NOV 2 PPLQLRLAESWVQFHLGINRHGLYSRSSPVVSKLLQDMRHFPPTISADYSQ  
gi|11359998| -----  
gi|14776441| -----  
gi|9368881| -----  
gi|13385516| -----  
gi|7504833| --VPE--DDNWERFYSNIGSCSVYSDDQIMDN-----

210 220 230 240 250  
.....|.....|.....|.....|.....|.....|.....|.....|.....|.....|  
NOV 2 DEKALLGACDCTQIVKPSGVHLKLVLRFSDFGKAMFKPMRQORDSETPVD  
gi|11359998| -EKALLGACDCTQIVKPSGVHLKLVLRFSDFGKAMFKPMRQORDSETPVD  
gi|14776441| -----FKPMRQORDSETPVD  
gi|9368881| -----FLSDKPFLFLSCF-----LRQTRQETPPD  
gi|13385516| -----  
gi|7504833| LLHDLNTSPIKRVHIMDGGTQVKFVFTFKNDKQAVFKPMRFGRDMSDPN

260 270 280 290 300  
.....|.....|.....|.....|.....|.....|.....|.....|.....|.....|  
NOV 2 FFYFIDFQRHNAETIAAFHLDRILDERRVPPTVGRIVNVTKELLEVTKNEI  
gi|11359998| FFYFIDFQRHNAETIAAFHLDRILDERRVPPTVGRIVNVTKELLEVTKNEI  
gi|14776441| FFYFIDFQRHNAETIAAFHLDRILDERRVPPTVGRIVNVTKELLEVTKNEI  
gi|9368881| FFYFSDYERHNAETIAAFHLDRILDERRVPPVAGRMVNVTKELRDVTRDKK  
gi|13385516| -----MKELIRDVTRDKK  
gi|7504833| BEYFSDYERHNAETIAAFHLDRVIGERRALPTVGRVILNMTELFEKA-EKK

310 320 330 340 350  
.....|.....|.....|.....|.....|.....|.....|.....|.....|.....|  
NOV 2 LQSVFFVSPASNVCFPAKCPYMCKTEYAVCGNPHILEGSLSAFLPSLNLA  
gi|11359998| LQSVFFVSPASNVCFPAKCPYMCKTEYAVCGNPHILEGSLSAFLPSLNLA  
gi|14776441| LQSVFFVSPASNVCFPAKCPYMCKTEYAVCGNPHILEGSLSAFLPSLNLA  
gi|9368881| LWRTFFLSPANNICFYGECSYICSTEHALCGKPDQIEGSLAAFLPDLSLA  
gi|13385516| LWRTFFVSPANNICFYGECSYICSTEHALCGRPDQIEGSLAAFLPDLSLA  
gi|7504833| LKKTFFVSPAKNFCFVSRCDYVCDTHATCGLPDMKEGSOVFLPDES AV

360 370 380 390 400  
.....|.....|.....|.....|.....|.....|.....|.....|.....|.....|  
NOV 2 PRLSVNPWIRSYTLAG-KEEWEVNPLYC-DIVKQIYPYNSORLLNVLD  
gi|11359998| PRLSVNPWIRSYTLAG-KEEWEVNPLYC-DIVKQIYPYNSORLLNVLD  
gi|14776441| PRLSVNPWIRSYTLAG-KEEWEVNPLYC-DIVKQIYPYNSORLLNVLD  
gi|9368881| KRKTWRNPWIRSYHKRK-KAEWEVDPDYC-EEVKQTPPYDSHRLDVMVD  
gi|13385516| KRKTWRNPWIRSYHKRK-KAEWEVDPDYC-EEVKQTPPYDSGHRLLDVMVD  
gi|7504833| PRKHNRSPYRRTYSKKNQVAEWQSEMNVCTDKVKTKRQAHGRLLDVMVD

410 420 430 440 450  
.....|.....|.....|.....|.....|.....|.....|.....|.....|.....|  
NOV 2 MAIFDFLIGNMDRHHYEMETKFGDD-GFLIHLDNARGFGRSHDEISILS  
gi|11359998| MAIFDFLIGNMDRHHYEMETKFGDD-GFLIHLDNARGFGRSHDEISILS  
gi|14776441| MAIFDFLIGNMDRHHYEMETKFGDD-GFLIHLDNARGFGRSHDEISILS  
gi|9368881| MTIFDFLIGNMDRHHYETFEKFGNE-TFLIHLDNARGFGRSHDEISILV  
gi|13385516| MTIFDFLIGNMDRHHYETFEKFGNE-TFLIHLDNARGFGRSHDEISILA  
gi|7504833| THILDFLIGNMDRHHYETFEKFGNE-TFLIHLDNARGFGRSHDEISILV

460 470 480 490 500  
.....|.....|.....|.....|.....|.....|.....|.....|.....|.....|  
NOV 2 PLSQCCMIKKKTLHLQLLAQADYRLSDVMRESILLEDQLSPVLTEPHLLA  
gi|11359998| PLSQCCMIKKKTLHLQLLAQADYRLSDVMRESILLEDQLSPVLTEPHLLA  
gi|14776441| PLSQCCMIKKKTLHLQLLAQADYRLSDVMRESILLEDQLSPVLTEPHLLA

```

gi|9368881| PLOCCCRIRKSTYLRLOLLAKEEYKLSLLMAESIRGDOVAPVLYOPHLEA
gi|13385516| PPHQCCRTIRKSTYLRLOLLAKEEYKLSLLMAESIRGDOVAPVLYOPHLEA
gi|7504833| PLOCCCLRPSYFQTLNMFYSTPKSLTKALHESLSKDPAPPTLAXKHYPY

          510      520      530      540      550
NOV 2      LDRRLQTLRLTVEGCTVAHGQOSVIVDGPVEQSAPDSGQANLTS-----
gi|11359998| LDRRLQTLRLTVEGCTVAHGQOSVIVDGPVEQSAPDSGQANLTS-----
gi|14776441| LDRRLQTLRLTVEGCTVAHGQOSVIVDGPVEQSAPDSGQANLTS-----
gi|9368881| LDRRLRVWLKAVRDCVERDGLHSVVDOLDTEHRAASAR-----
gi|13385516| LDRRLRVWLQAVRDCVERDGLSSVVEDDLATEHRASTER-----
gi|7504833| MERRIAKIMSHILECFESRGVAEVLVAEYNNPDVSDAEONDEEQSEEHQD

NOV 2      .....
gi|11359998| -----
gi|14776441| -----
gi|9368881| -----
gi|13385516| -----
gi|7504833| KKDDKKTV

```

The above defined information for NOV2 suggests that the NOV2 protein may function as a member of a family of novel secreted proteins related to angiogenesis. Therefore, the NOV2 nucleic acids and proteins of the invention are useful in potential therapeutic applications implicated in various diseases and disorders described below and/or other pathologies. For example, the NOV2 compositions of the present invention will have efficacy for treatment of patients suffering from abnormal angiogenesis, such as cancer and more specifically, aggressive, metastatic cancer, including tumors of the lungs, kidneys, brain, liver and breasts. The NOV2 nucleic acid encoding secreted proteins related to angiogenesis, and the secreted proteins related to angiogenesis of the invention, or fragments thereof, may further be useful in diagnostic applications, wherein the presence or amount of the nucleic acid or the protein are to be assessed.

### NOV3

A disclosed NOV3 nucleic acid of 1869 nucleotides (also referred to as SC124141642\_A) encoding a novel leucine rich-like protein is shown in Table 3A. An open reading frame was identified beginning with a ATG initiation codon at nucleotides 17-19 and ending with a TGA codon at nucleotides 1841-1843. Putative untranslated regions upstream from the initiation codon and downstream from the termination codon are underlined in Table 3A. The start and stop codons are in bold letters.

**Table 3A. NOV3 Nucleotide Sequence (SEQ ID NO:5)**

```

CTCCCCGCCGCCGCGCATGTGCGCAGGAGGATGGTGGCCGCGCCCTAGGCCACGCTCCGCACCATGACCTGCTGGCTGT
GCGTCCTGAGCCTGCCCTGTCTCTGCTGCCCGCGCGCGCCCGCGCTGGAGGCTGCCCGGCCGCTGCGAGTGCACC
GTGCAGACCGCGCGGTGGCTGCACGCGCGCGCGCTGACCGCGTGCCTGCGGACGCGCATCCCGGCCGAGACCGCTGCT
GGAGCTCAGCCGCAACCGCATCCGCTGCTGAACCGGGCGACCTGGCCGCGCTGCCCGCGCTGGAGGAGCTGGACCTGA
GCGAGAACGCCATCGCGCACGTGGAGCCCGCGCGCTTCGCCAACCTGCCCGCGCTGCGCGTCTGCGTCTCGGTGGCAAC
CAGCTGAAGTCTATCCCGCCCGGGGTCTTCACGCGCTGGACAACCTCAGCTGCTGGACCTGAGCGAGAACAGCTGGT

```

The disclosed NOV3 nucleic acid sequence maps to chromosome 19 and has 917 of 1521 bases (60%) identical to an insulin-like growth factor binding mRNA from Papio (GENBANK-ID: S83462) ( $E = 2.8e^{-42}$ ).

10

MCAGGWWRGPRPTLRTMTWCVLVSLPLLLLPAAPPPAGGCPARCECTVQTRAVACTRRRLTAVPDGTPAET  
RLEELSRNRIRCLNPGDLAALPALEELDSEGNIAHVEPGAFAFLPRLVLRLRGNQKLKIPPGVFTRLDNL  
TLDLSENKLVLILDDYTFQDLHSLRRLEVGDNLDLVFVSRRAGFALLALEELTLRCLNLTALSSEGLHRLSL  
GALRLHLAIASLEDQNFRLPLGLLHLEIDNWPLLEEVAAGSLRGNLTLSVTHHTNITAVPAALRHQAHL  
TCLNLSHNPISTVPRGSFDFLVLRELHLAALLAVVEPQAFGLGRQIRLNLNSNLSTLEESTFHSVNTL  
ETLRVDGNPLACDCLLLWIVQRRKTLNFDGRLPACATPAEVRGDALRNLPDSVLFYFVCRKPKIRERRLQR  
VTATAGEDVRFCLRAEGEPAPTVAWVTPQHRPVTATAGRARVLPGGTLEIQDARQDSGTYTCVASNAGGN  
DTYFATLVSRPEAPANRTPGEAHNETLAALRALPLDLTTILVSTAMGCITFLGVVLFCEVLLFWWSRGRGQHK  
NNFSVEYSFRKVDGPAAAAGCGGARKFLMMKMI

15

20

31

Table 3C. BLAST results for NOV3

Gene Index/ Identifier	Protein/ Organism	Length (aa)	Identity (%)	Positives (%)	Expect
<a href="#">gi 12309630 emb CAC22713.1 </a> (AL353746)	bA438B23.1 (neuronal leucine-rich repeat protein) [Homo sapiens]	606	339/603 (56%)	439/603 (72%)	0.0
<a href="#">gi 15301270 ref XP_053144.1 </a>	hypothetical protein XP_053144 [Homo sapiens]	614	333/621 (53%)	427/621 (68%)	1e-169
<a href="#">gi 9651089 dbj BAB03557.1 </a> (AB046639)	hypothetical protein [Macaca fascicularis]	614	332/621 (53%)	427/621 (68%)	1e-168
<a href="#">gi 12832048 dbj BAB32403.1 </a> (AK027262)	putative [Mus musculus]	614	332/621 (53%)	425/621 (67%)	1e-168
<a href="#">gi 14754729 ref XP_047947.1 </a>	hypothetical protein FLJ14594 [Homo sapiens]	315	159/314 (50%)	211/314 (66%)	5e-75

The homology of these sequences is shown graphically in the ClustalW analysis shown in Table 3D.

Table 3D. ClustalW Analysis of NOV3

- 1) NOV2 (SEQ ID NO:4)
- 2) [gi|12309630|emb|CAC22713.1|](#) (AL353746) bA438B23.1 (neuronal leucine-rich repeat protein) [Homo sapiens] (SEQ ID NO:76)
- 2) [gi|15301270|ref|XP\\_053144.1|](#) hypothetical protein XP\_053144 [Homo sapiens] (SEQ ID NO:77)
- 3) [gi|9651089|dbj|BAB03557.1|](#) (AB046639) hypothetical protein [Macaca fascicularis] (SEQ ID NO:78)
- 4) [gi|12832048|dbj|BAB32403.1|](#) (AK027262) putative [Mus musculus] (SEQ ID NO:79)
- 5) [gi|14754729|ref|XP\\_047947.1|](#) hypothetical protein FLJ14594 [Homo sapiens] (SEQ ID NO:80)

	10	20	30	40	50
NOV 3	MCAGG	WNRGPR	ETLR	TMT	CWLCVLS
gi 12309630	-----	MLHT---	ALSCW	QPF	LGLAV
gi 15301270	MLAGG	VRSMPSP	---	LLACW	QPI
gi 9651089	MLAGG	VRSMPSP	---	LLACW	QPI
gi 12832048	MLAGG	VRSMPSP	---	LLACW	QPI
gi 14754729	-----	-----	-----	-----	-----
	60	70	80	90	100
NOV 3	TRAV	CTRRRL	TA	VPGIP	AE
gi 12309630	NKSV	CHRRRL	TA	PEGIP	ET
gi 15301270	DRAV	CHRRRL	TA	VPGIP	ET
gi 9651089	DRAV	CHRRRL	TA	VPGIP	ET
gi 12832048	DRAV	CHRRRL	TA	VPGIP	ET
gi 14754729	-----	-----	-----	-----	-----
	110	120	130	140	150
NOV 3	LS	EN	ATAH	VEPG	AFA
gi 12309630	LS	EN	ATAH	VEPG	AFA
gi 15301270	LS	EN	ATAH	VEPG	AFA
gi 9651089	LS	EN	ATAH	VEPG	AFA
gi 12832048	LS	EN	ATAH	VEPG	AFA
gi 14754729	-----	-----	-----	-----	-----



gi | 12309630 | LSDNLTANVEPGAFNNLENLRSLRLKGNRLKLVPLGVFTGLSNLTKLDIS  
gi | 15301270 | LNENIVSAVEPGAFNNLENLRSLRLKGNRLKLVPLGVFTGLSNLTKLDIS  
gi | 9651089 | LNENIVSAVEPGAFNNLENLRSLRLKGNRLKLVPLGVFTGLSNLTKLDIS  
gi | 12832048 | LNENIVSAVEPGAFNNLENLRSLRLKGNRLKLVPLGVFTGLSNLTKLDIS  
gi | 14754729 |

160 170 180 190 200  
NOV 3  
gi | 12309630 | ENKIVILLDYTFQDLHSLRLLEVGDNDLVYISHRAFSGILSLEQLTLEKC  
gi | 15301270 | ENKIVILLDYMFQDLNLKSLEVGDNDLVYISHRAFSGILSLEQLTLEKC  
gi | 9651089 | ENKIVILLDYMFQDLNLKSLEVGDNDLVYISHRAFSGILSLEQLTLEKC  
gi | 12832048 | ENKIVILLDYMFQDLNLKSLEVGDNDLVYISHRAFSGILSLEQLTLEKC  
gi | 14754729 |

210 220 230 240 250  
NOV 3  
gi | 12309630 | NLTAISGESLGHLSLGLRLRLRLATASLEDQNFRLPGLLHLETONWPL  
gi | 15301270 | NLTAIVTEALSHLRSLISLHLKHLNINMPVYAFKRLVHLKHLETDYWP  
gi | 9651089 | NLTSIPTEALSHLHGLIVRLRLHLNINATRDYSFKRLVRLKVLEISHWPY  
gi | 12832048 | NLTSIPTEALSHLHGLIVRLRLHLNINATRDYSFKRLVRLKVLEISHWPY  
gi | 14754729 |

260 270 280 290 300  
NOV 3  
gi | 12309630 | LEEVAAGSLRGLNLTSLSVTHNLTAVPAAALREOHLTGLNLSNPIST  
gi | 15301270 | LDMMPANSLYGLNLTSLSVTHNLSTVPELAFKHLVYLTHNLNLSNPIST  
gi | 9651089 | LDTMTFPCLYGLNLTSLSITHONLTAVPELAVRHLVYLRLNLSNPIST  
gi | 12832048 | LDTMTFPCLYGLNLTSLSITHONLTAVPELAVRHLVYLRLNLSNPIST  
gi | 14754729 |

310 320 330 340 350  
NOV 3  
gi | 12309630 | VPRGSFRDLVRLREBELACALLAVVEPAFLGLRQIRLNLNLSNQLTLE  
gi | 15301270 | IEAGMPSDLRLQEIQLVGGQLAVVEPYAFRGLNLYRLVNLVSGNQLTLE  
gi | 9651089 | IEGLMLHELLRLQEIQLVGGQLAVVEPYAFRGLNLYRLVNLVSGNQLTLE  
gi | 12832048 | IEGLMLHELLRLQEIQLVGGQLAVVEPYAFRGLNLYRLVNLVSGNQLTLE  
gi | 14754729 | ----MLHELLRLQEIQLVGGQLAVVEPYAFRGLNLYRLVNLVSGNQLTLE

360 370 380 390 400  
NOV 3  
gi | 12309630 | ESTFHSVNTLETIRVDCNPLACDCRLLWVFRRLNLFQGLPACATPAE  
gi | 15301270 | ENVFSSPRALEVLSNNPLACDCRLLWVFRRLNLFQGGQPMACGPDIT  
gi | 9651089 | ESVFHSVGNLETLLDSNPLACDCRLLWVFRRLNLFNROQPTCATPEF  
gi | 12832048 | ESAFHSVGNLETLLDSNPLACDCRLLWVFRRLNLFNROQPTCATPEF  
gi | 14754729 | ESVFHSVGNLETLLDSNPLACDCRLLWVFRRLNLFNROQPTCATPEF

410 420 430 440 450  
NOV 3  
gi | 12309630 | VRGDALRNLPDSVLFYFVCRKPKIRERRLORVTATAGEDVRFICRAEGE  
gi | 15301270 | ITRERSFKDFHSTALSFFYFCKPKIREKKLOHTLVDEGQTVQLECSADGD  
gi | 9651089 | VQGKEFKDFPDVLLPNYFTCRRARIRDRKAQQVFVDEGHTVQFVCRADGD  
gi | 12832048 | VQGKEFKDFPDVLLPNYFTCRRARIRDRKAQQVFVDEGHTVQFVCRADGD  
gi | 14754729 | VQGKEFKDFPDVLLPNYFTCRRARIRDRKAQQVFVDEGHTVQFVCRADGD

460 470 480 490 500  
NOV 3  
gi | 12309630 | PAPTVANVTTPQHRPVTATSAGRARVLEPGTLEIQDARPODSCTYTCVASN  
gi | 15301270 | PGPVLSWVTPRRRFTTKSNGRATVLGDGTLEDRFAQDQDSGMYVCIASN  
gi | 9651089 | PPPAILWLSPRKHLVSAKSNGRLTVFPDGTLEVRVAQVQDNGTYLCIAAN  
gi | 12832048 | PPPAILWLSPRKHLVSAKSNGRLTVFPDGTLEVRVAQVQDNGTYLCIAAN  
gi | 14754729 | PPPAILWLSPRKHLVSAKSNGRLTVFPDGTLEVRVAQVQDNGTYLCIAAN

510 520 530 540 550

NOV 3	AGGNDTYFATLTVRPE-E---AANRTPGEAHN-----ETLAAIRAP
gi 12309630	AAGNDIFTASLTIVKGFASDRFLYANRTPMYMTD-SNDTISNGTNANT-ES
gi 15301270	AGGNDSPAHLLHVRSYSPDWPHQPNKTFATLSNQPGEGEANSTRATVPFP
gi 9651089	AGGNDSPAHLLHVRSYSPDWPHQPNKTFATLSNQPGEGEANSTRATVPFP
gi 12832048	AGGNDSPAHLLHVRSYSPDWPHQPNKTFATLSNQPGEGEANSTRATVPFP
gi 14754729	AGGNDSPAHLLHVRSYSPDWPHQPNKTFATLSNQPGEGEANSTRATVPFP
	560 570 580 590 600
NOV 3	LDLTLIIIVSTAMGCTIFLGVLVFCFVLLFVWSRGRGQHKNNFSVEYSFRK
gi 12309630	LDLTLIIIVSTAMGCTIFLGVLVFCFVLLFVWSRGRGQHKNNFSVEYSFRK
gi 15301270	FDIKTLIIATTMGFISFLGVVLFCLVLLFLWSRGGKNTKHNIELEYVPRK
gi 9651089	FDIKTLIIATTMGFISFLGVVLFCLVLLFLWSRGGKNTKHNIELEYVPRK
gi 12832048	FDIKTLIIATTMGFISFLGVVLFCLVLLFLWSRGGKNTKHNIELEYVPRK
gi 14754729	FDIKTLIIATTMGFISFLGVVLFCLVLLFLWSRGGKNTKHNIELEYVPRK
	610 620
NOV 3	VDGPAAAGQGGARKFNMKMI
gi 12309630	NNGAIVVEGEVAGPRRFNMKMI
gi 15301270	SDAGISS--ADAPRKFNMKMI
gi 9651089	SDAGISS--ADAPRKFNMKMI
gi 12832048	SDAGISS--ADAPRKFNMKMI
gi 14754729	SDAGISS--ADAPRKFNMKMI

Tables 3E-3G list the domain description from DOMAIN analysis results against NOV3. This indicates that the NOV3 sequence has properties similar to those of other proteins known to contain these domains.

5

Table 3E Domain Analysis of NOV3

gnl|Smart|smart00409, IG, Immunoglobulin (SEQ ID NO:81)  
 Length = 86 residues, 97.7% aligned  
 Score = 71.2 bits (173), Expect = 2e-13

NOV3	431	QRVTATAGEDVRFLCRAEGEPAPTVAVVTPQHRPVTATSAGRARVLPG-GTLEIQDARPO	489
		+ + +       +   +	
Smart00409	2	PSVTVKEGESVTLSCASGNPPPTVTWYKQGGKLLAESGRFSVSRSGGNSTLTISNVTPE	61
NOV3	490	DSGYTTCVASNAGGNDTYFATLTV	513
		+   +   +	
Smart00409	62	DSGYTTCATNSSGSASSGTTLTV	85

Table 3F Domain Analysis of NOV3

gnl|Smart|smart00408, IGc2, Immunoglobulin C-2 Type (SEQ ID NO:82)  
 Length = 63 residues, 96.8% aligned  
 Score = 57.8 bits (138), Expect = 2e-09

NOV3	438	GEDVRFLCRAEGEPAPTVAVVTPQHRPVTATSAGRARVLPGGTLEIQDARPDQSGTYTCV	497
		+   +                 +	
Smart00408	3	GESVTLTCPASGDPVPNITWLKDGK-----LPESRVVASGSLTIKNVSLEDSGLYTCV	57
NOV3	498	ASNAGG	503
		+	
Smart00408	58	ARNSVG	63

**Table 3G Domain Analysis of NOV3**

gnl|Pfam|pfam00047, ig, Immunoglobulin domain. Members of the immunoglobulin superfamily are found in hundreds of proteins of different functions. Examples include antibodies, the giant muscle kinase titin and receptor tyrosine kinases. Immunoglobulin-like domains may be involved in protein-protein and protein-ligand interactions. The Pfam alignments do not include the first and last strand of the immunoglobulin-like domain. (SEQ ID NO:83)  
 Length = 68 residues, 100.0% aligned  
 Score = 43.5 bits (101), Expect = 3e-05

```
NOV3      438  GEDVRFLCRAEG-EPAPTVAWVTPQHRPVTATSAGRARVLPGG-----TLEIQDARPO  489
          ||| || | | | ||| |+ | + || || | | | | + |
Pfam00047  1   GESVTLTCSVSGYPDPPTVTWLRDGKEIELLGSSSE-SRVSSGGRFSSISLSLTISSTVPE  59

NOV3      490  DSGTYTCVA  498
          |||||
Pfam00047  60  DSGTYTCVV  68
```

Leucine rich-like proteins generally comprise leucine-rich repeats (LRRs), relatively short motifs (22-28 residues in length) found in a variety of cytoplasmic, membrane and extracellular proteins. Although these proteins are associated with widely different functions, a common property involves protein-protein interaction. Although little is known about the 3-D structure of LRRs, it is believed that they can form amphipathic structures with hydrophilic surfaces capable of acting with membranes. In vitro studies of a synthetic LRR from *Drosophila* Toll protein have indicated that the peptides form gels by adopting beta-sheet structures that form extended filaments. These results are consistent with the idea that LRRs mediate protein-protein interactions and cellular adhesion. Other functions of LRR-containing proteins include, for example, binding to enzymes and vascular repair. The 3-D structure of ribonuclease inhibitor, a protein containing 15 LRRs, has been determined, revealing LRRs to be a new class of alpha/beta fold. LRRs form elongated non globular structures and are often flanked by cysteine-rich domains.

Leucine-rich-like proteins have been shown to be involved in protein-protein interactions that result in protein complexes, receptor ligand binding or cell adhesion. Leucine rich-like proteins have been shown to be useful in potential therapeutic applications implicated in lymphatic diseases, skin and connective tissue diseases, diabetes and kidney diseases, cancers, tumors and brain disorders, disorders that can be addressed by controlling and directing cell migration, Alzheimer's disease, stroke, tuberous sclerosis, hypercalcemia, Parkinson's disease, Huntington's disease, cerebral palsy, epilepsy, Lesch-Nyhan syndrome, multiple sclerosis, ataxia telangiectasia, leukodystrophies, behavioral disorders, addition, anxiety, pain, neuroprotection, inflammatory bowel disease, diverticular disease and Crohn's disease. These proteins and nucleic acids are further useful in the generation of antibodies for use in therapeutic or diagnostic methods.

The above defined information for NOV3 suggests that this leucine-rich protein may function as a member of a leucine-rich protein family. Therefore, the NOV3 nucleic acids and proteins of the invention are useful in potential therapeutic and diagnostic applications. For example, a cDNA encoding the NOV3 protein may be useful in gene therapy, and the NOV3 protein may be useful when administered to a subject in need thereof. By way of nonlimiting example, the compositions of the present invention will have efficacy for treatment of patients suffering from Lymphatic Diseases, Skin and Connective Tissue Diseases, Diabetes and Kidney Disease, Cancers, tumors, and Brain Disorders, disorders that can be addressed by controlling and directing cell migration, Alzheimer's disease, Stroke, Tuberous sclerosis, hypercalcaemia, Parkinson's disease, Huntington's disease, Cerebral palsy, Epilepsy, Lesch-Nyhan syndrome, Multiple sclerosis, Ataxia-telangiectasia, Leukodystrophies, Behavioral disorders, Addiction, Anxiety, Pain, Neuroprotection, Inflammatory bowel disease, Diverticular disease, and Crohn's Disease. The NOV3 nucleic acid encoding leucine-rich protein, and the leucine-rich protein of the invention, or fragments thereof, may further be useful in diagnostic applications, wherein the presence or amount of the nucleic acid or the protein are to be assessed.

#### NOV4

A disclosed NOV4 nucleic acid of 1049 nucleotides (designated CuraGen Acc. No. GMba39917\_A) encoding a novel cathepsin-L precursor-like protein is shown in Table 4A. An open reading frame was identified beginning with an ATG initiation codon at nucleotides 37-39 and ending with a TGA codon at nucleotides 1036-1038. Putative untranslated regions upstream from the initiation codon and downstream from the termination codon are underlined in Table 4A, and the start and stop codons are in bold letters.

**Table 4A. NOV4 Nucleotide Sequence (SEQ ID NO:7)**

```

ATCCTCATTTCCTTTCCCTTCCTAGATTTTGGAAACATGAATCCTTCACTCCTCCTGGCTGCCTTTTGCC
TGGGAATTGCCTCAGCTGCTCTAACACGTGACCACAGTTTAGACGCACAATGGACCAAGTGAAGGCAAA
GCACAAGAGATTATATGGCATGAATGGAGAAGGATGGAGAAGGAGCTGTGGGAGAAGGACGTGAAGATG
ATTGAGCAGCACAATCAGGAATACAGCCAAGGGAAACACAGCTTCACAATGGCCATGAACGCCTTTGGAG
ACATGGTAAGTGAAGAATTCAGGCAGGTGATGAATGGTTTCAATACCAGAAGCACAGGAAGGGGAAACA
GTTCCAGGAACGCCTGCTTCTGAGATCCCCACATCTGTGGACTGGAGAGAGAAAGGCTACATGACTCCT
GTGAAGGATCAGGGTCAGTGTGGCTCTTGTGGGCTTTAGTGCAACTGGTGCCTCTGGAAGGGCAGATGT
TTTGAAAAACAGGCAAACTTATCTCACTGAATGAGCTCAATCTGGTAGACTGCTCTGGGCCTCAAGGCAA
TGAAGGCTGCAATGGTGGCTTGATGAACTATCATTTTGAATTTGTTTCAGGACCACTCTGGGCAAGAAAGT
GAGACCTCATATCCTCTTGAAAGTAAGGTTAAACCTGTAGGTACAATCCCAAGTATTCTGCTGCTAATG
ACACTGGTTTGTGGACATCCCTTCACGGGAGAAGGACCTGGCGAAGGCAGTGGCAACTGTGGGGCCCAT
CTCTGTTGCTGTTGGTGAAGCCATGTCTTCTCCAGTTCTATAAAAAAGGTATTATTTTGAGCCACGC
TGTGACCTGAAGGCTGGATCATGCTATGCTGGTGGTGGCTACAGCTATGAAGGAGCAGACTCAGATA
ACAATAAATATTGGCTGGTGAAGACAGCTGGGGTAAAACTGGGGCATGGATGGCTACATAAAGATGGC
CAAAGACCGGAGGAACAACGTGGAATTGCCACAGCAGCCAGCTACCCCACTGTGTGAGCTGATGGATG

```

The nucleic acid sequence of NOV4, localized on chromosome 10, has 876 of 1022 bases (85%) identical to a *Homo sapiens* Cathepsin-L Precursor mRNA (GENBANK-ID: HSCATHL) ( $E = 2.6e^{-164}$ ).

A NOV4 polypeptide (SEQ ID NO:8) encoded by SEQ ID NO:7 is 333 amino acid residues and is presented using the one letter code in Table 4B. Signal P, Psort and/or Hydropathy results predict that NOV4 contains signal peptide and is likely to be localized at the plasma membrane with a certainty of 0.8200. The most likely cleavage site for a NOV4 peptide is between amino acids 17 and 18, at: ASA-AL.

**Table 4B. NOV4 protein sequence (SEQ ID NO:8)**

MNPSLLLAAPCLGIIASAALTRDHSLDAQWTKWAKHKRLYGMNGEGWRRSCWEKDVKMIEQHNQEYS QGKHSFTMAMNAFGDMVSEEFQVMNGFQYQKHKRGKQFQERLLPEIPTSDWREKGYMTPVKDQGG CGSCWAFSATGALEGMFWKTGKLIISLNEINLVDCSGPQGNEGCNGGLMNYHFEFVQDHSGQESETS YPLESKVKTCRYNPKYSAANDTGFDIPSREKDLAKAVATVGPIISVAVGASHVFFQFYKKGIFYFEPR CDPEGLDHAMLVVGYSEYEGADSDNNKYWLVKNSWGNWGMGDIKMAKDRRNNGIATAASYPTV
--

The NOV4 amino acid sequence has 256 of 33 amino acid residues (76%) identical to, and 288 of 333 residues (86%) positive with, the *Homo sapiens* 333 amino acid residue Cathepsin-L Precursor protein (P07711) ( $E = 2.1e^{-144}$ ). The global sequence homology is 80.781% amino acid homology and 76.877% amino acid identity.

NOV4 is expressed in at least the following tissues: Musculoskeletal System, Bone, Female Reproductive System, Placenta, Endocrine System, Adrenal Gland/Suprarenal gland, Respiratory System, Lung, Hematopoietic and Lymphatic System, Hematopoietic Tissues, Lymphoid tissue, Spleen, Gastro-intestinal/Digestive System, Liver, Whole Organism, Cardiovascular System, Adipose, Nervous System, Brain, Male Reproductive System, Testis. In addition, NOV4 is predicted to be expressed in the following tissues because of the expression pattern of a closely related *Sus scrofa* cathepsin L precursor homolog (GENBANK-ID: PIGPCL): Musculoskeletal System, Bone, Female Reproductive System, Placenta, Endocrine System, Adrenal Gland/Suprarenal gland, Respiratory System, Lung, Hematopoietic and Lymphatic System, Hematopoietic Tissues, Lymphoid tissue, Spleen, Gastro-intestinal/Digestive System, Liver, Whole Organism, Cardiovascular System, Adipose, Nervous System, Brain, Male Reproductive System and Testis.

NOV4 also has homology to the amino acid sequences shown in the BLASTP data listed in Table 4C.

Table 4C. BLAST results for NOV4					
Gene Index/ Identifier	Protein/ Organism	Length (aa)	Identity (%)	Positives (%)	Expect
gi 15214962 gb AAH12612.1 AAH12612 (BC012612)	Similar to cathepsin L [Homo sapiens]	333	257/333 (77%)	288/333 (86%)	1e-153
gi 4503155 ref NP_01903.1	cathepsin L [Homo sapiens]	333	256/333 (76%)	288/333 (85%)	1e-152
gi 11493685 gb AAG35605.1 AF201700_1 (AF201700)	cysteine protease [Cercopithecus aethiops]	333	252/333 (75%)	285/333 (84%)	1e-150
gi 5822035 pdb 1CS8 A	Chain A, Crystal Structure Of Procathepsin L	316	239/316 (75%)	270/316 (84%)	1e-140
gi 10185020 emb CAC08809.1  (AJ279008)	cathepsin L [Canis familiaris]	333	243/334 (72%)	276/334 (81%)	1e-140

The homology of these sequences is shown graphically in the ClustalW analysis shown in Table 4D.

Table 4D ClustalW Analysis of NOV4

- 1) NOV4 (SEQ ID NO:8)
- 2) gi|15214962|gb|AAH12612.1|AAH12612 (BC012612) Similar to cathepsin L [Homo sapiens] (SEQ ID NO:84)
- 3) gi|4503155|ref|NP\_001903.1| cathepsin L [Homo sapiens] (SEQ ID NO:85)
- 4) gi|11493685|gb|AAG35605.1|AF201700\_1 (AF201700) cysteine protease [Cercopithecus aethiops] (SEQ ID NO:86)
- 5) gi|5822035|pdb|1CS8|A Chain A, Crystal Structure Of Procathepsin L (SEQ ID NO:87)
- 6) gi|10185020|emb|CAC08809.1| (AJ279008) cathepsin L [Canis familiaris] (SEQ ID NO:88)

	10	20	30	40	50
NOV 4	.....	.....	.....	.....	.....
gi 15214962	MNPSLFLAALCLGIASAA	LTDRHSLDAQWTKWK	AKHRRLYGMNCEGWRRS		
gi 4503155	MNPTLLAALCLGIASAT	LTDFHSLDAQWTKWK	AMHNRLYGMNEEGWRRR		
gi 11493685	MNPTLLAALCLGIASAT	LTDFHSLDAQWTKWK	AMHNRLYGMNEEGWRRR		
gi 5822035	-----	SLTFDHSLEAQWTK	WKAMHNRLYGMNEEGWRRR		
gi 10185020	MNPSLFLAALCLGIASAA	PKFDOSLNAQWYQWK	ATHRRLYGMNEEGWRRR		
	60	70	80	90	100
NOV 4	.....	.....	.....	.....	.....
gi 15214962	QWEKDVKMIECHNQEYS	QGGKHSFTMAMNAFGDM	VSEEFQVMNGFQYQKH		
gi 4503155	VWEKNVKMIELHNQEYR	EGKHSFTMAMNAFGDM	TSEEFQVMNGFQNRKP		
gi 11493685	VWEKNMKMIELHNQEYR	EGKHSFTMAMNAFGDM	TSEEFQVMNGFQNRKP		
gi 5822035	VWEKNMKMIELHNQEYR	EGKHSFTMAMNAFGDM	TSEEFQVMNGFQNRKP		
gi 10185020	VWEKNMKMIELHNREYR	SGGKHGFTMAMNAFGDM	TNEEFQVMNGFQNRKH		
	110	120	130	140	150
NOV 4	.....	.....	.....	.....	.....
gi 15214962	RKGKVFQEPFLFYEA	PRSVDWREKGYVTPV	KNQGCQGSWAFSATGA	LEGGQ	
gi 4503155	RKGKVFQEPFLFYEA	PRSVDWREKGYVTPV	KNQGCQGSWAFSATGA	LEGGQ	
gi 11493685	RKGKVFQEPFLFYEA	PRSVDWREKGYVTPV	KNQGCQGSWAFSATGA	LEGGQ	
gi 5822035	RKGKVFQEPFLFYEA	PRSVDWREKGYVTPV	KNQGCQGSWAFSATGA	LEGGQ	
gi 10185020	RKGKVFQEPFLFYEA	PRSVDWREKGYVTPV	KNQGCQGSWAFSATGA	LEGGQ	
	160	170	180	190	200
NOV 4	.....	.....	.....	.....	.....
gi 15214962	MEWKTGRLISLSEQL	NLVDCSGPQGNEGCN	GGLMNYHFFVQDHS	CGQESSE	
	MEWKTGRLISLSEQL	NLVDCSGPQGNEGCN	GGLMNYHFFVQDHS	CGQESSE	

gi 4503155	MFRKTGRLLISLSEQNLVDCSGPQGNCGGGLMDYAFQYVQDNGGLDSEE
gi 11493685	MFRKTGRLLISLSEQNLVDCSGPQGNCGGGLMDYAFQYVQDNGGLDSEE
gi 5822035	MFRKTGRLLISLSEQNLVDCSGPQGNCGGGLMDYAFQYVQDNGGLDSEE
gi 10185020	MFRKTGRLLISLSEQNLVDCSRAQGNCGGGLMDYAFQYVQDNGGLDSEE
<div> <div>210220230240250</div> <div> <div>NOV 4</div> <div> <div>SYPLES-KVKTCTRYNPKYSAANDTGFDIPSRKDLAKAVATVGPISVAI</div> <div>gi 15214962 SYPYEA-TEESCKYNPKYSVANDTGFDIPKQEKALMKAVATVGPISVAI</div> <div>gi 4503155 SYPYEA-TEESCKYNPKYSVANDTGFDIPKQEKALMKAVATVGPISVAI</div> <div>gi 11493685 SYPYEA-TEESCKYNPKYSVANDTGFDIPKQEKALMKAVATVGPISVAI</div> <div>gi 5822035 SYPYEA-TEESCKYNPKYSVANDTGFDIPKQEKALMKAVATVGPISVAI</div> <div>gi 10185020 SYPYLGRDTETCTNPKPECSAANDTGFDIPKQEKALMKAVATVGPISVAI</div> </div> </div> </div>	
<div> <div>260270280290300</div> <div> <div>NOV 4</div> <div> <div>GASHVFFQFYKKGIFYFEPDCDPEGLDHAMLVVGYSYEGADSDNNKYWLVK</div> <div>gi 15214962 DAGHESFFFYKEGIYFEPDCSSEDMDHGVLVVGYGFESTESDNNKYWLVK</div> <div>gi 4503155 DAGHESFFFYKEGIYFEPDCSSEDMDHGVLVVGYGFESTESDNNKYWLVK</div> <div>gi 11493685 DAGHESFFFYKEGIYFEPDCSSEDMDHGVLVVGYGFESTESDNNKYWLVK</div> <div>gi 5822035 DAGHESFFFYKEGIYFEPDCSSEDMDHGVLVVGYGFESTESDNNKYWLVK</div> <div>gi 10185020 DAGHESFFFYKSGIFYFEPDCSSEDMDHGVLVVGYGFESTESDNNKYWLVK</div> </div> </div> </div>	
<div> <div>310320330</div> <div> <div>NOV 4</div> <div> <div>NSWGNWGMGGYVKMAKDRRNHCGIATAASYPTV</div> <div>gi 15214962 NSWGEWGMGGYVKMAKDRRNHCGIATAASYPTV</div> <div>gi 4503155 NSWGEWGMGGYVKMAKDRRNHCGIATAASYPTV</div> <div>gi 11493685 NSWGEWGMGGYVKMAKDRRNHCGIATAASYPTV</div> <div>gi 5822035 NSWGEWGMGGYVKMAKDRRNHCGIATAASYPTV</div> <div>gi 10185020 NSWGEWGMGGYVKMAKDRRNHCGIATAASYPTV</div> </div> </div> </div>	

- 5 Tables 4E and 4F list the domain description from DOMAIN analysis results against NOV4. This indicates that the NOV4 sequence has properties similar to those of other proteins known to contain these domains.

Table 4E. Domain Analysis of NOV4

gnl|Pfam|pfam00112, Peptidase\_C1, Papain family cysteine protease (SEQ ID NO:89)  
 Length = 220 residues, 100.0% aligned  
 Score = 266 bits (680), Expect = 1e-72

NOV4	114	IPTSVDWREKG-YMTPVKDQGCSCWAFSATGALEGQMFWKTG-KLISLNEELNVDCSG	171
Pfam00112	1	LPESFDWRDKGAVTPVKDQGCSCWAFSAVGALEGRYCIKTGGKLVSLSEQQLVDCSG	60
NOV4	172	PQGNCGGGLMNYHFEFVQDHSQSESTSYPLESK-VKTCRYNPKYS--AANDTGFDI	228
Pfam00112	61	D--NNGCNGGLPDNAFEYIIKG-GLPTESDYPTTGKGGTCKKNCKNSKNYAKIKGYGDV	117
NOV4	229	PSR-EKDLAKAVATVGPISVAVGASHVFFQFYKKGIFYFEPDCDPEGLDHAMLVVGYSYEG	287
Pfam00112	118	PNDEEALQAALATNGPVSVAIDAYEDDFQLYKSGIYKHTECGGENLDHAVLIVGYGTD-	176
NOV4	288	ADSDNNKYWLVKNSWGNWGMGGYVKMAKDRRNHCGIATAASYPT	332
Pfam00112	177	-GDGGKPYWIVKNSWGTWGENGYFRIARGGNNECGIASEASYPI	220

**Table 4F. Domain Analysis of NOV4**

gnl|Smart|smart00645, Pept\_C1, Papain family cysteine protease (SEQ ID NO:90)  
 Length = 218 residues, 100.0% aligned  
 Score = 251 bits (640), Expect = 6e-68

NOV4	114	IPTSVDWREKGYMTPVKDQGGQCGSCWAFSATGALEGQMFWKTG-KLISLNLNLVDCSGP	172
Smart0645	1	LPESFDWRKKGAVTFVKDQGGQCGSCWAFSATGALEGRYCIKTGGKLVSLSEQQLVDCSGG	60
NOV4	173	QNEGCGGLMNYHFEFVQDHSGQSETSYPLESK-VKTCRYNPKYSAA---NDTGFVDI	228
Smart0645	61	-GNNGCNGGLPDNAFEYIKKNGGLGTESCYPYTGKDGGPCPYTPKCSKKCVSGIKGYDVP	119
NOV4	229	PSREKDLAKAVATVGPISVAVGASHVFFQFYKKGIFYEPKCDPEGLDHAMLVVGYSYEGA	288
Smart0645	120	YNDEILKEAVANGGPPVSVAIDASD--FQFYKSGIYDHPGCGSGLLNHAVLIVGY---GT	174
NOV4	289	DSDNNKYWLKNSWGNWGMGDIKMAKDRRNCGI-ATAASYP	331
Smart0645	175	SENGKDYWIVKNSWGTDWGENGYFRIARGVNNECGIEASVASYP	218

Cathepsins are lysosomal proteases that are distributed in many normal tissues and are primarily responsible for intracellular catabolism and turnover. Studies suggest that cathepsin-

5 L may have some roles in terminal differentiation (PMID: 10699763, UI 20164186).

Cathepsin-L, a lysosomal cysteine proteinase belongs to the papain family. This proteinase is different from other members of the mammalian papain family cysteine proteinase in the following ways: (i) the cathepsin-L gene is activated by a variety of growth factors and activated oncogenes, (ii) procathepsin-L, a precursor form of cathepsin L is secreted from  
 10 various cells, (iii) the mRNA level of cathepsin-L is related to the in vivo metastatic potential of the transformed cells. Thus, the regulation of the cathepsin-L gene and the extracellular functions of secreted procathepsin-L are tightly coupled. (PMID: 9524064, UI:98182239).

Studies also suggest that cathepsin-L may have some roles in the terminal differentiation (PMID: 10699763, UI: 20164186). The increased level of cathepsins in tumors  
 15 together with their ability to degrade extracellular matrix protein has led to the hypothesis that they are involved in the process of invasion and metastasis. In 8 cases of dermatofibrosarcoma protuberans (DFS), five cases of atypical fibroxanthoma (AFX) and twenty cases of dermatofibroma (DF). Expression of cathepsins B and pro-D could be detected in 5 of the 8 cases (62.5%) of DFS, whereas cathepsin pro-L was found in 4 (50%) cases. All  
 20 AFX expressed cathepsin pro-L, whereas cathepsins B and pro-D were observed in 4 out of 5 cases. None of the malignant tumors showed a recurrence or metastasis after a period of four years. No expression of cathepsins in DF was found. In the epidermis and appendages, an expression of cathepsins pro-D, pro-L and B was seen. Cathepsins may be markers of



increased metabolism rather than specific markers of malignancy (PMID: 9649659, UI: 99075963).

The above defined information for NOV4 suggests that this NOV4 protein may function as a member of a cathepsin-L precursor-like protein family. Therefore, the NOV4 nucleic acids and proteins of the invention are useful in potential therapeutic applications implicated in various diseases and disorders described below and/or other pathologies. For example, the NOV4 compositions of the present invention will have efficacy for treatment of patients suffering from growth of soft tissue sarcomas; cathepsin L is induced in tumors by malignant transformation, growth factors, and tumor promoters suggesting they play an important role in tumor invasion and metastasis. Additionally, cathepsin L may be involved in bone resorption implicating possible roles in bone diseases such as osteoporosis, or bone cancers. Additional disorders include Cardiomyopathy, Atherosclerosis, Hypertension, Congenital heart defects, Aortic stenosis, Atrial septal defect (ASD), Atrioventricular (A-V) canal defect, Ductus arteriosus, Pulmonary stenosis, Subaortic stenosis, Ventricular septal defect (VSD), valve diseases, Tuberous sclerosis, Scleroderma, Transplantation, Adrenoleukodystrophy, Congenital Adrenal Hyperplasia, Diabetes, Von Hippel-Lindau (VHL) syndrome, Pancreatitis, Endometriosis, Fertility, Inflammatory bowel disease, Diverticular disease, Hirschsprung's disease, Crohn's Disease, Hemophilia, hypercoagulation, Idiopathic thrombocytopenic purpura, immunodeficiencies, Osteoporosis, Hypercalcaemia, Arthritis, Ankylosing spondylitis, Scoliosis, Endocrine dysfunctions, Diabetes, Growth and reproductive disorders, Psoriasis, Actinic keratosis, Acne, Hair growth, alopecia, pigmentation disorders, endocrine disorders. The NOV4 nucleic acid encoding cathepsin-L precursor-like protein, and the cathepsin-L precursor-like protein of the invention, or fragments thereof, may further be useful in diagnostic applications, wherein the presence or amount of the nucleic acid or the protein are to be assessed.

## NOV5

A disclosed NOV5 nucleic acid of 491 nucleotides (also referred to as GMba38118\_A) encoding a novel fatty acid-binding protein-like protein is shown in Table 5A. An open reading frame was identified beginning with an ATG initiation codon at nucleotides 10-12 and ending with a TAA codon at nucleotides 462-464. Putative untranslated regions upstream from the initiation codon and downstream from the termination codon are underlined in Table 5A, and the start and stop codons are in bold letters.

**Table 5A. NOV5 Nucleotide Sequence (SEQ ID NO:9)**

CATGCTGCCATGCCGACGTAGACCTGCTCTGCACGCCAGCCGCCGCCACCCACCATGGCCA

```

CAGTT CAGCAGCTGGAAGGAAGATGGCGCTGCTGGACAGCAAAGGCTTGTATGAATACATGA
AGGAGCTAGGAGTGGGAATAGCTTTGCAAAAAATGGGCGCAATGGCCAAGCCAGATTGTATCA
TCACTTGTGATGGCAGAAACCTCACCACAAAACCGAGAGCACTTTGAAAAACAACACAGTTT
CTTGTACCCTGGGAGATGAGTTTGAAGAAACCACAGCTGATGGCAGAAAAACACAGACTGTCT
GCAACTTTACAGATGGTGCATTGGTT CAGCATCAGGAGTGGGATGGGAAGGAAGCACATAA
CAAGAAAATTGAAAGATGGGAAATTAGTGGTGGAGTGTGTCATGAACAATGTCACCTGTACTC
GGATCTATGAAAAAGTAGAATAAAAATTCCATCATCCTTTGGACAGGAG

```

The NOV5 nucleic acid was identified on chromosome 13 and has 458 of 480 bases (97%) identical to a *Homo sapiens* Fatty Acid-Binding Protein mRNA (GENBANK-ID: HUMFABPHA) ( $E = 1.9e^{-97}$ )

- 5 A disclosed NOV5 polypeptide (SEQ ID NO:10) encoded by SEQ ID NO:9 is 135 amino acid residues and is presented using the one-letter code in Table 5B. Signal P, Psort and/or Hydropathy results predict that NOV5 does not have a signal peptide and is likely to be localized in the cytoplasm with a certainty of 0.6500.

**Table 5B. Encoded NOV5 protein sequence (SEQ ID NO:10)**

```

MATVQQLEGRWRLDLSKGFDEYMKELGVGIALQKMGAMAKPDCIITCDGRNLTTKTESTLKTTFQSCFTLGDE
FEETTADGRKTQTVCNFTDGLVQHQEWGKESTITRKLKDGKLVVECVMNNTCTRIYEKVE

```

10

The NOV5 amino acid sequence has 129 of 135 amino acid residues (95%) identical to, and 134 of 135 residues (99%) similar to, the *Homo sapiens* 135 amino acid residue Fatty Acid-Binding protein Q01469 ( $E = 6.1e^{-67}$ ). The global sequence homology is 97.037% amino acid similarity and 95.556% amino acid identity.

- 15 NOV5 is expressed in at least the following tissues: Sensory System.Skin, Nervous System.Brain, Male Reproductive System.Testis, Respiratory System.Lung, Larynx, Female Reproductive System, .Placenta, Whole Organism, Cardiovascular System.Heart, Endocrine System.Parathyroid Gland, Hematopoietic and Lymphatic System, Hematopoietic Tissues, Liver, Tonsils, Gastro-intestinal/Digestive System.Large Intestine, Colon, Stomach,
- 20 Oesophagus, Urinary System.Kidney. In addition, the NOV5 is predicted to be expressed in the following tissues because of the expression pattern of a closely related *Mus musculus* Fatty Acid-Binding Protein homolog (GENBANK-ID: ACC:Q05816): Sensory System.Skin, Nervous System.Brain, Male Reproductive System.Testis, Respiratory System.Lung, Larynx, Female Reproductive System, .Placenta, Whole Organism, Cardiovascular System.Heart,
- 25 Endocrine System.Parathyroid Gland, Hematopoietic and Lymphatic System, Hematopoietic Tissues, Liver, Tonsils, Gastro-intestinal/Digestive System.Large Intestine, Colon, Stomach, Oesophagus, Urinary System and Kidney.

NOV5 also has homology to the amino acid sequences shown in the BLASTP data listed in Table 5C.

Table 5C. BLAST results for NOV5					
Gene Index/ Identifier	Protein/ Organism	Length (aa)	Identity (%)	Positives (%)	Expect
<a href="#">gi 13651563 ref XP_015760.1</a>	similar to GASTRIN/CHOLECYST OKININ TYPE B RECEPTOR (CCK-B RECEPTOR) [Homo sapiens]	135	135/135 (100%)	135/135 (100%)	2e-65
<a href="#">gi 4557581 ref NP_01435.1</a>	fatty acid binding protein 5 (psoriasis- associated) [Homo sapiens]	135	129/135 (95%)	134/135 (98%)	3e-63
<a href="#">gi 13651468 ref XP_016351.1</a>	similar to GASTRIN/CHOLECYST OKININ TYPE B RECEPTOR (CCK-B RECEPTOR) [Homo sapiens]	135	125/135 (92%)	132/135 (97%)	6e-63
<a href="#">gi 13651882 ref XP_011655.5</a> fatty acid binding protein 5 (psoriasis- associated) [Homo sapiens]	fatty acid binding protein 5 (psoriasis- associated) [Homo sapiens]	135	120/135 (88%)	130/135 (95%)	1e-59
<a href="#">gi 14746180 ref XP_018419.2</a>	similar to GASTRIN/CHOLECYST OKININ TYPE B RECEPTOR (CCK-B RECEPTOR) [Homo sapiens]	135	119/135 (88%)	128/135 (94%)	5e-59

The homology of these sequences is shown graphically in the ClustalW analysis shown in Table 5D.

Table 5D Clustal W Sequence Alignment

- 1) NOV5 (SEQ ID NO:10)
- 2) [gi|13651563|ref|XP\\_015760.1](#) similar to GASTRIN/CHOLECYSTOKININ TYPE B RECEPTOR (CCK-B RECEPTOR) [Homo sapiens] (SEQ ID NO:91)
- 3) [gi|4557581|ref|NP\\_001435.1](#) fatty acid binding protein 5 (psoriasis-associated) [Homo sapiens] (SEQ ID NO:92)
- 4) [gi|13651468|ref|XP\\_016351.1](#) similar to GASTRIN/CHOLECYSTOKININ TYPE B RECEPTOR (CCK-B RECEPTOR) [Homo sapiens] (SEQ ID NO:93)
- 5) [gi|13651882|ref|XP\\_011655.5](#) fatty acid binding protein 5 (psoriasis-associated) [Homo sapiens] (SEQ ID NO:94)
- 6) [gi|14746180|ref|XP\\_018419.2](#) similar to GASTRIN/CHOLECYSTOKININ TYPE B RECEPTOR (CCK-B RECEPTOR) [Homo sapiens] (SEQ ID NO:95)

	10	20	30	40	50			
NOV 5	.....	.....	.....	.....	.....			
gi 13651563	MATVQQL	EGRWRL	LD	SKGFDEY	MKELGVGIALQKMGAMAKPDCIITCDGR			
gi 4557581	MATVQQL	EGRWRL	LD	SKGFDEY	MKELGVGIALQKMGAMAKPDCIITCDGR			
gi 13651468	MATVQQL	EGRWRL	LD	SKGFDEY	MKELGVGIALRKMGAMAKPDCIITCDGR			
gi 13651882	MATVQQL	EGRWRL	LD	SKGFDEY	MKELGVGIALRKMGAMAKPDCIITCDGR			
gi 14746180	MATVQQL	EGRWRL	LD	SKGFDEY	MKELGVGIALRKMGAMAKPDCIITCDGR			
	60	70	80	90	100			
NOV 5	.....	.....	.....	.....	.....			
gi 13651563	NLT	TKTESTL	KTTQF	SCTLGD	EFEE	TADGRKTQ	TCVNFTD	GALVQHQEW
gi 4557581	NLT	TKTESTL	KTTQF	SCTLGD	EFEE	TADGRKTQ	TCVNFTD	GALVQHQEW

gi 13651468	NLTIKTESTLKTTFQFSCPLGEEKFEETTADGRKTQTVCNFTDGALVQHQEW
gi 13651882	NLTIKTESTLKTTFQFSCPLGEEKFEETTADGRKTQTVCNFTDGALVQHQEW
gi 14746180	NLTIKTESTLKTTFQFSCPLGEEKFEETTADGRKTQTVCNFTDGALVQHQEW

  

	110	120	130
NOV 5	..... ..... ..... ..... .....		
gi 13651563	DGKESTITRKLKDGKLVVECVMMNNVTCTRIYEKVE		
gi 4557581	DGKESTITRKLKDGKLVVECVMMNNVTCTRIYEKVE		
gi 13651468	DGKESTITRKLKDGKLVVECVMMNNVTCTRIYEKVE		
gi 13651882	DGKESTITRKLKDGKLVVECVMMNNVTCTRIYEKVE		
gi 14746180	DGKESTITRKLKDGKLVVECVMMNNVTCTRIYEKVE		

Table 5E list the domain description from DOMAIN analysis results against NOV5.

This indicates that the NOV5 sequence has properties similar to those of other proteins known

5 to contain this domain.

**Table 5E. Domain Analysis of NOV5**

gnl|Pfam|pfam00061, lipocalin, Lipocalin / cytosolic fatty-acid binding protein family. Lipocalins are transporters for small hydrophobic molecules, such as lipids, steroid hormones, bilins, and retinoids. Alignment subsumes both the lipocalin and fatty acid binding protein signatures from PROSITE. This is supported on structural and functional grounds. Structure is an eight-stranded beta barrel. (SEQ ID NO:96)  
Length = 145 residues, 100.0% aligned  
Score = 47.8 bits (112), Expect = 4e-07

NOV5	6	QLEGRWRLDLSKGFDEYMK-ELGVGIALQKMGAMAK-PDCIITCDGRNLTKTESTLKT	63
		+   +   +     +         +   +   +     +	
Pfam00061	1	KFAGKWLVLASANFDPELKEELGVLEATRKETPLKEGNLEIVFDGDKNGICERTFGKLE	60
NOV5	64	QFSCITLGDEFEEETTADGRKTQTVCNFTDGALVQHQEWGKESTITRKLKDG-----	114
		+       +       ++ +     +     ++   +	
Pfam00061	61	KTK-KLGVEFDYYTGDNRFFVLDTDYDNYLLVCVQKGDGNETSRTAELYGRTPELSPEAL	119
NOV5	115	KLVVECVM-----NNVTCTRIYEKV	134
		+   +         +	
Pfam00061	120	ELFETATKELGIPEDNVVCTRQTERC	145

10 Fatty acid metabolism in mammalian cells depends on a flux of fatty acids, between the plasma membrane and mitochondria or peroxisomes for beta-oxidation, and between other cellular organelles for lipid synthesis. The fatty acid-binding protein (FABP) family consists of small, cytosolic proteins believed to be involved in the uptake, transport, and solubilization of their hydrophobic ligands. Members of this family have highly conserved sequences and

15 tertiary structures. Fatty acid-binding proteins were first isolated in the intestine (FABP2; OMIM- 134640) and later found in liver (FABP1; OMIM- 134650), striated muscle (FABP3; OMIM- 134651), adipocytes (FABP4; OMIM- 600434) and epidermal tissues (E-FABP; GDB ID:136450).

Epidermal fatty acid binding protein (E-FABP) was cloned by as a novel keratinocyte protein by Madsen et al (1992, PMID: 1512466) from skin of psoriasis patients. Later using quantitative Western blot analysis, Kingma et al. (1998, PMID: 9521644) have shown that in addition to the skin, bovine E-FABP is expressed in retina, testis, and lens. Since E-FABP was originally identified from the skin of psoriasis patients, it is also known as psoriasis-associated fatty acid-binding protein (PA-FABP). PA-FABP is a cytoplasmic protein, and is expressed in keratinocytes. It is highly up-regulated in psoriatic skin. It shares similarity to other members of the fatty acid-binding proteins and belongs to the *fabp/p2/crbp/crabp* family of transporter. PA-FABP is believed to have a high specificity for fatty acids, with highest affinity for c18 chain length. Decreasing the chain length or introducing double bonds reduces the affinity. PA-FABP may be involved in keratinocyte differentiation.

Immunohistochemical localization of the expression of E-FABP in psoriasis, basal and squamous cell carcinomas has been carried out in order to obtain indirect information, at the cellular level, on the transport of the fatty acids. (Masouye et al, 1996, PMID: 8726632). E-FABP was localized in the upper stratum spinosum and stratum granulosum in normal and non-lesional psoriatic skin. In contrast, lesional psoriatic epidermis strongly expressed E-FABP in all suprabasal layers, like nonkeratinized oral mucosa. The basal layer did not express E-FABP reactivity in any of these samples. Accordingly, basal cell carcinomas were E-FABP negative whereas only well-differentiated cells of squamous cell carcinomas expressed E-FABP. This suggests that E-FABP expression is related to the commitment of keratinocyte differentiation and that the putative role of E-FABP should not be restricted to the formation of the skin lipid barrier. Since the pattern of E-FABP expression mimics cellular FA transport, our results suggest that lesional psoriatic skin and oral mucosa have a higher metabolism/transport for FAs than normal and non-lesional psoriatic epidermis.

The above defined information for NOV5 suggests that this NOV5 protein may function as a member of a fatty acid-binding protein family. Therefore, the NOV5 nucleic acids and proteins of the invention are useful in potential therapeutic applications implicated in various diseases and disorders described below and/or other pathologies. For example, the NOV5 compositions of the present invention will have efficacy for treatment of patients suffering from psoriasis, basal and squamous cell carcinomas, obesity, diabetis, and/or other pathologies and disorders involving fatty acid transport of skin, oral mucosa as well as other organs, Cardiomyopathy, Atherosclerosis, Hypertension, Congenital heart defects, Aortic stenosis, Atrial septal defect (ASD), Atrioventricular (A-V) canal defect, Ductus arteriosus, Pulmonary stenosis, Subaortic stenosis, Ventricular septal defect (VSD), valve diseases,

Tuberous sclerosis, Scleroderma, Transplantation, Adrenoleukodystrophy, Congenital Adrenal Hyperplasia, Diabetes, Von Hippel-Lindau (VHL) syndrome, Pancreatitis, Endometriosis, Fertility, Inflammatory bowel disease, Diverticular disease, Hirschsprung's disease, Crohn's Disease, Hemophilia, hypercoagulation, Idiopathic thrombocytopenic purpura,

5 immunodeficiencies, Osteoporosis, Hypercalcaemia, Arthritis, Ankylosing spondylitis, Scoliosis, Endocrine dysfunctions, Diabetes, Growth and reproductive disorders, Psoriasis, Actinic keratosis, Acne, Hair growth, alopecia, pigmentation disorders and endocrine disorders. The NOV5 nucleic acid encoding fatty acid-binding protein, and the fatty acid-binding protein of the invention, or fragments thereof, may further be useful in diagnostic

10 applications, wherein the presence or amount of the nucleic acid or the protein are to be assessed.

## NOV6

NOV6 includes nine novel neurolysin precursor-like proteins disclosed below. The disclosed proteins have been named NOV6a, NOV6b, NOV6c, NOV6d, NOV6e, NOV6f,

15 NOV6g, NOV6h and NOV6i.

### NOV6a

A disclosed NOV6a nucleic acid of 2170 nucleotides (also referred to as SC133790496\_A) encoding a novel neurolysin precursor-like protein is shown in Table 6A. An open reading frame was identified beginning with an ATG initiation codon at nucleotides

20 16-18 and ending with a TGA codon at nucleotides 2128-2130. Putative untranslated regions upstream from the initiation codon and downstream from the termination codon are underlined in Table 6A, and the start and stop codons are in bold letters.

**Table 6A. NOV6a Nucleotide Sequence (SEQ ID NO:11)**

<p>CCTCTCAGCGCTCCCATGATCGCCCGGTGCGCTTTTGGCTGTGCGAAGCCTCCGCAGGGTTGGTGGTTCCA  GGATTTTACTCAGATGACGTTAGGAAGAGAAGTGATGCTCTCTCTTCAGGCAATGTCCTCTATACTGT  GGCTGGCAGAAATGTTTTAAGATGGGATCTTTCACCAGAGCAAATTAACAAGAACTGAGGAGCTCATT  GTGCAGACCAACAGGTGTACGATGCTGTTGGAATGCTCGGTATTGAGGAAGTAAGTTACGAGAACTGTC  TGCAGGCACTGGCAGATGTAGAAGTAAAGTATATAGTGGAAAGGACCATGCTAGACTTTCCCCAGCATGT  ATCCTCTGACAAAGAAGTACGAGCAGCAAGTACAGAAGCAGACAAAGACTTTCTCGTTTGTATATTGAG  ATGAGCATGAGAGGAGATATATTTGAGAGAATTGTTTCATTTACAGGAAACCTGTGATCTGGGGAAGATAA  AACCTGAGGCCAGACGATACTTGGAAAAGTCAATTAATGAGGAAAAGAAATGGGCTCCATCTTCCTGA  ACAAGTACAGAATGAAATCAAATCAATGAAGAAAAGAAATGAGTGAGCTATGTATTGATTTAACAACAAAC  CTCAATGAGGATGATACCTTCCTTGTATTTTCCAAGGCTGAAGTTGGTGTCTCTCTCTGATGATTTTCATTG  ACAGTTTAAAAAGACAGATGATGACAAGTATAAAATACCTTAAATATCCACACTATTTCCCTGTCAT  GAAGAAATGTTGTATCCCTGAAACCAAGAGGATGGAAATGGCTTTTAATACAAGGTGCAAGAGGAA  AACCCATAATTTTGCAGCAGCTACTCCCACTGCGAACCAAGGTGGCCAACTACTCGGTTATAGCACAC  ATGCTGACTTCGTCTTGAATGAACACTGCAAGAGCACAAAGCCGCGTAACAGCCTTTCTAGATGATTT  AAGCCAGAAGTTAAACCTTGGGTGAAGCAGAACGAGAGTTTATTTGAATTTGAAGAAAAGGAATGC  AAAGACAGGGGTTTTGAATATGATGGGAAAATCAATGCCTGGGATCTATATTACTACATGACTCAGACAG  AGGAAGCTCAAGTATTCATAGACCAAGAGTTCCCTCAAGGAATACTTCCCAATTGAGGTGGTCACTGAAGG  CTTGCTGAACACCTTACCAGGAGTTGTTGGGACTTTTCATTTGAACAAATGACAGATGCTCATGTTTGGAAC  AAGAGTGTACACTTTTACTGTGAAGGATAAAGCTACAGGAGAAGTATTGGGACAGTTCTATTTGGACC  TCTATCCAAGGGAAAGGAAAATACAATCATGCGGCCTGCTTCGGTCTCCAGCCTGGCTGCCTTCTGCCTGA  TGGAAGCCGGATGATGGCAGTGGCTGCCCTCGTGGTGAACCTCTCACAGCCAGTGGCAGGTCGTCCCTCT</p>
---

```

CTCTGAGACACGACGAGGTGAGGACTTACTTTTCATGAGTTTGGTCACGTGATGCATCAGATTTGTGCAC
AGACTGATTTTGCACGATTTAGCGGAACAAATGTGGAACACTGACTTTGTAGAGGTGCCATCGCAAAATGCT
TGAAAATTGGGTGTGGGACGTCGATTCCTCCGAAGATTGTCAAACATTATAAAGATGGAAGCCCTATT
GCAGACGATCTGCTTGAAAACTTGTGCTTCGCTTATGTTATTAGGTCTTCTGACCCTGCGCCAGATTG
TTTTGAGCAAAGTTGATCAGTCTCTTCATACCAACACATCGCTGGATGCTGCAAGTGAATATGCCAAATA
CTGCTCAGAAAATATTAGGAGTTGCAGCTACTCCAGGTACAAATATGCCAGCTACCTTTGGACATTTGGCA
GGGGGATACGATGGCCAATATTATGGATATCTTTGGAGTGAAGTATTTCCATGGATATGTTTTACAGCT
GTTTTAAAAAAGAGGGATAATGAATCCAGAGGTAGTTGGAATGAAATACAGAAACCTAATCCTGAAACC
TGGGGGATCTCTGGACGGCATGGACATGCTCCACAATTTCTTGAAACGTGAGCCAAACCAAAAAGCGTTC
CTAATGAGTAGAGGCCCTGCATGCTCCGTGAACCTGGGGATCTTTGGTAGCCGTCCATGCTCGGAGGACAAG

```

The disclosed NOV6a nucleic acid sequence was identified on chromosome 5 and has 1994 of 2170 (91%) identical to a *Sus scrofa* Neurolysin Precursor mRNA (GENBANK-ID: PIGSABP) (E = 0.0).

A disclosed NOV6a polypeptide (SEQ ID NO:12) encoded by SEQ ID NO:11 is 704 amino acid residues and is presented using the one-letter amino acid code in Table 6B. Signal P, Psort and/or Hydropathy results predict that NOV6a contains a signal peptide and is likely to be localized at the plasma membrane with a certainty of 0.7000. The most likely cleavage site for a NOV6a peptide is between amino acids 17 and 18, at: VGG-SR.

**Table 6B. Encoded NOV6a protein sequence (SEQ ID NO:12).**

```

MIARCLLAVRSLRRVGGSRILLRMTLGREVMSPLOAMSSYTVAGRNVLRWDLSPQIKTRTEELIVQTKQVYDAVG
MLGIEEVTYENCLQALADVEVKYIVERMTLDFPQHVSSDKEVRAASTEADKRLSRFDIEMSMRGDIFERI VHLQET
CDLGKIKPEARRYLEKSIKMGKRNLHLPEQVQNEIKSMKKRMSLECIDFNKNLNEDDTFLVFSKAEALGALPDDFI
DSLEKTDDDKYKITLKYPHYFPMKKCCI PETRRRMEMAFNTRCKEENTII LQQLPLRTRKVAKLGLYSTHADFLV
EMNTAKSTSRVTAFLDDLSQLKPLGEAREFTLNLKKKECKDRGFYDGGKINAWDLYYMTQTEELKYSIDQEF
KEYFPIEVVTEGLLNTYQELGLSFEQMTDAHVVNKSVTLYTVKDKATGEVLGGFYLDLYPREGKYNHAACFGLQP
GCLLPDGSRRMVAALVNFSPQPVAGRPSLLRHDEVRTYFHEFGHVMHQI CAQTDFAFSGTNVETDFVEVPSQML
ENWVDVDSLRLSKHYKDGSP IADDLLEKLVASLMLLGLLTLRQIVLSKVDQSLHTNTSLDAASEYAKYCSEILG
VAATPGTNMPATFGHLAGGYDGQYGYLWSEVFSMDMFYSCFKKEGIMNPEVVGMYRNLILKPGGSLDGMMLHN
FLKREPNQKAFLMSRGLHAP

```

The NOV6a amino acid sequence has 661 of 704 amino acid residues (93%) identical to, and 667 of 704 amino acid residues (96 %) similar to, the *Sus scrofa* 704 amino acid residue Neurolysin Precursor protein (Q02038) (E = 0.0). The global sequence homology is 95.164% amino acid homology and 94.026 % amino acid identity.

NOV6a is expressed in at least the following tissues: Whole Organism, Sensory System, Skin, Foreskin, Gastro-intestinal/DigestiveSystem, Large Intestine, Colon, Salivary Glands, Cardiovascular System, Vein, Umbilical Vein, Female Reproductive System, Uterus, Nervous System, Brain, Prosencephalon/Forebrain, Diencephalon, Thalamus, Cardiovascular System, Artery, Coronary Artery, Heart, Male Reproductive System and Prostate. In addition, NOV6a is predicted to be expressed in the following tissues because of the expression pattern of a closely related *Sus scrofa* Neurolysin Precursor homolog (GENBANK-ID: PIGSABP): Whole Organism, Sensory System, Skin, Foreskin, Gastro-intestinal/Digestive System, Large Intestine, Colon, Salivary Glands, Cardiovascular System, Vein, Umbilical Vein, Female

Reproductive System, Uterus, Nervous System, Brain, Prosencephalon/Forebrain, Diencephalon, Thalamus, Cardiovascular System, Artery, Coronary Artery, Heart, Male Reproductive System and Prostate.

NOV6a also has homology to the amino acid sequences shown in the BLASTP data listed in Table 6C.

Table 6C. BLAST results for NOV6a					
Gene Index/ Identifier	Protein/ Organism	Length (aa)	Identity (%)	Positives (%)	Expect
gi 417743 sp Q02038 NEUL_PIG	NEUROLYSIN PRECURSOR (NEUROTENSIN ENDOPEPTIDASE) (MITOCHONDRIAL OLIGOPEPTIDASE M [Sus scrofa])	704	661/705 (93%)	677/705 (95%)	0.0
gi 14149738 ref NP_065777.1	neurolysin; KIAA1226 protein; neurotensin endopeptidase [Homo sapiens]	704	700/705 (99%)	701/705 (99%)	0.0
gi 1171691 sp P42676 NEUL_RAT	NEUROLYSIN PRECURSOR (NEUROTENSIN ENDOPEPTIDASE) (MITOCHONDRIAL OLIGOPEPTIDASE M) [Rattus norvegicus]	704	626/703 (89%)	667/703 (94%)	0.0
gi 1783127 dbj BAA19063.1  (AB000172)	endopeptidase 24.16 type M2 [Sus scrofa]	745	652/691 (94%)	668/691 (96%)	0.0
gi 1783123 dbj BAA19061.1  (AB000170)	endopeptidase 24.16 type M3 [Sus scrofa]	681	644/682 (94%)	660/682 (96%)	0.0

The homology of these sequences is shown graphically in the ClustalW analysis shown in Table 6D.

Table 6D Information for the ClustalW proteins

- 1) NOV6a (SEQ ID NO:12)
- 2) gi|417743|sp|Q02038|NEUL\_PIG NEUROLYSIN PRECURSOR (NEUROTENSIN ENDOPEPTIDASE) (MITOCHONDRIAL OLIGOPEPTIDASE M [Sus scrofa]) (SEQ ID NO:97)
- 3) gi|14149738|ref|NP\_065777.1| neurolysin; KIAA1226 protein; neurotensin endopeptidase [Homo sapiens] (SEQ ID NO:98)
- 4) gi|1171691|sp|P42676|NEUL\_RAT NEUROLYSIN PRECURSOR (NEUROTENSIN ENDOPEPTIDASE) (MITOCHONDRIAL OLIGOPEPTIDASE M) [Rattus norvegicus] (SEQ ID NO:99)
- 5) gi|1783127|dbj|BAA19063.1| (AB000172) endopeptidase 24.16 type M2 [Sus scrofa] (SEQ ID NO:100)
- 6) gi|1783123|dbj|BAA19061.1| (AB000170) endopeptidase 24.16 type M3 [Sus scrofa] (SEQ ID NO:101)

	10	20	30	40	50
NOV6A	..... ..... ..... ..... ..... ..... ..... ..... ..... .....				
gi 417743	..... ..... ..... ..... ..... ..... ..... ..... ..... .....		MIARCTLL	-----	AV
gi 14149738	..... ..... ..... ..... ..... ..... ..... ..... ..... .....		MIIVCTLS	-----	AA
gi 1171691	..... ..... ..... ..... ..... ..... ..... ..... ..... .....		MIARCTLL	-----	AV
gi 1783127	..... ..... ..... ..... ..... ..... ..... ..... ..... .....		MITLCTLS	-----	TL
gi 1783123	MVYPEGHLARELGATFSSSAPLGGHPPFVWDCTLS	CRQGDWSQARPKTNA			



		60	70	80	90	100
NOV6A		RS	LR	RV	GG	SR
gi   417743		RL	HR	VG	GS	G
gi   14149738		RS	LR	RV	GG	SR
gi   1171691		RG	LR	AG	GS	SR
gi   1783127		ER	RG	VG	GS	G
gi   1783123		MT	LG	RE	AM	SP
		110	120	130	140	150
NOV6A		RT	EL	IA	Q	T
gi   417743		RT	EL	IA	Q	T
gi   14149738		RT	EL	IA	Q	T
gi   1171691		RT	EL	IA	Q	T
gi   1783127		RT	EL	IA	Q	T
gi   1783123		RT	EL	IA	Q	T
		160	170	180	190	200
NOV6A		QH	V	SS	D	K
gi   417743		QH	V	SS	D	K
gi   14149738		QH	V	SS	D	K
gi   1171691		QH	V	SS	D	K
gi   1783127		QH	V	SS	D	K
gi   1783123		QH	V	SS	D	K
		210	220	230	240	250
NOV6A		PE	AR	Y	LE	K
gi   417743		PE	AR	Y	LE	K
gi   14149738		PE	AR	Y	LE	K
gi   1171691		PE	AR	Y	LE	K
gi   1783127		PE	AR	Y	LE	K
gi   1783123		PE	AR	Y	LE	K
		260	270	280	290	300
NOV6A		DT	FL	V	F	S
gi   417743		DT	FL	V	F	S
gi   14149738		DT	FL	V	F	S
gi   1171691		DT	FL	V	F	S
gi   1783127		DT	FL	V	F	S
gi   1783123		DT	FL	V	F	S
		310	320	330	340	350
NOV6A		TR	R	M	E	M
gi   417743		TR	R	M	E	M
gi   14149738		TR	R	M	E	M
gi   1171691		TR	R	M	E	M
gi   1783127		TR	R	M	E	M
gi   1783123		TR	R	M	E	M
		360	370	380	390	400
NOV6A		K	S	T	S	R
gi   417743		K	S	T	S	R
gi   14149738		K	S	T	S	R
gi   1171691		K	S	T	S	R
gi   1783127		K	S	T	S	R
gi   1783123		K	S	T	S	R
		410	420	430	440	450
NOV6A		DL	H	Y	M	T
gi   417743		DL	H	Y	M	T
gi   14149738		DL	H	Y	M	T
gi   1171691		DL	H	Y	M	T
gi   1783127		DL	H	Y	M	T

gi 1783123	DLHYMTQTTEELKYSVDQELKKEYFPTEVVTEGLLNITYQELLGLSFEQVT
	.....460.....470.....480.....490.....500
NOV6A	DAHVVNKSVTLYTVKDKATGEVLGQFYLDLYPREGKYNHAACFGLQPGCL
gi 417743	DAHVVNKSVTLYTVKDKATGEVLGQFYLDLYPREGKYNHAACFGLQPGCL
gi 14149738	DAHVVNKSVTLYTVKDKATGEVLGQFYLDLYPREGKYNHAACFGLQPGCL
gi 1171691	DAHVVNKSVTLYTVKDKATGEVLGQFYLDLYPREGKYNHAACFGLQPGCL
gi 1783127	DAHVVNKSVTLYTVKDKATGEVLGQFYLDLYPREGKYNHAACFGLQPGCL
gi 1783123	DAHVVNKSVTLYTVKDKATGEVLGQFYLDLYPREGKYNHAACFGLQPGCL
	.....510.....520.....530.....540.....550
NOV6A	LPDGSRRMVAALVVNFSQPVAGRPSLLRHDEVRTYFHEFGHVMHQICAQ
gi 417743	LPDGSRRMVAALVVNFSQPVAGRPSLLRHDEVRTYFHEFGHVMHQICAQ
gi 14149738	LPDGSRRMVAALVVNFSQPVAGRPSLLRHDEVRTYFHEFGHVMHQICAQ
gi 1171691	LPDGSRRMVAALVVNFSQPVAGRPSLLRHDEVRTYFHEFGHVMHQICAQ
gi 1783127	LPDGSRRMVAALVVNFSQPVAGRPSLLRHDEVRTYFHEFGHVMHQICAQ
gi 1783123	LPDGSRRMVAALVVNFSQPVAGRPSLLRHDEVRTYFHEFGHVMHQICAQ
	.....560.....570.....580.....590.....600
NOV6A	TDFARFSGTNVETDFVEVPSQMLENWWVDVDSLRLRSKHYKDGSPITDDL
gi 417743	TDFARFSGTNVETDFVEVPSQMLENWWVDVDSLRLRSKHYKDGSPITDDL
gi 14149738	TDFARFSGTNVETDFVEVPSQMLENWWVDVDSLRLRSKHYKDGSPITDDL
gi 1171691	TDFARFSGTNVETDFVEVPSQMLENWWVDVDSLRLRSKHYKDGSPITDDL
gi 1783127	TDFARFSGTNVETDFVEVPSQMLENWWVDVDSLRLRSKHYKDGSPITDDL
gi 1783123	TDFARFSGTNVETDFVEVPSQMLENWWVDVDSLRLRSKHYKDGSPITDDL
	.....610.....620.....630.....640.....650
NOV6A	LEKLVASRLVNTGLLTLRQIVLSKVDQSLHTNTSLDAASEYAKYCTEILG
gi 417743	LEKLVASRLVNTGLLTLRQIVLSKVDQSLHTNTSLDAASEYAKYCTEILG
gi 14149738	LEKLVASRLVNTGLLTLRQIVLSKVDQSLHTNTSLDAASEYAKYCTEILG
gi 1171691	LEKLVASRLVNTGLLTLRQIVLSKVDQSLHTNTSLDAASEYAKYCTEILG
gi 1783127	LEKLVASRLVNTGLLTLRQIVLSKVDQSLHTNTSLDAASEYAKYCTEILG
gi 1783123	LEKLVASRLVNTGLLTLRQIVLSKVDQSLHTNTSLDAASEYAKYCTEILG
	.....660.....670.....680.....690.....700
NOV6A	VAATPGTNMPATFGHLAGGYDGQYYGYLWSEVFSMDMFYSCFKKEGIMNP
gi 417743	VAATPGTNMPATFGHLAGGYDGQYYGYLWSEVFSMDMFYSCFKKEGIMNP
gi 14149738	VAATPGTNMPATFGHLAGGYDGQYYGYLWSEVFSMDMFYSCFKKEGIMNP
gi 1171691	VAATPGTNMPATFGHLAGGYDGQYYGYLWSEVFSMDMFYSCFKKEGIMNP
gi 1783127	VAATPGTNMPATFGHLAGGYDGQYYGYLWSEVFSMDMFYSCFKKEGIMNP
gi 1783123	VAATPGTNMPATFGHLAGGYDGQYYGYLWSEVFSMDMFYSCFKKEGIMNP
	.....710.....720.....730.....740
NOV6A	EVVGMKYRNLILKPGGSLDGMMDLQNFLKREPNOKAFLMSRGLHAP
gi 417743	EVVGMKYRNLILKPGGSLDGMMDLQNFLKREPNOKAFLMSRGLHAP
gi 14149738	EVVGMKYRNLILKPGGSLDGMMDLQNFLKREPNOKAFLMSRGLHAP
gi 1171691	EVVGMKYRNLILKPGGSLDGMMDLQNFLKREPNOKAFLMSRGLHAP
gi 1783127	EVVGMKYRNLILKPGGSLDGMMDLQNFLKREPNOKAFLMSRGLHAP
gi 1783123	EVVGMKYRNLILKPGGSLDGMMDLQNFLKREPNOKAFLMSRGLHAP

Table 6E lists the domain description from DOMAIN analysis results against NOV6a. This indicates that the NOV6a sequence has properties similar to those of other proteins known to contain this domain.

Table 6E. Domain Analysis of NOV6a

gnl|Pfam|pfam01432, Peptidase\_M3, Peptidase family M3. This is the Thimet oligopeptidase family, large family of mammalian and bacterial oligopeptidases that cleave medium sized peptides. The group also contains mitochondrial intermediate peptidase which is encoded by nuclear DNA but functions within the mitochondria to remove the leader sequence. (SEQ ID NO:102)  
 Length = 603 residues, 100.0% aligned  
 Score = 617 bits (1592), Expect = 5e-178

NOV6a	88	CLQALADVEVKYIVERITMLDFPQHVSSDKEVRAASTADKRLSRFDIEMSMRGDIFERIV	147
		+   ++  + +       +  +    ++   +    ++  +	
Pfam01432	1	TLKALDELEDTLCRVYDLGEFLQSAHPDKELLEAAEEASEKLSSELMNYLSLREDLYTRLK	60
NOV6a	148	HLQ-ETCDLGKIKPEARRYLEKSIKMGKRNGLHLPEQVQNEIKSMKKRMSEL CIDFNKNL	206
		+ + +       +     +++ +    + + + +     +	
Pfam01432	61	AVLDDKSKSES LDP EARRVVEKF EKDFE KSGIGLP E EKREKPKLIK KELKELGIAFEKNL	120
NOV6a	207	NEDDTFLVFSKAE L GALPDDFIDSL EKTDDDKYKITLKYPHYFPVMKKCCIPETRRMEM	266
		++ +   + +       ++        +        ++	
Pfam01432	121	REKKHLLSFTEEKLAGLPEPVLASAEKTFEELGN-TLAYPT-LPLMKYCENNETREKLYS	178
NOV6a	267	AFNTRCKEENTII LQQLPLR TKVAKLLGYSTHAD FVLEMTAKSTSRVTAFLDDLSQKL	326
		+  +    ++      ++      +  + + +	
Pfam01432	179	AYHNRLESENRAIRKEALKRLAE LAYLLGRNTYANLLLEDKMAKNPEAVLRFLDSLRSKA	238
NOV6a	327	KPLGEAERE FILNLKKKECKDRGF EYDGKINAWDLYYYMTQT EELKYSIDQEF LKEYFPPI	386
		++      +      +           +	
Pfam01432	239	LPNNEIELAVIDELKKKEL-----GVNELLPWDHRYYSRLRYEEKYSLDPELLKPYFPL	292
NOV6a	387	EVVTEGLLNTYQELLGLSFEQMTDAHVWNKSVTLTYTKDKATGEVLGQFYLDLYPREGKY	446
		+     ++      +  +     +       +	
Pfam01432	293	TPLIEGLFRLFKELYGLTFEEAADGEVWHDPVRLGEVYDEILKGALGEFYLDLYARRGGK	352
NOV6a	447	NHAACFGLQPGCLLPDGSRRMMAVAALVVNFSQPVAGRPSLLRHDEVRTYFHEFGHVMHQI	506
		+     +    ++             +             +	
Pfam01432	353	RTGACSGG--GSLDG----QLPVAYLLCNFTKPSAGKPSLLTHDDVFTLFHEFGHSMHSM	406
NOV6a	507	CAQTDFAFSGT NVETDFVEVPSQMLENVWDVDSLRLSKHYKDGSP IADDLLEKLIVAS	566
		++  ++          ++  +    +  +               +      +	
Pfam01432	407	LSRTHYSYVSGTYVPIDFVEIP SILNENWLWEPLLLNLLSKHYKTGEPI PDELLEKFFAT	466
NOV6a	567	LM-LLGLLTLRQIVLSKVDQSLHTNTSLDAASEYAKYCSEILGVAAT--PGTNMPATFGH	623
		+ + +             + +	
Pfam01432	467	KFRQTGFATFEQIIHALLDQGLHHLTEEDLTEIYAE LNEKYFGLSAVDKPGTLWWARFPH	526
NOV6a	624	LAGGYDGQYYGYLWSEVFSMDMFYSCFKKEGIMNPEVVGMKYRNLI LKPGGSLDGMMLH	683
		++ + +  +   +  +               ++	
Pfam01432	527	FYGGYAANYVYLYATGLAADLFLAKFIKDGDLNRE-NGVRYRKEFLSSGGSKDPLEMLK	585
NOV6a	684	NFLKREP NQKAP LMSRGL	701
		++    +	
Pfam01432	586	KFLGDEPSKDPFLEAMGL	603

Novel variants for the NOV6a nucleic acid and Neurolysin Precursor-like protein sequences are also disclosed herein as variants of NOV6a. A variant sequence can include a single nucleotide polymorphism (SNP). A SNP can, in some instances, be referred to as a "cSNP" to denote that the nucleotide sequence containing the SNP originates as a cDNA. A SNP can arise in several ways. For example, a SNP may be due to a substitution of one nucleotide for another at the polymorphic site. Such a substitution can be either a transition or a transversion. A SNP can also arise from a deletion of a nucleotide or an insertion of a nucleotide, relative to a reference allele. In this case, the polymorphic site is a site at which

one allele bears a gap with respect to a particular nucleotide in another allele. SNPs occurring within genes may result in an alteration of the amino acid encoded by the gene at the position of the SNP. Intragenic SNPs may also be silent, however, in the case that a codon including a SNP encodes the same amino acid as a result of the redundancy of the genetic code. SNPs occurring outside the region of a gene, or in an intron within a gene, do not result in changes in any amino acid sequence of a protein but may result in altered regulation of the expression pattern for example, alteration in temporal expression, physiological response regulation, cell type expression regulation, intensity of expression, stability of transcribed message. Variants are reported individually, but any combination of all or a subset are also included.

- 10 A disclosed NOV6b nucleic acid (also referred to as 13375342) is a variant of NOV6a, encodes a novel neurolysin precursor-like protein, and is shown in Table 6F. NOV6b nucleotide changes are underlined in Table 6F.

**Table 6F. NOV6b Nucleotide Sequence (SEQ ID NO:13)**

CCTCTCAGCGCTCCCATGATCGCCCGGTGCTTTGGCTGTGCGAAGCCTCCGACGGGTGGTGGTTCAGGATTTTAC  
TCAGAATGACGTTAGGAAGAGAAGTGATGTCCTCTTCAGGCAATGCTTCCTATAGTGGCTGGCAGAAATGTTTT  
AAGATGGGATCTTTACAGAGCAAATTAACAAGAACTGAGGAGCTCATTGTGCAGACCAACAGGTGTACGATGCT  
GTTGGAATGCTCGGTATTGAGGAAGTAACCTACGAGAACTGCTCTGACGGCACTGGCAGATGTAGAAGTAAAGTATATAG  
TGGAAAGGACCATGCTAGACTTTCCCCAGCATGTATCTCTGACAAAGAAGTACGAGCAGCAAGTACAGAAGCAGACAA  
AAGACTTTCTCGTTTGTATTTGAGATGAGCATGAGAGGAGATATATTTGAGAGAATTGTTCAATTTACAGGAAACCTGT  
GATCTGGGGAAGATAAAACCTGAGGCCAGACGATACCTGGAAAAGTCAATTAATAATGGGAAAAGAAATGGGCTCCATC  
TTCCTGAACAAGTACAGAATGAAATCAATGAAGAAAGAATGAGTGAGCTATGTATTGATTTTAACAAAAACCT  
CAATGAGGATGATACCTTCCCTTGATTTTCCAAGGCTGAACCTGGTGTCTTCCTGATGATTTCATGACAGTTTAGAA  
AAGACAGATGATGACAAGTATAAAATTACCTTAAATATCCACACTATTTCCCTGTGATGAAGAAATGTTGTATCCCTG  
AAACCCAGAAAGGATGGAATGGCTTTTAAATACAAGGTGCAAGAGGAAACACCATAATTTTGACAGCAGCTACTCCC  
ACTGCGAAACCAAGGTGGCCAACTACTCGGTTATAGCACACATGCTGACTTCGTCCTTGAATGAACACTGCAAGAGC  
ACAAGCCGCGTAACCGGCTTTCTAGATGATTTAAGCCAGAAGTTAAACCCCTGGGTGAAGCAGAACGAGAGTTATTT  
TGAATTTGAAGAAAAGGAATGCAAGACAGGGGTTTGAATATGATGGGAAAATCAATGCCCTGGGATCTATATTACTA  
CATGACTCAGACAGGGAAGTCAAGTATTCATAGACCAAGAGTTCCTCAAGGAATACTTCCCAATTGAGGTGGTCACT  
GAAGGCTTGCTGAACACCTACCAGGAGTTGTTGGGACTTTCATTGAAACAAATGACAGATGCTCATGTTTGGAAACAAG  
GTGTACTACTTTATACTGTGAAGGATAAAGCTACAGGAGAAGTATTGGGACAGTTCTATTGGACCTCTATCCAGGGA  
AGGAAAATACAATCATGCGGCCCTGCTTCGGTCTCCAGCCTGGCTGCTTCCTGCTGATGGAAGCCGGATGATGGCAGTG  
GCTGCCCTCGTGGTGAACCTTCTCAGCCAGTGGCAGGTGCTCCCTCTCTCCTGAGACACGACGAGGTGAGGACTTACT  
TTCATGAGTTTGGTCAAGTGATGATCAGATTGTGTCACAGACTGATTTGACAGATTAGCGGAACAAATGTGGAAC  
TGACTTTGTAGAGGTGCCATCGCAATGCTTGAATAATGGGTGTGGGACGTCGATTCCTCCGAAAGATTGTCAAAACAT  
TATAAAGATGGAAGCCCTATTGACAGCATCTGCTTGAATAAACTGTGCTTCGCTTATGTTATTAGGCTCTCTGACCC  
TGCGCCAGATTGTTTGTAGCAAAGTGTATCAGTCTCTTCATACCAACACATCGCTGGATGCTGCAAGTGAATATGCCAA  
ATACCTGCTCAGAAATATTAGGAGTTGAGCTACTCCAGGTACAAATATGCCAGCTACCTTTGGACATTTGGCAGGGGA  
TACGATGGCCAAATATTGATATCTTTGGAGTGAAGTATTTCCATGGATATGTTTACAGCTGTTTAAAAAAGAAAG  
GGATAATGAATCCAGAGGTAGTTGGAATGAAATACAGAAACCTAATCTGAAACCTGGGGATCTCTGGACGGCATGGA  
CATGCTCCCAATTTCTTGAACGTGAGCCAAACCAAAAGCGTTCCTAATGAGTAGAGCCCTGCATGCTCCGTGAAT  
GGGATCTTTGGTAGCCGTCCATGCTGAGGACAAG

- 15 A disclosed NOVb polypeptide (SEQ ID NO:14) encoded by SEQ ID NO:13 is presented using the one-letter amino acid code in Table 6G. NOV6b amino acid changes, if any, are underlined in Table 6G.

**Table 6G. Encoded NOV6b protein sequence (SEQ ID NO:14).**

MIARCLLAVRSLRRVGGSRILLRMTLGREVMSPLQAMSSYTVAGRNVLRLDLSPEQIKTRTEELIVQTKQVYDAVGLGIEEVY  
ENCLQALADVEVKYIVERTMLDFPQHVSDDKEVRAASTEDAKRLSRFDIEMSMRGDI FERI VHLQETCDLGKIKPEARRYLEKSI  
KMGKRNGLHLPEQVQNEIKSMKKRMSLCLDFNKNLNEDDTFLVFSKAEALGALPDDFIDSLEKTDDEKDKYITLKYPHYFPVMKKC  
CIPETRRRMEMAFNTRCKEENTIIQLLLPLRTKVAKLLGYSTHADFLVLEMTAKSTSRTAFLLDLSQKLKPLGEAEREFTILNL

KKKECKDRGFYDGGKINAWDLYYMTQTEELKYSIDQEFLEKVFPIEVVTEGLLNTYQELLGLSFEQMTDAHVWNKSVTLTYTKD  
 KATGEVLGQFYLDLYPREGKYNHAACFGLQPGCLLPDGSRRMVAALVVNFSQPVAGRPSLLRHDEVRTYFHEFGHVMHQICAQT  
 DFARFSGTNVETDFVEVPSQMLENWWVDVSLRRLSKHYKDGSP IADDDLEKLVASLMLLGLLTLRQIVLSKVDQSLHTNTSLDA  
 ASEYAKYCSIELGVAATPGTNMPATFGLAGGYDGGYYGYLWSEVFSMDMFYSCFKKEGIMNPEVVGMKYRNLILKPGGSLDGM  
 MLHNFLKREPNOQAFILMSRGLHAP

A disclosed NOV6c nucleic acid (also referred to as c99.456) is a variant of NOV6a,  
 encodes a novel neurolysin precursor-like protein, and is shown in Table 6H. NOV6c  
 5 nucleotide changes are underlined in Table 6H.

**Table 6H. NOV6c Nucleotide Sequence (SEQ ID NO:15)**

CCTCTCAGCGCTCCCATGATCGCCCGGTGCCTTTTGGCTGTGCGAAGCCTCCGAGGGTTGGTGGTTCCAGGATTTC  
 TCAGAAATGACGTTAGGAAGAGAAGTGATGTCCTCTTCAGGCAATGTCTTCTTACTGTGGCTGGCAGAAATGTTTT  
 AAGATGGGATCTTTACCAGAGCAAATTAACAAGAACTGAGGAGCTCATTTGTGCAGACCAAACAGGTGTACGATGCT  
 GTTGAATGCTCGGTATTGAGGAAGTAACTTACGAGAACTGTCTGCAGGCACTGGCAGATGTAGAAGTAAAGTATATAG  
 TGGAAAGACCAATGCTAGACTTTCCCCAGCATGTATCCTCTGACAAAGAAGTACGAGCAGCAAGTACAGAAGCAGACAA  
 AAGACTTTCTCGTTTGATATTGAGATGAGCATGAGAGGAGATATATTGAGAGAATTGTTCAATTTACAGGAACCTGT  
 GATCTGGGGAAGATAAAACCTGAGGCCAGACGATCTTGGAAAAGTCAATTAATAATGGGAAAAGAAATGGGCTCCATC  
 TTCCTGAACAAGTACAGAATGAAATCAATCAATGAAGAAAAGTGAAGTGAAGCTATGTATTGATTTTAAACAAAACT  
 CAATGAGGATGATACCTTCTGTATTTTCAAGGCTGAACCTTGGTGTCTTTCCTGATGATTTCAATGACAGTTTAGAA  
 AAGACAGATGATGACAAAGTATAAAATACCTTAAATATCCACACTATTTCCCTGTGATGAAGAAATGTTGTATCCCTG  
 AAACCAAGAAGGATGGAATGGCTTTTAATACAAGGTGCAAGAGGAAACACCATAAATTTGCAGCAGCTACTCCC  
 ACTGCGAACCAAGGTGGCCAACTACTCGGTTATAGCACACATGCTGACTTCGTCTTGAATGAACACTGCAAGAGGC  
 ACAAGCCCGCTTAACAGCCTTTCTAGATGATTTAAGCCAGAAGTTAAACCCCTTGGGTGAAGCAGAACGAGAGTTATTT  
 TGAATTTGAAGAAAAGGAATGCAAGACAGGGGTTTGAATATGATGGGAAAATCAATGCCTGGGATCTATATTACTA  
 CATGACTCAGACAGAGGAAGTCAAGTATTCATAGACCAAGAGTTCCTCAAGGAATACTTCCCAATTGAGGTGGTCACT  
 GAAGGCTTGCTGAACACCTACCAGGAGTTGTGGGACTTTTCAATTTGAACAAATGACAGATGCTCATGTTTGAACAAGA  
 GTGTTACACTTTTACTGTGAAGGATAAAGCTACAGGAGAAGTATTGGGACAGTTCTATTGGACCTCTATCCAGGGA  
 AGGAAAATACAAATCATGCGCGCTGCTTCGGTCTCCAGCCTGGCTGCCCTTCTGCTGATGGAAGCCGGATGATGGCAGTG  
 GCTGCCCTCGTGGTGAACCTTCTCACAGCCAGTGGCAGGTGCTCCCTCTCTCTGAGACACGACGAGGTGAGGACTTACT  
 TTCATGAGTTTGGTCAGGTGATGATCAGATTTGTGCACAGACTGATTTTGCACGATTTAGCGGAACAAATGTGAAAC  
 TGACTTTGTAGAGGTGCCATCGCAAATGCTTGAATAATGGGTGTGGGACGTGATTCCTCCGAAGATTGTCAAACAT  
 TATAAGATGGAAGCCCTATTGCAGACGATCTGCTTGAATACTTGTGCTTCGCTTATGTTATTAGGTCTTCTGACCC  
 TGCGCCCAATTTGTTGAGCAAGTTGATCAGTCTCTTATACCAACACATCGCTGGATGCTGCAAGTGAATATGCCAA  
 ATACTGCTCAGAAAATATTAGGAGTTGCAGCTACTCCAGGTACAAATATGCCAGTACCTTTGGACATTTGGCAGGGGGA  
 TACGATGGCCAAATATTATGATATCTTTGGAGTGAAGTATTTCCATGGATATGTTTACAGCTGTTTAAAAAGAGAAG  
 GGATATGAATCCAGAGGTAGTTGGAATGAAATACAGAAACCTAATCTGAAACCTGGGGGATCTCTGGACGGCATGGA  
 CATGCTCCCAATTTCTGAAACGTGAGCCAAACCAAAAGCGTTCCTAATGAGTAGAGGCTGCATGCTCCGTGAAC  
 GGGGATCTTTGGTAGCCGTCCATGTCTGGAGGACAAG

A disclosed NOV6c polypeptide (SEQ ID NO:16) encoded by SEQ ID NO:15 is  
 presented using the one-letter amino acid code in Table 6I. NOV6c amino acid changes, if  
 any, are underlined in Table 6I.

**Table 6I. Encoded NOV6c protein sequence (SEQ ID NO:16).**

MIARCLLAVRSLRRVGGSRILLRMTLGREVMSPLOAMSSYTAVGRNVLRWDLSPQIKTRTEELIVQTKQVYDAVGLGIEVTV  
 ENCLQALADVEVKYIVERTMLDFPQHVSSDKEVRAASTEADKRLSRFDIEMSMRGDIFERIVHLQETCDLGKIKPEARRYLEKSI  
 KMGKRNGLHLPEQVQNEIKSMKKRMSELCDFNKLNEDDTFLVFSKAEIGALPDDFIDSLEKTDGDKYITLKYPHYFPVMKKC  
 CIPETRRRMEMAFNTRCKEENTIIILQQLPLRLTKVAKLLGYSTHADFVLEMTAKSTSRVTAFLDDLSQLKPLGEAEREFIILNL  
 KKKECKDRGFYDGGKINAWDLYYMTQTEELKYSIDQEFLEKVFPIEVVTEGLLNTYQELLGLSFEQMTDAHVWNKSVTLTYTKD  
 KATGEVLGQFYLDLYPREGKYNHAACFGLQPGCLLPDGSRRMVAALVVNFSQPVAGRPSLLRHDEVRTYFHEFGHVMHQICAQT  
 DFARFSGTNVETDFVEVPSQMLENWWVDVSLRRLSKHYKDGSP IADDDLEKLVASLMLLGLLTLRQIVLSKVDQSLHTNTSLDA  
 ASEYAKYCSIELGVAATPGTNMPATFGLAGGYDGGYYGYLWSEVFSMDMFYSCFKKEGIMNPEVVGMKYRNLILKPGGSLDGM  
 MLHNFLKREPNOQAFILMSRGLHAP

A disclosed NOV6d nucleic acid (also referred to as c99.457) is a variant of NOV6a,  
 encodes a novel neurolysin precursor-like protein, and is shown in Table 6J. NOV6d  
 nucleotide changes are underlined in Table 6J.

**Table 6J. NOV6d Nucleotide Sequence (SEQ ID NO:17)**

CCTCTCAGCGCTCCCATGATCGCCCGGTGCTTTTGGCTGTGCGAAGCCTCCGAGGGTTGGTGGTTCCAGGATTTTAC  
 TCAGAAATGACGTTAGGAAGAGAAGTGATGTCTCTCTTCAGGCAATGTCTTCTATACGTGGCTGGCAGAAATGTTTT  
 AAGATGGGATCTTTACCAAGAGCAAATTAACAAGAACTGAGGAGCTCATGTGCAGACCAACAGGTGTACGATGCT  
 GTTGAATGCTCGGTATTGAGGAAGTAACCTACGAGAACTGTCTGCAGGCACTGGCAGATGTAGAAGTAAGTATATAG  
 TGGAAAGGACCATGCTAGACTTTCCCAAGCATGTATCTCTGACAAAGAACTACGAGCAGCAAGTACAGAAAGCAGACAA  
 AAGACTTTCTCGTTTGTATTTGAGATGAGCATGAGAGGAGATATATTTGAGAGAATGTTTCATTTACAGGAAACCTGT  
 GATCTGGGGAAGATAAAACCTGAGGCCAGACGATACTTGGAAAAGTCAATTAATAATGGGAAAAGAAATGGGCTCCATC  
 TTCTTGAACAAGTACAGAAATGAAATCAAATCAATGAAGAAAAGAAATGAGTGAGCTATGTATTGATTTTAAACAAAACCT  
 CAATGAGGATGATACCTTCTTGTATTTTCCAAGGCTGAACCTTGGTGTCTTCTCTGATGATTTTATTGACAGTTTAGAA  
 AAGACAGATGATGACAAGTATAAAATTTACCTTAAATATCCACACTATTTCCCTGTCTATGAAGAAATGTTGTATCCCTGT  
 AAACCAAGAAAGGATGGAAATGGCTTTTAAATACAAGGTGCAAGAGGAAAACACCATAATTTTGAGCAGCTACTCCC  
 ACTGCGAACCAGGTGGCCAACTACTCGGTTATAGCACACATGCTGACTTCGTCTTGAATGAACACTGCAAGAGGC  
 ACAAGCCGCTAACAGCCTTTCTAGATGATTTAAGCCAGAAGTTAAACCCCTGGGTGAAGCAGAACGAGAGTTTATTT  
 TGAATTTGAAGAAAAGGAATGCAAGACAGGGGTTTGAATATGATGGGAAAATCAATGCCCTGGGATCTATATTACTA  
 CATGACTCAGACAGAGGAACCTCAAGTATTCATAGACCAAGAGTTCCTCAAGGAATACTTCCCAATTGAGGTGGTCACT  
 GAAGCTTGTCTGAACACCTACCAAGGAGTTGTTGGGACTTTTCAATTTGAACAAATGACAGATGCTCATGTTTGGAAACAAG  
 GTGTACACTTTTACTGTGAAGGATAAAGCTACAGGAGAAGTATTGGGACAGTTCTATTTGGACCTCTATCCAGGGA  
 AGGAAAATACAAATCATGCGGCTGTCTTGGTCTCCAGCCTGGCTGCTCTGCTGATGGAAGCCGATGATGGCAGTG  
 GCTGCCCTCGTGGTGAACCTTCTCACAGCCAGTGGCAGGTGCTCCCTCTCTCTGAGACACGACGAGGTGAGGACTTACT  
 TTCATGAGTTTGGTCACTGATGATCAGATTTGTGACAGACTGATTTTGCACGATTTAGCGGAACAAATGTGGAAC  
 TGACTTTGTAGAGGTGCCATCGCAAATGCTTGAATTTGGTGTGGGACGTCGATTCCTCCGAAAGATTGTCAAACAT  
 TATAAGATGGAAGCCCTATTGACAGCATCTGCTTGAACAACTTGTGCTTCTGCTTATGTTATTAGGTCTTCTGACCC  
 TGCGCCAGATGTTTGTAGCAAGTTGACCAAGTCTCTTATACCAACACATCGCTGGATGCTGCAAGTGAATATGCCAA  
 ATACTGCTCAGAAATATTAGGAGTTGCAGCTACTCCAGGTACAATATGCCAGCTACCTTTGGACATTTGGCAGGGGA  
 TACGATGGCCAAATATTATGGATATCTTTGGAGTGAAGTATTTCCATGGATATGTTTACAGCTGTTTAAAAAAGAAG  
 GGATATGAATCCAGAGGTAGTTGGAATGAAATACAGAAACCTAATCTGAAACCTGGGGGATCTCTGAGCGGATGGA  
 CATGCTCCAAATTTCTGAAACGTGAGCCAAACCAAAAGCGTTCCTAATGAGTAGAGGCTGCATGCTCCGTGAAC  
 GGGGATCTTTGGTAGCCGTCATGTCTGGAGGACAAG

A disclosed NOV6d polypeptide (SEQ ID NO:18) encoded by SEQ ID NO:17 is presented using the one-letter amino acid code in Table 6K. NOV6d amino acid changes, if any, are underlined in Table 6K.

**Table 6K. Encoded NOV6d protein sequence (SEQ ID NO:18).**

MIARCLLAVRSLLRVGSGRILLRMTLGREVMSPLOQMSYTVAGRNVLRLDLSPEQIKTRTEELIVQTKQVYDAVGLGIEEVTY  
 ENCLQALADVEVKYIIVERTMLDPPQHVSSDKEVRAASTEADKRLSRFDIEMSMRGDIFERI VHLQETCDLGKIKPEARRYLEKSI  
 KMGKRNGLHLPEQVQNEIKSMKRMSELCIDFNKNLNNEDDTFLVFSKAELGALPDDFIDSLEKTDKDKYITLKYPHYFPMKKC  
 CIPETRRRMEFAFNTRCKEENTILQQLPLRTRKVAKLLGYSTHADFLVEMNTAKSTSRVTAFLDDLSQLKPLGEAREFIFNL  
 KKKECKDRGFEDYDKINAWDLYYMTQTEELKYSIDQEFLEKYFPIEVVTEGLLNTYQELLGLSPEQMTDAHVNKSVTLTYTKD  
 KATGEVLGQFYLDLYPREGKYNHAACFLQPGCLLPDGRMMVAALVNVFSQPVAGRPSLLRHDEVRTYFHEFGHVMHQICAQ  
 DPARFSGTNNVETDFVEVPSQMLENWWVDVSLRRLSKHYKDGSPFIADDLLEKLVASLMLLGLLTLRQIVLSKVDQSLHNTSLDA  
 ASEYAKYCSBILGVAATPGTNMPATFGHLAGGYDGYGYLWSEVFSMDMFYSCFKKEGIMNPEVVGMYRNLILKPGSSLDGMD  
 MLHNFLEKREPQKAFILMSRGLHAP

5

A disclosed NOV6e nucleic acid (also referred to as c99.458) is a variant of NOV6a, encodes a novel neurolysin precursor-like protein, and is shown in Table 6L. NOV6e nucleotide changes are underlined in Table 6L.

**Table 6L. NOV6e Nucleotide Sequence (SEQ ID NO:19)**

CCTCTCAGCGCTCCCATGATCGCCCGGTGCTTTTGGCTGTGCGAAGCCTCCGAGGGTTGGTGGTTCCAGGATTTTAC  
 TCAGAAATGACGTTAGGAAGAGAAGTGATGTCTCTCTTCAGGCAATGTCTTCTATACGTGGCTGGCAGAAATGTTTT  
 AAGATGGGATCTTTACCAAGAGCAAATTAACAAGAACTGAGGAGCTCATGTGCAGACCAACAGGTGTACGATGCT  
 GTTGAATGCTCGGTATTGAGGAAGTAACCTACGAGAACTGTCTGCAGGCACTGGCAGATGTAGAAGTAAGTATATAG  
 TGGAAAGGACCATGCTAGACTTTCCCAAGCATGTATCTCTGACAAAGAACTACGAGCAGCAAGTACAGAAAGCAGACAA  
 AAGACTTTCTCGTTTGTATTTGAGATGAGCATGAGAGGAGATATATTTGAGAGAATGTTTCATTTACAGGAAACCTGT  
 GATCTGGGGAAGATAAAACCTGAGGCCAGACGATACTTGGAAAAGTCAATTAATAATGGGAAAAGAAATGGGCTCCATC  
 TTCTTGAACAAGTACAGAAATGAAATCAAATCAATGAAGAAAAGAAATGAGTGAGCTATGTATTGATTTTAAACAAAACCT  
 CAATGAGGATGATACCTTCTTGTATTTTCCAAGGCTGAACCTTGGTGTCTTCTCTGATGATTTTATTGACAGTTTAGAA  
 AAGACAGATGATGACAAGTATAAAATTTACCTTAAATATCCACACTATTTCCCTGTCTATGAAGAAATGTTGTATCCCTGT  
 AAACCAAGAAAGGATGGAAATGGCTTTTAAATACAAGGTGCAAGAGGAAAACACCATAATTTTGAGCAGCTACTCCC  
 ACTGCGAACCAGGTGGCCAACTACTCGGTTATAGCACACATGCTGACTTCGTCTTGAATGAACACTGCAAGAGGC  
 ACAAGCCGCTGAACAGCCTTTCTAGATGATTTAAGCCAGAAGTTAAACCCCTGGGTGAAGCAGAACGAGAGTTTATTT  
 TGAATTTGAAGAAAAGGAATGCAAGACAGGGGTTTGAATATGATGGGAAAATCAATGCCCTGGGATCTATATTACTA  
 CATGACTCAGACAGAGGAACCTCAAGTATTCATAGACCAAGAGTTCCTCAAGGAATACTTCCCAATTGAGGTGGTCACT

```

GAAGGCTTGCTGAACACCTACCAGGAGTTGTTGGGACTTTTCATTGAACAAATGACAGATGCTCATGTTTGGAAACAAGA
GTGTTACACTTTTACTGTGAAGGATAAAGCTACAGGAGAAGTATTGGGACAGTTCTATTGGACCTCTATCCAAGGGA
AGGAAAAATACAATCATGCGCGCTGCTTCGGTCTCCAGCCTGGCTGCCTTCTGCCTGATGGAAGCCGGATGATGGCAGTG
GCTGCCCTCGTGGTGAACCTTCTCACAGCCAGTGGCAGGTGCTCCCTCTCTCCTGAGACACGACGAGGTGAGGACTTACT
TTCATGAGTTTGGTCACGTGATGCATCAGATTGTTGCACAGACTGATTGTTGCACGATTTAGCGGAACAAATGTGGAAC
TGACTTTGTAGAGGTGCCATCGCAAAATGCTTGAATAATGGGTGTGGGACGTGCGATTCCCTCCGAAGATTGTCAAAACAT
TATAAGATGGAAGCCCTATTGCAGACGATCTGCTTGAATACTGTTGCTTCGCTTATGTTATTAGGTCTTCTGACCC
TGCGCCAGATTGTTTGGACAAAGTTGATCAGTCTCTCCATACCAACACATCGCTGGATGCTGCAAGTGAATATGCCAA
ATACTGCTCAGAAATATTAGGAGTTGAGCTACTCCAGGTACAAATATGCCAGTACCTTTGGACATTTGGCAGGGGGA
TACGATGGCCAAATATTATGGATATCTTTGGAGTGAAGTATTTCCATGGATATGTTTACAGCTGTTTAAAGAGGAG
GGATAATGAATCCAGAGGTAGTTGGAATGAAATACAGAAACCTAATCCTGAAACCTGGGGGATCTCTGGACGGCATGGA
CATGCTCCACAATTTCTTGAACGTGAGCCAAACCAAAAGCGTTCCTAATGAGTAGAGGCTGCGATGCTCCGTGAAC
GGGGATCTTTGGTAGCCGTCATGTCTGGAGGACAAG

```

A disclosed NOV6e polypeptide (SEQ ID NO:20) encoded by SEQ ID NO:19 is presented using the one-letter amino acid code in Table 6M. NOV6e amino acid changes, if any, are underlined in Table 6M.

**Table 6M. Encoded NOV6e protein sequence (SEQ ID NO:20).**

```

MIARCLLAVRSLRRVGGSRILLRMTLGREVMSPLQAMSSYTAVGRNVLRWDLSPQIKTRTEELIVQTRQVYDAVGMGLGIEEVTY
ENCLQALADLEVVKYIIVERTMLDFPQHVSSDKEVRAASTEADKRLSRFDIEMSMRGDI FERI VHLQBTCDLGIKPEARRYLEKSI
KMGKRNLHLPEQVQNEIKSMKKRMSLCLDFNKNLNEEDTFLVFSKAELGALPDDFIDSLEKTDKDKYKILTKYPHYPPVMKKC
CIPETRRRMEMAFNTRCKEENTII LQQLPLRTKVAKLLGYSTHADFLVLEMTAKSTSRVTAFLDDLSQLKPLGEAEREFFILNL
KKKECKDRGFPEYDGINAWDLYYMTQTEELKYSIDQEFLEKYFPPIEVVTEGLLNTYQELLGLSFEQMTDAHVWNKSVTLTYTKD
KATGEVLGQFYLDLYPREGKYNHAACFGLQPGCLLPDGSRRMVAALVVNFSQPVAGRPSLLRHDEVRTYFHEFGHVMHQICAQT
DFARFSGTINVETDFVEVPSQMLENWWVDVSLRRLSKHYKDGSP IADDLLEKLVASLMLLGLLTLRQIVLSKVDQSLHTNTSLDA
ASEYAKYCSEILGVAATPGTNMPATFGHLAGGYDGGYGYLWSEVFSMDMPYSCFKKEGIMNPEVVGMYRNLILKPGGSLDGM
MLHNFLLKREPQKAPFLMSRGLHAP

```

A disclosed NOV6f nucleic acid (also referred to as 13375341) is a variant of NOV6a, encodes a novel neurolysin precursor-like protein, and is shown in Table 6N. NOV6f nucleotide changes are underlined in Table 6N.

**Table 6N. NOV6f Nucleotide Sequence (SEQ ID NO:21)**

```

CCTCTCAGCGCTCCCATGATCGCCCGGTGCTTTTGGCTGTGCGAAGCCTCCGACGGGTGTTGGTTCCAGGATTTTAC
TCAGAAATGACGTTAGGAAGAGAGTATGATGTCCTCTTCAGGCAATGTCTTCTTACTGTGGCTGGCAGAAATGTTT
AAGATGGGATCTTTTACCAGAGCAAAATTAACAAGAACTGAGGAGCTCATGTGTCAGACCAACAGGTGATCGATGCT
GTTGGAATGCTCGGTATTGAGGAAGTAACCTACGAGAACTGTCTGACGGCACTGGCAGATGTAGAAGTAAAGTATATAG
TGGAAAGGACCATGCTAGACTTTCCCGCATGTATCCTCTGACAAAGAAATACGAGCAGCAAGTACAGAAAGCAGACAA
AAGACTTTCTCGTTTGTATTTGATATTGAGATGAGCATGAGAGGAGATATATTGAGAGAAATGTTTCATTTACAGGAACTCTG
GATCTGGGGAAGATAAAACCTGAGGCCAGACGATACTTGGAAAAGTCAATTAATAATGGGGAAGAAATGGGCTCCATC
TTCTGAAACAGTACAGAAATGAAATCAATGAAGAAAGAAATGAGTGAGCTATGTATTGATTTTAAACAAAACCT
CAATGAGGATGATACCTTCTTGTATTTTCCAAGGCTGAACCTGGTGCTCTTCTGATGATTTTATTGACAGTTTAGAA
AAGACAGATGATGACAAAGTATAAAATACCTTAAATATCCACACTATTTCCCTGTGATGAAGAAATGTTGTATCCCTG
AAACCAGAAAGGATGGAATGGCTTTAATACAGGTGCAAAGAGGAAACACCATAATTTGACAGCAGCTACTCCC
ACTGCGAACCAAGGTGGCCAACTACTCGGTTATAGCACACATGCTGACTTCGTCTTGAAATGAACACTGCAAGAGC
ACAAGCCCGTAACAGCCTTTCTAGATGATTTAAGCCAGAAAGTTAAACCCCTGGGTGAAGCAGAAACGAGAGTTTATTT
TGAATTTGAAGAAAAGGAATGCAAAGACAGGGGTTTGAATATGATGGGAAAATCAATGCTGGGATCTATATTACTA
CATGACTCAGACAGAGGAACCTCAAGTATTCATAGACCAAGAGTTCTCAAGGAATACTTCCAATTTAGGTGGTCACT
GAAGGCTTGCTGAACACCTACCAGGAGTTGTTGGGACTTTTCATTGAACAAATGACAGATGCTCATGTTTGGAAACAAGA
GTGTTACACTTTTACTGTGAAGGATAAAGCTACAGGAGAAGTATTGGGACAGTTCTATTGGACCTCTATCCAAGGGA
AGGAAAAATACAATCATGCGCGCTGCTTCGGTCTCCAGCCTGGCTGCCTTCTGCCTGATGGAAGCCGGATGATGGCAGTG
GCTGCCCTCGTGGTGAACCTTCTCACAGCCAGTGGCAGGTGCTCCCTCTCTCCTGAGACACGACGAGGTGAGGACTTACT
TTCATGAGTTTGGTCACGTGATGCATCAGATTGTTGCACAGACTGATTGTTGCACGATTTAGCGGAACAAATGTGGAAC
TGACTTTGTAGAGGTGCCATCGCAAAATGCTTGAATAATGGGTGTGGGACGTGCGATTCCCTCCGAAGATTGTCAAAACAT
TATAAGATGGAAGCCCTATTGCAGACGATCTGCTTGAATACTGTTGCTTCGCTTATGTTATTAGGTCTTCTGACCC
TGCGCCAGATTGTTTGGACAAAGTTGATCAGTCTCTTCATACCAACACATCGCCGGATGCTGCAAGTGAATATGCCAA
ATACTGCTCAGAAATATTAGGAGTTGAGCTACTCCAGGTACAAATATGCCAGTACCTTTGGACATTTGGCAGGGGGA
TACGATGGCCAAATATTATGGATATCTTTGGAGTGAAGTATTTCCATGGATATGTTTACAGCTGTTTAAAGAGGAG
GGATAATGAATCCAGAGGTAGTTGGAATGAAATACAGAAACCTAATCCTGAAACCTGGGGGATCTCTGGACGGCATGGA
CATGCTCCACAATTTCTTGAACGTGAGCCAAACCAAAAGCGTTCCTAATGAGTAGAGGCTGCGATGCTCCGTGAAC
GGGGATCTTTGGTAGCCGTCATGTCTGGAGGACAAG

```



A disclosed NOV6f polypeptide (SEQ ID NO:22) encoded by SEQ ID NO:21 is presented using the one-letter amino acid code in Table 6O. NOV6f amino acid changes, if any, are underlined in Table 6O.

**Table 6O. Encoded NOV6f protein sequence (SEQ ID NO:22).**

MIARCLLAVRSLRRVGGSRILLRMTLGRVMSPLQAMSSYTVAGRNVLRWDLSPQIKTRTEELIVQTKQVYDAVGMGLGIEEVTY  
ENCLQALADVEVKYIIVERTMLDFPQHVSSDKEVRAASTEADKRLSRFDIEMSMRGDI FERI VHLQETCDLGKIKPEARRYLEKSI  
KMGKRNGLHLPEQVQNEIKSMKKRMSEL CIDFNKNLNEDDTFLVFSKAELGALPDDFIDSLEKTDDDKYKITLKYPHYFPVMKKC  
CIPETRRLMEMAFNTRCKEENTII LQQLPLRTKVAKLLGYSTHADFLVLEMTAKSTSRVTAFLDQLS QKLKPLGEAREF ILNL  
KKKECKDRGFFEYD G KINAWDLYYMTQTEBLKYSIDQEF LKEYFPIEVVTEGLLNTYQELLGLSFEQMTDAHVWNKSVTLTYTVKD  
KATGEVLGQFYLDLYPREGKYNHAACFGLQPGCLLPDGSRRMVAALVVNFSSQPVAGRPSLLRHDEVRTYFHEFGHVMHQICAQT  
DFARFSGTNVETDFVEVPSQMLENWNVDVSLRRLSKHYKDGSP IADDLLEKLVASLMLLGLLTLRQIVLSKVDQSLHTNTPDA  
ASEYAKYCS EILGVAATPGTNMPATFGHLAGGYDGYGYLWSEVFSMDMFYSCFKKEGIMNPEVVGMYRNLLKPGGSLDGM  
MLHNF LKREP NQKAF LMSRGLHAP

- 5 A disclosed NOV6g nucleic acid (also referred to as c99.459) is a variant of NOV6a, encodes a novel neurolysin precursor-like protein, and is shown in Table 6P. NOV6g nucleotide changes are underlined in Table 6P.

**Table 6P. NOV6g Nucleotide Sequence (SEQ ID NO:23)**

CCTCTCAGCGCTCCCATGATCGCCCGGTGCCTTTTGGCTGTGCGAAGCCTCCGAGGGTGGTGGTTCCAGGATTTTAC  
TCAGAAATGACGTTAGGAAGAGAAGTGATGTCTCTCTTCAGGCAATGTCTCTCTATACTGTGGCTGGCAGAAATGTTTT  
AAGATGGGATCTTTACCCAGAGCAAATTAACCAAGAACTGAGGAGCTCATGTGCGAGCAACACAGGTGTACGATGCT  
GTTGGAATGCTCGGTATTGAGGAAGTAACCTTACGAGAACTGTCTGCGAGCACTGGCAGATGTAGAAGTAAGATATATAG  
TGGAAGGACCATGCTAGACTTTCCCGAGCATGTATCTCTCTGACAAAGAGTACGAGCAGCAAGTACAGAAGCAGACAA  
AAGACTTTCTCGTTTGTATATTGAGATGAGCATGAGAGGAGATATATTGAGAGAAATGTTTCATTTACAGGAAACCTGT  
GATCTGGGGAAGATAAAACCTGAGGCCAGACGATACCTTGGAAAAGTCAATTAATAATGGGGAAGAAATGGGCTCCATC  
TTCCTGAACAAATGACAAATGAAATCAATCAATGAAGAAAGAAATGAGTGAGCTATGTATTGATTTTAACAAAAACCT  
CAATGAGGATGATACCTTCTGTATTTTCCAAGGCTGAACTTGGTGCTCTCTCTGATGATTTCAATGACAGTTTAGAA  
AAGACAGATGATGACAAATATAAAATACCTTAAATATCCACACTATTTCCCTGTGATGAAGAAATGTTGATCCCTG  
AAACAGAGAAGGATGGAATGGCTTTTAATACAAGGTGCAAGAGGAGAAACACCATAAATTTGCGAGCAGCTACTCCC  
ACTGCGAACCAAGGTGGCCAACTACTCGGTTATAGCACACATGCTGACTTCGTCTTGAATGAACACTGCAAGAGC  
ACAAGCCCGGTAAACGCTTTCTAGATGATTTAAGCCAGAAATTAACCCCTGGGTGAAGCAGAACGAGAGTTTATTT  
TGAATTTGAAGAAAAGGAATGCAAGACAGGGGTTTGAATATGATGGGAAATCAATGCCCTGGGATCTATATTA  
CATGACTCAGACAGAGGAATCAAGTATTCATAGACCAAGAGTTCCTCAAGGAATACTTCCCAATTGAGGTGGTCACT  
GAAGGCTTGCTGAACACCTACAGGAGTTGTTGGGACTTTTCAATTTGAACAAATGACAGATGCTCATGTTTGGAAACA  
GTGTTTACACTTTATCTGTGAAGGATAAAGCTACAGGAGAAGTATTTGGGACAGTTCTATTGGACCTCTATCCAGGGA  
AGGAAAATACATATGCGGCCTGCTTCGGTCTCCAGCCTGGCTGCTCTGCTGATGGAAGCCGGATGATGGCAGTG  
GCTGCCCTCGTGGTGAACTTCTCACAGCCAGTGGCAGGTGCTCCCTCTCTCTGAGACACGACGAGGTGAGGACTTACT  
TTCATGAGTTTGGTCACGTGATGCATCAGATTTGTGCACAGACTGATTTGACGATTTAGCGGAACAAATGTGGAAC  
TGACTTTGTAGAGGTGCCATCGCAAATGCTTGAATAATGGGTGTTGGGACGTGATTCCTCCGAAAGATTGTCAAACAT  
TATAAGATGGAAGCCCTATTGACAGCATCTGCTTGAATAACTTGTGCTTCGCTTATGTTATTAGGTCTTCTGACCC  
TGCGCCAGATTGTTTGAAGCAAGTTGATCAGTCTTTCATACCAACACATCGCTGGATGCCGCAAGTGAATATGCCAA  
ATACTGCTCAGAAATATTAGGAGTTGCAGCTACTCCAGGTACAAATATGCCAGCTACCTTTGGACATTTGGCAGGGGA  
TACGATGCCCAATATTATGATATCTTTGAGTAGAAGTATTTCCATGGATATGTTTACAGCTGTTTAAAAAAGAAG  
GGATAATGAATCCAGAGGTAGTTGGAATGAAATACAGAACTAATCTGAAACCTGGGGGATCTCTGACGGCATGGA  
CATGCTCCCAATTTCTGAAACGTGAGCCAAACCAAAAGCGTTCCTAATGAGTAGAGGCCTGCATGCTCCGTGAAT  
GGGATCTTTGTTAGCCGTCCATGTCTGGAGACAAG

- 10 A disclosed NOV6g polypeptide (SEQ ID NO:24) encoded by SEQ ID NO:23 is presented using the one-letter amino acid code in Table 6Q. NOV6g amino acid changes, if any, are underlined in Table 6Q.

**Table 6Q. Encoded NOV6g protein sequence (SEQ ID NO:24).**

EEVTYENCLQALADVEVKYIIVERTMLDFPQHVSSDKEVRAASTEADKRLSRFDIEMSMRGDI FERI VHLQETCDLGKIKPEARRY  
LEKSIKMGKRNGLHLPEQVQNEIKSMKKRMSEL CIDFNKNLNEDDTFLVFSKAELGALPDDFIDSLEKTDDDKYKITLKYPHYFP  
VMKKCCIPETRRLMEMAFNTRCKEENTII LQQLPLRTKVAKLLGYSTHADFLVLEMTAKSTSRVTAFLDQLS QKLKPLGEAREF  
F ILNLKKKECKDRGFFEYD G KINAWDLYYMTQTEBLKYSIDQEF LKEYFPIEVVTEGLLNTYQELLGLSFEQMTDAHVWNKSVTL  
YT VKDKATGEVLGQFYLDLYPREGKYNHAACFGLQPGCLLPDGSRRMVAALVVNFSSQPVAGRPSLLRHDEVRTYFHEFGHVMHQ  
ICAQTDFA RFS G T N V E T D F V E V P S Q M L E N W N V D V S L R R L S K H Y K D G S P I A D D L L E K L V A S L M L L G L L T L R Q I V L S K V D Q S L H T N  
T S L D A A S E Y A K Y C S E I L G V A A T P G T N M P A T F G H L A G G Y D G Y G Y L W S E V F S M D M F Y S C F K K E G I M N P E V V G M Y R N L L K P G G S  
L D G M D M L H N F L K R E P N Q K A F L M S R G L H A P



A disclosed NOV6h nucleic acid (also referred to as c99.460) is a variant of NOV6a, encodes a novel neurolysin precursor-like protein, and is shown in Table 6R. NOV6h nucleotide changes are underlined in Table 6R.

**Table 6R. NOV6h Nucleotide Sequence (SEQ ID NO:25)**

CCCTCTCAGCGCTCCCATGATGCGCCCGGTGCTTTTGGCTGTGCGAAGCTCCGCAAGGTTGGTGGTTCCAGGATTTTAC  
TACAGAAATGACGTTAGGAAGAAGAGATGATGTCTCTCTCTCAGGCAAGTGTCTTCTATATCTGTGGCTCGGCAAGAAATGTTT  
AAGATGGGATCTTTACCAGAGCAAAATTAACAAACAAGATCAGGAGCTATTTGTGCAGACCAACAGGCTGACAGTCT  
GTTGGAATGCTCGGTATTGAGGAAGTAACTTACGAGAAGTGTCTGCAGGCACTGGCAGATGTAGAAGTAAAGTATATAG  
TGGAAAGGACCATCGTGTAGACTTTCCCCAGCATGTATCTCTGCACAAAGAAGTACAGCAGCAAGTACAGAAAGCAGACAA  
AAGACTTCTCGTTTGTATATTGAGATGAGCATGAGAGGAGATATATTGAGAGAATTGTTCACTTTTACAGGAAACCTGT  
GATCTGGGGAAGATAAAACCTGAGGCCAGACGATACCTTGAAAAGTCAATTAAATGGGGAAAAGAAATGGGCTCCATC  
TTCTTGAAACAAGTACAGAAATGAATCAAACTCAATGAAGAAGAAGATGAGTGAAGTATGTTATGTTTAAACAAAACCTC  
CAATGAGAGATGATACCTCCTTGTTATTTCGAAGTGTGAAGCTGGTGCTCTCTCTGATGATTTCAATGCAGTTTAGAA  
AAGACAGATGATGACAAGTATAAAATTACCTTAAAAATCCACACTATTTCCCTGTCTAGGAAGAAATGTTGTATCCCTG  
AAACCGACAAAGAAGGTGAAAATGGCTTTTAATACAAGGTGCAAGAGGAGAAAACCCATAATTTTGCAGCAGCTACTCCC  
ACTCGAACCAAGGTGGCCAAACTACTTCGGTTATAGCACATCGTGACTTCGTCTGAAATTGAACACATGCAAGAAGG  
ACAAGCCGCGTAACAGCGCTTTCTAGATGAAATTAAGCCAGAAGTTAAACCCCTTGGGTGAAGCAGAACGAGAGTTTATTT  
TGAATTTGAAGAAAAGGAATGCAAGACAGGGGTTTTGAATATGATGGGAAAAATCAATGCTCGGGATCTATATTACTATA  
CATGACTGACACAGAGGAATCAAGTATCCATAGACAGAGTCTCTCAAGGAATCTCCCAATTGAGGTGTCATCT  
GAAGGCTTGTGCAACACCTACCAGGAGTTGTGGGACTTTCAATTGAAACAATGACAGATGCTCATGTTTGGAAACAAGA  
GTGTTACACTTTTATCTGTGAAGGATAAAGCTACAGAGAAGTATGGGACAGTTCTAATTGGACCTCTATCCAAAGGA  
AGGAAAATCAATCATCGCGCTGCTTCGGTCTCAGGCTGGCTGCTCTCTGCTCTGAGGAGCCGATGATGGCAGTG  
GCTGCCCTCGTGGTGAACCTTTCACAGCCAGTCGGCAGGTGGTCCCTCTCTCTGAGACACGAGGAGTGAAGACTTACT  
TTCATGAGTTTGGTCAAGTGATGCATCAGATTTGTGCACACGATGATTTCGACGATTTAGCGGAAACAAATGTTGGAAC  
TGACTCTGTTGAGAGGTGCCATGCCAAATGCTTGAATAATGGGTGTGGGACGTCGATTCCTCCGAAGATTGTCAAAACAT  
TAAAGAATGGAAGCCCTATTGCACAGATCTGCTGGAATAACTTGTGCTTCGTTATGTTATAGGCTCTTGTGACCC  
TGCCTGATGATGTTTGTAGCAAGTTGATCAGTCTCTTCATACCAACACATCGCTGGATGCTGCAAGTGAATGCTGCTAA  
ATACTCGCTCAGAAATATTAGGAGTTGCAGTACTCCAGGTACAAATATGCCAGTACCTTTGGACATTTGAGCGGGGA  
TACAGATGGCCAAATATTAGGATATCTTGGAGTGAAGTATTTCCATGAGTATGTTTACAGCTGTTTAAAAAAGAGAG  
GGATAATGAATCCAGAGGTAGTTGGAAATGAATAACAGAAACCTAATCTGAAACCTGGGGGATCTCTGGACGGCATGGA  
CATGCTCCACAAATTTCTTGAACCGTAGGCCAACCAACAAAGCGTTCTTAATGAGTAGAGGCCCTGCATGCTCCGTGAACT  
GGGATCTTTGGTAGCCGTGCATGTCTGAGGACAAG

5

A disclosed NOV6h polypeptide (SEQ ID NO:26) encoded by SEQ ID NO:25 is presented using the one-letter amino acid code in Table 6S. NOV6h amino acid changes, if any, are underlined in Table 6S.

**Table 6S. Encoded NOV6h protein sequence (SEQ ID NO:26).**

MIARCLLAVRSLRRVGGSRILLRMTLGRVMSPLQAMSSYTVAGRNVLRWDLSPQIKTRTEELIVQTKQVYDVGMLGIEEVTY  
ENCLQALADVVEKYIVERTMLDFPQHVVSDKDEVRANSTEDKRLSRFDIESMGRDIFERIVHLEQCTDLGKIKPBARYLEKS  
KMGKRGHLPLPQEQVNEIKSMKKMRSELCIDFNKLNATEDTFLVFSKAEGLALPDDFIDSLEHTDDDKYKITLKYPHYFVPMKCK  
CIPETRRRMEMAFNTRCKEENTIIILQQLPLPLRTKVAKLLGYSTHADFVLEMNTAKSTSRVTAFLDDLSQKLKPLGEAREFII<sup>1</sup>NL  
KKCKEGRDGFVEYDGKINAWDLYYMTQTEELKYSIDQEPKFYEYPIEIVTEGLNLTQYBLLGSFEQMTDAHVMNSVTLTYVKD  
KATEVLGQGYFLDLPREGYKYNHAAFCGLPGCLLPGDGRSMAVAALVNVNFSQPVAGRPSLLRHDEVRTYTFHEFGVHMVHQICAQT  
DFARESGTNVETDFVEVPSQMLENVWDVDSLRLRLSKHYKDGSP<sup>2</sup>IADDLLEKLVASLMMLGLLTLRQIVLSKVDQSLHTNTSLDA  
ASEYAKYCYSEILGVAATPGTNMPATFGHLAGGYDGQYGYLWSEVFSMDMFCYCFKKEGIMNPEVVGMYRNLILKPGGSLDGM<sup>3</sup>D  
MLHNFLKREPNOQKAFMLSRGLHAP

10

A disclosed NOV6i nucleic acid (also referred to as c99.752) is a variant of NOV6a, encodes a novel neurolysin precursor-like protein, and is shown in Table 6T. NOV6i nucleotide changes are underlined in Table 6T.

**Table 6T. NOV6i Nucleotide Sequence (SEQ ID NO:27)**

CCTCTCAGCGCTCCCATGATCGCCCGGTGCCTTTTGCGTGTGCGAAGCCTCCGCAAGGGTTGGTGGTTCCAGGATTTTAC  
TCAAGATGACGTTAGGAAGAAGAGATGATGTCCTCTCTTCAGGCAGATGTCCTCTCATATCGTGCTGCGGCAAGATGTTT  
AAGATGGGATCTTTCCACGAGCAAAATAAAACAAGAACTGAGAGATCTCATTTGTCAGACAAACGGGTGTACATGCT  
GTTGGAATGCTCGGTATTGAGGAAGTAACTTACGAGAACTGTCTGCAGGCACCTGGCAGATGTAGAAGTAAAGTATATAG  
TGGAAAGGACCAATGCTAGACTTTCCCGACATGTAATCTCTGCAAAAAGAACTACGACGCAAGTACAGAAAGCAACAA  
AAGACTTTCCTGGTTTGATATTGAGATGAGCAGTGAAGGAGATATATTGAGAAATTTGTCATTATTAAGAAACCTGT

```

GATCTGGGGAAGATAAAACCTGAGGCCAGACGATACTTGGAAAAGTCAATTAATAATGGGGAAGAAATGGGCTCCATC
TTCTTGAAACAGTACAGAATGAAATCAAATCAATGAAGAAAAGATGAGTGAGCTATGTATTGATTTTAACAACAAACCT
CAATGAGGATGATACCTTCCTTGTATTTTCCAAGGCTGAACCTTGGTGTCTTCTCTGATGATTTCATTGACAGTTTAGAA
AAGACAGATGATGACAAGTATAAAATTACCTTAAATATCCACACTATTTCCCTGTATGAAGAAATGTTGTATCCCTG
AAACCAGAAGAAGGATGGAATGGCTTTTAAACAAGGTGCAAGAGGAAAACACCATAATTTTGCAGCAGCTACTCCC
ACTGCGAACCAGGTGGCCAAACTACTCGGTTATAGCACACATGCTGACTTCGTCTTGAATGAACACTGCAAGAGAGC
ACAAGCCGCTAACAGCCTTTCTAGATGATTAAAGCCAGAAGTTAAACCCCTTGGGTGAAGCAGAACGAGAGTTTATT
TGAATTTGAAGAAAAGGAATGCAAGACAGGGGTTTTGAATATGATGGGAAAATCAATGCCCTGGGATCTATATTACTA
CATGACTCAGACAGAGGAACCTCAAGTATTCATAGACCAAGAGTTCCTCAAGGAATACTTCCCAATTGAGGTGGTCACT
GAAGCTTGCTGAACACCTACCAGGAGTTGTTGGGACTTTCATTGAAACAAATGACAGATGCTCATGTTTGGAAACAAGA
GTGTTACACTTTTATACGTGAAGGATAAAGCTACAGGAGAAGTATGGGACAGTTCTATTGGACCTCTATCCAAGGGA
AGGAAAATACAATCATGCGGCCTGCTTCGGTCTCCAGCCTGGCTGCTCTGCTGATGGAAGCCGGATGATGCGAGTG
GCTGCCCTCGTGGTGAACCTTCTCACAGCCAGTGGCAGGTGCTCCCTCTCTCTCTGAGACACGACGAGGTGAGGACTTACT
TTCATGAGTTTGGTCACGTGATGCATCAGATTTGTGCACAGACTGATTTGCACGATTAGCGGAACAAATGTGGAAC
TGACTTTGTAGAGGTGCCATCGCAAATGCTTGAAAATGGGTGTGGGACGTCGATTCCTCCGAAGATTGTCAAAACAT
TATAAGATGGAAGCCCTATTCGACAGCATCTGCTTGAAAACCTTGTGCTTCGCTTATGTTATTAGGTCTTCTGACCC
TGCGCCAGATTGTTTGTAGCAAAGTTGATCAGTCTCTCATACCAACACATCGCTGGATGCTGCAAGTGAATGCCAA
ATACTGCACAGAAATATTAGGAGTTGCAGCTACTCCAGGTACAAATATGCCAGCTACCTTTGGACATTGGCAGGGGGA
TACGATGGCCAATATTATGGATATCTTTGGAGTGAAGTATTTCCATGGATATGTTTACAGCTGTTTAAAAAAGAAG
GGATATGAATCCAGAGGTAGTTGGAATGAAATACAAAACCTTAATCCTGAAACCTGGGGGATCTCGAGCGCATGGA
CATGCTCCACAATTTCTTGAACGTGAGCCAAACCAAAAGCGTTCCTAATGAGTAGAGGCTGCATGCTCCGTGAAC
GGGGATCTTGGTAGCCGTCCATGCTGAGGACAAG

```

A disclosed NOV6i polypeptide (SEQ ID NO:28) encoded by SEQ ID NO:27 is presented using the one-letter amino acid code in Table 6U. NOV6i amino acid changes, if any, are underlined in Table 6U.

**Table 6U. Encoded NOV6i protein sequence (SEQ ID NO:28).**

```

MIARCLLAVRSLRRVGGSRILLRMTLGREVMSPQLQAMSSYTVAGRNVLRWDLSPQIKTRTEELIVQTKQVYDAVGMGLIEEVTY
ENCILQALADVEVKYIVERTMLDFPQHVSSDKEVRAASTEADKRLSRFDIEMSMRGDIFERIVHLQETCDLGKIKPEARRYLEKSI
KMGIRNGLHLPEQVQNEIKSMKKRMSLECIDFNKNLNEDDTFLVFSKAELGALPDDFIDSLEKTDDDKYKITLKYPHYFPVMKKC
CIPETRRRMEMAFNTRCKEENTIILOQLPLRTKVAKLLGYSTHADFLVEMNTAKSTSRVTAFLDDLSQLKLPLGEAEREFILNL
KKKECKDRGFYDQKINAWDLYYMTQTBEELKYSIDQEFLEKYPPIEVVTEGLLNTYQELLGLSFEQMTDAHVNKSVTLTYTKD
KATGEVLGQFVLDLYPREGKYNHAACFGLQPGCLLPDGSRRMVAALVVNFSQPVAGRPSLLRHDEVRTYFHFEGHVMHQICAQT
DFARFSGTINVETDFVEVPSQMLENWWVDVSLRRLSKHYKDGSPADDDLEKLVASLMLLGLLTLRQIVLSKVDQSLHTNTSLDA
ASEYAKYCTEILGVAATPGTNMPATFGHLAGGYDQYGYLWSEVFSMDMFYSCFKKEGIMNPEVVGMYRNLILKPGGSLDGMD
MLHNFLLKREPQKAFILMSRGLHAP

```

5

Homologies to any of the above NOV6 proteins will be shared by the other NOV6 proteins insofar as they are homologous to each other as shown above. Any reference to NOV6 is assumed to refer to all three of the NOV6 proteins in general, unless otherwise noted.

10 A human genomic clone encompassing exons 1-3 of the neurotensin/neuromedin N gene was identified using a canine neurotensin complementary DNA probe. Sequence comparisons revealed that the 120-amino acid portion of the precursor sequence encoded by exons 1-3 is 89% identical to previously determined cow and dog sequences and that the proximal 250 bp of 5' flanking sequences are strikingly conserved between rat and human. The 5' flanking sequence contains cis-regulatory sites required for the induction of

15 neurotensin/neuromedin N gene expression in PC12 cells, including AP1 sites and two cyclic adenosine-5'-monophosphate response elements. Oligonucleotide probes based on the human sequence were used to examine the distribution of neurotensin/neuromedin N messenger RNA in the ventral mesencephalon of schizophrenics and age- and sex-matched controls. Neurotensin/neuromedin N messenger RNA was observed in ventral mesencephalic cells

some of which also contained melanin pigment or tyrosine hydroxylase messenger RNA. Neurons expressing neurotensin/neuromedin N messenger RNA were observed in the ventral mesencephalon of both schizophrenic and non-schizophrenic humans. PMID: 1436492, UI: 93063858

5        Neurotensin is a small neuropeptide of 13 amino acids that may function as a neurotransmitter or neuromodulator in the central nervous system. In the CNS, neurotensin is localized to the catecholamine-containing neurons. A catecholamine-producing cell line can also produce NT. Lithium salts, widely used in the treatment of manic-depressive patients, dramatically potentiate NT gene expression in this cell line. Gerhard et al. (1989) used a  
10        canine cDNA as a probe on a somatic cell hybrid panel to determine that the human gene is located on chromosome 12.

      The tridecapeptide neurotensin (162650) is widely distributed in various regions of the brain and in peripheral tissues. In the brain, neurotensin acts as a neuromodulator, in particular of dopamine transmission in the nigrostriatal and mesocorticolimbic systems, suggesting its  
15        possible implication in dopamine-associated behavioral neurodegenerative and neuropsychiatric disorders. Its various effects are mediated by specific membrane receptors. Vita et al. (1993) isolated a cDNA encoding the human neurotensin receptor and showed that it predicts a 418-amino acid protein that shares 84% homology with the rat protein. Le et al. (1997) also cloned the human neurotensin receptor (NTR) cDNA and its genomic DNA. The  
20        gene is encoded by 4 exons spanning more than 10 kb. The authors identified a highly polymorphic tetranucleotide repeat approximately 3 kb from the gene. Southern blot analysis revealed that the NTR gene is present in the human genome as a single-copy gene. Le et al. (1997) stated that the neurotensin receptor has 7 transmembrane spanning regions and high homology to other receptors that couple to G proteins.

25        The above defined information for NOV6 suggests that NOV6 may function as a member of a Neurolysin family. Therefore, the NOV6 nucleic acids and proteins of the invention are useful in potential therapeutic applications implicated in various diseases and disorders described below and/or other pathologies. For example, the NOV6 compositions of the present invention will have efficacy for treatment of patients suffering from behavioral  
30        neurodegenerative and neuropsychiatric disorders such as schizophrenia, anxiety disorders, bipolar disorders, depression, eating disorders, personality disorders, or sleeping disorders, Cardiomyopathy, Atherosclerosis, Hypertension, Congenital heart defects, Aortic stenosis, Atrial septal defect (ASD), Atrioventricular (A-V) canal defect, Ductus arteriosus, Pulmonary stenosis, Subaortic stenosis, Ventricular septal defect (VSD), valve diseases, Tuberous

sclerosis, Scleroderma, Transplantation, Adrenoleukodystrophy, Congenital Adrenal Hyperplasia, Diabetes, Von Hippel-Lindau (VHL) syndrome, Pancreatitis, Endometriosis, Fertility, Inflammatory bowel disease, Diverticular disease, Hirschsprung's disease, Crohn's Disease, Hemophilia, hypercoagulation, Idiopathic thrombocytopenic purpura,

5 immunodeficiencies, Osteoporosis, Hypercalcaemia, Arthritis, Ankylosing spondylitis, Scoliosis, Endocrine dysfunctions, Diabetes, Growth and reproductive disorders, Psoriasis, Actinic keratosis, Acne, Hair growth, alopecia, pigmentation disorders and endocrine disorders. The NOV6 nucleic acid encoding neurolysin precursor-like protein, and the neurolysin precursor-like protein of the invention, or fragments thereof, may further be useful

10 in diagnostic applications, wherein the presence or amount of the nucleic acid or the protein are to be assessed.

### NOV7

NOV7 includes six novel gamma-aminobutyric acid (GABA) transporter-like receptor proteins disclosed below. The disclosed proteins have been named NOV7a, NOV7b, NOV7c,

15 NOV7d, NOV7e and NOV7f.

### NOV7a

A disclosed NOV7a nucleic acid of 1763 nucleotides (also referred to as 12201) encoding a novel GABA transporter-like receptor protein is shown in Table 7A. An open reading frame was identified beginning with an ATG initiation codon at nucleotides 141-143

20 and ending with a TAG codon at nucleotides 1716-1719. Putative untranslated regions, if any, are found upstream from the initiation codon and downstream from the termination codon in Table 7A, and the start and stop codons are in bold letters.

**Table 7A. NOV7a Nucleotide Sequence (SEQ ID NO:29)**

TCATGAGCCAGAGAGCCCCGGGGCGCGCGGAGAGCAAGCGGAGATAGCGACTTTGCGCCCCCAGCC
CTCGCCTTCTGTCATCGCGTTCCCGCATCCTCGGGTCCTTCTGTCTTCCGCTGTCCCCACCGCGCC
ATGGCCACCTTGCTCCGAGCAAGCTGTCCAACGTGGCCACGTCCGTGTCCAACAAGTCCAGGCCAAGA
TGAGCGGCATGTTCCGAGGATGGGTTTTCAGGCGGCCACGGATGAGGAGGCGGTGGGCTTCGCGCATTG
CGACGACCTCGACTTTGAGCACCGCCAGGGCCTGCAGATGGACATCCTGAAAGCCGAGGGAGAGCCCTGC
GGGGACGAGGGCGCTGAAGCGCCCGTCGAGGAGACATCCATTATCAGCGAGGCGCGGAGCTCCTCTGC
CGCCCTCCGGCTCCAAGGACAGGTGGGAGGTGGTGGCAATTGGGGGCCACGACAAGCCCAAAATCAC
GGCGTGGGAGGCAGGCTGGAACGTGACCAACGCCATCCAGGGCATGTTCTGTCTGGGCCTACCCCTACGCC
ATCCTGCACGGCGGTACCTGGGGTTGTTTCTCATCATCTTCGCCGCCGTTGTGTGCTGTACACCGGCA
AGATCCTCATCGCGTGCCTGTACGAGGAGAATGAAGACGGCGAGGTGGTGGCGTGCAGGACTCGTACGT
GGCCATAGCCAAAGCTGCTGCGCCCGCGCTTCCCAACGCTGGGCGGCCGAGTGGTGAACGTAGCGCAG
ATCATCGAGCTGGTGATGACGTGCATCCTGTACGTGGTGGTGGTGGCAACCTCATGTACAACAGCTTCC
CGGGCTGCGCGTGTGCGAGAAGTCTGGTCCATTATCGCCACGGCCGTGCTGTGCTTGGCCTTCCT
TAAGAACCTCAAGGCCGTGTCCAAGTTCAGTCTGCTGTGCACTCTGGCCCACTTCGTATCAATATCCTG
GTCATAGCCTACTGTCTATCGCGGGCGCGGACTGGGCTGGGAGAAGGTCAAGTTCATACATGACGTCA
AGAAGTTCCCATCTCCATTGGCATCATCGTGTTCAGCTACAGTCTCAGATCTTCTGCTTCCGTGGA
GGGCAATATGACGAGCCAGCGAGTTCACCTGCATGATGAAGTGGACGCACATCGAGCCTGCGTGTCTC
AAGGCCTCTTCGCGCTCGTCGCCTACCTCACCTGGGCGGACGAGACCAAGGAGGTATCACGGATAACC

TGCCCGGCTCCATCCGCGCGTGGTCAACATCTTTCTGGTGGCCAAGGCGCTGTGTCTATCCTCTGCC  
 ATTCTTTGCCGCTGTCGAGGTGCTGGAGAAGTCGCTCTCCAGGAAGGCAGCCGCGCTTTTCCCGGCC  
 TGCTACAGCGCGCAGCGGCGCCTGAAGTCCTGGGGGCTGACGCTGCGCTGCGCGCTCGTCTTCACGC  
 TGCTCATGGCCATTTATGTGCCGCACTTCGCGCTGCTCATGGGCTCACCAGGAGCCTCAGGGCGCGCG  
 CCTCTGTTCTTGTGCTGCCAGCCTCTTTCACCTGCGCTGCTGCGCAAGCTGCTGTGGCACCAAGTC  
 TTCTTCGACGTCGCCATCTTCGTCATCGGCGGCATCTGCAGCGTGTCCGGCTTCGTGCACTCCCTCGAGG  
 GCCTCATCGAAGCCTACCGAACCAACGCGGAGGACTAGGGCGCAAGGCGAGCCCCGCGCGCTCTGC  
 GCTCTCTCCCTTC

The disclosed NOV7a nucleic acid sequence, localized to chromosome 20, has 1532 of 1695 bases (90%) identical to a *Homo sapiens* vesicular GABA transporter (VGAT) mRNA (gb: acc: AF030253) ( $E = 4.3e^{-308}$ ).

- 5 A disclosed NOV7a polypeptide (SEQ ID NO:30) encoded by SEQ ID NO:29 is 525 amino acid residues and is presented using the one-letter amino acid code in Table 7B. Signal P, Psort and/or Hydropathy results predict that NOV7a does not contain a signal peptide and is likely to be localized in the plasma membrane with a certainty of 0.6000.

**Table 7B. Encoded NOV7a protein sequence (SEQ ID NO:30).**

MATLLRSKLSNVATSVSNKSQAKMSGMFARMGFOAATDEEAVGFAHCDLDFEHRQGLQMDILKAEGEPC  
 GDEGAEPVEGDIHYQRGGGAPLPPSGSKDQVGGGGEFGGHDKPKITAWAAGWNVTNAIQGMFVLGLPYA  
 ILHGGYLGFLIIFAAVVCCYTGKILIACLYEENEDGEVVRVDSYVAIANACCAPRFTLGGRRVNVQAQ  
 IIELVMTCIILYVVVSGNLMYNSFPGLPVSQKWSIIATAVLLPCAFLKLNKAVSKFSLCTLAHFVINIL  
 VIAYCLSRARDWAEKVKFYIDVKKFPISIGIIVFSYTSQIFLPSLEGNMQQPSEFHCMMNWTHIAACVL  
 KGLFALVAYLTWADETKEVITDNLPGSIRAVVNI FLVAKALLSYPLPFFAAVEVLEKSLFQEGSRAFFPA  
 CYSYDGLRLKSWGLTLRCALVVFLLMAIYVPHFALLMGLTGSITGAGLCFLPLSLFHLRLLRKLLWHQV  
 FFDVAIFVIGGICSVSGFEVHSLEGLIEAYRTNAED

10

The NOV7a amino acid sequence has 518 of 525 amino acid residues (98%) identical to, and 519 of 525 amino acid residues (98%) similar to the *Homo Sapiens* 525 amino acid residue vesicular GABA transporter protein (SPTREMBL-ACC: O35458) ( $E = 0.0$ ).

- NOV7a is expressed in at least the following tissues/cell lines: Brain, HS-528T/MCF-  
 15 7, BT549/MDA-MB-231, OVCAR-3/OVCAR-4, IGROV-1, OVCAR-8, SK-OV-3 & OVCAR-5.

Novel variants for the NOV7a nucleic acid and vesicular GABA transporter-like protein are also disclosed herein as variants of NOV7a. Variants, as described above, are reported individually, but any combination of all or a subset are also included.

- 20 A disclosed NOV7b nucleic acid (also referred to as 13374575) is a variant of NOV7a, encodes a novel vesicular GABA transporter-like protein, and is shown in Table 7C. NOV7b nucleotide changes are underlined in Table 7C.

**Table 7C. NOV7b Nucleotide Sequence (SEQ ID NO:31)**

GAAGGGAGAGAGCGCAGAAGCGCGCGGGGGCTCGCCCTAGTCCTCCGCGTGGTTCCGTAGGCTTCGATG  
 AGGCCCTCGAGGGAGTGCAAGAGCGGACACGCTGCAGATGCCCGCGATGACGAAGATGGCGACGTCGAAGAAGACTT  
 GGTGCCACAGCAGCTTGCGCCAGAGCAGGCGCAGGTGAAGAGAGGCTGGGCAGCAAGAAACAGAGGCCGGCGCCGCTGAG  
 GCTGCCGCTGAGGCCATGAGCAGCGCGAAGTGCGGCACATAAATGGCCATGAGCAGCGTGAAGACGACGAGCGCGCAG  
 CGCAGCGTCAGCCCCCAGGACTTCAGGCGCCCGTCCGCGCTGTAGCAGGCCGGGAAAAAGGCGCGGCTGCCTTCTGGA  
 AGAGCGACTTCTCCAGCACCTCGACAGCGGCAAGAATGGCAGAGGATAGGACACAGCGCCTTGGCCACCGGAAAGAT

```

GTTGACCACGGCGCGGATGGAGCCGGGACAGGTTATCCGTGATGGCCTCCTTGGTCTCGTCGGCCAGGTGAGGTAGGCG
ACGAGCCGGAAGAGGCCCTTGACACGACAGGCTGCGATGTGCGTCCAGTTCATCATGCAGTGGAACTCGCTGGGCTGCT
GCATATTGCCCTCCAGCGAAGGCAGGAAGATCTGAGACGTGTAGCTGAACACGATGATGCCAATGGAGATGGGGAAGCTT
CTTGACGTGATGTAGAACTTGACCTTCTCCAGGCCAGTTCGCGCGCCCGGATAGACAGTAGGCTATGACCAGGATA
TTGATGACGAAGTGGGCCAGAGTGCACAGCAGACTGAACTTGGACACGGCCTTGAGGTTCTTAAGGAAGGCGCAGGCA
GCAGCACGGCCGTGGCGATAATGGACAGGACTTCTGCGACACGGGACGCCCGGGAAGCTGTTGATCATGAGGTTGCC
ACTCACCACACGTCAGGATGCACGTATCACCAGCTCGATGATCTGCGTACGTTTACCACCTCGGCCCGCCAGCGTT
GGGAAGCCGGGGCGCAGCAGGCGTTGGCTATGGCCACGTACGAGTCCCGCAGCGCACCACCTCGCCGCTTTCATTTCT
CCTCGTACAGGCACGCGATGAGGATCTTGCCGGTGTAGCAGCACACAACGGCGCGGAAGATGATGAGAAACAACCCAG
GTAGCCGCGGTGAGGATGGCGTAGGGTAGGCCAGCAGAACATGCCCTGGATGGCGTTGGTCACGTTCCAGCCTGCC
TCCACGCGCGTGAATTTGGGCTTGTGCTGGCCCCGAATTCGCCACACCTCCACCTGGTCTTGGAGCCGAGGGCG
GCAGAGGAGCTCCGCTGCTGATAATGGATGTCTCCTCGACGGGCGCTTCAGCGCCCTCGTCCCGCAGGGGCTC
TCCCTCGGCTTTCAGGATGTCCATCTGCAGGCGCTGGCGGTGCTCAAAGTCGAGGTCGTCGCAATGCGCGAAGCCACC
GCCTCTCATCCGTGGCGCGCTGAAAACCCATCCTGGCGAACATGCCGCTCATCTTGGCCTGGGACTTGTGGACACGG
ACGTGGCCACGTTGGACAGCTTGCTGCGGAGCAAGGTGGCCATGGCGCGGTGGGGACAGCGGAAAGGACAGAAGGACC
CGAGGATGCGGGGAACGCGATGCAAGAAGGCGAGGGCTGGGGGGCGCAAAGTCGCTATCTCCGCTTGCTCTCCG

```

A disclosed NOV7b polypeptide (SEQ ID NO:32) encoded by SEQ ID NO:31 is presented using the one-letter amino acid code in Table 7D. NOV7b amino acid changes, if any, are underlined in Table 7D.

5

**Table 7D. Encoded NOV7b protein sequence (SEQ ID NO:32).**

```

MATLLRSKLSNVATSVSNKSQAKMSGMFARMGFAQATDEAVGFAHCDLDFEHRQGLQMDILKABGEPCGDEGAEPVEGDIHY
QRGSGAPLPSPSGSKDQVGGGGGFFGGHDKPKITAWAGWNVNTAIQGMFVLGLPYAILHGGYLGFLIIIFAAVCCYTGKILIACL
YEENEDGEVVRVRSYVAIANACCAPRFPITLGGRVNVNAQIIELVMTCILYVVVSGNLMYNSFPGLPVSQKWSIIATAVLLPCA
FLKNLKAIVSKPSLLCTLAHFVINILVIAVCLSRARDWANEKVKFYIDVKKFPISIGIIVFSYTSQIFLPSLEGNNMQPSEFHCNM
NWTIHAACVLKGLFALVAYLTWADETKEAITDNLPGSIRAVVNIFFVAKALLSYPLPFFAAVEVLEKSLFQEGSRAFFPACYSYG
GRLSWGLTLRLCALVVFLLMAIYVPHFALLMGLTGLSLTGAGLCFLPLSLFHLRLLLWRKLLWHQVFFDVAFIVIGICSVSGFVH
SLEGLIEAYRTNAED

```

A disclosed NOV7c nucleic acid (also referred to as 13374576) is a variant of NOV7a, encodes a novel vesicular GABA transporter-like protein, and is shown in Table 7E. NOV7c nucleotide changes are underlined in Table 7E.

**Table 7E. NOV7c Nucleotide Sequence (SEQ ID NO:33)**

```

GAAGGGAGAGAGCGCAGAAGCGCGCGGGGGCTCGCCCTTGCGCCCTAGTCTCCGCGTTGGTTCGGTAGGCTTCGATG
AGGCCCTCGAGGGAGTGCAAGAGCCGGACACGCTGCAGATGCCGCGGATGACGAAGATGGCGACGTCGAAGAAGACTT
GGTGCCACAGCAGCTTGCGCCAGAGCAGGCGCAGGTGAAAGAGGCTGGGCAGCAAGAAACAGAGGCCGGCGCCCGTGAG
CTGCGCGGTGAGGCCCATGAGCAGCGCGAAGTGGCGCACATAATGGCCATGAGCAGCGTGAAGACGACGAGCGCGCAG
CGCAGCGTCAGCCCCCAGGACTTCAGGCGCGCGTGCCTGCTGCTAGCAGGCGGGGAAAGGCGCGGCTGCTTCTGGA
AGAGCGACTTCTCAGCACCTCGACAGCGGCAAGAATGGCAGAGGATAGGACAAACAGCGCCCTTGGCCACAGAAAGAT
GTTGACCACGCGCGGATGGAGCCGGGCGAGTTATCCGTGATGACCTCCTTGGTCTCGTCGGCCAGGTGAGGTAGGCG
ACGAGCGCGAAGAGGCCCTTGAGCACGACGCGTGCATGTGCGTCCAGTTCATCATGCAGTGGAACTCGCTGGGCTGCT
GCATATTGCCCTCCAGCGAAGCGAGGAAGATCTGAGACGTGTAGCTGAACACGATGATGCCAATGGAGATGGGGAAGCTT
CTTGACGTGATGTAGAACTTGACCTTCTCCAGGCCAGTTCGCGCGCCCGCGATAGACAGTAGGCTATGACCAGGATA
TTGATGACGAAGTGGGCCAGAGTGCACAGCAGACTGAACTTGGACACGGCCTTGAGGTTCTTAAGGAAGGCGCAGGCA
GCAGCACGGCCGTGGCGATAATGGACCAAGGACTTCTGCGACACGGGACGCCCGGGAAGCTGTTGATCATGAGGTGCC
ACTCACCACACGTCAGGATGCACGTATCACCAGCTCGATGATCTGCGTACGTTTACCACCTCGGCCCGCCAGCGTT
GGGAAGCGCGGGGCGCAGCAGGCGTTGGCTATGGCCACGTACGAGTCCCGCAGCGCACCACCTCGCCGCTTTCATTTCT
CCTCGTACAGGCACGCGATGAGGATCTTGCCGGTGTAGCAGCACACAACGGCGCGAAGATGATGAGAAACAACCCAG
GTAGCCGCGGTGACGAGTGGCGTAGGGTAGGCCAGCAGAACATGCCCTGGATGGCGTTGGTCACGTTCCAGCCTGCC
TCCACGCGGTGATTTGGGCTTGTGCTGGCCCCGAATTCGCCACACCTCCACCTGGTCTTGGAGCCGAGGGCG
GCAGAGGAGCTCCGCTGCTCGCTGATAATGGATGTCTCCTCGACGGGCGCTTCAGCGCCCTCGTCCCGCAGGGCTC
TCCCTCGGCTTTCAGGATGTCCATCTGCAGGCCCTGGCGGTGCTCAAAGTCGAGGTCGTCGCAATGCGCGAAGCCACC
GCCTCTCATCCGTGGCGCGCTGAAAACCCATCCTGGCGAACATGCCGCTCATCTTGGCCTGGGACTTGTGGACACGG
ACGTGGCCACGTTGGACAGCTTGCTGCGGAGCAAGGTGGCCATGGCGCGGTGGGGACAGCGGAAAGGACAGAAGGACC
CGAGGATGCGGGGAACGCGATGCAAGAAGGCGAGGGCTGGGGGGCGCAAAGTCGCTATCTCCGCTTGCTCTCCG

```

10

A disclosed NOV7c polypeptide (SEQ ID NO:34) encoded by SEQ ID NO:33 is presented using the one-letter amino acid code in Table 7F. NOV7c amino acid changes, if any, are underlined in Table 7F.

**Table 7F. Encoded NOV7c protein sequence (SEQ ID NO:34).**

MATLLRSKLSNVATSVSNKSQAKMSGMFARMGFQAATDEEAVGFAHCDLDFEHRQGLQMDILKAEGEPCGDEGAEPVEGDIHY  
 QRGSGAPLPSPSGSKDQVGGGGFEGGHDKPKITAWAGWNVTNAIQGMFVLGLPYAILHGGYLGLFLIIFAAVCCYTGKILIACL  
 YEENEDGEVVRVRSYVAIANACAPRFPPTLGGRVNVNAQIIELVMTICILYVVVSGNLMYNSFPGLPVSQKWSIIATAVLLPCA  
 FLKNLKAVSKFSLCTLAHFVINILVIAYCLSRARDWAWEKVKFYIDVKKFPIISIGIIVFSYTSQIFLPSLEGNMQPSEFHCMM  
 NWTHIAACVLKGLFALVAYLTWADETKEVITDNLPGSIRAVVNI FLVAKALLSYPLPFFAAVEVLEKSLFQEGSRAFFPACYSGD  
 GRLKSWGLTLRCALVVFTLLMAIYVPHFALLMGLTGSLTGAGLCFLLPSLFHLRLLRKLLWHQVFFDVAIFVIGGICSVSGFVH  
 SLEGLIEAYRTNAED

A disclosed NOV7d nucleic acid (also referred to as 13374577) is a variant of NOV7a,  
 encodes a novel vesicular GABA transporter-like protein, and is shown in Table 7G. NOV7d  
 5 nucleotide changes are underlined in Table 7G.

**Table 7G. NOV7d Nucleotide Sequence (SEQ ID NO:35)**

GAAGGGAGAGAGCGCAGAAGCGCGGGGGGCTCGCCCTTGCGCCCTAGTCCTCCGCGTTGGTTTCGGTAGGCTTCGATG  
 AGGCCCTCGAGGGAGTGCACGAAGCCGGACACGCTGCAGATGCCGCCGATGACGAAGATGGCGACGTCGAAGAAGACTT  
 GGTGCCACAGCAGCTTGCGCCAGAGCAGGCGCAGGTGAAGAGGCTGGGCAGCAAGAAACAGAGGCCGGCGCCCGTGAG  
 GCTGCCGCTGAGGCCCATGAGCAGCGCGAAGTGCAGCACATAAATGGCCATGAGCAGCGTGAAGACGACGAGCGCGCAG  
 CGCAGCGTCAGCCCCAGGACTTCAGGCGCCCGTCCGCGCTGTAGCAGGCCGGGAAAAAGGCGCGGCTGCCTTCTCTGGA  
 AGAGCGACTTCTCCAGCAGCTCGACAGCGCAAGAATGGCAGAGGATAGGACAACAGCGCCTTGGCCACAGAAAGAT  
 GTTGACCAACGCGCGGATGGAGCGGGCAGGTTATCCGTGATGGCTCCTTGGTCTCGTCGGCCAGGTGAGGTAGGCG  
 ACGAGCGCAAGAGGCCCTTGAGCAGCAGGCTGCGATGTGCGTCCAGTTCATCATGCAGTGGAACTCGCTGGGCTGCT  
 GCATATTGCCCTCCAGCGAAGGCAGGAAGATCTGAGACGTGTAGCTGAACACGATGATGCCAATGGAGATGGGGAACTT  
 CTTGACGTCGATGTAGAACTTGACCTTCTCCAGGCCAGTTCGCGCGCCCGCGATAGACAGTAGGCTATGACACAGGATA  
 TTGATGACGAAGTGGGCCAGAGTGCACAGCAGACTGAACTGGACACGGCCCTTGAGGTTCTTAAGGAAGGCGCAAGGCA  
 GCAGCAGCGCGTGGCGATAATGGACAGGACTTCTGCGACACGGGCGAGCCCGGGAAGCTGTTGATCATGAGGTGCGC  
 ACTCACCACCAGTACAGGATGCACGTTCATCACCAGTTCGATGATCTGCGCTACGTTTACCACCTCGGCGCGCCAGCGTT  
 GGGAAAGCGCGGGCGCAGCAGGCGTTGGCTATGGCCCGGTACGAGTCCCGCACGCGCACCACTCGCGCTTCTTATCT  
 CCTCGTACAGCAGCGATGAGGATCTTGCCTGTTAGCAGCACAACCGCGCGAAGATGATGAGAAACAACCCAG  
 GTAGCCGCGTGCAGGATGGCGTAGGGTAGGCCAGCAGCAACATGCCCTGGATGGCGTTGGTCACGTTCCAGCTGCC  
 TCCACAGCGCGTGAATTTGGGCTTGTGCTGGCCCCGAATTGCGCACCACTCCACCTGGTCTTGGAGCCGGAGGGCG  
 GCAGAGGAGCTCCGCTGCCTCGTGATAATGGATGTCTCCCTCGACGGGCGCTTACGCGCCCTCGTCCCGCAGGGCTC  
 TCCCTCGCTTTTACGATGTCCATCTGCAGGCCCTGGCGGTGCTCAAAGTCAAGGTCGTCGCAATGCGCGAAGCCACC  
 GCCTCTCATCCGTGGCGCCTGAAAACCCATCTGGCGAACAATGCGCTCATCTTGGCTGGGACTTGTGGACACGG  
 ACGTGGCCACGTTGGACAGCTTGTGCGGAGCAAGGTGGCCATGGCGCGGTGGGGACAGCGGAAAGACAGAAGGACC  
 CGAGGATGCGGGGAACGCGATGCAAGAAGCGAGGCTGGGGGCGCAAGTTCGCTATCTCCGCTTGCTCTCCGC

A disclosed NOV7d polypeptide (SEQ ID NO:36) encoded by SEQ ID NO:35 is  
 presented using the one-letter amino acid code in Table 7H. NOV7d amino acid changes, if  
 any, are underlined in Table 7H.

**Table 7H. Encoded NOV7d protein sequence (SEQ ID NO:36).**

MATLLRSKLSNVATSVSNKSQAKMSGMFARMGFQAATDEEAVGFAHCDLDFEHRQGLQMDILKAEGEPCGDEGAEPVEGDIHY  
 QRGSGAPLPSPSGSKDQVGGGGFEGGHDKPKITAWAGWNVTNAIQGMFVLGLPYAILHGGYLGLFLIIFAAVCCYTGKILIACL  
 YEENEDGEVVRVRSYVAIANACAPRFPPTLGGRVNVNAQIIELVMTICILYVVVSGNLMYNSFPGLPVSQKWSIIATAVLLPCA  
 FLKNLKAVSKFSLCTLAHFVINILVIAYCLSRARDWAWEKVKFYIDVKKFPIISIGIIVFSYTSQIFLPSLEGNMQPSEFHCMM  
 NWTHIAACVLKGLFALVAYLTWADETKEAITDNLPGSIRAVVNI FLVAKALLSYPLPFFAAVEVLEKSLFQEGSRAFFPACYSGD  
 GRLKSWGLTLRCALVVFTLLMAIYVPHFALLMGLTGSLTGAGLCFLLPSLFHLRLLRKLLWHQVFFDVAIFVIGGICSVSGFVH  
 SLEGLIEAYRTNAED

10

A disclosed NOV7e nucleic acid (also referred to as 13374578) is a variant of NOV7a,  
 encodes a novel vesicular GABA transporter-like protein, and is shown in Table 7I. NOV7e  
 nucleotide changes are underlined in Table 7I.

**Table 7I. NOV7e Nucleotide Sequence (SEQ ID NO:37)**

GAAGGGAGAGAGCGCAGAAGCGCGGGGGGCTCGCCCTTGCGCCCTAGTCCTCCGCGTTGGTTTCGGTAGGCTTCGATG  
 AGGCCCTCGAGGGAGTGCACGAAGCCGGACACGCTGCAGATGCCGCCGATGACGAAGATGGCGACGTCGAAGAAGACTT  
 GGTGCCACAGCAGCTTGCGCCAGAGCAGGCGCAGGTGAAGAGGCTGGGCAGCAAGAAACAGAGGCCGGCGCCCGTGAG

5

MATLLRSKLSNVATSVSNKSQAKMSGFMARMGFQAATDEEAVGFACDDDLFEHQGLQMDILKAEGEPCGDEGAEPVEGDIHY  
QRGSGAPLPPSGSKDQVGGEFGFGHDKPKITAWAEGWVNVTNAIQGMFVLGLPYAILHGGLGLGLFLIIFAAVVCYCTGKILIALC  
YEENEDGEVVRVRSYVAIANACAPRPFITLGGRVNVNAQIIELVMTIIVVVSGNLMYNSFGLPVPSQKWSIATAVILPCL  
FLKNLKA VKSFLSLCTLAHFVINTLIYVAYCLSRDWARWAEKVFYIDVKPEPISIGIIVFSYTSQIFLPSLSEGNMQPSEFHCMM  
NWTHTAACVLKGLFALVAYLTWADETKEAITDNLPGSIRAVVNI FLVAKALLSYLPPFAAEVLEKSLFQEGSRAFFPACYSGD  
GRLLKSWGLTLRCLAVVFTLLMAIYVPHFALLMGLTGSLTGAGLCFLLPSPHLRLRLWRKLLWHQVFFDVAIFVIGGICSVSGFVH  
SLEGLIEAYRTNAED

10

GAAGGGAGAGAGCGCAGAAGCGCGCGGGGGCTCGCCCTTGCGCCCTAGTCCTCCGCGTTGGTTCCGTAGGCTTCGATG  
AGGCCCTCGAGGGAGTGCACGAAGCCGGACACGCTGCAGATGCGCCCGATGACGAAGATGGCGACCTCGAGGAAGACTTC  
GGTGCCACACGACGCTTCGCGCAGACGAGCCGAGGTGAAGAGGCTGGGCAGCAAGAACACGAGCCGCGCCGTGAG  
GCTGCCGGTGAGGCCCATGAGCAGCGCGAAGTGGCGCAATAAATGGCCATGAGCAGCGTGAAGACGACGAGCGCGCAC  
CGCAGCGCTCAGCCCCAGCACTTCAGCGCCCGTTCGCCCTGTAGCAGGCCGGGAAAAAGCGCGCTGCCCTCTCTGGA  
AGAGCGACTTCTCCAGCACTTCGACAGCGCGCAAGAATGGCAGAGGATAGGACAACAGCGCTCTGGCCACAAGAAT  
GTTGACCTGCGCCGGATGGAGCCGGCAGGTTATCCGTGATGGCTCTTGTTCTCTGTCGGCCAGGTGAGGTAGCG  
ACGAGCGCGAAGAGGCCCTTGAGCACAGCAGGCTCGCATGTCGCTTCAGTTCATGCATGAGTGGAACTCGCTGGGCTGCT  
GCATATTGCCCTCCAGCGAAGCGAGGAGCTGTAGACGTGTAGCTGAACACGATGATCCAAATGGAGATGGGAACTT  
CTTGACCTGCTGTAGAACTTGACTTCTCCAGGCCCGAGTGCAGCGCCCGATAGACAGATGAGCTATGACCAGGATA  
TTGATGACCAAGTGGGCCGAGGTGCACACGACAGCTGAATCTGGACACGGCCCTTGAGTTGCTTAAGGAAGCGCGAAGCA  
CGACACGGCCGTGGGCATAATGGACAGGACTTCTGCGACACGGGCGAGCCCGGAAGCTGTTGTACATGAGGTTGCC  
ACTCACCAACCGTACAGATGCACTGATCACAGCTCGATGCTGCGCTACGTTACACTCTGGCGCCGACGCT  
GGGAAGCGCGGGGCGACGAGCGGTGGCTATGGCCACGTACGAGTCCCGCACGGCACCACTCGCCGCTCTCATCT  
CCTCGTACAGGCACGCGATGAGGATCTTGCCCGTGTAGCAGCACACACCGCGCGAGATGATGAGAAACACCCACG  
TAGGCCCGCTGCAGATGGCGTAGGTAGGCGAGCCAGCAGCAACTCCCTGATGGCTGGTACGCTTCAGCTCCAGCTGCC  
TCCCAGAGCGCTGATTTGGGCTTGTGCTGGTCCCCGAATTCCGCACACCACTCCACCTGGCTCTGGAGCGAGGGCG  
GCCAGGGAGCTCGCTGCCCTGTAAATGGATGTTCTCCCTCGACGGGGCGCTTCAGCGCCCTCGTCCCGCGAGGCTC  
TCCCTCGGCTTTCAGATGTTCATCTGCAGGCCCTGGCGGTGCTCAAAGTGCAGGTCGTGCAATGCGCGAAGCCCAAC  
GCCTCCTCATCCGTGGCCGCTGAAACCCATCCTGGCGAACATGCCGCTCATCTTGGCTCGGACTTGTGGACAGG  
ACGTGGCCACGCTTGACAGCTTCTCGCGAGGACGTGGCCCATGGCCGCGGTGGGGACAGCGGAAGAGCAGAGGACC  
CGAGATGTCGGGGAACCGCATGCAAGAAGGACGAGGCTGGGGGGCGCAAGTTCGCTATCTCCGCTGCTCTCCG



A disclosed NOV7f polypeptide (SEQ ID NO:40) encoded by SEQ ID NO:39 is presented using the one-letter amino acid code in Table 7L. NOV7f amino acid changes, if any, are underlined in Table 7L.

**Table 7L. Encoded NOV7f protein sequence (SEQ ID NO:40).**

MATLLRSKLSNVATSVSNKSQAKMSGMFARMGFQAATDEEAVGFHACDDLDPEHRQGLQMDILKAEGEPCGDEGAEPVEGDIHY  
 QRGSGAPLPPSGSKDQVGGGGFEGDHDKPKITAEAGWNVNAINAQGMFVLGLPYAILHGGYLGFLIIFAAVVCCYTGKILIA  
 YEENEDGEVVRVDSYVAIANACAPRFPFLLGGRVNVNAQIIELVMTICILYVVVSGNLMYNSFPGLPVSQKSWSIATAVLLPCA  
 FLKNLKAVSKFSLLLCTLAHFVINILVIAYCLSRARDWAEKVKFYIDVKKFPISIGIIVFSYTSQIFLPSLEGNMQPSEFHCMM  
 NWTHIAACVLKGLFALVAVLTWADETKEAITDNLPGSIRAVVNI FLVAKALLSYPLPFAAVEVLEKSLFQEGSRAFFPACYS  
 GDLRLKSWGLTLRCALVVFLLMAIYVPHFALLMGLTGSLLTGAGLCFLPLSLPHLRLLWRKLLWHQVFFDVAIFVIGGICSVSGFVH  
 SLEGLIEAYRTNAED

5 NOV7a – NOV7f are very closely homologous as is shown in the nucleic acid alignment in Table 7M and the amino acid alignment in Table 7N.

**Table 7M Nucleic Acid Alignment of NOV7a – NOV7f.**

	10	20	30	40	50
NOV7a ba122o1	TCATGAGCCAGAGAGCCCGGGCGCGCGCGGAGCAAGCGGAGATAG				
NOV7b 13374575	---GAAGGGAGAGAGCGCAGAAAGCGCGCGG---GGGGCTCGCCC---TTG				
NOV7c 13374576	---GAAGGGAGAGAGCGCAGAAAGCGCGCGG---GGGGCTCGCCC---TTG				
NOV7d 13374577	---GAAGGGAGAGAGCGCAGAAAGCGCGCGG---GGGGCTCGCCC---TTG				
NOV7e 13374578	---GAAGGGAGAGAGCGCAGAAAGCGCGCGG---GGGGCTCGCCC---TTG				
NOV7f 13374579	---GAAGGGAGAGAGCGCAGAAAGCGCGCGG---GGGGCTCGCCC---TTG				

  

	60	70	80	90	100
NOV7a ba122o1	CGACTTTCGGCCCGCCAGCC-CTCGCCTTCTTCATCGCGTTCGCGCAT				
NOV7b 13374575	CGCCCTAGTCCTCCGCGTTCGGTTCGGTAGGCTTCGATGAGGCCCTCGAGG				
NOV7c 13374576	CGCCCTAGTCCTCCGCGTTCGGTTCGGTAGGCTTCGATGAGGCCCTCGAGG				
NOV7d 13374577	CGCCCTAGTCCTCCGCGTTCGGTTCGGTAGGCTTCGATGAGGCCCTCGAGG				
NOV7e 13374578	CGCCCTAGTCCTCCGCGTTCGGTTCGGTAGGCTTCGATGAGGCCCTCGAGG				
NOV7f 13374579	CGCCCTAGTCCTCCGCGTTCGGTTCGGTAGGCTTCGATGAGGCCCTCGAGG				

  

	110	120	130	140	150
NOV7a ba122o1	CCTCGGGTCTTTCGCTTCCTTCGCGTTCGCCACCGCCGCTATGCCAC				
NOV7b 13374575	GAGTGCACGAAGCCGGACACGCTGCAGATGCCGCCGATGACGAAGATGGC				
NOV7c 13374576	GAGTGCACGAAGCCGGACACGCTGCAGATGCCGCCGATGACGAAGATGGC				
NOV7d 13374577	GAGTGCACGAAGCCGGACACGCTGCAGATGCCGCCGATGACGAAGATGGC				
NOV7e 13374578	GAGTGCACGAAGCCGGACACGCTGCAGATGCCGCCGATGACGAAGATGGC				
NOV7f 13374579	GAGTGCACGAAGCCGGACACGCTGCAGATGCCGCCGATGACGAAGATGGC				

  

	160	170	180	190	200
NOV7a ba122o1	TTGCTCCGACCAAGCTGTCCAAAGTGGCCAGCTTCCTGTCCTACAGT				
NOV7b 13374575	G-ACGTCGAAGAAGACTTGGTGCCACAGCAGCTT--GCGCCAGAGCAGGC				
NOV7c 13374576	G-ACGTCGAAGAAGACTTGGTGCCACAGCAGCTT--GCGCCAGAGCAGGC				
NOV7d 13374577	G-ACGTCGAAGAAGACTTGGTGCCACAGCAGCTT--GCGCCAGAGCAGGC				
NOV7e 13374578	G-ACGTCGAAGAAGACTTGGTGCCACAGCAGCTT--GCGCCAGAGCAGGC				
NOV7f 13374579	G-ACGTCGAAGAAGACTTGGTGCCACAGCAGCTT--GCGCCAGAGCAGGC				

  

	210	220	230	240	250
NOV7a ba122o1	CCAGGCCAA---GATGAGCGGCATGTTCCGCCAGATGCGTTTTCAGCG				
NOV7b 13374575	GCAGGTGAAAGAGGCTGGGCAGCAAGAA--ACAGAGGCCGCGCCCGTGAG				
NOV7c 13374576	GCAGGTGAAAGAGGCTGGGCAGCAAGAA--ACAGAGGCCGCGCCCGTGAG				
NOV7d 13374577	GCAGGTGAAAGAGGCTGGGCAGCAAGAA--ACAGAGGCCGCGCCCGTGAG				
NOV7e 13374578	GCAGGTGAAAGAGGCTGGGCAGCAAGAA--ACAGAGGCCGCGCCCGTGAG				
NOV7f 13374579	GCAGGTGAAAGAGGCTGGGCAGCAAGAA--ACAGAGGCCGCGCCCGTGAG				

  

	260	270	280	290	300
NOV7a ba122o1	GCCAGGATGAGGAGCGGGTGGGCTTCGCGCATGCG--ACGACCTCGAC				
NOV7b 13374575	GCTGCCGGTGAGGC--CCATGAGCAGCGCGAAGTGCGGCACATAAATGGC				
NOV7c 13374576	GCTGCCGGTGAGGC--CCATGAGCAGCGCGAAGTGCGGCACATAAATGGC				
NOV7d 13374577	GCTGCCGGTGAGGC--CCATGAGCAGCGCGAAGTGCGGCACATAAATGGC				

NOV7e 13374578 GCTGCCGGTGAGGC--CCATGAGCAGCGCGAAGTGC CGGCACATAAAATGGC  
NOV7f 13374579 GCTGCCGGTGAGGC--CCATGAGCAGCGCGAAGTGC CGGCACATAAAATGGC

310 320 330 340 350  
NOV7a ba122o1 TTGTAGCACCCTCCCGGCTGAGATGGACATCTGAAAGCCAGGG-AG  
NOV7b 13374575 CATGAGCAGCGTGAAGACG-ACGAGCGCGCAGCGCAGCGTCAGCCCCAG  
NOV7c 13374576 CATGAGCAGCGTGAAGACG-ACGAGCGCGCAGCGCAGCGTCAGCCCCAG  
NOV7d 13374577 CATGAGCAGCGTGAAGACG-ACGAGCGCGCAGCGCAGCGTCAGCCCCAG  
NOV7e 13374578 CATGAGCAGCGTGAAGACG-ACGAGCGCGCAGCGCAGCGTCAGCCCCAG  
NOV7f 13374579 CATGAGCAGCGTGAAGACG-ACGAGCGCGCAGCGCAGCGTCAGCCCCAG

360 370 380 390 400  
NOV7a ba122o1 AGCTCTCGCGGACGAGCGCGCTGAGCGCCCTCGAGGAGACATCCAT  
NOV7b 13374575 GACTTCAGGCGCCCGTCGCGCTGTAGCAGGCGGGAAAAAGGCG-CGGC  
NOV7c 13374576 GACTTCAGGCGCCCGTCGCGCTGTAGCAGGCGGGAAAAAGGCG-CGGC  
NOV7d 13374577 GACTTCAGGCGCCCGTCGCGCTGTAGCAGGCGGGAAAAAGGCG-CGGC  
NOV7e 13374578 GACTTCAGGCGCCCGTCGCGCTGTAGCAGGCGGGAAAAAGGCG-CGGC  
NOV7f 13374579 GACTTCAGGCGCCCGTCGCGCTGTAGCAGGCGGGAAAAAGGCG-CGGC

410 420 430 440 450  
NOV7a ba122o1 TATCAGCGAGGCGCGGAGCTCTCTGCGCGCTC-CGGCTCCAAAGACC  
NOV7b 13374575 TGCTTCTCTGGAAGAGCGACTTCTCCAGCACCTCGACAGCGGCAAGAAT  
NOV7c 13374576 TGCTTCTCTGGAAGAGCGACTTCTCCAGCACCTCGACAGCGGCAAGAAT  
NOV7d 13374577 TGCTTCTCTGGAAGAGCGACTTCTCCAGCACCTCGACAGCGGCAAGAAT  
NOV7e 13374578 TGCTTCTCTGGAAGAGCGACTTCTCCAGCACCTCGACAGCGGCAAGAAT  
NOV7f 13374579 TGCTTCTCTGGAAGAGCGACTTCTCCAGCACCTCGACAGCGGCAAGAAT

460 470 480 490 500  
NOV7a ba122o1 AG-GTGGGAGGTGTGGTGAATTGGGGCCACGACAGCCCAAAATCAC  
NOV7b 13374575 GGCAGAGGATAGGACAACAGCGCCTTGGCCACCGAAAGATGTTGACCAC  
NOV7c 13374576 GGCAGAGGATAGGACAACAGCGCCTTGGCCACCGAAAGATGTTGACCAC  
NOV7d 13374577 GGCAGAGGATAGGACAACAGCGCCTTGGCCACCGAAAGATGTTGACCAC  
NOV7e 13374578 GGCAGAGGATAGGACAACAGCGCCTTGGCCACCGAAAGATGTTGACCAC  
NOV7f 13374579 GGCAGAGGATAGGACAACAGCGCCTTGGCCACCGAAAGATGTTGACCAC

510 520 530 540 550  
NOV7a ba122o1 GGCCTGG--GAGGACGGCTGGAACCTGACCAACCGCATCCAGGGCATGTT  
NOV7b 13374575 GGCCTGGATGGAGCCGGGCAGGTTATCCGTGATGGCTCCTTGGTCTCGT  
NOV7c 13374576 GGCCTGGATGGAGCCGGGCAGGTTATCCGTGATGACCTCCTTGGTCTCGT  
NOV7d 13374577 GGCCTGGATGGAGCCGGGCAGGTTATCCGTGATGGCTCCTTGGTCTCGT  
NOV7e 13374578 GGCCTGGATGGAGCCGGGCAGGTTATCCGTGATGGCTCCTTGGTCTCGT  
NOV7f 13374579 GGCCTGGATGGAGCCGGGCAGGTTATCCGTGATGGCTCCTTGGTCTCGT

560 570 580 590 600  
NOV7a ba122o1 CGTGTGGGCTACCTACCGCATCTGACCGCGGCTACCTGGGTTGT  
NOV7b 13374575 CGGCCCAGGTGAGGTAGGCGACGAGC-GCGAAGAGGCC-CTTGAGCACGC  
NOV7c 13374576 CGGCCCAGGTGAGGTAGGCGACGAGC-GCGAAGAGGCC-CTTGAGCACGC  
NOV7d 13374577 CGGCCCAGGTGAGGTAGGCGACGAGC-GCGAAGAGGCC-CTTGAGCACGC  
NOV7e 13374578 CGGCCCAGGTGAGGTAGGCGACGAGC-GCGAAGAGGCC-CTTGAGCACGC  
NOV7f 13374579 CGGCCCAGGTGAGGTAGGCGACGAGC-GCGAAGAGGCC-CTTGAGCACGC

610 620 630 640 650  
NOV7a ba122o1 TTCTCATCATCTTCGCGCCCGTTGT-GTGTGCTACACCGGCAAGAT--C  
NOV7b 13374575 AGGCTGCGATGTGCGTCCAGTTCATCATGCAGTGGAACTCGCTGGGCTGC  
NOV7c 13374576 AGGCTGCGATGTGCGTCCAGTTCATCATGCAGTGGAACTCGCTGGGCTGC  
NOV7d 13374577 AGGCTGCGATGTGCGTCCAGTTCATCATGCAGTGGAACTCGCTGGGCTGC  
NOV7e 13374578 AGGCTGCGATGTGCGTCCAGTTCATCATGCAGTGGAACTCGCTGGGCTGC  
NOV7f 13374579 AGGCTGCGATGTGCGTCCAGTTCATCATGCAGTGGAACTCGCTGGGCTGC

660 670 680 690 700  
NOV7a ba122o1 CTCATCGCGTGCCTGTACGAGGACATGAGAGCGCGAGGTGGTGC-GCG  
NOV7b 13374575 TGCATATTGCCCTCCAGCGAAGGCAGGAAGATCTGAGACGTGTAGCTGAA  
NOV7c 13374576 TGCATATTGCCCTCCAGCGAAGGCAGGAAGATCTGAGACGTGTAGCTGAA  
NOV7d 13374577 TGCATATTGCCCTCCAGCGAAGGCAGGAAGATCTGAGACGTGTAGCTGAA  
NOV7e 13374578 TGCATATTGCCCTCCAGCGAAGGCAGGAAGATCTGAGACGTGTAGCTGAA  
NOV7f 13374579 TGCATATTGCCCTCCAGCGAAGGCAGGAAGATCTGAGACGTGTAGCTGAA

710 720 730 740 750  
NOV7a ba122o1 TGCGGAGCTCGTACGTGGCCATAGCCACGCTGCTGCCGCCCGCTTC  
NOV7b 13374575 CACGATGATGCCA-ATGGAGATGGGGAACCTCTTGACGTCGATGTAGAAC

NOV7c 13374576	CACGATGATGCCA-ATGGAGATGGGGAACCTTCTTGACGTCGATGTAGAAC
NOV7d 13374577	CACGATGATGCCA-ATGGAGATGGGGAACCTTCTTGACGTCGATGTAGAAC
NOV7e 13374578	CACGATGATGCCA-ATGGAGATGGGGAACCTTCTTGACGTCGATGTAGAAC
NOV7f 13374579	CACGATGATGCCA-ATGGAGATGGGGAACCTTCTTGACGTCGATGTAGAAC
<div>760 770 780 790 800</div>	
NOV7a ba122o1	CCACAGCTGGGC--GGCCGAGTGGTCAACGTAGCGCAGATCATCGAGC-I
NOV7b 13374575	TTGACCTTCTCCAGGCCCACTCGCGCGCCCGCGATAGACAGTAGGCTAT
NOV7c 13374576	TTGACCTTCTCCAGGCCCACTCGCGCGCCCGCGATAGACAGTAGGCTAT
NOV7d 13374577	TTGACCTTCTCCAGGCCCACTCGCGCGCCCGCGATAGACAGTAGGCTAT
NOV7e 13374578	TTGACCTTCTCCAGGCCCACTCGCGCGCCCGCGATAGACAGTAGGCTAT
NOV7f 13374579	TTGACCTTCTCCAGGCCCACTCGCGCGCCCGCGATAGACAGTAGGCTAT
<div>810 820 830 840 850</div>	
NOV7a ba122o1	GGTGTGACCTGCATCCT--GTACCTGGTGGTGAGTGGCAACCTCAGT
NOV7b 13374575	GACCAGGATATTGATGACGAAGTGGGCCAGAGTGCACAGCAGACTGAACT
NOV7c 13374576	GACCAGGATATTGATGACGAAGTGGGCCAGAGTGCACAGCAGACTGAACT
NOV7d 13374577	GACCAGGATATTGATGACGAAGTGGGCCAGAGTGCACAGCAGACTGAACT
NOV7e 13374578	GACCAGGATATTGATGACGAAGTGGGCCAGAGTGCACAGCAGACTGAACT
NOV7f 13374579	GACCAGGATATTGATGACGAAGTGGGCCAGAGTGCACAGCAGACTGAACT
<div>860 870 880 890 900</div>	
NOV7a ba122o1	ACACAGCTTCCCGGGCGGCCCGTCTCGCAGAGTCTCTGCTCATTATC
NOV7b 13374575	TGGACACGGCCTTGAGGTTCTTAAGGAAGGCGCAAGGCAGCAGCACGGCC
NOV7c 13374576	TGGACACGGCCTTGAGGTTCTTAAGGAAGGCGCAAGGCAGCAGCACGGCC
NOV7d 13374577	TGGACACGGCCTTGAGGTTCTTAAGGAAGGCGCAAGGCAGCAGCACGGCC
NOV7e 13374578	TGGACACGGCCTTGAGGTTCTTAAGGAAGGCGCAAGGCAGCAGCACGGCC
NOV7f 13374579	TGGACACGGCCTTGAGGTTCTTAAGGAAGGCGCAAGGCAGCAGCACGGCC
<div>910 920 930 940 950</div>	
NOV7a ba122o1	GCCACGGCCGTGCTGCTGCTTGGCCTTCTTAAGGAACCTCAAGGCCGT
NOV7b 13374575	GTGGCGATAATGGACCAGGACTTCTGCGACACGGGCAGCCCCGGGAAGCT
NOV7c 13374576	GTGGCGATAATGGACCAGGACTTCTGCGACACGGGCAGCCCCGGGAAGCT
NOV7d 13374577	GTGGCGATAATGGACCAGGACTTCTGCGACACGGGCAGCCCCGGGAAGCT
NOV7e 13374578	GTGGCGATAATGGACCAGGACTTCTGCGACACGGGCAGCCCCGGGAAGCT
NOV7f 13374579	GTGGCGATAATGGACCAGGACTTCTGCGACACGGGCAGCCCCGGGAAGCT
<div>960 970 980 990 1000</div>	
NOV7a ba122o1	GTCCAGTTTCAGTCTGCTGTGCACTCTGGCCCACTTCGTCTCAATATCC
NOV7b 13374575	GTTGTACATGAGGTTGCCACTCACCACCACGTAC--AGGATGCACGTCA
NOV7c 13374576	GTTGTACATGAGGTTGCCACTCACCACCACGTAC--AGGATGCACGTCA
NOV7d 13374577	GTTGTACATGAGGTTGCCACTCACCACCACGTAC--AGGATGCACGTCA
NOV7e 13374578	GTTGTACATGAGGTTGCCACTCACCACCACGTAC--AGGATGCACGTCA
NOV7f 13374579	GTTGTACATGAGGTTGCCACTCACCACCACGTAC--AGGATGCACGTCA
<div>1010 1020 1030 1040 1050</div>	
NOV7a ba122o1	TGGTATAGCCCTACTGTCTATCGCGGCGCGGCACTGGGCTGGAGAG
NOV7b 13374575	TCACCA--GCTCGATGATCTGCGCTACGTTTACCACCTCGGCC--GCCCAGC
NOV7c 13374576	TCACCA--GCTCGATGATCTGCGCTACGTTTACCACCTCGGCC--GCCCAGC
NOV7d 13374577	TCACCA--GCTCGATGATCTGCGCTACGTTTACCACCTCGGCC--GCCCAGC
NOV7e 13374578	TCACCA--GCTCGATGATCTGCGCTACGTTTACCACCTCGGCC--GCCCAGC
NOV7f 13374579	TCACCA--GCTCGATGATCTGCGCTACGTTTACCACCTCGGCC--GCCCAGC
<div>1060 1070 1080 1090 1100</div>	
NOV7a ba122o1	GTCAAGTCTTACATCGACGTCAAGAACTTCCGATCTCCATTTGCC-ATCA
NOV7b 13374575	GTTGGGAAGCGCGGGGCGCAGCAGGCGTTGGCTATGGCCACGTACGAGTC
NOV7c 13374576	GTTGGGAAGCGCGGGGCGCAGCAGGCGTTGGCTATGGCCACGTACGAGTC
NOV7d 13374577	GTTGGGAAGCGCGGGGCGCAGCAGGCGTTGGCTATGGCCACGTACGAGTC
NOV7e 13374578	GTTGGGAAGCGCGGGGCGCAGCAGGCGTTGGCTATGGCCACGTACGAGTC
NOV7f 13374579	GTTGGGAAGCGCGGGGCGCAGCAGGCGTTGGCTATGGCCACGTACGAGTC
<div>1110 1120 1130 1140 1150</div>	
NOV7a ba122o1	TCCGTTCAGGTAACGCTCTCAGATCTTCTGCTCTCGCTGGAGGGCAAT
NOV7b 13374575	CCGCACGC--GCACCACTCGCCGTCTTCATTCTCCTCGTACAGGCACGG
NOV7c 13374576	CCGCACGC--GCACCACTCGCCGTCTTCATTCTCCTCGTACAGGCACGG
NOV7d 13374577	CCGCACGC--GCACCACTCGCCGTCTTCATTCTCCTCGTACAGGCACGG
NOV7e 13374578	CCGCACGC--GCACCACTCGCCGTCTTCATTCTCCTCGTACAGGCACGG
NOV7f 13374579	CCGCACGC--GCACCACTCGCCGTCTTCATTCTCCTCGTACAGGCACGG
<div>1160 1170 1180 1190 1200</div>	

NOV7a ba122o1 ATG CAG CAG C CAG CAG T T C C A T G A T G A A C T G G A C G C A C A T C G C  
 NOV7b 13374575 ATG AGG --ATCTTGCCGGTGTAGCAGCAC--ACAACGGCGGCGAAGATGAT  
 NOV7c 13374576 ATG AGG --ATCTTGCCGGTGTAGCAGCAC--ACAACGGCGGCGAAGATGAT  
 NOV7d 13374577 ATG AGG --ATCTTGCCGGTGTAGCAGCAC--ACAACGGCGGCGAAGATGAT  
 NOV7e 13374578 ATG AGG --ATCTTGCCGGTGTAGCAGCAC--ACAACGGCGGCGAAGATGAT  
 NOV7f 13374579 ATG AGG --ATCTTGCCGGTGTAGCAGCAC--ACAACGGCGGCGAAGATGAT

1210 1220 1230 1240 1250  
 NOV7a ba122o1 AGCCTGCGTGCTCAAG-GCCCTCTTGGC-SCTCGTCCCTACCTCACTG  
 NOV7b 13374575 GAGAAACAACCCAGGTAGCCGCCGTGCAGGATGGCGTAGGGTAGGCCCA  
 NOV7c 13374576 GAGAAACAACCCAGGTAGCCGCCGTGCAGGATGGCGTAGGGTAGGCCCA  
 NOV7d 13374577 GAGAAACAACCCAGGTAGCCGCCGTGCAGGATGGCGTAGGGTAGGCCCA  
 NOV7e 13374578 GAGAAACAACCCAGGTAGCCGCCGTGCAGGATGGCGTAGGGTAGGCCCA  
 NOV7f 13374579 GAGAAACAACCCAGGTAGCCGCCGTGCAGGATGGCGTAGGGTAGGCCCA

1260 1270 1280 1290 1300  
 NOV7a ba122o1 GGC CGA C G A G A C C A A G G G C G T C A T C A C G G T A A C C T G C C G G C T C A T C C  
 NOV7b 13374575 GCACGAACATGCCCTGGATGGCGTTGGTCACGTTCCAGCCTGCCTC--CC  
 NOV7c 13374576 GCACGAACATGCCCTGGATGGCGTTGGTCACGTTCCAGCCTGCCTC--CC  
 NOV7d 13374577 GCACGAACATGCCCTGGATGGCGTTGGTCACGTTCCAGCCTGCCTC--CC  
 NOV7e 13374578 GCACGAACATGCCCTGGATGGCGTTGGTCACGTTCCAGCCTGCCTC--CC  
 NOV7f 13374579 GCACGAACATGCCCTGGATGGCGTTGGTCACGTTCCAGCCTGCCTC--CC

1310 1320 1330 1340 1350  
 NOV7a ba122o1 GCGCCGTGGTCAACATCTTCTGGTGGCAAGSCGCTGTGTCTATCCCT  
 NOV7b 13374575 ACGCCGTGATTTTGGGCTTGTCTGTGGCCCCGAATTCCGCCACCACCTCCC  
 NOV7c 13374576 ACGCCGTGATTTTGGGCTTGTCTGTGGCCCCGAATTCCGCCACCACCTCCC  
 NOV7d 13374577 ACGCCGTGATTTTGGGCTTGTCTGTGGCCCCGAATTCCGCCACCACCTCCC  
 NOV7e 13374578 ACGCCGTGATTTTGGGCTTGTCTGTGGCCCCGAATTCCGCCACCACCTCCC  
 NOV7f 13374579 ACGCCGTGATTTTGGGCTTGTCTGTGGCCCCGAATTCCGCCACCACCTCCC

1360 1370 1380 1390 1400  
 NOV7a ba122o1 CTG C A T T C T T T G C C G C T G T C A G G T G C T G G A G A G C T C G T C T T C C A G G A  
 NOV7b 13374575 AC-CTGCTCCTTGGAGCCGGAG-3GCGGCAGAGGAGCTCCGCTGCCTCGC  
 NOV7c 13374576 AC-CTGCTCCTTGGAGCCGGAG-3GCGGCAGAGGAGCTCCGCTGCCTCGC  
 NOV7d 13374577 AC-CTGCTCCTTGGAGCCGGAG-3GCGGCAGAGGAGCTCCGCTGCCTCGC  
 NOV7e 13374578 AC-CTGCTCCTTGGAGCCGGAG-3GCGGCAGAGGAGCTCCGCTGCCTCGC  
 NOV7f 13374579 AC-CTGCTCCTTGGAGCCGGAG-3GCGGCAGAGGAGCTCCGCTGCCTCGC

1410 1420 1430 1440 1450  
 NOV7a ba122o1 AGCAGCCG-CGCTTTTCCCGCCTGCTACAGCGCGGACGGCGCGCTG  
 NOV7b 13374575 TGATAATGGATGTCTCCCTCGACGGGCGCTTCAGCGCCCTCGTCCCGCA  
 NOV7c 13374576 TGATAATGGATGTCTCCCTCGACGGGCGCTTCAGCGCCCTCGTCCCGCA  
 NOV7d 13374577 TGATAATGGATGTCTCCCTCGACGGGCGCTTCAGCGCCCTCGTCCCGCA  
 NOV7e 13374578 TGATAATGGATGTCTCCCTCGACGGGCGCTTCAGCGCCCTCGTCCCGCA  
 NOV7f 13374579 TGATAATGGATGTCTCCCTCGACGGGCGCTTCAGCGCCCTCGTCCCGCA

1460 1470 1480 1490 1500  
 NOV7a ba122o1 AAGCTCTGGGGCTGACGCTGCGCTGCGCTCTGCTG-TCTTCACGCTGC  
 NOV7b 13374575 GGGCTCTCCCT-CGGCTTTCAGGATGTCCATCTGCAGGCCCTGGCGGTGC  
 NOV7c 13374576 GGGCTCTCCCT-CGGCTTTCAGGATGTCCATCTGCAGGCCCTGGCGGTGC  
 NOV7d 13374577 GGGCTCTCCCT-CGGCTTTCAGGATGTCCATCTGCAGGCCCTGGCGGTGC  
 NOV7e 13374578 GGGCTCTCCCT-CGGCTTTCAGGATGTCCATCTGCAGGCCCTGGCGGTGC  
 NOV7f 13374579 GGGCTCTCCCT-CGGCTTTCAGGATGTCCATCTGCAGGCCCTGGCGGTGC

1510 1520 1530 1540 1550  
 NOV7a ba122o1 TCA T G C C A T T T A T G T G C C G C A C T G C C G C T G C A T G G G C - C T C A C C G  
 NOV7b 13374575 TCAAAGTCGAGGTCGT--CGCAATGCGCGAAGCCCACCGCTCCTCATCC  
 NOV7c 13374576 TCAAAGTCGAGGTCGT--CGCAATGCGCGAAGCCCACCGCTCCTCATCC  
 NOV7d 13374577 TCAAAGTCGAGGTCGT--CGCAATGCGCGAAGCCCACCGCTCCTCATCC  
 NOV7e 13374578 TCAAAGTCGAGGTCGT--CGCAATGCGCGAAGCCCACCGCTCCTCATCC  
 NOV7f 13374579 TCAAAGTCGAGGTCGT--CGCAATGCGCGAAGCCCACCGCTCCTCATCC

1560 1570 1580 1590 1600  
 NOV7a ba122o1 GAGGCCACAGGGCGCGGCCCTCTGTTT-CTTGGCTGCCAGCCTCTTTCA  
 NOV7b 13374575 GTGGCCGCCTGAAAACCCATCCTGGCGAACATGCCGCTCATC----TTGG  
 NOV7c 13374576 GTGGCCGCCTGAAAACCCATCCTGGCGAACATGCCGCTCATC----TTGG  
 NOV7d 13374577 GTGGCCGCCTGAAAACCCATCCTGGCGAACATGCCGCTCATC----TTGG  
 NOV7e 13374578 GTGGCCGCCTGAAAACCCATCCTGGCGAACATGCCGCTCATC----TTGG  
 NOV7f 13374579 GTGGCCGCCTGAAAACCCATCCTGGCGAACATGCCGCTCATC----TTGG

	1610	1620	1630	1640	1650
NOV7a ba122o1	CCTGCGCTGCTCTGCGCAAGCTGCTGCGGACCAAGTCTTCTTGGACG				
NOV7b 13374575	CCTGGGACTTGTGTGGACACGGAC	GTGGCCACGTTGGACAGCTTGCTGCG			
NOV7c 13374576	CCTGGGACTTGTGTGGACACGGAC	GTGGCCACGTTGGACAGCTTGCTGCG			
NOV7d 13374577	CCTGGGACTTGTGTGGACACGGAC	GTGGCCACGTTGGACAGCTTGCTGCG			
NOV7e 13374578	CCTGGGACTTGTGTGGACACGGAC	GTGGCCACGTTGGACAGCTTGCTGCG			
NOV7f 13374579	CCTGGGACTTGTGTGGACACGGAC	GTGGCCACGTTGGACAGCTTGCTGCG			

  

	1660	1670	1680	1690	1700
NOV7a ba122o1	TGCGCATCTTCGTCATCGGCGGCATCTGCAGCGTGTCCGGCTTCGTGCAC				
NOV7b 13374575	GAGCAAGGT	GGCCATGGCGGCGGTGGGGACAGCGGAAAGGAC			
NOV7c 13374576	GAGCAAGGT	GGCCATGGCGGCGGTGGGGACAGCGGAAAGGAC			
NOV7d 13374577	GAGCAAGGT	GGCCATGGCGGCGGTGGGGACAGCGGAAAGGAC			
NOV7e 13374578	GAGCAAGGT	GGCCATGGCGGCGGTGGGGACAGCGGAAAGGAC			
NOV7f 13374579	GAGCAAGGT	GGCCATGGCGGCGGTGGGGACAGCGGAAAGGAC			

  

	1710	1720	1730	1740	1750
NOV7a ba122o1	TCCCTCGAGGGCCTCATCGAAGCTACCGAACCAACGCGACGACTAGGG				
NOV7b 13374575	A	GAAGGACCCGAGGATGCGGGGAACCGGATGCAAGAAGGCGAGGG			
NOV7c 13374576	A	GAAGGACCCGAGGATGCGGGGAACCGGATGCAAGAAGGCGAGGG			
NOV7d 13374577	A	GAAGGACCCGAGGATGCGGGGAACCGGATGCAAGAAGGCGAGGG			
NOV7e 13374578	A	GAAGGACCCGAGGATGCGGGGAACCGGATGCAAGAAGGCGAGGG			
NOV7f 13374579	A	GAAGGACCCGAGGATGCGGGGAACCGGATGCAAGAAGGCGAGGG			

  

	1760	1770	1780	1790
NOV7a ba122o1	CGCAAGGGCGAGCCCCGCGCGCTCTCGGCTCTCTCCCTTC			
NOV7b 13374575	CTGGGGGGCGCAAAGTCGCTA	TCTCCGCTTGCTCTCCGC		
NOV7c 13374576	CTGGGGGGCGCAAAGTCGCTA	TCTCCGCTTGCTCTCCGC		
NOV7d 13374577	CTGGGGGGCGCAAAGTCGCTA	TCTCCGCTTGCTCTCCGC		
NOV7e 13374578	CTGGGGGGCGCAAAGTCGCTA	TCTCCGCTTGCTCTCCGC		
NOV7f 13374579	CTGGGGGGCGCAAAGTCGCTA	TCTCCGCTTGCTCTCCGC		

Table 7N Amino Acid Alignment of NOV7a – NOV7f.

	10	20	30	40	50
NOV7a ba122o1	MATLLRSKLSNVATSVSNKSQA	KMSGMFARMGFOAATDEEAVGFAHCDDL			
NOV7b 13374575	MATLLRSKLSNVATSVSNKSQA	KMSGMFARMGFOAATDEEAVGFAHCDDL			
NOV7c 13374576	MATLLRSKLSNVATSVSNKSQA	KMSGMFARMGFOAATDEEAVGFAHCDDL			
NOV7d 13374577	MATLLRSKLSNVATSVSNKSQA	KMSGMFARMGFOAATDEEAVGFAHCDDL			
NOV7e 13374578	MATLLRSKLSNVATSVSNKSQA	KMSGMFARMGFOAATDEEAVGFAHCDDL			
NOV7f 13374579	MATLLRSKLSNVATSVSNKSQA	KMSGMFARMGFOAATDEEAVGFAHCDDL			

  

	60	70	80	90	100
NOV7a ba122o1	DFEHRQGLQMDILKAEGEPCGDEGAEPVEGDIHYQRGSGAPLPPSGSKD				
NOV7b 13374575	DFEHRQGLQMDILKAEGEPCGDEGAEPVEGDIHYQRGSGAPLPPSGSKD				
NOV7c 13374576	DFEHRQGLQMDILKAEGEPCGDEGAEPVEGDIHYQRGSGAPLPPSGSKD				
NOV7d 13374577	DFEHRQGLQMDILKAEGEPCGDEGAEPVEGDIHYQRGSGAPLPPSGSKD				
NOV7e 13374578	DFEHRQGLQMDILKAEGEPCGDEGAEPVEGDIHYQRGSGAPLPPSGSKD				
NOV7f 13374579	DFEHRQGLQMDILKAEGEPCGDEGAEPVEGDIHYQRGSGAPLPPSGSKD				

  

	110	120	130	140	150
NOV7a ba122o1	QVGGGGEFGGHDKPKITAEAGWNVN	TAIQGMFVLGLPYAILHGGYLG			
NOV7b 13374575	QVGGGGEFGGHDKPKITAEAGWNVN	TAIQGMFVLGLPYAILHGGYLG			
NOV7c 13374576	QVGGGGEFGGHDKPKITAEAGWNVN	TAIQGMFVLGLPYAILHGGYLG			
NOV7d 13374577	QVGGGGEFGGHDKPKITAEAGWNVN	TAIQGMFVLGLPYAILHGGYLG			
NOV7e 13374578	QVGGGGEFGGHDKPKITAEAGWNVN	TAIQGMFVLGLPYAILHGGYLG			
NOV7f 13374579	QVGGGGEFGGHDKPKITAEAGWNVN	TAIQGMFVLGLPYAILHGGYLG			

  

	160	170	180	190	200
NOV7a ba122o1	LIIFAAVVCCYTGKILIACLYEENEDGEVVRV	RDSYVAIANACCAPRPPT			
NOV7b 13374575	LIIFAAVVCCYTGKILIACLYEENEDGEVVRV	RDSYVAIANACCAPRPPT			
NOV7c 13374576	LIIFAAVVCCYTGKILIACLYEENEDGEVVRV	RDSYVAIANACCAPRPPT			
NOV7d 13374577	LIIFAAVVCCYTGKILIACLYEENEDGEVVRV	RDSYVAIANACCAPRPPT			
NOV7e 13374578	LIIFAAVVCCYTGKILIACLYEENEDGEVVRV	RDSYVAIANACCAPRPPT			
NOV7f 13374579	LIIFAAVVCCYTGKILIACLYEENEDGEVVRV	RDSYVAIANACCAPRPPT			

  

	210	220	230	240	250
NOV7a ba122o1	LGGRRVNVNAQIIELVMTCILYVVVSGNLMYNSFPGLPVSQKSWSI	IATAV			

NOV7b 13374575	LGGRVVNVAQIIELVMTCILYVVVSGNLMYNSFFGLPVSQKWSIIATAV
NOV7c 13374576	LGGRVVNVAQIIELVMTCILYVVVSGNLMYNSFFGLPVSQKWSIIATAV
NOV7d 13374577	LGGRVVNVAQIIELVMTCILYVVVSGNLMYNSFFGLPVSQKWSIIATAV
NOV7e 13374578	LGGRVVNVAQIIELVMTCILYVVVSGNLMYNSFFGLPVSQKWSIIATAV
NOV7f 13374579	LGGRVVNVAQIIELVMTCILYVVVSGNLMYNSFFGLPVSQKWSIIATAV
	260 270 280 290 300
NOV7a ba122o1	LLPCAFKLNKKA VSKFSLCTLAHFVINILVIAYCLSRARDWAEKVKFY
NOV7b 13374575	LLPCAFKLNKKA VSKFSLCTLAHFVINILVIAYCLSRARDWAEKVKFY
NOV7c 13374576	LLPCAFKLNKKA VSKFSLCTLAHFVINILVIAYCLSRARDWAEKVKFY
NOV7d 13374577	LLPCAFKLNKKA VSKFSLCTLAHFVINILVIAYCLSRARDWAEKVKFY
NOV7e 13374578	LLPCAFKLNKKA VSKFSLCTLAHFVINILVIAYCLSRARDWAEKVKFY
NOV7f 13374579	LLPCAFKLNKKA VSKFSLCTLAHFVINILVIAYCLSRARDWAEKVKFY
	310 320 330 340 350
NOV7a ba122o1	IDVKKFPISIGIIVFSYTSQIFLPSLEGNMQQPSEFHCMMNWTHIAACVL
NOV7b 13374575	IDVKKFPISIGIIVFSYTSQIFLPSLEGNMQQPSEFHCMMNWTHIAACVL
NOV7c 13374576	IDVKKFPISIGIIVFSYTSQIFLPSLEGNMQQPSEFHCMMNWTHIAACVL
NOV7d 13374577	IDVKKFPISIGIIVFSYTSQIFLPSLEGNMQQPSEFHCMMNWTHIAACVL
NOV7e 13374578	IDVKKFPISIGIIVFSYTSQIFLPSLEGNMQQPSEFHCMMNWTHIAACVL
NOV7f 13374579	IDVKKFPISIGIIVFSYTSQIFLPSLEGNMQQPSEFHCMMNWTHIAACVL
	360 370 380 390 400
NOV7a ba122o1	KGLFALVAYLTWADETKEAITDNLPGSIRAVVNIFLVAKALLSYPLPFFA
NOV7b 13374575	KGLFALVAYLTWADETKEAITDNLPGSIRAVVNIFLVAKALLSYPLPFFA
NOV7c 13374576	KGLFALVAYLTWADETKEAITDNLPGSIRAVVNIFLVAKALLSYPLPFFA
NOV7d 13374577	KGLFALVAYLTWADETKEAITDNLPGSIRAVVNIFLVAKALLSYPLPFFA
NOV7e 13374578	KGLFALVAYLTWADETKEAITDNLPGSIRAVVNIFLVAKALLSYPLPFFA
NOV7f 13374579	KGLFALVAYLTWADETKEAITDNLPGSIRAVVNIFLVAKALLSYPLPFFA
	410 420 430 440 450
NOV7a ba122o1	AVEVLEKSLFQEGSRAFFPACYSGDGRKLSWGLTLRCALVVFTLLMAIYV
NOV7b 13374575	AVEVLEKSLFQEGSRAFFPACYSGDGRKLSWGLTLRCALVVFTLLMAIYV
NOV7c 13374576	AVEVLEKSLFQEGSRAFFPACYSGDGRKLSWGLTLRCALVVFTLLMAIYV
NOV7d 13374577	AVEVLEKSLFQEGSRAFFPACYSGDGRKLSWGLTLRCALVVFTLLMAIYV
NOV7e 13374578	AVEVLEKSLFQEGSRAFFPACYSGDGRKLSWGLTLRCALVVFTLLMAIYV
NOV7f 13374579	AVEVLEKSLFQEGSRAFFPACYSGDGRKLSWGLTLRCALVVFTLLMAIYV
	460 470 480 490 500
NOV7a ba122o1	PHFALLMGLTGSITGAGLCFLLPSLFHLRLLWRKLLWHQVFFDVAIFVIG
NOV7b 13374575	PHFALLMGLTGSITGAGLCFLLPSLFHLRLLWRKLLWHQVFFDVAIFVIG
NOV7c 13374576	PHFALLMGLTGSITGAGLCFLLPSLFHLRLLWRKLLWHQVFFDVAIFVIG
NOV7d 13374577	PHFALLMGLTGSITGAGLCFLLPSLFHLRLLWRKLLWHQVFFDVAIFVIG
NOV7e 13374578	PHFALLMGLTGSITGAGLCFLLPSLFHLRLLWRKLLWHQVFFDVAIFVIG
NOV7f 13374579	PHFALLMGLTGSITGAGLCFLLPSLFHLRLLWRKLLWHQVFFDVAIFVIG
	510 520
NOV7a ba122o1	GICSVSGFVHSLEGLIEAYRTNAED
NOV7b 13374575	GICSVSGFVHSLEGLIEAYRTNAED
NOV7c 13374576	GICSVSGFVHSLEGLIEAYRTNAED
NOV7d 13374577	GICSVSGFVHSLEGLIEAYRTNAED
NOV7e 13374578	GICSVSGFVHSLEGLIEAYRTNAED
NOV7f 13374579	GICSVSGFVHSLEGLIEAYRTNAED

- Homologies to any of the above NOV7 proteins will be shared by the other NOV7 proteins insofar as they are homologous to each other as shown above. Any reference to NOV7 is assumed to refer to all three of the NOV7 proteins in general, unless otherwise noted.

NOV7a also has homology to the amino acid sequence shown in the BLASTP data listed in Table 70.

Table 70. BLAST results for NOV7a					
Gene Index/ Identifier	Protein/ Organism	Length (aa)	Identity (%)	Positives (%)	Expect
gi 14388326 dbj BAB60726.1  (AB062931)	hypothetical protein [Macaca fascicularis]	525	520/525 (99%)	521/525 (99%)	0.0
gi 13929106 ref NP_113970.1	vesicular inhibitory amino acid transporter [Rattus norvegicus]	525	518/526 (98%)	521/526 (98%)	0.0
gi 13396317 emb CAC15529.2  (AL133519)	bA12201.1 (A novel protein (ortholog of the mouse vesicular inhibitory amino acid transporter, VIAAT) [Homo sapiens]	525	524/525 (99%)	524/525 (99%)	0.0
gi 6678569 ref NP_035334.1	vesicular inhibitory amino acid transporter [Mus musculus]	521	507/522 (97%)	511/522 (97%)	0.0
gi 7303217 gb AAF58280.1  (AE003815)	CG8394 gene product [Drosophila melanogaster]	543	203/419 (48%)	282/419 (66%)	1e-110

The homology of these sequences is shown graphically in the ClustalW analysis shown in Table 7P.

Table 7P. Information for the ClustalW proteins

- 1) NOV7a (SEQ ID NO:30)
- 2) gi|14388326|dbj|BAB60726.1| (AB062931) hypothetical protein [Macaca fascicularis] (SEQ ID NO:103)
- 3) gi|13929106|ref|NP\_113970.1| vesicular inhibitory amino acid transporter [Rattus norvegicus] (SEQ ID NO:104)
- 4) gi|13396317|emb|CAC15529.2| (AL133519) bA12201.1 (A novel protein (ortholog of the mouse vesicular inhibitory amino acid transporter, VIAAT) [Homo sapiens] (SEQ ID NO:105)
- 5) gi|6678569|ref|NP\_035334.1| vesicular inhibitory amino acid transporter [Mus musculus] (SEQ ID NO:106)
- 6) gi|7303217|gb|AAF58280.1| (AE003815) CG8394 gene product [Drosophila melanogaster] (SEQ ID NO:107)

	10	20	30	40	50
NOV7A	..... ..... ..... ..... .....				
gi 14388326	---MATLLRSKLS---	NVATSVS---	NKSQAKMSGMFARMG---		
gi 13929106	---MATLLRSKLS---	NVATSVS---	NKSQAKMSGMFARMG---		
gi 13396317	---MATLLRSKLS---	NVATSVS---	NKSQAKMSGMFARMG---		
gi 6678569	---MATLLRSKLS---	NVATSVS---	NKSQAKMSGMFARMG---		
gi 7303217	MSFIAKLKATPLPPLRNILNVAVQTARQQIPERKDYEQPPGSTAQOHHS				
	60	70	80	90	100
NOV7A	..... ..... ..... ..... .....				
gi 14388326	FQAATDEEAVGFAHCDDLDFEHRQGLQMDILKAEGEPCGDEGAEAP---				
gi 13929106	FQAATDEEAVGFAHCDDLDFEHRQGLQMDILKAEGEPCGDEGAEAP---				
gi 13396317	FQAATDEEAVGFAHCDDLDFEHRQGLQMDILKAEGEPCGDEGAEAP---				
gi 6678569	FQAATDEEAVGFAHCDDLDFEHRQGLQMDILKAEGEPCGDEGAEAP---				
gi 7303217	QQAQHKAMEAGMDGGLTTEMSSNPFRNAGSWTNDGEGGDDGDGEYRNEYQ				
	110	120	130	140	150
	..... ..... ..... ..... .....				



NOV7A  
gi | 14388326 | ----VEGDIHYQRGSGAPLPPSGSKDQ-VGGGGEGFGGHDKPKITAWAEGW  
gi | 13929106 | ----VEGDIHYQRGSGAPLPPSGSKDQAVGAGGEGFGGHDKPKITAWAEGW  
gi | 13396317 | ----VEGDIHYQRGSGAPLPPSGSKDQ-VGGGGEGFGGHDKPKITAWAEGW  
gi | 6678569 | ----VEGDIHYQRGSGAPLPPSGSKDQAVGAGGEGFGGHDKPKITAWAEGW  
gi | 7303217 | STSFNEVDGRVQQTDFRQGSIASEGSSFVCEGEGGGG--CKIDEFCANW

160 170 180 190 200  
NOV7A  
gi | 14388326 | NVTNAIQGMFVLGLPYAILHGGYLGLFLIIFAAVVCCYTGKILIACLYEE  
gi | 13929106 | NVTNAIQGMFVLGLPYAILHGGYLGLFLIIFAAVVCCYTGKILIACLYEE  
gi | 13396317 | NVTNAIQGMFVLGLPYAILHGGYLGLFLIIFAAVVCCYTGKILIACLYEE  
gi | 6678569 | NVTNAIQGMFVLGLPYAILHGGYLGLFLIIFAAVVCCYTGKILIACLYEE  
gi | 7303217 | NVTNAIQGMFVLSLPFAVLHGGYWAIVAMVGTAFICCYTGKIVLVQCLYEP

210 220 230 240 250  
NOV7A  
gi | 14388326 | N-EDGEVVRVRSYVAIANACCAPRFPTLGGRVVNVAQIIELVMTCILYV  
gi | 13929106 | N-EDGEVVRVRSYVAIANACCAPRFPTLGGRVVNVAQIIELVMTCILYV  
gi | 13396317 | N-EDGEVVRVRSYVAIANACCAPRFPTLGGRVVNVAQIIELVMTCILYV  
gi | 6678569 | N-EDGEVVRVRSYVAIANACCAPRFPTLGGRVVNVAQIIELVMTCILYV  
gi | 7303217 | DPATGQMVVRVRSYVAIAKVCFG---PKLGARAVSHAQIIELVMTCILYV

260 270 280 290 300  
NOV7A  
gi | 14388326 | VVSGNLMYNSFPGLPVSQKSWSIATAVLLPCAFLKNLKA VSKFSLCTL  
gi | 13929106 | VVSGNLMYNSFPGLPVSQKSWSIATAVLLPCAFLKNLKA VSKFSLCTL  
gi | 13396317 | VVSGNLMYNSFPGLPVSQKSWSIATAVLLPCAFLKNLKA VSKFSLCTL  
gi | 6678569 | VVSGNLMYNSFPGLPVSQKSWSIATAVLLPCAFLKNLKA VSKFSLCTL  
gi | 7303217 | VVCGDLHAGTYFQGSFDSRSWMI FVGIRLLP MGF LKSLK MVS TISFWCTM

310 320 330 340 350  
NOV7A  
gi | 14388326 | AHFVINILVIAYCLSRARDWAEKVKFYIDVKKFPI SIGIIVFSYTSQIF  
gi | 13929106 | AHFVINILVIAYCLSRARDWAEKVKFYIDVKKFPI SIGIIVFSYTSQIF  
gi | 13396317 | AHFVINILVIAYCLSRARDWAEKVKFYIDVKKFPI SIGIIVFSYTSQIF  
gi | 6678569 | AHFVINILVIAYCLSRARDWAEKVKFYIDVKKFPI SIGIIVFSYTSQIF  
gi | 7303217 | SHIVINAVILCYCLLQIGDWGSKVRFSIDMENFPISLGVIIVFSYTSQIF

360 370 380 390 400  
NOV7A  
gi | 14388326 | LPSLEGNMQOPSEFHCMNWNTHIAACVLKGLFALVAYLTWADETKEVITD  
gi | 13929106 | LPSLEGNMQOPSEFHCMNWNTHIAACVLKGLFALVAYLTWADETKEVITD  
gi | 13396317 | LPSLEGNMQOPSEFHCMNWNTHIAACVLKGLFALVAYLTWADETKEVITD  
gi | 6678569 | LPSLEGNMQOPSEFHCMNWNTHIAACVLKGLFALVAYLTWADETKEVITD  
gi | 7303217 | LPTLEGNMIDRSKFNWMLDWSHIAAAVEKAGEGYICFLTFOQNTQQOVITN

410 420 430 440 450  
NOV7A  
gi | 14388326 | NLPGS-IRAVVNI FLVAKALLSYPLPFFAAVEVLEKSLFQEGSRAFFPAC  
gi | 13929106 | NLPGS-IRAVVNI FLVAKALLSYPLPFFAAVEVLEKSLFQEGSRAFFPAC  
gi | 13396317 | NLPGS-IRAVVNI FLVAKALLSYPLPFFAAVEVLEKSLFQEGSRAFFPAC  
gi | 6678569 | NLPGS-IRAVVNI FLVAKALLSYPLPFFAAVEVLEKSLFQEGSRAFFPAC  
gi | 7303217 | NLHSQGFGKGVNFFLVKALLSYPLPYAAACELERNFERGPPPTKFPPTI

460 470 480 490 500  
NOV7A  
gi | 14388326 | YSGDGR LKSWGLTLRCALVVFTLLMATYVPHFALLMGLTGS LTGAGLCFL  
gi | 13929106 | YSGDGR LKSWGLTLRCALVVFTLLMATYVPHFALLMGLTGS LTGAGLCFL  
gi | 13396317 | YSGDGR LKSWGLTLRCALVVFTLLMATYVPHFALLMGLTGS LTGAGLCFL  
gi | 6678569 | YSGDGR LKSWGLTLRCALVVFTLLMATYVPHFALLMGLTGS LTGAGLCFL  
gi | 7303217 | WNL DGE LKSWGLGFRVGVIVSTILMATIPIPHSILMGFIGSFTCTMLSET



		510	520	530	540	550
NOV7A		LPSLFHLRLLRKLLWHQVFFDVAIFVIGGICSVSGFVHSLEGLIEAYRT				
gi 14388326		LPSLFHLRLLRKLLWHQVFFDVAIFVIGGICSVSGFVHSLEGLIEAYRT				
gi 13929106		LPSLFHLRLLRKLLWHQVFFDVAIFVIGGICSVSGFVHSLEGLIEAYRT				
gi 13396317		LPSLFHLRLLRKLLWHQVFFDVAIFVIGGICSVSGFVHSLEGLIEAYRT				
gi 6678569		LPSLFHLRLLRKLLWHQVFFDVAIFVIGGICSVSGFVHSLECKFAGLET				
gi 7303217		WPCYFHKKIKGHLDDOKETAKDYLIIGIGVLFGLVIGIYDSGNALINAEET				
NOV7A	....	NAED				
gi 14388326		NAED				
gi 13929106		NAED				
gi 13396317		NAED				
gi 6678569		---				
gi 7303217		GLPF				

Table 7Q lists the domain description from DOMAIN analysis results against NOV7a.

This indicates that the NOV7a sequence has properties similar to those of other proteins known to contain this domain.

5

**Table 7Q. Domain Analysis of NOV7a**

gnl|Pfam|pfam01490, Aa trans, Transmembrane amino acid transporter protein. This transmembrane region is found in many amino acid transporters including UNC-47 and MTR. UNC-47 encodes a vesicular amino butyric acid (GABA) transporter, (VGAT). UNC-47 is predicted to have 10 transmembrane domains. MTR is a N system amino acid transporter system protein involved in methyltryptophan resistance. Other members of this family include proline transporters and amino acid permeases. (SEQ ID NO:107)  
Length = 370 residues, 87.8% aligned  
Score = 182 bits (461), Expect = 5e-47

NOV7a	143	HGGYLGFLFIIFAAVVCCYTGKILIACLYEENEDGEVVRVRSYVAIANACCAPRFPTLG	202
Pfam01490	5	LGWIPGLVLLLAGFITLYTGLLLSECYE-----YVPGKRNDSYLDLGRSAYGGKGLLLT	59
NOV7a	203	GRVVNVAQIIELVMTICILYVVVSGNLMYNSFP-----GLPVSQKSWSIATAVLLPCAF	256
Pfam01490	60	SPVVG---QYVNLFGVNIIGYLILAGDLLPKIISFPCGDNCDHLDGNSWIIIFAAIIITLSF	116
NOV7a	257	LKNLKAWS--KFSLLCTLAHFVI---NILVIAYCLSRARDWAWKVKFY---IDVKKFPI	308
Pfam01490	117	IPNFNLLSISLSAFSSLAYLSIISPLIIVAVIAGIFVLLGAVYGILWSPSFTKLTGLFL	176
NOV7a	309	SIGIIVFSYTSQIFLPSLEGNMQQPSE--FHCMMNWTIAACVLKGLFALVAYLTWADET	366
Pfam01490	177	AIGIIVFAFEHGAHVLLPIQNTMKSPSAKFKKVLNVAIIVTVLYILVGGFFGYLTFGNV	236
NOV7a	367	KEVITDNLPGSIRAVVNIFLVAKALLSYPLPFFAAVEVLEKSLFQEGSRAFFPACYSGD	425
Pfam01490	237	KGNILLNLPNPFVLIIVNLNLVVAILLTFPLQAFPIVRIIENLLTKKNFA-----P	288
NOV7a	426	GRLSWGLTLRCALVVFTLLMAIYVPHFALLMGLTGSLSGA	466
Pfam01490	289	NKSKLLRVVIRSGLVVFTLLIALLVPFFGDFLSLVGATSGA	329

Synaptic vesicles from mammalian brain are among the best characterized trafficking organelles. However, so far it has not been possible to characterize vesicle subpopulations that are specific for a given neurotransmitter. Taking advantage of the recent molecular

characterization of vesicular neurotransmitter transporters, we have used an antibody specific for the vesicular GABA transporter (VGAT) to isolate GABA-specific synaptic vesicles. The isolated vesicles are of exceptional purity as judged by electron microscopy.

Immunoblotting revealed that isolated vesicles contain most of the major synaptic vesicle proteins in addition to VGAT and are devoid of vesicular monoamine and acetylcholine transporters. The vesicles are 10-fold enriched in GABA uptake activity when compared with the starting vesicle fraction. Furthermore, glutamate uptake activity and glutamate-induced but not chloride-induced acidification are selectively lost during immunoisolation. We conclude that the population of GABA-containing synaptic vesicles is separable and distinct from vesicle populations transporting other neurotransmitters. Sagne et al., *FEBS Lett* 1997:10, 417(2):177-83.

Proteins belonging to the GABA transporter family of proteins play an important role in signal transduction of different cell type such as neuronal and muscle cells. NOV7 protein is the human ortholog of VGAT (vesicular GABA transporter) from *Rattus norvegicus* and unc-47 from *C. elegans* which are involved in packaging GABA in synaptic vesicles. NOV7 protein has a domain similar to the amino acid permease domain found in integral membrane proteins that regulate transport of amino acids.

The above defined information for NOV7 suggests that this NOV7 protein may function as a member of a GABA transporter family. Therefore, the NOV7 nucleic acids and proteins of the invention are useful in potential therapeutic applications implicated in various diseases and disorders described below and/or other pathologies. For example, the NOV7 compositions of the present invention will have efficacy for treatment of patients suffering from cancer, trauma, regeneration (in vitro and in vivo), viral/bacterial/parasitic infections, fertility and neurological disorders. The NOV7 nucleic acid encoding GABA transporter receptor-like protein, and the GABA transporter receptor-like protein of the invention, or fragments thereof, may further be useful in diagnostic applications, wherein the presence or amount of the nucleic acid or the protein are to be assessed.

## NOV8

NOV8 includes two novel integrin alpha 7 (ITGA7) precursor-like receptor proteins disclosed below. The disclosed proteins have been named NOV8a and NOV8b.

### NOV8a

A disclosed NOV8a nucleic acid of 3432 nucleotides (also referred to AC073487\_da1) encoding a novel ITGA7 precursor-like receptor protein is shown in Table 8A. An open

reading frame was identified beginning with an ATG initiation codon at nucleotides 1-3 and ending with a TAA codon at nucleotides 3430-3432. The start and stop codons are in bold letters.

**Table 8A. NOV8a Nucleotide Sequence (SEQ ID NO:41)**

ATGGCCGGGGCTCGGAGCCGCGACCCGTTGGGGGGCTCCGGGATTGGCTACCTTTTGGCTCCCTGCTCGTCAACTGCTC  
TCTTCTCAGCGGTGTGCGCTTCAATCTGGACGTGATGGGTGCTTGCCTGCGCAAGGAGGCGAGCCAGGCAGCTCTTCGGCTT  
CTCTGTGGCCCTGCACCCGGCAGCTCGCAGCCCGGACCCAGCAGCCCACTGCTGGTGGGTGCTCCCAAGGCCCTGGCT  
CTTCTGGGCGAGCAGGCGAATCGCACTGGAGGCTCTTCGCTTGCCTGGCTGGAGGAGACTGACTGCTACAGAGT  
GGACATCGACAGGCGAGCTGATATGCAAAAGGAAGCAAGGAGAACCAAGTGGTGGGAGTCACTGTTTCGGAGCCAGGGGC  
CTGGGGCAAGATTGTACCTGTGCACACCGATATGAGGCAAGGCGAGTGGACAGATCTGGAGACGCGGGATATG  
ATTGGTCTGCTGCTTGTGCTCAGCCAGGACCTGCCATCCGGGATGAGTGGATGGTGGGGAAATGGAAGTTCTGTGAGGG  
ACGCCCCCAAGGCCATGAACAATTGGGTTCGCCAGCAGGGCACAGCTGCCGCTTCTCCCTGATAGCCACTACCTCC  
TCTTTGGGGCCCCAGGAACCTATAATTGGAAGGGCAGGGCAGGGTGGAGCTCTGTGCACAGGGCTCAGCGACCTGGCA  
CACCTGGACACGCTCCCTACGAGGCGGGGGGAGAGAGGAGCAGGACCCCGCTCATCCCGCTCCCTGCCAACAGCTA  
CTTTGGGTGTCTTTGTGACCAACATTGATAGCTCAGACCCGACAGCTGGTGTATAAACTTTGGACCTCTGACC  
GGCTCCAGGACAGCCGGAGACTTGGCCCTCAATAGCTACTTAGGCTTCTCTATTGACTCGGGGAAAGGTCTGGTGGCT  
GCAGAGAGCTGAGCTTTGTGGCTGGAGCCCCCGGCCAACCAAGGGTGTCTGGTCACTCTCGCAGAGGACAGCGC  
CAGTCCGCTGGTCCCGAGGTTATGCTGTCTGGGAGCGCTGACCTCCGGCTTTGGCTACTCACTGGCTGTGGCTGACC  
TCAACAGTATGGGTGGCCAGACCTGATAGTGGGTGCCCTACTTCTTTGAGCGCCAGAAGAGCTGGGGGGTGTCTGT  
TATGTGACTTGAACAGGGGGGTCACTGGGCTGGGATCTCCCTCTCCGGCTCTCGGCTCCCTGACTCCATGTTCTGG  
GATCAGCTGGCTGTCTGGGGGACCTCAACCAAGATGGCTTTCCAGATATTGCACTGGGTGGCCCTTTGATGGTGTGAT  
GGAAAGTCTTTCATCTACCATGGAGCAGCTGGGGGTGTGCGCAAACTTCAAGGTGCTGGAGGCGAGGCTGGGGC  
ATCAAGAGCTTCGGCTACTCCCTGTGACGCGCTTGGATATGGATGGGAACCAATACCTGACCTGCTGGTGGGCTCCCT  
GGCTGACACCCGAGCTGCTCTCAGGGCCAGACCCATCTCCATGCTCTCCATGAGGTCTCTATTGCTCCACGAGCATCG  
ACCTGGAGCAGCCCAACTGTGCTGGCGGCCACTCGGTCTGTGTGGACCTAAGGGTCTGTTTCAGCTACATTCAGTCC  
AGCAGCTATAGCCCTACTGTGGCCCTGGACTATGTGTAGATGCGGACACAGACCGGAGGCTCCGGGGCCAGGTTCCCG  
TGTGACGTTCTGAGCCGTAACCTGGAAGAACCAAGCAGGCTCGGGCAGGCTGGGTGAAGCAGCAGCATGACC  
GAGTCTGTGGAGACGCCATGTTCCAGCTCCAGGAATGTCAAGACAAGCTTCGGGCCATTGTAGTGAACCTTGTCTAC  
AGTCTCCAGACCCCTCGGCTCCGGCGACAGGCTCCTGGCCAGGGGTGCCTCCAGTGGCCCCATCTCAATGCCACCA  
GCCAGCAGCCAGCGGGCAGAGATCCACTTCTGGAAGCAAGGCTGTGGTGAAGACAAGATCTGCCAGAGCAATCTGCAGC  
TGGTCCGCGCCGCTTCTGTACCCGGGTGAGCGACACGGAATTCACCTCTGCCATGGATGTGGATGGAACAACAGCC  
CTGTTTTCAGCTGGGTGGGCGAGCCAGTCAITGGCTGGAGCTGATGGTCACCAACCTGCCATCGGACCCAGCCCA  
GGCTGATGGGATGATGCCATGAAGCCAGCTCCTGGTCTATGCTTCTGACTCACTGCACTACTCAGGGGTCCGGCCCC  
TGGACGAGAAGCACTCTGCTGTCCAATGAGAATGCCTCCATGTTGAGTGTGAGCTGGGGAACCCATGAAGAGAGGT  
GCCAGGTCACTTCTACCTCATCTTAGCACCTCCGGGATCAGCATTGAGACCAAGGAACTGGAGGTAGAGCTGCTGTT  
GGCCAGCATCAGTGAAGCAGGCTGCATCCAGTCTCTGACAGCCCGTGTCTTCTATTGAGTGCCTACTGTCCATTGCAG  
GGATGGCCATTCCCGAGCACTCTTCTCTGCTGGTGTGGTGGGGCGAGAGAGCATGCACTGTGAGCGGGATGTGGGC  
AGCAAGGTCAAGTATGAGTCAAGGTACCGTAAGTAACCAAGGCCAGTCTGCTCAGAACCTGGGCTCTGCTTCTCAACATCAT  
GTGGCTCATGAGATTGCCAATGGGAAGTGGTGTGTATCCCAATGCAGGTTGAGCTGGAGGGCGGGCAGGGGCTGGGC  
AGAAAGGGCTTTGCTCTCCAGGAGGCCAACATCTCCACCTGGATGTGGACAGTAGGGATAGGAGGGCGGGAGGCTG  
GAGCCACTGAGCAGCAGGAGCTGTGAGCGGCGAGGAGCCAGCATGTCTGGTGGCCAGTGTCTCTGTGCAAGAA  
GAAAACATCACCTGGACTGCGCCGGGGCAGGCCAAGTGTGTGGTGTTCAGCTGCCACTCTACAGCTTTGACCGCG  
CGGCTGTGCTGCATGTCTGGGGCCGCTCTGTGGAACAGCACCTTCTGGAGGAGTACTCAGCTGTGAAGTCCCTGGAAGTG  
ATTGATCCGGGCAACATCAGTGAAGTCTCCATAAAGAACTTGATGCTCCGAGATGCCCTCCAGTGTATCCAGTGAT  
GGTATCTTGGACCCATGGCTGTGGTGGCAGAGGAGTCCCTGGTGGGTCACTCTCTGGCTGTACTGGCTGGGCTGCT  
TGGTGTAGCACTGCTGTGTGCTCTCTGTGGAAGTGTGGCTTCTTCCATCGGAGCAGCCAGAGCTCATTTTCCACAC  
AATATACCCGGGCTGTCTGGCTGTGCAGCTTACGACATGGAAGTTGGGGTCCAGGGACTGTGGGGTAA

5 The disclosed NOV8a nucleic acid sequence, localized to chromosome 12, has 2531 of 2561 bases (98%) identical to a 3485 bp *Homo sapiens* integrin alpha-7 mRNA (GENBANK- ID: AF072132|acc:AF072132) (E = 0.0).

A disclosed NOV8a polypeptide (SEQ ID NO:42) encoded by SEQ ID NO:41 is 1143 amino acid residues and is presented using the one-letter amino acid code in Table 8B. Signal  
10 P, Psort and/or Hydropathy results predict that NOV8a does not contain a signal peptide and is likely to be localized to the endoplasmic reticulum or nucleus with a certainty of 0.6000.

**Table 8B. Encoded NOV8a protein sequence (SEQ ID NO:42).**

MAGARSRDPLGLRLDLLPFWLPARRTALLTAVAFNLDVMGALRKEASQAASSASLWPCTRHVAAPDPSSPL  
LVGAPQALALPGQQANRTGGFLFACPLSLEETDCYRVIDIQADMQKESKENQWLGVSVRSQGPQGGKIVTCA  
HRYEARQVRVDQILETRDMIGRCFVLSQDLAIRDDELGGGEWKFCEGRPQGHEQFGFCQQGTAAAFSPDSHYL  
LFGAPGTYNWKGATARVELCAQGSADLAHLDDGPYEAGGEKEQDPRLI PVPANSYFGLLFVTNIDSSDPDQL

```

VYKTLDPADRLPGPAGDLALNSYLGFSIDSGKGLVRAEELS FVAGAPRANHKGAVVILRKDSASRLVPEVM
LSGERLTSGFGYSLAVADLNSDGWPD LIVGAPYFFERQEELGGAVYVYLNQGGHWAGISPLRLCGSPDSMF
GISLAVLGDNLQDGFDPDIAGVAPFDGDKVFIYHGSSLGVVAKPSQVLEGEAVGIKSGYSLSGSLDMGDN
QYPDLLVGS LADTAVLFRARPI LHVSHEVSIAPRSIDLEQPN CAGGHSVCVDLRVCF SYIAVPSSYSPTVA
LDYVL DADTDRRLRGQVPRVTF LSRNLEEPKHQASGT VWLKHQHDRVCGDAMFQLQENVKDKLRAIVVTL S
YSLQTPRLRRQAPGQGLPPVAFILNAHQPSQRAEIHFLKQCGEDKIQSNLQLVRARFCTRVSDTEFQP
LPMDDVDGTTALFALSQGPVIGLELMVTNLPSPDPAQPPADGDDAHEAQLLVMLPDSLHYSGVRALDEKPLCL
SNENASHVECELGNPMKRGAQVTFYLLISTSGIS IETTELEVE LLLATISEQELHPVSARARVFIELPLSI
AGMAIPQQLFFSGVVRGERAMQSERDVGSKVKYEVTVSNQGSRLTGS AFLNIMWPHEIANGKWL LYPMQ
VELEGGQGPQKGLCSPPRPNILHLDVDSRDRRRRRELEPPEQQEPGERQEPSMSWWPVSSAEKKKNTLDC
ARGTANCVVFCPLYSFDRAAVLHVWGR LWNSTFLEEYSAVKSLEVI VRANITVKS SIKNMLRDASTVIP
VMVYLDPMMAVVAEGVPWWVIL LAVLAGLLVLALLVLLWKCGFFHRSSQSSSFPTNYHRA CLAVQPSAMEV
GGPGTVG

```

The NOV8a amino acid sequence has 975 of 1113 amino acid residues (87%) identical to, and 1032 of 1113 amino acid residues (92%) similar to, the *Mus musculus* 1161 amino acid residue integrin alpha 7 precursor protein (SPTREMBL-ACC: O88731)(E = 0.0).

### NOV8b

A disclosed NOV8b nucleic acid of 3110 nucleotides (also referred to CG53926-02) encoding a novel ITGA7 precursor-like receptor protein is shown in Table 8C. An open reading frame was identified beginning with an ATG initiation codon at nucleotides 1-3 and ending with a TAA codon at nucleotides 3106-3108. A putative untranslated region downstream from the termination codon is underlined in Table 8C, and the start and stop codons are in bold letters.

**Table 8C. NOV8b Nucleotide Sequence (SEQ ID NO:43)**

```

ATGGCCGGGGCTCGGAGCCGCGACCCGTTGGGGGGCCTCCGGGATTGTGCTACCTTTTGGCTCCCTGCTCG
TCCAAGTCTCTTCTCACGGCTGTGCGCTTCAATCTGGACGTGATGGGTGCCTTGCAGCAAGGAGCGAGCC
AGGCAGCCTCTTCGGCTTCTCTGTGGCCCTGCACCCCGCACGTGCGAGCCCCGGACCCAGCAGCCCACTG
CTGGTGGGTGCTCCCCAGGCCCTGGCTCTTCTGGGCAGCAGGCGAATCGCACTGGAGGCTCTTCGCTTG
CCCGTTGAGCCTGGAGGAGACTGACTGCTACAGAGTGGACATCGACCAGGGAGCTGATATGCAAAAGGAAA
GCAAGGAGAACCAAGTGGTTGGGAGTCAAGTGTTCGGAGCCAGGGGCATTTGGTTCGCTGCTTGTGCTCAGCCA
GGACCTGGCCATCCGGGATGAGTTGGATGGTGGGGAATGGAAGTTCTGTGAGGGACGCCCCAAGGCCATG
AACATTTGGGTTCTGCCAGCAGGGCACAGCTGCCGCTTCTCCCTGATAGCCACTACCTCCTTTGGG
GCCCCAGGAACCTATAATTGGAAGGGCACGGCCAGGTTGGAGTCTGTGTCACAGGGCTCAGCGGACCTGGC
ACACCTGGACGACGGTCCCTACGAGGCGGGGGAGAGAAGGAGCAGGACCCCCGCTCATCCCGGTCCCTG
CCAACAGCTACTTTGGGTTGCTTTTGTGACCAACATTGATAGCTCAGACCCGACCAGCTGGTGATATAA
ACTTTGGACCTGCTGACCGGCTCCCAGGACAGCCGGAGACTTGGCCCTCAATAGCTACTTAGGCTTCTC
TATTGACTCGGGAAAGGTCTGGTGCGTGCAAGAGCTGAGCTTTGTGGCTGGAGCCCCCGGCCAACC
ACAAGGGTGCTGTGCTCATCCTGCGCAAGGACAGCGCCAGTGCCTGGTGCCCGAGGTTATGCTGTCTGGG
GAGCGCTGACCTCCGGCTTTGGCTACTCACTGGCTGTGGCTGACCTCAACAGTGATGGGTGGCCAGACCT
GATAGTGGGTGCCCCCTACTTCTTTGAGCGCCAAAGAAGAGCTGGGGGGTGTGTGTATGTGTAATGAACC
AGGGGGGTCACTGGGCTGGGATCTCCCTCTCCGGCTCTGCGGCTCCCTGACTCCATGTTCTGGGATCAGC
CTGGCTGTCTGGGGACCTCAACCAAGATGGCTTTCCAGATATTGAGTGGGTGCCCCCTTGATGGTGTA
TGGGAAAGTCTTCATCTACCATGGGAGCAGCTGGGGGTTGTGCGCAAACTTCACAGGTGCTGGAGGGCG
AGGCTGTGGGCATCAAGAGCTTCCGGTACTCCCTGTGAGGAGCTTGGATATGGATGGGAACCAATACCTT
GACCTGCTGTGGTGGGCTCCCTGGCTGACACCGAGTGTCTTTCAGGGCCAGACCCATCCTCCATGTCTCCA
TGAGGTCTCTATTGCTCCACGAAGCATCGACCTGGAGCAGCCCACTGTGCTGGCGGCACTCGGTCTGTG
TGGACCTAAGGGTCTGTTTTCAGCTACATTGCACTGCCAGCAGCTATAGCCCTACTGTGGCCCTGGACTAT
GTGTTAGATGCGGACACAGACCGGAGGCTCCGGGGCCAGGTTCCCGTGTGACGTTCTGAGCCGTAACTT
GGAAGAACCACGACACAGGCTCCGGCACCGTGTGGCTGAAGCACCAGCATGACCGAGTCTGTGGAGACG
CCATGTTCCAGCTCCAGGAAAATGTCAAAGACAAGCTTCGGGCCATTGTAGTGACCTTGTCTACAGTCTC
CAGACCCCTCGGCTCCGGGACAGGCTCCTGGCCAGGGGCTGCCTCCAGTGGCCCCCATCTCAATGCCCA
CCAGCCAGCACCCAGGGGAGAGATCCACTTCTGAGCAAGGCTGTGGTGAAGACAAGATCTGCCAGA

```

```

GCAATCTGCAGCTGGTCCGCGCCCGCTTCTGTACCCGGGTACGCGACAGGAATCCAACCTCTGCCCATG
GATGTGGATGGAACAACAGCCCTGTTTGCAGTGTGGGAGCCAGTCATTGGCCTGGAGCTGATGGTCAC
CAACCTGCCATCGGACCCAGCCAGCCAGGCTGATGGGGATGATGCCCATGAAGCCAGCTCCTGGTCA
TGCTTCTCTGACTCACTGCACTACTCAGGGGTCCGGGCCCTGGACCCTGCGGAGAAGCCACTCTGCCTGTCC
AATGAGAATGCCTCCCATGTTGAGTGTGAGCTGGGGAACCCATGAAGAGAGGTGCCAGGTACCTTCTA
CCTCATCCTTAGCACCTCCGGGATCAGCATTGAGACCACGGAACGGAGGTAGAGCTGCTGTTGGCCACGA
TCAGTGAGCAGGAGCTGCATCCAGTCTCTGCACGAGCCGCTGTCTTATTGAGCTGCCACTGTCCATTGCA
GGAATGGCCATTCCCCAGCAACTCTTCTTCTCTGGTGTGGTGAGGGGCGAGAGGCCATGCAGTCTGAGCG
GGATGTGGGCGAGCAAGGACTGCGCCCGGGGCACGGCCAACGTGTGTGGTGTTCAGCTGCCCACTCTACAGCT
TTGACCGCGCGGCTGTGCTGCATGTCTGGGGCCGTCTCTGGAACAGCACCTTCTGGAGGAGTACTCAGCT
GTGAAGTCCCTGGAAGTGATTGTCCGGGCCAATCAGAGTGAAGTCTCCATAAAGGACTTGATGCTCCG
AGATGCCTCCACAGTGATCCAGTGATGGTATACTTGGACCCATGGCTGTGGTGGCAGAAGGAGTGCCCT
GGTGGGTCACTCCTCTGGCTGACTGGCTGGGCTGTGGTGTAGCACTGCTGGTGTGCTCCTGTGGGAAG
TGTGGCTTCTCCATCGGAGCAGCCAGAGCTCATCTTTCCACCAACTATCACCGGGCTGTCTGGCTGT
GCAGCCTTCAGCATGGAAGTTGGGGTCCAGGGACTGTGGGGTAAC

```

The disclosed NOV8b nucleic acid sequence, localized to chromosome 12, has 1856 of 1867 bases (99%) identical to a *Homo sapiens* integrin alpha-7 mRNA (gb:GENBANK-ID:AF032108|acc:AF032108.1) (E = 0.0).

- 5 A disclosed NOV8b polypeptide (SEQ ID NO:44) encoded by SEQ ID NO:43 is 1035 amino acid residues and is presented using the one-letter amino acid code in Table 8D. Signal P, Psort and/or Hydropathy results predict that NOV8b does not contain a signal peptide and is likely to be localized to the endoplasmic reticulum with a certainty of 0.8500.

**Table 8D. Encoded NOV8b protein sequence (SEQ ID NO:44).**

```

MAGARSRDPLGGLRDLFPFWLPARRTALLTAVAFNLDVMGALRKEASQAASSASLWPCTRHVAAPDPSSPL
LVGAPQALALPGQANRTGGLFACPLSLEETDCYRVDIDQADMQKESKENQWLGVSVRSQGGKIVTCA
HRYEARQVRVDQILETRDMIGRCFVLSQDLAIRDELGGWKFCEGRPOGHEQFGFCQQTAAAFSPDSHYL
LFGAPGTYNWKGATARVELCAQGSADLAHLDDGPIYAGGEEQDPRILPVPANSYFGLLFVTNIDSSDPDQL
VYKTLDPADRLPGPAGDLALNSYLGFSIDSGKGLVRAEELSFVAGAPRANHKGAVVILRKDSASRLVPEVM
LSGERLTSGFGYSLAVADLNSDGWPDILVGPYFFERQEEELGGAVVYVNLQGGHWAGISPLRLCGSPDSMF
GISLAVLGDLDNQDGFDPDIAGAPFDGDGKVFYHSGSLGVVAKPSQVLEGEAVGIKSPGYSLSGSLDMDGN
QYPDLLVGLSADTAVLFRARFILHVSHEVSIAPRSIDLEQPNACGGHVSVCVLDLRVCFYSYIAVPSYSPTVA
LDYVLDADTDRRLRGQVPRVTFILSRNLEEPKHQASGTVWLKHQHDRVCGDAMFQLQENVKDKLRAIVVTL
YSLQTPRLRRQAPGQGLPPVAPILNAHQPSQRAEIHFLKQCGEDKICQSNLQLVRARFCTRVSDETFQ
LPMDDVDGTTALFALSGQPVIGLELMVTNLPSPDPAQPDAGDDAHEAQLLVMLPDSLHSGVRLDPAEKPL
CLSNENASHVECELGPNPMKRGAQVTFFYLILSTSGISITTELEVELELLATISEQELHPVSARARVFIELPL
SIAGMAIPQQLFFSGVVRGERAMQSERDVGSKDCARGTANCVVFSCLYSPFRAAVLHVWGRLLWNSTFLEE
YSAVKSLEIVIRANITVKSISKDLMLRDASTVIVPMVYLDPMVVAEGVPWWVILLAVLAGLLVLLVLL
LWKCGFFHRSSQSSSFPTNYHRACLAVQPSAMEVGGPGTVG

```

10

The NOV8b amino acid sequence has 843 of 884 amino acid residues (95%) identical to, and 844 of 884 amino acid residues (95%) similar to, the *Homo sapiens* 1181 amino acid residue integrin alpha-7 precursor protein (ptnr:SWISSNEW-ACC:Q13683) (E = 0.0).

- 15 NOV8b is expressed in at least the following tissues: skeletal muscle, cardiac muscle, small intestine, colon, ovary, prostate, lung and testis.

The NOV8a and 8b proteins are very closely homologous as shown in the alignment in Table 8E.

**Table 8E Alignment of NOV8a and 8b.**

```

      10      20      30      40      50
...|...|...|...|...|...|...|...|...|...|

```

NOV8a AC073487_da1	MAGARSRDPLGGRLDLLPFWLPARRTALLTAVAFNLDVMGALRKEASQAA
NOV8b CG53926-02	MAGARSRDPLGGRLDLLPFWLPARRTALLTAVAFNLDVMGALRKEASQAA
	60 70 80 90 100
NOV8a AC073487_da1	SSASLWPCTRHVAAPDPSSPLLVGAPQALALPGQANRTGGLFACPLSLE
NOV8b CG53926-02	SSASLWPCTRHVAAPDPSSPLLVGAPQALALPGQANRTGGLFACPLSLE
	110 120 130 140 150
NOV8a AC073487_da1	ETDCYRVDIDQGADMQESKENQWLGVSRSQGPGGKIVTCAHRYEARQR
NOV8b CG53926-02	ETDCYRVDIDQGADMQESKENQWLGVSRSQGPGGKIVTCAHRYEARQR
	160 170 180 190 200
NOV8a AC073487_da1	VDQILETRDMIGRCFVLSQDLAIRDELDDGGEWKFCGRPQGHEQFGFCQC
NOV8b CG53926-02	VDQILETRDMIGRCFVLSQDLAIRDELDDGGEWKFCGRPQGHEQFGFCQC
	210 220 230 240 250
NOV8a AC073487_da1	GTAAAFSPDSHYLLFGAPGTYNWKGRTARVELCAQGSADLAHLDDGPFYBAG
NOV8b CG53926-02	GTAAAFSPDSHYLLFGAPGTYNWKGRTARVELCAQGSADLAHLDDGPFYBAG
	260 270 280 290 300
NOV8a AC073487_da1	GEKEQDPRLIPVPANSYFGLLFVTNIDSSDPDQLVYKTLDPADRLPGPAG
NOV8b CG53926-02	GEKEQDPRLIPVPANSYFGLLFVTNIDSSDPDQLVYKTLDPADRLPGPAG
	310 320 330 340 350
NOV8a AC073487_da1	DLALNSYLGFSIDSGKGLVRAEELSFVAGAPRANHKGAVVILRKDSASRL
NOV8b CG53926-02	DLALNSYLGFSIDSGKGLVRAEELSFVAGAPRANHKGAVVILRKDSASRL
	360 370 380 390 400
NOV8a AC073487_da1	VPEVMLSGERLTSGFGYSLAVADLNSDGNPDILVGAIFYFFERQBELGGAV
NOV8b CG53926-02	VPEVMLSGERLTSGFGYSLAVADLNSDGNPDILVGAIFYFFERQBELGGAV
	410 420 430 440 450
NOV8a AC073487_da1	VVYLNQGGHWAGISPLRLCGSPDSMFGISLAVLGDLMQDGFPIAVGAPF
NOV8b CG53926-02	VVYLNQGGHWAGISPLRLCGSPDSMFGISLAVLGDLMQDGFPIAVGAPF
	460 470 480 490 500
NOV8a AC073487_da1	DGDGKVFITYHGSSLGVAKPSQVLEGEAVGIKSFYSLSGSLDMDGNQYP
NOV8b CG53926-02	DGDGKVFITYHGSSLGVAKPSQVLEGEAVGIKSFYSLSGSLDMDGNQYP
	510 520 530 540 550
NOV8a AC073487_da1	DLVGLSLADTAVLFRARPILHVSHEVSIAPRSIDLEQPNACGGHSVCVDL
NOV8b CG53926-02	DLVGLSLADTAVLFRARPILHVSHEVSIAPRSIDLEQPNACGGHSVCVDL
	560 570 580 590 600
NOV8a AC073487_da1	RVCFSYIAVPSSSYPTVALDYVLDADTDRLRGQVPRVTFLSRNLEEPKH
NOV8b CG53926-02	RVCFSYIAVPSSSYPTVALDYVLDADTDRLRGQVPRVTFLSRNLEEPKH
	610 620 630 640 650
NOV8a AC073487_da1	QASGTVWLKHQHDRVCGDAMFQLENVCKLRAIVVTLISYSLOTPLRLRRC
NOV8b CG53926-02	QASGTVWLKHQHDRVCGDAMFQLENVCKLRAIVVTLISYSLOTPLRLRRC
	660 670 680 690 700
NOV8a AC073487_da1	APGQGLPPVAPILNAHQPSQRAETHFLKQCGEDKICQSNLQLVRARFC
NOV8b CG53926-02	APGQGLPPVAPILNAHQPSQRAETHFLKQCGEDKICQSNLQLVRARFC
	710 720 730 740 750
NOV8a AC073487_da1	TRVSDTEFQPLPMDVDGTTALFALSQGPVIGLELMVTNLPSPDPAQPQADG
NOV8b CG53926-02	TRVSDTEFQPLPMDVDGTTALFALSQGPVIGLELMVTNLPSPDPAQPQADG
	760 770 780 790 800
NOV8a AC073487_da1	DDAHEAQLLVMLPDSLHYSGVRALD--EKPLCLSNENASHVECELGNPMK
NOV8b CG53926-02	DDAHEAQLLVMLPDSLHYSGVRALDPAEKPLCLSNENASHVECELGNPMK
	810 820 830 840 850

```

      .....|.....|.....|.....|.....|.....|.....|.....|.....|.....|
NOV8a AC073487_da1 RGAQVTFYLILSTSGISIEETTELEVELLATISEQELHPVSARARVFIEL
NOV8b CG53926-02  RGAQVTFYLILSTSGISIEETTELEVELLATISEQELHPVSARARVFIEL

      860      870      880      890      900
NOV8a AC073487_da1 PLSTAGMAIPQQLFFSGVVRGERAMQSERDVGSKVKYEYVTVSNQGQSLRT
NOV8b CG53926-02  PLSTAGMAIPQQLFFSGVVRGERAMQSERDVGS-----

      910      920      930      940      950
NOV8a AC073487_da1 LGS AFLNIMWPHEIANGKWL LYPMQVELHGGGQPGQKGLCSPPRRPNILHL
NOV8b CG53926-02  -----K-----

      960      970      980      990      1000
NOV8a AC073487_da1 DVDSRDRRRRELEPPQQEPGERQEPMSWVPVSSAEKKKNITLDCARGT
NOV8b CG53926-02  -----DCARGT

      1010     1020     1030     1040     1050
NOV8a AC073487_da1 ANC VVFSCPLYSFDRRAAVLHVWGRLWNSTFLEEYSAVKSLLEVIVRANITV
NOV8b CG53926-02  ANC VVFSCPLYSFDRRAAVLHVWGRLWNSTFLEEYSAVKSLLEVIVRANITV

      1060     1070     1080     1090     1100
NOV8a AC073487_da1 KSSIKMLMLRDASTVIPVMVYLDPMVAV AEGVPWVWVILLAVLAGLLVLAL
NOV8b CG53926-02  KSSIKMLMLRDASTVIPVMVYLDPMVAV AEGVPWVWVILLAVLAGLLVLAL

      1110     1120     1130     1140
NOV8a AC073487_da1 LVLL LKCGFFHRSSQSSSFPTNYHRA CLAVQPSAMEVGGPGTVG
NOV8b CG53926-02  LVLL LKCGFFHRSSQSSSFPTNYHRA CLAVQPSAMEVGGPGTVG

```

- Homologies to either of the above NOV8 proteins will be shared by the other NOV8 protein insofar as they are homologous to each other as shown above. Any reference to NOV8 is assumed to refer to both of the NOV8 proteins in general, unless otherwise noted.

The disclosed NOV8 polypeptide has homology to the amino acid sequences shown in the BLASTP data listed in Table 8F.

Table 8F. BLAST results for NOV8a					
Gene Index/ Identifier	Protein/ Organism	Length (aa)	Identity (%)	Positives (%)	Expect
<a href="#">gi 6680480 ref NP_032424.1 </a>	integrin alpha 7 [Mus musculus]	1135	899/1095 (82%)	960/1095 (87%)	0.0
<a href="#">gi 12643785 sp Q61738 ITA7 MOUSE</a>	INTEGRIN ALPHA-7 PRECURSOR [Mus musculus]	1179	941/1095 (85%)	1002/1095 (90%)	0.0
<a href="#">gi 4504753 ref NP_002197.1 </a>	integrin alpha 7 precursor [Homo sapiens]	1137	1025/1125 (91%)	1029/1125 (91%)	0.0
<a href="#">gi 3158408 qb AAC18968.1  (AF052050)</a>	integrin alpha 7 [Homo sapiens]	1137	1023/1125 (90%)	1027/1125 (90%)	0.0
<a href="#">gi 7447667 pir JC5951</a>	integrin alpha 7 chain variant [Homo sapiens]	1062	617/702 (87%)	619/702 (87%)	e-157

10

The homology between these and other sequences is shown graphically in the ClustalW analysis shown in Table 8G.

Table 8G. ClustalW Analysis of NOV8

- 1) Novel NOV8a (SEQ ID NO:42)
- 2) Novel NOV8b (SEQ ID NO:44)
- 3) gi|6680480|ref|NP\_032424.1| integrin alpha 7 [Mus musculus] (SEQ ID NO:108)
- 4) gi|12643785|sp|O61738|ITA7\_MOUSE INTEGRIN ALPHA-7 PRECURSOR [Mus musculus] (SEQ ID NO:109)
- 5) gi|4504753|ref|NP\_002197.1| integrin alpha 7 precursor [Homo sapiens] (SEQ ID NO:110)
- 6) gi|3158408|gb|AAC18968.1| (AF052050) integrin alpha 7 [Homo sapiens] (SEQ ID NO:111)
- 7) gi|7447667|pir|JC5951 integrin alpha 7 chain variant [Homo sapiens] (SEQ ID NO:112)

	10	20	30	40	50	
NOV8a	..... ..... ..... ..... ..... ..... ..... ..... ..... .....					
NOV8b	..... ..... ..... ..... ..... ..... ..... ..... ..... .....					
gi 6680480	MAGARSRDPLCGLRDLLPEWLPARRTALLTAVAFNLDVMGALRKEASQAA					
gi 12643785	MAGARSRDPLCGLRDLLPEWLPARRTALLTAVAFNLDVMGALRKEASQAA					
gi 4504753	MARIPRCDFLRPPGIYLLITSLLAGLFLPPATAFNLDVMGALRKEG-EPG					
gi 3158408	MAGARSRDPLCGLRDLLPEWLPARRTALLTAVAFNLDVMGALRKEG-EPG					
gi 7447667	MAGARSRDPLCGLRDLLPEWLPARRTALLTAVAFNLDVMGALRKEG-EPG					
	60	70	80	90	100	
NOV8a	..... ..... ..... ..... ..... ..... ..... ..... ..... .....					
NOV8b	..... ..... ..... ..... ..... ..... ..... ..... ..... .....					
gi 6680480	SSASLWPCTRHVAAPDPSSPLLVGAPQALALPGQQANRTGGFLFACPLSLE					
gi 12643785	SSASLWPCTRHVAAPDPSSPLLVGAPQALALPGQQANRTGGFLFACPLSLE					
gi 4504753	SLFGFSVALHRQLQPRPQSWLLVGAPQALALPGQQANRTGGFLFACPLSLE					
gi 3158408	SLFGFSVALHRQLQPRPQSWLLVGAPQALALPGQQANRTGGFLFACPLSLE					
gi 7447667	SLFGFSVALHRQLQPRPQSWLLVGAPQALALPGQQANRTGGFLFACPLSLE					
	110	120	130	140	150	
NOV8a	..... ..... ..... ..... ..... ..... ..... ..... ..... .....					
NOV8b	..... ..... ..... ..... ..... ..... ..... ..... ..... .....					
gi 6680480	ETDCYRVDIDQADMOKESKENQWLGVSVRSQGGKIVTCAHRYEARQR					
gi 12643785	ETDCYRVDIDQADMOKESKENQWLGVSVRSQGGKIVTCAHRYEARQR					
gi 4504753	ETDCYRVDIDQADMOKESKENQWLGVSVRSQGGKIVTCAHRYEARQR					
gi 3158408	ETDCYRVDIDQADMOKESKENQWLGVSVRSQGGKIVTCAHRYEARQR					
gi 7447667	ETDCYRVDIDQADMOKESKENQWLGVSVRSQGGKIVTCAHRYEARQR					
	160	170	180	190	200	
NOV8a	..... ..... ..... ..... ..... ..... ..... ..... ..... .....					
NOV8b	..... ..... ..... ..... ..... ..... ..... ..... ..... .....					
gi 6680480	VDQILETRDMIGRCFVLSQDLAIRDELDDGGEWKFCEGRPQGHEQFGFCQQ					
gi 12643785	VDQILETRDMIGRCFVLSQDLAIRDELDDGGEWKFCEGRPQGHEQFGFCQQ					
gi 4504753	VDQILETRDMIGRCFVLSQDLAIRDELDDGGEWKFCEGRPQGHEQFGFCQQ					
gi 3158408	VDQILETRDMIGRCFVLSQDLAIRDELDDGGEWKFCEGRPQGHEQFGFCQQ					
gi 7447667	VDQILETRDMIGRCFVLSQDLAIRDELDDGGEWKFCEGRPQGHEQFGFCQQ					
	210	220	230	240	250	
NOV8a	..... ..... ..... ..... ..... ..... ..... ..... ..... .....					
NOV8b	..... ..... ..... ..... ..... ..... ..... ..... ..... .....					
gi 6680480	GTAAAFSPDSHYLLFGAPGTYNWKG---TARVELCAQGSADLAHLDDGPYEAG					
gi 12643785	GTAAAFSPDSHYLLFGAPGTYNWKG---TARVELCAQGSADLAHLDDGPYEAG					
gi 4504753	GTAAAFSPDSHYLLFGAPGTYNWKG---TARVELCAQGSADLAHLDDGPYEAG					
gi 3158408	GTAAAFSPDSHYLLFGAPGTYNWKG---TARVELCAQGSADLAHLDDGPYEAG					
gi 7447667	GTAAAFSPDSHYLLFGAPGTYNWKG---TARVELCAQGSADLAHLDDGPYEAG					
	260	270	280	290	300	
NOV8a	..... ..... ..... ..... ..... ..... ..... ..... ..... .....					
NOV8b	..... ..... ..... ..... ..... ..... ..... ..... ..... .....					
gi 6680480	GEKEQDPRILIPVANSYFG---LLFVTNIDSSDPDQLVYKTLDPADRLGPGAG					
gi 12643785	GEKEQDPRILIPVANSYFG---LLFVTNIDSSDPDQLVYKTLDPADRLGPGAG					
gi 4504753	GEKEQDPRILIPVANSYFG---LLFVTNIDSSDPDQLVYKTLDPADRLGPGAG					



```

gi|3158408|-----LLFVTNIDSSDPDQLVYKTLDPADRLPGPAG
gi|7447667|-----LLFVTNIDSSDPDQLVYKTLDPADRLPGPAG

      310      320      330      340      350
NOV8a DLALNSYLGFSDSGKGLVRAEELSFVAGAPRANHKGAVVILRKDSASRL
NOV8b DLALNSYLGFSDSGKGLVRAEELSFVAGAPRANHKGAVVILRKDSASRL
gi|6680480|DLALNSYLGFSDSGKGLMRSEELSFVAGAPRANHKGAVVILRKDSATRL
gi|12643785|DLALNSYLGFSDSGKGLMRSEELSFVAGAPRANHKGAVVILRKDSATRL
gi|4504753|DLALNSYLGFSDSGKGLVRAEELSFVAGAPRANHKGAVVILRKDSASRL
gi|3158408|DLALNSYLGFSDSGKGLVRAEELSFVAGAPRANHKGAVVILRKDSASRL
gi|7447667|DLALNSYLGFSDSGKGLVRAEELSFVAGAPRANHKGAVVILRKDSASRL

      360      370      380      390      400
NOV8a VPEVMLSGERLTSGFGYSLAVADLNSDGWPD LIVGAPYFFERQEELGGAV
NOV8b VPEVMLSGERLTSGFGYSLAVADLNSDGWPD LIVGAPYFFERQEELGGAV
gi|6680480|VPEVMLSGERLTSGFGYSLAVTDLNNDGWADLIVGAPYFFERQEELGGAV
gi|12643785|VPEVMLSGERLTSGFGYSLAVTDLNNDGWADLIVGAPYFFERQEELGGAV
gi|4504753|VPEVMLSGERLTSGFGYSLAVADLNSDGWPD LIVGAPYFFERQEELGGAV
gi|3158408|VPEVMLSGERLTSGFGYSLAVADLNSDGWPD LIVGAPYFFERQEELGGAV
gi|7447667|VPEVMLSGERLTSGFGYSLAVADLNSDGWPD LIVGAPYFFERQEELGGAV

      410      420      430      440      450
NOV8a YVYLNQGGHWAGISPLRLCGSPDSMFGISLAVLGD LNQDGFDPDIAVGAPF
NOV8b YVYLNQGGHWAGISPLRLCGSPDSMFGISLAVLGD LNQDGFDPDIAVGAPF
gi|6680480|YVYLNQGGHWADTSPRLTCGSPDSMFGISLAVLGD LNQDGFDPDIAVGAPF
gi|12643785|YVYLNQGGHWADTSPRLTCGSPDSMFGISLAVLGD LNQDGFDPDIAVGAPF
gi|4504753|YVYLNQGGHWAGISPLRLCGSPDSMFGISLAVLGD LNQDGFDPDIAVGAPF
gi|3158408|YVYLNQGGHWAGISPLRLCGSPDSMFGISLAVLGD LNQDGFDPDIAVGAPF
gi|7447667|YVYLNQGGHWAGISPLRLCGSPDSMFGISLAVLGD LNQDGFDPDIAVGAPF

      460      470      480      490      500
NOV8a DGDGKVFIIYHGSSLG VVAKPSQVLEGEAVGIKSF GYSLSGSLDMDGNQYP
NOV8b DGDGKVFIIYHGSSLG VVAKPSQVLEGEAVGIKSF GYSLSGSLDMDGNQYP
gi|6680480|DGDGKVFIIYHGSSLG VVAKPSQVLEGEAVGIKSF GYSLSGGLDMDGNHYP
gi|12643785|DGDGKVFIIYHGSSLG VVAKPSQVLEGEAVGIKSF GYSLSGGLDMDGNHYP
gi|4504753|DGDGKVFIIYHGSSLG VVAKPSQVLEGEAVGIKSF GYSLSGSLDMDGNQYP
gi|3158408|DGDGKVFIIYHGSSLG VVAKPSQVLEGEAVGIKSF GYSLSGSLDMDGNQYP
gi|7447667|DGDGKVFIIYHGSSLG VVAKPSQVLEGEAVGIKSF GYSLSGSLDMDGNQYP

      510      520      530      540      550
NOV8a DLLVGS LADTAVLFRARPILHVSHEVSTAPRSIDLEQ PNCAGGHSVCVDL
NOV8b DLLVGS LADTAVLFRARPILHVSHEVSTAPRSIDLEQ PNCAGGHSVCVDL
gi|6680480|DLLVGS LADTAVLFRARPILHVSHEVSTAPRSIDLEQ PNCAGGHSVCVDL
gi|12643785|DLLVGS LADTAVLFRARPILHVSHEVSTAPRSIDLEQ PNCAGGHSVCVDL
gi|4504753|DLLVGS LADTAVLFRARPILHVSHEVSTAPRSIDLEQ PNCAGGHSVCVDL
gi|3158408|DLLVGS LADTAVLFRARPILHVSHEVSTAPRSIDLEQ PNCAGGHSVCVDL
gi|7447667|DLLVGS LADTAVLFRARPILHVSHEVSTAPRSIDLEQ PNCAGGHSVCVDL

      560      570      580      590      600
NOV8a RVCFSYI AVPSSYSPTVALDYVLDADTDRRLRGQVPRVTFLSRNLEEPKH
NOV8b RVCFSYI AVPSSYSPTVALDYVLDADTDRRLRGQVPRVTFLSRNLEEPKH
gi|6680480|KICFSYI AVPSSYSPTVALDYVLDGDTDRRLRGQVPRVTFLSRGLDDLKH
gi|12643785|KICFSYI AVPSSYSPTVALDYVLDGDTDRRLRGQVPRVTFLSRGLDDLKH
gi|4504753|RVCFSYI AVPSSYSPTVALDYVLDADTDRRLRGQVPRVTFLSRNLEEPKH
gi|3158408|RVCFSYI AVPSSYSPTVALDYVLDADTDRRLRGQVPRVTFLSRNLEEPKH
gi|7447667|RVCFSYI AVPSSYSPTVALDYVLDADTDRRLRGQVPRVTFLSRNLEEPKH

      610      620      630      640      650
NOV8a QASGT VVWLKHQHDRVCGDAMFQLQENVKDKLRAIVVTL SYSLQTPRLRRQ
NOV8b QASGT VVWLKHQHDRVCGDAMFQLQENVKDKLRAIVVTL SYSLQTPRLRRQ
gi|6680480|QSSGT VVWLKHQHDRVCGDAMFQLQENVKDKLRAIVVTL SYGLTTPFLRRQ
gi|12643785|QSSGT VVWLKHQHDRVCGDAMFQLQENVKDKLRAIVVTL SYGLTTPFLRRQ
gi|4504753|QASGT VVWLKHQHDRVCGDAMFQLQENVKDKLRAIVVTL SYSLQTPRLRRQ

```

gi | 3158408 | QASGTVWLKHQHDRVCGDAMFQLOENVKDKLRAIVTVLSYSLQTPRLRRQ  
gi | 7447667 | QASGTVWLKHQHDRVCGDAMFQLOENVKDKLRAIVTVLSYSLQTPRLRRQ

660 670 680 690 700  
NOV8a APGQGLPPVAPILNAHQPSQRAETHFLKQCGGEDKICQSNLQLVHARFC  
NOV8b APGQGLPPVAPILNAHQPSQRAETHFLKQCGGEDKICQSNLQLVHARFC  
gi | 6680480 | APGQGLPPVAPILNAHQPSQRAETHFLKQCGGEDKICQSNLQLVHARFC  
gi | 12643785 | APGQGLPPVAPILNAHQPSQRAETHFLKQCGGEDKICQSNLQLVHARFC  
gi | 4504753 | APGQGLPPVAPILNAHQPSQRAETHFLKQCGGEDKICQSNLQLVHARFC  
gi | 3158408 | APGQGLPPVAPILNAHQPSQRAETHFLKQCGGEDKICQSNLQLVHARFC  
gi | 7447667 | APGQGLPPVAPILNAHQPSQRAETHFLKQCGGEDKICQSNLQLVHARFC

710 720 730 740 750  
NOV8a TRVSDTEFQPLPMDVDGTTALFALSGQPVIGLELMVTNLPSPDPAQPADG  
NOV8b TRVSDTEFQPLPMDVDGTTALFALSGQPVIGLELMVTNLPSPDPAQPADG  
gi | 6680480 | TRVSDTEFQPLPMDVDGTTALFALSGQPVIGLELMVTNLPSPDPAQPADG  
gi | 12643785 | TRVSDTEFQPLPMDVDGTTALFALSGQPVIGLELMVTNLPSPDPAQPADG  
gi | 4504753 | TRVSDTEFQPLPMDVDGTTALFALSGQPVIGLELMVTNLPSPDPAQPADG  
gi | 3158408 | TRVSDTEFQPLPMDVDGTTALFALSGQPVIGLELMVTNLPSPDPAQPADG  
gi | 7447667 | TRVSDTEFQPLPMDVDGTTALFALSGQPVIGLELMVTNLPSPDPAQPADG

760 770 780 790 800  
NOV8a DDAHEAQLLVMLPDSLEHYSVGRALD--EKPLCLSNENASHVECELGNPMK  
NOV8b DDAHEAQLLVMLPDSLEHYSVGRALDPAEKPLCLSNENASHVECELGNPMK  
gi | 6680480 | DDAHEAQLLVMLPDSLEHYSVGRALDPAEKPLCLSNENASHVECELGNPMK  
gi | 12643785 | DDAHEAQLLVMLPDSLEHYSVGRALDPAEKPLCLSNENASHVECELGNPMK  
gi | 4504753 | DDAHEAQLLVMLPDSLEHYSVGRALDPAEKPLCLSNENASHVECELGNPMK  
gi | 3158408 | DDAHEAQLLVMLPDSLEHYSVGRALDPAEKPLCLSNENASHVECELGNPMK  
gi | 7447667 | DDAHEAQLLVMLPDSLEHYSVGRALDPAEKPLCLSNENASHVECELGNPMK

810 820 830 840 850  
NOV8a RGAQVTFYLLISTSGISITTELEVALLATISEQELHPVSARARVFIEL  
NOV8b RGAQVTFYLLISTSGISITTELEVALLATISEQELHPVSARARVFIEL  
gi | 6680480 | RGAQVTFYLLISTSGISITTELEVALLATISEQELHPVSARARVFIEL  
gi | 12643785 | RGAQVTFYLLISTSGISITTELEVALLATISEQELHPVSARARVFIEL  
gi | 4504753 | RGAQVTFYLLISTSGISITTELEVALLATISEQELHPVSARARVFIEL  
gi | 3158408 | RGAQVTFYLLISTSGISITTELEVALLATISEQELHPVSARARVFIEL  
gi | 7447667 | RGAQVTFYLLISTSGISITTELEVALLATISEQELHPVSARARVFIEL

860 870 880 890 900  
NOV8a PLSIAGMAIPQQLFFSGVVRGERAMQSERDVGSKVKYEVTVSNQGQSLRT  
NOV8b PLSIAGMAIPQQLFFSGVVRGERAMQSERDVGSKVKYEVTVSNQGQSLRT  
gi | 6680480 | PLSIAGMAIPQQLFFSGVVRGERAMQSERDVGSKVKYEVTVSNQGQSLRT  
gi | 12643785 | PLSIAGMAIPQQLFFSGVVRGERAMQSERDVGSKVKYEVTVSNQGQSLRT  
gi | 4504753 | PLSIAGMAIPQQLFFSGVVRGERAMQSERDVGSKVKYEVTVSNQGQSLRT  
gi | 3158408 | PLSIAGMAIPQQLFFSGVVRGERAMQSERDVGSKVKYEVTVSNQGQSLRT  
gi | 7447667 | PLSIAGMAIPQQLFFSGVVRGERAMQSERDVGSKVKYEVTVSNQGQSLRT

910 920 930 940 950  
NOV8a LGSANLNIMWPHEIANGKWLLYPMVELEGGQGPGRGICSPRPNILHL  
NOV8b LGSANLNIMWPHEIANGKWLLYPMVELEGGQGPGRGICSPRPNILHL  
gi | 6680480 | LGSANLNIMWPHEIANGKWLLYPMVELEGGQGPGRGICSPRPNILHL  
gi | 12643785 | LGSANLNIMWPHEIANGKWLLYPMVELEGGQGPGRGICSPRPNILHL  
gi | 4504753 | LGSANLNIMWPHEIANGKWLLYPMVELEGGQGPGRGICSPRPNILHL  
gi | 3158408 | LGSANLNIMWPHEIANGKWLLYPMVELEGGQGPGRGICSPRPNILHL  
gi | 7447667 | LGSANLNIMWPHEIANGKWLLYPMVELEGGQGPGRGICSPRPNILHL

960 970 980 990 1000  
NOV8a DVDSRDRRRRELPEPEQEPGERQEPSMSWWPVSSAEKKNTLDCARGT  
NOV8b DVDSRDRRRRELPEPEQEPGERQEPSMSWWPVSSAEKKNTLDCARGT  
gi | 6680480 | DVDSRDRRRRELPEPEQEPGERQEPSMSWWPVSSAEKKNTLDCARGT  
gi | 12643785 | DVDSRDRRRRELPEPEQEPGERQEPSMSWWPVSSAEKKNTLDCARGT  
gi | 4504753 | DVDSRDRRRRELPEPEQEPGERQEPSMSWWPVSSAEKKNTLDCARGT

gi 3158408	DVDSRDRRRRELEPPEQEPGERCEPSMSWVPVSSAEKKNITLDCARGT
gi 7447667	DVDSRDRRRRELEPPEQEPGERCEPSMSWVPVSSAEKKNITLDCARGT
	1010 1020 1030 1040 1050
NOV8a	ANCVVFSCPLYSFDRAAVLHVWGRLWNSTFLEEYSAVKSLEVIVRANITV
NOV8b	ANCVVFSCPLYSFDRAAVLHVWGRLWNSTFLEEYSAVKSLEVIVRANITV
gi 6680480	ANCVVFSCPLYSFDRAAVLHVWGRLWNSTFLEEYSAVKSLEVIVRANITV
gi 12643785	ANCVVFSCPLYSFDRAAVLHVWGRLWNSTFLEEYSAVKSLEVIVRANITV
gi 4504753	ANCVVFSCPLYSFDRAAVLHVWGRLWNSTFLEEYSAVKSLEVIVRANITV
gi 3158408	ANCVVFSCPLYSFDRAAVLHVWGRLWNSTFLEEYSAVKSLEVIVRANITV
gi 7447667	ANCVVFSCPLYSFDRAAVLHVWGRLWNSTFLEEYSAVKSLEVIVRANITV
	1060 1070 1080 1090 1100
NOV8a	KSSIKNLMRLDASTVIPVMVYLDPMVAVGVPWWVILLAVLAGLLVLAL
NOV8b	KSSIKNLMRLDASTVIPVMVYLDPMVAVGVPWWVILLAVLAGLLVLAL
gi 6680480	KSSIKNLMRLDASTVIPVMVYLDPMVAVGVPWWVILLAVLAGLLVLAL
gi 12643785	KSSIKNLMRLDASTVIPVMVYLDPMVAVGVPWWVILLAVLAGLLVLAL
gi 4504753	KSSIKNLMRLDASTVIPVMVYLDPMVAVGVPWWVILLAVLAGLLVLAL
gi 3158408	KSSIKNLMRLDASTVIPVMVYLDPMVAVGVPWWVILLAVLAGLLVLAL
gi 7447667	KSSIKNLMRLDASTVIPVMVYLDPMVAVGVPWWVILLAVLAGLLVLAL
	1110 1120 1130 1140 1150
NOV8a	LVLLLLWKCGFFHRSQSSSFPTNYHRACIAYQP
NOV8b	LVLLLLWKCGFFHRSQSSSFPTNYHRACIAYQP
gi 6680480	LVLLLLWKCGFFKRAKHPEATVPQYHAVKIPREDRQQFKEEKTGTLRNNW
gi 12643785	LVLLLLWKCGFFKRAKHPEATVPQYHAVKIPREDRQQFKEEKTGTLRNNW
gi 4504753	LVLLLLWKCGFFKRAKHPEATVPQYHAVKIPREDRQQFKEEKTGTLRNNW
gi 3158408	LVLLLLWKCGFFKRAKHPEATVPQYHAVKIPREDRQQFKEEKTGTLRNNW
gi 7447667	LVLLLLWKCGFFKRAKHPEATVPQYHAVKIPREDRQQFKEEKTGTLRNNW
	1160 1170 1180
NOV8a	-----S-AMEVG-----GPGTVG
NOV8b	-----S-AMEVG-----GPGTVG
gi 6680480	GNSQWEGSDAHPILAADWHPELGPDPGHVPATA
gi 12643785	GNSQWEGSDAHPILAADWHPELGPDPGHVPATA
gi 4504753	GSPRREGPDADHPILAADGHPELGPDPGHGPGTA
gi 3158408	GSPRREGPDADHPILAADGHPELGPDPGHGPGTA
gi 7447667	GSPRREGPDADHPILAADGHPELGPDPGHGPGTA

Table 8H-J lists the domain description from DOMAIN analysis results against NOV8a. This indicates that the NOV8a sequence has properties similar to those of other proteins known to contain these domains.

**Table 8H. Domain Analysis of NOV8a**

gnl|Smart|smart00191, Int\_alpha, Integrin alpha (beta-propellor repeats).; Integrins are cell adhesion molecules that mediate cell-extracellular matrix and cell-cell interactions. They contain both alpha and beta subunits. Alpha integrins are proposed to contain a domain containing a 7-fold repeat that adopts a beta-propellor fold. Some of these domains contain an inserted von Willebrand factor type-A domain. Some repeats contain putative calcium-binding sites. The 7-fold repeat domain is homologous to a similar domain in phosphatidylinositol-glycan-specific phospholipase D. (SEQ ID NO:113)  
Length = 56 residues, 100.0% aligned  
Score = 62.4 bits (150), Expect = 1e-10

NOV8a 422 PDSMFGISLAVLGDNLQDGFDPDIAVGAPFDGD---GKVFIIYHGSSLGVVAKPSQVLE 475

Smart00191 1      || || |+| +||+| ||+||+ |||| | | ||+| ||| | | |  
 PGSYFGYSVAGVGDVNGDGYPDLLVGAPRANDAETGAVYVYFGSS-GGRCIPLQNLS 56

**Table 8I. Domain Analysis of NOV8a**

gnl|Smart|smart00191, Int\_alpha, Integrin alpha (beta-propellor repeats). (SEQ ID NO:114)  
 Length = 56 residues, 96.4% aligned  
 Score = 53.1 bits (126), Expect = 8e-08

NOV8a            363    SGFGYSLA-VADLNSDGWPDLLVGAPYFFERQEELGGAVYVYL-NQGGHWAGISPLR 417  
 |||||+| | |+| ||+||+||| + + ||||| + || + |  
 Smart00191    3       SYFGYSVAGVGDVNGDGYPDLLVGAPRANDAE---TGAVYVYFGSSGGRCIPLQNLS 56

**Table 8J. Domain Analysis of NOV8a**

gnl|Smart|smart00191, Int\_alpha, Integrin alpha (beta-propellor repeats). (SEQ ID NO:115)  
 Length = 56 residues, 98.2% aligned  
 Score = 38.1 bits (87), Expect = 0.003

NOV8a            305    NSYLGFSIDSGKGLVRAEELSFGVAGAPRAN--HKGAVVILRKDSASRLVPEVMLS 357  
 || |+|+ + + ||||| ||| + | |+| ||  
 Smart00191    2       GSYFGYSVAGVGDVNGDGYPDLLVGAPRANDAETGAVYVYFGSSGGRCIPLQNLS 56

5

Expression of the alpha-7 integrin gene (ITGA7) is developmentally regulated during the formation of skeletal muscle. Increased levels of expression and production of isoforms containing different cytoplasmic and extracellular domains accompany myogenesis. From examining the rat and human genomes by Southern blot analysis and in situ hybridization, Wang et al. (Genomics 26: 563-570, 1995) determined that both genomes contain a single alpha-7 gene. In the human, ITGA7 is present on 12q13, as localized by fluorescence in situ hybridization (Wang et al., 1995). Phylogenetic analysis of the integrin alpha-chain sequences suggested that the early integrin genes evolved in 2 pathways to form the I-integrins and the non-I-integrins. The I-integrin alpha chains apparently arose as a result of an early insertion into the non-I-gene. The I-chain subfamily further evolved by duplications within the same chromosome. The non-I-integrin alpha-chain genes are located in clusters on chromosomes 2, 12, and 17, which coincides closely with the localization of the human homeobox gene clusters. Non-I-integrin alpha-chain genes appear to have evolved in parallel and in proximity to the HOX clusters. Thus, the HOX genes that underlie the design of body structure and the integrin genes that underlie informed cell-cell and cell-matrix interactions appear to have evolved in parallel and coordinate fashions.

ITGA7 is a specific cellular receptor for the basement membrane protein laminin-1, as well as for the laminin isoforms -2 and -4. The alpha-7 subunit is expressed mainly in skeletal and cardiac muscle and may be involved in differentiation and migration processes during

myogenesis. Three cytoplasmic and 2 extracellular splice variants are developmentally regulated and expressed in different sites in the muscle. In adult muscle, the alpha-7A and alpha-7B subunits are concentrated in myotendinous junctions but can also be detected in neuromuscular junctions and along the sarcolemmal membrane. To study the involvement of alpha-7 integrin during myogenesis and its role in muscle integrity and function, Mayer et al. (*Nature Genet.* 17: 318-323, 1997) generated a null allele of the ITGA7 gene in the germline of mice by homologous recombination in embryonic stem (ES) cells. To their surprise, mice homozygous for the mutation were viable and fertile, indicating that the gene is not essential for myogenesis. However, histologic analysis of skeletal muscle showed typical signs of progressive muscular dystrophy starting soon after birth, but with a distinct variability in different muscle types. The histopathologic changes indicated an impairment of function of the myotendinous junctions. Thus, ITGA7 represents an indispensable linkage between the muscle fiber and extracellular matrix that is independent of the dystrophin-dystroglycan complex-mediated interaction of the cytoskeleton with the muscle basement membrane.

The basal lamina of muscle fibers plays a crucial role in the development and function of skeletal muscle. An important laminin receptor in muscle is integrin alpha-7/beta-1D. Integrin beta-1 (ITGB1; 135630) is expressed throughout the body, while integrin alpha-7 is more muscle-specific. To address the role of integrin alpha-7 in human muscle disease, Hayashi et al. (*Nature Genet.* 19: 94-97, 1998) determined alpha-7 protein expression in muscle biopsies from 117 patients with unclassified congenital myopathy and congenital muscular dystrophy by immunocytochemistry. They found 3 unrelated patients with integrin alpha-7 deficiency and normal laminin alpha-2 chain expression. (Deficiency of LAMA2 (156225) causes congenital muscular dystrophy, and a secondary deficiency of integrin alpha-7 was observed in some cases.) The 3 patients were found to carry mutations in the ITGA7 gene. Hayashi et al. (1998) noted that the finding in these patients accords well with the findings in Itga7 knockout mice (Mayer et al., 1997).

The protein similarity information, expression pattern, and map location for the NOV 8 (ITGA7-like) protein and nucleic acid disclosed herein suggest that NOV8 may have important structural and/or physiological functions characteristic of the ITGA7 family.

Therefore, the NOV8 nucleic acids and proteins of the invention are useful in potential therapeutic applications implicated in various diseases and disorders described below and/or other pathologies. For example, the NOV8 compositions of the present invention will have efficacy for treatment of patients suffering from Eosinophilic myeloproliferative disorder, Pseudohypoaldosteronism, type IIC, Pseudohypoaldosteronism typeI, Spastic paraplegia-10,

Hemolytic anemia due to triosephosphate isomerase deficiency, Immunodeficiency with hyper-IgM, type 2, C1r/C1s deficiency, combined, C1s deficiency, isolated, Leukemia, acute lymphoblastic, Periodic fever, familial, Hypertension, Episodic ataxia/myokymia syndrome, Immunodeficiency with hyper-IgM, type 2, Muscular dystrophy, Lesch-Nyhan syndrome, Myasthenia gravis and other muscular and cellular adhesion disorders. The NOV8 nucleic acid encoding ITGA7-like protein, and the ITGA7-like protein of the invention, or fragments thereof, may further be useful in diagnostic applications, wherein the presence or amount of the nucleic acid or the protein are to be assessed.

## NOV9

NOV9 includes six novel TMS-2-like proteins disclosed below. The disclosed proteins have been named NOV9a, NOV9b, NOV9c, NOV9d, NOV9e and NOV9f.

### NOV9a

A disclosed NOV9a nucleic acid of 1374 nucleotides (also referred to 124141642\_EXT\_da1) encoding a novel TMS-2-like protein is shown in Table 9A. An open reading frame was identified beginning with an ATG initiation codon at nucleotides 1-3 and ending with a TGA codon at nucleotides 1372-1374. The start and stop codons are in bold letters.

**Table 9A. NOV9a Nucleotide Sequence (SEQ ID NO:45)**

```

ATGGGGGCGCTGCCTGGGAGCCTGCTCCCTGCTCAGCTGCGTGAGTCCTGCTGGCTGTGCGTCCTGCCTCTG
CGGCTCTGCCCCCTGCATCCTGTGTCAGCTGCTGCCCCGCCAGCCGCAACTCCACCGTGAGCCGCTCATCT
TCACGTTCTTCTCTTCTTCTGGGGGTGTTGGTGTCCATCATTATGCTGAGCCCCGGGCGTGAGAGTCAGCTC
TACAAGCTGCCCTGGGTGTGTGAGGAGGGGGCGGGATCCCCACCGTCCTGCAGGGCCACATCGACTGTGG
CTCCCTGCTTGGCTACCGCGCTGTCTACCGCATGTGCTTCGCCACGGCGGCCTTCTTCTTTTTCACCC
TGCTCATGCTCTGCGTGAGCAGCAGCCGGGACCCCCGGGCTGCCATCCAGAATGGGTTTGGTTCTTTAAG
TTCTGATCCTGGTGGGCCTCACCGTGGGTGCCTTCTACATTCTGACGGCTCCTTCACCAACATCTGGTT
CTACTTCGGCGTCTGTTGGCTCCTTCTCTTCTCATCCTCATCCAGCTGGTGCTGCTCATCGACTTTGCGCACT
CCTGGAACCAGCGTGGCTGGGCAAGGCCGAGGAGTGCGATTCCCGTGCTGGTACGCATCACTCTCTCTCT
TCTACTTGTCTGTGATCGCGGCCGTGGCGCTGATGTTTCATGTAATACTGAGCCAGCGGCTGCCACGA
GGGCAAGGTCTTCATCAGCCTCAACCTCACCTTCTGTGTCTGCGTGTCCATCGCTGCTGCTGCTGCCCCAAGG
TCCAGGTGAGCCTGCCTAACTCGGGTCTGCTGCAGGCCTCGGTTCATCACCCTCTACACCATGTTTGTCAAC
TGGTCAGCCCTATCCAGTATCCCTGAACAGAAATGCAACCCCATTTGCCAACCCAGCTGGGCAACGAGAC
AGTTGTGGCAGGCCCGAGGGCTATGAGACCCAGTGGTGGGATGCCCGAGCATTGTGGGCCTCATCATCT
TCCTCCTGTGCACCTCTTTCATCAGTCTGCGCTCCTCAGACCACCGGCAGGTGAACAGCCTGATGCAGACC
GAGGAGTGCCACCTATGCTAGACGCCACACAGCAGCAGCAGGTGGCAGCCTGTGAGGGCCGGGCTT
TGACAACGAGCAGGACGGCGTCACCTACAGCTACTCCTTCTTCCACTTCTGCTGGTGTGCTGCGCTCACTGC
ACGTCATGATGACGCTCACCAACTGGTACAAGTGCGTAGAGACCCGGAAGATGATCAGCAGCTGGACCGCC
GTGTGGGTGAAGATCTGTGCCAGCTGGGCAGGGCTGCTCCTTACCTGTGGACCCTGGTAGCCCCACTCCT
CCTGCGCAACCGCGACTTCAGCTGA

```

The disclosed NOV9a nucleic acid sequence, localized to chromosome 1, has 359 of 554 bases (64%) identical to a 1759 bp *Homo sapiens* transmembrane protein SBBI99 mRNA from (GENBANK-ID: AF153979|acc:AF153979) ( $E = 4.5e^{-50}$ ).

A disclosed NOV9a polypeptide (SEQ ID NO:46) encoded by SEQ ID NO:45 is 457 amino acid residues and is presented using the one-letter amino acid code in Table 9B. Signal P, Psort and/or Hydropathy results predict that NOV8a has a signal peptide and is likely to be localized to the plasma membrane with a certainty of 0.6760. The most likely cleavage site for a NOV9a peptide is between amino acids 69 and 70, at: VES-QL.

**Table 9B. Encoded NOV9a protein sequence (SEQ ID NO:46).**

MGACLGACSLSCVSPAGCASCLCGSAPCILCSCCPASRNSTVSRLIPTFFFLGLVLSIIMLSPGVESQL  
YKLPWVCEEAGIPTVLQGHIDCGSLLGYRAVYRMCFTAAFFFTLLMLCVSSSRDPRAAIQNGFWFFK  
FLILVGLTVGAFYIPDGSFTNIWFYFGVVGSLFLILQLVLLIDFAHSWNQRWLGAECDSRAWYASLSS  
STCLSIAAVALMFMYTTEPSGCHGKVFISLNLTFVCVCSIAAVLPKVQVSLPNSGLLQASVITLYTMEVFT  
WSALSSIPEQKCNPHLPTQLGNETTVAGPEGYETQWWDAPSIVGLIIFLLCTLFISLRSSDHRQVNSLMQT  
EECPMLDATQQQQVAACEGRAFDNEQDGVTSYSFFHFCLVLASLHVMMTLTNWYKCVETRMISTWTA  
VWVKICASWAGLLLYLWTLVAPLLLRNDRFS

The NOV9a amino acid sequence has 249 of 456 amino acid residues (54%) identical to, and 328 of 456 amino acid residues (71%) similar to, the *Mus musculus* 453 amino acid residue membrane protein TMS-2 protein (SPTREMBL-ACC: Q9QZI8) ( $E = 2.1e^{-135}$ ).

NOV9a also has homology to the amino acid sequences shown in the BLASTP data listed in Table 9C.

**Table 9C. BLAST results for NOV9a**

Gene Index/ Identifier	Protein/ Organism	Length (aa)	Identity (%)	Positives (%)	Expect
<a href="#">gi 15077634 gb AAK83284.1 AF352325.1</a> (AF352325)	FKSG84 [Homo sapiens]	456	437/462 (94%)	438/462 (94%)	0.0
<a href="#">gi 9790269 ref NP_062734.1</a>	tumor differentially expressed 1, like; membrane protein TMS-2 [Mus musculus]	453	248/465 (53%)	327/465 (69%)	1e-131
<a href="#">gi 11282574 pir T46332</a>	hypothetical protein DKFZp434H0413.1 [Homo sapiens]	457	249/465 (53%)	328/465 (69%)	1e-126
<a href="#">gi 14750715 ref XP_051568.1</a>	KIAA1253 protein [Homo sapiens]	453	249/465 (53%)	328/465 (69%)	1e-125
<a href="#">gi 6382026 dbj BAA86567.1</a> (AB033079)	KIAA1253 protein [Homo sapiens]	472	249/465 (53%)	328/465 (69%)	1e-125

The homology of these sequences is shown graphically in the ClustalW analysis shown in Table 9D.

**Table 9D Information for the ClustalW proteins**

- 1) NOV9a (SEQ ID NO:46)
- 2) [gi|15077634|gb|AAK83284.1|AF352325.1](#) (AF352325) FKSG84 [Homo sapiens] (SEQ ID NO:116)
- 3) [gi|9790269|ref|NP\\_062734.1](#) tumor differentially expressed 1, like; membrane protein TMS-2 [Mus musculus] (SEQ ID NO:117)

- 4) gi|11282574|pir|T46332 hypothetical protein DKFZp434H0413.1 [Homo sapiens] (SEQ ID NO:118)  
 5) gi|14750715|ref|XP\_051568.1| KIAA1253 protein [Homo sapiens] (SEQ ID NO:119)  
 6) gi|6382026|dbj|BAA86567.1| (AB033079) KIAA1253 protein [Homo sapiens] (SEQ ID NO:120)

```

      10      20      30      40      50
NOV9A      .....MGAQLGACSTLLSCVSPAGCASCLCGSAPCCL
gi|15077634|.....MGAQLGACSTLLSCVSPAGCASCLCGSAPCCL
gi|9790269|.....MGSVLGLCSVAS.....WIPCLCGSAPCCL
gi|11282574|.....DVVEMGSVLGLCSMAS.....WIPCLCGSAPCCL
gi|14750715|.....MGSVLGLCSMAS.....WIPCLCGSAPCCL
gi|6382026|RERSCLHLVCIRCSCDVVEMGSVLGLCSMAS.....WIPCLCGSAPCCL

      60      70      80      90     100
NOV9A      CSCCPASRNSTVSRLLTFTFFLPLGVIVSILMLSPGVESOLYKLEFWVCBEG
gi|15077634|CSCCPASRNSTVSRLLTFTFFLPLGVIVSILMLSPGVESOLYKLEFWVCBEG
gi|9790269|CRCCPSGNNSTVTRLIYALFLLVGVCVACVMLIPGMEEQLNKIPGFCEN-
gi|11282574|CRCCPSGNNSTVTRLIYALFLLVGVCVACVMLIPGMEEQLNKIPGFCEN-
gi|14750715|CRCCPSGNNSTVTRLIYALFLLVGVCVACVMLIPGMEEQLNKIPGFCEN-
gi|6382026|CRCCPSGNNSTVTRLIYALFLLVGVCVACVMLIPGMEEQLNKIPGFCEN-

      110     120     130     140     150
NOV9A      AGIPTVLQGHLD CGSLG GYRAVYRMCFATAAFTFFFTLLMLCVSSSRDPR
gi|15077634|AGIPTVLQGHLD CGSLG GYRAVYRMCFATAAFTFFFTLLMLCVSSSRDPR
gi|9790269|-----EKGVVPCNILVG YKAVYRLCFGLAMFYLLLSLLMIKVKSSSDPR
gi|11282574|-----EKGVVPCNILVG YKAVYRLCFGLAMFYLLLSLLMIKVKSSSDPR
gi|14750715|-----EKGVVPCNILVG YKAVYRLCFGLAMFYLLLSLLMIKVKSSSDPR
gi|6382026|-----EKGVVPCNILVG YKAVYRLCFGLAMFYLLLSLLMIKVKSSSDPR

      160     170     180     190     200
NOV9A      AATONGFWFFKFLILVGLTVGAFTIPDGSTFTNWFYFGVVGSTFLFILIQL
gi|15077634|AATONGFWFFKFLILVGLTVGAFTIPDGSTFTNWFYFGVVGSTFLFILIQL
gi|9790269|AAVHNGFWFFKFATAVAILIIGAFTIPEGTFTTWFYVGMAGAFCFILIQL
gi|11282574|AAVHNGFWFFKFATAVAILIIGAFTIPEGTFTTWFYVGMAGAFCFILIQL
gi|14750715|AAVHNGFWFFKFATAVAILIIGAFTIPEGTFTTWFYVGMAGAFCFILIQL
gi|6382026|AAVHNGFWFFKFATAVAILIIGAFTIPEGTFTTWFYVGMAGAFCFILIQL

      210     220     230     240     250
NOV9A      VLLIDFAHSWNORMLCKAEECDTSRAWYASLSST-----CLSTAVALMFM
gi|15077634|VLLIDFAHSWNORMLCKAEECDTSRAWYAGLFFFTLLFLLSLTAVALMFM
gi|9790269|VLLIDFAHSWNESWVEKMEEGNSRCWYAALLSATALNYLLSLVAVLFFV
gi|11282574|VLLIDFAHSWNESWVEKMEEGNSRCWYAALLSATALNYLLSLVAVLFFV
gi|14750715|VLLIDFAHSWNESWVEKMEEGNSRCWYAALLSATALNYLLSLVAVLFFV
gi|6382026|VLLIDFAHSWNESWVEKMEEGNSRCWYAALLSATALNYLLSLVAVLFFV

      260     270     280     290     300
NOV9A      YYTEPSCGCECKVFISINLTFCVCVSTAAVLPKVOVSLPNSGLLQSSVIT
gi|15077634|YYTEPSCGCECKVFISINLTFCVCVSTAAVLPKVOVSLPNSGLLQSSVIT
gi|9790269|YYTHPASCENKAFISVNMLLCIGASVMSILPKIQESQPRSGLLQSSVIT
gi|11282574|YYTHPASCENKAFISVNMLLCIGASVMSILPKIQESQPRSGLLQSSVIT
gi|14750715|YYTHPASCENKAFISVNMLLCIGASVMSILPKIQESQPRSGLLQSSVIT
gi|6382026|YYTHPASCENKAFISVNMLLCIGASVMSILPKIQESQPRSGLLQSSVIT

      310     320     330     340     350
NOV9A      IYTMFVTWSALSSIPBOKCNPHLPTOLGNETVVAGP-EGYETQWWDAPSI
gi|15077634|IYTMFVTWSALSSIPBOKCNPHLPTOLGNETVVAGP-EGYETQWWDAPSI
gi|9790269|VYTMYLTSAMTNEPETNCNPSLLSIIGYNTTSTVPKQGSVQWWHAQGI
gi|11282574|VYTMYLTSAMTNEPETNCNPSLLSIIGYNTTSTVPKQGSVQWWHAQGI
gi|14750715|VYTMYLTSAMTNEPETNCNPSLLSIIGYNTTSTVPKQGSVQWWHAQGI
gi|6382026|VYTMYLTSAMTNEPETNCNPSLLSIIGYNTTSTVPKQGSVQWWHAQGI

      360     370     380     390     400
      .....

```



A disclosed NOV9b nucleic acid (also referred to as 13375406) is a variant of NOV9a, encodes a novel TMS-2-like protein, and is shown in Table 9E. NOV9b nucleotide changes are underlined in Table 9E.

**Table 9E. NOV9b Nucleotide Sequence (SEQ ID NO:47)**

ATGGGGGSCCTGCCTGGGAGCCTGCTCCCTGCTCAGCTGCGTGAAGTCTGCTGGCTGTGCGTCTCTGCCTCTGCGGCTCTG  
CCCCCTGCATCTGTGTGACGACTCTGCTCCGCGCAGCCGCACTCCACGAGTGAGCCGCGCTCATCTTCAAGTTCTTCCTCTT  
CTGGGGGGTGTGTGTGTCATCATCTTATGCTAGCCCGGGCTGGAGATCAGCTCTACAAGTCCGCTGGGTGTGTGAG  
GAGGGGGCCGGGATCCCCACCCTCTCTGCAGGGCCACATCGACTGTGGCTCCCTGCTTGGCTACCGCGCTGTCTACCGCA  
TGTGCTTCGCGACCGCGGCTCTCTCTCTTTTACCCTGCTCATGCTCTGCGTGAGACAGCAGCGGGAGCCCCGGGAC  
TGCCATCGACAAGTGGGTTTGGTTTCTTAAAGTCTCGATCTGCTGGGCTCACCGTGGGTGCTCTATACCTCCCTGAGC  
GGCTCCTTACCAACATCTGGTTCTACTTGGCGTGTGGGCTCCTTCTCTTCAATCCTCATCCAGCTGGTGTCTCTCA  
TCGATCTTGTGGCATCTCTGGACAACGGCGGTGGCTGGGCAAGCGCAGGAGTGGCATTCCTGGCTGGTATCGCATCAT  
CTCTCTTCTACTGTCTGTGCATCGCGGGCTGGCGCTGATGTTCTATGTACTACATGAGCCGAGCGCTGGACCGCCAG  
GGCAAGGTCTTATCATCAGCCTCAACCTCACCTTCTGTGTCTGCGTGTCCATCGCTGTGTCTCTGCCCAAGGTCCAGGTGA  
GCTCGCTTAACCTGGGCTGTGCTGCAGGCTCGGTGATCAACCTTACACCATGTTGTCACCTGGTTCAGCCCTATCCAG  
TATCCCTGACAGAAATGCAACCCCATTTGCAACCCAGCTGGGCGACAGACAGTGTGTGCGAGCCCGGAGGGCTAT  
GAGACCCAGTGGTGGGATGCCCGAGCATGTGTGGGCTCATCATCTTCTCTCTGTGCACCTCTTTCATCAGTCTGCGCT  
CTCTCAGACACCGGAGGTGAACAGCCTGATGCAGACCGAGGAGTGCCACCTATGCTAGACGCCACAGCAGCAGCA  
CGAGGTGGCAGCTGTGAGGGCGGGGCTTTGACAACGAGCAGGACGGCGTCACTACAGCTACTCTTCTTCCACTTC  
TGCTGTGTCTGGCTCACTGCAGCTCATGATGACGCTACCAACTGGTACAAGTGCCTAGAGACCCGGAAGATGATCA  
GACGCTGGAACCGCGTGTGGGTGAAGATCTGTGCCAGCTGGGCGAGGCTGCTCTTCACTGAGCTCCCTGTTAGCCCC  
ATCTCTCTGCTGCAACCGCGACTTCAGCTGA

10 A disclosed NOV9b polypeptide (SEQ ID NO:48) encoded by SEQ ID NO:47 is presented using the one-letter amino acid code in Table 9F. NOV9b amino acid changes, if any, are underlined in Table 9F.

**Table 9F. Encoded NOV9b protein sequence (SEQ ID NO:48).**

MGACLCGACSLLCVSPAGCASCCLCGSAPCILCSCCPASRNSTVSRLIPTFFLFLGVLSIIMLSPGVESQLYKLPVWCCEGAGIP  
TLQGHIDCGSLGLGYRVRNCFWATAAFFFTLLMLCVSSSRDPRAIQNGFWFFKFLILVLGTGAFVJPDGSEFTNIWFYFVG  
VGSFLFLILQLVLLEDFAHSNMQRLWKLKAECECDRLAWYASSLSSTCLSLIAAVALGMYFTEPGSCHEGKVPISLNLTFCCVCSIA  
AVLPKVQVSLPNSGLLQASVITLYTMFVTVSALSSSIPEQKCNPHLPTQLGNETVVGAPGEYETQWWDAPSIVGLIIFFLCTLPIS  
LRSSDHRQNSAGMLQTECECPMLDATQQQQQVAAACEGRAFDNEQDGVTVSYSFHFCLVLASLHVMTLTLNNYKCVETRMISTWT  
AVVVKICASWAGLILYLWTLVAPLLLRNDFAS

A disclosed NOV9c nucleic acid (also referred to as 13375405) is a variant of NOV9a, encodes a novel TMS-2-like protein, and is shown in Table 9G. NOV9c nucleotide changes are underlined in Table 9G.

**Table 9G. NOV9c Nucleotide Sequence (SEO ID NO:49)**

ATGGGGGCGCTGCCTGGGAGCCTGCTCCCTGCTCAGCTGCGTAGTCTCTGCTGGCTGTGCGTCTGCTCTGCGGCTCTG  
CCCCCTGCATCCTGTGTCAGCTGCTGCCCGCAGCGCACTCGACGTCAGCGCCCTCATCTTCACGTTCTTCCTCTTG  
CTCTGGGGGTGTGTGTGCATCATTTATGTGACGCCGGGCTGAGGATCAGCTTACAAGCTGCCCTGGGTGTGTGAG  
GAGGGGGCCGGGATCCCCACCGTCTGTCAGGGCCATATGCACTGTGGCTCCCTGCTTGGCTACC CGCGCTGTCTACCGC  
TGTCCTTCGCGACCGCGGCTCTTCTCTCTTTTACCCCTGCTCATGCTCTGCTGTAGCAGCAGCGCGGACCCCCGGGC  
TGCACTGCAGAAATGGGTTTGGTTCTTTAAGTCTCTGATCTGCTGGGCTCACCGTGGGTGCTCTACATCTTCGAG  
GGCTCCTTACCAACATCTGGTCTACTTCTGGCGTCTGTTGGGCTCCTTCTCTTTCATCTCTATCCAGCTGGTGTCTGCTCA  
TCGACTTTGGCGCATCTCTGGAGAACCGCGGTGGCTGGCGAAGCGCAGGAGTGCAGTTCCCGTGCCTGGTACGCTACACT  
CTCTCTTCTACTTGCTGTGATCGCGGCCGTGGCGGATGATGTTCTATGTACTACATGTAGCCCAAGGCTGGCTGCACGAG  
GGCAAGGTCTTTCATCAGCCTCAACCTCACCTTCTGTGTCTGCGTGTCCATCGCTGCTGTCTGCGCCAAGGTCCAGGTGA  
GCTCGCTTAACCTCGGCTGTGCTGACGCGCTCGGTATCACCTCTTACAACGATGTGTGTCAGCTGGTCAACGATATCCAG  
TATCCCTGAAACAGAAATCGACACCCCATTTGCAACACCGCTGGGCAACGAGACAGTGTGTGCGACCGCCAGGGGCTAT  
GAGACCCAGTGGTGGGATGCCCGAGCATGTGGGCTCATCATCTTCTCTCTGTGCACCTCTTTCATCAGTCTGCGCT  
CTCAGACCAACCGGAGGTGAACAGCCTGATGACAGCGAGGAGTGGCCACTATGCTAGACCTACACAGCAGCAGCAGCA  
CGAGGTGGCAGCTGTGTAGGGCCCGGCTTTGACAAAGCAGCAGCAGCGCTCACTACAGCTACTCTCTTCTTCCACTTC  
TGCTGTGTGCTGCGCTCACTGCACGTATGATGACGCTACCAACTGGTACAAGTGCCTAGAGACCCGGAAGATGATCA  
GACGCTGTGACCGCGTGTGGGTGAAGATATGTGCGACAGCTGGGCGAGGCTGCTCCTCTACCTGTGGAACCTGTGAGCCCC  
ATCTCCTCTGGCAGACCGCGACTTCAGCTGA

5

A disclosed NOV9c polypeptide (SEQ ID NO:50) encoded by SEQ ID NO:49 is presented using the one-letter amino acid code in Table 9H. NOV9c amino acid changes, if any, are underlined in Table 9H.

**Table 9H. Encoded NOV9c protein sequence (SEQ ID NO:50).**

MGACLGACSLLCVSPAGCASCLCGSAPCILSCCPSARNSTVSRLIHTFFLFLGLVLSIIMLSPGVESQLYKLPVWCEEAGIP  
VTLQHIGIDCGSLGLGYRAVMCFATAAFFFFLLMLCVSSSDPRAAIOGVFWFFKFLYLVGLTVGAFYIPDGSGFTNWFYFVG  
VGSFLLFLQLVLLIDFAHSWNQRWLKGAECDSRAWAYALSSTSCSIAAVALNMFMYTEPSGCGHKVPSILNLTFCVCSVIA  
AVLPKQVQSLPNSGLLQASVITLYTMFTVWSALSSISPEQKCNPHLPQLTQGNETVVGAPGEYETQWWDAPSIVGLTIIFLLCTLFIS  
LRSSDHRQVNSLMQTECPMLMDATQQQQVQACEGRAFDNEQDGVTVSYSFFHFCLVLASLHVMMTLTNKYCKVETRKMISTWT  
AVVVKICASWAGLLLLVLTWLVAPILLRNRDPS

10

A disclosed NOV9d nucleic acid (also referred to as 13375404) is a variant of NOV9a, encodes a novel TMS-2-like protein, and is shown in Table 9I. NOV9d nucleotide changes are underlined in Table 9I.

**Table 9I. NOV9d Nucleotide Sequence (SEO ID NO:51)**

ATGGGGGCGCTGCTGGGAGCTGCTCCCTGCTCAGCTGCGTGAAGTCTGCTGGGCTGTGCGTCTGCGCTCTGCGGCTCTG  
CCCCCTGCATCTCTGTCAGCTGCTGCCCGCAGCGCACTCCAGCGTACGCGCTCATCTACAGTTCTTCTCTCTCTG  
CTCTGGGGGTGTGGTGGTCCATCATTTAGCTGTCAGCGCGGGCTGAGAGTAGCTCTACAAGTGCCTGGGTGTGTGAG  
GAGGGGGCGGGATCCCCACCGTCTGTGAGGGCCATCGACTGTGGCTCCCTGCTTGGGTACCGCGCTGTCTACCGCA  
TGTGCTTCGCCAGCGCGGCTCTCTCTCTTTTTCACCTGCTCATGCTCTGCGTGAAGCAGCAGCGGAGCCCCGGGG  
TGCAATCGCAAGTGGTGTGTGGTCTTTAAGTTCTGATCTCTGTGGGCTCACCGTGGGTGCTTCTACATTTCTCA  
GGCTCTCTTCCCAACATCTGGTCTACTTCTGGGCTCGTGGGCTCCTTCTCTTTCATCCTCATCCAGCTGGTGTCTCA  
TCGACTTTGCGCATCTGCTGACACCGCGGTGGCTGGGCAGGCGGAGATGCGATTCCCTGCTGGTGTACGATCACT  
CTCTCTTCTACTCTGCTGTGATCGACGCGCTGGGCGCATGTTCTATGATACATGAGGCCACGGGCTGCCACAG

GGCAAGGCTCTTCATCAGCCTCAACCTCACCTTCTGTGCTGCGTGTCCATCGCTGCTGTCTCTGCCAAGGTCAGGTTGA  
GCCTGCCTAACTCGGGTCTGCTGACGGCCTCGGTATCACCCTCTACACCATGTTTGTCAGCTGGTGCAGCCCTATCCAG  
TATCCTCTGACCAAGAATGACACCCCATTTGCAACCCAGCTGGCTCAGCAGACAGTGTGTGCGACGCCGACGGGGCTAT  
GAGACCCAGTGGTGGGATGCCCGAGCATTTGTGGGCTCATCATCTTCTCTGTGCACCCTCTTCATCAGTCTGCGCT  
CCTCAGACCAACCGGAGAGCTGAACAGCTGATGCAGACCGAGAGTGGCCACTTGTAGTACGCCCAACAGCAGCAGCA  
GCAGGTGGCAGCTGTGAGGGCCGGGCTTTGACAACGACGAGCAGCGCTCACTACAGTACTCTCTTCTTCCACTTC  
TGCCGTGGTCTGGCCTCACTGCAGCTCATGATGACGCTACCAAATGGTACAAGTGCCTAGAGACCCGGAGATGATCA  
GCAGGTGACCGCCCTGTGGGTGGAAGATCTGTGCCAGCTGGGACGGGCTGCTCTTCACTGTGGAACCTGGTAGCCCC  
ACTCCTCTCTCGCATCGGCGACTTCAGCTGA

A disclosed NOV9d polypeptide (SEQ ID NO:52) encoded by SEQ ID NO:51 presented using the one-letter amino acid code in Table 9J. NOV9d amino acid changes, if any, are underlined in Table 9J.

**Table 9J. Encoded NOV9d protein sequence (SEQ ID NO:52).**

MGACLGACSLSCVSPAGCASCLCGSAPCILSCCPASRNSTVSRLIPTFFFLVLGLVLSIIMLSPGVESQLYKLPWVCBEGAGIP  
VTLQGHIDCGSLGLGYRAVRYMCFATAAFFFFLITLMLCVSSSDPRAAIQNGFWFFKFLILVLGTGVAQFIPDGSGFTVYFPGV  
TGSFDFILILQLVLIDIPAHSGNWQRWLKGAECDSRAWAYSLSSSTLCISAAVAFMFFMYTTEPSGCBHGKVFISLNLTFVCVWSIA  
AVLPKVQVSLPNSGLLQASVITLTYMTFVWTWSALSSIPEQKCNPHLPTQLGNETVVASPEGYETQWWDAPSIVGLIIFLLCTLPIS  
LRSSDHRQVNSLMQTEECPPMLDATQQQQQVAACEGRAFDNEQDGVTSYSFFHFCLVLASLHVMTLTLNNYKCVETRMISTWT  
AVVWKICASWAGGLLWLTWLVAPLLLRNDFS

A disclosed NOV9e nucleic acid (also referred to as 13375403) is a variant of NOV9a, encodes a novel TMS-2-like protein, and is shown in Table 9K. NOV9e nucleotide changes are underlined in Table 9K.

**Table 9K. NOV9e Nucleotide Sequence (SEQ ID NO:53)**

ATGGGGGCGCTGCGCTGGGAGCCTGCTCCCTGCTCAGCTGCGTGAGTCTGCTGGGCTGTGCGTCTTGCTCTGCGGCTCTG  
CCCCCTGCATCTCTGTCAGCTGCTGCCCGCGCAGCGCAGCTCACCGAGCGCGCTCATCTTCTACGTTTCTTCTCTT  
CTCGGGGTGTGGTGTTCATCATTTAGTCTGAGCCCGGGCGTGAGAGTACGCTTACAAGCTGCCCTGGGTGTGTGAG  
GAGGGGGCGGGATCCCCACCGTCTCTGCAGGGCCACATCGACTGTGGCTCCCTGCTTGGCTACCGCGCTGTCTACCGCA  
TGTGCTTCTCGACCGCGCGCTCTCTCTCTTTTACCCCTGCTCATGCTCTGCGTGAGCAGCAGCGGAGCCCCGGGG  
TGCCATCCGAAATGGGTTTGGTCTTTAAGTTCCTGATCTCTGGGCGCTCACCGTGGGTGCCTTCTACATTCTCAG  
GGCTCTCTTACCAACATCTGGTTCCTACTTTCGGCGTCTGGGGCTCCTTCTCTTATCCTCATCCAGCTGGTGTCTCTCA  
TCGACTTCTGGCGACTCTCTGGAACACCGCGGTGGCTGGGCAAGCGCGAGGATGCGCATTCGCCGTGGTTCAGCATCACT  
CTCTCTTCTACTGTCTGTGCATCGCGCGCGCGGGCGTGATGTTCTATGTACTACAGTACGCCACCGGCTGCCACGAG  
GGCAAGGTCTTTCATCAGCCTCAACCTTACCTTCTGTGTCTGCGTGTCCATCGCTGCTGTCTCTGCCAAGGTCCAGGTGA  
GCTTCTGCTTAACCTGGGTCTGCTGTCAGGCGCTCGGTGATCAACCTTACACCATGTTTGTCTACCTGGTTCAGGATTCAGC  
TATCCCTGAACAGAAATGCAACCCCCATTGCAACCCAGCTGGGCAACGAGACAGTGTGTGGCAGGCCGCCCGGGCTTAT  
GAGACCCAGTGGTGGGATGCCCGGAGCATGTGGGGCTCATCATCTTCTCTCTGTGCACCCTTTCATCAGTCTGCGCT  
CTCTCAGACACCGCGAGTGAACAGCCCTGATCGAGACCGAGGAGTGCCCACTATGCTAGACGCCCAACGAGCAGCA  
CGAGGTGGCAGCTGTGAGGGCGCGGGCTTTGACAACGAGCAGGACGCGGTCACTACAGCTACTCTTCTTCCATTCT  
TGCTGTGTCTGGCTCACTGCACGTATGATGACGCTACCAAAGTGGTACAAGTGCCTAGAGACCCGGAAGATGATCA  
GCTGCGTGAGACCGCGCTGTGGTGAAGATCTGTGCGCAGCTGGGCGAGGCTGCTCCTCTACTCTTGGACCTTGGTAGCCCC  
ACTCCTCTCGCAGACCGCATCTCACTGTA

A disclosed NOV9e polypeptide (SEQ ID NO:54) encoded by SEQ ID NO:53 is presented using the one-letter amino acid code in Table 9L. NOV9e amino acid changes, if any, are underlined in Table 9L.

**Table 9L. Encoded NOV9e protein sequence (SEQ ID NO:54).**

MGACLGACSLSCVSPAGCASCLCGSAPCILCSCCPASRNSTVSRLIPTFFLGLVLVSIIMLSPGVESQLYKLPWVCEEAGIGP  
TVLQGHIDCGSLGLGYRAVYRMCPTAAEFFFTLLMLCVSSSRDPPRAAIGNGFWFFKFLILVGLTGAFYIPDGSFNTNIFYFVG  
VGSFLLIQLQVLLDIFAHSNQRWLQKABECDSRAWYASLSSTLCSIAAAALMFMYTEBGCCHKGVFISILTLCTFVCVSI  
AVLPKVQVSLPNSGLLQASVITLYTMFVTWSALSSIPEQKCNPHLPQLGLNETVVGAPGEYETQWWDAPISVGLIIFLLCTLFIS  
LRSSDHRQVNSGLMTEQCEPPLMDATQQQQVAAACEGRAFDNEQDGVTSYSFFHCLVLASLHVMTLLTNKYKCVETRMISTWT  
AVVWKICASWAGMLLWLTWLVAIDLLLRNDVAS

The lactose permease is an integral membrane protein that cotransports H(+) and lactose into the bacterial cytoplasm (Green AL, et.al.; J Biol Chem 2000 Jul 28;275(30):23240-6 ). Previous work has shown that bulky substitutions at glycine 64, which is found on the cytoplasmic edge of transmembrane segment 2 (TMS-2), cause a substantial decrease in the maximal velocity of lactose uptake without significantly affecting the K(m) values (Jessen-Marshall, A. E., Parker, N. J., and Brooker, R. J. (1997) J. Bacteriol. 179, 2616-2622). In the current study, mutagenesis was conducted along the face of TMS-2 that contains glycine-64. Single amino acid substitutions that substantially changed side-chain volume at codons 52, 57, 59, 63, and 66 had little or no effect on transport activity, whereas substitutions at codons 49, 53, 56, and 60 were markedly defective and/or had lower levels of expression. According to helical wheel plots, Phe-49, Ser-53, Ser-56, Gln-60, and Gly-64 form a continuous stripe along one face of TMS-2. Several of the TMS-2 mutants (S56Y, S56L, S56Q, Q60A, and Q60V) were used as parental strains to isolate mutants that restore transport activity. These mutations were either first-site mutations or second-site suppressors in TMS-1, TMS-2, TMS-7 or TMS-11. A kinetic analysis showed that the suppressors had a higher rate of lactose transport compared with the corresponding parental strains. Overall, the results of this study are consistent with the notion that a face on TMS-2, containing Phe-49, Ser-53, Ser-56, Gln-60, and Gly-64, plays a critical role in conformational changes associated with lactose transport. We hypothesize that TMS-2 slides across TMS-7 and TMS-11 when the lactose permease interconverts between the C1 and C2 conformations. This idea is discussed within the context of a revised model for the structure of the lactose permease.

The protein similarity information, expression pattern, and map location for the NOV9 suggest that NOV9 may have important structural and/or physiological functions characteristic of the TMS-2 family. Therefore, the NOV9 nucleic acids and proteins of the invention are useful in potential therapeutic applications implicated in various diseases and disorders described below and/or other pathologies. For example, the NOV9 compositions of the present invention will have efficacy for treatment of patients suffering from Von Hippel-Lindau (VHL) syndrome, Alzheimer's disease, Stroke, Tuberous sclerosis, hypercalcaemia, Parkinson's disease, Huntington's disease, Cerebral palsy, Epilepsy, Lesch-Nyhan syndrome, Multiple sclerosis, Ataxia-telangiectasia, Leukodystrophies, Behavioral disorders, Addiction, Anxiety, Pain, Neuroprotection, Endocrine dysfunctions, Diabetes, obesity, Growth and Reproductive disorders, Multiple sclerosis, Leukodystrophies, Pain, Neuroprotection and transporter disorders. The NOV9 nucleic acid encoding ITGA7-like protein, and the ITGA7-like protein of the invention, or fragments thereof, may further be useful in diagnostic

applications, wherein the presence or amount of the nucleic acid or the protein are to be assessed.

## NOV10

- 5 A disclosed NOV10 nucleic acid of 2295 nucleotides (also referred to AC073487\_dal) encoding a novel UNC5 Receptor-like receptor protein is shown in Table 10A. An open reading frame was identified beginning with an ATG initiation codon at nucleotides 64-66 and ending with a TGA codon at nucleotides 2902-2904. Putative untranslated regions upstream from the initiation codon and downstream from the termination codon are underlined in Table 10A, and the start and stop codons are in bold letters.

**Table 10A. NOV10 Nucleotide Sequence (SEQ ID NO:55)**

```

CGCGGAGACTGGGGCCAGGGAGACAGCCCTGGGGGAGAGGCGCCGAACAGGCGCGGGAGCATGGGGG
CCGGAGCGGAGCTCGGGGCGCGCTGCTGCTGGCACTGCTGCTGCTGCTGGGACCGAGGCTGAGCCAAAGCAG
GTAGGAAGCGATCGGGTGAGGTGCTCCCTGACTCCTTCCCGTCAGCGCCAGCAGAGCCGCTGCCCTACTTC
CTGCAGGAGCCACAGGACGCCCTACATTGTGAAGAACAAGCCTGTGGAGCTCCGCTGCCGCGCCTTCCCCGC
CACACAGATCTACTTCAAGTGCAACGGCGAGTGGGTGAGCCAGAACGACCACGTCACACAGGAAGGCGCTGG
ATGAGGCCACCTGGGGGCGCGGGGCGGCTGCGGGTGCGCGAGGTGCAGATCGAGGTGTGCGCGGCAGCAG
GTGGAGGAGCTCTTTGGGCTGGAGGATTACTGGTGCCAGTGCGTGCGCTGGAGCTCCGCGGGCACCACCAA
GAGTCGCGGAGCCTACGTCCGTCATCGCTGTCTGCGCAAGAACTTCGATCAGGAGCCTCTGGGCAAGGAGG
TGCCCTGGACCATGAGGTTCTCTGCACTGCGCGCCGCCGAGGGGGTGCCCTGTGGCCGAGGTGGAATGG
CTCAAGAATGAGGATGTCATCGACCCACCCAGGACACCAACTTCTGCTCACCATCGACCAACCTCAT
CATCCGCCAGGCCCGCCTGTGCGACACTGCCAACTATACCTGCGTGGCCAAAGAACATCGTGGCCAAACGCC
GGAGCACCCTGCCACCGTCATCGTCTACGTGAATGGCGGCTGGTCCAGCTGGGCAGAGTGGTCACCTGCG
TCCAACCGCTGTGGCCGAGGCTGGCAGAAGCGCACCCGACCTGCACCAACCCCGCTCCACTCAACGGAGG
GGCCTTCTGCGAGGGCCAGGCATTCCAGAAGACCGCCTGCACCACCATCTGCCAGTCGATGGGGCGTGGA
CGGAGTGGAGCAAGTGGTCAGCCTGCAGCACTGAGTGTGCCCACTGGCGTAGCCGCGAGTGCATGGCGCCC
CCACCCAGAACGGAGGCGGTGACTGCAGCGGACGCTGCTCGACTCTAAGAACTGCACAGATGGGCTGTG
CATGCAAAAGTGAACCTGTCCCGCAGTGTGAGGCGCTCAGGGGATGCGGCGCTGTATGCGGGGCTCGTGG
TGGCCATCTTCGTGGTGTGCGCAATCTCATGGCGGTGGGGGTGGTGGTGTACCGCCGCAACTGCCGTGAC
TTCGACACAGACACTCACTGACTCATCTGCTGCCCTGACTGGTGGTTTCCACCCCGTCAACTTTAAGACGGC
AAGGCCAGTAACCCGAGCTCCTACACCCCTCTGTGCTCTGACCTGACAGCGAGCGCGGCATCTACC
GCGGACCCGTGTATGCCCTGCAGGACTCCACCGACAAAATCCCATGACCAACTCTCTCTGCTGGACCCC
TTACCCAGCCTTAAGGTCAAGGTCTACAGCTCCAGCACCACGGGCTCTGGGCCAGGCCTGGCAGATGGGGC
TGACCTGCTGGGGGTCTTGCCGCTGGCACATACCCTAGCGATTTCGCCCGGGACACCACTTCTCTGCACC
TGCGCAGCGCCAGCCTCGGTTCCAGCAGCTCTTGGGCTGCCCCGAGACCCAGGGAGCAGCGTCAGCGGC
ACCTTTGGCTGCTGGGTGGGAGGCTCAGCATCCCCGGCACAGGTGTGAGCTTGTGGTGGCCAAATGGAGC
CATTCCCCAGGGCAAGTTCTACGAGATGTATCTACTCATCAACAAGGCAGAAAGTACCCTGCCGCTTTCAG
AAGGACCCAGACAGATTAGAGCCCTCGGTGACCTGTGGACCCACAGGCGCTCTGCTGTGCCGCCCGCTC
ATCCTCACCATGCCCCACTGTGCCGAAGTCAGTGCCCGTGAATGATCTTTCAGCTCAAGACCCAGGCCCA
CCAGGCGCACTGGGAGCAGGAGGTGGTGACCTGGATGAGGAGACCCTGAACACACCCCTGCTACTGCCAGC
TGGAGCCCAGGGCCTGTACATCCTGCTGGACAGCTGGGCACCTACGTGTTACGGGCGAGTCTTATTC
CGCTCAGCAGTCAAGCGGCTCCAGCTGGCCGCTCTCGCCCCCGCCCTCTGCACCTCCCTGGAGTACAGCCT
CCGGGTCTACTGCTGGAGGACACGCTGTAGCACTGAAGGAGGTGCTGGAGCTGGAGCGGACTCTGGGCG
GATACTTGGTGGAGGAGCCGAAACCGCTAATGTTCAAGGACAGTTACCACAACCTGCGCCTCTCCCTCCAT
GACCTCCCCCATGCCATTGGAGGAGCAAGCTGCTGGCCAAATACCAGGAGATCCCCTTCTATCACATTG
GAGTGGCAGCCAGAAAGGCCCTCCACTGCACCTTCAACCTGGAGAGGCACAGCTTGGCCTCCACAGAGCTCA
CCTGCAAGATCTGCGTGGGCAAGTGAAGGGGAGGGCCAGATATCCAGCTGCATACCACTCTGGCAGAG
ACACTGCTGCTCCTTGGACACTCTCTGCTGCGCCCTGGCAGCAGTACCAACCCAGCTGGGACCTTA
TGCCTTCAAGATCCCACTGTCCATCCGCGAGAAGATATGCAACAGCCTAGATGCCCCCAACTCACGGGGCA
ATGACTGGCGGATGTAGCACAGAAGCTCTCTATGGACCGGTACCTGAATTACTTGGCCACCAAGCGAGC
CCCACGGGTGTGATCCTGGACCTCTGGGAAGCTCTGAGCAGGACGATGGGGACCTCAACAGCCTGGCGAG
TGCCTTGGAGGAGATGGGCAAGAGTGAGATGCTGGTGGCTGTGGCCACCGACGGGGACTGCTGAGCCTCT
GGGACAGCGGGCTGGCAGGAGTGGCAGGAGGAGTGCAGGAGGCGCTGGGGCAGCCTCTGATGGGGAT
GTTTGGCCTCTGC

```

The disclosed NOV10 nucleic acid sequence, localized to chromosome 10, has 2213 of 2841 bases (77%) identical to a 2838 bp *Rattus norvegicus* transmembrane receptor UNCH2 mRNA (GENBANK-ID: RNU87306) (E = 0.0).

A disclosed NOV10 polypeptide (SEQ ID NO:56) encoded by SEQ ID NO:55 is 946 amino acid residues and is presented using the one-letter amino acid code in Table 10B. Signal P, Psort and/or Hydropathy results predict that NOV10 does not contain a signal peptide and is likely to be localized at the plasma membrane with a certainty of 0.5140. The most likely cleavage site for a NOV10 peptide is between amino acids 26 and 27, at: SGA-GR.

**Table 10B. Encoded NOV10 protein sequence (SEQ ID NO:56).**

```

MGARSGARGALLLALLLCWDPRLSQAGRKRSGEVLPDSFSPAPAEPLPYFLQEPQDAYIVKNKPVELRCRA
FPATQIYFKCNGEWSQNDHVTQEGLEATLGARGGLRVREVQIEVSRQQVEELFGLLEDYWCQCVAWSSAG
TTKSRRAYVRIACLRKNFDQEPGLKEVPLDHEVLLQCRPPEGVPVAEVEWLKNEDVIDPTQDTNFIILLTIDH
NLIIRQARLSDTANYTCVAKNIVAKRRSTTATVIVYVNGGWSSWAWSPCSNRCGRGWQKRTRCTNPAPL
NGGAFCEGQAFQKTACTTICPVDGAWTEWSKWSACSTCAHWSRECMAPPPQNGGRDCSGTLLDSKNCTD
GLCMQSEPVPAVLEASGDAALYAGLVVAIFVVVAILMAVGVVVYRRNCRDFDITDSSAALTGGFHPVNF
KTARPSNPQLLHPSVPPDLTASAGIYRGPVYALQDSTDKIPMTNSPLLDPLPSLKVKVYSSSTTGSGPGLA
DGADLLGVLPPGTYPSPDFARDTHFLHRSASLGSQQLLGLPRDPGSSVSGTFGCLGGRLSIPGTGVSLLVP
NGAIPQGGKFYEMYLKAEESTLPLSEGTQTVLSPSVTCGPTGLLLCRPVILTMPHCAEVSARDWIFQLKT
QAHQGHWEQEVVTLDEETLNTPCYCQLEPRACHILLDQLGTYVFTGESYSRSASVAKRLQLAVFAPALCTSLE
YSLRVYCLEDTFVALKEVLELERTLGGYLVEEPKPLMFKDSYHNLRLSLHDLPHAHWSKLLAKYQEIIPFY
HIWGSQKALHCTFTLERHSLASTELTCKICVRQVEGEGQIFQLHTTAEPTAGSLDTLCSAPGSTVTTQL
GPYAFKIPLSIRQKICNSLDAPNSRGNDWRMLAQKLSMDRYLNYFATKASPTGVILDLWEALQDDGDLNS
LASALEEMGKSEMLVAVATDGDC

```

10

The NOV10 amino acid sequence has 860 of 946 amino acid residues (90%) identical to, and 893 of 946 amino acid residues (94%) similar to, the *Rattus norvegicus* 945 amino acid residue transmembrane receptor UNCH2 mRNA (ACC:O08722)(E = 0.0). The global sequence homology is 93.617 % amino acid homology and 91.383 % amino acid identity.

NOV10 is expressed in at least the following tissues: Respiratory System, Lung; Urinary System, Kidney; Gastro-intestinal/Digestive System, Liver, Small Intestine; Whole Organism; Female Reproductive System, Placenta, Chorionic Villus. In addition, the sequence is predicted to be expressed in the following tissues because of the expression pattern of (GENBANK-ID: ACC:O08722) Transmembrane Receptor UNCH2 homolog in species *Rattus norvegicus* : Respiratory System, Lung; Urinary System, Kidney; Gastro-intestinal/Digestive System, Liver, Small Intestine; Whole Organism; Female Reproductive System, Placenta, Chorionic Villus.

The disclosed NOV10 polypeptide has homology to the amino acid sequences shown in the BLASTP data listed in Table 10C.

25

Table 10C. BLAST results for NOV10

Gene Index/ Identifier	Protein/ Organism	Length (aa)	Identity (%)	Positives (%)	Expect
<a href="#">gi 6678505 ref NP_033498.1</a>	UNC-5 homolog (C. elegans) 3 [Mus musculus]	931	597/910 (65%)	707/910 (77%)	0.0
<a href="#">gi 4507837 ref NP_03719.1</a>	unc5 (C.elegans homolog) c; homolog of C. elegans transmembrane receptor Unc5 [Homo sapiens]	931	585/910 (64%)	702/910 (76%)	0.0
<a href="#">gi 12857776 dbj BAB31108.1</a> (AK018177)	putative [Mus musculus]	945	861/951 (90%)	899/951 (93%)	0.0
<a href="#">gi 11559982 ref NP_071543.1</a>	transmembrane receptor Unc5H2 [Rattus norvegicus]	945	860/951 (90%)	893/951 (93%)	0.0
<a href="#">gi 15296526 ref XP_042940.2</a>	unc5 (C.elegans homolog) c [Homo sapiens]	931	586/910 (64%)	703/910 (76%)	0.0

The homology between these and other sequences is shown graphically in the ClustalW analysis shown in Table 10D.

Table 10D. ClustalW Analysis of NOV10

- 1) Novel NOV10 (SEQ ID NO:56)
- 2) [gi|6678505|ref|NP\\_033498.1](#) UNC-5 homolog (C. elegans) 3 [Mus musculus] (SEQ ID NO:121)
- 3) [gi|4507837|ref|NP\\_03719.1](#) unc5 (C.elegans homolog) c; homolog of C. elegans transmembrane receptor Unc5 [Homo sapiens] (SEQ ID NO:122)
- 4) [gi|12857776|dbj|BAB31108.1](#) (AK018177) putative [Mus musculus] (SEQ ID NO:123)
- 5) [gi|11559982|ref|NP\\_071543.1](#) transmembrane receptor Unc5H2 [Rattus norvegicus] (SEQ ID NO:124)
- 6) [gi|15296526|ref|XP\\_042940.2](#) unc5 (C.elegans homolog) c [Homo sapiens] (SEQ ID NO:125)

	10	20	30	40	50
NOV 10	.....	.....	.....	.....	.....
gi 6678505	-----MGARSGA-RGALLLALLLCWDPRSSQAGRKRSGE-----VLP				
gi 4507837	MRKGLRATAARCGGLGGLYLLQMLVLPALALLSASGTGSAADDDFFHELP				
gi 12857776	-----MRARSGV-RSALLLALLLCWDPTPSLAGVDSAGQ-----VLP				
gi 11559982	-----MRARSGA-RGALLLALLLCWDPTPSLAGIDSAGQ-----ALP				
gi 15296526	MRKGLRATAARCGGLGGLYLLQMLVLPALALLSASGTGSAADDDFFHELP				
	60	70	80	90	100
NOV 10	.....	.....	.....	.....	.....
gi 6678505	DSFPSAPAEPLPYFLPEPODAYIVKNKPVELRCRAFPATQIYFKCNGEWV				
gi 4507837	ETFPSDPPEPLPHFLDEPEEAYIVKNKPVNLYCKASPATQIYFKCNSWV				
gi 12857776	DSYPSAPAEQLPYFLPEPODAYIVKNKPVELRCRAFPATQIYFKCNGEWV				
gi 11559982	DSFPSAPAEQLPHFLPEPEEAYIVKNKPVNLYCKASPATQIYFKCNGEWV				
gi 15296526	ETFPSDPPEPLPHFLDEPEEAYIVKNKPVNLYCKASPATQIYFKCNSWV				
	110	120	130	140	150
NOV 10	.....	.....	.....	.....	.....
gi 6678505	SQNDHVTQESLDEATLGARGGLRVREVQIEVSQQQVEELFGLEDYWCQCV				
gi 4507837	HQKDHVVDERVDETS-----GLIVREVSTIEISQQQVEELFGPEDYWCQCV				
gi 12857776	SQNDHVTQESLDEAT-----GLRVREVQIEVSQQQVEELFGLEDYWCQCV				
gi 11559982	SQKGHVTQESLDEAT-----GLRVREVQIEVSQQQVEELFGLEDYWCQCV				
gi 15296526	HQKDHVVDERVDETS-----GLIVREVSTIEISQQQVEELFGPEDYWCQCV				

160 170 180 190 200  
NOV 10  
gi|6678505|  
gi|4507837|  
gi|12857776|  
gi|11559982|  
gi|15296526|

210 220 230 240 250  
NOV 10  
gi|6678505|  
gi|4507837|  
gi|12857776|  
gi|11559982|  
gi|15296526|

260 270 280 290 300  
NOV 10  
gi|6678505|  
gi|4507837|  
gi|12857776|  
gi|11559982|  
gi|15296526|

310 320 330 340 350  
NOV 10  
gi|6678505|  
gi|4507837|  
gi|12857776|  
gi|11559982|  
gi|15296526|

360 370 380 390 400  
NOV 10  
gi|6678505|  
gi|4507837|  
gi|12857776|  
gi|11559982|  
gi|15296526|

410 420 430 440 450  
NOV 10  
gi|6678505|  
gi|4507837|  
gi|12857776|  
gi|11559982|  
gi|15296526|

460 470 480 490 500  
NOV 10  
gi|6678505|  
gi|4507837|  
gi|12857776|  
gi|11559982|  
gi|15296526|

510 520 530 540 550  
NOV 10  
gi|6678505|  
gi|4507837|  
gi|12857776|  
gi|11559982|



gi | 15296526 | IKVYNTS--GAVTPQDDISEPTSKLSQMTQS--LLENEALSLEKNOSTAR

560 570 580 590 600  
NOV 10 QOLLGLPRDPGSSVSCTFGCLGGRLSTPGTGVSLLPNGAIPQCKFYEMY  
gi | 6678505 | Q-----TDPSCIAFGTENSLSGGHLITPNSGVSLLPAGAIPQGRVYEMY  
gi | 4507837 | Q-----TDPSCIAFGSENSLSGGHLITPNSGVSLLPAGAIPQGRVYEMY  
gi | 12857776 | QHLLGLPRDPGSSVSCTFGCLGGRLSTPGTGVSLLPNGAIPQCKFYDLY  
gi | 11559982 | QHLLGLPRDPGSSVSCTFGCLGGRLSTPGTGVSLLPNGAIPQCKFYDLY  
gi | 15296526 | Q-----TDPSCIAFGSENSLSGGHLITPNSGVSLLPAGAIPQGRVYEMY

610 620 630 640 650  
NOV 10 LRLINKAESTLPLSEGTQTVLSPSVTCGPTGLLLCRPVLLTMPHCAEVSAR  
gi | 6678505 | VIVHRKEMMRPMDQSQTLLTPVWSCGPPGALLTRPVLLTMHCADPSTE  
gi | 4507837 | VIVHRKETMRPMDQSQTLLTPVWSCGPPGALLTRPVLLTMHCADPSTE  
gi | 12857776 | LRLINKAESTLPLSEGTQTVLSPSVTCGPTGLLLCRPVLLTMPHCAEVIAG  
gi | 11559982 | LRLINKAESTLPLSEGTQTVLSPSVTCGPTGLLLCRPVLLTMPHCAEVIAG  
gi | 15296526 | VIVHRKETMRPMDQSQTLLTPVWSCGPPGALLTRPVLLTMHCADPSTE

660 670 680 690 700  
NOV 10 DWIFOLKTOAHQGHWE-EVVITDEETLNTPCYCOLEPRACHILLDOLGTY  
gi | 6678505 | DWKILKNOAQOGWE-DVVVYGEENFTTPCYIQLDAEACHILLENLSTY  
gi | 4507837 | DWKILKNOAQOGWE-DVVVYGEENFTTPCYIQLDAEACHILLENLSTY  
gi | 12857776 | DWIFOLKTOAHQGHWE-EVVITDEETLNTPCYCOLEAKSCHILLDOLGTY  
gi | 11559982 | DWIFOLKTOAHQGHWE-EVVITDEETLNTPCYCOLEAKSCHILLDOLGTY  
gi | 15296526 | DWKILKNOAQOGWE-DVVVYGEENFTTPCYIQLDAEACHILLENLSTY

710 720 730 740 750  
NOV 10 VFTGESYSRSVAVKRLQLAIFAPALCTSLEYSTRVYCLDDTPVALKEVLEL  
gi | 6678505 | ALVGSTTKAAAKRLKLAIFGELCCSLEYSTRVYCLDDTPDALKEVLEL  
gi | 4507837 | ALVGSTTKAAAKRLKLAIFGELCCSLEYSTRVYCLDDTPDALKEVLEL  
gi | 12857776 | VFTGESYSRSVAVKRLQLAIFAPALCTSLEYSTRVYCLDDTPVALKEVLEL  
gi | 11559982 | VFTGESYSRSVAVKRLQLAIFAPALCTSLEYSTRVYCLDDTPVALKEVLEL  
gi | 15296526 | ALVGSTTKAAAKRLKLAIFGELCCSLEYSTRVYCLDDTPDALKEVLEL

760 770 780 790 800  
NOV 10 ERTGGYLVEEPKPLEFKDSYHNLRSLTHDIPHAHRSKLLAKYQEIIFY  
gi | 6678505 | EROMGGOLLEEPKALEFKGSTHNLRSLTHDIAHSLWRSKLLAKYQEIIFY  
gi | 4507837 | ERTGGOLLEEPKALEFKGSTHNLRSLTHDIAHSLWRSKLLAKYQEIIFY  
gi | 12857776 | ERTGGYLVEEPKPLEFKDSYHNLRSLTHDIPHAHRSKLLAKYQEIIFY  
gi | 11559982 | ERTGGYLVEEPKPLEFKDSYHNLRSLTHDIPHAHRSKLLAKYQEIIFY  
gi | 15296526 | EROMGGOLLEEPKALEFKGSTHNLRSLTHDIAHSLWRSKLLAKYQEIIFY

810 820 830 840 850  
NOV 10 HVMGSGQRALHCTFTLERHSLASTETCKVCVRQVEGEGQIFQLNCTVSE  
gi | 6678505 | HVMGSGQRALHCTFTLERHSLNIVELVCKVCVRQVEGEGQIFQLNCTVSE  
gi | 4507837 | HVMGSGQRALHCTFTLERHSLNIVELVCKVCVRQVEGEGQIFQLNCTVSE  
gi | 12857776 | HVMGSGQRALHCTFTLERHSLASTETCKVCVRQVEGEGQIFQLNCTVSE  
gi | 11559982 | HVMGSGQRALHCTFTLERHSLASTETCKVCVRQVEGEGQIFQLNCTVSE  
gi | 15296526 | HVMGSGQRALHCTFTLERHSLNIVELVCKVCVRQVEGEGQIFQLNCTVSE

860 870 880 890 900  
NOV 10 TPAGSIDTLCSAPGSETVTTQGPYAFKIPLSIRQKICSSLDAPNSRGNDW  
gi | 6678505 | EPTG-IDLPLLDPAITITTGTGSAFISIPLPIRQKICSSLDAPOTRGEDW  
gi | 4507837 | EPTG-IDLPLLDPAITITTGTGSAFISIPLPIRQKICSSLDAPOTRGEDW  
gi | 12857776 | TPAGSIDALCSAPGNAITTTQGPYAFKIPLSIRQKICSSLDAPDSRGNDW  
gi | 11559982 | TPAGSIDALCSAPGNAITTTQGPYAFKIPLSIRQKICSSLDAPNSRGNDW  
gi | 15296526 | EPTG-IDLPLLDPAITITTGTGSAFISIPLPIRQKICSSLDAPOTRGEDW

910 920 930 940 950  
NOV 10 RMLAOKLSMDRYLNYFATKSSPTGVILDLWEALQDDGDLNLSLALEEM  
gi | 6678505 | RMLAHKLANMDRYLNYFATKSSPTGVILDLWEALNFFDGNLSMLAAVLEEM  
gi | 4507837 | RMLAHKLANMDRYLNYFATKSSPTGVILDLWEALNFFDGNLSMLAAVLEEM

```

gi|12857776| RMLAOKLSMDRYLNYFATKASPTGVILDLWEAKQDDDCDINSLSASALEEM
gi|11559982| RMLAOKLSMDRYLNYFATKASPTGVILDLWEAKQDDDCDINSLSASALEEM
gi|15296526| RMLAHKLNLDRLNYFATKSSPTGVILDLWEAKNFPDGNLSMCAAVLEEM

```

960

```

NOV 10      . . . . .
gi|6678505|  CRSEMLVAVATDQDC
gi|4507837|  CRHETVVSIAAEGQY
gi|12857776| CRSEMLVAVATDQDC
gi|11559982| CRSEMLVAVATDQDC
gi|15296526| CRHETVVSIAAEGQY

```

Table 10E-I lists the domain description from DOMAIN analysis results against NOV10. This indicates that the NOV10 sequence has properties similar to those of other proteins known to contain these domains.

Table 10E. Domain Analysis of NOV10

gnl|Smart|smart00218, ZU5, Domain present in ZO-1 and Unc5-like netrin receptors; Domain of unknown function. (SEQ ID NO:126)  
Length = 104 residues, 100.0% aligned  
Score = 149 bits (376), Expect = 7e-37

```

NOV10  541  PGSSVSGTFTGCLGGRLSIPGTGVSLVLPNGAIPQGKFYEMYLLINKAESTLPLSEGTQTV  600
          |  ||||  ||||  | ||  |++  ||||  |  ||++  ||  |  |+
00218   1    PSFLVSGTFTDARGGRLRGPRGTGVRLLIIPGAIPQGTRYTCYLVVHDKLSTPPPLEEGETL  60

NOV10  601  LSPSVTCGPTGLLLCRPVILTMPHCAEVSARDWIFQLKTOAHQG  644
          |||  ||||  |  ||||  +|||  +  |||  |  +  |
00218   61   LSPVVECGPHGALFLRPVILEVPHCASLRPRDWEIVLLRSENGG  104

```

Table 10F. Domain Analysis of NOV10

gnl|Pfam|pfam00791, ZU5, ZU5 domain. Domain present in ZO-1 and Unc5-like netrin receptors Domain of unknown function. (SEQ ID NO:127)  
Length = 104 residues, 100.0% aligned  
Score = 147 bits (371), Expect = 3e-36

```

NOV10  541  PGSSVSGTFTGCLGGRLSIPGTGVSLVLPNGAIPQGKFYEMYLLINKAESTLPLSEGTQTV  600
          |  ||||  ||||  | ||  |++  ||||  |  ||++  ||  |  |+
00791   1    SGFLVSGTFTDARGGRLRGPRGTGVRLLIIPGAIPQGTRYTCYLVVHDKLSTPPPLEEGETL  60

NOV10  601  LSPSVTCGPTGLLLCRPVILTMPHCAEVSARDWIFQLKTOAHQG  644
          |||  ||||  |  ||||  +|||  +  |||  |  +  |
00791   61   LSPVVECGPHGALFLRPVILEVPHCASLRPRDWELVLLRSENGG  104

```

Table 10G. Domain Analysis of NOV10

gnl|Smart|smart00005, DEATH, DEATH domain, found in proteins involved in cell death (apoptosis).; Alpha-helical domain present in a variety of proteins with apoptotic functions. Some (but not all) of these domains form homotypic and heterotypic dimers. (SEQ ID NO:128)  
Length = 96 residues, 99.0% aligned  
Score = 64.7 bits (156), Expect = 2e-11

```

NOV10  853  GPYAFKIPLSIRQKICNSLDAPNSRCNDWRMLAQKLSM-DRYLNYFATKAS-----PTGV  906
          |  |  +  |++  ||  +  |++  ||++  ++  ++  |++  +
00005   1    PPGAASLTETLTREKLAKLLD--HDLGDDWRELARKLGLSEADIDQIETESPRDLAEQSYQ  58

```

NOV10 907 ILDLWEALQQDDGDLNSLASALEEMGKSEMLVAVATD 943  
 +| ||| + + | +| || +| + + + ++  
 00005 59 LLRLWEQREGKNATLGLLEALRKMGRDDAVELLRSE 95

**Table 10H. Domain Analysis of NOV10**

gnl|Smart|smart00209, TSP1, Thrombospondin type 1 repeats; Type 1 repeats in thrombospondin-1 bind and activate TGF-beta. (SEQ ID NO:129)  
 Length = 51 residues, 100.0% aligned  
 Score = 62.0 bits (149), Expect = 1e-10

NOV10 254 WSSWAEWSPCSNRCGRGWQKRTRTCTNPAPLNGGAFCEGQAFQKTACTT-ICP 305  
 | +| || || || || || || || || || || + || || ||  
 00209 1 WGEWSEWSPCSVTTCGGGVQTRTRCCNPPP--NGGGPCTGPDTETRACNEQPCP 51

**Table 10I. Domain Analysis of NOV10**

gnl|Smart|smart00409, IG, Immunoglobulin. (SEQ ID NO:130)  
 Length = 86 residues, 100.0% aligned  
 Score = 48.9 bits (115), Expect = 1e-06

NOV10 164 PLGKEVPLDHEVLLQCRPPEGVPVAEVEWLKNEVDIDPTQDTNFLTIDHN---LIIRQA 220  
 | | | | | | | | | | | | | | + + | ++ | | |  
 00409 1 PPSVTVKEGESVTLSCAS-GNPPPTVTWYKQGGKL-LAESGRFSVSRSGNSTLTISNV 58  
 NOV10 221 RLSDTANYTCVAKNIVAKRRSTTATVIVY 249  
 | + | | | | | | | + |  
 00409 59 TPEDSGTYTCAATNSSGSASSGT-TLTVL 86

5 Migration of neurons from proliferative zones to their functional sites is fundamental to the normal development of the central nervous system. Mice homozygous for the rostral cerebellar malformation (rcm) mutation exhibit cerebellar and midbrain defects, apparently as  
 10 a result of abnormal neuronal migration. Ackerman et al. (1997) reported that in rcm-mutant mice, the cerebellum is smaller and has fewer folia than in wildtype, ectopic cerebellar cells are present in midbrain regions by 3 days after birth, and there are abnormalities in postnatal cerebellar-neuronal migration. The authors isolated cDNAs encoding the rcm protein (Rcm). Sequence analysis revealed that the predicted 931-amino acid mouse protein is a  
 15 transmembrane protein that contains 2 immunoglobulin (Ig)-like domains and 2 type I thrombospondin (THBS1; 188060) motifs in the extracellular region. Ig and THBS1 domains are also found in the extracellular region of the *C. elegans* UNC5 transmembrane protein, and the C-terminal 865-amino acid region of Rcm is 30% identical to UNC5. Ackerman et al. (1997) stated that the UNC5 protein is essential for dorsal guidance of pioneer axons and for  
 20 the movement of cells away from the netrin ligand. In the developing brain of vertebrates, netrin-1 (601614) plays a role in both cell migration and axonal guidance. Leonardo et al. (1997) demonstrated that Rcm binds netrin-1 in vitro. Ackerman et al. (1997) concluded that Rcm and its ligand are important in critical migratory and/or cell-proliferation events during

cerebellar development. Przyborski et al. (1998) found that disruption of the mouse *rcm* gene, also called the *Unc5h3* gene, resulted in a failure of tangentially migrating granule cells to recognize the rostral boundary of the cerebellum.

By searching an EST database for sequences related to the *Unc5h3* gene, Ackerman and Knowles (1998) identified a partial human fetal brain cDNA encoding UNC5C, the human *Unc5h3* homolog. Using 5-prime RACE, they cloned a cDNA corresponding to the entire UNC5C coding region. The predicted 931-amino acid human protein has the overall domain structure of UNC5 family proteins, and is 97% identical to *Unc5h3*. Northern blot analysis revealed that the 9.5-kb UNC5 mRNA is expressed in brain and heart, and at low levels in kidney.

The protein similarity information, expression pattern, and map location for the NOV10 (UNC5 receptor-like) protein and nucleic acid disclosed herein suggest that NOV10 may have important structural and/or physiological functions characteristic of the UNC5 receptor family. Therefore, the NOV10 nucleic acids and proteins of the invention are useful in potential therapeutic applications implicated in various diseases and disorders described below and/or other pathologies. For example, the NOV10 compositions of the present invention will have efficacy for treatment of patients suffering from inflammatory and infectious diseases such as AIDS, cancer therapy, Neurologic diseases, Brain and/or autoimmune disorders like encephalomyelitis, neurodegenerative disorders, Alzheimer's Disease, Parkinson's Disorder, immune disorders, and hematopoietic disorders, endocrine diseases, muscle disorders, inflammation and wound repair, bacterial, fungal, protozoal and viral infections (particularly infections caused by HIV-1 or HIV-2), pain, cancer (including but not limited to Neoplasm; adenocarcinoma; lymphoma; prostate cancer; uterus cancer), anorexia, bulimia, asthma, Parkinson's disease, acute heart failure, hypotension, hypertension, urinary retention, osteoporosis, Crohn's disease; multiple sclerosis; and Treatment of Albright Hereditary Osteodystrophy, angina pectoris, myocardial infarction, ulcers, asthma, allergies, benign prostatic hypertrophy, and psychotic and neurological disorders, including anxiety, schizophrenia, manic depression, delirium, dementia, severe mental retardation and dyskinesias, such as Huntington's disease or Gilles de la Tourette syndrome and/or other pathologies and disorders. The NOV10 nucleic acid encoding UNC5 Receptor-like protein, and the UNC5 Receptor-like protein of the invention, or fragments thereof, may further be useful in diagnostic applications, wherein the presence or amount of the nucleic acid or the protein are to be assessed.

NOV11

NOV11 includes three novel Hepatocyte Growth Factor-like proteins disclosed below. The disclosed proteins have been named NOV11a, NOV11b and NOV11c.

### NOV11a

- A disclosed NOV11a nucleic acid of 1782 nucleotides (also referred to
- 5 GMba446g13\_A) encoding a novel TMS-2-like protein is shown in Table 11A. An open reading frame was identified beginning with an ATG initiation codon at nucleotides 22-24 and ending with a TGA codon at nucleotides 1723-1725. Putative untranslated regions upstream from the initiation codon and downstream from the termination codon are underlined in Table 11A, and the start and stop codons are in bold letters.

**Table 11A. NOV11a Nucleotide Sequence (SEQ ID NO:57)**

```

CAGGGCAGCGCTCGCCATTGAATGACTTCCAGGTGCTCCGGGGCACAGAGCTACCTGCTACATGCCGTGGT
GCCTGGGCCTTGGCAGGAGGATGTGGCAGATGCTGAAGAGTGTGCTGGTGCCTGTGGGCCCTTAACGGACT
GCTGGGCCCTTCCACTACAATGTGAGCAGCCATGGTTGCCAACTGCTGCCATGGACTCAACACTCGCCCCAC
TCAAGGCTGTGGCATTCTGGGCGCTGTGACCTTTCAGAAAGAAAGACTACATACGGACCTGCATCATGAA
CAATGGGGTTGGGTACCGGGGCACCATGGCCACGACCGTGGGTGGCCTGTCTGCCAGGCTTGGAGCCACA
AGTTCGCCGAATGATCACAAGTACATGCCACGCTCCGGAATGGCCTGGAAGAGAACTTCTGCCATAACCTT
GATGGCGACCCCGAGGTCTTGGTGCCACACAAGACCCCTGCCGTGCGCTTCCAGAGCTGCGGCATCAA
ATCCTGCCGGGTGGCCGCGTGTGTCTGGTGCAATGGCGAGGAATACCGCGGCGCGGTAGACCGCACCGAGT
CAGGGCGCGAGTGCCAGCGCTGGGATCTTCAGCACCCGACCCAGCACCCCTTCGAGCCGGGCGAGTTCCCTC
GACCAAGGTCTGGACGACAACATTGCGGGAATCCTGACGGCTCCGAGCGGCCATGGTGTACACTACGGA
TCCGCAGATCGAGCGAGAATTCTGTGACCTCCCCCGCTGCGGTTCCGAGGCACAGCCCCGCAAGAGGCCA
CAAGTGTACGTGCTTCCGCGGAAGGGTGAGGGCTACCGGGGCACAGCCAATACCACCACCGCGGGCGTA
CCTTGCCAGCGTTGGGACGCGCAAATCCCGCATCAGCACCGATTACGCCAGAAAAATACGCGTGCAAGGA
CCTTCGGGAGAACTTCTGCCGGAACCTCGACGCTCAGAGGCGCCCTGGTGCTTCACTGCGGCCCGGCA
TGCGCGTGGGCTTTTGTACCAGATCCGGCGTGTACAGACGAGTGGCGCCCCAGGACTGCTACCACGGC
GCGGGGGAGCAGTACC CGGCACGGTTCAGCAAGACCCGCAAGGGTGTCCAGTGCCAGCGCGCTCCGCTGA
GACGCGCACAAGCCGAGTTACGTTTACCTCCGAACCGCATGCACAACCTGGAGGAGAACTTCTGCCAGA
CCCCAGATGGGGATAGCCATGGGCCCTGGTGCTACAGATGGACCAAGGACCCATTGCACTACTGTGCC
CTGCGACGCTGCGCTGATGACCAGCGCCATCAATCTGGACCCCCCGACAGGTGCAGTTTGAGAAGTG
TGGCAAGAGGGTGGATCGGCTGGATCAGCGTCGTTCCAAGCTGCGCGTGGCTGGGGCCATCCGGGCAACT
CACCTTGGACAGTCAGCTTGGGGAATCGGCAGGGCCAGCATTCTGCGGGGGTCTCTAGTGAAGGAGCAG
TGGATACTGACTGCCCGCAGTGCTTCTCTCCAGCATATGCCTCTCACGGGCTATGAGGTATGGTTGGG
CACCTGTTCAGAAACCAACATGGAGAGCCAGGCCTACAGCGGGTCCAGTAGCCAAGATGCTGTGTG
GGCCCTCAGGCTCCAGCTTGTCTGCTCAAGCTGGAGAGGTCTGTGACCCTGAACCAGCGTGTGGCCCTG
ATCTGCCTGCCCGCTGAATGATATGTGGTGCCTCCAGGACCAAGTGTGAGATTGCAGGCCGGGTGAGAC
CAAAGGT

```

The disclosed NOV11a nucleic acid sequence, localized to chromosome 1, has 1735 of 1787 bases (97%) identical to a *Homo sapiens* Macrophage Stimulating Protein mRNA (GENBANK-ID: RNU87306) (E = 0.0).

- A disclosed NOV11a polypeptide (SEQ ID NO:58) encoded by SEQ ID NO:57 is 567
- 15 amino acid residues and is presented using the one-letter amino acid code in Table 11B. Signal P, Psort and/or Hydropathy results predict that NOV11a does not contain a signal peptide and is likely to be localized to the peroxisome (microbody) with a certainty of 0.4531 and to the cytoplasm with a certainty of 0.4500. NOV11a is similar to the hepatocyte growth factor family, some members of which are released extracellularly. Therefore it is likely that

NOV11a is available at the same sub-cellular localization and hence accessible to a diagnostic probe and for various therapeutic applications

**Table 11B. Encoded NOV11a protein sequence (SEQ ID NO:58).**

MTSRCSGAQSLLHAVVPGPWQEDVADAEACAGRCGLTDCWAFHYNVSSHGCQLLPWTQHSPLHWSG  
 RCDLFLQKKDYIRTCIMNNGVGYRGTMATTVGGLSCQAWSHKFPNDHKYMPTLRNGLEENFCHNPDGDPGGP  
 WCHTTDPVAVRFQSCGKSCRVAAACVWCNGEYRGAVDRTESGRECQRWDLQHPHQHPFEPGRFLDQGLDDN  
 YCRNPDGSERPWCYTTDPQIEREFCDLPRCGSEAQPRQEATSVSCFRGKGEGYRGTTANTTTAGVPCQRWDA  
 QIPHQHRTPEKYACKDLRENFCRNLDGSEAPWCFTLRPGMRVGFYQIRRCTDDVRPDQCYHGAGEQYRG  
 TVSKTRKGVQCQRASAETPHKPQFTTSEPHAQLEENFCQTPDGDSHGWPWCYTMDPRTPFDYCALRRCAD  
 QPPSILDPDQVQFEKCGKRVDRDLQRRSKLRVAGGHGPGNSPWTVSLGNRQGHFCGGSILVKEQWILTARQ  
 CFSSQHMLPTGYEVWLGTLFQNPQHGEFGLQRPVPAKMLCGPSGSQVLVLLKLEERSVTLNQRVALICLPPE

5 The NOV11a amino acid sequence has 249 of 456 amino acid residues (54%) identical to, and 552 of 567 amino acid residues (97%) identical to, and 556 or 567 amino acid residues (98%) similar to, the *Homo sapiens* 567 amino acid residue Hepatocyte Growth Factor protein (Q13208) (E = 0.0). The global sequence homology is 97.707 % amino acid homology and  
 10 97.354 % amino acid identity.

NOV11a is expressed in at least the following tissues: lung, liver, kidney, brain, . In addition, NOV11a is predicted to be expressed in the following tissues because of the expression pattern of a closely related *Bos taurus* Growth Factor homolog in species (GENBANK-ID: AW657716) : lymph node, ovary, fat, hypothalamus, and pituitary.

15 NOV11a also has homology to the amino acid sequences shown in the BLASTP data listed in Table 11C.

**Table 11C. BLAST results for NOV11a**

Gene Index/ Identifier	Protein/ Organism	Length (aa)	Identity (%)	Positives (%)	Expect
<a href="#">gi 1141775 gb AAC63092.1 </a> (U28054)	hepatocyte growth factor-like protein homolog [Homo sapiens]	567	552/567 (97%)	556/567 (97%)	0.0
<a href="#">gi 123114 sp P26927 HGFL HUMAN</a>	HEPATOCYTE GROWTH FACTOR-LIKE PROTEIN PRECURSOR (MACROPHAGE STIMULATORY PROTEIN) (MSP) [Homo sapiens]	771	532/557 (95%)	540/557 (96%)	0.0
<a href="#">gi 10337615 ref NP_066278.1 </a>	macrophage stimulating 1 (hepatocyte growth factor-like) [Homo sapiens]	711	532/557 (95%)	540/557 (96%)	0.0

gi 15294659 ref XP_054070.1	macrophage stimulating 1 (hepatocyte growth factor-like) [Homo sapiens]	711	532/557 (95%)	540/557 (96%)	0.0
gi 90615 pir A40332	macrophage-stimulating protein 1 precursor [Mus musculus]	716	435/565 (76%)	479/565 (83%)	0.0

The homology of these sequences is shown graphically in the ClustalW analysis shown in Table 11D.

**Table 11D Information for the ClustalW proteins**

- 1) NOV11a (SEQ ID NO:58)
- 2) gi|1141775|gb|AAC63092.1| (U28054) hepatocyte growth factor-like protein homolog [Homo sapiens] (SEQ ID NO:131)
- 3) gi|123114|sp|P26927|HGFL\_HUMAN HEPATOCYTE GROWTH FACTOR-LIKE PROTEIN PRECURSOR (MACROPHAGE STIMULATORY PROTEIN) (MSP) [Homo sapiens] (SEQ ID NO:132)
- 4) gi|10337615|ref|NP\_066278.1| macrophage stimulating 1 (hepatocyte growth factor-like) [Homo sapiens] (SEQ ID NO:133)
- 5) gi|15294659|ref|XP\_054070.1| macrophage stimulating 1 (hepatocyte growth factor-like) [Homo sapiens] (SEQ ID NO:134)
- 6) gi|90615|pir|A40332| macrophage-stimulating protein 1 precursor [Mus musculus] (SEQ ID NO:135)

	10	20	30	40	50
NOV 11a	..... ..... ..... ..... ..... .....	MTSRCS	GAQS	YLLHAVVPGPWQEDV	
gi 1141775	..... ..... ..... ..... ..... .....	MTSRCS	GAQS	YLLHAVVPGPWQEDV	
gi 123114	..... ..... ..... ..... ..... .....	MGWLPDLLLL	QYLGVEGQ	RSPLNDFQVLRGTELO	LLHAVVPGPWQEDV
gi 10337615	..... ..... ..... ..... ..... .....	MGWLPDLLLL	QYLGVEGQ	RSPLNDFQVLRGTELO	LLHAVVPGPWQEDV
gi 15294659	..... ..... ..... ..... ..... .....	MGWLPDLLLL	QYLGVEGQ	RSPLNDFQVLRGTELO	LLHAVVPGPWQEDV
gi 90615	..... ..... ..... ..... ..... .....	MGWLPDLLLL	QCSRALGQ	RSPLNDFQVLRGTELR	NLLTAVPGPWQEDV
	60	70	80	90	100
NOV 11a	..... ..... ..... ..... ..... .....	ADAEECAGRCG	PLDCWAFHYNVSSHG	COLLPWTOHSPHSRL	WHSGRCDL
gi 1141775	..... ..... ..... ..... ..... .....	ADAEECAGRCG	PLDCWAFHYNVSSHG	COLLPWTOHSPHSRL	WHSGRCDL
gi 123114	..... ..... ..... ..... ..... .....	ADAEECAGRCG	PLMDCRAFHYNVSSHG	COLLPWTOHSPHTR	LRSGRCDL
gi 10337615	..... ..... ..... ..... ..... .....	ADAEECAGRCG	PLMDCRAFHYNVSSHG	COLLPWTOHSPHTR	LRSGRCDL
gi 15294659	..... ..... ..... ..... ..... .....	ADAEECAGRCG	PLMDCRAFHYNVSSHG	COLLPWTOHSPHTR	LRSGRCDL
gi 90615	..... ..... ..... ..... ..... .....	ADAEECARRCG	PLMDCRAFHYNVSSHG	COLLPWTOHSPHTR	LRSLCHL
	110	120	130	140	150
NOV 11a	..... ..... ..... ..... ..... .....	FQKKDYV	RTCIMNNGVG	YRGTMATTVGGLSC	QAWSHKFPNDHKYMP
gi 1141775	..... ..... ..... ..... ..... .....	FQKKDYV	RTCIMNNGVG	YRGTMATTVGGLSC	QAWSHKFPNDHKYMP
gi 123114	..... ..... ..... ..... ..... .....	FQKKDYV	RTCIMNNGVG	YRGTMATTVGGLPC	QAWSHKFPNDHKYTP
gi 10337615	..... ..... ..... ..... ..... .....	FQKKDYV	RTCIMNNGVG	YRGTMATTVGGLPC	QAWSHKFPNDHKYTP
gi 15294659	..... ..... ..... ..... ..... .....	FQKKDYV	RTCIMNNGVG	YRGTMATTVGGLPC	QAWSHKFPNDHKYTP
gi 90615	..... ..... ..... ..... ..... .....	FQKKDYV	RTCIMNNGV	SYRGTVARTAGGLPC	QAWSRFPNDHKYTP
	160	170	180	190	200
NOV 11a	..... ..... ..... ..... ..... .....	GLEENFC	RNPDPGPGPWCE	TTDPAVRFQSCG	IKSCRVAACVWCNGE
gi 1141775	..... ..... ..... ..... ..... .....	GLEENFC	RNPDPGPGPWCE	TTDPAVRFQSCG	IKSCLVAACVWCNGE
gi 123114	..... ..... ..... ..... ..... .....	GLEENFC	RNPDPGPGPWCE	TTDPAVRFQSCG	IKSCREAAACVWCNGE
gi 10337615	..... ..... ..... ..... ..... .....	GLEENFC	RNPDPGPGPWCE	TTDPAVRFQSCG	IKSCREAAACVWCNGE
gi 15294659	..... ..... ..... ..... ..... .....	GLEENFC	RNPDPGPGPWCE	TTDPAVRFQSCG	IKSCREAAACVWCNGE
gi 90615	..... ..... ..... ..... ..... .....	GLEENFC	RNPDPGPGPWCE	TTDPAVRFQSCG	IKTCREAVCVLCNGE
	210	220	230	240	250
	..... ..... ..... ..... ..... .....				

NOV 11A GAVDRTESGRECORWDLQHPHQHPFEPGKFLDQGLDDNYCRNPDGSERPW  
gi 1141775 | GAVDRTESGRECORWDLQHPHQHPFEPGKFLDQGLDDNYCRNPDGSERPW  
gi 123114 | GAVDRTESGRECORWDLQHPHQHPFEPGKFLDQGLDDNYCRNPDGSERPW  
gi 10337615 | GAVDRTESGRECORWDLQHPHQHPFEPGKFLDQGLDDNYCRNPDGSERPW  
gi 15294659 | GAVDRTESGRECORWDLQHPHQHPFEPGKFLDQGLDDNYCRNPDGSERPW  
gi 90615 | GEVDVTESGRECORWDLQHPHQHPFEPGKFLDQGLDDNYCRNPDGSERPW

260 270 280 290 300  
NOV 11A CYTTDPQIEREFCDLPRCG-----SEAQPRQEATSVSCFRGKGEGY  
gi 1141775 | CYTTDPQIEREFCDLPRCG-----SEAQPRQEATSVSCFRGKGEGY  
gi 123114 | CYTTDPQIEREFCDLPRCG-----SEAQPRQEATSVSCFRGKGEGY  
gi 10337615 | CYTTDPQIEREFCDLPRCG-----SEAQPRQEATSVSCFRGKGEGY  
gi 15294659 | CYTTDPQIEREFCDLPRCG-----SEAQPRQEATSVSCFRGKGEGY  
gi 90615 | CYTTDPQIEREFCDLPRCG-----SEAQPRQEATSVSCFRGKGEGY

310 320 330 340 350  
NOV 11A RGTANTTTAGVPCQRWDAQIPHQHRFTPEKYACKDLRENFCRNPDGSEAP  
gi 1141775 | RGTANTTTAGVPCQRWDAQIPHQHRFTPEKYACKDLRENFCRNPDGSEAP  
gi 123114 | RGTANTTTAGVPCQRWDAQIPHQHRFTPEKYACKDLRENFCRNPDGSEAP  
gi 10337615 | RGTANTTTAGVPCQRWDAQIPHQHRFTPEKYACKDLRENFCRNPDGSEAP  
gi 15294659 | RGTANTTTAGVPCQRWDAQIPHQHRFTPEKYACKDLRENFCRNPDGSEAP  
gi 90615 | RGTANTTTAGVPCQRWDAQIPHQHRFTPEKYACKDLRENFCRNPDGSEAP

360 370 380 390 400  
NOV 11A WCFTLRPGMRVGFQCYQIRRCTDDVRPQDCYHGAGEQYRGTVSKTRKGVQC  
gi 1141775 | WCFTLRPGMRVGFQCYQIRRCTDDVRPQDCYHGAGEQYRGTVSKTRKGVQC  
gi 123114 | WCFTLRPGMRVGFQCYQIRRCTDDVRPQDCYHGAGEQYRGTVSKTRKGVQC  
gi 10337615 | WCFTLRPGMRVGFQCYQIRRCTDDVRPQDCYHGAGEQYRGTVSKTRKGVQC  
gi 15294659 | WCFTLRPGMRVGFQCYQIRRCTDDVRPQDCYHGAGEQYRGTVSKTRKGVQC  
gi 90615 | WCFTLRPGMRVGFQCYQIRRCTDDVRPQDCYHGAGEQYRGTVSKTRKGVQC

410 420 430 440 450  
NOV 11A QRWSAETPHKPOFTFTSEPHAQLEENFCRNPDGDSHGWPWCYTMDPRTTFFD  
gi 1141775 | QRWSAETPHKPOFTFTSEPHAQLEENFCRNPDGDSHGWPWCYTMDPRTTFFD  
gi 123114 | QRWSAETPHKPOFTFTSEPHAQLEENFCRNPDGDSHGWPWCYTMDPRTTFFD  
gi 10337615 | QRWSAETPHKPOFTFTSEPHAQLEENFCRNPDGDSHGWPWCYTMDPRTTFFD  
gi 15294659 | QRWSAETPHKPOFTFTSEPHAQLEENFCRNPDGDSHGWPWCYTMDPRTTFFD  
gi 90615 | QRWSAETPHKPOFTFTSEPHAQLEENFCRNPDGDSHGWPWCYTMDPRTTFFD

460 470 480 490 500  
NOV 11A YCALRRCADDQPPSILDPDQVQFEKCGKRVDRDLQRRSKLRVAGGHPGN  
gi 1141775 | YCALRRCADDQPPSILDPDQVQFEKCGKRVDRDLQRRSKLRVAGGHPGN  
gi 123114 | YCALRRCADDQPPSILDPDQVQFEKCGKRVDRDLQRRSKLRVAGGHPGN  
gi 10337615 | YCALRRCADDQPPSILDPDQVQFEKCGKRVDRDLQRRSKLRVAGGHPGN  
gi 15294659 | YCALRRCADDQPPSILDPDQVQFEKCGKRVDRDLQRRSKLRVAGGHPGN  
gi 90615 | YCALRRCADDQPPSILDPDQVQFEKCGKRVDRDLQRRSKLRVAGGHPGN

510 520 530 540 550  
NOV 11A SPWTVSLNRQGHFCGGSVLVKEQWILTARQCFSSCHMPLTGVEVWLGTLL  
gi 1141775 | SPWTVSLNRQGHFCGGSVLVKEQWILTARQCFSSCHMPLTGVEVWLGTLL  
gi 123114 | SPWTVSLNRQGHFCGGSVLVKEQWILTARQCFSSCHMPLTGVEVWLGTLL  
gi 10337615 | SPWTVSLNRQGHFCGGSVLVKEQWILTARQCFSSCHMPLTGVEVWLGTLL  
gi 15294659 | SPWTVSLNRQGHFCGGSVLVKEQWILTARQCFSSCHMPLTGVEVWLGTLL  
gi 90615 | SPWTVSLNRQGHFCGGSVLVKEQWILTARQCFSSCHMPLTGVEVWLGTLL

560 570 580 590 600  
NOV 11A FQNPQHGEPSLQRPVPVAKMVCGPSGSQLVLLKLESVTLNQRVALICLPP  
gi 1141775 | FQNPQHGEPSLQRPVPVAKMVCGPSGSQLVLLKLESVTLNQRVALICLPP  
gi 123114 | FQNPQHGEPSLQRPVPVAKMVCGPSGSQLVLLKLESVTLNQRVALICLPP  
gi 10337615 | FQNPQHGEPSLQRPVPVAKMVCGPSGSQLVLLKLESVTLNQRVALICLPP  
gi 15294659 | FQNPQHGEPSLQRPVPVAKMVCGPSGSQLVLLKLESVTLNQRVALICLPP  
gi 90615 | FQNPQHGEPSLQRPVPVAKMVCGPSGSQLVLLKLESVTLNQRVALICLPP



Table 11E-J lists the domain description from DOMAIN analysis results against  
5 NOV11a. This indicates that the NOV11a sequence has properties similar to those of other  
proteins known to contain these domains.

gnl|Pfam|pfam00051, kringle, Kringle domain. Kringle domains have been found in plasminogen, hepatocyte growth factors, prothrombin, and apolipoprotein A. Structure is disulfide-rich, nearly all-beta. (SEQ ID NO:136)  
Length = 79 residues, 100.0% aligned  
Score = 114 bits (284), Expect = 2e-26

gnl|Pfam|pfam00051, kringle, Kringle domain. (SEQ ID NO:137)  
Length = 79 residues, 100.0% aligned  
Score = 106 bits (264), Expect = 4e-24

105

**Table 11G. Domain Analysis of NOV11a**

gnl|Pfam|pfam00051, kringle, Kringle domain. (SEQ ID NO:138)  
 Length = 79 residues, 100.0% aligned  
 Score = 98.6 bits (244), Expect = 9e-22

```
NOV11a 345  CYHGAGEQYRGTVSKTRKGVQCQRASAETPHK-PQFTTSEPHAQLEENFCQTPDGDSHG 403
          ||| ||| ||| ||| ||| ||| ++|||+ ++| | |||+| |||
00051 1    CYHNGENYRGTTASTTESGAPCQRWDSQTPHRHSKYTPERYPAKGLGENYCRNPDGDER- 59
NOV11a 404  PWCYTMDPRTPFDDYCALRRRC 423
          ||| ||| ++| + ||
00051 60  PWCYTTPRVRWEYCDIPRC 79
```

**Table 11H. Domain Analysis of NOV11a**

gnl|Pfam|pfam00051, kringle, Kringle domain. (SEQ ID NO:139)  
 Length = 79 residues, 100.0% aligned  
 Score = 94.4 bits (233), Expect = 2e-20

```
NOV11a 85    CIMNNGVGVRGTMATTVGGGLSCQAWSHKFPNDHKYM---PTLRNGLBENFCHNPDGDPGG 141
          ||| ||| ||| ++| | ||| + |+ | || ||| ||| |||
00051 1    CYHNGENYRGTTASTTESGAPCQRWDSQTPHRHSKYTPERYPAKGLGENYCRNPDGDE-R 59
NOV11a 142  PWCHTTDPAVRFQSCGIKSC 161
          |||+||| ||++ |||
00051 60  PWCYTTPRVRWEYCDIPRC 79
```

**Table 11I. Domain Analysis of NOV11a**

gnl|Smart|smart00130, KR, Kringle domain; Named after a Danish pastry.  
 Found in several serine proteases and in ROR-like receptors. Can occur  
 in up to 38 copies (in apolipoprotein(a)). Plasminogen-like kringles  
 possess affinity for free lysine and lysine- containing peptides. (SEQ  
 ID NO:140)  
 Length = 83 residues, 97.6% aligned  
 Score = 112 bits (280), Expect = 6e-26

```
NOV11a 166  CVCNNGEYRGAVDRTESGRECRWDLQHPHQPFEPGRFLDQGLDDNYCRNPDG-SERP 224
          | ||| ||| |++|+ ||| | ||| | ||| + ||+ ||| ||| |||
00130 3    CYAGNGESYRGTTASTTKSGKPCQRWDSQTPHLHRFTPERFPGLGLEHNYCRNPDGDEGP 62
NOV11a 225  WCYTTDPQIEREFCDLPRCGS 245
          ||| ||| + |++|+|
00130 63  WCYTTDPNVRWEYCDIPQCES 83
```

**Table 11J. Domain Analysis of NOV11a**

gnl|Smart|smart00130, KR, Kringle domain; (SEQ ID NO:141)  
 Length = 83 residues, 100.0% aligned  
 Score = 108 bits (271), Expect = 6e-25

```
NOV11a 343  QDCYHGAGEQYRGTVSKTRKGVQCQRASAETPHK-PQFTTSEPHAQLEENFCQTPDGDSH 402
          +||| | ||| ||| |++| ++|| | ||| +|+ ||| |||
00130 1    RDCYAGNGESYRGTTASTTKSGKPCQRWDSQTPHLHRFTPERFPGLGLEHNYCRNPDGDSE 60
NOV11a 403  GPWCYTMDPRTPFDDYCALRRCAD 425
          ||| ||| ++| + +|
00130 61  GPWCYTTPNVRWEYCDIPQCES 83
```

Novel variants for the NOV11a nucleic acid and hepatocyte growth factor-like protein are also disclosed herein as variants of NOV11a. Variants, as described above, are reported individually, but any combination of all or a subset are also included.

- 5 A disclosed NOV11b nucleic acid (also referred to as cg34a.348) is a variant of NOV11a, encodes a novel hepatocyte growth factor-like protein, and is shown in Table 11K. NOV11b nucleotide changes are underlined in Table 11K.

**Table 11K. NOV11b Nucleotide Sequence (SEQ ID NO:59)**

TGCAGCCTCCAGCCAGAAGGATGGGGTGGCTCCCACTCCTGCTGCTTCTGACTCAATGCTTAGGGGTCCTGGGCAGCG  
CTCGCCATTGAATGACTTCGAGGTGCTCCGGGGCAGAGCTACAGCGGCTGCTACAAGCGGTGGTCCCGGGCCTTGG  
CAGGAGGATGTGGCAGATGCTGAAGAGTGTGCTGGTTCGCTGTGGGCCCTTAATGGACTGCCGGGCGTTCCACTACAATG  
TGAGCAGCCATGGTTGCCAACTGCTGCCATGGACTCAACACTCACCCACACGAGGCTGCGGCATTCTGGGCGCTGTGA  
CCTCTTCAGGAGAAAGACTACATACGGAAGCTGATCATGAACAATGGGGTGGGTACCGGGGCACCATGGCCACGACC  
GTGGGTGGCTCTCCTGCCAGGCTTGGAGCCACAAGTTCCGGAACGATCACAGGTACATGCCACGCTCCGGAATGGCC  
TGGAAGAGAACTTCTGCCGTAAACCTGATGGCGACCCCGAGGTCCCTTGGTGCCACACAACAGACCTTCCCGTGGCGCTT  
CCAGAGCTGCGGCATCAAATCCTGCGGCTCTGCCGCTGTGTCTGGTGCAATGGCGAGGAATACCGCGGCGCGGTAGAC  
CGCACCGAGTCAGGGCGCGAGTGCCAGCGCTGGGATCTTCAGCACCCGACACGACCCCTTCGAGCGGGCAAGTACC  
CCGACCAAGGTCGTGACGACAACCTATTGCCGGAATCCTGACGGCTCCGAGCGGCCATGGTGCTACACTACGGATCCGCA  
GATCGAGCGAGAATTCTGTGACCTCCCCGCTGCGGTTCGAGGCACAGCCCGCCCAAGAGGCCACAAGTGTGAGCTGC  
TTCCGCGGGAAGGGTGGGGCTACCGGGGCACAGCCAATACCACACCGCGGGCGTACCTTGCCAGCGTTGGGACGCGC  
AAATCCCGCATCAGCACCGATTACCGCAGAAAAATACGCGTGCAAGGACCTTCGGGAGAACTTCTGCTGGAACCCCGA  
CGGCTCAGAGGCGCCTGTGTCTTACACTGCGGCCCGGCATGCGCGTGGGCTTTGTCTACAGATCCGGCGTGTGTACA  
GACGACGTGCGGCCCCAGGGTTGCTACCAAGCGCGCGGGGAGCAGTACCGCGGCACGGTCAGCAAGACCCGCAAGGGTG  
TCCAGTGCCAGCGCGCTCCGCTGAGACGCGCGCACAGCCGCACTTTACCTTTACCTCCGAACCGCATGCACAACCTGGA  
GGAGAACTTCTCCGCGACCCAGATGGGGATAGCTATGGGCCCTGGTGCTACACGATGGACCAAGGACCCCAATTTCGAC  
TACTGTGCCCTGCGACGCTGCGCTGATGACCAAGCGCCATCAATCCTGGACCCCCCGACAGGTGTCAGTTTGAAGT  
GTGGCAAGAGGGTGGATCGGCTGGATCAGCGTTGTTCCAAGCTGCGCGTGGCTGGGGGCCATCCGGGCAACTCACCTTG  
GACAGTCAGCTTGGGAATAGGCAGGGCCAGCATTTCTGCGGGGGTCTCTAGTGAAGGAGCAGTGGATACTGACTGCC  
CGGCAGTGCTTCTCTCCAGCCATATGCTCTCACGGGCTATGAGGTATGGTTGGGCACCCCTGTTCCAGAACCCACAAC  
ATGGAGAGCCAGGCCCTACAGCGGTCCTCAGTAGCAGATGCTGTGTGGGCCCTCAGGCTCTCAGCTTGTCTGCTCAA  
GCTGGAGAGATCTGTGACCTGAACCAAGCGCTGTGGCCCTGATCTGCTGGCCGCTGAATGGTATGTGGTCCCTCCAGGG  
ACCAAGTGTGAGATTGACAGCCCGGGGTGAGACCAAGGTACGGGTAATGACACAGTCTTAATGTGGCCCTTGTGAAATG  
TCATCTCCAACAGGAGTGAACATCAAGCACCGAGGACATGTGCGGAGAGCGAGATGTGCACTGAGGGACTGTTGGC  
CCCTGTGGGGGCTGTGAGGGGGTGAATACGGGGGCCACTTGCCCTGCTTTACCCACAACCTGCTGGGTCTGGGAAGGA  
ATTAGAAATCCCACCGAGTATGCGCAAGGTGCGCTGCGCAGCCGTCTTACACGTGTCTCTGTGTTTGTGACTGGA  
TTCACAGGTATGAGACTGGGTTAGGCCAGCCTTGACGCCATATGCTTTGGGGAGGACAAAACCT

- 10 A disclosed NOV11b polypeptide (SEQ ID NO:60) encoded by SEQ ID NO:59 is presented using the one-letter amino acid code in Table 11L. NOV11b amino acid changes, if any, are underlined in Table 11L.

**Table 11L. Encoded NOV11b protein sequence (SEQ ID NO:60).**

MGWLPLLLLTQCLGVPGQSRSLNDFEVLRGTELQRLQLQAVVPGPWQEDVADAECAGRCGPLMDCRAFHYNVSSHGQCLLPWTQ  
HSPHTRLRHSGRDLFQEKDYIRTCIMNNGVYRGTMATTVGGLSCQAWSHKFPNDHRYMPTLRNGLEENFCRNPDPGDPGGPWCH  
TTDPFAVRFQSCGKISCSRAACVWCNGEYRGAVDRTESGRECQRWDLQHPHQHPFEPGKYPDQGLDDNYCRNPDGSRPWCYTDD  
PQIEREFCDLPRCGSEAQPRQEAATSVSCFRGKGEGYRGTAATTTAGVPCQRWDAQIPHQHFTPEKYACKDLRENFCWNPDGSEA  
PWCFTLRPGMRVGFYQIRRCTDDVRPQGCYHAGEQYRGTVSKTRKGVQCQRASAETPHKPQFTFTSEPHAQLEENFCRDPDGD  
SYGFWCYTMDPRTPFYCALRRCAADDQPPSILDPDQVQFEKCGKRVDRDLQRCCKLRVAGGHGPGNSPWTVSLNRQGHFCGGS  
LVKEQWILTARQCFSSSHMPLTGVEVWLGLTFQNPQHGEPLQRPVAKMLCGPSGSLVLLKLERSVTLNQRVALICLPPFWYV  
VPPGTKEIAGRGETKGTGNDTVLNLVALLNVISNQECNKHGRHVRESEMCTEGLLAPVGACEGGDYGGPLACFTHCNWLLEGIR  
IPNRVCARSRPAVFTRVSVFVDWIHKVMRLG

- 15 A disclosed NOV11c nucleic acid (also referred to as cg34a.349) is a variant of NOV11a, encodes a novel hepatocyte growth factor-like protein, and is shown in Table 11M. NOV11c nucleotide changes are underlined in Table 11M.

**Table 11M. NOV11c Nucleotide Sequence (SEQ ID NO:61)**

TGCAGCCTCCAGCCAGAAGGATGGGGTGGCTCCCACTCCTGCTGCTTCTGACTCAATGCTTAGGGGTCCCTGGGCAGCG  
CTCGCCATTGAATGACTTCGAGGTGCTCGGGGACAGAGCTACAGCGCGCTGTCTACAAGCGGTGGTGCCCGGGCCTTGG  
CAGGAGGATGTGGGAGATCTCGAAGAGTGTGCTGGTCTGCTGTGGCGCCTTAATGGACTGCGCGGCGTTCCACTACAATG  
TGAGCAGGCATCTGGTTGGCCAACTGCTGCTGCAATGGAATCAACACTACCCCAACAGAGGTGCGGCATTTCTGGCGCGTGTGA  
CCTCTTCCAGGAGAAAGACTACATACGGACTCGCATATGAACAATGGGGTTGGGTACCGGGGACCAATGGGCCACGAC  
GTGGGTGGCCTGTCTGCCAGGCTTGGAGATCAAGAATTCGCCAAGCTACAGGTACATGCCACGCTCCGGAATGGC  
TGAAGAGAACTTTTCGCGTAAACCTGTAGGTGGGACCCCGAGGTTCTTGGTGCCACAACAGAGCCTTCGCTGGCGCTT  
CCAGAGTGTGGGCATCAAACTCTGCGCGTCTGCCGCGTGTGTCTGTGGTCAATGGCGAGGAATACCGCGCGCGGTAGAC  
CGACCGGAGTCAGGCGCGAGTGCCAGCGCTGGGATCTTCAGCACCCCGCACCGCACCCCTTTCGAGCGCGGCAAGTACC  
CCGACCAAGGTTCTGAGCAGCACTATTGTCCGGAATCTTCAGCGCTCCGAGCGGCATGGCTTACACTACGGAATCCGCA  
GATCCGCGAGAAATTCTGTGACTCTCCCGCGTCGGTTCCGAGGCACAGCCCGCGCAAGAGGCCAGATGTGTCACTGTGC  
TTCCGCGGGGAAGGTTGAGGGCTACCGGGGACAGCCAAATACCACCCGCGGGCGTACTCTGCCAGCGTTGGGACGCGC  
AAATTCGCGCATCAGCACCGAATTTACGCGAGAAAATACCGGTGCAAGGACTCTCGGAGAACTTCTGCGGAACCCGA  
CGGCTCAGAGGCGCCCTGTGTCTTACCCTTCGCGGCGCGGATCGCGCTTGGGCTTTGTCTACAGATCTCGGCGTGTGTACA  
GACGACGTGGCGGCGCCAGGGTTGTCTACCAACGCGCGGGGAGCAGTACCGCGGCACGGTTCAGCAAGACCCGCAAGGTT  
TCCAGTCCGACGCGCGCTCCGTGTGAGACGCGCACAGGCGCAGTTTACTTACTTCCGAACCGCATGCACAATGGA  
GGAGAATCTTCGCGCGACCCAGTATGGGATAGCTATGTGGCCCTGTGTGCTACACGATGACACCAAGGACCCCAATTGCA  
TACTGTGCCCTTCGCGCGCTTCGCTGTATGACCGCGCCCAATCAATCTCGGACCCCGACAGGTCAGTTTGAAGAAT  
GTGCAAGAGGGTGTGATCGGCTGGATCAGCGTTGTCCAAGTCTCGCGTGCCTGGGGGCGATTCGCGGCAACTCAACCTG  
GACAGTCAGCTTCGCGAATAGGCAGGGCGCAGTATTCTCGGGGGGCTCTCTAGTGAAGGAGCAGTGGATAGTCACTGCC  
CGGCAGTGTCTTCTCTCCAGCAGTATCTTCCGCTCTCACCGGCTATGAGGTATGGTTGGGCAACCTGTTCCGAAGCCCAAC  
ATGAGAGCGAGGCTCAGCGCGGTCCGAGTAGCCAGAGTGTCTGTGGGCGCTCAGCCTCTCAGCTGTCTGCTGTCTCAA  
GCTGGAGAGATCTGTGACCTGAAACAGCGCTGTGGCCGTGATCTGCTTGCCTGCGCCTGAATGGTATGTGGTGCCTCCAGG  
ACCAAGTGTGAGATTGTGAGGCGGGGTGAGACCAAGGATACGGTATGACACAGCTCTAATGTGGCTTGTCTGTAATG  
TCATCTCCAAACAGAGATGTAACTAAGCACGAGGACATGTGCGGAGAGCAGAGATGTGCACTGAGGACATGTGGC  
CCTGTGGGGGCTGTGAGGGGGGTGACTACGGGGGCCATCTGCCTGTCTTACCCACAACCTGTGTGGTCTCTGGAAGGA  
ATTAGAATCCCCAAACGAGTATGCGCAAGTGCCTGCGCTGCGCAGCGCTTCTCACAGTGTCTCTGTGTTTGTGGACTGGA  
TTCACAAGGTCTAGAGACTGGGTTAGGCCAGCGCTGACGCCATATCTTGGGGAGAGCAAAACTT

5

**Table 11N. Encoded NOV11c protein sequence (SEQ ID NO:62).**

MGWLP LLLLLL TQCLGVPGQ RSP LND FEVL RGT ELQR LLIQAVVPGPWQ EDVADAEBCAGRCGPLMDCRAFHYNVSSHGCQLLPWTQ  
HSPHTRLRHSGRCDLFEQKDYIACITCMNNGVGYRGTMAITVGGLSQAWSHKFPNDHRYMPTLRNGLEENFCRNPDDGPGPWPCH  
TDTPAVRFQSCGIKSCRSAAWVCNCEIEYRGAVDRTBSGRCQWDLQHPHQHFEYBPGKYVDQGLDNDYCRNPDDGSGERPWCYTDD  
PQIEREFCDLPRCGSEAQPRQEATSVSCFRGKGEGYRGTA NTITAGVPCQRWDAQIPHQHRFTPEKYACKDLRENFCRNPDGSEA  
PWCFTLPRGMVRGPFYCYIRRCTDDVVRQCGHYGAGEYRGTVSKTRKGVQCSQASAEPTHKQFPTFSPEHAQLEENFCRNPDDG  
SYGFWCYTMDPRTFDFYCALRRACDDQPSILDDPPQVQFEKKGVPKAVRDLQRCSKLRVAGHGFHNSGSPWTSYLRNRQGHQFCCGS  
LVKEQWILTARQCFSSSHMPLTGVEVWLGTLFQNPQHGEPEGLQRVPVAKMLCGPSGSQLVLLKLSRVTLNQRVALICLPPPEWYV  
VPPGTKCEIAGRGETKGTGNDTVLNLVALNLVINSQECN1KXRGHVRSEMCETGLLAPVAGACGGDYGGPLACFTHNCVWLGBIR  
IPNRVRCASRGWPAVFTVRVSEVVDNTHKVMRLG

In vitro, normal human melanocytes require synergistic mitogens, in addition to the common growth factors present in serum, in order to proliferate. The peptide growth factors that confer stimulation are fibroblast growth factors (such as bFGF/FGF2), hepatocyte growth factor/scatter factor (HGF/SF), mast/stem cell factor (M/SCF), endothelins (such as ET-1) and melanotropin (MSH). The proper function of these factors and their cognate receptors is likely to be important in vivo, as all five ligands are produced in the skin, and disruption of their normal function, by elimination due to deletions or mutations, or overproduction due to ectopic expression, disrupts the normal distribution of melanocytes. The synergistic growth factors activate intracellular signal transduction cascades and maintain the intermediate effectors at optimal levels and duration required for nuclear translocation and modification of transcription factors. The consequent induction of immediate-early response genes, such as

cyclins, and subsequent activation of cyclin-dependent kinases (CDK4, CDK6 and CDK2) inactivates the retinoblastoma family of proteins (pRb, p107 and p130, together termed pocket proteins), and releases their suppressive association with E2F transcription factors. Molecular events that disrupt this tight control of pocket proteins and cause their inactivation, increase  
5 E2F transcriptional activity and confer autonomous growth on melanocytes. (10761990)

Organ culture and transplantation experiments in the early 1960s and 1970s have demonstrated that growth and morphogenesis of the epithelium of the mammary gland are controlled by mesenchymal-epithelial interactions. The identification of molecules that provide the essential signals exchanged in mesenchymal-epithelial interactions is an area of  
10 active research. Recent evidence suggests that morphogenic programs of epithelia can be triggered by mesenchymal factors that signal via tyrosine kinase receptors. This review concentrates on the effects of two mesenchymal factors, Hepatocyte Growth Factor/Scatter Factor and neuregulin, on morphogenesis and differentiation of mammary epithelial cells in vitro and signalling pathways involved during morphogenesis of mammary epithelial cells  
15 (10959405).

Increasing evidence indicates that HGF acts as a multifunctional cytokine on different cell types. This review addresses the molecular mechanisms that are responsible for the pleiotropic effects of HGF. HGF binds with high affinity to its specific tyrosine kinase receptor c-met, thereby stimulating not only cell proliferation and differentiation, but also cell  
20 migration and tumorigenesis. The three fundamental principles of medicine-prevention, diagnosis, and therapy-may be benefited by the rational use of HGF. In renal tubular cells, HGF induces mitogenic and morphogenetic responses. In animal models of toxic or ischemic acute renal failure, HGF acts in a renotropic and nephroprotective manner. HGF expression is rapidly up-regulated in the remnant kidney of nephrectomized rats, inducing compensatory  
25 growth. In a mouse model of chronic renal disease, HGF inhibits the progression of tubulointerstitial fibrosis and kidney dysfunction. Increased HGF mRNA transcripts were detected in mesenchymal and tubular epithelial cells of rejecting kidney. In transplanted patients, elevated HGF levels may indicate renal rejection. When HGF is considered as a therapeutic agent in human medicine, for example, to stimulate kidney regeneration after acute  
30 injury, strategies need to be developed to stimulate cell regeneration and differentiation without an induction of tumorigenesis. (10760078)

The protein similarity information, expression pattern, and map location for the NOV11 protein and nucleic acid suggest that NOV11 may have important structural and/or physiological functions characteristic of the hepatocyte growth factor family. Therefore, the

NOV11 nucleic acids and proteins of the invention are useful in potential therapeutic applications implicated in various diseases and disorders described below and/or other pathologies. For example, the NOV11 compositions of the present invention will have efficacy for treatment of patients suffering from various diseases involving blood coagulation, and hepatocellular carcinoma; cancers including but not limited to lung, breast and ovarian cancer; tumor suppression, senescence, growth regulation, modulation of apoptosis, reproductive control and associated disorders of reproduction, endometrial hyperplasia and adenocarcinoma, psychotic and neurological disorders, Alzheimers disease, endocrine disorders, inflammatory disorders, gastro-intestinal disorders and disorders of the respiratory system; hematopoiesis, immunotherapy, immunodeficiency diseases, all inflammatory diseases; cancer therapy; autoimmune diseases; obesity, modulation of myofibroblast development; applications to modulation of wound healing; potential applications to control of angiogenesis muscle disorders, neurologic diseases and/or other pathologies and disorders. The NOV11 nucleic acid encoding hepatocyte growth factor-like protein, and the hepatocyte growth factor-like protein of the invention, or fragments thereof, may further be useful in diagnostic applications, wherein the presence or amount of the nucleic acid or the protein are to be assessed.

## NOV12

A disclosed NOV12 nucleic acid of 1407 nucleotides (also referred to GMAC023940\_A) encoding a novel 26S protease regulatory subunit-like protein is shown in Table 12A. An open reading frame was identified beginning with an ATG initiation codon at nucleotides 58-60 and ending with a TGA codon at nucleotides 1377-1379. Putative untranslated regions upstream from the initiation codon and downstream from the termination codon are underlined in Table 12A, and the start and stop codons are in bold letters.

**Table 12A. NOV12 Nucleotide Sequence (SEQ ID NO:63)**

```

ACTTGAATCATCAACATAAAGAAAAAATGTTAAAAGCTCTCCAGGCCAAGGCAAGATGGGTCAAAGTCA
GAGTGGTGGTCATGGTCCTGGAGGTGGCAAGAAGGATGACAAGGACAAGAAAAAGAAATATGAACCTCCTG
TACCAACTACAGTGGGAAAAAGAAAGAAAAACAAAGGGACCAGATGCTGCCAGCAAACCTGCCACTGGTG
ACACCTCACACTCAGTGCCAGTTAAAATTACTGAGTTAGAGAGAATTAAGACTATCTTCTCATGGAGGA
AGAATTCATTAGAAATCAGGAACAAATGAAACCATTAGAAGAAAAGCAAGAAGGGAAAAGATCAAAGTGG
ATGATCTGAGGGGGACCCCAATGTCTAGTAGGAATCTTGAAGAGATCATTTGATGACAATCATGCCATCGTG
TCTACATCTGTGGGCTCAGAACACTACATCAGCATTCTTTTCAATTTGCAGACAAGGATCTTCTGGAACCTGG
CTGCTCGGTCAGGCTCAACCACAAGGTGCATACCATGATAGGGGTGCTGATGGATGACATGGATCCCCTGG
TCACAGTGATGAAGGTGGAAGGGCCCCCAAGAGACCTATGCAGATACTGGGGGGTTGGACAACCAAATT
CGGGAATTAAGGAATCTGTGGAGCTTCTCTCACCCATCCTGAATATTATGAAGAGATGGGTATAAAGCC
TCCAAAGGGGGTCATTCTCTGTGGTCCACCTGGCACAGGTAAAACCTTGTTAGCCAAAGCAGTAGCAAACC
AAACCTCAGCCACTTTCTTGAGAGTGGTTGGCTCTGAACTTATTGAGAAGTACCTAGGTGATGGGCCAAA
CTCGGACGGGAATTTGTTTCGAGTTGCTGAAGAACGTGCACCGTCCATTGTGTTTATTGATGAAATTGACGC
CATTTGGACAAAAAGATATGACTCCAATTCTGGTGGTGAGAGAGAAATTGAGGAAACAGTTGGAAGTGC
TGAACCACTTGGATGGATTGATTCTAGGGTAGATGTGAAAGCTATCATGGCCACAAACCAAATAGAAACT
TTGGATCCAGCGCTTATCAGACCAGGCCGATTGGCAGGAAGATTGAGTTCCCCCTGCCTGATGAAAAGAC
GAAGAAGCCCATCTTTTCTAGATTCACACAAGCAGGATGACGCTGGCTGATGATGTAACCTGCACGACTTGA

```

TCATGGCTAAAGATGACCTCTCTGGTGCTGACATCAAGGCAGTCTGTACAGAAGCTGGTCTGATGGCCTTA  
 AGAGAACGTAGAATGAAAGTAACAAATGAAGACTTCAAAAAATCTAAAGAAAATGTTCTTTATAAGAAACA  
 GGAAGACACCCCTGAGGGGCTGTATCTCTAGTGAACCTACGGCTGCCATCAGGAAAATG

The disclosed NOV12 nucleic acid sequence, localized to chromosome 12, has 1320 of 1362 bases (96%) identical to a *Homo sapiens* 26S Protease Regulatory Subunit 4 mRNA (GENBANK-ID: HUM26SPSIV) ( $E = 8.6e^{-285}$ ).

A disclosed NOV12 polypeptide (SEQ ID NO:64) encoded by SEQ ID NO:63 is 440 amino acid residues and is presented using the one-letter amino acid code in Table 12B. Signal P, Psort and/or Hydropathy results predict that NOV12 does not contain a signal peptide and is likely to be localized in the nucleus with a certainty of 0.9800.

**Table 12B. Encoded NOV12 protein sequence (SEQ ID NO:64).**

MGQSQSGGHGPGGGKKDDKDKKKKYEPVPTTVGKKKKKTGKPDAAASKLPLVTPHTQCQLKLLKLERIKDY  
 LLMEEEFIRNQEOMKPLEEKQEGKRSKVDDLRTGTPMSVGILEEIIIDNHAIVSTSVGSEHYIISLSPADKD  
 LLEPGCSVRLNHKVTMTIGVLMDDMDPLVTVMKVEKAPQETYADTGGLDNQIREIKESVELPLTHPEYYEE  
 MGIKPPKGVILCGPPGTGKTLAKAVANQTSATFLRVVGSELIQKYLGDGPKLGRELFRVAEERAPSIVFI  
 DEIDAIGTKRYDSNSGGEREIQRTTLELLNQLDGFDSRVDVKAIMATNQIETLDPALIRPGRIGRKIEFPL  
 PDEKTKKPIFQIHTSRMTLADDVTLHDLIMAKDDLSGADIKAVCTEAGLMALRERRRMKVITNEDFKKSKENV  
 LYKKQEDTPEGLYL

The NOV12 amino acid sequence has 414 of 440 amino acid residues (94 %) identical to, and 422 of 440 amino acid residues (95 %) similar to, the 440 amino acid residue 26S Protease Regulatory Subunit 4 protein from *Homo sapiens* (Q03527) ( $E = 6.3e^{-218}$ ). The global sequence homology is 94.545 % amino acid homology and 94.091 % amino acid identity.

NOV12 is expressed in at least the following tissues: parathyroid-tumor, skin, Colon carcinoma, neuroepithelium, lung carcinoma, brain, liver, kidney, neuron, spleen, olfactory, T-cell, cartilage, ovary, heart. In addition, NOV12 is predicted to be expressed in the following tissues because of the expression pattern of a closely related *Mus musculus* 26S protease regulatory subunit homolog (GENBANK-ID: AI325227): parathyroid-tumor, skin, Colon carcinoma, neuroepithelium, lung carcinoma, brain, liver, kidney, neuron, spleen, olfactory, T-cell, cartilage, ovary, heart.

NOV12 also has homology to the amino acid sequences shown in the BLASTP data listed in Table 12C.

**Table 12C. BLAST results for NOV12**

Gene Index/ Identifier	Protein/ Organism	Length (aa)	Identity (%)	Positives (%)	Expect
---------------------------	-------------------	----------------	-----------------	------------------	--------

gi 4506207 ref NP_002793.1	proteasome (prosome,macropain) 26S subunit, ATPase, 1; Proteasome 26S subunit [Homo sapiens]	440	414/440 (94%)	422/440 (95%)	0.0
gi 6679501 ref NP_032973.1	protease (prosome, macropain) 26S subunit, ATPase 1 [Mus musculus]	440	415/440 (94%)	422/440 (95%)	0.0
gi 345717 pir A44468	26S proteasome regulatory chain 4 [validated] [Homo sapiens]	440	413/440 (93%)	421/440 (94%)	0.0
gi 2492516 sp Q90732 PRS4_CHICK	26S PROTEASE REGULATORY SUBUNIT 4 (P26S4) [Gallus gallus]	440	409/440 (92%)	418/440 (94%)	0.0
gi 7301070 gb AAF56205.1  (AE003745)	Pros26.4 gene product [Drosophila melanogaster]	439	379/440 (86%)	406/440 (92%)	0.0

The homology of these sequences is shown graphically in the ClustalW analysis shown in Table 12D.

**Table 12D Information for the ClustalW proteins**

- 1) NOV12 (SEQ ID NO:64)
- 2) gi|4506207|ref|NP\_002793.1| proteasome (prosome,macropain) 26S subunit, ATPase, 1; Proteasome 26S subunit [Homo sapiens] (SEQ ID NO:142)
- 3) gi|6679501|ref|NP\_032973.1| protease (prosome, macropain) 26S subunit, ATPase 1 [Mus musculus] (SEQ ID NO:143)
- 4) gi|345717|pir|A44468 26S proteasome regulatory chain 4 [validated] [Homo sapiens] (SEQ ID NO:144)
- 5) gi|2492516|sp|Q90732|PRS4\_CHICK 26S PROTEASE REGULATORY SUBUNIT 4 (P26S4) [Gallus gallus] (SEQ ID NO:145)
- 6) gi|7301070|gb|AAF56205.1| (AE003745) Pros26.4 gene product [Drosophila melanogaster] (SEQ ID NO:146)

	10	20	30	40	50
NOV 12	.....	.....	.....	.....	.....
gi 4506207	MGQSQSGGHGPGGGKKDDKDKKKKYEPVPVTRVGGKKKKTKGPDAAASKLP				
gi 6679501	MGQSQSGGHGPGGGKKDDKDKKKKYEPVPVTRVGGKKKKTKGPDAAASKLP				
gi 345717	MGQSQSGGHGPGGGKKDDKDKKKKYEPVPVTRVGGKKKKTKGPDAAASKLP				
gi 2492516	MGQSQSGGHGPGGGKKDDKDKKKKYEPVPVTRVGGKKKKTKGPDAAASKLP				
gi 7301070	MGQNS-AQGAGKKDDKDKKKKYEPVPVTRVGGKKRRAKGPDAAMKLP				
	60	70	80	90	100
NOV 12	.....	.....	.....	.....	.....
gi 4506207	LVTPTHQCRLKLLKLERIKDYLLMEEEFIRNQEQMKPLEEKQEEERSKVD				
gi 6679501	LVTPTHQCRLKLLKLERIKDYLLMEEEFIRNQEQMKPLEEKQEEERSKVD				
gi 345717	LVTPTHQCRLKLLKLERIKDYLLMEEEFIRNQEQMKPLEEKQEEERSKVD				
gi 2492516	LVTPTHQCRLKLLKLERIKDYLLMEEEFIRNQEQMKPLEEKQEEERSKVD				
gi 7301070	QVTPHTCRLKLLKLERIKDYLLMEDEFIRNQERIKPDEKNEEERSKVD				
	110	120	130	140	150
NOV 12	.....	.....	.....	.....	.....
gi 4506207	DLRGTPMSVGLLEEIIDNHAIVSTSVGSEHYVLSILSFVDKDLLEPGCSV				
gi 6679501	DLRGTPMSVGLLEEIIDNHAIVSTSVGSEHYVLSILSFVDKDLLEPGCSV				
gi 345717	DLRGTPMSVGLLEEIIDNHAIVSTSVGSEHYVLSILSFVDKDLLEPGCSV				
gi 2492516	DLRGTPMSVGLLEEIIDNHAIVSTSVGSEHYVLSILSFVDKDLLEPGCSV				



gi 7301070	DLRGTPMSVGNLEETIIDDNHAIVSTSVGSEHYVSILSFVDKDLQLEPGCSV
	.....160.....170.....180.....190.....200.....
NOV 12	RLNHKVVHATMIGVLMDDMDPLVTVMKVEKAPQETYADIGGLDNQIQEIKES
gi 4506207	LLNHKVVHAVIGVLMDDTDPLVTVMKVEKAPQETYADIGGLDNQIQEIKES
gi 6679501	LLNHKVVHAVIGVLMDDTDPLVTVMKVEKAPQETYADIGGLDNQIQEIKES
gi 345717	LLNHKVVHAVIGVLMDDTDPLVTVMKVEKAPQETYADIGGLDNQIQEIKES
gi 2492516	LLNHKVVHAVIGVLMDDTDPLVTVMKVEKAPQETYADIGGLDNQIQEIKES
gi 7301070	LLNHKVVHAVVGVLSDDTDPMTVTVMKVEKAPQETYADIGGLDNQIQEIKES
	.....210.....220.....230.....240.....250.....
NOV 12	VELPLTHPEYYEEMGIKPPKGVILCGPPGTGKTLAKAVANQTSATFLRV
gi 4506207	VELPLTHPEYYEEMGIKPPKGVILYGPPTGKTLAKAVANQTSATFLRV
gi 6679501	VELPLTHPEYYEEMGIKPPKGVILYGPPTGKTLAKAVANQTSATFLRV
gi 345717	VELPLTHPEYYEEMGIKPPKGVILYGPPTGKTLAKAVANQTSATFLRV
gi 2492516	VELPLTHPEYYEEMGIKPPKGVILYGPPTGKTLAKAVANQTSATFLRV
gi 7301070	VELPLTHPEYYEEMGIKPPKGVILYGPPTGKTLAKAVANQTSATFLRV
	.....260.....270.....280.....290.....300.....
NOV 12	VGSELIQKYLGDGPKLRELFRVAEERAPSIVFIDEIDAIGTKRYDSNSG
gi 4506207	VGSELIQKYLGDGPKLVRELFRVAEEHAPSIVFIDEIDAIGTKRYDSNSG
gi 6679501	VGSELIQKYLGDGPKLVRELFRVAEEHAPSIVFIDEIDAIGTKRYDSNSG
gi 345717	VGSELIQKYLGDGPKLVRELFRVAEEHAPSIVFIDEIDAIGTKRYDSNSG
gi 2492516	VGSELIQKYLGDGPKLVRELFRVAEEHAPSIVFIDEIDAIGTKRYDSNSG
gi 7301070	VGSELIQKYLGDGPKLVRELFRVAEEHAPSIVFIDEIDAIGTKRYDSNSG
	.....310.....320.....330.....340.....350.....
NOV 12	GEREIQRTMLELLNQLDGFDSRDVKAIMATNCIETLDPALIRPGRIGRK
gi 4506207	GEREIQRTMLELLNQLDGFDSRGDVKVIMATNRIETLDPALIRPGRIDRK
gi 6679501	GEREIQRTMLELLNQLDGFDSRGDVKVIMATNRIETLDPALIRPGRIDRK
gi 345717	GEREIQRTMLELLNQLDGFDSRGDVKVIMATNRIETLDPALIRPGRIDRK
gi 2492516	GEREIQRTMLELLNQLDGFDSRGDVKVIMATNRIETLDPALIRPGRIDRK
gi 7301070	GEREIQRTMLELLNQLDGFDSRGDVKVIMATNRIETLDPALIRPGRIDRK
	.....360.....370.....380.....390.....400.....
NOV 12	IEFPLPDEKTKKRIHQIHTSRMTLADDVTLDDLIMAKDDLSGADIKAVCT
gi 4506207	IEFPLPDEKTKKRIFQIHTSRMTLADDVTLDDLIMAKDDLSGADIKAICT
gi 6679501	IEFPLPDEKTKKRIFQIHTSRMTLADDVTLDDLIMAKDDLSGADIKAICT
gi 345717	IEFPLPDEKTKKRIFQIHTSRMTLADDVTLDDLIMAKDDLSGADIKAICT
gi 2492516	IEFPLPDEKTKKRIFQIHTSRMTLADDVTLDDLIMAKDDLSGADIKAICT
gi 7301070	IEFPLPDEKTKKRIFQIHTSRMTLADDVTLDDLIMAKDDLSGADIKAICT
	.....410.....420.....430.....440.....
NOV 12	EAGLMALRERRRMKVTNEDFKKSKENVLYKKQEGTPEGLYL
gi 4506207	EAGLMALRERRRMKVTNEDFKKSKENVLYKKQEGTPEGLYL
gi 6679501	EAGLMALRERRRMKVTNEDFKKSKENVLYKKQEGTPEGLYL
gi 345717	EAGLMALRERRRMKVTNEDFKKSKENVLYKKQEGTPEGLYL
gi 2492516	EAGLMALRERRRMKVTNEDFKKSKENVLYKKQEGTPEGLYL
gi 7301070	EAGLMALRERRRMKVTNEDFKKSKENVLYKKQEGTPEGLYL

Table 12E and 12F lists the domain description from DOMAIN analysis results against NOV12. This indicates that the NOV12 sequence has properties similar to those of other proteins known to contain these domains.

**Table 12E. Domain Analysis of NOV12**

gnl|Pfam|pfam00004, AAA, ATPase family associated with various cellular activities (AAA). AAA family proteins often perform chaperone-like functions that assist in the assembly, operation, or disassembly of protein complexes. (SEQ ID NO:147)  
 Length = 186 residues, 100.0% aligned  
 Score = 200 bits (509), Expect = 1e-52

```

NOV12  221  GVILCGPPGTGKTLAKAVANQTSATFLRVVGSELIQKYLGDGPKLGRELFRVAERAPS  280
          |++| ||||| ||||| ||||| + | + |||| + || + | || | + | + ||
00004   1    GILLYGPPGTGKTLAKAVAKELGVFFIIBISGSELLSKYVGESEKLVRAFLSLARKSAPC  60

NOV12  281  IVFIDEIDAIGTKRYDSNSGGEREIQRITLLELNQLDGFDSRVDVKAIMATNQIETLDPA  340
          | + ||||| + || | + | | + || + || + | ||| + + |||
00004   61  IIFIDEIDALAPKRGDVGTDVSS--RVNQQLITEMDGFELSNVIVIGATNRPDLDPDA  118

NOV12  341  LIRPGRIGRKIEFPLPDEKTKKPIFQIHTSRMTLADDVTLHDLIMAKDDLSGADIKAVCT  400
          | + ||| | + || |||| + + | + || + | || | ++ ||| + + |
00004  119  LLRPGRFDRRIEVLPLDEEERLEILKIHKKKPLEKVDLDEIARRTPGFGADLALALCR  178

NOV12  401  EAGLMAIR  408
          || | + |
00004  179  EAALRAIR  186
  
```

**Table 12F. Domain Analysis of NOV12**

gnl|Smart|smart00382, AAA, ATPases associated with a variety of cellular activities; AAA - ATPases associated with a variety of cellular activities. This profile/alignment only detects a fraction of this vast family. The poorly conserved N-terminal helix is missing from the alignment. (SEQ ID NO:148)  
 Length = 151 residues, 100.0% aligned  
 Score = 62.4 bits (150), Expect = 5e-11

```

NOV12  218  PPKGVLICGPPGTGKTLAKAVANQTSATFLRVV-----GSELIQK  258
          | + |++ |||| + ||| ||| + | + | + |
00382   1    PGEVVLIVGPPGSGKTTARALARELGPDGGGVYIIDGEDLREEALLQLRLVLVGEDK  60

NOV12  259  YLGDGPKLGRELFRVAERAPSIVFIDEIDAIGTKRYDSNSGGEREIQRITLLELNQLDGF  318
          || + | + | + | ++ + ||| ++ + + ||| |
00382   61  LSGSGGQRIRLALALARKLKPVDVLIIDETISLLDAE-----QEALLLLEELLRLLLL  113

NOV12  319  FDSRVDVKAIMATNQIETLDPALIRPGRIGRKIEFPLPD  357
          + | | || | ||| + | | + |
00382  114  LLKEENVTVIATTNDETDLIPALLRR-RFDRRIVLLRIL  151
  
```

- 5 In eukaryotic cells, the vast majority of proteins in the cytosol and nucleus are degraded via the proteasome-ubiquitin pathway. The 26S proteasome is a huge protein degradation machine of 2.5 MDa, built of approximately 35 different subunits. It contains a proteolytic core complex, the 20S proteasome and one or two 19S regulatory complexes which associate with the termini of the barrel-shaped 20S core. The 19S regulatory complex serves to
- 10 recognize ubiquitylated target proteins and is implicated to have a role in their unfolding and translocation into the interior of the 20S complex where they are degraded into oligopeptides. While much progress has been made in recent years in elucidating the structure, assembly and enzymatic mechanism of the 20S complex, our knowledge of the functional organization of

the 19S regulator is rather limited. Most of its subunits have been identified, but specific functions can be assigned to only a few of them. (10582236)

The ATP/ubiquitin-dependent 26S proteasome is a central regulator of cell cycle progression and stress responses. While investigating the application of peptide aldehyde proteasome inhibitors to block signal-induced IkappaBalpha degradation in human LNCaP prostate carcinoma cells, we observed that persistent inhibition of proteasomal activity signals a potent cell death program. Biochemically, this program included substantial upregulation of PAR-4 (prostate apoptosis response-4), a putative pro-apoptotic effector protein and stabilization of c-jun protein, a potent pro-death effector in certain cells. Also observed was modest downregulation of bcl-XL, a pro-survival effector protein. However, in contrast to some recent reports stable, high level, expression of functional bcl-2 protein in prostate carcinoma cells failed to signal protection against cell death induction by proteasome inhibitors. Also in disagreement to a recent report, no evidence was found for activation of the JNK stress kinase pathway. A role for p53, a protein regulated by the proteasome pathway, was ruled out, since comparable cell death induction by proteasome inhibitors occurred in PC-3 cells that do not express functional p53 protein. These data signify that the ubiquitin/proteasome pathway represents a potential therapeutic target for prostate cancers irrespective of bcl-2 expression or p53 mutations (9879995)

The protein similarity information, expression pattern, and map location for NOV12 suggest that NOV12 may have important structural and/or physiological functions characteristic of the 26S protease regulatory subunit family. Therefore, the NOV12 nucleic acids and proteins of the invention are useful in potential therapeutic applications implicated in various diseases and disorders described below and/or other pathologies. For example, the NOV12 compositions of the present invention will have efficacy for treatment of patients suffering from eye/lens disorders including but not limited to cataract and Aphakia, Alzheimer's disease, neurodegenerative disorders, inflammation and modulation of the immune response, viral pathogenesis, aging-related disorders, neurologic disorders, cancer and/or other pathologies and disorders. The NOV12 nucleic acid encoding 26S protease regulatory subunit-like protein, and the 26S protease regulatory subunit-like protein of the invention, or fragments thereof, may further be useful in diagnostic applications, wherein the presence or amount of the nucleic acid or the protein are to be assessed.

#### **NOVX Nucleic Acids and Polypeptides**

One aspect of the invention pertains to isolated nucleic acid molecules that encode NOVX polypeptides or biologically active portions thereof. Also included in the invention are

nucleic acid fragments sufficient for use as hybridization probes to identify NOVX-encoding nucleic acids (*e.g.*, NOVX mRNAs) and fragments for use as PCR primers for the amplification and/or mutation of NOVX nucleic acid molecules. As used herein, the term “nucleic acid molecule” is intended to include DNA molecules (*e.g.*, cDNA or genomic DNA), RNA molecules (*e.g.*, mRNA), analogs of the DNA or RNA generated using  
5 nucleotide analogs, and derivatives, fragments and homologs thereof. The nucleic acid molecule may be single-stranded or double-stranded, but preferably is comprised double-stranded DNA.

An NOVX nucleic acid can encode a mature NOVX polypeptide. As used herein, a  
10 “mature” form of a polypeptide or protein disclosed in the present invention is the product of a naturally occurring polypeptide or precursor form or proprotein. The naturally occurring polypeptide, precursor or proprotein includes, by way of nonlimiting example, the full-length gene product, encoded by the corresponding gene. Alternatively, it may be defined as the polypeptide, precursor or proprotein encoded by an ORF described herein. The product  
15 “mature” form arises, again by way of nonlimiting example, as a result of one or more naturally occurring processing steps as they may take place within the cell, or host cell, in which the gene product arises. Examples of such processing steps leading to a “mature” form of a polypeptide or protein include the cleavage of the N-terminal methionine residue encoded by the initiation codon of an ORF, or the proteolytic cleavage of a signal peptide or leader  
20 sequence. Thus a mature form arising from a precursor polypeptide or protein that has residues 1 to N, where residue 1 is the N-terminal methionine, would have residues 2 through N remaining after removal of the N-terminal methionine. Alternatively, a mature form arising from a precursor polypeptide or protein having residues 1 to N, in which an N-terminal signal sequence from residue 1 to residue M is cleaved, would have the residues from residue M+1 to  
25 residue N remaining. Further as used herein, a “mature” form of a polypeptide or protein may arise from a step of post-translational modification other than a proteolytic cleavage event. Such additional processes include, by way of non-limiting example, glycosylation, myristoylation or phosphorylation. In general, a mature polypeptide or protein may result from the operation of only one of these processes, or a combination of any of them.

30 The term “probes”, as utilized herein, refers to nucleic acid sequences of variable length, preferably between at least about 10 nucleotides (nt), 100 nt, or as many as approximately, *e.g.*, 6,000 nt, depending upon the specific use. Probes are used in the detection of identical, similar, or complementary nucleic acid sequences. Longer length probes are generally obtained from a natural or recombinant source, are highly specific, and

much slower to hybridize than shorter-length oligomer probes. Probes may be single- or double-stranded and designed to have specificity in PCR, membrane-based hybridization technologies, or ELISA-like technologies.

The term "isolated" nucleic acid molecule, as utilized herein, is one, which is separated from other nucleic acid molecules which are present in the natural source of the nucleic acid. Preferably, an "isolated" nucleic acid is free of sequences which naturally flank the nucleic acid (*i.e.*, sequences located at the 5'- and 3'-termini of the nucleic acid) in the genomic DNA of the organism from which the nucleic acid is derived. For example, in various embodiments, the isolated NOVX nucleic acid molecules can contain less than about 5 kb, 4 kb, 3 kb, 2 kb, 1 kb, 0.5 kb or 0.1 kb of nucleotide sequences which naturally flank the nucleic acid molecule in genomic DNA of the cell/tissue from which the nucleic acid is derived (*e.g.*, brain, heart, liver, spleen, etc.). Moreover, an "isolated" nucleic acid molecule, such as a cDNA molecule, can be substantially free of other cellular material or culture medium when produced by recombinant techniques, or of chemical precursors or other chemicals when chemically synthesized.

A nucleic acid molecule of the invention, *e.g.*, a nucleic acid molecule having the nucleotide sequence SEQ ID NOS:1, 3, 5, 7, 9, 11, 13, 15, 17, 19, 21, 23, 25, 27, 29, 31, 33, 35, 37, 39, 41, 43, 45, 47, 49, 51, 53, 55, 57, 59, 61 and 63, or a complement of this aforementioned nucleotide sequence, can be isolated using standard molecular biology techniques and the sequence information provided herein. Using all or a portion of the nucleic acid sequence of SEQ ID NOS:1, 3, 5, 7, 9, 11, 13, 15, 17, 19, 21, 23, 25, 27, 29, 31, 33, 35, 37, 39, 41, 43, 45, 47, 49, 51, 53, 55, 57, 59, 61 and 63 as a hybridization probe, NOVX molecules can be isolated using standard hybridization and cloning techniques (*e.g.*, as described in Sambrook, *et al.*, (eds.), MOLECULAR CLONING: A LABORATORY MANUAL 2<sup>nd</sup> Ed., Cold Spring Harbor Laboratory Press, Cold Spring Harbor, NY, 1989; and Ausubel, *et al.*, (eds.), CURRENT PROTOCOLS IN MOLECULAR BIOLOGY, John Wiley & Sons, New York, NY, 1993.)

A nucleic acid of the invention can be amplified using cDNA, mRNA or alternatively, genomic DNA, as a template and appropriate oligonucleotide primers according to standard PCR amplification techniques. The nucleic acid so amplified can be cloned into an appropriate vector and characterized by DNA sequence analysis. Furthermore, oligonucleotides corresponding to NOVX nucleotide sequences can be prepared by standard synthetic techniques, *e.g.*, using an automated DNA synthesizer.

As used herein, the term "oligonucleotide" refers to a series of linked nucleotide residues, which oligonucleotide has a sufficient number of nucleotide bases to be used in a PCR reaction. A short oligonucleotide sequence may be based on, or designed from, a genomic or cDNA sequence and is used to amplify, confirm, or reveal the presence of an identical, similar or complementary DNA or RNA in a particular cell or tissue.

Oligonucleotides comprise portions of a nucleic acid sequence having about 10 nt, 50 nt, or 100 nt in length, preferably about 15 nt to 30 nt in length. In one embodiment of the invention, an oligonucleotide comprising a nucleic acid molecule less than 100 nt in length would further comprise at least 6 contiguous nucleotides SEQ ID NOS:1, 3, 5, 7, 9, 11, 13, 15, 17, 19, 21, 23, 25, 27, 29, 31, 33, 35, 37, 39, 41, 43, 45, 47, 49, 51, 53, 55, 57, 59, 61 and 63, or a complement thereof. Oligonucleotides may be chemically synthesized and may also be used as probes.

In another embodiment, an isolated nucleic acid molecule of the invention comprises a nucleic acid molecule that is a complement of the nucleotide sequence shown in SEQ ID NOS:1, 3, 5, 7, 9, 11, 13, 15, 17, 19, 21, 23, 25, 27, 29, 31, 33, 35, 37, 39, 41, 43, 45, 47, 49, 51, 53, 55, 57, 59, 61 and 63, or a portion of this nucleotide sequence (*e.g.*, a fragment that can be used as a probe or primer or a fragment encoding a biologically-active portion of an NOVX polypeptide). A nucleic acid molecule that is complementary to the nucleotide sequence shown NOS:1, 3, 5, 7, 9, 11, 13, 15, 17, 19, 21, 23, 25, 27, 29, 31, 33, 35, 37, 39, 41, 43, 45, 47, 49, 51, 53, 55, 57, 59, 61 or 63 is one that is sufficiently complementary to the nucleotide sequence shown NOS:1, 3, 5, 7, 9, 11, 13, 15, 17, 19, 21, 23, 25, 27, 29, 31, 33, 35, 37, 39, 41, 43, 45, 47, 49, 51, 53, 55, 57, 59, 61 or 63 that it can hydrogen bond with little or no mismatches to the nucleotide sequence shown SEQ ID NOS:1, 3, 5, 7, 9, 11, 13, 15, 17, 19, 21, 23, 25, 27, 29, 31, 33, 35, 37, 39, 41, 43, 45, 47, 49, 51, 53, 55, 57, 59, 61 and 63, thereby forming a stable duplex.

As used herein, the term "complementary" refers to Watson-Crick or Hoogsteen base pairing between nucleotides units of a nucleic acid molecule, and the term "binding" means the physical or chemical interaction between two polypeptides or compounds or associated polypeptides or compounds or combinations thereof. Binding includes ionic, non-ionic, van der Waals, hydrophobic interactions, and the like. A physical interaction can be either direct or indirect. Indirect interactions may be through or due to the effects of another polypeptide or compound. Direct binding refers to interactions that do not take place through, or due to, the effect of another polypeptide or compound, but instead are without other substantial chemical intermediates.

Fragments provided herein are defined as sequences of at least 6 (contiguous) nucleic acids or at least 4 (contiguous) amino acids, a length sufficient to allow for specific hybridization in the case of nucleic acids or for specific recognition of an epitope in the case of amino acids, respectively, and are at most some portion less than a full length sequence.

- 5 Fragments may be derived from any contiguous portion of a nucleic acid or amino acid sequence of choice. Derivatives are nucleic acid sequences or amino acid sequences formed from the native compounds either directly or by modification or partial substitution. Analogs are nucleic acid sequences or amino acid sequences that have a structure similar to, but not identical to, the native compound but differs from it in respect to certain components or side
- 10 chains. Analogs may be synthetic or from a different evolutionary origin and may have a similar or opposite metabolic activity compared to wild type. Homologs are nucleic acid sequences or amino acid sequences of a particular gene that are derived from different species.

- Derivatives and analogs may be full length or other than full length, if the derivative or analog contains a modified nucleic acid or amino acid, as described below. Derivatives or
- 15 analogs of the nucleic acids or proteins of the invention include, but are not limited to, molecules comprising regions that are substantially homologous to the nucleic acids or proteins of the invention, in various embodiments, by at least about 70%, 80%, or 95% identity (with a preferred identity of 80-95%) over a nucleic acid or amino acid sequence of identical size or when compared to an aligned sequence in which the alignment is done by a
- 20 computer homology program known in the art, or whose encoding nucleic acid is capable of hybridizing to the complement of a sequence encoding the aforementioned proteins under stringent, moderately stringent, or low stringent conditions. *See e.g.* Ausubel, *et al.*, CURRENT PROTOCOLS IN MOLECULAR BIOLOGY, John Wiley & Sons, New York, NY, 1993, and below.

- A "homologous nucleic acid sequence" or "homologous amino acid sequence," or
- 25 variations thereof, refer to sequences characterized by a homology at the nucleotide level or amino acid level as discussed above. Homologous nucleotide sequences encode those sequences coding for isoforms of NOVX polypeptides. Isoforms can be expressed in different tissues of the same organism as a result of, for example, alternative splicing of RNA. Alternatively, isoforms can be encoded by different genes. In the invention, homologous
- 30 nucleotide sequences include nucleotide sequences encoding for an NOVX polypeptide of species other than humans, including, but not limited to: vertebrates, and thus can include, *e.g.*, frog, mouse, rat, rabbit, dog, cat cow, horse, and other organisms. Homologous nucleotide sequences also include, but are not limited to, naturally occurring allelic variations and mutations of the nucleotide sequences set forth herein. A homologous nucleotide sequence

does not, however, include the exact nucleotide sequence encoding human NOVX protein. Homologous nucleic acid sequences include those nucleic acid sequences that encode conservative amino acid substitutions (see below) in SEQ ID NOS:1, 3, 5, 7, 9, 11, 13, 15, 17, 19, 21, 23, 25, 27, 29, 31, 33, 35, 37, 39, 41, 43, 45, 47, 49, 51, 53, 55, 57, 59, 61 and 63, as well as a polypeptide possessing NOVX biological activity. Various biological activities of the NOVX proteins are described below.

An NOVX polypeptide is encoded by the open reading frame ("ORF") of an NOVX nucleic acid. An ORF corresponds to a nucleotide sequence that could potentially be translated into a polypeptide. A stretch of nucleic acids comprising an ORF is uninterrupted by a stop codon. An ORF that represents the coding sequence for a full protein begins with an ATG "start" codon and terminates with one of the three "stop" codons, namely, TAA, TAG, or TGA. For the purposes of this invention, an ORF may be any part of a coding sequence, with or without a start codon, a stop codon, or both. For an ORF to be considered as a good candidate for coding for a *bona fide* cellular protein, a minimum size requirement is often set, e.g., a stretch of DNA that would encode a protein of 50 amino acids or more.

The nucleotide sequences determined from the cloning of the human NOVX genes allows for the generation of probes and primers designed for use in identifying and/or cloning NOVX homologues in other cell types, e.g. from other tissues, as well as NOVX homologues from other vertebrates. The probe/primer typically comprises substantially purified oligonucleotide. The oligonucleotide typically comprises a region of nucleotide sequence that hybridizes under stringent conditions to at least about 12, 25, 50, 100, 150, 200, 250, 300, 350 or 400 consecutive sense strand nucleotide sequence SEQ ID NOS:1, 3, 5, 7, 9, 11, 13, 15, 17, 19, 21, 23, 25, 27, 29, 31, 33, 35, 37, 39, 41, 43, 45, 47, 49, 51, 53, 55, 57, 59, 61 and 63; or an anti-sense strand nucleotide sequence of SEQ ID NOS:1, 3, 5, 7, 9, 11, 13, 15, 17, 19, 21, 23, 25, 27, 29, 31, 33, 35, 37, 39, 41, 43, 45, 47, 49, 51, 53, 55, 57, 59, 61 and 63; or of a naturally occurring mutant of SEQ ID NOS:1, 3, 5, 7, 9, 11, 13, 15, 17, 19, 21, 23, 25, 27, 29, 31, 33, 35, 37, 39, 41, 43, 45, 47, 49, 51, 53, 55, 57, 59, 61 and 63.

Probes based on the human NOVX nucleotide sequences can be used to detect transcripts or genomic sequences encoding the same or homologous proteins. In various embodiments, the probe further comprises a label group attached thereto, e.g. the label group can be a radioisotope, a fluorescent compound, an enzyme, or an enzyme co-factor. Such probes can be used as a part of a diagnostic test kit for identifying cells or tissues which mis-express an NOVX protein, such as by measuring a level of an NOVX-encoding nucleic acid in



a sample of cells from a subject *e.g.*, detecting NOVX mRNA levels or determining whether a genomic NOVX gene has been mutated or deleted.

“A polypeptide having a biologically-active portion of an NOVX polypeptide” refers to polypeptides exhibiting activity similar, but not necessarily identical to, an activity of a polypeptide of the invention, including mature forms, as measured in a particular biological assay, with or without dose dependency. A nucleic acid fragment encoding a "biologically-active portion of NOVX" can be prepared by isolating a portion SEQ ID NOS:1, 3, 5, 7, 9, 11, 13, 15, 17, 19, 21, 23, 25, 27, 29, 31, 33, 35, 37, 39, 41, 43, 45, 47, 49, 51, 53, 55, 57, 59, 61 and 63, that encodes a polypeptide having an NOVX biological activity (the biological activities of the NOVX proteins are described below), expressing the encoded portion of NOVX protein (*e.g.*, by recombinant expression *in vitro*) and assessing the activity of the encoded portion of NOVX.

### **NOVX Nucleic Acid and Polypeptide Variants**

The invention further encompasses nucleic acid molecules that differ from the nucleotide sequences shown in SEQ ID NOS:1, 3, 5, 7, 9, 11, 13, 15, 17, 19, 21, 23, 25, 27, 29, 31, 33, 35, 37, 39, 41, 43, 45, 47, 49, 51, 53, 55, 57, 59, 61 and 63 due to degeneracy of the genetic code and thus encode the same NOVX proteins as that encoded by the nucleotide sequences shown in SEQ ID NOS:1, 3, 5, 7, 9, 11, 13, 15, 17, 19, 21, 23, 25, 27, 29, 31, 33, 35, 37, 39, 41, 43, 45, 47, 49, 51, 53, 55, 57, 59, 61 and 63. In another embodiment, an isolated nucleic acid molecule of the invention has a nucleotide sequence encoding a protein having an amino acid sequence shown in SEQ ID NOS:2, 4, 6, 8, 10, 12, 14, 16, 18, 20, 22, 24, 26, 28, 30, 32, 34, 36, 38, 40, 42, 44, 46, 48, 50, 52, 54, 56, 58, 60, 62 and 64.

In addition to the human NOVX nucleotide sequences shown in SEQ ID NOS:1, 3, 5, 7, 9, 11, 13, 15, 17, 19, 21, 23, 25, 27, 29, 31, 33, 35, 37, 39, 41, 43, 45, 47, 49, 51, 53, 55, 57, 59, 61 and 63, it will be appreciated by those skilled in the art that DNA sequence polymorphisms that lead to changes in the amino acid sequences of the NOVX polypeptides may exist within a population (*e.g.*, the human population). Such genetic polymorphism in the NOVX genes may exist among individuals within a population due to natural allelic variation. As used herein, the terms "gene" and "recombinant gene" refer to nucleic acid molecules comprising an open reading frame (ORF) encoding an NOVX protein, preferably a vertebrate NOVX protein. Such natural allelic variations can typically result in 1-5% variance in the nucleotide sequence of the NOVX genes. Any and all such nucleotide variations and resulting amino acid polymorphisms in the NOVX polypeptides, which are the result of natural allelic

variation and that do not alter the functional activity of the NOVX polypeptides, are intended to be within the scope of the invention.

Moreover, nucleic acid molecules encoding NOVX proteins from other species, and thus that have a nucleotide sequence that differs from the human SEQ ID NOS:1, 3, 5, 7, 9, 11, 13, 15, 17, 19, 21, 23, 25, 27, 29, 31, 33, 35, 37, 39, 41, 43, 45, 47, 49, 51, 53, 55, 57, 59, 61 and 63 are intended to be within the scope of the invention. Nucleic acid molecules corresponding to natural allelic variants and homologues of the NOVX cDNAs of the invention can be isolated based on their homology to the human NOVX nucleic acids disclosed herein using the human cDNAs, or a portion thereof, as a hybridization probe according to standard hybridization techniques under stringent hybridization conditions.

Accordingly, in another embodiment, an isolated nucleic acid molecule of the invention is at least 6 nucleotides in length and hybridizes under stringent conditions to the nucleic acid molecule comprising the nucleotide sequence of SEQ ID NOS:1, 3, 5, 7, 9, 11, 13, 15, 17, 19, 21, 23, 25, 27, 29, 31, 33, 35, 37, 39, 41, 43, 45, 47, 49, 51, 53, 55, 57, 59, 61 and 63. In another embodiment, the nucleic acid is at least 10, 25, 50, 100, 250, 500, 750, 1000, 1500, or 2000 or more nucleotides in length. In yet another embodiment, an isolated nucleic acid molecule of the invention hybridizes to the coding region. As used herein, the term "hybridizes under stringent conditions" is intended to describe conditions for hybridization and washing under which nucleotide sequences at least 60% homologous to each other typically remain hybridized to each other.

Homologs (*i.e.*, nucleic acids encoding NOVX proteins derived from species other than human) or other related sequences (*e.g.*, paralogs) can be obtained by low, moderate or high stringency hybridization with all or a portion of the particular human sequence as a probe using methods well known in the art for nucleic acid hybridization and cloning.

As used herein, the phrase "stringent hybridization conditions" refers to conditions under which a probe, primer or oligonucleotide will hybridize to its target sequence, but to no other sequences. Stringent conditions are sequence-dependent and will be different in different circumstances. Longer sequences hybridize specifically at higher temperatures than shorter sequences. Generally, stringent conditions are selected to be about 5 °C lower than the thermal melting point (T<sub>m</sub>) for the specific sequence at a defined ionic strength and pH. The T<sub>m</sub> is the temperature (under defined ionic strength, pH and nucleic acid concentration) at which 50% of the probes complementary to the target sequence hybridize to the target sequence at equilibrium. Since the target sequences are generally present at excess, at T<sub>m</sub>, 50% of the probes are occupied at equilibrium. Typically, stringent conditions will be those in

which the salt concentration is less than about 1.0 M sodium ion, typically about 0.01 to 1.0 M sodium ion (or other salts) at

pH 7.0 to 8.3 and the temperature is at least about 30°C for short probes, primers or

oligonucleotides (*e.g.*, 10 nt to 50 nt) and at least about 60°C for longer probes, primers and

5 oligonucleotides. Stringent conditions may also be achieved with the addition of destabilizing agents, such as formamide.

Stringent conditions are known to those skilled in the art and can be found in Ausubel, *et al.*, (eds.), CURRENT PROTOCOLS IN MOLECULAR BIOLOGY, John Wiley & Sons, N.Y.

(1989), 6.3.1-6.3.6. Preferably, the conditions are such that sequences at least about 65%,

10 70%, 75%, 85%, 90%, 95%, 98%, or 99% homologous to each other typically remain

hybridized to each other. A non-limiting example of stringent hybridization conditions are

hybridization in a high salt buffer comprising 6X SSC, 50 mM Tris-HCl (pH 7.5), 1 mM

EDTA, 0.02% PVP, 0.02% Ficoll, 0.02% BSA, and 500 mg/ml denatured salmon sperm DNA at 65°C, followed by one or more washes in 0.2X SSC, 0.01% BSA at 50°C. An isolated

15 nucleic acid molecule of the invention that hybridizes under stringent conditions to the sequences SEQ ID NOS:1, 3, 5, 7, 9, 11, 13, 15, 17, 19, 21, 23, 25, 27, 29, 31, 33, 35, 37, 39, 41, 43, 45, 47, 49, 51, 53, 55, 57, 59, 61 and 63, corresponds to a naturally-occurring nucleic acid molecule. As used herein, a "naturally-occurring" nucleic acid molecule refers to an RNA or DNA molecule having a nucleotide sequence that occurs in nature (*e.g.*, encodes a  
20 natural protein).

In a second embodiment, a nucleic acid sequence that is hybridizable to the nucleic acid molecule comprising the nucleotide sequence of SEQ ID NOS:1, 3, 5, 7, 9, 11, 13, 15, 17, 19, 21, 23, 25, 27, 29, 31, 33, 35, 37, 39, 41, 43, 45, 47, 49, 51, 53, 55, 57, 59, 61 and 63, or fragments, analogs or derivatives thereof, under conditions of moderate stringency is provided.

25 A non-limiting example of moderate stringency hybridization conditions are hybridization in 6X SSC, 5X Denhardt's solution, 0.5% SDS and 100 mg/ml denatured salmon sperm DNA at 55°C, followed by one or more washes in 1X SSC, 0.1% SDS at 37°C. Other conditions of moderate stringency that may be used are well-known within the art. *See, e.g.*, Ausubel, *et al.* (eds.), 1993, CURRENT PROTOCOLS IN MOLECULAR BIOLOGY, John Wiley & Sons, NY, and  
30 Kriegler, 1990; GENE TRANSFER AND EXPRESSION, A LABORATORY MANUAL, Stockton Press, NY.

In a third embodiment, a nucleic acid that is hybridizable to the nucleic acid molecule comprising the nucleotide sequences SEQ ID NOS:1, 3, 5, 7, 9, 11, 13, 15, 17, 19, 21, 23, 25, 27, 29, 31, 33, 35, 37, 39, 41, 43, 45, 47, 49, 51, 53, 55, 57, 59, 61 and 63, or fragments,

analogous or derivatives thereof, under conditions of low stringency, is provided. A non-limiting example of low stringency hybridization conditions are hybridization in 35% formamide, 5X SSC, 50 mM Tris-HCl (pH 7.5), 5 mM EDTA, 0.02% PVP, 0.02% Ficoll, 0.2% BSA, 100 mg/ml denatured salmon sperm DNA, 10% (wt/vol) dextran sulfate at 40°C, followed by one  
5 or more washes in 2X SSC, 25 mM Tris-HCl (pH 7.4), 5 mM EDTA, and 0.1% SDS at 50°C. Other conditions of low stringency that may be used are well known in the art (e.g., as employed for cross-species hybridizations). See, e.g., Ausubel, *et al.* (eds.), 1993, CURRENT PROTOCOLS IN MOLECULAR BIOLOGY, John Wiley & Sons, NY, and Kriegler, 1990, GENE TRANSFER AND EXPRESSION, A LABORATORY MANUAL, Stockton Press, NY; Shilo and  
10 Weinberg, 1981. *Proc Natl Acad Sci USA* 78: 6789-6792.

### Conservative Mutations

In addition to naturally-occurring allelic variants of NOVX sequences that may exist in the population, the skilled artisan will further appreciate that changes can be introduced by  
15 mutation into the nucleotide sequences SEQ ID NOS:1, 3, 5, 7, 9, 11, 13, 15, 17, 19, 21, 23, 25, 27, 29, 31, 33, 35, 37, 39, 41, 43, 45, 47, 49, 51, 53, 55, 57, 59, 61 and 63, thereby leading to changes in the amino acid sequences of the encoded NOVX proteins, without altering the functional ability of said NOVX proteins. For example, nucleotide substitutions leading to amino acid substitutions at "non-essential" amino acid residues can be made in the sequence  
20 SEQ ID NOS:2, 4, 6, 8, 10, 12, 14, 16, 18, 20, 22, 24, 26, 28, 30, 32, 34, 36, 38, 40, 42, 44, 46, 48, 50, 52, 54, 56, 58, 60, 62 and 64. A "non-essential" amino acid residue is a residue that can be altered from the wild-type sequences of the NOVX proteins without altering their biological activity, whereas an "essential" amino acid residue is required for such biological activity. For example, amino acid residues that are conserved among the NOVX proteins of  
25 the invention are predicted to be particularly non-amenable to alteration. Amino acids for which conservative substitutions can be made are well-known within the art.

Another aspect of the invention pertains to nucleic acid molecules encoding NOVX proteins that contain changes in amino acid residues that are not essential for activity. Such NOVX proteins differ in amino acid sequence from SEQ ID NOS:1, 3, 5, 7, 9, 11, 13, 15, 17,  
30 19, 21, 23, 25, 27, 29, 31, 33, 35, 37, 39, 41, 43, 45, 47, 49, 51, 53, 55, 57, 59, 61 and 63 yet retain biological activity. In one embodiment, the isolated nucleic acid molecule comprises a nucleotide sequence encoding a protein, wherein the protein comprises an amino acid sequence at least about 45% homologous to the amino acid sequences SEQ ID NOS:2, 4, 6, 8, 10, 12, 14, 16, 18, 20, 22, 24, 26, 28, 30, 32, 34, 36, 38, 40, 42, 44, 46, 48, 50, 52, 54, 56, 58,

60, 62 and 64. Preferably, the protein encoded by the nucleic acid molecule is at least about 60% homologous to SEQ ID NOS:2, 4, 6, 8, 10, 12, 14, 16, 18, 20, 22, 24, 26, 28, 30, 32, 34, 36, 38, 40, 42, 44, 46, 48, 50, 52, 54, 56, 58, 60, 62 and 64; more preferably at least about 70% homologous SEQ ID NOS:2, 4, 6, 8, 10, 12, 14, 16, 18, 20, 22, 24, 26, 28, 30, 32, 34, 36, 38, 40, 42, 44, 46, 48, 50, 52, 54, 56, 58, 60, 62 and 64; still more preferably at least about 80% homologous to SEQ ID NOS:2, 4, 6, 8, 10, 12, 14, 16, 18, 20, 22, 24, 26, 28, 30, 32, 34, 36, 38, 40, 42, 44, 46, 48, 50, 52, 54, 56, 58, 60, 62 and 64; even more preferably at least about 90% homologous to SEQ ID NOS:2, 4, 6, 8, 10, 12, 14, 16, 18, 20, 22, 24, 26, 28, 30, 32, 34, 36, 38, 40, 42, 44, 46, 48, 50, 52, 54, 56, 58, 60, 62 and 64; and most preferably at least about 95% homologous to SEQ ID NOS:2, 4, 6, 8, 10, 12, 14, 16, 18, 20, 22, 24, 26, 28, 30, 32, 34, 36, 38, 40, 42, 44, 46, 48, 50, 52, 54, 56, 58, 60, 62 and 64.

An isolated nucleic acid molecule encoding an NOVX protein homologous to the protein of SEQ ID NOS:2, 4, 6, 8, 10, 12, 14, 16, 18, 20, 22, 24, 26, 28, 30, 32, 34, 36, 38, 40, 42, 44, 46, 48, 50, 52, 54, 56, 58, 60, 62 and 64 can be created by introducing one or more nucleotide substitutions, additions or deletions into the nucleotide sequence of SEQ ID NOS:1, 3, 5, 7, 9, 11, 13, 15, 17, 19, 21, 23, 25, 27, 29, 31, 33, 35, 37, 39, 41, 43, 45, 47, 49, 51, 53, 55, 57, 59, 61 and 63, such that one or more amino acid substitutions, additions or deletions are introduced into the encoded protein.

Mutations can be introduced into SEQ ID NOS:1, 3, 5, 7, 9, 11, 13, 15, 17, 19, 21, 23, 25, 27, 29, 31, 33, 35, 37, 39, 41, 43, 45, 47, 49, 51, 53, 55, 57, 59, 61 and 63 by standard techniques, such as site-directed mutagenesis and PCR-mediated mutagenesis. Preferably, conservative amino acid substitutions are made at one or more predicted, non-essential amino acid residues. A "conservative amino acid substitution" is one in which the amino acid residue is replaced with an amino acid residue having a similar side chain. Families of amino acid residues having similar side chains have been defined within the art. These families include amino acids with basic side chains (*e.g.*, lysine, arginine, histidine), acidic side chains (*e.g.*, aspartic acid, glutamic acid), uncharged polar side chains (*e.g.*, glycine, asparagine, glutamine, serine, threonine, tyrosine, cysteine), nonpolar side chains (*e.g.*, alanine, valine, leucine, isoleucine, proline, phenylalanine, methionine, tryptophan), beta-branched side chains (*e.g.*, threonine, valine, isoleucine) and aromatic side chains (*e.g.*, tyrosine, phenylalanine, tryptophan, histidine). Thus, a predicted non-essential amino acid residue in the NOVX protein is replaced with another amino acid residue from the same side chain family. Alternatively, in another embodiment, mutations can be introduced randomly along all or part of an NOVX coding sequence, such as by saturation mutagenesis, and the resultant mutants

can be screened for NOVX biological activity to identify mutants that retain activity.

Following mutagenesis SEQ ID NOS:1, 3, 5, 7, 9, 11, 13, 15, 17, 19, 21, 23, 25, 27, 29, 31, 33, 35, 37, 39, 41, 43, 45, 47, 49, 51, 53, 55, 57, 59, 61 and 63, the encoded protein can be expressed by any recombinant technology known in the art and the activity of the protein can be determined.

The relatedness of amino acid families may also be determined based on side chain interactions. Substituted amino acids may be fully conserved "strong" residues or fully conserved "weak" residues. The "strong" group of conserved amino acid residues may be any one of the following groups: STA, NEQK, NHQK, NDEQ, QHRK, MILV, MILF, HY, FYW, wherein the single letter amino acid codes are grouped by those amino acids that may be substituted for each other. Likewise, the "weak" group of conserved residues may be any one of the following: CSA, ATV, SAG, STNK, STPA, SGND, SNDEQK, NDEQHK, NEQHRK, VLIM, HFY, wherein the letters within each group represent the single letter amino acid code.

In one embodiment, a mutant NOVX protein can be assayed for (i) the ability to form protein:protein interactions with other NOVX proteins, other cell-surface proteins, or biologically-active portions thereof, (ii) complex formation between a mutant NOVX protein and an NOVX ligand; or (iii) the ability of a mutant NOVX protein to bind to an intracellular target protein or biologically-active portion thereof; (e.g. avidin proteins).

In yet another embodiment, a mutant NOVX protein can be assayed for the ability to regulate a specific biological function (e.g., regulation of insulin release).

#### Antisense Nucleic Acids

Another aspect of the invention pertains to isolated antisense nucleic acid molecules that are hybridizable to or complementary to the nucleic acid molecule comprising the nucleotide sequence of SEQ ID NOS:1, 3, 5, 7, 9, 11, 13, 15, 17, 19, 21, 23, 25, 27, 29, 31, 33, 35, 37, 39, 41, 43, 45, 47, 49, 51, 53, 55, 57, 59, 61 and 63, or fragments, analogs or derivatives thereof. An "antisense" nucleic acid comprises a nucleotide sequence that is complementary to a "sense" nucleic acid encoding a protein (e.g., complementary to the coding strand of a double-stranded cDNA molecule or complementary to an mRNA sequence). In specific aspects, antisense nucleic acid molecules are provided that comprise a sequence complementary to at least about 10, 25, 50, 100, 250 or 500 nucleotides or an entire NOVX coding strand, or to only a portion thereof. Nucleic acid molecules encoding fragments, homologs, derivatives and analogs of an NOVX protein of SEQ ID NOS:2, 4, 6, 8, 10, 12, 14, 16, 18, 20, 22, 24, 26, 28, 30, 32, 34, 36, 38, 40, 42, 44, 46, 48, 50, 52, 54, 56, 58, 60, 62 and 64, or antisense nucleic acids complementary to an NOVX nucleic acid sequence of

SEQ ID NOS:1, 3, 5, 7, 9, 11, 13, 15, 17, 19, 21, 23, 25, 27, 29, 31, 33, 35, 37, 39, 41, 43, 45, 47, 49, 51, 53, 55, 57, 59, 61 and 63, are additionally provided.

In one embodiment, an antisense nucleic acid molecule is antisense to a "coding region" of the coding strand of a nucleotide sequence encoding an NOVX protein. The term "coding region" refers to the region of the nucleotide sequence comprising codons which are translated into amino acid residues. In another embodiment, the antisense nucleic acid molecule is antisense to a "noncoding region" of the coding strand of a nucleotide sequence encoding the NOVX protein. The term "noncoding region" refers to 5' and 3' sequences which flank the coding region that are not translated into amino acids (*i.e.*, also referred to as 5' and 3' untranslated regions).

Given the coding strand sequences encoding the NOVX protein disclosed herein, antisense nucleic acids of the invention can be designed according to the rules of Watson and Crick or Hoogsteen base pairing. The antisense nucleic acid molecule can be complementary to the entire coding region of NOVX mRNA, but more preferably is an oligonucleotide that is antisense to only a portion of the coding or noncoding region of NOVX mRNA. For example, the antisense oligonucleotide can be complementary to the region surrounding the translation start site of NOVX mRNA. An antisense oligonucleotide can be, for example, about 5, 10, 15, 20, 25, 30, 35, 40, 45 or 50 nucleotides in length. An antisense nucleic acid of the invention can be constructed using chemical synthesis or enzymatic ligation reactions using procedures known in the art. For example, an antisense nucleic acid (*e.g.*, an antisense oligonucleotide) can be chemically synthesized using naturally-occurring nucleotides or variously modified nucleotides designed to increase the biological stability of the molecules or to increase the physical stability of the duplex formed between the antisense and sense nucleic acids (*e.g.*, phosphorothioate derivatives and acridine substituted nucleotides can be used).

Examples of modified nucleotides that can be used to generate the antisense nucleic acid include: 5-fluorouracil, 5-bromouracil, 5-chlorouracil, 5-iodouracil, hypoxanthine, xanthine, 4-acetylcytosine, 5-(carboxyhydroxymethyl) uracil, 5-carboxymethylaminomethyl-2-thiouridine, 5-carboxymethylaminomethyluracil, dihydrouracil, beta-D-galactosylqueosine, inosine, N6-isopentenyladenine, 1-methylguanine, 1-methylinosine, 2,2-dimethylguanine, 2-methyladenine, 2-methylguanine, 3-methylcytosine, 5-methylcytosine, N6-adenine, 7-methylguanine, 5-methylaminomethyluracil, 5-methoxyaminomethyl-2-thiouracil, beta-D-mannosylqueosine, 5'-methoxycarboxymethyluracil, 5-methoxyuracil, 2-methylthio-N6-isopentenyladenine, uracil-5-oxyacetic acid (v), wybutoxosine, pseudouracil, queosine, 2-thiocytosine, 5-methyl-2-thiouracil, 2-thiouracil, 4-thiouracil, 5-methyluracil,

uracil-5-oxyacetic acid methylester, uracil-5-oxyacetic acid (v), 5-methyl-2-thiouracil, 3-(3-amino-3-N-2-carboxypropyl) uracil, (acp3)w, and 2,6-diaminopurine. Alternatively, the antisense nucleic acid can be produced biologically using an expression vector into which a nucleic acid has been subcloned in an antisense orientation (*i.e.*, RNA transcribed from the inserted nucleic acid will be of an antisense orientation to a target nucleic acid of interest, described further in the following subsection).

The antisense nucleic acid molecules of the invention are typically administered to a subject or generated *in situ* such that they hybridize with or bind to cellular mRNA and/or genomic DNA encoding an NOVX protein to thereby inhibit expression of the protein (*e.g.*, by inhibiting transcription and/or translation). The hybridization can be by conventional nucleotide complementarity to form a stable duplex, or, for example, in the case of an antisense nucleic acid molecule that binds to DNA duplexes, through specific interactions in the major groove of the double helix. An example of a route of administration of antisense nucleic acid molecules of the invention includes direct injection at a tissue site. Alternatively, antisense nucleic acid molecules can be modified to target selected cells and then administered systemically. For example, for systemic administration, antisense molecules can be modified such that they specifically bind to receptors or antigens expressed on a selected cell surface (*e.g.*, by linking the antisense nucleic acid molecules to peptides or antibodies that bind to cell surface receptors or antigens). The antisense nucleic acid molecules can also be delivered to cells using the vectors described herein. To achieve sufficient nucleic acid molecules, vector constructs in which the antisense nucleic acid molecule is placed under the control of a strong pol II or pol III promoter are preferred.

In yet another embodiment, the antisense nucleic acid molecule of the invention is an  $\alpha$ -anomeric nucleic acid molecule. An  $\alpha$ -anomeric nucleic acid molecule forms specific double-stranded hybrids with complementary RNA in which, contrary to the usual  $\beta$ -units, the strands run parallel to each other. *See, e.g.*, Gaultier, *et al.*, 1987. *Nucl. Acids Res.* 15: 6625-6641. The antisense nucleic acid molecule can also comprise a 2'-o-methylribonucleotide (*See, e.g.*, Inoue, *et al.* 1987. *Nucl. Acids Res.* 15: 6131-6148) or a chimeric RNA-DNA analogue (*See, e.g.*, Inoue, *et al.*, 1987. *FEBS Lett.* 215: 327-330).



**Ribozymes and PNA Moieties**

Nucleic acid modifications include, by way of non-limiting example, modified bases, and nucleic acids whose sugar phosphate backbones are modified or derivatized. These modifications are carried out at least in part to enhance the chemical stability of the modified  
5 nucleic acid, such that they may be used, for example, as antisense binding nucleic acids in therapeutic applications in a subject.

In one embodiment, an antisense nucleic acid of the invention is a ribozyme. Ribozymes are catalytic RNA molecules with ribonuclease activity that are capable of cleaving a single-stranded nucleic acid, such as an mRNA, to which they have a  
10 complementary region. Thus, ribozymes (*e.g.*, hammerhead ribozymes as described in Haselhoff and Gerlach 1988. *Nature* 334: 585-591) can be used to catalytically cleave NOVX mRNA transcripts to thereby inhibit translation of NOVX mRNA. A ribozyme having specificity for an NOVX-encoding nucleic acid can be designed based upon the nucleotide sequence of an NOVX cDNA disclosed herein (*i.e.*, SEQ ID NOS:1, 3, 5, 7, 9, 11, 13, 15, 17,  
15 19, 21, 23, 25, 27, 29, 31, 33, 35, 37, 39, 41, 43, 45, 47, 49, 51, 53, 55, 57, 59, 61 and 63). For example, a derivative of a *Tetrahymena* L-19 IVS RNA can be constructed in which the nucleotide sequence of the active site is complementary to the nucleotide sequence to be cleaved in an NOVX-encoding mRNA. *See, e.g.*, U.S. Patent 4,987,071 to Cech, *et al.* and U.S. Patent 5,116,742 to Cech, *et al.* NOVX mRNA can also be used to select a catalytic  
20 RNA having a specific ribonuclease activity from a pool of RNA molecules. *See, e.g.*, Bartel *et al.*, (1993) *Science* 261:1411-1418.

Alternatively, NOVX gene expression can be inhibited by targeting nucleotide sequences complementary to the regulatory region of the NOVX nucleic acid (*e.g.*, the NOVX promoter and/or enhancers) to form triple helical structures that prevent transcription of the  
25 NOVX gene in target cells. *See, e.g.*, Helene, 1991. *Anticancer Drug Des.* 6: 569-84; Helene, *et al.* 1992. *Ann. N.Y. Acad. Sci.* 660: 27-36; Maher, 1992. *Bioassays* 14: 807-15.

In various embodiments, the NOVX nucleic acids can be modified at the base moiety, sugar moiety or phosphate backbone to improve, *e.g.*, the stability, hybridization, or solubility of the molecule. For example, the deoxyribose phosphate backbone of the nucleic acids can  
30 be modified to generate peptide nucleic acids. *See, e.g.*, Hyrup, *et al.*, 1996. *Bioorg Med Chem* 4: 5-23. As used herein, the terms "peptide nucleic acids" or "PNAs" refer to nucleic acid mimics (*e.g.*, DNA mimics) in which the deoxyribose phosphate backbone is replaced by a pseudopeptide backbone and only the four natural nucleobases are retained. The neutral backbone of PNAs has been shown to allow for specific hybridization to DNA and RNA under

conditions of low ionic strength. The synthesis of PNA oligomers can be performed using standard solid phase peptide synthesis protocols as described in Hyrup, *et al.*, 1996. *supra*; Perry-O'Keefe, *et al.*, 1996. *Proc. Natl. Acad. Sci. USA* 93: 14670-14675.

PNAs of NOVX can be used in therapeutic and diagnostic applications. For example, 5 PNAs can be used as antisense or antigene agents for sequence-specific modulation of gene expression by, *e.g.*, inducing transcription or translation arrest or inhibiting replication. PNAs of NOVX can also be used, for example, in the analysis of single base pair mutations in a gene (*e.g.*, PNA directed PCR clamping; as artificial restriction enzymes when used in combination with other enzymes, *e.g.*, S<sub>I</sub> nucleases (*See*, Hyrup, *et al.*, 1996. *supra*); or as probes or primers 10 for DNA sequence and hybridization (*See*, Hyrup, *et al.*, 1996, *supra*; Perry-O'Keefe, *et al.*, 1996. *supra*).

In another embodiment, PNAs of NOVX can be modified, *e.g.*, to enhance their stability or cellular uptake, by attaching lipophilic or other helper groups to PNA, by the formation of PNA-DNA chimeras, or by the use of liposomes or other techniques of drug 15 delivery known in the art. For example, PNA-DNA chimeras of NOVX can be generated that may combine the advantageous properties of PNA and DNA. Such chimeras allow DNA recognition enzymes (*e.g.*, RNase H and DNA polymerases) to interact with the DNA portion while the PNA portion would provide high binding affinity and specificity. PNA-DNA chimeras can be linked using linkers of appropriate lengths selected in terms of base stacking, 20 number of bonds between the nucleobases, and orientation (*see*, Hyrup, *et al.*, 1996. *supra*). The synthesis of PNA-DNA chimeras can be performed as described in Hyrup, *et al.*, 1996. *supra* and Finn, *et al.*, 1996. *Nucl Acids Res* 24: 3357-3363. For example, a DNA chain can be synthesized on a solid support using standard phosphoramidite coupling chemistry, and modified nucleoside analogs, *e.g.*, 5'-(4-methoxytrityl)amino-5'-deoxy-thymidine 25 phosphoramidite, can be used between the PNA and the 5' end of DNA. *See, e.g.*, Mag, *et al.*, 1989. *Nucl Acid Res* 17: 5973-5988. PNA monomers are then coupled in a stepwise manner to produce a chimeric molecule with a 5' PNA segment and a 3' DNA segment. *See, e.g.*, Finn, *et al.*, 1996. *supra*. Alternatively, chimeric molecules can be synthesized with a 5' DNA segment and a 3' PNA segment. *See, e.g.*, Petersen, *et al.*, 1975. *Bioorg. Med. Chem. Lett.* 5: 30 1119-11124.

In other embodiments, the oligonucleotide may include other appended groups such as peptides (*e.g.*, for targeting host cell receptors *in vivo*), or agents facilitating transport across the cell membrane (*see, e.g.*, Letsinger, *et al.*, 1989. *Proc. Natl. Acad. Sci. U.S.A.* 86: 6553-6556; Lemaitre, *et al.*, 1987. *Proc. Natl. Acad. Sci.* 84: 648-652; PCT Publication No.

WO88/09810) or the blood-brain barrier (*see, e.g.*, PCT Publication No. WO 89/10134). In addition, oligonucleotides can be modified with hybridization triggered cleavage agents (*see, e.g.*, Krol, *et al.*, 1988. *BioTechniques* 6:958-976) or intercalating agents (*see, e.g.*, Zon, 1988. *Pharm. Res.* 5: 539-549). To this end, the oligonucleotide may be conjugated to another molecule, *e.g.*, a peptide, a hybridization triggered cross-linking agent, a transport agent, a hybridization-triggered cleavage agent, and the like.

### NOVX Polypeptides

A polypeptide according to the invention includes a polypeptide including the amino acid sequence of NOVX polypeptides whose sequences are provided in SEQ ID NOS:2, 4, 6, 8, 10, 12, 14, 16, 18, 20, 22, 24, 26, 28, 30, 32, 34, 36, 38, 40, 42, 44, 46, 48, 50, 52, 54, 56, 58, 60, 62 and 64. The invention also includes a mutant or variant protein any of whose residues may be changed from the corresponding residues shown in SEQ ID NOS:2, 4, 6, 8, 10, 12, 14, 16, 18, 20, 22, 24, 26, 28, 30, 32, 34, 36, 38, 40, 42, 44, 46, 48, 50, 52, 54, 56, 58, 60, 62 and 64 while still encoding a protein that maintains its NOVX activities and physiological functions, or a functional fragment thereof.

In general, an NOVX variant that preserves NOVX-like function includes any variant in which residues at a particular position in the sequence have been substituted by other amino acids, and further include the possibility of inserting an additional residue or residues between two residues of the parent protein as well as the possibility of deleting one or more residues from the parent sequence. Any amino acid substitution, insertion, or deletion is encompassed by the invention. In favorable circumstances, the substitution is a conservative substitution as defined above.

One aspect of the invention pertains to isolated NOVX proteins, and biologically-active portions thereof, or derivatives, fragments, analogs or homologs thereof. Also provided are polypeptide fragments suitable for use as immunogens to raise anti-NOVX antibodies. In one embodiment, native NOVX proteins can be isolated from cells or tissue sources by an appropriate purification scheme using standard protein purification techniques. In another embodiment, NOVX proteins are produced by recombinant DNA techniques. Alternative to recombinant expression, an NOVX protein or polypeptide can be synthesized chemically using standard peptide synthesis techniques.

An "isolated" or "purified" polypeptide or protein or biologically-active portion thereof is substantially free of cellular material or other contaminating proteins from the cell or tissue source from which the NOVX protein is derived, or substantially free from chemical precursors or other chemicals when chemically synthesized. The language "substantially free

of cellular material" includes preparations of NOVX proteins in which the protein is separated from cellular components of the cells from which it is isolated or recombinantly-produced. In one embodiment, the language "substantially free of cellular material" includes preparations of NOVX proteins having less than about 30% (by dry weight) of non-NOVX proteins (also referred to herein as a "contaminating protein"), more preferably less than about 20% of non-NOVX proteins, still more preferably less than about 10% of non-NOVX proteins, and most preferably less than about 5% of non-NOVX proteins. When the NOVX protein or biologically-active portion thereof is recombinantly-produced, it is also preferably substantially free of culture medium, *i.e.*, culture medium represents less than about 20%, more preferably less than about 10%, and most preferably less than about 5% of the volume of the NOVX protein preparation.

The language "substantially free of chemical precursors or other chemicals" includes preparations of NOVX proteins in which the protein is separated from chemical precursors or other chemicals that are involved in the synthesis of the protein. In one embodiment, the language "substantially free of chemical precursors or other chemicals" includes preparations of NOVX proteins having less than about 30% (by dry weight) of chemical precursors or non-NOVX chemicals, more preferably less than about 20% chemical precursors or non-NOVX chemicals, still more preferably less than about 10% chemical precursors or non-NOVX chemicals, and most preferably less than about 5% chemical precursors or non-NOVX chemicals.

Biologically-active portions of NOVX proteins include peptides comprising amino acid sequences sufficiently homologous to or derived from the amino acid sequences of the NOVX proteins (*e.g.*, the amino acid sequence shown in SEQ ID NOS:2, 4, 6, 8, 10, 12, 14, 16, 18, 20, 22, 24, 26, 28, 30, 32, 34, 36, 38, 40, 42, 44, 46, 48, 50, 52, 54, 56, 58, 60, 62 and 64) that include fewer amino acids than the full-length NOVX proteins, and exhibit at least one activity of an NOVX protein. Typically, biologically-active portions comprise a domain or motif with at least one activity of the NOVX protein. A biologically-active portion of an NOVX protein can be a polypeptide which is, for example, 10, 25, 50, 100 or more amino acid residues in length.

Moreover, other biologically-active portions, in which other regions of the protein are deleted, can be prepared by recombinant techniques and evaluated for one or more of the functional activities of a native NOVX protein.

In an embodiment, the NOVX protein has an amino acid sequence shown SEQ ID NOS:2, 4, 6, 8, 10, 12, 14, 16, 18, 20, 22, 24, 26, 28, 30, 32, 34, 36, 38, 40, 42, 44, 46, 48, 50,

52, 54, 56, 58, 60, 62 and 64. In other embodiments, the NOVX protein is substantially homologous to SEQ ID NOS:2, 4, 6, 8, 10, 12, 14, 16, 18, 20, 22, 24, 26, 28, 30, 32, 34, 36, 38, 40, 42, 44, 46, 48, 50, 52, 54, 56, 58, 60, 62 and 64, and retains the functional activity of the protein of SEQ ID NOS:2, 4, 6, 8, 10, 12, 14, 16, 18, 20, 22, 24, 26, 28, 30, 32, 34, 36, 38, 40, 42, 44, 46, 48, 50, 52, 54, 56, 58, 60, 62 and 64, yet differs in amino acid sequence due to natural allelic variation or mutagenesis, as described in detail, below. Accordingly, in another embodiment, the NOVX protein is a protein that comprises an amino acid sequence at least about 45% homologous to the amino acid sequence SEQ ID NOS:2, 4, 6, 8, 10, 12, 14, 16, 18, 20, 22, 24, 26, 28, 30, 32, 34, 36, 38, 40, 42, 44, 46, 48, 50, 52, 54, 56, 58, 60, 62 and 64, and retains the functional activity of the NOVX proteins of SEQ ID NOS:2, 4, 6, 8, 10, 12, 14, 16, 18, 20, 22, 24, 26, 28, 30, 32, 34, 36, 38, 40, 42, 44, 46, 48, 50, 52, 54, 56, 58, 60, 62 and 64.

### Determining Homology Between Two or More Sequences

To determine the percent homology of two amino acid sequences or of two nucleic acids, the sequences are aligned for optimal comparison purposes (*e.g.*, gaps can be introduced in the sequence of a first amino acid or nucleic acid sequence for optimal alignment with a second amino or nucleic acid sequence). The amino acid residues or nucleotides at corresponding amino acid positions or nucleotide positions are then compared. When a position in the first sequence is occupied by the same amino acid residue or nucleotide as the corresponding position in the second sequence, then the molecules are homologous at that position (*i.e.*, as used herein amino acid or nucleic acid "homology" is equivalent to amino acid or nucleic acid "identity").

The nucleic acid sequence homology may be determined as the degree of identity between two sequences. The homology may be determined using computer programs known in the art, such as GAP software provided in the GCG program package. *See*, Needleman and Wunsch, 1970. *J Mol Biol* 48: 443-453. Using GCG GAP software with the following settings for nucleic acid sequence comparison: GAP creation penalty of 5.0 and GAP extension penalty of 0.3, the coding region of the analogous nucleic acid sequences referred to above exhibits a degree of identity preferably of at least 70%, 75%, 80%, 85%, 90%, 95%, 98%, or 99%, with the CDS (encoding) part of the DNA sequence shown in SEQ ID NOS:1, 3, 5, 7, 9, 11, 13, 15, 17, 19, 21, 23, 25, 27, 29, 31, 33, 35, 37, 39, 41, 43, 45, 47, 49, 51, 53, 55, 57, 59, 61 and 63.

The term "sequence identity" refers to the degree to which two polynucleotide or polypeptide sequences are identical on a residue-by-residue basis over a particular region of comparison. The term "percentage of sequence identity" is calculated by comparing two

optimally aligned sequences over that region of comparison, determining the number of positions at which the identical nucleic acid base (*e.g.*, A, T, C, G, U, or I, in the case of nucleic acids) occurs in both sequences to yield the number of matched positions, dividing the number of matched positions by the total number of positions in the region of comparison (*i.e.*, the window size), and multiplying the result by 100 to yield the percentage of sequence identity. The term "substantial identity" as used herein denotes a characteristic of a polynucleotide sequence, wherein the polynucleotide comprises a sequence that has at least 80 percent sequence identity, preferably at least 85 percent identity and often 90 to 95 percent sequence identity, more usually at least 99 percent sequence identity as compared to a reference sequence over a comparison region.

### Chimeric and Fusion Proteins

The invention also provides NOVX chimeric or fusion proteins. As used herein, an NOVX "chimeric protein" or "fusion protein" comprises an NOVX polypeptide operatively-linked to a non-NOVX polypeptide. An "NOVX polypeptide" refers to a polypeptide having an amino acid sequence corresponding to an NOVX protein SEQ ID NOS:2, 4, 6, 8, 10, 12, 14, 16, 18, 20, 22, 24, 26, 28, 30, 32, 34, 36, 38, 40, 42, 44, 46, 48, 50, 52, 54, 56, 58, 60, 62 and 64, whereas a "non-NOVX polypeptide" refers to a polypeptide having an amino acid sequence corresponding to a protein that is not substantially homologous to the NOVX protein, *e.g.*, a protein that is different from the NOVX protein and that is derived from the same or a different organism. Within an NOVX fusion protein the NOVX polypeptide can correspond to all or a portion of an NOVX protein. In one embodiment, an NOVX fusion protein comprises at least one biologically-active portion of an NOVX protein. In another embodiment, an NOVX fusion protein comprises at least two biologically-active portions of an NOVX protein. In yet another embodiment, an NOVX fusion protein comprises at least three biologically-active portions of an NOVX protein. Within the fusion protein, the term "operatively-linked" is intended to indicate that the NOVX polypeptide and the non-NOVX polypeptide are fused in-frame with one another. The non-NOVX polypeptide can be fused to the N-terminus or C-terminus of the NOVX polypeptide.

In one embodiment, the fusion protein is a GST-NOVX fusion protein in which the NOVX sequences are fused to the C-terminus of the GST (glutathione S-transferase) sequences. Such fusion proteins can facilitate the purification of recombinant NOVX polypeptides.

In another embodiment, the fusion protein is an NOVX protein containing a heterologous signal sequence at its N-terminus. In certain host cells (*e.g.*, mammalian host

cells), expression and/or secretion of NOVX can be increased through use of a heterologous signal sequence.

In yet another embodiment, the fusion protein is an NOVX-immunoglobulin fusion protein in which the NOVX sequences are fused to sequences derived from a member of the immunoglobulin protein family. The NOVX-immunoglobulin fusion proteins of the invention can be incorporated into pharmaceutical compositions and administered to a subject to inhibit an interaction between an NOVX ligand and an NOVX protein on the surface of a cell, to thereby suppress NOVX-mediated signal transduction *in vivo*. The NOVX-immunoglobulin fusion proteins can be used to affect the bioavailability of an NOVX cognate ligand.

Inhibition of the NOVX ligand/NOVX interaction may be useful therapeutically for both the treatment of proliferative and differentiative disorders, as well as modulating (*e.g.* promoting or inhibiting) cell survival. Moreover, the NOVX-immunoglobulin fusion proteins of the invention can be used as immunogens to produce anti-NOVX antibodies in a subject, to purify NOVX ligands, and in screening assays to identify molecules that inhibit the interaction of NOVX with an NOVX ligand.

An NOVX chimeric or fusion protein of the invention can be produced by standard recombinant DNA techniques. For example, DNA fragments coding for the different polypeptide sequences are ligated together in-frame in accordance with conventional techniques, *e.g.*, by employing blunt-ended or stagger-ended termini for ligation, restriction enzyme digestion to provide for appropriate termini, filling-in of cohesive ends as appropriate, alkaline phosphatase treatment to avoid undesirable joining, and enzymatic ligation. In another embodiment, the fusion gene can be synthesized by conventional techniques including automated DNA synthesizers. Alternatively, PCR amplification of gene fragments can be carried out using anchor primers that give rise to complementary overhangs between two consecutive gene fragments that can subsequently be annealed and reamplified to generate a chimeric gene sequence (*see, e.g.*, Ausubel, *et al.* (eds.) CURRENT PROTOCOLS IN MOLECULAR BIOLOGY, John Wiley & Sons, 1992). Moreover, many expression vectors are commercially available that already encode a fusion moiety (*e.g.*, a GST polypeptide). An NOVX-encoding nucleic acid can be cloned into such an expression vector such that the fusion moiety is linked in-frame to the NOVX protein.

#### **NOVX Agonists and Antagonists**

The invention also pertains to variants of the NOVX proteins that function as either NOVX agonists (*i.e.*, mimetics) or as NOVX antagonists. Variants of the NOVX protein can be generated by mutagenesis (*e.g.*, discrete point mutation or truncation of the NOVX protein).

An agonist of the NOVX protein can retain substantially the same, or a subset of, the biological activities of the naturally occurring form of the NOVX protein. An antagonist of the NOVX protein can inhibit one or more of the activities of the naturally occurring form of the NOVX protein by, for example, competitively binding to a downstream or upstream member of a cellular signaling cascade which includes the NOVX protein. Thus, specific biological effects can be elicited by treatment with a variant of limited function. In one embodiment, treatment of a subject with a variant having a subset of the biological activities of the naturally occurring form of the protein has fewer side effects in a subject relative to treatment with the naturally occurring form of the NOVX proteins.

10 Variants of the NOVX proteins that function as either NOVX agonists (*i.e.*, mimetics) or as NOVX antagonists can be identified by screening combinatorial libraries of mutants (*e.g.*, truncation mutants) of the NOVX proteins for NOVX protein agonist or antagonist activity. In one embodiment, a variegated library of NOVX variants is generated by combinatorial mutagenesis at the nucleic acid level and is encoded by a variegated gene library. A variegated library of NOVX variants can be produced by, for example, enzymatically ligating a mixture of synthetic oligonucleotides into gene sequences such that a degenerate set of potential NOVX sequences is expressible as individual polypeptides, or alternatively, as a set of larger fusion proteins (*e.g.*, for phage display) containing the set of NOVX sequences therein. There are a variety of methods which can be used to produce libraries of potential NOVX variants from a degenerate oligonucleotide sequence. Chemical synthesis of a degenerate gene sequence can be performed in an automatic DNA synthesizer, and the synthetic gene then ligated into an appropriate expression vector. Use of a degenerate set of genes allows for the provision, in one mixture, of all of the sequences encoding the desired set of potential NOVX sequences. Methods for synthesizing degenerate oligonucleotides are well-known within the art. *See, e.g.*, Narang, 1983. *Tetrahedron* 39: 3; Itakura, *et al.*, 1984. *Annu. Rev. Biochem.* 53: 323; Itakura, *et al.*, 1984. *Science* 198: 1056; Ike, *et al.*, 1983. *Nucl. Acids Res.* 11: 477.

### Polypeptide Libraries

30 In addition, libraries of fragments of the NOVX protein coding sequences can be used to generate a variegated population of NOVX fragments for screening and subsequent selection of variants of an NOVX protein. In one embodiment, a library of coding sequence fragments can be generated by treating a double stranded PCR fragment of an NOVX coding sequence with a nuclease under conditions wherein nicking occurs only about once per molecule, denaturing the double stranded DNA, renaturing the DNA to form double-stranded



DNA that can include sense/antisense pairs from different nicked products, removing single stranded portions from reformed duplexes by treatment with  $S_1$  nuclease, and ligating the resulting fragment library into an expression vector. By this method, expression libraries can be derived which encodes N-terminal and internal fragments of various sizes of the NOVX proteins.

Various techniques are known in the art for screening gene products of combinatorial libraries made by point mutations or truncation, and for screening cDNA libraries for gene products having a selected property. Such techniques are adaptable for rapid screening of the gene libraries generated by the combinatorial mutagenesis of NOVX proteins. The most widely used techniques, which are amenable to high throughput analysis, for screening large gene libraries typically include cloning the gene library into replicable expression vectors, transforming appropriate cells with the resulting library of vectors, and expressing the combinatorial genes under conditions in which detection of a desired activity facilitates isolation of the vector encoding the gene whose product was detected. Recursive ensemble mutagenesis (REM), a new technique that enhances the frequency of functional mutants in the libraries, can be used in combination with the screening assays to identify NOVX variants. See, e.g., Arkin and Yourvan, 1992. *Proc. Natl. Acad. Sci. USA* 89: 7811-7815; Delgrave, et al., 1993. *Protein Engineering* 6:327-331.

#### **Anti-NOVX Antibodies**

Also included in the invention are antibodies to NOVX proteins, or fragments of NOVX proteins. The term "antibody" as used herein refers to immunoglobulin molecules and immunologically active portions of immunoglobulin (Ig) molecules, i.e., molecules that contain an antigen binding site that specifically binds (immunoreacts with) an antigen. Such antibodies include, but are not limited to, polyclonal, monoclonal, chimeric, single chain,  $F_{ab}$ ,  $F_{ab}'$  and  $F_{(ab)2}$  fragments, and an  $F_{ab}$  expression library. In general, an antibody molecule obtained from humans relates to any of the classes IgG, IgM, IgA, IgE and IgD, which differ from one another by the nature of the heavy chain present in the molecule. Certain classes have subclasses as well, such as IgG<sub>1</sub>, IgG<sub>2</sub>, and others. Furthermore, in humans, the light chain may be a kappa chain or a lambda chain. Reference herein to antibodies includes a reference to all such classes, subclasses and types of human antibody species.

An isolated NOVX-related protein of the invention may be intended to serve as an antigen, or a portion or fragment thereof, and additionally can be used as an immunogen to generate antibodies that immunospecifically bind the antigen, using standard techniques for polyclonal and monoclonal antibody preparation. The full-length protein can be used or,

alternatively, the invention provides antigenic peptide fragments of the antigen for use as immunogens. An antigenic peptide fragment comprises at least 6 amino acid residues of the amino acid sequence of the full length protein and encompasses an epitope thereof such that an antibody raised against the peptide forms a specific immune complex with the full length  
5 protein or with any fragment that contains the epitope. Preferably, the antigenic peptide comprises at least 10 amino acid residues, or at least 15 amino acid residues, or at least 20 amino acid residues, or at least 30 amino acid residues. Preferred epitopes encompassed by the antigenic peptide are regions of the protein that are located on its surface; commonly these are hydrophilic regions.

10 In certain embodiments of the invention, at least one epitope encompassed by the antigenic peptide is a region of NOVX-related protein that is located on the surface of the protein, *e.g.*, a hydrophilic region. A hydrophobicity analysis of the human NOVX-related protein sequence will indicate which regions of a NOVX-related protein are particularly hydrophilic and, therefore, are likely to encode surface residues useful for targeting antibody  
15 production. As a means for targeting antibody production, hydropathy plots showing regions of hydrophilicity and hydrophobicity may be generated by any method well known in the art, including, for example, the Kyte Doolittle or the Hopp Woods methods, either with or without Fourier transformation. See, *e.g.*, Hopp and Woods, 1981, *Proc. Nat. Acad. Sci. USA* 78: 3824-3828; Kyte and Doolittle 1982, *J. Mol. Biol.* 157: 105-142, each of which is incorporated  
20 herein by reference in its entirety. Antibodies that are specific for one or more domains within an antigenic protein, or derivatives, fragments, analogs or homologs thereof, are also provided herein.

A protein of the invention, or a derivative, fragment, analog, homolog or ortholog thereof, may be utilized as an immunogen in the generation of antibodies that  
25 immunospecifically bind these protein components.

Various procedures known within the art may be used for the production of polyclonal or monoclonal antibodies directed against a protein of the invention, or against derivatives, fragments, analogs homologs or orthologs thereof (see, for example, *Antibodies: A Laboratory Manual*, Harlow and Lane, 1988, Cold Spring Harbor Laboratory Press, Cold Spring Harbor,  
30 NY, incorporated herein by reference). Some of these antibodies are discussed below.

### **Polyclonal Antibodies**

For the production of polyclonal antibodies, various suitable host animals (*e.g.*, rabbit, goat, mouse or other mammal) may be immunized by one or more injections with the native protein, a synthetic variant thereof, or a derivative of the foregoing. An appropriate

immunogenic preparation can contain, for example, the naturally occurring immunogenic protein, a chemically synthesized polypeptide representing the immunogenic protein, or a recombinantly expressed immunogenic protein. Furthermore, the protein may be conjugated to a second protein known to be immunogenic in the mammal being immunized. Examples of such immunogenic proteins include but are not limited to keyhole limpet hemocyanin, serum albumin, bovine thyroglobulin, and soybean trypsin inhibitor. The preparation can further include an adjuvant. Various adjuvants used to increase the immunological response include, but are not limited to, Freund's (complete and incomplete), mineral gels (e.g., aluminum hydroxide), surface active substances (e.g., lysolecithin, pluronic polyols, polyanions, peptides, oil emulsions, dinitrophenol, etc.), adjuvants usable in humans such as Bacille Calmette-Guerin and *Corynebacterium parvum*, or similar immunostimulatory agents. Additional examples of adjuvants which can be employed include MPL-TDM adjuvant (monophosphoryl Lipid A, synthetic trehalose dicorynomycolate).

The polyclonal antibody molecules directed against the immunogenic protein can be isolated from the mammal (e.g., from the blood) and further purified by well known techniques, such as affinity chromatography using protein A or protein G, which provide primarily the IgG fraction of immune serum. Subsequently, or alternatively, the specific antigen which is the target of the immunoglobulin sought, or an epitope thereof, may be immobilized on a column to purify the immune specific antibody by immunoaffinity chromatography. Purification of immunoglobulins is discussed, for example, by D. Wilkinson (The Scientist, published by The Scientist, Inc., Philadelphia PA, Vol. 14, No. 8 (April 17, 2000), pp. 25-28).

### Monoclonal Antibodies

The term "monoclonal antibody" (MAb) or "monoclonal antibody composition", as used herein, refers to a population of antibody molecules that contain only one molecular species of antibody molecule consisting of a unique light chain gene product and a unique heavy chain gene product. In particular, the complementarity determining regions (CDRs) of the monoclonal antibody are identical in all the molecules of the population. MAbs thus contain an antigen binding site capable of immunoreacting with a particular epitope of the antigen characterized by a unique binding affinity for it.

Monoclonal antibodies can be prepared using hybridoma methods, such as those described by Kohler and Milstein, *Nature*, 256:495 (1975). In a hybridoma method, a mouse, hamster, or other appropriate host animal, is typically immunized with an immunizing agent to

elicit lymphocytes that produce or are capable of producing antibodies that will specifically bind to the immunizing agent. Alternatively, the lymphocytes can be immunized in vitro.

The immunizing agent will typically include the protein antigen, a fragment thereof or a fusion protein thereof. Generally, either peripheral blood lymphocytes are used if cells of human origin are desired, or spleen cells or lymph node cells are used if non-human mammalian sources are desired. The lymphocytes are then fused with an immortalized cell line using a suitable fusing agent, such as polyethylene glycol, to form a hybridoma cell (Goding, MONOCLONAL ANTIBODIES: PRINCIPLES AND PRACTICE, Academic Press, (1986) pp. 59-103). Immortalized cell lines are usually transformed mammalian cells, particularly myeloma cells of rodent, bovine and human origin. Usually, rat or mouse myeloma cell lines are employed. The hybridoma cells can be cultured in a suitable culture medium that preferably contains one or more substances that inhibit the growth or survival of the unfused, immortalized cells. For example, if the parental cells lack the enzyme hypoxanthine guanine phosphoribosyl transferase (HGPRT or HPRT), the culture medium for the hybridomas typically will include hypoxanthine, aminopterin, and thymidine ("HAT medium"), which substances prevent the growth of HGPRT-deficient cells.

Preferred immortalized cell lines are those that fuse efficiently, support stable high level expression of antibody by the selected antibody-producing cells, and are sensitive to a medium such as HAT medium. More preferred immortalized cell lines are murine myeloma lines, which can be obtained, for instance, from the Salk Institute Cell Distribution Center, San Diego, California and the American Type Culture Collection, Manassas, Virginia. Human myeloma and mouse-human heteromyeloma cell lines also have been described for the production of human monoclonal antibodies (Kozbor, *J. Immunol.*, 133:3001 (1984); Brodeur et al., MONOCLONAL ANTIBODY PRODUCTION TECHNIQUES AND APPLICATIONS, Marcel Dekker, Inc., New York, (1987) pp. 51-63).

The culture medium in which the hybridoma cells are cultured can then be assayed for the presence of monoclonal antibodies directed against the antigen. Preferably, the binding specificity of monoclonal antibodies produced by the hybridoma cells is determined by immunoprecipitation or by an in vitro binding assay, such as radioimmunoassay (RIA) or enzyme-linked immunoabsorbent assay (ELISA). Such techniques and assays are known in the art. The binding affinity of the monoclonal antibody can, for example, be determined by the Scatchard analysis of Munson and Pollard, *Anal. Biochem.*, 107:220 (1980). Preferably, antibodies having a high degree of specificity and a high binding affinity for the target antigen are isolated.

After the desired hybridoma cells are identified, the clones can be subcloned by limiting dilution procedures and grown by standard methods. Suitable culture media for this purpose include, for example, Dulbecco's Modified Eagle's Medium and RPMI-1640 medium. Alternatively, the hybridoma cells can be grown in vivo as ascites in a mammal.

5       The monoclonal antibodies secreted by the subclones can be isolated or purified from the culture medium or ascites fluid by conventional immunoglobulin purification procedures such as, for example, protein A-Sepharose, hydroxylapatite chromatography, gel electrophoresis, dialysis, or affinity chromatography.

10       The monoclonal antibodies can also be made by recombinant DNA methods, such as those described in U.S. Patent No. 4,816,567. DNA encoding the monoclonal antibodies of the invention can be readily isolated and sequenced using conventional procedures (e.g., by using oligonucleotide probes that are capable of binding specifically to genes encoding the heavy and light chains of murine antibodies). The hybridoma cells of the invention serve as a preferred source of such DNA. Once isolated, the DNA can be placed into expression vectors,  
15       which are then transfected into host cells such as simian COS cells, Chinese hamster ovary (CHO) cells, or myeloma cells that do not otherwise produce immunoglobulin protein, to obtain the synthesis of monoclonal antibodies in the recombinant host cells. The DNA also can be modified, for example, by substituting the coding sequence for human heavy and light chain constant domains in place of the homologous murine sequences (U.S. Patent No.  
20       4,816,567; Morrison, *Nature* 368, 812-13 (1994)) or by covalently joining to the immunoglobulin coding sequence all or part of the coding sequence for a non-immunoglobulin polypeptide. Such a non-immunoglobulin polypeptide can be substituted for the constant domains of an antibody of the invention, or can be substituted for the variable domains of one antigen-combining site of an antibody of the invention to create a chimeric bivalent antibody.

## 25       **Humanized Antibodies**

      The antibodies directed against the protein antigens of the invention can further comprise humanized antibodies or human antibodies. These antibodies are suitable for administration to humans without engendering an immune response by the human against the administered immunoglobulin. Humanized forms of antibodies are chimeric immunoglobulins,  
30       immunoglobulin chains or fragments thereof (such as Fv, Fab, Fab', F(ab')<sub>2</sub> or other antigen-binding subsequences of antibodies) that are principally comprised of the sequence of a human immunoglobulin, and contain minimal sequence derived from a non-human immunoglobulin. Humanization can be performed following the method of Winter and co-workers (Jones et al., *Nature*, 321:522-525 (1986); Riechmann et al., *Nature*, 332:323-327 (1988); Verhoeven et al.,

*Science*, 239:1534-1536 (1988)), by substituting rodent CDRs or CDR sequences for the corresponding sequences of a human antibody. (See also U.S. Patent No. 5,225,539.) In some instances, Fv framework residues of the human immunoglobulin are replaced by corresponding non-human residues. Humanized antibodies can also comprise residues which are found neither in the recipient antibody nor in the imported CDR or framework sequences. In general, the humanized antibody will comprise substantially all of at least one, and typically two, variable domains, in which all or substantially all of the CDR regions correspond to those of a non-human immunoglobulin and all or substantially all of the framework regions are those of a human immunoglobulin consensus sequence. The humanized antibody optimally also will comprise at least a portion of an immunoglobulin constant region (Fc), typically that of a human immunoglobulin (Jones et al., 1986; Riechmann et al., 1988; and Presta, *Curr. Op. Struct. Biol.*, 2:593-596 (1992)).

### Human Antibodies

Fully human antibodies relate to antibody molecules in which essentially the entire sequences of both the light chain and the heavy chain, including the CDRs, arise from human genes. Such antibodies are termed "human antibodies", or "fully human antibodies" herein. Human monoclonal antibodies can be prepared by the trioma technique; the human B-cell hybridoma technique (see Kozbor, et al., 1983 *Immunol Today* 4: 72) and the EBV hybridoma technique to produce human monoclonal antibodies (see Cole, et al., 1985 In: MONOCLONAL ANTIBODIES AND CANCER THERAPY, Alan R. Liss, Inc., pp. 77-96). Human monoclonal antibodies may be utilized in the practice of the present invention and may be produced by using human hybridomas (see Cote, et al., 1983. *Proc Natl Acad Sci USA* 80: 2026-2030) or by transforming human B-cells with Epstein Barr Virus in vitro (see Cole, et al., 1985 In: MONOCLONAL ANTIBODIES AND CANCER THERAPY, Alan R. Liss, Inc., pp. 77-96).

In addition, human antibodies can also be produced using additional techniques, including phage display libraries (Hoogenboom and Winter, *J. Mol. Biol.*, 227:381 (1991); Marks et al., *J. Mol. Biol.*, 222:581 (1991)). Similarly, human antibodies can be made by introducing human immunoglobulin loci into transgenic animals, e.g., mice in which the endogenous immunoglobulin genes have been partially or completely inactivated. Upon challenge, human antibody production is observed, which closely resembles that seen in humans in all respects, including gene rearrangement, assembly, and antibody repertoire. This approach is described, for example, in U.S. Patent Nos. 5,545,807; 5,545,806; 5,569,825; 5,625,126; 5,633,425; 5,661,016, and in Marks et al. (*Bio/Technology* 10, 779-783 (1992)); Lonberg et al. (*Nature* 368 856-859 (1994)); Morrison (*Nature* 368, 812-13 (1994)); Fishwild

et al, (*Nature Biotechnology* 14, 845-51 (1996)); Neuberger (*Nature Biotechnology* 14, 826 (1996)); and Lonberg and Huszar (*Intern. Rev. Immunol.* 13 65-93 (1995)).

Human antibodies may additionally be produced using transgenic nonhuman animals which are modified so as to produce fully human antibodies rather than the animal's  
5 endogenous antibodies in response to challenge by an antigen. (See PCT publication WO94/02602). The endogenous genes encoding the heavy and light immunoglobulin chains in the nonhuman host have been incapacitated, and active loci encoding human heavy and light chain immunoglobulins are inserted into the host's genome. The human genes are incorporated, for example, using yeast artificial chromosomes containing the requisite human  
10 DNA segments. An animal which provides all the desired modifications is then obtained as progeny by crossbreeding intermediate transgenic animals containing fewer than the full complement of the modifications. The preferred embodiment of such a nonhuman animal is a mouse, and is termed the Xenomouse<sup>TM</sup> as disclosed in PCT publications WO 96/33735 and WO 96/34096. This animal produces B cells which secrete fully human immunoglobulins.  
15 The antibodies can be obtained directly from the animal after immunization with an immunogen of interest, as, for example, a preparation of a polyclonal antibody, or alternatively from immortalized B cells derived from the animal, such as hybridomas producing monoclonal antibodies. Additionally, the genes encoding the immunoglobulins with human variable regions can be recovered and expressed to obtain the antibodies directly, or can be  
20 further modified to obtain analogs of antibodies such as, for example, single chain Fv molecules.

An example of a method of producing a nonhuman host, exemplified as a mouse, lacking expression of an endogenous immunoglobulin heavy chain is disclosed in U.S. Patent No. 5,939,598. It can be obtained by a method including deleting the J segment genes from at  
25 least one endogenous heavy chain locus in an embryonic stem cell to prevent rearrangement of the locus and to prevent formation of a transcript of a rearranged immunoglobulin heavy chain locus, the deletion being effected by a targeting vector containing a gene encoding a selectable marker; and producing from the embryonic stem cell a transgenic mouse whose somatic and germ cells contain the gene encoding the selectable marker.

30 A method for producing an antibody of interest, such as a human antibody, is disclosed in U.S. Patent No. 5,916,771. It includes introducing an expression vector that contains a nucleotide sequence encoding a heavy chain into one mammalian host cell in culture, introducing an expression vector containing a nucleotide sequence encoding a light chain into

another mammalian host cell, and fusing the two cells to form a hybrid cell. The hybrid cell expresses an antibody containing the heavy chain and the light chain.

In a further improvement on this procedure, a method for identifying a clinically relevant epitope on an immunogen, and a correlative method for selecting an antibody that  
5 binds immunospecifically to the relevant epitope with high affinity, are disclosed in PCT publication WO 99/53049.

### **F<sub>ab</sub> Fragments and Single Chain Antibodies**

According to the invention, techniques can be adapted for the production of single-chain antibodies specific to an antigenic protein of the invention (see e.g., U.S. Patent  
10 No. 4,946,778). In addition, methods can be adapted for the construction of F<sub>ab</sub> expression libraries (see e.g., Huse, et al., 1989 Science 246: 1275-1281) to allow rapid and effective identification of monoclonal F<sub>ab</sub> fragments with the desired specificity for a protein or derivatives, fragments, analogs or homologs thereof. Antibody fragments that contain the  
15 idiotypes to a protein antigen may be produced by techniques known in the art including, but not limited to: (i) an F<sub>(ab')<sub>2</sub></sub> fragment produced by pepsin digestion of an antibody molecule; (ii) an F<sub>ab</sub> fragment generated by reducing the disulfide bridges of an F<sub>(ab')<sub>2</sub></sub> fragment; (iii) an F<sub>ab</sub> fragment generated by the treatment of the antibody molecule with papain and a reducing agent and (iv) F<sub>v</sub> fragments.

### **Bispecific Antibodies**

20 Bispecific antibodies are monoclonal, preferably human or humanized, antibodies that have binding specificities for at least two different antigens. In the present case, one of the binding specificities is for an antigenic protein of the invention. The second binding target is any other antigen, and advantageously is a cell-surface protein or receptor or receptor subunit.

Methods for making bispecific antibodies are known in the art. Traditionally, the  
25 recombinant production of bispecific antibodies is based on the co-expression of two immunoglobulin heavy-chain/light-chain pairs, where the two heavy chains have different specificities (Milstein and Cuello, *Nature*, 305:537-539 (1983)). Because of the random assortment of immunoglobulin heavy and light chains, these hybridomas (quadromas) produce a potential mixture of ten different antibody molecules, of which only one has the correct  
30 bispecific structure. The purification of the correct molecule is usually accomplished by affinity chromatography steps. Similar procedures are disclosed in WO 93/08829, published 13 May 1993, and in Traunecker *et al.*, 1991 *EMBO J.*, 10:3655-3659.



Antibody variable domains with the desired binding specificities (antibody-antigen combining sites) can be fused to immunoglobulin constant domain sequences. The fusion preferably is with an immunoglobulin heavy-chain constant domain, comprising at least part of the hinge, CH2, and CH3 regions. It is preferred to have the first heavy-chain constant region (CH1) containing the site necessary for light-chain binding present in at least one of the fusions. DNAs encoding the immunoglobulin heavy-chain fusions and, if desired, the immunoglobulin light chain, are inserted into separate expression vectors, and are co-transfected into a suitable host organism. For further details of generating bispecific antibodies see, for example, Suresh et al., *Methods in Enzymology*, 121:210 (1986).

According to another approach described in WO 96/27011, the interface between a pair of antibody molecules can be engineered to maximize the percentage of heterodimers which are recovered from recombinant cell culture. The preferred interface comprises at least a part of the CH3 region of an antibody constant domain. In this method, one or more small amino acid side chains from the interface of the first antibody molecule are replaced with larger side chains (e.g. tyrosine or tryptophan). Compensatory "cavities" of identical or similar size to the large side chain(s) are created on the interface of the second antibody molecule by replacing large amino acid side chains with smaller ones (e.g. alanine or threonine). This provides a mechanism for increasing the yield of the heterodimer over other unwanted end-products such as homodimers.

Bispecific antibodies can be prepared as full length antibodies or antibody fragments (e.g.  $F(ab')_2$  bispecific antibodies). Techniques for generating bispecific antibodies from antibody fragments have been described in the literature. For example, bispecific antibodies can be prepared using chemical linkage. Brennan et al., *Science* 229:81 (1985) describe a procedure wherein intact antibodies are proteolytically cleaved to generate  $F(ab')_2$  fragments. These fragments are reduced in the presence of the dithiol complexing agent sodium arsenite to stabilize vicinal dithiols and prevent intermolecular disulfide formation. The  $Fab'$  fragments generated are then converted to thionitrobenzoate (TNB) derivatives. One of the  $Fab'$ -TNB derivatives is then reconverted to the  $Fab'$ -thiol by reduction with mercaptoethylamine and is mixed with an equimolar amount of the other  $Fab'$ -TNB derivative to form the bispecific antibody. The bispecific antibodies produced can be used as agents for the selective immobilization of enzymes.

Additionally,  $Fab'$  fragments can be directly recovered from *E. coli* and chemically coupled to form bispecific antibodies. Shalaby et al., *J. Exp. Med.* 175:217-225 (1992) describe the production of a fully humanized bispecific antibody  $F(ab')_2$  molecule. Each  $Fab'$

fragment was separately secreted from *E. coli* and subjected to directed chemical coupling in vitro to form the bispecific antibody. The bispecific antibody thus formed was able to bind to cells overexpressing the ErbB2 receptor and normal human T cells, as well as trigger the lytic activity of human cytotoxic lymphocytes against human breast tumor targets.

5 Various techniques for making and isolating bispecific antibody fragments directly from recombinant cell culture have also been described. For example, bispecific antibodies have been produced using leucine zippers. Kostelny et al., *J. Immunol.* 148(5):1547-1553 (1992). The leucine zipper peptides from the Fos and Jun proteins were linked to the Fab' portions of two different antibodies by gene fusion. The antibody homodimers were reduced  
10 at the hinge region to form monomers and then re-oxidized to form the antibody heterodimers. This method can also be utilized for the production of antibody homodimers. The "diabody" technology described by Hollinger et al., *Proc. Natl. Acad. Sci. USA* 90:6444-6448 (1993) has provided an alternative mechanism for making bispecific antibody fragments. The fragments comprise a heavy-chain variable domain (V<sub>H</sub>) connected to a light-chain variable domain (V<sub>L</sub>)  
15 by a linker which is too short to allow pairing between the two domains on the same chain. Accordingly, the V<sub>H</sub> and V<sub>L</sub> domains of one fragment are forced to pair with the complementary V<sub>L</sub> and V<sub>H</sub> domains of another fragment, thereby forming two antigen-binding sites. Another strategy for making bispecific antibody fragments by the use of single-chain Fv (sFv) dimers has also been reported. See, Gruber et al., *J. Immunol.* 152:5368 (1994).

20 Antibodies with more than two valencies are contemplated. For example, trispecific antibodies can be prepared. Tutt et al., *J. Immunol.* 147:60 (1991).

Exemplary bispecific antibodies can bind to two different epitopes, at least one of which originates in the protein antigen of the invention. Alternatively, an anti-antigenic arm of an immunoglobulin molecule can be combined with an arm which binds to a triggering  
25 molecule on a leukocyte such as a T-cell receptor molecule (e.g. CD2, CD3, CD28, or B7), or Fc receptors for IgG (FcγR), such as FcγRI (CD64), FcγRII (CD32) and FcγRIII (CD16) so as to focus cellular defense mechanisms to the cell expressing the particular antigen. Bispecific antibodies can also be used to direct cytotoxic agents to cells which express a particular antigen. These antibodies possess an antigen-binding arm and an arm which binds a cytotoxic  
30 agent or a radionuclide chelator, such as EOTUBE, DPTA, DOTA, or TETA. Another bispecific antibody of interest binds the protein antigen described herein and further binds tissue factor (TF).

## Heteroconjugate Antibodies

Heteroconjugate antibodies are also within the scope of the present invention. Heteroconjugate antibodies are composed of two covalently joined antibodies. Such antibodies have, for example, been proposed to target immune system cells to unwanted cells (U.S. Patent No. 4,676,980), and for treatment of HIV infection (WO 91/00360; WO 92/200373; EP 03089). It is contemplated that the antibodies can be prepared in vitro using known methods in synthetic protein chemistry, including those involving crosslinking agents. For example, immunotoxins can be constructed using a disulfide exchange reaction or by forming a thioether bond. Examples of suitable reagents for this purpose include iminothiolate and methyl-4-mercaptobutyrimidate and those disclosed, for example, in U.S. Patent No. 4,676,980.

## Effector Function Engineering

It can be desirable to modify the antibody of the invention with respect to effector function, so as to enhance, e.g., the effectiveness of the antibody in treating cancer. For example, cysteine residue(s) can be introduced into the Fc region, thereby allowing interchain disulfide bond formation in this region. The homodimeric antibody thus generated can have improved internalization capability and/or increased complement-mediated cell killing and antibody-dependent cellular cytotoxicity (ADCC). See Caron et al., J. Exp Med., 176: 1191-1195 (1992) and Shopes, J. Immunol., 148: 2918-2922 (1992). Homodimeric antibodies with enhanced anti-tumor activity can also be prepared using heterobifunctional cross-linkers as described in Wolff et al. Cancer Research, 53: 2560-2565 (1993). Alternatively, an antibody can be engineered that has dual Fc regions and can thereby have enhanced complement lysis and ADCC capabilities. See Stevenson et al., Anti-Cancer Drug Design, 3: 219-230 (1989).

## Immunoconjugates

The invention also pertains to immunoconjugates comprising an antibody conjugated to a cytotoxic agent such as a chemotherapeutic agent, toxin (e.g., an enzymatically active toxin of bacterial, fungal, plant, or animal origin, or fragments thereof), or a radioactive isotope (i.e., a radioconjugate).

Chemotherapeutic agents useful in the generation of such immunoconjugates have been described above. Enzymatically active toxins and fragments thereof that can be used include diphtheria A chain, nonbinding active fragments of diphtheria toxin, exotoxin A chain (from *Pseudomonas aeruginosa*), ricin A chain, abrin A chain, modeccin A chain, alpha-sarcin, Aleurites fordii proteins, dianthin proteins, Phytolaca americana proteins (PAPI, PAPII, and

PAP-S), momordica charantia inhibitor, curcin, crotin, sapaonaria officinalis inhibitor, gelonin, mitogellin, restrictocin, phenomycin, enomycin, and the tricothecenes. A variety of radionuclides are available for the production of radioconjugated antibodies. Examples include  $^{212}\text{Bi}$ ,  $^{131}\text{I}$ ,  $^{131}\text{In}$ ,  $^{90}\text{Y}$ , and  $^{186}\text{Re}$ .

5           Conjugates of the antibody and cytotoxic agent are made using a variety of bifunctional protein-coupling agents such as N-succinimidyl-3-(2-pyridyldithiol) propionate (SPDP), iminothiolane (IT), bifunctional derivatives of imidoesters (such as dimethyl adipimidate HCL), active esters (such as disuccinimidyl suberate), aldehydes (such as glutaraldehyde), bis-azido compounds (such as bis (p-azidobenzoyl) hexanediamine), bis-  
10   diazonium derivatives (such as bis-(p-diazoniumbenzoyl)-ethylenediamine), diisocyanates (such as tolyene 2,6-diisocyanate), and bis-active fluorine compounds (such as 1,5-difluoro-2,4-dinitrobenzene). For example, a ricin immunotoxin can be prepared as described in Vitetta et al., Science, 238: 1098 (1987). Carbon-14-labeled 1-isothiocyanatobenzyl-3-methyldiethylene triaminepentaacetic acid (MX-DTPA) is an exemplary chelating agent for  
15   conjugation of radionucleotide to the antibody. See WO94/11026.

          In another embodiment, the antibody can be conjugated to a "receptor" (such as streptavidin) for utilization in tumor pretargeting wherein the antibody-receptor conjugate is administered to the patient, followed by removal of unbound conjugate from the circulation using a clearing agent and then administration of a "ligand" (e.g., avidin) that is in turn  
20   conjugated to a cytotoxic agent.

          In one embodiment, methods for the screening of antibodies that possess the desired specificity include, but are not limited to, enzyme-linked immunosorbent assay (ELISA) and other immunologically-mediated techniques known within the art. In a specific embodiment, selection of antibodies that are specific to a particular domain of an NOVX protein is  
25   facilitated by generation of hybridomas that bind to the fragment of an NOVX protein possessing such a domain. Thus, antibodies that are specific for a desired domain within an NOVX protein, or derivatives, fragments, analogs or homologs thereof, are also provided herein.

          Anti-NOVX antibodies may be used in methods known within the art relating to the  
30   localization and/or quantitation of an NOVX protein (e.g., for use in measuring levels of the NOVX protein within appropriate physiological samples, for use in diagnostic methods, for use in imaging the protein, and the like). In a given embodiment, antibodies for NOVX proteins, or derivatives, fragments, analogs or homologs thereof, that contain the antibody

derived binding domain, are utilized as pharmacologically-active compounds (hereinafter "Therapeutics").

An anti-NOVX antibody (*e.g.*, monoclonal antibody) can be used to isolate an NOVX polypeptide by standard techniques, such as affinity chromatography or immunoprecipitation.

5 An anti-NOVX antibody can facilitate the purification of natural NOVX polypeptide from cells and of recombinantly-produced NOVX polypeptide expressed in host cells. Moreover, an anti-NOVX antibody can be used to detect NOVX protein (*e.g.*, in a cellular lysate or cell supernatant) in order to evaluate the abundance and pattern of expression of the NOVX protein. Anti-NOVX antibodies can be used diagnostically to monitor protein levels in tissue  
10 as part of a clinical testing procedure, *e.g.*, to, for example, determine the efficacy of a given treatment regimen. Detection can be facilitated by coupling (*i.e.*, physically linking) the antibody to a detectable substance. Examples of detectable substances include various enzymes, prosthetic groups, fluorescent materials, luminescent materials, bioluminescent materials, and radioactive materials. Examples of suitable enzymes include horseradish  
15 peroxidase, alkaline phosphatase,  $\beta$ -galactosidase, or acetylcholinesterase; examples of suitable prosthetic group complexes include streptavidin/biotin and avidin/biotin; examples of suitable fluorescent materials include umbelliferone, fluorescein, fluorescein isothiocyanate, rhodamine, dichlorotriazinylamine fluorescein, dansyl chloride or phycoerythrin; an example of a luminescent material includes luminol; examples of bioluminescent materials include  
20 luciferase, luciferin, and aequorin, and examples of suitable radioactive material include  $^{125}\text{I}$ ,  $^{131}\text{I}$ ,  $^{35}\text{S}$  or  $^3\text{H}$ .

#### NOVX Recombinant Expression Vectors and Host Cells

Another aspect of the invention pertains to vectors, preferably expression vectors, containing a nucleic acid encoding an NOVX protein, or derivatives, fragments, analogs or  
25 homologs thereof. As used herein, the term "vector" refers to a nucleic acid molecule capable of transporting another nucleic acid to which it has been linked. One type of vector is a "plasmid", which refers to a circular double stranded DNA loop into which additional DNA segments can be ligated. Another type of vector is a viral vector, wherein additional DNA segments can be ligated into the viral genome. Certain vectors are capable of autonomous  
30 replication in a host cell into which they are introduced (*e.g.*, bacterial vectors having a bacterial origin of replication and episomal mammalian vectors). Other vectors (*e.g.*, non-episomal mammalian vectors) are integrated into the genome of a host cell upon introduction into the host cell, and thereby are replicated along with the host genome. Moreover, certain vectors are capable of directing the expression of genes to which they are

operatively-linked. Such vectors are referred to herein as "expression vectors". In general, expression vectors of utility in recombinant DNA techniques are often in the form of plasmids. In the present specification, "plasmid" and "vector" can be used interchangeably as the plasmid is the most commonly used form of vector. However, the invention is intended to  
5 include such other forms of expression vectors, such as viral vectors (*e.g.*, replication defective retroviruses, adenoviruses and adeno-associated viruses), which serve equivalent functions.

The recombinant expression vectors of the invention comprise a nucleic acid of the invention in a form suitable for expression of the nucleic acid in a host cell, which means that the recombinant expression vectors include one or more regulatory sequences, selected on the  
10 basis of the host cells to be used for expression, that is operatively-linked to the nucleic acid sequence to be expressed. Within a recombinant expression vector, "operably-linked" is intended to mean that the nucleotide sequence of interest is linked to the regulatory sequence(s) in a manner that allows for expression of the nucleotide sequence (*e.g.*, in an *in vitro* transcription/translation system or in a host cell when the vector is introduced into the  
15 host cell).

The term "regulatory sequence" is intended to include promoters, enhancers and other expression control elements (*e.g.*, polyadenylation signals). Such regulatory sequences are described, for example, in Goeddel, GENE EXPRESSION TECHNOLOGY: METHODS IN ENZYMOLOGY 185, Academic Press, San Diego, Calif. (1990). Regulatory sequences include  
20 those that direct constitutive expression of a nucleotide sequence in many types of host cell and those that direct expression of the nucleotide sequence only in certain host cells (*e.g.*, tissue-specific regulatory sequences). It will be appreciated by those skilled in the art that the design of the expression vector can depend on such factors as the choice of the host cell to be transformed, the level of expression of protein desired, etc. The expression vectors of the  
25 invention can be introduced into host cells to thereby produce proteins or peptides, including fusion proteins or peptides, encoded by nucleic acids as described herein (*e.g.*, NOVX proteins, mutant forms of NOVX proteins, fusion proteins, etc.).

The recombinant expression vectors of the invention can be designed for expression of NOVX proteins in prokaryotic or eukaryotic cells. For example, NOVX proteins can be  
30 expressed in bacterial cells such as *Escherichia coli*, insect cells (using baculovirus expression vectors) yeast cells or mammalian cells. Suitable host cells are discussed further in Goeddel, GENE EXPRESSION TECHNOLOGY: METHODS IN ENZYMOLOGY 185, Academic Press, San Diego, Calif. (1990). Alternatively, the recombinant expression vector can be transcribed and translated *in vitro*, for example using T7 promoter regulatory sequences and T7 polymerase.

Expression of proteins in prokaryotes is most often carried out in *Escherichia coli* with vectors containing constitutive or inducible promoters directing the expression of either fusion or non-fusion proteins. Fusion vectors add a number of amino acids to a protein encoded therein, usually to the amino terminus of the recombinant protein. Such fusion vectors typically serve three purposes: (i) to increase expression of recombinant protein; (ii) to increase the solubility of the recombinant protein; and (iii) to aid in the purification of the recombinant protein by acting as a ligand in affinity purification. Often, in fusion expression vectors, a proteolytic cleavage site is introduced at the junction of the fusion moiety and the recombinant protein to enable separation of the recombinant protein from the fusion moiety subsequent to purification of the fusion protein. Such enzymes, and their cognate recognition sequences, include Factor Xa, thrombin and enterokinase. Typical fusion expression vectors include pGEX (Pharmacia Biotech Inc; Smith and Johnson, 1988. *Gene* 67: 31-40), pMAL (New England Biolabs, Beverly, Mass.) and pRIT5 (Pharmacia, Piscataway, N.J.) that fuse glutathione S-transferase (GST), maltose E binding protein, or protein A, respectively, to the target recombinant protein.

Examples of suitable inducible non-fusion *E. coli* expression vectors include pTrc (Amrann *et al.*, (1988) *Gene* 69:301-315) and pET 11d (Studier *et al.*, GENE EXPRESSION TECHNOLOGY: METHODS IN ENZYMOLOGY 185, Academic Press, San Diego, Calif. (1990) 60-89).

One strategy to maximize recombinant protein expression in *E. coli* is to express the protein in a host bacteria with an impaired capacity to proteolytically cleave the recombinant protein. See, e.g., Gottesman, GENE EXPRESSION TECHNOLOGY: METHODS IN ENZYMOLOGY 185, Academic Press, San Diego, Calif. (1990) 119-128. Another strategy is to alter the nucleic acid sequence of the nucleic acid to be inserted into an expression vector so that the individual codons for each amino acid are those preferentially utilized in *E. coli* (see, e.g., Wada, *et al.*, 1992. *Nucl. Acids Res.* 20: 2111-2118). Such alteration of nucleic acid sequences of the invention can be carried out by standard DNA synthesis techniques.

In another embodiment, the NOVX expression vector is a yeast expression vector. Examples of vectors for expression in yeast *Saccharomyces cerevisiae* include pYepSec1 (Baldari, *et al.*, 1987. *EMBO J.* 6: 229-234), pMFa (Kurjan and Herskowitz, 1982. *Cell* 30: 933-943), pJRY88 (Schultz *et al.*, 1987. *Gene* 54: 113-123), pYES2 (Invitrogen Corporation, San Diego, Calif.), and picZ (InVitrogen Corp, San Diego, Calif.).

Alternatively, NOVX can be expressed in insect cells using baculovirus expression vectors. Baculovirus vectors available for expression of proteins in cultured insect cells (e.g.,

SF9 cells) include the pAc series (Smith, *et al.*, 1983. *Mol. Cell. Biol.* 3: 2156-2165) and the pVL series (Lucklow and Summers, 1989. *Virology* 170: 31-39).

In yet another embodiment, a nucleic acid of the invention is expressed in mammalian cells using a mammalian expression vector. Examples of mammalian expression vectors  
5 include pCDM8 (Seed, 1987. *Nature* 329: 840) and pMT2PC (Kaufman, *et al.*, 1987. *EMBO J.* 6: 187-195). When used in mammalian cells, the expression vector's control functions are often provided by viral regulatory elements. For example, commonly used promoters are derived from polyoma, adenovirus 2, cytomegalovirus, and simian virus 40. For other suitable expression systems for both prokaryotic and eukaryotic cells see, *e.g.*, Chapters 16 and 17 of  
10 Sambrook, *et al.*, MOLECULAR CLONING: A LABORATORY MANUAL. 2nd ed., Cold Spring Harbor Laboratory, Cold Spring Harbor Laboratory Press, Cold Spring Harbor, N.Y., 1989.

In another embodiment, the recombinant mammalian expression vector is capable of directing expression of the nucleic acid preferentially in a particular cell type (*e.g.*, tissue-specific regulatory elements are used to express the nucleic acid). Tissue-specific  
15 regulatory elements are known in the art. Non-limiting examples of suitable tissue-specific promoters include the albumin promoter (liver-specific; Pinkert, *et al.*, 1987. *Genes Dev.* 1: 268-277), lymphoid-specific promoters (Calame and Eaton, 1988. *Adv. Immunol.* 43: 235-275), in particular promoters of T cell receptors (Winoto and Baltimore, 1989. *EMBO J.* 8: 729-733) and immunoglobulins (Banerji, *et al.*, 1983. *Cell* 33: 729-740; Queen and  
20 Baltimore, 1983. *Cell* 33: 741-748), neuron-specific promoters (*e.g.*, the neurofilament promoter; Byrne and Ruddle, 1989. *Proc. Natl. Acad. Sci. USA* 86: 5473-5477), pancreas-specific promoters (Edlund, *et al.*, 1985. *Science* 230: 912-916), and mammary gland-specific promoters (*e.g.*, milk whey promoter; U.S. Pat. No. 4,873,316 and European Application Publication No. 264,166). Developmentally-regulated promoters are also  
25 encompassed, *e.g.*, the murine hox promoters (Kessel and Gruss, 1990. *Science* 249: 374-379) and the  $\alpha$ -fetoprotein promoter (Campes and Tilghman, 1989. *Genes Dev.* 3: 537-546).

The invention further provides a recombinant expression vector comprising a DNA molecule of the invention cloned into the expression vector in an antisense orientation. That is, the DNA molecule is operatively-linked to a regulatory sequence in a manner that allows  
30 for expression (by transcription of the DNA molecule) of an RNA molecule that is antisense to NOVX mRNA. Regulatory sequences operatively linked to a nucleic acid cloned in the antisense orientation can be chosen that direct the continuous expression of the antisense RNA molecule in a variety of cell types, for instance viral promoters and/or enhancers, or regulatory sequences can be chosen that direct constitutive, tissue specific or cell type specific expression



of antisense RNA. The antisense expression vector can be in the form of a recombinant plasmid, phagemid or attenuated virus in which antisense nucleic acids are produced under the control of a high efficiency regulatory region, the activity of which can be determined by the cell type into which the vector is introduced. For a discussion of the regulation of gene expression using antisense genes *see, e.g.,* Weintraub, *et al.*, "Antisense RNA as a molecular tool for genetic analysis," *Reviews-Trends in Genetics*, Vol. 1(1) 1986.

Another aspect of the invention pertains to host cells into which a recombinant expression vector of the invention has been introduced. The terms "host cell" and "recombinant host cell" are used interchangeably herein. It is understood that such terms refer not only to the particular subject cell but also to the progeny or potential progeny of such a cell. Because certain modifications may occur in succeeding generations due to either mutation or environmental influences, such progeny may not, in fact, be identical to the parent cell, but are still included within the scope of the term as used herein.

A host cell can be any prokaryotic or eukaryotic cell. For example, NOVX protein can be expressed in bacterial cells such as *E. coli*, insect cells, yeast or mammalian cells (such as Chinese hamster ovary cells (CHO) or COS cells). Other suitable host cells are known to those skilled in the art.

Vector DNA can be introduced into prokaryotic or eukaryotic cells via conventional transformation or transfection techniques. As used herein, the terms "transformation" and "transfection" are intended to refer to a variety of art-recognized techniques for introducing foreign nucleic acid (*e.g.,* DNA) into a host cell, including calcium phosphate or calcium chloride co-precipitation, DEAE-dextran-mediated transfection, lipofection, or electroporation. Suitable methods for transforming or transfecting host cells can be found in Sambrook, *et al.* (MOLECULAR CLONING: A LABORATORY MANUAL, 2nd ed., Cold Spring Harbor Laboratory, Cold Spring Harbor Laboratory Press, Cold Spring Harbor, N.Y., 1989), and other laboratory manuals.

For stable transfection of mammalian cells, it is known that, depending upon the expression vector and transfection technique used, only a small fraction of cells may integrate the foreign DNA into their genome. In order to identify and select these integrants, a gene that encodes a selectable marker (*e.g.,* resistance to antibiotics) is generally introduced into the host cells along with the gene of interest. Various selectable markers include those that confer resistance to drugs, such as G418, hygromycin and methotrexate. Nucleic acid encoding a selectable marker can be introduced into a host cell on the same vector as that encoding NOVX or can be introduced on a separate vector. Cells stably transfected with the introduced

nucleic acid can be identified by drug selection (*e.g.*, cells that have incorporated the selectable marker gene will survive, while the other cells die).

A host cell of the invention, such as a prokaryotic or eukaryotic host cell in culture, can be used to produce (*i.e.*, express) NOVX protein. Accordingly, the invention further provides methods for producing NOVX protein using the host cells of the invention. In one embodiment, the method comprises culturing the host cell of invention (into which a recombinant expression vector encoding NOVX protein has been introduced) in a suitable medium such that NOVX protein is produced. In another embodiment, the method further comprises isolating NOVX protein from the medium or the host cell.

## 10 Transgenic NOVX Animals

The host cells of the invention can also be used to produce non-human transgenic animals. For example, in one embodiment, a host cell of the invention is a fertilized oocyte or an embryonic stem cell into which NOVX protein-coding sequences have been introduced. Such host cells can then be used to create non-human transgenic animals in which exogenous NOVX sequences have been introduced into their genome or homologous recombinant animals in which endogenous NOVX sequences have been altered. Such animals are useful for studying the function and/or activity of NOVX protein and for identifying and/or evaluating modulators of NOVX protein activity. As used herein, a "transgenic animal" is a non-human animal, preferably a mammal, more preferably a rodent such as a rat or mouse, in which one or more of the cells of the animal includes a transgene. Other examples of transgenic animals include non-human primates, sheep, dogs, cows, goats, chickens, amphibians, etc. A transgene is exogenous DNA that is integrated into the genome of a cell from which a transgenic animal develops and that remains in the genome of the mature animal, thereby directing the expression of an encoded gene product in one or more cell types or tissues of the transgenic animal. As used herein, a "homologous recombinant animal" is a non-human animal, preferably a mammal, more preferably a mouse, in which an endogenous NOVX gene has been altered by homologous recombination between the endogenous gene and an exogenous DNA molecule introduced into a cell of the animal, *e.g.*, an embryonic cell of the animal, prior to development of the animal.

A transgenic animal of the invention can be created by introducing NOVX-encoding nucleic acid into the male pronuclei of a fertilized oocyte (*e.g.*, by microinjection, retroviral infection) and allowing the oocyte to develop in a pseudopregnant female foster animal. The human NOVX cDNA sequences SEQ ID NOS:1, 3, 5, 7, 9, 11, 13, 15, 17, 19, 21, 23, 25, 27, 29, 31, 33, 35, 37, 39, 41, 43, 45, 47, 49, 51, 53, 55, 57, 59, 61 and 63 can be introduced as a

transgene into the genome of a non-human animal. Alternatively, a non-human homologue of the human NOVX gene, such as a mouse NOVX gene, can be isolated based on hybridization to the human NOVX cDNA (described further *supra*) and used as a transgene. Intronic sequences and polyadenylation signals can also be included in the transgene to increase the efficiency of expression of the transgene. A tissue-specific regulatory sequence(s) can be operably-linked to the NOVX transgene to direct expression of NOVX protein to particular cells. Methods for generating transgenic animals via embryo manipulation and microinjection, particularly animals such as mice, have become conventional in the art and are described, for example, in U.S. Patent Nos. 4,736,866; 4,870,009; and 4,873,191; and Hogan, 1986. In: MANIPULATING THE MOUSE EMBRYO, Cold Spring Harbor Laboratory Press, Cold Spring Harbor, N.Y. Similar methods are used for production of other transgenic animals. A transgenic founder animal can be identified based upon the presence of the NOVX transgene in its genome and/or expression of NOVX mRNA in tissues or cells of the animals. A transgenic founder animal can then be used to breed additional animals carrying the transgene. Moreover, transgenic animals carrying a transgene-encoding NOVX protein can further be bred to other transgenic animals carrying other transgenes.

To create a homologous recombinant animal, a vector is prepared which contains at least a portion of an NOVX gene into which a deletion, addition or substitution has been introduced to thereby alter, *e.g.*, functionally disrupt, the NOVX gene. The NOVX gene can be a human gene (*e.g.*, the cDNA of SEQ ID NOS:1, 3, 5, 7, 9, 11, 13, 15, 17, 19, 21, 23, 25, 27, 29, 31, 33, 35, 37, 39, 41, 43, 45, 47, 49, 51, 53, 55, 57, 59, 61 and 63), but more preferably, is a non-human homologue of a human NOVX gene. For example, a mouse homologue of human NOVX gene of SEQ ID NOS:1, 3, 5, 7, 9, 11, 13, 15, 17, 19, 21, 23, 25, 27, 29, 31, 33, 35, 37, 39, 41, 43, 45, 47, 49, 51, 53, 55, 57, 59, 61 and 63 can be used to construct a homologous recombination vector suitable for altering an endogenous NOVX gene in the mouse genome. In one embodiment, the vector is designed such that, upon homologous recombination, the endogenous NOVX gene is functionally disrupted (*i.e.*, no longer encodes a functional protein; also referred to as a "knock out" vector).

Alternatively, the vector can be designed such that, upon homologous recombination, the endogenous NOVX gene is mutated or otherwise altered but still encodes functional protein (*e.g.*, the upstream regulatory region can be altered to thereby alter the expression of the endogenous NOVX protein). In the homologous recombination vector, the altered portion of the NOVX gene is flanked at its 5'- and 3'-termini by additional nucleic acid of the NOVX gene to allow for homologous recombination to occur between the exogenous NOVX gene

carried by the vector and an endogenous NOVX gene in an embryonic stem cell. The additional flanking NOVX nucleic acid is of sufficient length for successful homologous recombination with the endogenous gene. Typically, several kilobases of flanking DNA (both at the 5'- and 3'-termini) are included in the vector. *See, e.g., Thomas, et al., 1987. Cell* 51: 503 for a description of homologous recombination vectors. The vector is then introduced into an embryonic stem cell line (*e.g., by electroporation*) and cells in which the introduced NOVX gene has homologously-recombined with the endogenous NOVX gene are selected. *See, e.g., Li, et al., 1992. Cell* 69: 915.

The selected cells are then injected into a blastocyst of an animal (*e.g., a mouse*) to form aggregation chimeras. *See, e.g., Bradley, 1987. In: TERATOCARCINOMAS AND EMBRYONIC STEM CELLS: A PRACTICAL APPROACH, Robertson, ed. IRL, Oxford, pp. 113-152.* A chimeric embryo can then be implanted into a suitable pseudopregnant female foster animal and the embryo brought to term. Progeny harboring the homologously-recombined DNA in their germ cells can be used to breed animals in which all cells of the animal contain the homologously-recombined DNA by germline transmission of the transgene. Methods for constructing homologous recombination vectors and homologous recombinant animals are described further in Bradley, 1991. *Curr. Opin. Biotechnol.* 2: 823-829; PCT International Publication Nos.: WO 90/11354; WO 91/01140; WO 92/0968; and WO 93/04169.

In another embodiment, transgenic non-humans animals can be produced that contain selected systems that allow for regulated expression of the transgene. One example of such a system is the cre/loxP recombinase system of bacteriophage P1. For a description of the cre/loxP recombinase system, *See, e.g., Lakso, et al., 1992. Proc. Natl. Acad. Sci. USA* 89: 6232-6236. Another example of a recombinase system is the FLP recombinase system of *Saccharomyces cerevisiae*. *See, O'Gorman, et al., 1991. Science* 251:1351-1355. If a cre/loxP recombinase system is used to regulate expression of the transgene, animals containing transgenes encoding both the Cre recombinase and a selected protein are required. Such animals can be provided through the construction of "double" transgenic animals, *e.g., by mating two transgenic animals, one containing a transgene encoding a selected protein and the other containing a transgene encoding a recombinase.*

Clones of the non-human transgenic animals described herein can also be produced according to the methods described in Wilmut, *et al., 1997. Nature* 385: 810-813. In brief, a cell (*e.g., a somatic cell*) from the transgenic animal can be isolated and induced to exit the growth cycle and enter G<sub>0</sub> phase. The quiescent cell can then be fused, *e.g., through the use of electrical pulses*, to an enucleated oocyte from an animal of the same species from which the

quiescent cell is isolated. The reconstructed oocyte is then cultured such that it develops to morula or blastocyte and then transferred to pseudopregnant female foster animal. The offspring borne of this female foster animal will be a clone of the animal from which the cell (*e.g.*, the somatic cell) is isolated.

## 5 **Pharmaceutical Compositions**

The NOVX nucleic acid molecules, NOVX proteins, and anti-NOVX antibodies (also referred to herein as "active compounds") of the invention, and derivatives, fragments, analogs and homologs thereof, can be incorporated into pharmaceutical compositions suitable for administration. Such compositions typically comprise the nucleic acid molecule, protein, or  
10 antibody and a pharmaceutically acceptable carrier. As used herein, "pharmaceutically acceptable carrier" is intended to include any and all solvents, dispersion media, coatings, antibacterial and antifungal agents, isotonic and absorption delaying agents, and the like, compatible with pharmaceutical administration. Suitable carriers are described in the most recent edition of Remington's Pharmaceutical Sciences, a standard reference text in the field,  
15 which is incorporated herein by reference. Preferred examples of such carriers or diluents include, but are not limited to, water, saline, finger's solutions, dextrose solution, and 5% human serum albumin. Liposomes and non-aqueous vehicles such as fixed oils may also be used. The use of such media and agents for pharmaceutically active substances is well known in the art. Except insofar as any conventional media or agent is incompatible with the active  
20 compound, use thereof in the compositions is contemplated. Supplementary active compounds can also be incorporated into the compositions.

A pharmaceutical composition of the invention is formulated to be compatible with its intended route of administration. Examples of routes of administration include parenteral, *e.g.*, intravenous, intradermal, subcutaneous, oral (*e.g.*, inhalation), transdermal (*i.e.*, topical),  
25 transmucosal, and rectal administration. Solutions or suspensions used for parenteral, intradermal, or subcutaneous application can include the following components: a sterile diluent such as water for injection, saline solution, fixed oils, polyethylene glycols, glycerine, propylene glycol or other synthetic solvents; antibacterial agents such as benzyl alcohol or methyl parabens; antioxidants such as ascorbic acid or sodium bisulfite; chelating agents such  
30 as ethylenediaminetetraacetic acid (EDTA); buffers such as acetates, citrates or phosphates, and agents for the adjustment of tonicity such as sodium chloride or dextrose. The pH can be adjusted with acids or bases, such as hydrochloric acid or sodium hydroxide. The parenteral preparation can be enclosed in ampoules, disposable syringes or multiple dose vials made of glass or plastic.

Pharmaceutical compositions suitable for injectable use include sterile aqueous solutions (where water soluble) or dispersions and sterile powders for the extemporaneous preparation of sterile injectable solutions or dispersion. For intravenous administration, suitable carriers include physiological saline, bacteriostatic water, Cremophor EL™ (BASF, Parsippany, N.J.) or phosphate buffered saline (PBS). In all cases, the composition must be sterile and should be fluid to the extent that easy syringeability exists. It must be stable under the conditions of manufacture and storage and must be preserved against the contaminating action of microorganisms such as bacteria and fungi. The carrier can be a solvent or dispersion medium containing, for example, water, ethanol, polyol (for example, glycerol, propylene glycol, and liquid polyethylene glycol, and the like), and suitable mixtures thereof. The proper fluidity can be maintained, for example, by the use of a coating such as lecithin, by the maintenance of the required particle size in the case of dispersion and by the use of surfactants. Prevention of the action of microorganisms can be achieved by various antibacterial and antifungal agents, for example, parabens, chlorobutanol, phenol, ascorbic acid, thimerosal, and the like. In many cases, it will be preferable to include isotonic agents, for example, sugars, polyalcohols such as manitol, sorbitol, sodium chloride in the composition. Prolonged absorption of the injectable compositions can be brought about by including in the composition an agent which delays absorption, for example, aluminum monostearate and gelatin.

Sterile injectable solutions can be prepared by incorporating the active compound (*e.g.*, an NOVX protein or anti-NOVX antibody) in the required amount in an appropriate solvent with one or a combination of ingredients enumerated above, as required, followed by filtered sterilization. Generally, dispersions are prepared by incorporating the active compound into a sterile vehicle that contains a basic dispersion medium and the required other ingredients from those enumerated above. In the case of sterile powders for the preparation of sterile injectable solutions, methods of preparation are vacuum drying and freeze-drying that yields a powder of the active ingredient plus any additional desired ingredient from a previously sterile-filtered solution thereof.

Oral compositions generally include an inert diluent or an edible carrier. They can be enclosed in gelatin capsules or compressed into tablets. For the purpose of oral therapeutic administration, the active compound can be incorporated with excipients and used in the form of tablets, troches, or capsules. Oral compositions can also be prepared using a fluid carrier for use as a mouthwash, wherein the compound in the fluid carrier is applied orally and swished and expectorated or swallowed. Pharmaceutically compatible binding agents, and/or

adjuvant materials can be included as part of the composition. The tablets, pills, capsules, troches and the like can contain any of the following ingredients, or compounds of a similar nature: a binder such as microcrystalline cellulose, gum tragacanth or gelatin; an excipient such as starch or lactose, a disintegrating agent such as alginic acid, Primogel, or corn starch; a  
5 lubricant such as magnesium stearate or Sterotes; a glidant such as colloidal silicon dioxide; a sweetening agent such as sucrose or saccharin; or a flavoring agent such as peppermint, methyl salicylate, or orange flavoring.

For administration by inhalation, the compounds are delivered in the form of an aerosol spray from pressured container or dispenser which contains a suitable propellant, *e.g.*,  
10 a gas such as carbon dioxide, or a nebulizer.

Systemic administration can also be by transmucosal or transdermal means. For transmucosal or transdermal administration, penetrants appropriate to the barrier to be permeated are used in the formulation. Such penetrants are generally known in the art, and include, for example, for transmucosal administration, detergents, bile salts, and fusidic acid  
15 derivatives. Transmucosal administration can be accomplished through the use of nasal sprays or suppositories. For transdermal administration, the active compounds are formulated into ointments, salves, gels, or creams as generally known in the art.

The compounds can also be prepared in the form of suppositories (*e.g.*, with conventional suppository bases such as cocoa butter and other glycerides) or retention enemas  
20 for rectal delivery.

In one embodiment, the active compounds are prepared with carriers that will protect the compound against rapid elimination from the body, such as a controlled release formulation, including implants and microencapsulated delivery systems. Biodegradable, biocompatible polymers can be used, such as ethylene vinyl acetate, polyanhydrides,  
25 polyglycolic acid, collagen, polyorthoesters, and polylactic acid. Methods for preparation of such formulations will be apparent to those skilled in the art. The materials can also be obtained commercially from Alza Corporation and Nova Pharmaceuticals, Inc. Liposomal suspensions (including liposomes targeted to infected cells with monoclonal antibodies to viral antigens) can also be used as pharmaceutically acceptable carriers. These can be prepared  
30 according to methods known to those skilled in the art, for example, as described in U.S. Patent No. 4,522,811.

It is especially advantageous to formulate oral or parenteral compositions in dosage unit form for ease of administration and uniformity of dosage. Dosage unit form as used herein refers to physically discrete units suited as unitary dosages for the subject to be treated;

each unit containing a predetermined quantity of active compound calculated to produce the desired therapeutic effect in association with the required pharmaceutical carrier. The specification for the dosage unit forms of the invention are dictated by and directly dependent on the unique characteristics of the active compound and the particular therapeutic effect to be achieved, and the limitations inherent in the art of compounding such an active compound for the treatment of individuals.

The nucleic acid molecules of the invention can be inserted into vectors and used as gene therapy vectors. Gene therapy vectors can be delivered to a subject by, for example, intravenous injection, local administration (*see, e.g.*, U.S. Patent No. 5,328,470) or by stereotactic injection (*see, e.g.*, Chen, *et al.*, 1994. *Proc. Natl. Acad. Sci. USA* 91: 3054-3057). The pharmaceutical preparation of the gene therapy vector can include the gene therapy vector in an acceptable diluent, or can comprise a slow release matrix in which the gene delivery vehicle is imbedded. Alternatively, where the complete gene delivery vector can be produced intact from recombinant cells, *e.g.*, retroviral vectors, the pharmaceutical preparation can include one or more cells that produce the gene delivery system.

The pharmaceutical compositions can be included in a container, pack, or dispenser together with instructions for administration.

#### **Screening and Detection Methods**

The isolated nucleic acid molecules of the invention can be used to express NOVX protein (*e.g.*, via a recombinant expression vector in a host cell in gene therapy applications), to detect NOVX mRNA (*e.g.*, in a biological sample) or a genetic lesion in an NOVX gene, and to modulate NOVX activity, as described further, below. In addition, the NOVX proteins can be used to screen drugs or compounds that modulate the NOVX protein activity or expression as well as to treat disorders characterized by insufficient or excessive production of NOVX protein or production of NOVX protein forms that have decreased or aberrant activity compared to NOVX wild-type protein (*e.g.*; diabetes (regulates insulin release); obesity (binds and transport lipids); metabolic disturbances associated with obesity, the metabolic syndrome X as well as anorexia and wasting disorders associated with chronic diseases and various cancers, and infectious disease (possesses anti-microbial activity) and the various dyslipidemias. In addition, the anti-NOVX antibodies of the invention can be used to detect and isolate NOVX proteins and modulate NOVX activity. In yet a further aspect, the invention can be used in methods to influence appetite, absorption of nutrients and the disposition of metabolic substrates in both a positive and negative fashion.



The invention further pertains to novel agents identified by the screening assays described herein and uses thereof for treatments as described, *supra*.

### Screening Assays

5 The invention provides a method (also referred to herein as a "screening assay") for identifying modulators, *i.e.*, candidate or test compounds or agents (*e.g.*, peptides, peptidomimetics, small molecules or other drugs) that bind to NOVX proteins or have a stimulatory or inhibitory effect on, *e.g.*, NOVX protein expression or NOVX protein activity. The invention also includes compounds identified in the screening assays described herein.

10 In one embodiment, the invention provides assays for screening candidate or test compounds which bind to or modulate the activity of the membrane-bound form of an NOVX protein or polypeptide or biologically-active portion thereof. The test compounds of the invention can be obtained using any of the numerous approaches in combinatorial library methods known in the art, including: biological libraries; spatially addressable parallel solid phase or solution phase libraries; synthetic library methods requiring deconvolution; the  
15 "one-bead one-compound" library method; and synthetic library methods using affinity chromatography selection. The biological library approach is limited to peptide libraries, while the other four approaches are applicable to peptide, non-peptide oligomer or small molecule libraries of compounds. *See, e.g.*, Lam, 1997. *Anticancer Drug Design* 12: 145.

A "small molecule" as used herein, is meant to refer to a composition that has a  
20 molecular weight of less than about 5 kD and most preferably less than about 4 kD. Small molecules can be, *e.g.*, nucleic acids, peptides, polypeptides, peptidomimetics, carbohydrates, lipids or other organic or inorganic molecules. Libraries of chemical and/or biological mixtures, such as fungal, bacterial, or algal extracts, are known in the art and can be screened with any of the assays of the invention.

25 Examples of methods for the synthesis of molecular libraries can be found in the art, for example in: DeWitt, *et al.*, 1993. *Proc. Natl. Acad. Sci. U.S.A.* 90: 6909; Erb, *et al.*, 1994. *Proc. Natl. Acad. Sci. U.S.A.* 91: 11422; Zuckermann, *et al.*, 1994. *J. Med. Chem.* 37: 2678; Cho, *et al.*, 1993. *Science* 261: 1303; Carrell, *et al.*, 1994. *Angew. Chem. Int. Ed. Engl.* 33: 2059; Carell, *et al.*, 1994. *Angew. Chem. Int. Ed. Engl.* 33: 2061; and Gallop, *et al.*, 1994. *J.*  
30 *Med. Chem.* 37: 1233.

Libraries of compounds may be presented in solution (*e.g.*, Houghten, 1992. *Biotechniques* 13: 412-421), or on beads (Lam, 1991. *Nature* 354: 82-84), on chips (Fodor, 1993. *Nature* 364: 555-556), bacteria (Ladner, U.S. Patent No. 5,223,409), spores (Ladner, U.S. Patent 5,233,409), plasmids (Cull, *et al.*, 1992. *Proc. Natl. Acad. Sci. USA* 89:

1865-1869) or on phage (Scott and Smith, 1990. *Science* 249: 386-390; Devlin, 1990. *Science* 249: 404-406; Cwirla, *et al.*, 1990. *Proc. Natl. Acad. Sci. U.S.A.* 87: 6378-6382; Felici, 1991. *J. Mol. Biol.* 222: 301-310; Ladner, U.S. Patent No. 5,233,409.).

In one embodiment, an assay is a cell-based assay in which a cell which expresses a  
5 membrane-bound form of NOVX protein, or a biologically-active portion thereof, on the cell  
surface is contacted with a test compound and the ability of the test compound to bind to an  
NOVX protein determined. The cell, for example, can be of mammalian origin or a yeast cell.  
Determining the ability of the test compound to bind to the NOVX protein can be  
accomplished, for example, by coupling the test compound with a radioisotope or enzymatic  
10 label such that binding of the test compound to the NOVX protein or biologically-active  
portion thereof can be determined by detecting the labeled compound in a complex. For  
example, test compounds can be labeled with  $^{125}\text{I}$ ,  $^{35}\text{S}$ ,  $^{14}\text{C}$ , or  $^3\text{H}$ , either directly or indirectly,  
and the radioisotope detected by direct counting of radioemission or by scintillation counting.  
Alternatively, test compounds can be enzymatically-labeled with, for example, horseradish  
15 peroxidase, alkaline phosphatase, or luciferase, and the enzymatic label detected by  
determination of conversion of an appropriate substrate to product. In one embodiment, the  
assay comprises contacting a cell which expresses a membrane-bound form of NOVX protein,  
or a biologically-active portion thereof, on the cell surface with a known compound which  
binds NOVX to form an assay mixture, contacting the assay mixture with a test compound,  
20 and determining the ability of the test compound to interact with an NOVX protein, wherein  
determining the ability of the test compound to interact with an NOVX protein comprises  
determining the ability of the test compound to preferentially bind to NOVX protein or a  
biologically-active portion thereof as compared to the known compound.

In another embodiment, an assay is a cell-based assay comprising contacting a cell  
25 expressing a membrane-bound form of NOVX protein, or a biologically-active portion thereof,  
on the cell surface with a test compound and determining the ability of the test compound to  
modulate (*e.g.*, stimulate or inhibit) the activity of the NOVX protein or biologically-active  
portion thereof. Determining the ability of the test compound to modulate the activity of  
NOVX or a biologically-active portion thereof can be accomplished, for example, by  
30 determining the ability of the NOVX protein to bind to or interact with an NOVX target  
molecule. As used herein, a "target molecule" is a molecule with which an NOVX protein  
binds or interacts in nature, for example, a molecule on the surface of a cell which expresses  
an NOVX interacting protein, a molecule on the surface of a second cell, a molecule in the  
extracellular milieu, a molecule associated with the internal surface of a cell membrane or a

cytoplasmic molecule. An NOVX target molecule can be a non-NOVX molecule or an NOVX protein or polypeptide of the invention. In one embodiment, an NOVX target molecule is a component of a signal transduction pathway that facilitates transduction of an extracellular signal (*e.g.* a signal generated by binding of a compound to a membrane-bound NOVX molecule) through the cell membrane and into the cell. The target, for example, can be a second intercellular protein that has catalytic activity or a protein that facilitates the association of downstream signaling molecules with NOVX.

Determining the ability of the NOVX protein to bind to or interact with an NOVX target molecule can be accomplished by one of the methods described above for determining direct binding. In one embodiment, determining the ability of the NOVX protein to bind to or interact with an NOVX target molecule can be accomplished by determining the activity of the target molecule. For example, the activity of the target molecule can be determined by detecting induction of a cellular second messenger of the target (*i.e.* intracellular  $\text{Ca}^{2+}$ , diacylglycerol,  $\text{IP}_3$ , etc.), detecting catalytic/enzymatic activity of the target on an appropriate substrate, detecting the induction of a reporter gene (comprising an NOVX-responsive regulatory element operatively linked to a nucleic acid encoding a detectable marker, *e.g.*, luciferase), or detecting a cellular response, for example, cell survival, cellular differentiation, or cell proliferation.

In yet another embodiment, an assay of the invention is a cell-free assay comprising contacting an NOVX protein or biologically-active portion thereof with a test compound and determining the ability of the test compound to bind to the NOVX protein or biologically-active portion thereof. Binding of the test compound to the NOVX protein can be determined either directly or indirectly as described above. In one such embodiment, the assay comprises contacting the NOVX protein or biologically-active portion thereof with a known compound which binds NOVX to form an assay mixture, contacting the assay mixture with a test compound, and determining the ability of the test compound to interact with an NOVX protein, wherein determining the ability of the test compound to interact with an NOVX protein comprises determining the ability of the test compound to preferentially bind to NOVX or biologically-active portion thereof as compared to the known compound.

In still another embodiment, an assay is a cell-free assay comprising contacting NOVX protein or biologically-active portion thereof with a test compound and determining the ability of the test compound to modulate (*e.g.* stimulate or inhibit) the activity of the NOVX protein or biologically-active portion thereof. Determining the ability of the test compound to modulate the activity of NOVX can be accomplished, for example, by determining the ability

of the NOVX protein to bind to an NOVX target molecule by one of the methods described above for determining direct binding. In an alternative embodiment, determining the ability of the test compound to modulate the activity of NOVX protein can be accomplished by determining the ability of the NOVX protein further modulate an NOVX target molecule. For example, the catalytic/enzymatic activity of the target molecule on an appropriate substrate can be determined as described, *supra*.

In yet another embodiment, the cell-free assay comprises contacting the NOVX protein or biologically-active portion thereof with a known compound which binds NOVX protein to form an assay mixture, contacting the assay mixture with a test compound, and determining the ability of the test compound to interact with an NOVX protein, wherein determining the ability of the test compound to interact with an NOVX protein comprises determining the ability of the NOVX protein to preferentially bind to or modulate the activity of an NOVX target molecule.

The cell-free assays of the invention are amenable to use of both the soluble form or the membrane-bound form of NOVX protein. In the case of cell-free assays comprising the membrane-bound form of NOVX protein, it may be desirable to utilize a solubilizing agent such that the membrane-bound form of NOVX protein is maintained in solution. Examples of such solubilizing agents include non-ionic detergents such as n-octylglucoside, n-dodecylglucoside, n-dodecylmaltoside, octanoyl-N-methylglucamide, decanoyl-N-methylglucamide, Triton<sup>®</sup> X-100, Triton<sup>®</sup> X-114, Thesit<sup>®</sup>, Isotridecypoly(ethylene glycol ether)<sub>n</sub>, N-dodecyl--N,N-dimethyl-3-ammonio-1-propane sulfonate, 3-(3-cholamidopropyl) dimethylamminiol-1-propane sulfonate (CHAPS), or 3-(3-cholamidopropyl)dimethylamminiol-2-hydroxy-1-propane sulfonate (CHAPSO).

In more than one embodiment of the above assay methods of the invention, it may be desirable to immobilize either NOVX protein or its target molecule to facilitate separation of complexed from uncomplexed forms of one or both of the proteins, as well as to accommodate automation of the assay. Binding of a test compound to NOVX protein, or interaction of NOVX protein with a target molecule in the presence and absence of a candidate compound, can be accomplished in any vessel suitable for containing the reactants. Examples of such vessels include microtiter plates, test tubes, and micro-centrifuge tubes. In one embodiment, a fusion protein can be provided that adds a domain that allows one or both of the proteins to be bound to a matrix. For example, GST-NOVX fusion proteins or GST-target fusion proteins can be adsorbed onto glutathione sepharose beads (Sigma Chemical, St. Louis, MO) or glutathione derivatized microtiter plates, that are then combined with the test compound or the

test compound and either the non-adsorbed target protein or NOVX protein, and the mixture is incubated under conditions conducive to complex formation (*e.g.*, at physiological conditions for salt and pH). Following incubation, the beads or microtiter plate wells are washed to remove any unbound components, the matrix immobilized in the case of beads, complex  
5 determined either directly or indirectly, for example, as described, *supra*. Alternatively, the complexes can be dissociated from the matrix, and the level of NOVX protein binding or activity determined using standard techniques.

Other techniques for immobilizing proteins on matrices can also be used in the screening assays of the invention. For example, either the NOVX protein or its target  
10 molecule can be immobilized utilizing conjugation of biotin and streptavidin. Biotinylated NOVX protein or target molecules can be prepared from biotin-NHS (N-hydroxy-succinimide) using techniques well-known within the art (*e.g.*, biotinylation kit, Pierce Chemicals, Rockford, Ill.), and immobilized in the wells of streptavidin-coated 96 well plates (Pierce Chemical). Alternatively, antibodies reactive with NOVX protein or target  
15 molecules, but which do not interfere with binding of the NOVX protein to its target molecule, can be derivatized to the wells of the plate, and unbound target or NOVX protein trapped in the wells by antibody conjugation. Methods for detecting such complexes, in addition to those described above for the GST-immobilized complexes, include immunodetection of complexes using antibodies reactive with the NOVX protein or target molecule, as well as enzyme-linked  
20 assays that rely on detecting an enzymatic activity associated with the NOVX protein or target molecule.

In another embodiment, modulators of NOVX protein expression are identified in a method wherein a cell is contacted with a candidate compound and the expression of NOVX mRNA or protein in the cell is determined. The level of expression of NOVX mRNA or  
25 protein in the presence of the candidate compound is compared to the level of expression of NOVX mRNA or protein in the absence of the candidate compound. The candidate compound can then be identified as a modulator of NOVX mRNA or protein expression based upon this comparison. For example, when expression of NOVX mRNA or protein is greater (*i.e.*, statistically significantly greater) in the presence of the candidate compound than in its  
30 absence, the candidate compound is identified as a stimulator of NOVX mRNA or protein expression. Alternatively, when expression of NOVX mRNA or protein is less (statistically significantly less) in the presence of the candidate compound than in its absence, the candidate compound is identified as an inhibitor of NOVX mRNA or protein expression. The level of

NOVX mRNA or protein expression in the cells can be determined by methods described herein for detecting NOVX mRNA or protein.

In yet another aspect of the invention, the NOVX proteins can be used as "bait proteins" in a two-hybrid assay or three hybrid assay (*see, e.g.*, U.S. Patent No. 5,283,317; Zervos, *et al.*, 1993. *Cell* 72: 223-232; Madura, *et al.*, 1993. *J. Biol. Chem.* 268: 12046-12054; Bartel, *et al.*, 1993. *Biotechniques* 14: 920-924; Iwabuchi, *et al.*, 1993. *Oncogene* 8: 1693-1696; and Brent WO 94/10300), to identify other proteins that bind to or interact with NOVX ("NOVX-binding proteins" or "NOVX-bp") and modulate NOVX activity. Such NOVX-binding proteins are also likely to be involved in the propagation of signals by the NOVX proteins as, for example, upstream or downstream elements of the NOVX pathway.

The two-hybrid system is based on the modular nature of most transcription factors, which consist of separable DNA-binding and activation domains. Briefly, the assay utilizes two different DNA constructs. In one construct, the gene that codes for NOVX is fused to a gene encoding the DNA binding domain of a known transcription factor (*e.g.*, GAL-4). In the other construct, a DNA sequence, from a library of DNA sequences, that encodes an unidentified protein ("prey" or "sample") is fused to a gene that codes for the activation domain of the known transcription factor. If the "bait" and the "prey" proteins are able to interact, *in vivo*, forming an NOVX-dependent complex, the DNA-binding and activation domains of the transcription factor are brought into close proximity. This proximity allows transcription of a reporter gene (*e.g.*, LacZ) that is operably linked to a transcriptional regulatory site responsive to the transcription factor. Expression of the reporter gene can be detected and cell colonies containing the functional transcription factor can be isolated and used to obtain the cloned gene that encodes the protein which interacts with NOVX.

The invention further pertains to novel agents identified by the aforementioned screening assays and uses thereof for treatments as described herein.

#### Detection Assays

Portions or fragments of the cDNA sequences identified herein (and the corresponding complete gene sequences) can be used in numerous ways as polynucleotide reagents. By way of example, and not of limitation, these sequences can be used to: (i) map their respective genes on a chromosome; and, thus, locate gene regions associated with genetic disease; (ii) identify an individual from a minute biological sample (tissue typing); and (iii) aid in forensic identification of a biological sample. Some of these applications are described in the subsections, below.

## Chromosome Mapping

Once the sequence (or a portion of the sequence) of a gene has been isolated, this sequence can be used to map the location of the gene on a chromosome. This process is called chromosome mapping. Accordingly, portions or fragments of the NOVX sequences, SEQ ID NOS:1, 3, 5, 7, 9, 11, 13, 15, 17, 19, 21, 23, 25, 27, 29, 31, 33, 35, 37, 39, 41, 43, 45, 47, 49, 51, 53, 55, 57, 59, 61 and 63, or fragments or derivatives thereof, can be used to map the location of the NOVX genes, respectively, on a chromosome. The mapping of the NOVX sequences to chromosomes is an important first step in correlating these sequences with genes associated with disease.

Briefly, NOVX genes can be mapped to chromosomes by preparing PCR primers (preferably 15-25 bp in length) from the NOVX sequences. Computer analysis of the NOVX sequences can be used to rapidly select primers that do not span more than one exon in the genomic DNA, thus complicating the amplification process. These primers can then be used for PCR screening of somatic cell hybrids containing individual human chromosomes. Only those hybrids containing the human gene corresponding to the NOVX sequences will yield an amplified fragment.

Somatic cell hybrids are prepared by fusing somatic cells from different mammals (e.g., human and mouse cells). As hybrids of human and mouse cells grow and divide, they gradually lose human chromosomes in random order, but retain the mouse chromosomes. By using media in which mouse cells cannot grow, because they lack a particular enzyme, but in which human cells can, the one human chromosome that contains the gene encoding the needed enzyme will be retained. By using various media, panels of hybrid cell lines can be established. Each cell line in a panel contains either a single human chromosome or a small number of human chromosomes, and a full set of mouse chromosomes, allowing easy mapping of individual genes to specific human chromosomes. See, e.g., D'Eustachio, *et al.*, 1983. *Science* 220: 919-924. Somatic cell hybrids containing only fragments of human chromosomes can also be produced by using human chromosomes with translocations and deletions.

PCR mapping of somatic cell hybrids is a rapid procedure for assigning a particular sequence to a particular chromosome. Three or more sequences can be assigned per day using a single thermal cycler. Using the NOVX sequences to design oligonucleotide primers, sub-localization can be achieved with panels of fragments from specific chromosomes.

Fluorescence *in situ* hybridization (FISH) of a DNA sequence to a metaphase chromosomal spread can further be used to provide a precise chromosomal location in one

step. Chromosome spreads can be made using cells whose division has been blocked in metaphase by a chemical like colcemid that disrupts the mitotic spindle. The chromosomes can be treated briefly with trypsin, and then stained with Giemsa. A pattern of light and dark bands develops on each chromosome, so that the chromosomes can be identified individually.

- 5 The FISH technique can be used with a DNA sequence as short as 500 or 600 bases. However, clones larger than 1,000 bases have a higher likelihood of binding to a unique chromosomal location with sufficient signal intensity for simple detection. Preferably 1,000 bases, and more preferably 2,000 bases, will suffice to get good results at a reasonable amount of time. For a review of this technique, *see*, Verma, *et al.*, HUMAN CHROMOSOMES: A  
10 MANUAL OF BASIC TECHNIQUES (Pergamon Press, New York 1988).

Reagents for chromosome mapping can be used individually to mark a single chromosome or a single site on that chromosome, or panels of reagents can be used for marking multiple sites and/or multiple chromosomes. Reagents corresponding to noncoding regions of the genes actually are preferred for mapping purposes. Coding sequences are more  
15 likely to be conserved within gene families, thus increasing the chance of cross hybridizations during chromosomal mapping.

Once a sequence has been mapped to a precise chromosomal location, the physical position of the sequence on the chromosome can be correlated with genetic map data. Such data are found, *e.g.*, in McKusick, MENDELIAN INHERITANCE IN MAN, available on-line  
20 through Johns Hopkins University Welch Medical Library). The relationship between genes and disease, mapped to the same chromosomal region, can then be identified through linkage analysis (co-inheritance of physically adjacent genes), described in, *e.g.*, Egeland, *et al.*, 1987. *Nature*, 325: 783-787.

Moreover, differences in the DNA sequences between individuals affected and  
25 unaffected with a disease associated with the NOVX gene, can be determined. If a mutation is observed in some or all of the affected individuals but not in any unaffected individuals, then the mutation is likely to be the causative agent of the particular disease. Comparison of affected and unaffected individuals generally involves first looking for structural alterations in the chromosomes, such as deletions or translocations that are visible from chromosome  
30 spreads or detectable using PCR based on that DNA sequence. Ultimately, complete sequencing of genes from several individuals can be performed to confirm the presence of a mutation and to distinguish mutations from polymorphisms.

### Tissue Typing



The NOVX sequences of the invention can also be used to identify individuals from minute biological samples. In this technique, an individual's genomic DNA is digested with one or more restriction enzymes, and probed on a Southern blot to yield unique bands for identification. The sequences of the invention are useful as additional DNA markers for RFLP

5 ("restriction fragment length polymorphisms," described in U.S. Patent No. 5,272,057).

Furthermore, the sequences of the invention can be used to provide an alternative technique that determines the actual base-by-base DNA sequence of selected portions of an individual's genome. Thus, the NOVX sequences described herein can be used to prepare two PCR primers from the 5'- and 3'-termini of the sequences. These primers can then be used to

10 amplify an individual's DNA and subsequently sequence it.

Panels of corresponding DNA sequences from individuals, prepared in this manner, can provide unique individual identifications, as each individual will have a unique set of such DNA sequences due to allelic differences. The sequences of the invention can be used to obtain such identification sequences from individuals and from tissue. The NOVX sequences

15 of the invention uniquely represent portions of the human genome. Allelic variation occurs to some degree in the coding regions of these sequences, and to a greater degree in the noncoding regions. It is estimated that allelic variation between individual humans occurs with a frequency of about once per each 500 bases. Much of the allelic variation is due to single nucleotide polymorphisms (SNPs), which include restriction fragment length polymorphisms

20 (RFLPs).

Each of the sequences described herein can, to some degree, be used as a standard against which DNA from an individual can be compared for identification purposes. Because greater numbers of polymorphisms occur in the noncoding regions, fewer sequences are necessary to differentiate individuals. The noncoding sequences can comfortably provide

25 positive individual identification with a panel of perhaps 10 to 1,000 primers that each yield a noncoding amplified sequence of 100 bases. If predicted coding sequences, such as those in SEQ ID NOS:1, 3, 5, 7, 9, 11, 13, 15, 17, 19, 21, 23, 25, 27, 29, 31, 33, 35, 37, 39, 41, 43, 45, 47, 49, 51, 53, 55, 57, 59, 61 and 63 are used, a more appropriate number of primers for positive individual identification would be 500-2,000.

### 30 **Predictive Medicine**

The invention also pertains to the field of predictive medicine in which diagnostic assays, prognostic assays, pharmacogenomics, and monitoring clinical trials are used for prognostic (predictive) purposes to thereby treat an individual prophylactically. Accordingly, one aspect of the invention relates to diagnostic assays for determining NOVX protein and/or

nucleic acid expression as well as NOVX activity, in the context of a biological sample (*e.g.*, blood, serum, cells, tissue) to thereby determine whether an individual is afflicted with a disease or disorder, or is at risk of developing a disorder, associated with aberrant NOVX expression or activity. The disorders include metabolic disorders, diabetes, obesity, infectious disease, anorexia, cancer-associated cachexia, cancer, neurodegenerative disorders, Alzheimer's Disease, Parkinson's Disorder, immune disorders, and hematopoietic disorders, and the various dyslipidemias, metabolic disturbances associated with obesity, the metabolic syndrome X and wasting disorders associated with chronic diseases and various cancers. The invention also provides for prognostic (or predictive) assays for determining whether an individual is at risk of developing a disorder associated with NOVX protein, nucleic acid expression or activity. For example, mutations in an NOVX gene can be assayed in a biological sample. Such assays can be used for prognostic or predictive purpose to thereby prophylactically treat an individual prior to the onset of a disorder characterized by or associated with NOVX protein, nucleic acid expression, or biological activity.

Another aspect of the invention provides methods for determining NOVX protein, nucleic acid expression or activity in an individual to thereby select appropriate therapeutic or prophylactic agents for that individual (referred to herein as "pharmacogenomics"). Pharmacogenomics allows for the selection of agents (*e.g.*, drugs) for therapeutic or prophylactic treatment of an individual based on the genotype of the individual (*e.g.*, the genotype of the individual examined to determine the ability of the individual to respond to a particular agent.)

Yet another aspect of the invention pertains to monitoring the influence of agents (*e.g.*, drugs, compounds) on the expression or activity of NOVX in clinical trials.

These and other agents are described in further detail in the following sections.

## **Diagnostic Assays**

An exemplary method for detecting the presence or absence of NOVX in a biological sample involves obtaining a biological sample from a test subject and contacting the biological sample with a compound or an agent capable of detecting NOVX protein or nucleic acid (*e.g.*, mRNA, genomic DNA) that encodes NOVX protein such that the presence of NOVX is detected in the biological sample. An agent for detecting NOVX mRNA or genomic DNA is a labeled nucleic acid probe capable of hybridizing to NOVX mRNA or genomic DNA. The nucleic acid probe can be, for example, a full-length NOVX nucleic acid, such as the nucleic acid of SEQ ID NOS:1, 3, 5, 7, 9, 11, 13, 15, 17, 19, 21, 23, 25, 27, 29, 31, 33, 35, 37, 39, 41, 43, 45, 47, 49, 51, 53, 55, 57, 59, 61 and 63, or a portion thereof, such as an oligonucleotide of

at least 15, 30, 50, 100, 250 or 500 nucleotides in length and sufficient to specifically hybridize under stringent conditions to NOVX mRNA or genomic DNA. Other suitable probes for use in the diagnostic assays of the invention are described herein.

5 An agent for detecting NOVX protein is an antibody capable of binding to NOVX protein, preferably an antibody with a detectable label. Antibodies can be polyclonal, or more preferably, monoclonal. An intact antibody, or a fragment thereof (*e.g.*, Fab or F(ab')<sub>2</sub>) can be used. The term "labeled", with regard to the probe or antibody, is intended to encompass direct labeling of the probe or antibody by coupling (*i.e.*, physically linking) a detectable substance to the probe or antibody, as well as indirect labeling of the probe or antibody by  
10 reactivity with another reagent that is directly labeled. Examples of indirect labeling include detection of a primary antibody using a fluorescently-labeled secondary antibody and end-labeling of a DNA probe with biotin such that it can be detected with fluorescently-labeled streptavidin. The term "biological sample" is intended to include tissues, cells and biological fluids isolated from a subject, as well as tissues, cells and fluids present within a  
15 subject. That is, the detection method of the invention can be used to detect NOVX mRNA, protein, or genomic DNA in a biological sample *in vitro* as well as *in vivo*. For example, *in vitro* techniques for detection of NOVX mRNA include Northern hybridizations and *in situ* hybridizations. *In vitro* techniques for detection of NOVX protein include enzyme linked immunosorbent assays (ELISAs), Western blots, immunoprecipitations, and  
20 immunofluorescence. *In vitro* techniques for detection of NOVX genomic DNA include Southern hybridizations. Furthermore, *in vivo* techniques for detection of NOVX protein include introducing into a subject a labeled anti-NOVX antibody. For example, the antibody can be labeled with a radioactive marker whose presence and location in a subject can be detected by standard imaging techniques.

25 In one embodiment, the biological sample contains protein molecules from the test subject. Alternatively, the biological sample can contain mRNA molecules from the test subject or genomic DNA molecules from the test subject. A preferred biological sample is a peripheral blood leukocyte sample isolated by conventional means from a subject.

In another embodiment, the methods further involve obtaining a control biological  
30 sample from a control subject, contacting the control sample with a compound or agent capable of detecting NOVX protein, mRNA, or genomic DNA, such that the presence of NOVX protein, mRNA or genomic DNA is detected in the biological sample, and comparing the presence of NOVX protein, mRNA or genomic DNA in the control sample with the presence of NOVX protein, mRNA or genomic DNA in the test sample.

The invention also encompasses kits for detecting the presence of NOVX in a biological sample. For example, the kit can comprise: a labeled compound or agent capable of detecting NOVX protein or mRNA in a biological sample; means for determining the amount of NOVX in the sample; and means for comparing the amount of NOVX in the sample with a standard. The compound or agent can be packaged in a suitable container. The kit can further  
5 comprise instructions for using the kit to detect NOVX protein or nucleic acid.

### Prognostic Assays

The diagnostic methods described herein can furthermore be utilized to identify subjects having or at risk of developing a disease or disorder associated with aberrant NOVX  
10 expression or activity. For example, the assays described herein, such as the preceding diagnostic assays or the following assays, can be utilized to identify a subject having or at risk of developing a disorder associated with NOVX protein, nucleic acid expression or activity. Alternatively, the prognostic assays can be utilized to identify a subject having or at risk for developing a disease or disorder. Thus, the invention provides a method for identifying a  
15 disease or disorder associated with aberrant NOVX expression or activity in which a test sample is obtained from a subject and NOVX protein or nucleic acid (*e.g.*, mRNA, genomic DNA) is detected, wherein the presence of NOVX protein or nucleic acid is diagnostic for a subject having or at risk of developing a disease or disorder associated with aberrant NOVX expression or activity. As used herein, a "test sample" refers to a biological sample obtained  
20 from a subject of interest. For example, a test sample can be a biological fluid (*e.g.*, serum), cell sample, or tissue.

Furthermore, the prognostic assays described herein can be used to determine whether a subject can be administered an agent (*e.g.*, an agonist, antagonist, peptidomimetic, protein, peptide, nucleic acid, small molecule, or other drug candidate) to treat a disease or disorder  
25 associated with aberrant NOVX expression or activity. For example, such methods can be used to determine whether a subject can be effectively treated with an agent for a disorder. Thus, the invention provides methods for determining whether a subject can be effectively treated with an agent for a disorder associated with aberrant NOVX expression or activity in which a test sample is obtained and NOVX protein or nucleic acid is detected (*e.g.*, wherein  
30 the presence of NOVX protein or nucleic acid is diagnostic for a subject that can be administered the agent to treat a disorder associated with aberrant NOVX expression or activity).

The methods of the invention can also be used to detect genetic lesions in an NOVX gene, thereby determining if a subject with the lesioned gene is at risk for a disorder

characterized by aberrant cell proliferation and/or differentiation. In various embodiments, the methods include detecting, in a sample of cells from the subject, the presence or absence of a genetic lesion characterized by at least one of an alteration affecting the integrity of a gene encoding an NOVX-protein, or the misexpression of the NOVX gene. For example, such genetic lesions can be detected by ascertaining the existence of at least one of: (i) a deletion of one or more nucleotides from an NOVX gene; (ii) an addition of one or more nucleotides to an NOVX gene; (iii) a substitution of one or more nucleotides of an NOVX gene, (iv) a chromosomal rearrangement of an NOVX gene; (v) an alteration in the level of a messenger RNA transcript of an NOVX gene, (vi) aberrant modification of an NOVX gene, such as of the methylation pattern of the genomic DNA, (vii) the presence of a non-wild-type splicing pattern of a messenger RNA transcript of an NOVX gene, (viii) a non-wild-type level of an NOVX protein, (ix) allelic loss of an NOVX gene, and (x) inappropriate post-translational modification of an NOVX protein. As described herein, there are a large number of assay techniques known in the art which can be used for detecting lesions in an NOVX gene. A preferred biological sample is a peripheral blood leukocyte sample isolated by conventional means from a subject. However, any biological sample containing nucleated cells may be used, including, for example, buccal mucosal cells.

In certain embodiments, detection of the lesion involves the use of a probe/primer in a polymerase chain reaction (PCR) (*see, e.g.*, U.S. Patent Nos. 4,683,195 and 4,683,202), such as anchor PCR or RACE PCR, or, alternatively, in a ligation chain reaction (LCR) (*see, e.g.*, Landegran, *et al.*, 1988, *Science* 241: 1077-1080; and Nakazawa, *et al.*, 1994, *Proc. Natl. Acad. Sci. USA* 91: 360-364), the latter of which can be particularly useful for detecting point mutations in the NOVX-gene (*see*, Abravaya, *et al.*, 1995, *Nucl. Acids Res.* 23: 675-682). This method can include the steps of collecting a sample of cells from a patient, isolating nucleic acid (*e.g.*, genomic, mRNA or both) from the cells of the sample, contacting the nucleic acid sample with one or more primers that specifically hybridize to an NOVX gene under conditions such that hybridization and amplification of the NOVX gene (if present) occurs, and detecting the presence or absence of an amplification product, or detecting the size of the amplification product and comparing the length to a control sample. It is anticipated that PCR and/or LCR may be desirable to use as a preliminary amplification step in conjunction with any of the techniques used for detecting mutations described herein.

Alternative amplification methods include: self sustained sequence replication (*see*, Guatelli, *et al.*, 1990, *Proc. Natl. Acad. Sci. USA* 87: 1874-1878), transcriptional amplification system (*see*, Kwoh, *et al.*, 1989, *Proc. Natl. Acad. Sci. USA* 86: 1173-1177); Q $\beta$  Replicase

(see, Lizardi, *et al*, 1988. *BioTechnology* 6: 1197), or any other nucleic acid amplification method, followed by the detection of the amplified molecules using techniques well known to those of skill in the art. These detection schemes are especially useful for the detection of nucleic acid molecules if such molecules are present in very low numbers.

5 In an alternative embodiment, mutations in an NOVX gene from a sample cell can be identified by alterations in restriction enzyme cleavage patterns. For example, sample and control DNA is isolated, amplified (optionally), digested with one or more restriction endonucleases, and fragment length sizes are determined by gel electrophoresis and compared. Differences in fragment length sizes between sample and control DNA indicates mutations in  
10 the sample DNA. Moreover, the use of sequence specific ribozymes (see, e.g., U.S. Patent No. 5,493,531) can be used to score for the presence of specific mutations by development or loss of a ribozyme cleavage site.

In other embodiments, genetic mutations in NOVX can be identified by hybridizing a sample and control nucleic acids, e.g., DNA or RNA, to high-density arrays containing  
15 hundreds or thousands of oligonucleotides probes. See, e.g., Cronin, *et al.*, 1996. *Human Mutation* 7: 244-255; Kozal, *et al.*, 1996. *Nat. Med.* 2: 753-759. For example, genetic mutations in NOVX can be identified in two dimensional arrays containing light-generated DNA probes as described in Cronin, *et al.*, *supra*. Briefly, a first hybridization array of probes can be used to scan through long stretches of DNA in a sample and control to identify base  
20 changes between the sequences by making linear arrays of sequential overlapping probes. This step allows the identification of point mutations. This is followed by a second hybridization array that allows the characterization of specific mutations by using smaller, specialized probe arrays complementary to all variants or mutations detected. Each mutation array is composed of parallel probe sets, one complementary to the wild-type gene and the  
25 other complementary to the mutant gene.

In yet another embodiment, any of a variety of sequencing reactions known in the art can be used to directly sequence the NOVX gene and detect mutations by comparing the sequence of the sample NOVX with the corresponding wild-type (control) sequence. Examples of sequencing reactions include those based on techniques developed by Maxim and  
30 Gilbert, 1977. *Proc. Natl. Acad. Sci. USA* 74: 560 or Sanger, 1977. *Proc. Natl. Acad. Sci. USA* 74: 5463. It is also contemplated that any of a variety of automated sequencing procedures can be utilized when performing the diagnostic assays (see, e.g., Naeve, *et al.*, 1995. *Biotechniques* 19: 448), including sequencing by mass spectrometry (see, e.g., PCT

International Publication No. WO 94/16101; Cohen, *et al.*, 1996. *Adv. Chromatography* 36: 127-162; and Griffin, *et al.*, 1993. *Appl. Biochem. Biotechnol.* 38: 147-159).

Other methods for detecting mutations in the NOVX gene include methods in which protection from cleavage agents is used to detect mismatched bases in RNA/RNA or  
5 RNA/DNA heteroduplexes. *See, e.g.*, Myers, *et al.*, 1985. *Science* 230: 1242. In general, the art technique of "mismatch cleavage" starts by providing heteroduplexes of formed by hybridizing (labeled) RNA or DNA containing the wild-type NOVX sequence with potentially mutant RNA or DNA obtained from a tissue sample. The double-stranded duplexes are treated with an agent that cleaves single-stranded regions of the duplex such as which will  
10 exist due to basepair mismatches between the control and sample strands. For instance, RNA/DNA duplexes can be treated with RNase and DNA/DNA hybrids treated with S<sub>1</sub> nuclease to enzymatically digesting the mismatched regions. In other embodiments, either DNA/DNA or RNA/DNA duplexes can be treated with hydroxylamine or osmium tetroxide and with piperidine in order to digest mismatched regions. After digestion of the mismatched  
15 regions, the resulting material is then separated by size on denaturing polyacrylamide gels to determine the site of mutation. *See, e.g.*, Cotton, *et al.*, 1988. *Proc. Natl. Acad. Sci. USA* 85: 4397; Saleeba, *et al.*, 1992. *Methods Enzymol.* 217: 286-295. In an embodiment, the control DNA or RNA can be labeled for detection.

In still another embodiment, the mismatch cleavage reaction employs one or more  
20 proteins that recognize mismatched base pairs in double-stranded DNA (so called "DNA mismatch repair" enzymes) in defined systems for detecting and mapping point mutations in NOVX cDNAs obtained from samples of cells. For example, the mutY enzyme of *E. coli* cleaves A at G/A mismatches and the thymidine DNA glycosylase from HeLa cells cleaves T at G/T mismatches. *See, e.g.*, Hsu, *et al.*, 1994. *Carcinogenesis* 15: 1657-1662. According to  
25 an exemplary embodiment, a probe based on an NOVX sequence, *e.g.*, a wild-type NOVX sequence, is hybridized to a cDNA or other DNA product from a test cell(s). The duplex is treated with a DNA mismatch repair enzyme, and the cleavage products, if any, can be detected from electrophoresis protocols or the like. *See, e.g.*, U.S. Patent No. 5,459,039.

In other embodiments, alterations in electrophoretic mobility will be used to identify  
30 mutations in NOVX genes. For example, single strand conformation polymorphism (SSCP) may be used to detect differences in electrophoretic mobility between mutant and wild type nucleic acids. *See, e.g.*, Orita, *et al.*, 1989. *Proc. Natl. Acad. Sci. USA*: 86: 2766; Cotton, 1993. *Mutat. Res.* 285: 125-144; Hayashi, 1992. *Genet. Anal. Tech. Appl.* 9: 73-79. Single-stranded DNA fragments of sample and control NOVX nucleic acids will be denatured

and allowed to renature. The secondary structure of single-stranded nucleic acids varies according to sequence, the resulting alteration in electrophoretic mobility enables the detection of even a single base change. The DNA fragments may be labeled or detected with labeled probes. The sensitivity of the assay may be enhanced by using RNA (rather than DNA), in which the secondary structure is more sensitive to a change in sequence. In one embodiment, the subject method utilizes heteroduplex analysis to separate double stranded heteroduplex molecules on the basis of changes in electrophoretic mobility. *See, e.g., Keen, et al., 1991. Trends Genet. 7: 5.*

In yet another embodiment, the movement of mutant or wild-type fragments in polyacrylamide gels containing a gradient of denaturant is assayed using denaturing gradient gel electrophoresis (DGGE). *See, e.g., Myers, et al., 1985. Nature 313: 495.* When DGGE is used as the method of analysis, DNA will be modified to insure that it does not completely denature, for example by adding a GC clamp of approximately 40 bp of high-melting GC-rich DNA by PCR. In a further embodiment, a temperature gradient is used in place of a denaturing gradient to identify differences in the mobility of control and sample DNA. *See, e.g., Rosenbaum and Reissner, 1987. Biophys. Chem. 265: 12753.*

Examples of other techniques for detecting point mutations include, but are not limited to, selective oligonucleotide hybridization, selective amplification, or selective primer extension. For example, oligonucleotide primers may be prepared in which the known mutation is placed centrally and then hybridized to target DNA under conditions that permit hybridization only if a perfect match is found. *See, e.g., Saiki, et al., 1986. Nature 324: 163; Saiki, et al., 1989. Proc. Natl. Acad. Sci. USA 86: 6230.* Such allele specific oligonucleotides are hybridized to PCR amplified target DNA or a number of different mutations when the oligonucleotides are attached to the hybridizing membrane and hybridized with labeled target DNA.

Alternatively, allele specific amplification technology that depends on selective PCR amplification may be used in conjunction with the instant invention. Oligonucleotides used as primers for specific amplification may carry the mutation of interest in the center of the molecule (so that amplification depends on differential hybridization; *see, e.g., Gibbs, et al., 1989. Nucl. Acids Res. 17: 2437-2448*) or at the extreme 3'-terminus of one primer where, under appropriate conditions, mismatch can prevent, or reduce polymerase extension (*see, e.g., Prossner, 1993. Tibtech. 11: 238*). In addition it may be desirable to introduce a novel restriction site in the region of the mutation to create cleavage-based detection. *See, e.g., Gasparini, et al., 1992. Mol. Cell Probes 6: 1.* It is anticipated that in certain embodiments



amplification may also be performed using *Taq* ligase for amplification. *See, e.g.*, Barany, 1991. *Proc. Natl. Acad. Sci. USA* 88: 189. In such cases, ligation will occur only if there is a perfect match at the 3'-terminus of the 5' sequence, making it possible to detect the presence of a known mutation at a specific site by looking for the presence or absence of amplification.

5       The methods described herein may be performed, for example, by utilizing pre-packaged diagnostic kits comprising at least one probe nucleic acid or antibody reagent described herein, which may be conveniently used, *e.g.*, in clinical settings to diagnose patients exhibiting symptoms or family history of a disease or illness involving an NOVX gene.

10       Furthermore, any cell type or tissue, preferably peripheral blood leukocytes, in which NOVX is expressed may be utilized in the prognostic assays described herein. However, any biological sample containing nucleated cells may be used, including, for example, buccal mucosal cells.

### **Pharmacogenomics**

15       Agents, or modulators that have a stimulatory or inhibitory effect on NOVX activity (*e.g.*, NOVX gene expression), as identified by a screening assay described herein can be administered to individuals to treat (prophylactically or therapeutically) disorders (The disorders include metabolic disorders, diabetes, obesity, infectious disease, anorexia, cancer-associated cachexia, cancer, neurodegenerative disorders, Alzheimer's Disease, Parkinson's

20   Disorder, immune disorders, and hematopoietic disorders, and the various dyslipidemias, metabolic disturbances associated with obesity, the metabolic syndrome X and wasting disorders associated with chronic diseases and various cancers.) In conjunction with such treatment, the pharmacogenomics (*i.e.*, the study of the relationship between an individual's genotype and that individual's response to a foreign compound or drug) of the individual may

25   be considered. Differences in metabolism of therapeutics can lead to severe toxicity or therapeutic failure by altering the relation between dose and blood concentration of the pharmacologically active drug. Thus, the pharmacogenomics of the individual permits the selection of effective agents (*e.g.*, drugs) for prophylactic or therapeutic treatments based on a consideration of the individual's genotype. Such pharmacogenomics can further be used to

30   determine appropriate dosages and therapeutic regimens. Accordingly, the activity of NOVX protein, expression of NOVX nucleic acid, or mutation content of NOVX genes in an individual can be determined to thereby select appropriate agent(s) for therapeutic or prophylactic treatment of the individual.

Pharmacogenomics deals with clinically significant hereditary variations in the response to drugs due to altered drug disposition and abnormal action in affected persons. See *e.g.*, Eichelbaum, 1996. *Clin. Exp. Pharmacol. Physiol.*, 23: 983-985; Linder, 1997. *Clin. Chem.*, 43: 254-266. In general, two types of pharmacogenetic conditions can be differentiated. Genetic conditions transmitted as a single factor altering the way drugs act on the body (altered drug action) or genetic conditions transmitted as single factors altering the way the body acts on drugs (altered drug metabolism). These pharmacogenetic conditions can occur either as rare defects or as polymorphisms. For example, glucose-6-phosphate dehydrogenase (G6PD) deficiency is a common inherited enzymopathy in which the main clinical complication is hemolysis after ingestion of oxidant drugs (anti-malarials, sulfonamides, analgesics, nitrofurans) and consumption of fava beans.

As an illustrative embodiment, the activity of drug metabolizing enzymes is a major determinant of both the intensity and duration of drug action. The discovery of genetic polymorphisms of drug metabolizing enzymes (*e.g.*, N-acetyltransferase 2 (NAT 2) and cytochrome P450 enzymes CYP2D6 and CYP2C19) has provided an explanation as to why some patients do not obtain the expected drug effects or show exaggerated drug response and serious toxicity after taking the standard and safe dose of a drug. These polymorphisms are expressed in two phenotypes in the population, the extensive metabolizer (EM) and poor metabolizer (PM). The prevalence of PM is different among different populations. For example, the gene coding for CYP2D6 is highly polymorphic and several mutations have been identified in PM, which all lead to the absence of functional CYP2D6. Poor metabolizers of CYP2D6 and CYP2C19 quite frequently experience exaggerated drug response and side effects when they receive standard doses. If a metabolite is the active therapeutic moiety, PM show no therapeutic response, as demonstrated for the analgesic effect of codeine mediated by its CYP2D6-formed metabolite morphine. At the other extreme are the so called ultra-rapid metabolizers who do not respond to standard doses. Recently, the molecular basis of ultra-rapid metabolism has been identified to be due to CYP2D6 gene amplification.

Thus, the activity of NOVX protein, expression of NOVX nucleic acid, or mutation content of NOVX genes in an individual can be determined to thereby select appropriate agent(s) for therapeutic or prophylactic treatment of the individual. In addition, pharmacogenetic studies can be used to apply genotyping of polymorphic alleles encoding drug-metabolizing enzymes to the identification of an individual's drug responsiveness phenotype. This knowledge, when applied to dosing or drug selection, can avoid adverse reactions or therapeutic failure and thus enhance therapeutic or prophylactic efficiency when

treating a subject with an NOVX modulator, such as a modulator identified by one of the exemplary screening assays described herein.

### Monitoring of Effects During Clinical Trials

Monitoring the influence of agents (*e.g.*, drugs, compounds) on the expression or activity of NOVX (*e.g.*, the ability to modulate aberrant cell proliferation and/or differentiation) can be applied not only in basic drug screening, but also in clinical trials. For example, the effectiveness of an agent determined by a screening assay as described herein to increase NOVX gene expression, protein levels, or upregulate NOVX activity, can be monitored in clinical trials of subjects exhibiting decreased NOVX gene expression, protein levels, or downregulated NOVX activity. Alternatively, the effectiveness of an agent determined by a screening assay to decrease NOVX gene expression, protein levels, or downregulate NOVX activity, can be monitored in clinical trials of subjects exhibiting increased NOVX gene expression, protein levels, or upregulated NOVX activity. In such clinical trials, the expression or activity of NOVX and, preferably, other genes that have been implicated in, for example, a cellular proliferation or immune disorder can be used as a "read out" or markers of the immune responsiveness of a particular cell.

By way of example, and not of limitation, genes, including NOVX, that are modulated in cells by treatment with an agent (*e.g.*, compound, drug or small molecule) that modulates NOVX activity (*e.g.*, identified in a screening assay as described herein) can be identified. Thus, to study the effect of agents on cellular proliferation disorders, for example, in a clinical trial, cells can be isolated and RNA prepared and analyzed for the levels of expression of NOVX and other genes implicated in the disorder. The levels of gene expression (*i.e.*, a gene expression pattern) can be quantified by Northern blot analysis or RT-PCR, as described herein, or alternatively by measuring the amount of protein produced, by one of the methods as described herein, or by measuring the levels of activity of NOVX or other genes. In this manner, the gene expression pattern can serve as a marker, indicative of the physiological response of the cells to the agent. Accordingly, this response state may be determined before, and at various points during, treatment of the individual with the agent.

In one embodiment, the invention provides a method for monitoring the effectiveness of treatment of a subject with an agent (*e.g.*, an agonist, antagonist, protein, peptide, peptidomimetic, nucleic acid, small molecule, or other drug candidate identified by the screening assays described herein) comprising the steps of (i) obtaining a pre-administration sample from a subject prior to administration of the agent; (ii) detecting the level of expression of an NOVX protein, mRNA, or genomic DNA in the preadministration sample; (iii) obtaining

one or more post-administration samples from the subject; (iv) detecting the level of expression or activity of the NOVX protein, mRNA, or genomic DNA in the post-administration samples; (v) comparing the level of expression or activity of the NOVX protein, mRNA, or genomic DNA in the pre-administration sample with the NOVX protein, mRNA, or genomic DNA in the post administration sample or samples; and (vi) altering the administration of the agent to the subject accordingly. For example, increased administration of the agent may be desirable to increase the expression or activity of NOVX to higher levels than detected, *i.e.*, to increase the effectiveness of the agent. Alternatively, decreased administration of the agent may be desirable to decrease expression or activity of NOVX to lower levels than detected, *i.e.*, to decrease the effectiveness of the agent.

### Methods of Treatment

The invention provides for both prophylactic and therapeutic methods of treating a subject at risk of (or susceptible to) a disorder or having a disorder associated with aberrant NOVX expression or activity. The disorders include cardiomyopathy, atherosclerosis, hypertension, congenital heart defects, aortic stenosis, atrial septal defect (ASD), atrioventricular (A-V) canal defect, ductus arteriosus, pulmonary stenosis, subaortic stenosis, ventricular septal defect (VSD), valve diseases, tuberous sclerosis, scleroderma, obesity, transplantation, adrenoleukodystrophy, congenital adrenal hyperplasia, prostate cancer, neoplasm; adenocarcinoma, lymphoma, uterus cancer, fertility, hemophilia, hypercoagulation, idiopathic thrombocytopenic purpura, immunodeficiencies, graft versus host disease, AIDS, bronchial asthma, Crohn's disease; multiple sclerosis, treatment of Albright Hereditary Osteodystrophy, and other diseases, disorders and conditions of the like.

These methods of treatment will be discussed more fully, below.

### Disease and Disorders

Diseases and disorders that are characterized by increased (relative to a subject not suffering from the disease or disorder) levels or biological activity may be treated with Therapeutics that antagonize (*i.e.*, reduce or inhibit) activity. Therapeutics that antagonize activity may be administered in a therapeutic or prophylactic manner. Therapeutics that may be utilized include, but are not limited to: (i) an aforementioned peptide, or analogs, derivatives, fragments or homologs thereof; (ii) antibodies to an aforementioned peptide; (iii) nucleic acids encoding an aforementioned peptide; (iv) administration of antisense nucleic acid and nucleic acids that are "dysfunctional" (*i.e.*, due to a heterologous insertion within the coding sequences of coding sequences to an aforementioned peptide) that are utilized to

"knockout" endogenous function of an aforementioned peptide by homologous recombination (see, e.g., Capecchi, 1989. *Science* 244: 1288-1292); or ( $\nu$ ) modulators (*i.e.*, inhibitors, agonists and antagonists, including additional peptide mimetic of the invention or antibodies specific to a peptide of the invention) that alter the interaction between an aforementioned peptide and its binding partner.

Diseases and disorders that are characterized by decreased (relative to a subject not suffering from the disease or disorder) levels or biological activity may be treated with Therapeutics that increase (*i.e.*, are agonists to) activity. Therapeutics that upregulate activity may be administered in a therapeutic or prophylactic manner. Therapeutics that may be utilized include, but are not limited to, an aforementioned peptide, or analogs, derivatives, fragments or homologs thereof; or an agonist that increases bioavailability.

Increased or decreased levels can be readily detected by quantifying peptide and/or RNA, by obtaining a patient tissue sample (*e.g.*, from biopsy tissue) and assaying it *in vitro* for RNA or peptide levels, structure and/or activity of the expressed peptides (or mRNAs of an aforementioned peptide). Methods that are well-known within the art include, but are not limited to, immunoassays (*e.g.*, by Western blot analysis, immunoprecipitation followed by sodium dodecyl sulfate (SDS) polyacrylamide gel electrophoresis, immunocytochemistry, etc.) and/or hybridization assays to detect expression of mRNAs (*e.g.*, Northern assays, dot blots, *in situ* hybridization, and the like).

## **Prophylactic Methods**

In one aspect, the invention provides a method for preventing, in a subject, a disease or condition associated with an aberrant NOVX expression or activity, by administering to the subject an agent that modulates NOVX expression or at least one NOVX activity. Subjects at risk for a disease that is caused or contributed to by aberrant NOVX expression or activity can be identified by, for example, any or a combination of diagnostic or prognostic assays as described herein. Administration of a prophylactic agent can occur prior to the manifestation of symptoms characteristic of the NOVX aberrancy, such that a disease or disorder is prevented or, alternatively, delayed in its progression. Depending upon the type of NOVX aberrancy, for example, an NOVX agonist or NOVX antagonist agent can be used for treating the subject. The appropriate agent can be determined based on screening assays described herein. The prophylactic methods of the invention are further discussed in the following subsections.

## **Therapeutic Methods**

Another aspect of the invention pertains to methods of modulating NOVX expression or activity for therapeutic purposes. The modulatory method of the invention involves contacting a cell with an agent that modulates one or more of the activities of NOVX protein activity associated with the cell. An agent that modulates NOVX protein activity can be an agent as described herein, such as a nucleic acid or a protein, a naturally-occurring cognate ligand of an NOVX protein, a peptide, an NOVX peptidomimetic, or other small molecule. In one embodiment, the agent stimulates one or more NOVX protein activity. Examples of such stimulatory agents include active NOVX protein and a nucleic acid molecule encoding NOVX that has been introduced into the cell. In another embodiment, the agent inhibits one or more NOVX protein activity. Examples of such inhibitory agents include antisense NOVX nucleic acid molecules and anti-NOVX antibodies. These modulatory methods can be performed *in vitro* (e.g., by culturing the cell with the agent) or, alternatively, *in vivo* (e.g., by administering the agent to a subject). As such, the invention provides methods of treating an individual afflicted with a disease or disorder characterized by aberrant expression or activity of an NOVX protein or nucleic acid molecule. In one embodiment, the method involves administering an agent (e.g., an agent identified by a screening assay described herein), or combination of agents that modulates (e.g., up-regulates or down-regulates) NOVX expression or activity. In another embodiment, the method involves administering an NOVX protein or nucleic acid molecule as therapy to compensate for reduced or aberrant NOVX expression or activity.

Stimulation of NOVX activity is desirable *in situations* in which NOVX is abnormally downregulated and/or in which increased NOVX activity is likely to have a beneficial effect. One example of such a situation is where a subject has a disorder characterized by aberrant cell proliferation and/or differentiation (e.g., cancer or immune associated disorders). Another example of such a situation is where the subject has a gestational disease (e.g., preclampsia).

#### **Determination of the Biological Effect of the Therapeutic**

In various embodiments of the invention, suitable *in vitro* or *in vivo* assays are performed to determine the effect of a specific Therapeutic and whether its administration is indicated for treatment of the affected tissue.

In various specific embodiments, *in vitro* assays may be performed with representative cells of the type(s) involved in the patient's disorder, to determine if a given Therapeutic exerts the desired effect upon the cell type(s). Compounds for use in therapy may be tested in suitable animal model systems including, but not limited to rats, mice, chicken, cows, monkeys, rabbits, and the like, prior to testing in human subjects. Similarly, for *in vivo*

testing, any of the animal model system known in the art may be used prior to administration to human subjects.

### **Prophylactic and Therapeutic Uses of the Compositions of the Invention**

5 The NOVX nucleic acids and proteins of the invention are useful in potential prophylactic and therapeutic applications implicated in a variety of disorders including, but not limited to: metabolic disorders, diabetes, obesity, infectious disease, anorexia, cancer-associated cancer, neurodegenerative disorders, Alzheimer's Disease, Parkinson's Disorder, immune disorders, hematopoietic disorders, and the various dyslipidemias, metabolic disturbances associated with obesity, the metabolic syndrome X and wasting disorders  
10 associated with chronic diseases and various cancers.

As an example, a cDNA encoding the NOVX protein of the invention may be useful in gene therapy, and the protein may be useful when administered to a subject in need thereof. By way of non-limiting example, the compositions of the invention will have efficacy for treatment of patients suffering from: metabolic disorders, diabetes, obesity, infectious disease,  
15 anorexia, cancer-associated cachexia, cancer, neurodegenerative disorders, Alzheimer's Disease, Parkinson's Disorder, immune disorders, hematopoietic disorders, and the various dyslipidemias.

Both the novel nucleic acid encoding the NOVX protein, and the NOVX protein of the invention, or fragments thereof, may also be useful in diagnostic applications, wherein the  
20 presence or amount of the nucleic acid or the protein are to be assessed. A further use could be as an anti-bacterial molecule (*i.e.*, some peptides have been found to possess anti-bacterial properties). These materials are further useful in the generation of antibodies, which immunospecifically-bind to the novel substances of the invention for use in therapeutic or diagnostic methods.

25 The invention will be further described in the following examples, which do not limit the scope of the invention described in the claims.

### **Examples**

#### **30 EXAMPLE 1: Identification of NOVX Nucleic Acids**

TblastN using CuraGen Corporation's sequence file for polypeptides or homologs was run against the Genomic Daily Files made available by GenBank or from files downloaded

from the individual sequencing centers. Exons were predicted by homology and the intron/exon boundaries were determined using standard genetic rules. Exons were further selected and refined by means of similarity determination using multiple BLAST (for example, tBlastN, BlastX, and BlastN) searches, and, in some instances, GeneScan and Grail.

5 Expressed sequences from both public and proprietary databases were also added when available to further define and complete the gene sequence. The DNA sequence was then manually corrected for apparent inconsistencies thereby obtaining the sequences encoding the full-length protein.

The novel NOVX target sequences identified in the present invention were subjected to  
10 the exon linking process to confirm the sequence. PCR primers were designed by starting at the most upstream sequence available, for the forward primer, and at the most downstream sequence available for the reverse primer. Table 11A shows the sequences of the PCR primers used for obtaining different clones. In each case, the sequence was examined, walking inward from the respective termini toward the coding sequence, until a suitable sequence that is either  
15 unique or highly selective was encountered, or, in the case of the reverse primer, until the stop codon was reached. Such primers were designed based on in silico predictions for the full length cDNA, part (one or more exons) of the DNA or protein sequence of the target sequence, or by translated homology of the predicted exons to closely related human sequences from other species. These primers were then employed in PCR amplification based  
20 on the following pool of human cDNAs: adrenal gland, bone marrow, brain - amygdala, brain - cerebellum, brain - hippocampus, brain - substantia nigra, brain - thalamus, brain -whole, fetal brain, fetal kidney, fetal liver, fetal lung, heart, kidney, lymphoma - Raji, mammary gland, pancreas, pituitary gland, placenta, prostate, salivary gland, skeletal muscle, small intestine, spinal cord, spleen, stomach, testis, thyroid, trachea, uterus. Usually the resulting  
25 amplicons were gel purified, cloned and sequenced to high redundancy. The PCR product derived from exon linking was cloned into the pCR2.1 vector from Invitrogen. The resulting bacterial clone has an insert covering the entire open reading frame cloned into the pCR2.1 vector. Table 17B shows a list of these bacterial clones. The resulting sequences from all clones were assembled with themselves, with other fragments in CuraGen Corporation's  
30 database and with public ESTs. Fragments and ESTs were included as components for an assembly when the extent of their identity with another component of the assembly was at least 95% over 50 bp. In addition, sequence traces were evaluated manually and edited for corrections if appropriate. These procedures provide the sequence reported herein.



Physical clone: Exons were predicted by homology and the intron/exon boundaries were determined using standard genetic rules. Exons were further selected and refined by means of similarity determination using multiple BLAST (for example, tBlastN, BlastX, and BlastN) searches, and, in some instances, GeneScan and Grail. Expressed sequences from both public and proprietary databases were also added when available to further define and complete the gene sequence. The DNA sequence was then manually corrected for apparent inconsistencies thereby obtaining the sequences encoding the full-length protein.

**Example 2: Identification of Single Nucleotide Polymorphisms in NOVX nucleic acid sequences**

Variant sequences are also included in this application. A variant sequence can include a single nucleotide polymorphism (SNP). A SNP can, in some instances, be referred to as a "cSNP" to denote that the nucleotide sequence containing the SNP originates as a cDNA. A SNP can arise in several ways. For example, a SNP may be due to a substitution of one nucleotide for another at the polymorphic site. Such a substitution can be either a transition or a transversion. A SNP can also arise from a deletion of a nucleotide or an insertion of a nucleotide, relative to a reference allele. In this case, the polymorphic site is a site at which one allele bears a gap with respect to a particular nucleotide in another allele. SNPs occurring within genes may result in an alteration of the amino acid encoded by the gene at the position of the SNP. Intragenic SNPs may also be silent, when a codon including a SNP encodes the same amino acid as a result of the redundancy of the genetic code. SNPs occurring outside the region of a gene, or in an intron within a gene, do not result in changes in any amino acid sequence of a protein but may result in altered regulation of the expression pattern. Examples include alteration in temporal expression, physiological response regulation, cell type expression regulation, intensity of expression, and stability of transcribed message.

SeqCalling assemblies produced by the exon linking process were selected and extended using the following criteria. Genomic clones having regions with 98% identity to all or part of the initial or extended sequence were identified by BLASTN searches using the relevant sequence to query human genomic databases. The genomic clones that resulted were selected for further analysis because this identity indicates that these clones contain the genomic locus for these SeqCalling assemblies. These sequences were analyzed for putative coding regions as well as for similarity to the known DNA and protein sequences. Programs used for these analyses include Grail, Genscan, BLAST, HMMER, FASTA, Hybrid and other relevant programs.

Some additional genomic regions may have also been identified because selected SeqCalling assemblies map to those regions. Such SeqCalling sequences may have overlapped with regions defined by homology or exon prediction. They may also be included because the location of the fragment was in the vicinity of genomic regions identified by similarity or exon prediction that had been included in the original predicted sequence. The sequence so identified was manually assembled and then may have been extended using one or more additional sequences taken from CuraGen Corporation's human SeqCalling database. SeqCalling fragments suitable for inclusion were identified by the CuraTools™ program SeqExtend or by identifying SeqCalling fragments mapping to the appropriate regions of the genomic clones analyzed.

The regions defined by the procedures described above were then manually integrated and corrected for apparent inconsistencies that may have arisen, for example, from miscalled bases in the original fragments or from discrepancies between predicted exon junctions, EST locations and regions of sequence similarity, to derive the final sequence disclosed herein. When necessary, the process to identify and analyze SeqCalling assemblies and genomic clones was reiterated to derive the full length sequence.

**Example 3: Quantitative expression analysis of clones in various cells and tissues**

The quantitative expression of various clones was assessed using microtiter plates containing RNA samples from a variety of normal and pathology-derived cells, cell lines and tissues using real time quantitative PCR (RTQ PCR). RTQ PCR was performed on a Perkin-Elmer Biosystems ABI PRISM® 7700 Sequence Detection System. Various collections of samples are assembled on the plates, and referred to as Panel 1 (containing normal tissues and cancer cell lines), Panel 2 (containing samples derived from tissues from normal and cancer sources), Panel 3 (containing cancer cell lines), Panel 4 (containing cells and cell lines from normal tissues and cells related to inflammatory conditions), Panel 5D/5I (containing human tissues and cell lines with an emphasis on metabolic diseases), AI\_comprehensive\_panel (containing normal tissue and samples from autoinflammatory diseases), Panel CNSD.01 (containing samples from normal and diseased brains) and CNS\_neurodegeneration\_panel (containing samples from normal and diseased brains).

RNA integrity from all samples is controlled for quality by visual assessment of agarose gel electropherograms using 28S and 18S ribosomal RNA staining intensity ratio as a guide (2:1 to 2.5:1 28s:18s) and the absence of low molecular weight RNAs that would be indicative of degradation products. Samples are controlled against genomic DNA contamination by RTQ PCR reactions run in the absence of reverse transcriptase using probe

and primer sets designed to amplify across the span of a single exon.

First, the RNA samples were normalized to reference nucleic acids such as constitutively expressed genes (for example,  $\beta$ -actin and GAPDH). Normalized RNA (5  $\mu$ l) was converted to cDNA and analyzed by RTQ-PCR using One Step RT-PCR Master Mix  
5 Reagents (PE Biosystems; Catalog No. 4309169) and gene-specific primers according to the manufacturer's instructions. Probes and primers were designed for each assay according to Perkin Elmer Biosystem's *Primer Express* Software package (version I for Apple Computer's Macintosh Power PC) or a similar algorithm using the target sequence as input. Default  
10 settings were used for reaction conditions and the following parameters were set before selecting primers: primer concentration = 250 nM, primer melting temperature ( $T_m$ ) range = 58°-60° C, primer optimal  $T_m$  = 59° C, maximum primer difference = 2° C, probe does not have 5' G, probe  $T_m$  must be 10° C greater than primer  $T_m$ , amplicon size 75 bp to 100 bp. The probes and primers selected (see below) were synthesized by SyntheGen (Houston, TX, USA). Probes were double purified by HPLC to remove uncoupled dye and evaluated by  
15 mass spectroscopy to verify coupling of reporter and quencher dyes to the 5' and 3' ends of the probe, respectively. Their final concentrations were: forward and reverse primers, 900 nM each, and probe, 200nM.

PCR conditions: Normalized RNA from each tissue and each cell line was spotted in each well of a 96 well PCR plate (Perkin Elmer Biosystems). PCR cocktails including two  
20 probes (a probe specific for the target clone and another gene-specific probe multiplexed with the target probe) were set up using 1X TaqMan™ PCR Master Mix for the PE Biosystems 7700, with 5 mM MgCl<sub>2</sub>, dNTPs (dA, G, C, U at 1:1:1:2 ratios), 0.25 U/ml AmpliTaq Gold™ (PE Biosystems), and 0.4 U/ $\mu$ l RNase inhibitor, and 0.25 U/ $\mu$ l reverse transcriptase. Reverse transcription was performed at 48° C for 30 minutes followed by amplification/PCR cycles as  
25 follows: 95° C 10 min, then 40 cycles of 95° C for 15 seconds, 60° C for 1 minute. Results were recorded as CT values (cycle at which a given sample crosses a threshold level of fluorescence) using a log scale, with the difference in RNA concentration between a given sample and the sample with the lowest CT value being represented as 2 to the power of delta CT. The percent relative expression is then obtained by taking the reciprocal of this RNA  
30 difference and multiplying by 100.

### **Panels 1, 1.1, 1.2, and 1.3D**

The plates for Panels 1, 1.1, 1.2 and 1.3D include 2 control wells (genomic DNA control and chemistry control) and 94 wells containing cDNA from various samples. The samples in these panels are broken into 2 classes: samples derived from cultured cell lines and

samples derived from primary normal tissues. The cell lines are derived from cancers of the following types: lung cancer, breast cancer, melanoma, colon cancer, prostate cancer, CNS cancer, squamous cell carcinoma, ovarian cancer, liver cancer, renal cancer, gastric cancer and pancreatic cancer. Cell lines used in these panels are widely available through the American Type Culture Collection (ATCC), a repository for cultured cell lines, and were cultured using the conditions recommended by the ATCC. The normal tissues found on these panels are comprised of samples derived from all major organ systems from single adult individuals or fetuses. These samples are derived from the following organs: adult skeletal muscle, fetal skeletal muscle, adult heart, fetal heart, adult kidney, fetal kidney, adult liver, fetal liver, adult lung, fetal lung, various regions of the brain, the spleen, bone marrow, lymph node, pancreas, salivary gland, pituitary gland, adrenal gland, spinal cord, thymus, stomach, small intestine, colon, bladder, trachea, breast, ovary, uterus, placenta, prostate, testis and adipose.

In the results for Panels 1, 1.1, 1.2 and 1.3D, the following abbreviations are used:

ca. = carcinoma,  
 \* = established from metastasis,  
 met = metastasis,  
 s cell var = small cell variant,  
 non-s = non-sm = non-small,  
 squam = squamous,  
 pl. eff = pl effusion = pleural effusion,  
 glio = glioma,  
 astro = astrocytoma, and  
 neuro = neuroblastoma.

#### **General Screening Panel v1.4**

The plates for Panel 1.4 include 2 control wells (genomic DNA control and chemistry control) and 94 wells containing cDNA from various samples. The samples in Panel 1.4 are broken into 2 classes: samples derived from cultured cell lines and samples derived from primary normal tissues. The cell lines are derived from cancers of the following types: lung cancer, breast cancer, melanoma, colon cancer, prostate cancer, CNS cancer, squamous cell carcinoma, ovarian cancer, liver cancer, renal cancer, gastric cancer and pancreatic cancer. Cell lines used in Panel 1.4 are widely available through the American Type Culture Collection (ATCC), a repository for cultured cell lines, and were cultured using the conditions

recommended by the ATCC. The normal tissues found on Panel 1.4 are comprised of pools of samples derived from all major organ systems from 2 to 5 different adult individuals or fetuses. These samples are derived from the following organs: adult skeletal muscle, fetal skeletal muscle, adult heart, fetal heart, adult kidney, fetal kidney, adult liver, fetal liver, adult lung, fetal lung, various regions of the brain, the spleen, bone marrow, lymph node, pancreas, salivary gland, pituitary gland, adrenal gland, spinal cord, thymus, stomach, small intestine, colon, bladder, trachea, breast, ovary, uterus, placenta, prostate, testis and adipose.

### **Panels 2D and 2.2**

The plates for Panels 2D and 2.2 generally include 2 control wells and 94 test samples composed of RNA or cDNA isolated from human tissue procured by surgeons working in close cooperation with the National Cancer Institute's Cooperative Human Tissue Network (CHTN) or the National Disease Research Initiative (NDRI). The tissues are derived from human malignancies and in cases where indicated many malignant tissues have "matched margins" obtained from noncancerous tissue just adjacent to the tumor. These are termed normal adjacent tissues and are denoted "NAT" in the results below. The tumor tissue and the "matched margins" are evaluated by two independent pathologists (the surgical pathologists and again by a pathologists at NDRI or CHTN). This analysis provides a gross histopathological assessment of tumor differentiation grade. Moreover, most samples include the original surgical pathology report that provides information regarding the clinical stage of the patient. These matched margins are taken from the tissue surrounding (i.e. immediately proximal) to the zone of surgery (designated "NAT", for normal adjacent tissue, in Table RR). In addition, RNA and cDNA samples were obtained from various human tissues derived from autopsies performed on elderly people or sudden death victims (accidents, etc.). These tissues were ascertained to be free of disease and were purchased from various commercial sources such as Clontech (Palo Alto, CA), Research Genetics, and Invitrogen.

### **Panel 3D**

The plates of Panel 3D are comprised of 94 cDNA samples and two control samples. Specifically, 92 of these samples are derived from cultured human cancer cell lines, 2 samples of human primary cerebellar tissue and 2 controls. The human cell lines are generally obtained from ATCC (American Type Culture Collection), NCI or the German tumor cell bank and fall into the following tissue groups: Squamous cell carcinoma of the tongue, breast cancer, prostate cancer, melanoma, epidermoid carcinoma, sarcomas, bladder carcinomas, pancreatic cancers, kidney cancers, leukemias/lymphomas, ovarian/uterine/cervical, gastric,

colon, lung and CNS cancer cell lines. In addition, there are two independent samples of cerebellum. These cells are all cultured under standard recommended conditions and RNA extracted using the standard procedures. The cell lines in panel 3D and 1.3D are of the most common cell lines used in the scientific literature.

5     **Panels 4D, 4R, and 4.1D**

Panel 4 includes samples on a 96 well plate (2 control wells, 94 test samples) composed of RNA (Panel 4R) or cDNA (Panels 4D/4.1D) isolated from various human cell lines or tissues related to inflammatory conditions. Total RNA from control normal tissues such as colon and lung (Stratagene, La Jolla, CA) and thymus and kidney (Clontech) were employed. Total RNA from liver tissue from cirrhosis patients and kidney from lupus patients was obtained from BioChain (Biochain Institute, Inc., Hayward, CA). Intestinal tissue for RNA preparation from patients diagnosed as having Crohn's disease and ulcerative colitis was obtained from the National Disease Research Interchange (NDRI) (Philadelphia, PA).

15     Astrocytes, lung fibroblasts, dermal fibroblasts, coronary artery smooth muscle cells, small airway epithelium, bronchial epithelium, microvascular dermal endothelial cells, microvascular lung endothelial cells, human pulmonary aortic endothelial cells, human umbilical vein endothelial cells were all purchased from Clonetics (Walkersville, MD) and grown in the media supplied for these cell types by Clonetics. These primary cell types were activated with various cytokines or combinations of cytokines for 6 and/or 12-14 hours, as indicated. The following cytokines were used; IL-1 beta at approximately 1-5 ng/ml, TNF alpha at approximately 5-10 ng/ml, IFN gamma at approximately 20-50 ng/ml, IL-4 at approximately 5-10 ng/ml, IL-9 at approximately 5-10 ng/ml, IL-13 at approximately 5-10 ng/ml. Endothelial cells were sometimes starved for various times by culture in the basal media from Clonetics with 0.1% serum.

25     Mononuclear cells were prepared from blood of employees at CuraGen Corporation, using Ficoll. LAK cells were prepared from these cells by culture in DMEM 5% FCS (Hyclone), 100  $\mu$ M non essential amino acids (Gibco/Life Technologies, Rockville, MD), 1 mM sodium pyruvate (Gibco), mercaptoethanol  $5.5 \times 10^{-5}$  M (Gibco), and 10 mM Hepes (Gibco) and Interleukin 2 for 4-6 days. Cells were then either activated with 10-20 ng/ml PMA and 1-2  $\mu$ g/ml ionomycin, IL-12 at 5-10 ng/ml, IFN gamma at 20-50 ng/ml and IL-18 at 5-10 ng/ml for 6 hours. In some cases, mononuclear cells were cultured for 4-5 days in DMEM 5% FCS (Hyclone), 100  $\mu$ M non essential amino acids (Gibco), 1 mM sodium pyruvate (Gibco), mercaptoethanol  $5.5 \times 10^{-5}$  M (Gibco), and 10 mM Hepes (Gibco) with PHA (phytohemagglutinin) or PWM (pokeweed mitogen) at approximately 5  $\mu$ g/ml. Samples

were taken at 24, 48 and 72 hours for RNA preparation. MLR (mixed lymphocyte reaction) samples were obtained by taking blood from two donors, isolating the mononuclear cells using Ficoll and mixing the isolated mononuclear cells 1:1 at a final concentration of approximately  $2 \times 10^6$  cells/ml in DMEM 5% FCS (Hyclone), 100  $\mu$ M non essential amino acids (Gibco), 1 mM sodium pyruvate (Gibco), mercaptoethanol ( $5.5 \times 10^{-5}$  M) (Gibco), and 10 mM Hepes (Gibco). The MLR was cultured and samples taken at various time points ranging from 1- 7 days for RNA preparation.

Monocytes were isolated from mononuclear cells using CD14 Miltenyi Beads, +ve VS selection columns and a Vario Magnet according to the manufacturer's instructions.

Monocytes were differentiated into dendritic cells by culture in DMEM 5% fetal calf serum (FCS) (Hyclone, Logan, UT), 100  $\mu$ M non essential amino acids (Gibco), 1 mM sodium pyruvate (Gibco), mercaptoethanol  $5.5 \times 10^{-5}$  M (Gibco), and 10 mM Hepes (Gibco), 50 ng/ml GMCSF and 5 ng/ml IL-4 for 5-7 days. Macrophages were prepared by culture of monocytes for 5-7 days in DMEM 5% FCS (Hyclone), 100  $\mu$ M non essential amino acids (Gibco), 1 mM sodium pyruvate (Gibco), mercaptoethanol  $5.5 \times 10^{-5}$  M (Gibco), 10 mM Hepes (Gibco) and 10% AB Human Serum or MCSF at approximately 50 ng/ml. Monocytes, macrophages and dendritic cells were stimulated for 6 and 12-14 hours with lipopolysaccharide (LPS) at 100 ng/ml. Dendritic cells were also stimulated with anti-CD40 monoclonal antibody (Pharmingen) at 10  $\mu$ g/ml for 6 and 12-14 hours.

CD4 lymphocytes, CD8 lymphocytes and NK cells were also isolated from mononuclear cells using CD4, CD8 and CD56 Miltenyi beads, positive VS selection columns and a Vario Magnet according to the manufacturer's instructions. CD45RA and CD45RO CD4 lymphocytes were isolated by depleting mononuclear cells of CD8, CD56, CD14 and CD19 cells using CD8, CD56, CD14 and CD19 Miltenyi beads and positive selection. Then CD45RO beads were used to isolate the CD45RO CD4 lymphocytes with the remaining cells being CD45RA CD4 lymphocytes. CD45RA CD4, CD45RO CD4 and CD8 lymphocytes were placed in DMEM 5% FCS (Hyclone), 100  $\mu$ M non essential amino acids (Gibco), 1 mM sodium pyruvate (Gibco), mercaptoethanol  $5.5 \times 10^{-5}$  M (Gibco), and 10 mM Hepes (Gibco) and plated at  $10^6$  cells/ml onto Falcon 6 well tissue culture plates that had been coated overnight with 0.5  $\mu$ g/ml anti-CD28 (Pharmingen) and 3  $\mu$ g/ml anti-CD3 (OKT3, ATCC) in PBS. After 6 and 24 hours, the cells were harvested for RNA preparation. To prepare chronically activated CD8 lymphocytes, we activated the isolated CD8 lymphocytes for 4 days on anti-CD28 and anti-CD3 coated plates and then harvested the cells and expanded them in DMEM 5% FCS (Hyclone), 100  $\mu$ M non essential amino acids (Gibco), 1 mM sodium

pyruvate (Gibco), mercaptoethanol  $5.5 \times 10^{-5}$  M (Gibco), and 10 mM Hepes (Gibco) and IL-2. The expanded CD8 cells were then activated again with plate bound anti-CD3 and anti-CD28 for 4 days and expanded as before. RNA was isolated 6 and 24 hours after the second activation and after 4 days of the second expansion culture. The isolated NK cells were  
5 cultured in DMEM 5% FCS (Hyclone), 100  $\mu$ M non essential amino acids (Gibco), 1 mM sodium pyruvate (Gibco), mercaptoethanol  $5.5 \times 10^{-5}$  M (Gibco), and 10 mM Hepes (Gibco) and IL-2 for 4-6 days before RNA was prepared.

To obtain B cells, tonsils were procured from NDRI. The tonsil was cut up with sterile dissecting scissors and then passed through a sieve. Tonsil cells were then spun down and  
10 resuspended at  $10^6$  cells/ml in DMEM 5% FCS (Hyclone), 100  $\mu$ M non essential amino acids (Gibco), 1 mM sodium pyruvate (Gibco), mercaptoethanol  $5.5 \times 10^{-5}$  M (Gibco), and 10 mM Hepes (Gibco). To activate the cells, we used PWM at 5  $\mu$ g/ml or anti-CD40 (Pharmingen) at approximately 10  $\mu$ g/ml and IL-4 at 5-10 ng/ml. Cells were harvested for RNA preparation at 24, 48 and 72 hours.

To prepare the primary and secondary Th1/Th2 and Tr1 cells, six-well Falcon plates were coated overnight with 10  $\mu$ g/ml anti-CD28 (Pharmingen) and 2  $\mu$ g/ml OKT3 (ATCC), and then washed twice with PBS. Umbilical cord blood CD4 lymphocytes (Poietic Systems, German Town, MD) were cultured at  $10^5$  -  $10^6$  cells/ml in DMEM 5% FCS (Hyclone), 100  $\mu$ M non essential amino acids (Gibco), 1 mM sodium pyruvate (Gibco), mercaptoethanol  $5.5 \times 10^{-5}$  M (Gibco), 10 mM Hepes (Gibco) and IL-2 (4 ng/ml). IL-12 (5 ng/ml) and anti-IL4 (1  
20  $\mu$ g/ml) were used to direct to Th1, while IL-4 (5 ng/ml) and anti-IFN gamma (1  $\mu$ g/ml) were used to direct to Th2 and IL-10 at 5 ng/ml was used to direct to Tr1. After 4-5 days, the activated Th1, Th2 and Tr1 lymphocytes were washed once in DMEM and expanded for 4-7 days in DMEM 5% FCS (Hyclone), 100  $\mu$ M non essential amino acids (Gibco), 1 mM sodium  
25 pyruvate (Gibco), mercaptoethanol  $5.5 \times 10^{-5}$  M (Gibco), 10 mM Hepes (Gibco) and IL-2 (1 ng/ml). Following this, the activated Th1, Th2 and Tr1 lymphocytes were re-stimulated for 5 days with anti-CD28/OKT3 and cytokines as described above, but with the addition of anti-CD95L (1  $\mu$ g/ml) to prevent apoptosis. After 4-5 days, the Th1, Th2 and Tr1 lymphocytes were washed and then expanded again with IL-2 for 4-7 days. Activated Th1 and Th2  
30 lymphocytes were maintained in this way for a maximum of three cycles. RNA was prepared from primary and secondary Th1, Th2 and Tr1 after 6 and 24 hours following the second and third activations with plate bound anti-CD3 and anti-CD28 mAbs and 4 days into the second and third expansion cultures in Interleukin 2.



The following leukocyte cells lines were obtained from the ATCC: Ramos, EOL-1, KU-812. EOL cells were further differentiated by culture in 0.1 mM dbcAMP at  $5 \times 10^5$  cells/ml for 8 days, changing the media every 3 days and adjusting the cell concentration to  $5 \times 10^5$  cells/ml. For the culture of these cells, we used DMEM or RPMI (as recommended by the ATCC), with the addition of 5% FCS (Hyclone), 100  $\mu$ M non essential amino acids (Gibco), 1 mM sodium pyruvate (Gibco), mercaptoethanol  $5.5 \times 10^{-5}$  M (Gibco), 10 mM Hepes (Gibco). RNA was either prepared from resting cells or cells activated with PMA at 10 ng/ml and ionomycin at 1  $\mu$ g/ml for 6 and 14 hours. Keratinocyte line CCD106 and an airway epithelial tumor line NCI-H292 were also obtained from the ATCC. Both were cultured in DMEM 5% FCS (Hyclone), 100  $\mu$ M non essential amino acids (Gibco), 1 mM sodium pyruvate (Gibco), mercaptoethanol  $5.5 \times 10^{-5}$  M (Gibco), and 10 mM Hepes (Gibco). CCD1106 cells were activated for 6 and 14 hours with approximately 5 ng/ml TNF alpha and 1 ng/ml IL-1 beta, while NCI-H292 cells were activated for 6 and 14 hours with the following cytokines: 5 ng/ml IL-4, 5 ng/ml IL-9, 5 ng/ml IL-13 and 25 ng/ml IFN gamma.

For these cell lines and blood cells, RNA was prepared by lysing approximately  $10^7$  cells/ml using Trizol (Gibco BRL). Briefly, 1/10 volume of bromochloropropane (Molecular Research Corporation) was added to the RNA sample, vortexed and after 10 minutes at room temperature, the tubes were spun at 14,000 rpm in a Sorvall SS34 rotor. The aqueous phase was removed and placed in a 15 ml Falcon Tube. An equal volume of isopropanol was added and left at -20 degrees C overnight. The precipitated RNA was spun down at 9,000 rpm for 15 min in a Sorvall SS34 rotor and washed in 70% ethanol. The pellet was redissolved in 300  $\mu$ l of RNase-free water and 35  $\mu$ l buffer (Promega) 5  $\mu$ l DTT, 7  $\mu$ l RNAsin and 8  $\mu$ l DNase were added. The tube was incubated at 37 degrees C for 30 minutes to remove contaminating genomic DNA, extracted once with phenol chloroform and re-precipitated with 1/10 volume of 3 M sodium acetate and 2 volumes of 100% ethanol. The RNA was spun down and placed in RNase free water. RNA was stored at -80 degrees C.

#### **Panels CNSD.01, CNS\_1 and CNS\_1.1**

The plates for Panel CNSD.01, CNS\_1 and CNS1.1 include two control wells and 94 test samples comprised of cDNA isolated from postmortem human brain tissue obtained from the Harvard Brain Tissue Resource Center. Brains are removed from calvaria of donors between 4 and 24 hours after death, sectioned by neuroanatomists, and frozen at -80°C in liquid nitrogen vapor. All brains are sectioned and examined by neuropathologists to confirm diagnoses with clear associated neuropathology.

Disease diagnoses are taken from patient records. The panel contains two brains from each of the following diagnoses: Alzheimer's disease, Parkinson's disease, Huntington's disease, Progressive Supranuclear Palsy, Depression, and "Normal controls". Within each of these brains, the following regions are represented: cingulate gyrus, temporal pole, globus palladus, substantia nigra, Brodman Area 4 (primary motor strip), Brodman Area 7 (parietal cortex), Brodman Area 9 (prefrontal cortex), and Brodman area 17 (occipital cortex). Not all brain regions are represented in all cases; e.g., Huntington's disease is characterized in part by neurodegeneration in the globus palladus, thus this region is impossible to obtain from confirmed Huntington's cases. Likewise Parkinson's disease is characterized by degeneration of the substantia nigra making this region more difficult to obtain. Normal control brains were examined for neuropathology and found to be free of any pathology consistent with neurodegeneration.

In the labels employed to identify tissues in the CNS panel, the following abbreviations are used:

*PSP = Progressive supranuclear palsy*

Sub Nigra = Substantia nigra

Glob Palladus= Globus palladus

Temp Pole = Temporal pole

Cing Gyr = Cingulate gyrus

BA 4 = Brodman Area 4

#### **Panel CNS\_Neurodegeneration\_V1.0**

The plates for Panel CNS\_Neurodegeneration\_V1.0 include two control wells and 47 test samples comprised of cDNA isolated from postmortem human brain tissue obtained from the Harvard Brain Tissue Resource Center (McLean Hospital) and the Human Brain and Spinal Fluid Resource Center (VA Greater Los Angeles Healthcare System). Brains are removed from calvaria of donors between 4 and 24 hours after death, sectioned by neuroanatomists, and frozen at -80°C in liquid nitrogen vapor. All brains are sectioned and examined by neuropathologists to confirm diagnoses with clear associated neuropathology.

Disease diagnoses are taken from patient records. The panel contains six brains from Alzheimer's disease (AD) patients, and eight brains from "Normal controls" who showed no evidence of dementia prior to death. The eight normal control brains are divided into two categories: Controls with no dementia and no Alzheimer's like pathology (Controls) and

controls with no dementia but evidence of severe Alzheimer's like pathology, (specifically senile plaque load rated as level 3 on a scale of 0-3; 0 = no evidence of plaques, 3 = severe AD senile plaque load). Within each of these brains, the following regions are represented:

hippocampus, temporal cortex (Broddmann Area 21), parietal cortex (Broddmann area 7), and occipital cortex (Brodmann area 17). These regions were chosen to encompass all levels of neurodegeneration in AD. The hippocampus is a region of early and severe neuronal loss in AD; the temporal cortex is known to show neurodegeneration in AD after the hippocampus; the parietal cortex shows moderate neuronal death in the late stages of the disease; the occipital cortex is spared in AD and therefore acts as a "control" region within AD patients.

Not all brain regions are represented in all cases.

In the labels employed to identify tissues in the CNS\_Neurodegeneration\_V1.0 panel, the following abbreviations are used:

AD = Alzheimer's disease brain; patient was demented and showed AD-like pathology upon autopsy

Control = Control brains; patient not demented, showing no neuropathology

Control (Path) = Control brains; pateint not demented but showing sever AD-like pathology

SupTemporal Ctx = Superior Temporal Cortex

Inf Temporal Ctx = Inferior Temporal Cortex

#### NOV1: ALPHA-2-MACROGLOBULIN

Expression of the NOV1 gene (SC\_78316254\_A) was assessed using the primer-probe sets Ag1180 and Ag1312, described in Table 13. Results from RTQ-PCR runs are shown in Tables 14, 15, 16, 17, 18 and 19.

Table 13. Probe Name Ag1180/Ag1312 (Identical Sequence)

Primers	Sequences	TM	Length	Start Position	SEQ ID NO:
Forward	5'-CCTGGAATAGGGTACCAGAAG-3'	59	22	3027	149
Probe	FAM-5'ACACAGCAATGGCTCATACAGTGCCT-3'-TAMRA	68.9	26	3063	150
Reverse	5'-TCAGCCATGTGTTTCCATT-3'	59	20	3105	151

Table 14. Panel 1.2

Tissue Name	Relative Expression(%)	Relative Expression(%)
-------------	------------------------	------------------------

	1.2tm1392f_ ag1180	1.2tm1998f_ ag1180
Endothelial cells	0.0	0.0
Heart (fetal)	0.0	0.0
Pancreas	0.0	0.0
Pancreatic ca. CAPAN 2	1.0	2.6
Adrenal Gland (new lot*)	0.0	0.0
Thyroid	0.0	0.0
Salivary gland	1.7	7.6
Pituitary gland	0.2	0.0
Brain (fetal)	0.1	0.0
Brain (whole)	0.6	0.4
Brain (amygdala)	0.8	1.1
Brain (cerebellum)	0.0	0.1
Brain (hippocampus)	1.1	2.6
Brain (thalamus)	0.3	1.4
Cerebral Cortex	2.3	4.7
Spinal cord	3.0	1.2
CNS ca. (glio/astro) U87-MG	0.0	0.0
CNS ca. (glio/astro) U-118-MG	0.0	0.0
CNS ca. (astro) SW1783	0.0	0.0
CNS ca.* (neuro; met ) SK-N-AS	0.0	0.0
CNS ca. (astro) SF-539	0.0	0.0
CNS ca. (astro) SNB-75	0.0	0.0
CNS ca. (glio) SNB-19	0.0	0.0
CNS ca. (glio) U251	0.0	0.0
CNS ca. (glio) SF-295	0.0	0.0
Heart	0.0	0.2
Skeletal Muscle (new lot*)	5.4	0.0
Bone marrow	0.0	0.0
Thymus	0.5	0.5
Spleen	0.0	0.0
Lymph node	0.0	0.0
Colorectal	0.0	0.0
Stomach	4.5	2.1
Small intestine	0.0	0.0
Colon ca. SW480	0.0	0.0
Colon ca.* (SW480 met)SW620	0.0	0.0
Colon ca. HT29	0.0	0.0
Colon ca. HCT-116	0.0	0.0
Colon ca. CaCo-2	0.0	0.0
83219 CC Well to Mod Diff (ODO3866)	0.0	0.0
Colon ca. HCC-2998	0.0	0.0
Gastric ca.* (liver met) NCI-N87	100.0	100.0
Bladder	0.0	0.0
Trachea	1.1	0.2

Kidney	0.0	0.0
Kidney (fetal)	0.0	0.0
Renal ca. 786-0	0.0	0.0
Renal ca. A498	0.0	0.0
Renal ca. RXF 393	0.0	0.0
Renal ca. ACHN	0.0	0.0
Renal ca. UO-31	0.0	0.0
Renal ca. TK-10	0.0	0.0
Liver	0.0	0.0
Liver (fetal)	0.0	0.0
Liver ca. (hepatoblast) HepG2	0.0	0.0
Lung	0.0	0.0
Lung (fetal)	0.0	0.0
Lung ca. (small cell) LX-1	0.0	0.0
Lung ca. (small cell) NCI-H69	0.0	0.0
Lung ca. (s.cell var.) SHP-77	0.0	0.0
Lung ca. (large cell) NCI-H460	0.0	0.0
Lung ca. (non-sm. cell) A549	0.0	0.0
Lung ca. (non-s.cell) NCI-H23	0.0	0.0
Lung ca. (non-s.cell) HOP-62	0.0	0.0
Lung ca. (non-s.cl) NCI-H522	0.0	0.1
Lung ca. (squam.) SW 900	0.0	0.0
Lung ca. (squam.) NCI-H596	0.0	0.0
Mammary gland	1.1	1.8
Breast ca.* (pl. effusion) MCF-7	0.0	0.0
Breast ca.* (pl.ef) MDA-MB-231	0.0	0.0
Breast ca.* (pl. effusion) T47D	0.0	0.0
Breast ca. BT-549	0.0	0.0
Breast ca. MDA-N	0.0	0.0
Ovary	0.1	0.3
Ovarian ca. OVCAR-3	0.2	0.2
Ovarian ca. OVCAR-4	0.0	0.0
Ovarian ca. OVCAR-5	0.0	0.0
Ovarian ca. OVCAR-8	0.0	0.0
Ovarian ca. IGROV-1	0.0	0.2
Ovarian ca.* (ascites) SK-OV-3	0.0	0.0
Uterus	0.0	0.2
Placenta	1.6	0.4
Prostate	0.4	1.4
Prostate ca.* (bone met) PC-3	0.0	0.0
Testis	4.0	0.7
Melanoma Hs688(A).T	0.0	0.0
Melanoma* (met) Hs688(B).T	0.0	0.0
Melanoma UACC-62	0.0	0.0
Melanoma M14	0.0	0.0

Melanoma LOX IMVI	0.0	0.0
Melanoma* (met) SK-MEL-5	0.0	0.0

Table 15. Panel 1.3D

Tissue Name	Relative Expression(%)	Tissue Name	Relative Expression(%)
	1.3dx4tm5588 f ag1180_a2		1.3dx4tm5588 f ag1180_a2
Liver adenocarcinoma	0.0	Kidney (fetal)	0.0
Pancreas	0.0	Renal ca. 786-0	0.0
Pancreatic ca. CAPAN 2	11.3	Renal ca. A498	0.0
Adrenal gland	0.0	Renal ca. RXF 393	0.0
Thyroid	1.6	Renal ca. ACHN	0.0
Salivary gland	7.6	Renal ca. UO-31	0.0
Pituitary gland	0.8	Renal ca. TK-10	0.0
Brain (fetal)	4.5	Liver	0.0
Brain (whole)	8.9	Liver (fetal)	0.0
Brain (amygdala)	22.7	Liver ca. (hepatoblast) HepG2	0.0
Brain (cerebellum)	8	Lung	0.0
Brain (hippocampus)	4.9	Lung (fetal)	0.9
Brain (substantia nigra)	1.9	Lung ca. (small cell) LX-1	0.0
Brain (thalamus)	6.7	Lung ca. (small cell) NCI-H69	0.0
Cerebral Cortex	6.8	Lung ca. (s.cell var.) SHP-77	0.0
Spinal cord	47.6	Lung ca. (large cell) NCI-H460	0.0
CNS ca. (glio/astro) U87-MG	0.0	Lung ca. (non-sm. cell) A549	0.0
CNS ca. (glio/astro) U-118-MG	0.0	Lung ca. (non-s.cell) NCI-H23	0.0
CNS ca. (astro) SW1783	0.0	Lung ca. (non-s.cell) HOP-62	0.0
CNS ca.* (neuro; met) SK-N-AS	0.0	Lung ca. (non-s.cl) NCI-H522	0.0
CNS ca. (astro) SF-539	0.0	Lung ca. (squam.) SW 900	0.0
CNS ca. (astro) SNB-75	0.0	Lung ca. (squam.) NCI-H596	0.0
CNS ca. (glio) SNB-19	0.0	Mammary gland	3.0
CNS ca. (glio) U251	0.0	Breast ca.* (pl. effusion) MCF-7	0.9
CNS ca. (glio) SF-295	0.0	Breast ca.* (pl.ef) MDA-MB-231	0.0
Heart (fetal)	0.0	Breast ca.* (pl. effusion) T47D	0.0
Heart	0.0	Breast ca. BT-549	0.0
Fetal Skeletal	0.0	Breast ca. MDA-N	0.0
Skeletal muscle	0.9	Ovary	2.5
Bone marrow	0.0	Ovarian ca. OVCAR-3	0.2
Thymus	14	Ovarian ca. OVCAR-4	0.0
Spleen	1.4	Ovarian ca. OVCAR-5	0.0
Lymph node	0.0	Ovarian ca. OVCAR-8	0.0
Colorectal	0.0	Ovarian ca. IGROV-1	0.0
Stomach	17.8	Ovarian ca.* (ascites) SK-OV-3	0.3
Small intestine	0.0	Uterus	0.0
Colon ca. SW480	0.0	Placenta	11.3

Colon ca.* (SW480 met)SW620.0	0.0	Prostate	0.0
Colon ca. HT29	0.0	Prostate ca.* (bone met)PC-3	0.0
Colon ca. HCT-116	0.0	Testis	17.1
Colon ca. CaCo-2	0.0	Melanoma Hs688(A).T	0.0
83219 CC Well to Mod Diff (ODO3866)	0.0	Melanoma* (met) Hs688(B).T	0.0
Colon ca. HCC-2998	0.0	Melanoma UACC-62	0.9
Gastric ca.* (liver met) NCI-N87	100	Melanoma M14	0.0
Bladder	0.0	Melanoma LOX IMVI	0.0
Trachea	7.6	Melanoma* (met) SK-MEL-5	0.0
Kidney	0.4	Adipose	0.0

Table 16. Panel 2D

Tissue Name	Relative Expression(%)	Tissue Name	Relative Expression(%)
	2dx4tm4715f_a g1180_a2		2dx4tm4715f_a g1180_a2
Normal Colon GENPAK 061003	0.1	Kidney NAT Clontech 8120608	0.0
83219 CC Well to Mod Diff (ODO3866)	0.1	Kidney Cancer Clontech 8120613	0.0
83220 CC NAT (ODO3866)	0.0	Kidney NAT Clontech 8120614	0.0
83221. CC Gr.2 rectosigmoid (ODO3868)	0.0	Kidney Cancer Clontech 9010320	0.0
83222 CC NAT (ODO3868)	0.0	Kidney NAT Clontech 9010321	0.0
83235 CC Mod Diff (ODO3920)	0.0	Normal Uterus GENPAK 061018	0.0
83236 CC NAT (ODO3920)	0.0	Uterus Cancer GENPAK 064011	0.4
83237 CC Gr.2 ascend colon (ODO3921)	0.0	Normal Thyroid Clontech A+ 6570-1	0.4
83238 CC NAT (ODO3921)	0.0	Thyroid Cancer GENPAK 064010	0.0
83241 CC from Partial Hepatectomy (ODO4309)	0.0	Thyroid Cancer INVITROGEN A302152	0.0
83242 Liver NAT (ODO4309)	0.0	Thyroid NAT INVITROGEN A302153	0.0
87472 Colon mets to lung (OD04451-01)	0.0	Normal Breast GENPAK 061019	0.1
87473 Lung NAT (OD04451-02)	0.0	84877 Breast Cancer (OD04566)	0.0
Normal Prostate Clontech A+ 6546-1	3.3	85975 Breast Cancer (OD04590-01)	0.0
84140 Prostate Cancer (OD04410)	0.0	85976 Breast Cancer Mets (OD04590-03)	0.0
84141 Prostate NAT (OD04410)	0.6	87070 Breast Cancer Metastasis (OD04655-05)	0.0
87073 Prostate Cancer (OD04720-01)	0.5	GENPAK Breast Cancer 064006	1.2
87074 Prostate NAT (OD04720-02)	0.8	Breast Cancer Res. Gen. 1024	0.0
Normal Lung GENPAK 061010	0.1	Breast Cancer Clontech 9100266	0.0
83239 Lung Met to Muscle (ODO4286)	0.0	Breast NAT Clontech 9100265	0.0
83240 Muscle NAT (ODO4286)	0.0	Breast Cancer INVITROGEN A209073	0.2
84136 Lung Malignant Cancer	0.0	Breast NAT INVITROGEN	0.1

(OD03126)		A2090734	
84137 Lung NAT (OD03126)	0.0	Normal Liver GENPAK 061009	0.0
84871 Lung Cancer (OD04404)	18.5	Liver Cancer GENPAK 064003	0.0
84872 Lung NAT (OD04404)	0.0	Liver Cancer Research Genetics RNA 1025	0.0
84875 Lung Cancer (OD04565)	0.1	Liver Cancer Research Genetics RNA 1026	0.0
84876 Lung NAT (OD04565)	0.0	Paired Liver Cancer Tissue Research Genetics RNA 6004-T	0.0
85950 Lung Cancer (OD04237-01)	0.0	Paired Liver Tissue Research Genetics RNA 6004-N	0.0
85970 Lung NAT (OD04237-02)	0.0	Paired Liver Cancer Tissue Research Genetics RNA 6005-T	0.0
83255 Ocular Mel Met to Liver (ODO4310)	0.1	Paired Liver Tissue Research Genetics RNA 6005-N	0.0
83256 Liver NAT (ODO4310)	0.0	Normal Bladder GENPAK 061001	0.0
84139 Melanoma Mets to Lung (OD04321)	0.0	Bladder Cancer Research Genetics RNA 1023	0.0
84138 Lung NAT (OD04321)	0.0	Bladder Cancer INVITROGEN A302173	13.0
Normal Kidney GENPAK 061008	0.0	87071 Bladder Cancer (OD04718-01)	0.6
83786 Kidney Ca, Nuclear grade 2 (OD04338)	0.0	87072 Bladder Normal Adjacent (OD04718-03)	0.0
83787 Kidney NAT (OD04338)	0.0	Normal Ovary Res. Gen.	0.0
83788 Kidney Ca Nuclear grade 1/2 (OD04339)	0.0	Ovarian Cancer GENPAK 064008	0.8
83789 Kidney NAT (OD04339)	0.0	87492 Ovary Cancer (OD04768-07)	100
83790 Kidney Ca, Clear cell type (OD04340)	0.0	87493 Ovary NAT (OD04768-08)	0.0
83791 Kidney NAT (OD04340)	0.0	Normal Stomach GENPAK 061017	0.0
83792 Kidney Ca, Nuclear grade 3 (OD04348)	0.0	Gastric Cancer Clontech 9060358	0.0
83793 Kidney NAT (OD04348)	0.0	NAT Stomach Clontech 9060359	0.0
87474 Kidney Cancer (OD04622-01)	0.0	Gastric Cancer Clontech 9060395	0.2
87475 Kidney NAT (OD04622-03)	0.0	NAT Stomach Clontech 9060394	0.0
85973 Kidney Cancer (OD04450-01)	0.0	Gastric Cancer Clontech 9060397	0.1
85974 Kidney NAT (OD04450-03)	0.0	NAT Stomach Clontech 9060396	0.0
Kidney Cancer Clontech 8120607	0.0	Gastric Cancer GENPAK 064005	0.0

Table 17 Panel 2.2

Tissue Name	Relative Expression(%)	Tissue Name	Relative Expression(%)
	2.2x4tm6329f_a g1180 a1		2.2x4tm6329f_a g1180 a1
Normal Colon GENPAK 061003	0.0	83793 Kidney NAT (OD04348)	0.0
97759 Colon cancer (OD06064)	5.0	98938 Kidney malignant cancer (OD06204B)	0.4
97760 Colon cancer NAT (OD06064)	1.6	98939 Kidney normal adjacent tissue (OD06204B)	0.0



97778 Colon cancer (OD06159)	0.0	85973 Kidney Cancer (OD04450-01)	0.0
97779 Colon cancer NAT (OD06159)	0.0	85974 Kidney NAT (OD04450-03)	1.1
98861 Colon cancer (OD06297-04)	0.0	Kidney Cancer Clontech 8120613	0.0
98862 Colon cancer NAT (OD06297-015)	0.0	Kidney NAT Clontech 8120614	0.0
83237 CC Gr.2 ascend colon (ODO3921)	0.0	Kidney Cancer Clontech 9010320	0.0
83238 CC NAT (ODO3921)	0.0	Kidney NAT Clontech 9010321	1.0
97766 Colon cancer metastasis (OD06104)	0.0	Kidney Cancer Clontech 8120607	0.0
97767 Lung NAT (OD06104)	0.0	Kidney NAT Clontech 8120608	0.0
87472 Colon mets to lung (OD04451-01)	0.0	Normal Uterus GENPAK 061018	3.4
87473 Lung NAT (OD04451-02)	0.0	Uterus Cancer GENPAK 064011	0.0
Normal Prostate Clontech A+ 6546-1 (8090438)	0.0	Normal Thyroid Clontech A+ 6570-1 (7080817)	0.0
84140 Prostate Cancer (OD04410)	0.0	Thyroid Cancer GENPAK 064010	0.0
84141 Prostate NAT (OD04410)	1.3	Thyroid Cancer INVITROGEN A302152	0.0
Normal Ovary Res. Gen.	1.9	Thyroid NAT INVITROGEN A302153	0.0
98863 Ovarian cancer (OD06283-03)	0.0	Normal Breast GENPAK 061019	0.0
98865 Ovarian cancer NAT/fallopian tube (OD06283-07)	0.0	84877 Breast Cancer (OD04566)	0.0
Ovarian Cancer GENPAK 064008	8.2	Breast Cancer Res. Gen. 1024	0.0
97773 Ovarian cancer (OD06145)	0.0	85975 Breast Cancer (OD04590-01)	0.0
97775 Ovarian cancer NAT (OD06145)	0.0	85976 Breast Cancer Mets (OD04590-03)	0.0
98853 Ovarian cancer (OD06455-03)	5.5	87070 Breast Cancer Metastasis (OD04655-05)	0.4
98854 Ovarian NAT (OD06455-07) Fallopian tube	0.0	GENPAK Breast Cancer 064006	12.1
Normal Lung GENPAK 061010	0.0	Breast Cancer Clontech 9100266	0.0
92337 Invasive poor diff. lung adeno (ODO4945-01)	9.6	Breast NAT Clontech 9100265	0.0
92338 Lung NAT (ODO4945-03)	0.0	Breast Cancer INVITROGEN A209073	0.3
84136 Lung Malignant Cancer (OD03126)	0.0	Breast NAT INVITROGEN A2090734	0.0
84137 Lung NAT (OD03126)	0.7	97763 Breast cancer (OD06083)	1.8
90372 Lung Cancer (OD05014A)	0.0	97764 Breast cancer node metastasis (OD06083)	0.0
90373 Lung NAT (OD05014B)	0.0	Normal Liver GENPAK 061009	0.2
97761 Lung cancer (OD06081)	5.9	Liver Cancer Research Genetics RNA 1026	0.0
97762 Lung cancer NAT (OD06081)	0.0	Liver Cancer Research Genetics RNA 1025	1.0
85950 Lung Cancer (OD04237-01)	0.0	Paired Liver Cancer Tissue Research Genetics RNA 6004-T	2.1
85970 Lung NAT (OD04237-02)	0.0	Paired Liver Tissue Research Genetics RNA 6004-N	0.0
83255 Ocular Mel Met to Liver	0.0	Paired Liver Cancer Tissue	0.0

(ODO4310)		Research Genetics RNA 6005-T	
83256 Liver NAT (ODO4310)	0.0	Paired Liver Tissue Research Genetics RNA 6005-N	0.5
84139 Melanoma Mets to Lung (OD04321)	0.0	Liver Cancer GENPAK 064003	0.5
84138 Lung NAT (OD04321)	0.0	Normal Bladder GENPAK 061001	0.0
Normal Kidney GENPAK 061008	0.0	Bladder Cancer Research Genetics RNA 1023	0.0
83786 Kidney Ca, Nuclear grade 2 (OD04338)	0.0	Bladder Cancer INVITROGEN A302173	100.0
83787 Kidney NAT (OD04338)	0.0	Normal Stomach GENPAK 061017	1.6
83788 Kidney Ca Nuclear grade 1/2 (OD04339)	0.4	Gastric Cancer Clontech 9060397	0.0
83789 Kidney NAT (OD04339)	0.0	NAT Stomach Clontech 9060396	0.0
83790 Kidney Ca, Clear cell type (OD04340)	0.0	Gastric Cancer Clontech 9060395	2.3
83791 Kidney NAT (OD04340)	0.0	NAT Stomach Clontech 9060394	1.9
83792 Kidney Ca, Nuclear grade 3 (OD04348)	0.0	Gastric Cancer GENPAK 064005	0.0

Table 18. Panel 3D

Tissue Name	Relative Expression(%)	Tissue Name	Relative Expression(%)
	3dtm4779f_ag1180		3dtm4779f_ag1180
94905_Daoy_Medulloblastoma/Cerebellum_sscDNA	0	94954_Ca Ski_Cervical epidermoid carcinoma (metastasis)_sscDNA	0
94906_TE671_Medulloblastoma/Cerebellum_sscDNA	0	94955_ES-2_Ovarian clear cell carcinoma_sscDNA	0
94907_D283_Med_Medulloblastoma/Cerebellum_sscDNA	0	94957_Ramos/6h stim_Stimulated with PMA/ionomycin 6h_sscDNA	0
94908_PFSK-1_Primitive Neuroectodermal/Cerebellum_sscDNA	0	94958_Ramos/14h stim_Stimulated with PMA/ionomycin 14h_sscDNA	0
94909_XF-498_CNS_sscDNA	0.0	94962_MEG-01_Chronic myelogenous leukemia (megakaryoblast)_sscDNA	0.0
94910_SNB-78_CNS/glioma_sscDNA	0.0	94963_Raji_Burkitt's lymphoma_sscDNA	0.0
94911_SF-268_CNS/glioblastoma_sscDNA	0.0	94964_Daudi_Burkitt's lymphoma_sscDNA	0.0
94912_T98G_Glioblastoma_sscDNA	0.0	94965_U266_B-cell plasmacytoma/myeloma_sscDNA	0.0
96776_SK-N-SH_Neuroblastoma (metastasis)_sscDNA	0.0	94968_CA46_Burkitt's lymphoma_sscDNA	0.0
94913_SF-295_CNS/glioblastoma_sscDNA	0.0	94970_RL_non-Hodgkin's B-cell lymphoma_sscDNA	0.0
94914_Cerebellum_sscDNA	2.4	94972_JM1_pre-B-cell lymphoma/leukemia_sscDNA	0.0
96777_Cerebellum_sscDNA	0.5	94973_Jurkat_T cell leukemia_sscDNA	0.0
94916_NCI-H292_Mucoepidermoid lung	0.0	94974_TF-1_Erythroleukemia_sscDNA	0.0

carcinoma_sscDNA			
94917_DMS-114_Small cell lung cancer_sscDNA	0.0	94975_HUT 78_T-cell lymphoma_sscDNA	0.0
94918_DMS-79_Small cell lung cancer/neuroendocrine_sscDNA	0.0	94977_U937_Histiocytic lymphoma_sscDNA	0.0
94919_NCI-H146_Small cell lung cancer/neuroendocrine_sscDNA	0.0	94980_KU-812_Myelogenous leukemia_sscDNA	0.3
94920_NCI-H526_Small cell lung cancer/neuroendocrine_sscDNA	0.0	94981_769-P_Clear cell renal carcinoma_sscDNA	0.0
94921_NCI-N417_Small cell lung cancer/neuroendocrine_sscDNA	0.0	94983_Caki-2_Clear cell renal carcinoma_sscDNA	0.0
94923_NCI-H82_Small cell lung cancer/neuroendocrine_sscDNA	0.0	94984_SW 839_Clear cell renal carcinoma_sscDNA	0.0
94924_NCI-H157_Squamous cell lung cancer (metastasis)_sscDNA	0.0	94986_G401_Wilms' tumor_sscDNA	0.0
94925_NCI-H1155_Large cell lung cancer/neuroendocrine_sscDNA	0.0	94987_Hs766T_Pancreatic carcinoma (LN metastasis)_sscDNA	0.0
94926_NCI-H1299_Large cell lung cancer/neuroendocrine_sscDNA	0.0	94988_CAPAN-1_Pancreatic adenocarcinoma (liver metastasis)_sscDNA	2.3
94927_NCI-H727_Lung carcinoid_sscDNA	0.0	94989_SU86.86_Pancreatic carcinoma (liver metastasis)_sscDNA	0.2
94928_NCI-UMC-11_Lung carcinoid_sscDNA	0.3	94990_BxPC-3_Pancreatic adenocarcinoma_sscDNA	0.3
94929_LX-1_Small cell lung cancer_sscDNA	0.0	94991_HPAC_Pancreatic adenocarcinoma_sscDNA	4.9
94930_Colo-205_Colon cancer_sscDNA	0.0	94992_MIA PaCa-2_Pancreatic carcinoma_sscDNA	0.0
94931_KM12_Colon cancer_sscDNA	100.0	94993_CFPAC-1_Pancreatic ductal adenocarcinoma_sscDNA	0.0
94932_KM20L2_Colon cancer_sscDNA	0.0	94994_PANC-1_Pancreatic epithelioid ductal carcinoma_sscDNA	0.0
94933_NCI-H716_Colon cancer_sscDNA	0.0	94996_T24_Bladder carcinma (transitional cell)_sscDNA	0.0
94935_SW-48_Colon adenocarcinoma_sscDNA	0.0	94997_5637_Bladder carcinoma_sscDNA	2.1
94936_SW1116_Colon adenocarcinoma_sscDNA	1.3	94998_HT-1197_Bladder carcinoma_sscDNA	2.6
94937_LS 174T_Colon adenocarcinoma_sscDNA	0.0	94999_UM-UC-3_Bladder carcinma (transitional cell)_sscDNA	0.0
94938_SW-948_Colon adenocarcinoma_sscDNA	0.0	95000_A204_Rhabdomyosarcoma_sscDNA	0.0
94939_SW-480_Colon adenocarcinoma_sscDNA	0.0	95001_HT-1080_Fibrosarcoma_sscDNA	0.0
94940_NCI-SNU-5_Gastric carcinoma_sscDNA	0.0	95002_MG-63_Osteosarcoma (bone)_sscDNA	0.0
94941_KATO III_Gastric carcinoma_sscDNA	0.0	95003_SK-LMS-1_Leiomyosarcoma (vulva)_sscDNA	0.0
94943_NCI-SNU-16_Gastric carcinoma_sscDNA	0.0	95004_SJRH30_Rhabdomyosarcoma (met to bone marrow)_sscDNA	0.0
94944_NCI-SNU-1_Gastric carcinoma_sscDNA	0.0	95005_A431_Epidermoid carcinoma_sscDNA	0.0
94946_RF-1_Gastric adenocarcinoma_sscDNA	0.0	95007_WM266-4_Melanoma_sscDNA	0.0

94947_RF-48_Gastric adenocarcinoma sscDNA	0.0	95010_DU 145_Prostate carcinoma (brain metastasis) sscDNA	0.0
96778_MKN-45_Gastric carcinoma sscDNA	0.0	95012_MDA-MB-468_Breast adenocarcinoma sscDNA	0.3
94949_NCI-N87_Gastric carcinoma sscDNA	86.5	95013_SCC-4_Squamous cell carcinoma of tongue sscDNA	4.8
94951_OVCAR-5_Ovarian carcinoma sscDNA	0.0	95014_SCC-9_Squamous cell carcinoma of tongue sscDNA	0.0
94952_RL95-2_Uterine carcinoma sscDNA	1.3	95015_SCC-15_Squamous cell carcinoma of tongue sscDNA	0.0
94953_HelaS3_Cervical adenocarcinoma sscDNA	0.0	95017_CAL 27_Squamous cell carcinoma of tongue sscDNA	2.4

Table 19. Panel 4D/4R

Tissue Name	Relative Expression(%)		Relative Expression(%)		
	4dtm1922f_ag1180	4rtm1957f_ag1180	4Dtm1889_f ag1312	4Dtm1914f_a_g1312	4Rtm2856_f ag1312
93768_Secondary Th1_anti-CD28/anti-CD3	0.0	0.0	0.0	17.8	0.0
93769_Secondary Th2_anti-CD28/anti-CD3	0.0	0.0	0.0	0.0	0.0
93770_Secondary Tr1_anti-CD28/anti-CD3	0.0	0.0	0.0	0.0	0.0
93573_Secondary Th1_resting day 4-6 in IL-2	0.0	0.0	0.0	0.0	0.0
93572_Secondary Th2_resting day 4-6 in IL-2	0.0	0.0	0.0	0.0	0.0
93571_Secondary Tr1_resting day 4-6 in IL-2	0.0	0.0	0.0	0.0	0.0
93568_primary Th1_anti-CD28/anti-CD3	0.0	0.0	0.0	0.0	0.0
93569_primary Th2_anti-CD28/anti-CD3	0.1	0.0	0.1	0.0	0.0
93570_primary Tr1_anti-CD28/anti-CD3	0.0	0.0	0.0	0.0	0.0
93565_primary Th1_resting dy 4-6 in IL-2	0.0	0.0	0.0	0.0	0.0
93566_primary Th2_resting dy 4-6 in IL-2	0.0	0.0	0.0	0.0	0.0
93567_primary Tr1_resting dy 4-6 in IL-2	0.0	0.0	0.0	0.0	0.0
93351_CD45RA CD4 lymphocyte_anti-CD28/anti-CD3	0.0	0.0	0.0	0.0	0.0
93352_CD45RO CD4 lymphocyte_anti-CD28/anti-CD3	0.0	0.0	0.0	0.0	0.0
93251_CD8 Lymphocytes_anti-CD28/anti-CD3	0.0	0.0	0.0	0.0	0.0
93353_chronic CD8 Lymphocytes 2ry_resting dy 4-6 in IL-2	0.0	0.0	0.0	0.0	0.0
93574_chronic CD8 Lymphocytes 2ry_activated CD3/CD28	0.0	0.0	0.0	0.0	0.0

93354 CD4 none	0.0	0.0	0.0	0.0	0.0
93252_Secondary Th1/Th2/Tr1_anti-CD95 CH11	0.0	0.0	0.0	0.0	0.4
93103_LAK cells resting	0.0	0.0	0.0	0.0	0.0
93788_LAK cells IL-2	0.0	0.0	0.0	0.0	0.0
93787_LAK cells_IL-2+IL- 12	0.0	0.0	0.0	0.0	0.0
93789_LAK cells_IL-2+IFN gamma	0.0	0.0	0.0	0.0	0.0
93790_LAK cells_IL-2+ IL- 18	0.0	0.0	0.0	0.0	0.0
93104_LAK cells_PMA/ionomycin and IL-18	0.0	0.0	0.0	0.0	0.0
93578_NK Cells IL- 2 resting	0.0	0.0	0.0	0.0	0.0
93109_Mixed Lymphocyte Reaction_Two Way MLR	0.0	0.0	0.0	0.0	0.0
93110_Mixed Lymphocyte Reaction_Two Way MLR	0.0	0.0	0.0	0.0	0.0
93111_Mixed Lymphocyte Reaction_Two Way MLR	0.0	0.0	0.0	0.0	0.0
93112_Mononuclear Cells (PBMCs) resting	0.0	0.0	0.0	0.0	0.0
93113_Mononuclear Cells (PBMCs) PWM	0.0	0.0	0.0	0.0	0.0
93114_Mononuclear Cells (PBMCs) PHA-L	0.2	0.0	0.0	0.0	0.0
93249_Ramos (B cell) none	0.0	0.0	0.0	0.0	0.0
93250_Ramos (B cell) ionomycin	0.0	0.0	0.0	0.0	0.0
93349_B lymphocytes PWM	0.0	0.0	0.0	0.0	0.0
93350_B lymphocytes_CD40L and IL- 4	0.0	0.0	0.0	0.0	0.3
92665_EOL-1 (Eosinophil)_dbcAMP differentiated	0.0	0.0	0.0	0.0	0.0
93248_EOL-1 (Eosinophil)_dbcAMP/PMA ionomycin	0.0	0.0	0.0	0.0	0.0
93356_Dendritic Cells none	0.0	0.0	0.0	0.0	0.0
93355_Dendritic Cells_LPS 100 ng/ml	0.0	0.0	0.0	0.0	0.0
93775_Dendritic Cells_anti- CD40	0.0	0.0	0.0	0.0	0.0
93774_Monocytes resting	0.0	0.0	0.0	0.0	0.0
93776_Monocytes_LPS 50 ng/ml	0.1	0.0	0.1	0.0	0.0
93581_Macrophages resting	0.0	0.0	0.0	0.0	0.0
93582_Macrophages_LPS 100 ng/ml	0.0	0.0	0.0	0.0	0.0
93098_HUVEC (Endothelial) none	0.0	0.0	0.0	0.0	0.0

93099_HUVEC (Endothelial) starved	0.0	0.0	0.0	0.0	0.0
93100_HUVEC (Endothelial) IL-1b	0.0	0.0	0.0	0.0	0.0
93779_HUVEC (Endothelial) IFN gamma	0.0	0.0	0.0	0.0	0.0
93102_HUVEC (Endothelial)_TNF alpha + IFN gamma	0.0	0.0	0.0	0.0	0.0
93101_HUVEC (Endothelial)_TNF alpha + IL4	0.0	0.0	0.0	0.0	0.0
93781_HUVEC (Endothelial) IL-11	0.0	0.0	0.0	0.0	0.0
93583 Lung Microvascular Endothelial Cells none	0.0	0.0	0.0	0.0	0.0
93584 Lung Microvascular Endothelial Cells TNFa (4 ng/ml) and IL1b (1 ng/ml)	0.0	0.0	0.0	0.0	0.0
92662_Microvascular Dermal endothelium none	0.0	0.0	0.0	0.0	0.0
92663_Microvascular Dermal endothelium TNFa (4 ng/ml) and IL1b (1 ng/ml)	0.0	0.0	0.0	0.0	0.0
93773_Bronchial epithelium TNFa (4 ng/ml) and IL1b (1 ng/ml) **	5.3	2.0	5.7	3.3	1.7
93347_Small Airway Epithelium none	28.7	32.1	38.7	29.7	41.2
93348_Small Airway Epithelium TNFa (4 ng/ml) and IL1b (1 ng/ml)	100.0	100.0	100.0	100.0	100.0
92668_Coronary Artery SMC resting	0.0	0.0	0.0	0.0	0.0
92669_Coronary Artery SMC TNFa (4 ng/ml) and IL1b (1 ng/ml)	0.0	0.0	0.0	0.0	0.0
93107_astrocytes resting	0.0	0.0	0.0	0.0	0.0
93108_astrocytes TNFa (4 ng/ml) and IL1b (1 ng/ml)	0.0	0.0	0.0	0.0	0.0
92666_KU-812 (Basophil) resting	0.0	0.0	0.0	0.0	0.0
92667_KU-812 (Basophil) PMA/ionoycin	0.0	0.0	0.0	0.1	0.0
93579_CCD1106 (Keratinocytes) none	1.7	0.8	1.7	1.3	1.0
93580_CCD1106 (Keratinocytes)_TNFa and IFNg **	15.3	22.4	14.8	10.9	2.8
93791 Liver Cirrhosis	0.0	0.0	0.0	0.0	0.0
93792 Lupus Kidney	0.0	0.0	0.0	0.0	0.0
93577 NCI-H292	0.3	0.0	0.0	0.0	0.0
93358 NCI-H292 IL-4	0.3	0.0	0.0	0.0	0.3
93360 NCI-H292 IL-9	0.0	0.0	0.0	0.0	0.1
93359 NCI-H292 IL-13	0.0	0.0	0.1	0.0	0.0
93357 NCI-H292 IFN	0.0	0.0	0.0	0.0	0.0

gamma					
93777 HPAEC -	0.0	0.0	0.0	0.0	0.0
93778 HPAEC_IL-1 beta/TNA alpha	0.0	0.0	0.0	0.0	0.0
93254 Normal Human Lung Fibroblast none	0.0	0.0	0.0	0.0	0.0
93253 Normal Human Lung Fibroblast TNFa (4 ng/ml) and IL-1b (1 ng/ml)	0.0	0.0	0.0	0.0	0.0
93257 Normal Human Lung Fibroblast IL-4	0.0	0.0	0.0	0.0	0.0
93256 Normal Human Lung Fibroblast IL-9	0.0	0.0	0.0	0.0	0.0
93255 Normal Human Lung Fibroblast IL-13	0.0	0.0	0.0	0.0	0.0
93258 Normal Human Lung Fibroblast IFN gamma	0.0	0.0	0.0	0.0	0.0
93106 Dermal Fibroblasts CCD1070 resting	0.0	0.0	0.0	0.0	0.0
93361 Dermal Fibroblasts CCD1070 TNF alpha 4 ng/ml	0.0	0.0	0.0	0.0	0.0
93105 Dermal Fibroblasts CCD1070 IL-1 beta 1 ng/ml	0.0	0.0	0.0	0.0	0.0
93772 dermal fibroblast IFN gamma	0.0	0.0	0.0	0.0	0.0
93771 dermal fibroblast IL-4	0.0	0.0	0.0	0.0	0.0
93260 IBD Colitis 2	0.0	0.0	0.0	0.0	0.0
93261 IBD Crohns	0.0	0.0	0.0	0.0	0.0
735010 Colon normal	0.0	0.0	0.0	0.0	0.0
735019 Lung none	0.0	0.0	0.0	0.0	0.0
64028-1 Thymus none	0.1	0.0	0.2	0.0	0.0
64030-1 Kidney none	1.8	3.2	3.0	2.8	2.7

**Panel 1.2 Summary:** Ag1180 Results from two experiments using the same probe/primer sets are in good agreement. The NOV1 gene is most highly expressed in gastric cancer cell lines (CT = 23.7, 24) and at more moderate levels in pancreatic cancer cell lines (CT = 29.0, 30.7). Therefore, expression of the NOV1 gene could be used to distinguish gastric cell line derived material from other samples. In addition, these results suggest that therapeutic modulation of this gene or its protein product could be effective in the treatment of gastric cancer.

Among metabolically relevant tissues, the NOV1 gene is moderately expressed in adult skeletal muscle and adult heart tissue. (adult CT=34.2/32.8: fetal CT=39.6/40) This result suggests that the NOV1 gene, the protein encoded by NOV1 gene, or antibodies designed with the protein could be used to distinguish those tissues from the corresponding fetal tissues.

**Panel 1.3D Summary:** Ag1180 Moderate levels of expression of the NOV1 gene are detected in gastric cancer cell lines (CT=30.4) and lower levels in pancreatic cancer cell lines (CT = 33.5). This result is consistent with the expression profile observed in Panel 1.2. See Panel 1.2 for potential utility of this gene.

5        Among tissues involved in central nervous system function, the NOV1 gene is specifically expressed at low to moderate levels in the amygdala, cerebellum, cortex, hippocampus and thalamus, and expressed highly in the spinal cord and cerebral cortex. Alpha-2-macroglobulin has been implicated in Alzheimer's disease, both genetically and biochemically in the clearance of beta amyloid. The high similarity of the NOV1 gene protein  
10       product to alpha-2-macroglobulin suggests probable similarity of function. Therefore, agents that affect the NOV1 gene product activity may have efficacy in treating Alzheimer's disease. If the NOV1 gene is involved in A-beta clearance, then agents that increase its expression, concentration, or activity may aid in the clearance of A-beta, which is a hallmark of Alzheimer's disease histopathology.

15       **Panel 2D Summary:** Ag1180 Expression of the NOV1 gene is highest in ovarian cancer (CT = 25.6) and is overexpressed in 2/2 ovarian cancers when compared to the normal margins. Furthermore, the NOV1 gene is also overexpressed in bladder cancer, breast cancer and prostate cancer relative to the normal controls. Thus, NOV1 gene expression could be used as a marker of these cancerous tissues. In addition, therapeutic modulation of this gene  
20       product, through the use of small molecule drugs or antibodies, could be useful for the treatment of ovarian, bladder, breast and prostate cancer.

**Panel 2.2 Summary:** Ag1180 Expression of NOV1 is highest in bladder cancer tissue (CT = 31.3) and is overexpressed in bladder cancers when compared to the normal margins. Thus, expression of the NOV1 gene could be used to distinguish bladder cancer from normal  
25       bladder tissue or other tissues. In addition, therepeutic modulation of the NOV1 gene or its protein product could potentially be useful in the treatment of bladder cancer. There is also low but significant expression of the NOV1 gene in ovarian cancer, breast cancer, and lung cancer. Thus, expression of this gene could be used to distinguish between these cancerous tissues and their normal counterparts.

30       **Panel 3D Summary:** Ag1180 The NOV1 gene is moderately expressed in colon cancer cell line (CT = 29.7) and gastric cancer cell line (CT = 29.9) and expressed at low levels in pancreatic cancer cell line (CT = 34). These results are consistent with the expression patterns observed in panels 1.2 and 1.3D. Thus, expression of this gene could be used to distinguish colon and stomach cancers from other tissues.



**Panel 4D/4R Summary: Ag1180/Ag1312** Five experiments using the same

probe/primer set show results that are in excellent agreement. Expression of the NOV1 gene is detected at moderate levels in small airway epithelium (CT = 28) and is slightly upregulated when treated with TNF-alpha + IL-1beta (CT = 26-27). The NOV1 gene encodes a protein that is most likely a macroglobulin-like molecule belonging to a class of proteinase inhibitor that can behave as a potent modulator of the inflammatory reaction and tissue repair mechanism. Therefore, protein therapeutics designed against the NOV1 gene product could modulate the inflammatory responses observed in asthma, emphysema. In addition, the presence of expression in keratinocytes stimulated with the inflammatory cytokines TNF-alpha + IL-1beta (CT = 29) suggests potential utility of the NOV1 gene product in skin related disease such as psoriasis, eczema, and contact dermatitis. Since this class of protein can in some situations act as acute phase protein, antibody targets against the protein encoded by the NOV1 gene might also be useful against the previously mentioned diseases. (Allgayer et al., Clin Exp Metastasis 16(1):62-73, 1998; Khalifa et al., Chemioterapia 6:736-7, 1987; Blacker et al., Nat Genet 19:357-60, 1998; Mikhailenko et al., J Biol Chem. Aug 15, 2001.)

**NOV2: Secreted Proteins Related to Angiogenesis**

Expression of the NOV2 gene (AC005799\_A) was assessed using the primer-probe set Ag1385, described in Table 20. Results from RTQ-PCR runs are shown in Tables 21, 22, and 23.

**Table 20.** Probe Name Ag1385

Primers	Sequences	TM	Length	Start Position	SEQ ID NO:
Forward	5'-AGGTCACCAAGAATGAAATCCT-3'	59	22	278	152
Probe	FAM-5'-TGTTTCTTTGTCTCTCCAGCGAGCA-3'-TAMRA	69.2	26	306	153
Reverse	5'-CTTGCACATGTATGGACACTTG-3'	59.1	22	348	154

**Table 21.** Panel 1.2

Tissue Name	Relative Expression(%)	
	1.2tm1609f_ ag1385	1.2tm1812f_ ag1385
Endothelial cells	0.0	0.0
Heart (fetal)	16.8	8.6
Pancreas	0.0	0.2

Pancreatic ca. CAPAN 2	0.0	0.0
Adrenal Gland (new lot*)	1.4	3.3
Thyroid	0.3	0.4
Salivary gland	100.0	100.0
Pituitary gland	0.8	1.1
Brain (fetal)	0.5	0.2
Brain (whole)	0.5	0.2
Brain (amygdala)	0.8	0.4
Brain (cerebellum)	0.2	0.2
Brain (hippocampus)	2.4	1.1
Brain (thalamus)	12.5	6.8
Cerebral Cortex	3.3	1.4
Spinal cord	1.7	2.8
CNS ca. (glio/astro) U87-MG	0.0	0
CNS ca. (glio/astro) U-118-MG	0.5	0.5
CNS ca. (astro) SW1783	0.2	0.1
CNS ca.* (neuro; met ) SK-N-AS	0.0	0.0
CNS ca. (astro) SF-539	0.0	0.0
CNS ca. (astro) SNB-75	0.5	0.4
CNS ca. (glio) SNB-19	0.0	0.0
CNS ca. (glio) U251	0.0	0.0
CNS ca. (glio) SF-295	1.8	1.8
Heart	6.3	16.5
Skeletal Muscle (new lot*)	2.4	5.4
Bone marrow	1.1	0.8
Thymus	1.0	0.3
Spleen	1.3	0.9
Lymph node	2.6	0.6
Colorectal	0.6	0.4
Stomach	8.5	1.7
Small intestine	6.9	2.8
Colon ca. SW480	0.0	0.0
Colon ca.* (SW480 met)SW620	0.0	0.0
Colon ca. HT29	0.0	0.0
Colon ca. HCT-116	0.0	0.0
Colon ca. CaCo-2	0.2	0.3
83219 CC Well to Mod Diff (ODO3866)	1.4	0.8
Colon ca. HCC-2998	0.0	0.0
Gastric ca.* (liver met) NCI-N87	0.0	0.0
Bladder	29.9	20.9
Trachea	3.6	2.5
Kidney	35.1	25.5
Kidney (fetal)	4.8	2.9
Renal ca. 786-0	0.0	0.0
Renal ca. A498	0.0	0.0

Renal ca. RXF 393	0.0	0.0
Renal ca. ACHN	0.0	0.0
Renal ca. UO-31	0.0	0.0
Renal ca. TK-10	0.0	0.0
Liver	37.4	28.7
Liver (fetal)	16.6	12
Liver ca. (hepatoblast) HepG2	0.0	0.0
Lung	2.5	0.5
Lung (fetal)	14.1	5.7
Lung ca. (small cell) LX-1	0.0	0.0
Lung ca. (small cell) NCI-H69	0.5	0.3
Lung ca. (s.cell var.) SHP-77	0.0	0.0
Lung ca. (large cell) NCI-H460	0.7	0.2
Lung ca. (non-sm. cell) A549	0.0	0.0
Lung ca. (non-s.cell) NCI-H23	0.4	0.3
Lung ca (non-s.cell) HOP-62	0.1	0.2
Lung ca. (non-s.cl) NCI-H522	0.0	0.0
Lung ca. (squam.) SW 900	16.5	10.4
Lung ca. (squam.) NCI-H596	2.5	1.8
Mammary gland	11.8	6.2
Breast ca.* (pl. effusion) MCF-7	0.0	0.0
Breast ca.* (pl.ef) MDA-MB-231	0.0	0.0
Breast ca.* (pl. effusion) T47D	0.0	0.0
Breast ca. BT-549	0.5	0.4
Breast ca. MDA-N	0.0	0.0
Ovary	21.5	11.7
Ovarian ca. OVCAR-3	0.2	0.2
Ovarian ca. OVCAR-4	10.9	7.6
Ovarian ca. OVCAR-5	0.5	0.3
Ovarian ca. OVCAR-8	0.0	0.0
Ovarian ca. IGROV-1	1.3	0.9
Ovarian ca.* (ascites) SK-OV-3	2.8	2.1
Uterus	9.0	6.2
Placenta	4.2	0.6
Prostate	3.1	1.6
Prostate ca.* (bone met) PC-3	1.7	1.9
Testis	1.6	1.8
Melanoma Hs688(A).T	0.3	0.2
Melanoma* (met) Hs688(B).T	1.6	1.3
Melanoma UACC-62	0.0	0.0
Melanoma M14	0.0	0.0
Melanoma LOX IMVI	0.0	0.0
Melanoma* (met) SK-MEL-5	0.0	0.0

Table 22. Panel 2D

Tissue Name	Relative Expression(%)	
	2Dtm2327f_ ag1385	2Dtm3180f_ ag1385
Normal Colon GENPAK 061003	9.4	10.0
83219 CC Well to Mod Diff (ODO3866)	6.1	5.6
83220 CC NAT (ODO3866)	2.0	1.1
83221 CC Gr.2 rectosigmoid (ODO3868)	2.3	1.8
83222 CC NAT (ODO3868)	0.9	1.1
83235 CC Mod Diff (ODO3920)	1.1	1.9
83236 CC NAT (ODO3920)	2.5	2.8
83237 CC Gr.2 ascend colon (ODO3921)	3.4	4.5
83238 CC NAT (ODO3921)	1.6	2.4
83241 CC from Partial Hepatectomy (ODO4309)	10.5	14.8
83242 Liver NAT (ODO4309)	55.5	66.4
87472 Colon mets to lung (OD04451-01)	20.7	14.7
87473 Lung NAT (OD04451-02)	25.9	20.2
Normal Prostate Clontech A+ 6546-1	3.5	1.9
84140 Prostate Cancer (OD04410)	7.7	5.3
84141 Prostate NAT (OD04410)	8.2	9.9
87073 Prostate Cancer (OD04720-01)	3.4	2.3
87074 Prostate NAT (OD04720-02)	8.5	8.7
Normal Lung GENPAK 061010	34.9	34.2
83239 Lung Met to Muscle (ODO4286)	22.1	33.9
83240 Muscle NAT (ODO4286)	54.7	29.5
84136 Lung Malignant Cancer (OD03126)	55.9	36.9
84137 Lung NAT (OD03126)	64.6	66.0
84871 Lung Cancer (OD04404)	37.1	46.7
84872 Lung NAT (OD04404)	82.4	44.4
84875 Lung Cancer (OD04565)	13.1	10.8
84876 Lung NAT (OD04565)	23.2	18.8
85950 Lung Cancer (OD04237-01)	27.2	16.3
85970 Lung NAT (OD04237-02)	52.8	32.8
83255 Ocular Mel Met to Liver (ODO4310)	1.1	0.6
83256 Liver NAT (ODO4310)	78.5	39.8
84139 Melanoma Mets to Lung (OD04321)	2.0	2.0
84138 Lung NAT (OD04321)	55.1	31.9
Normal Kidney GENPAK 061008	17.4	13.9
83786 Kidney Ca, Nuclear grade 2 (OD04338)	88.9	99.3
83787 Kidney NAT (OD04338)	20.9	21.0
83788 Kidney Ca Nuclear grade 1/2 (OD04339)	27.5	25.2
83789 Kidney NAT (OD04339)	28.1	20.6
83790 Kidney Ca, Clear cell type (OD04340)	14.6	12.0
83791 Kidney NAT (OD04340)	36.6	24.3
83792 Kidney Ca, Nuclear grade 3 (OD04348)	15.7	7.9
83793 Kidney NAT (OD04348)	50.3	35.4
87474 Kidney Cancer (OD04622-01)	85.3	65.5

87475 Kidney NAT (OD04622-03)	7.1	6.3
85973 Kidney Cancer (OD04450-01)	9.0	5.5
85974 Kidney NAT (OD04450-03)	27.4	18.8
Kidney Cancer Clontech 8120607	4.7	2.4
Kidney NAT Clontech 8120608	24.8	10.1
Kidney Cancer Clontech 8120613	1.6	0.4
Kidney NAT Clontech 8120614	13.6	14.4
Kidney Cancer Clontech 9010320	100.0	94.0
Kidney NAT Clontech 9010321	77.9	49.0
Normal Uterus GENPAK 061018	16.8	10.7
Uterus Cancer GENPAK 064011	64.6	40.3
Normal Thyroid Clontech A+ 6570-1	16.7	4.6
Thyroid Cancer GENPAK 064010	29.5	18.0
Thyroid Cancer INVITROGEN A302152	94.6	66.0
Thyroid NAT INVITROGEN A302153	9.2	6.0
Normal Breast GENPAK 061019	30.1	15.1
84877 Breast Cancer (OD04566)	7.2	4.0
85975 Breast Cancer (OD04590-01)	8.0	4.7
85976 Breast Cancer Mets (OD04590-03)	11.0	5.0
87070 Breast Cancer Metastasis (OD04655-05)	5.9	3.9
GENPAK Breast Cancer 064006	14.4	8.2
Breast Cancer Res. Gen. 1024	27.0	18.7
Breast Cancer Clontech 9100266	9.3	7.6
Breast NAT Clontech 9100265	25.5	18.2
Breast Cancer INVITROGEN A209073	15.0	13.4
Breast NAT INVITROGEN A2090734	32.3	17.7
Normal Liver GENPAK 061009	58.2	45.1
Liver Cancer GENPAK 064003	42.0	31.9
Liver Cancer Research Genetics RNA 1025	44.1	40.9
Liver Cancer Research Genetics RNA 1026	85.3	81.8
Paired Liver Cancer Tissue Research Genetics RNA 6004-T	86.5	60.7
Paired Liver Tissue Research Genetics RNA 6004-N	37.9	31.4
Paired Liver Cancer Tissue Research Genetics RNA 6005-T	92.0	77.9
Paired Liver Tissue Research Genetics RNA 6005-N	25.3	18.3
Normal Bladder GENPAK 061001	18.7	19.2
Bladder Cancer Research Genetics RNA 1023	4.0	4.3
Bladder Cancer INVITROGEN A302173	8.0	4.9
87071 Bladder Cancer (OD04718-01)	9.4	8.0
87072 Bladder Normal Adjacent (OD04718-03)	41.2	25.5
Normal Ovary Res. Gen.	10.0	9.3
Ovarian Cancer GENPAK 064008	76.8	100.0
87492 Ovary Cancer (OD04768-07)	54.7	62.0
87493 Ovary NAT (OD04768-08)	16.7	14.4
Normal Stomach GENPAK 061017	17.1	20.3
Gastric Cancer Clontech 9060358	2.2	1.2

NAT Stomach Clontech 9060359	11.6	11.6
Gastric Cancer Clontech 9060395	7.2	5.1
NAT Stomach Clontech 9060394	10.4	9.5
Gastric Cancer Clontech 9060397	7.3	9.0
NAT Stomach Clontech 9060396	8.5	6.6
Gastric Cancer GENPAK 064005	5.7	4.9

Table 23. Panel 4D/4R

Tissue Name	Relative Expression(%)	
	4dtm1923f_ ag1385	4rtm1959f_ ag1385
93768 Secondary Th1 anti-CD28/anti-CD3	0.0	0.0
93769 Secondary Th2 anti-CD28/anti-CD3	0.0	0.0
93770 Secondary Tr1 anti-CD28/anti-CD3	0.0	0.0
93573 Secondary Th1 resting day 4-6 in IL-2	0.0	0.0
93572 Secondary Th2 resting day 4-6 in IL-2	0.0	0.0
93571 Secondary Tr1 resting day 4-6 in IL-2	0.0	0.0
93568 primary Th1 anti-CD28/anti-CD3	0.0	0.0
93569 primary Th2 anti-CD28/anti-CD3	0.0	0.0
93570 primary Tr1 anti-CD28/anti-CD3	0.0	0.0
93565 primary Th1 resting dy 4-6 in IL-2	0.0	0.0
93566 primary Th2 resting dy 4-6 in IL-2	0.0	0.0
93567 primary Tr1 resting dy 4-6 in IL-2	0.0	0.0
93351 CD45RA CD4 lymphocyte anti-CD28/anti-CD3	0.6	0.6
93352 CD45RO CD4 lymphocyte anti-CD28/anti-CD3	0.0	0.0
93251 CD8 Lymphocytes anti-CD28/anti-CD3	0.0	0.1
93353 chronic CD8 Lymphocytes 2ry resting dy 4-6 in IL-2	0.0	0.0
93574 chronic CD8 Lymphocytes 2ry activated CD3/CD28	0.0	0.0
93354 CD4 none	0.0	0.1
93252 Secondary Th1/Th2/Tr1 anti-CD95 CH11	0.0	0.0
93103 LAK cells resting	62.4	65.1
93788 LAK cells IL-2	0.4	0.2
93787 LAK cells IL-2+IL-12	4.6	7.0
93789 LAK cells IL-2+IFN gamma	4.6	8.5
93790 LAK cells IL-2+ IL-18	3.6	5.7
93104 LAK cells PMA/ionomycin and IL-18	14.9	17.6
93578 NK Cells IL-2 resting	0.0	0.0
93109 Mixed Lymphocyte Reaction Two Way MLR	18.3	16.4
93110 Mixed Lymphocyte Reaction Two Way MLR	14.2	21.3
93111 Mixed Lymphocyte Reaction Two Way MLR	3.7	4.0
93112 Mononuclear Cells (PBMCs) resting	0.4	0.3
93113 Mononuclear Cells (PBMCs) PWM	3.2	5.9
93114 Mononuclear Cells (PBMCs) PHA-L	26.1	28.5
93249 Ramos (B cell) none	0.0	0.0
93250 Ramos (B cell) ionomycin	0.0	0.0

93349 B lymphocytes PWM	0.0	0.0
93350 B lymphocytes CD40L and IL-4	0.2	0.4
92665 EOL-1 (Eosinophil) dbcAMP differentiated	0.0	0.0
93248 EOL-1 (Eosinophil) dbcAMP/PMA/ionomycin	0.0	0.0
93356 Dendritic Cells none	31.0	41.5
93355 Dendritic Cells LPS 100 ng/ml	80.1	91.4
93775 Dendritic Cells anti-CD40	49.7	57.8
93774 Monocytes resting	0.7	0.2
93776 Monocytes LPS 50 ng/ml	29.7	37.9
93581 Macrophages resting	20.7	15.2
93582 Macrophages LPS 100 ng/ml	100.0	100.0
93098 HUVEC (Endothelial) none	0.0	0.0
93099 HUVEC (Endothelial) starved	0.1	0.0
93100 HUVEC (Endothelial) IL-1b	0.0	0.0
93779 HUVEC (Endothelial) IFN gamma	0.0	0.0
93102 HUVEC (Endothelial) TNF alpha + IFN gamma	0.0	0.0
93101 HUVEC (Endothelial) TNF alpha + IL4	0.0	0.0
93781 HUVEC (Endothelial) IL-11	0.0	0.0
93583 Lung Microvascular Endothelial Cells none	0.0	0.0
93584 Lung Microvascular Endothelial Cells TNFa (4 ng/ml) and IL1b (1 ng/ml)	0.0	0.0
92662 Microvascular Dermal endothelium none	0.0	0.0
92663 Microvascular Dermal endothelium TNFa (4 ng/ml) and IL1b (1 ng/ml)	0.0	0.0
93773 Bronchial epithelium TNFa (4 ng/ml) and IL1b (1 ng/ml) **	0.3	0.2
93347 Small Airway Epithelium none	1.2	0.3
93348 Small Airway Epithelium TNFa (4 ng/ml) and IL1b (1 ng/ml)	1.4	3.1
92668 Coronary Artery SMC resting	0.0	0.4
92669 Coronary Artery SMC TNFa (4 ng/ml) and IL1b (1 ng/ml)	0.0	0.2
93107 astrocytes resting	0.0	0.0
93108 astrocytes TNFa (4 ng/ml) and IL1b (1 ng/ml)	0.0	0.0
92666 KU-812 (Basophil) resting	0.0	0.0
92667 KU-812 (Basophil) PMA/ionomycin	0.0	0.0
93579 CCD1106 (Keratinocytes) none	0.0	0.0
93580 CCD1106 (Keratinocytes) TNFa and IFNg **	0.0	0.0
93791 Liver Cirrhosis	12.9	23.5
93792 Lupus Kidney	17.6	25.9
93577 NCI-H292	0.0	0.0
93358 NCI-H292 IL-4	0.0	0.2
93360 NCI-H292 IL-9	0.2	0.0
93359 NCI-H292 IL-13	0.0	0.2
93357 NCI-H292 IFN gamma	0.0	0.0
93777 HPAEC -	0.0	0.0
93778 HPAEC IL-1 beta/TNA alpha	0.0	0.0
93254 Normal Human Lung Fibroblast none	0.3	0.8
93253 Normal Human Lung Fibroblast TNFa (4 ng/ml) and IL-1b	0.5	0.9

(1 ng/ml)		
93257 Normal Human Lung Fibroblast IL-4	0.5	0.8
93256 Normal Human Lung Fibroblast IL-9	0.0	0.7
93255 Normal Human Lung Fibroblast IL-13	1.1	0.0
93258 Normal Human Lung Fibroblast IFN gamma	2.3	1.9
93106 Dermal Fibroblasts CCD1070 resting	6.0	6.4
93361 Dermal Fibroblasts CCD1070 TNF alpha 4 ng/ml	4.1	4.3
93105 Dermal Fibroblasts CCD1070 IL-1 beta 1 ng/ml	3.8	3.8
93772 dermal fibroblast IFN gamma	62.8	90.1
93771 dermal fibroblast IL-4	15.8	8.2
93260 IBD Colitis 2	0.9	0.5
93261 IBD Crohns	0.5	2.4
735010 Colon normal	1.7	4.3
735019 Lung none	45.4	75.3
64028-1 Thymus none	35.1	25.7
64030-1 Kidney none	7.1	14.8

**Panel 1.2 Summary:** Ag1385 Results from two experiments using the same probe/primer set are in very good agreement. The NOV2 gene is expressed in high to moderate levels across a wide variety of tissues. In this panel, expression of the NOV2 gene appears to be generally restricted to normal tissue as compared to cultured cancer cell lines. The NOV2 gene is most highly expressed in the salivary gland, liver, kidney, bladder, stomach and small intestine. Based on its homology to well characterized secreted molecules, the NOV2 gene product may be useful as a protein or antibody target for diseases involving any or all of these tissues.

The NOV2 gene is widely expressed in tissues involved in central nervous system function, including the amygdala (CT = 30), cerebellum (CT = 32), hippocampus (CT = 28), thalamus (CT = 26), cerebral cortex (CT = 28), spinal cord (CT = 27-29), cerebellum, substantia nigra and the developing brain. There is considerable evidence that angiogenesis occurs in response to ischemic stroke, and that re-vascularization occurs as part of the CNS healing process. Since the NOV2 gene is predicted to be involved in angiogenesis, therapeutic up-regulation of this gene or its protein product may therefore facilitate or enhance the recovery process in the days following stroke.

**Panel 2D Summary:** Ag1385 Results from two experiments using the same probe/primer set are in very good agreement. The NOV2 gene is expressed across a wide variety of tissue samples, with highest expression seen in normal kidney and ovarian cancer (CT = 25). In particular, there is substantial overexpression of this gene in ovarian cancer when compared to normal ovarian tissue. Thus, this gene could potentially be used to



distinguish ovarian cancer from normal ovarian tissue. In addition, therapeutic modulation of the NOV2 gene or its protein product could be useful in the treatment of ovarian cancer.

**Panel 4D/4R Summary:** Ag1385 Results from two experiments using the same probe/primer set are in excellent agreement. Expression of the NOV2 gene is highest in LPS treated macrophages and dendritic cells (CTs = 29.7/27.7). The NOV2 gene is also expressed at moderate levels in LPS treated monocytes and dermal fibroblasts stimulated with IFN gamma. The NOV2 gene most likely encodes a novel uncharacterized secreted protein that could be a potential protein or antibody target used in modulating the inflammatory response in immune mediated diseases such as rheumatoid arthritis (RA), inflammatory bowel disease (IBD), lung inflammatory diseases and infectious diseases. In addition, the presence of the NOV2 gene in activated dermal fibroblasts suggests a potential use for NOV2 protein product in the treatment of psoriasis and other related inflammatory skin diseases. (Wei et al., Collateral growth and angiogenesis around cortical stroke. Stroke 32:2179-84. 2001; Cheung et al., Induction of angiogenesis related genes in the contralateral cortex with a rat three-vessel occlusion model. Chin J Physiol 43:119-24, 2000; Marti et al., Am J Pathol. 156:965-76, 2000)

#### NOV3: Leucine Rich-like

Expression of the NOV3 gene (SC124141642\_A) was assessed using the primer-probe sets Ag1388 and Ag2455, described in Tables 24 and 25. Results of the RTQ-PCR runs are shown in Tables 26, 27, 28, 29 and 30.

Table 24. Probe Name Ag1388

Primers	Sequences	TM	Length	Start Position	SEQ ID NO:
Forward	5'-CTGGTAATCCTGCTGGACTACA-3'	59.3	22	412	155
Probe	FAM-5'-CTTCCAGGACCTGCACAGCCTG-3'-TAMRA	69.5	23	434	156
Reverse	5'-AGACGAATACCAGGTCGTTGT-3'	58.6	21	476	157

Table 25. Probe Name Ag2455

Primers	Sequences	TM	Length	Start Position	SEQ ID NO:
Forward	5'-GCTGGTAATCCTGCTGGACTA-3'	59.3	21	475	158
Probe	FAM-5'-ACTTCCAGGACCTGCACAGCCTG-3'-TAMRA	69.9	24	497	159
Reverse	5'-AGACGAATACCAGGTCGTTGT-3'	58.6	21	540	160

Table 26. Panel 1.2

Tissue Name	Relative Expression(%)	Tissue Name	Relative Expression(%)
	1.2tm1617f_ ag1388		1.2tm1617f_ ag1388
Endothelial cells	0.9	Renal ca. 786-0	0.3
Heart (fetal)	0.7	Renal ca. A498	0.2
Pancreas	0.2	Renal ca. RXF 393	1.7
Pancreatic ca. CAPAN 2	0.2	Renal ca. ACHN	0.0
Adrenal Gland (new lot*)	6.1	Renal ca. UO-31	0.2
Thyroid	0.9	Renal ca. TK-10	0.0
Salivary gland	18.3	Liver	1.7
Pituitary gland	0.0	Liver (fetal)	2.0
Brain (fetal)	1.1	Liver ca. (hepatoblast) HepG2	2.9
Brain (whole)	10.5	Lung	1.6
Brain (amygdala)	7.4	Lung (fetal)	0.4
Brain (cerebellum)	100.0	Lung ca. (small cell) LX-1	1.3
Brain (hippocampus)	12.4	Lung ca. (small cell) NCI-H69	6.6
Brain (thalamus)	20.2	Lung ca. (s.cell var.) SHP-77	0.0
Cerebral Cortex	20.4	Lung ca. (large cell) NCI-H460	0.9
Spinal cord	1.6	Lung ca. (non-sm. cell) A549	2.7
CNS ca. (glio/astro) U87-MG	3.3	Lung ca. (non-s.cell) NCI-H23	0.3
CNS ca. (glio/astro) U-118-MG	3.4	Lung ca (non-s.cell) HOP-62	0.0
CNS ca. (astro) SW1783	1.1	Lung ca. (non-s.cl) NCI-H522	0.5
CNS ca.* (neuro; met ) SK-N-AS	2.5	Lung ca. (squam.) SW 900	1.3
CNS ca. (astro) SF-539	1.3	Lung ca. (squam.) NCI-H596	3.3
CNS ca. (astro) SNB-75	1.7	Mammary gland	3.3
CNS ca. (glio) SNB-19	0.7	Breast ca.* (pl. effusion) MCF-7	6.3
CNS ca. (glio) U251	0.0	Breast ca.* (pl.ef) MDA-MB-231	0.2
CNS ca. (glio) SF-295	0.2	Breast ca.* (pl. effusion) T47D	15.6
Heart	1.0	Breast ca. BT-549	0.5
Skeletal Muscle (new lot*)	0.2	Breast ca. MDA-N	0.3
Bone marrow	38.4	Ovary	0.6
Thymus	0.9	Ovarian ca. OVCAR-3	2.9
Spleen	6.8	Ovarian ca. OVCAR-4	0.7
Lymph node	6.0	Ovarian ca. OVCAR-5	1.3
Colorectal	0.5	Ovarian ca. OVCAR-8	1.1
Stomach	60.7	Ovarian ca. IGROV-1	5.7
Small intestine	5.9	Ovarian ca.* (ascites) SK-OV-3	3.9
Colon ca. SW480	0.1	Uterus	2.4
Colon ca.* (SW480 met)SW620	1.2	Placenta	1.8
Colon ca. HT29	0.2	Prostate	2.4
Colon ca. HCT-116	0.4	Prostate ca.* (bone met)PC-3	0.3
Colon ca. CaCo-2	1.1	Testis	4.2
83219 CC Well to Mod Diff (ODO3866)	2.7	Melanoma Hs688(A).T	0.2
Colon ca. HCC-2998	6.9	Melanoma* (met) Hs688(B).T	0.7
Gastric ca.* (liver met) NCI-N87	0.5	Melanoma UACC-62	0.1

Bladder	9.7	Melanoma M14	0.0
Trachea	4.8	Melanoma LOX IMVI	0.0
Kidney	0.8	Melanoma* (met) SK-MEL-5	0.0
Kidney (fetal)	0.4		

Table 27. Panel 1.3D

Tissue Name	Relative Expression(%)	Tissue Name	Relative Expression(%)
	1.3dtm4554f_ag2455		1.3dtm4554f_ag2455
Liver adenocarcinoma	0.0	Kidney (fetal)	0.0
Pancreas	1.4	Renal ca. 786-0	0.0
Pancreatic ca. CAPAN 2	0.0	Renal ca. A498	0.0
Adrenal gland	6.0	Renal ca. RXF 393	1.2
Thyroid	2.0	Renal ca. ACHN	0.0
Salivary gland	1.8	Renal ca. UO-31	0.0
Pituitary gland	1.4	Renal ca. TK-10	0.0
Brain (fetal)	5.1	Liver	0.0
Brain (whole)	32.3	Liver (fetal)	4.9
Brain (amygdala)	50.7	Liver ca. (hepatoblast) HepG2	2.0
Brain (cerebellum)	84.1	Lung	10.3
Brain (hippocampus)	72.7	Lung (fetal)	0.2
Brain (substantia nigra)	7.2	Lung ca. (small cell) LX-1	0.2
Brain (thalamus)	48.6	Lung ca. (small cell) NCI-H69	0.8
Cerebral Cortex	90.8	Lung ca. (s.cell var.) SHP-77	0.0
Spinal cord	39.5	Lung ca. (large cell) NCI-H460	0.0
CNS ca. (glio/astro) U87-MG	1.5	Lung ca. (non-sm. cell) A549	0.9
CNS ca. (glio/astro) U-118-MG	0.0	Lung ca. (non-s.cell) NCI-H23	0.0
CNS ca. (astro) SW1783	1.0	Lung ca. (non-s.cell) HOP-62	0.0
CNS ca.* (neuro; met) SK-N-AS	0.5	Lung ca. (non-s.cl) NCI-H522	1.2
CNS ca. (astro) SF-539	0.0	Lung ca. (squam.) SW 900	0.0
CNS ca. (astro) SNB-75	0.0	Lung ca. (squam.) NCI-H596	2.7
CNS ca. (glio) SNB-19	3.1	Mammary gland	1.2
CNS ca. (glio) U251	0.0	Breast ca.* (pl. effusion) MCF-7	0.8
CNS ca. (glio) SF-295	0.0	Breast ca.* (pl.ef) MDA-MB-231	0.0
Heart (fetal)	1.1	Breast ca.* (pl. effusion) T47D	1.9
Heart	0.0	Breast ca. BT-549	0.0
Fetal Skeletal	2.5	Breast ca. MDA-N	0.0
Skeletal muscle	1.1	Ovary	0.4
Bone marrow	36.9	Ovarian ca. OVCAR-3	2.6
Thymus	21.3	Ovarian ca. OVCAR-4	0.0
Spleen	100.0	Ovarian ca. OVCAR-5	1.1
Lymph node	29.3	Ovarian ca. OVCAR-8	0.8
Colorectal	0.2	Ovarian ca. IGROV-1	0.8
Stomach	0.6	Ovarian ca.* (ascites) SK-OV-3	0.0

Small intestine	4.0	Uterus	3.0
Colon ca. SW480	0.0	Placenta	9.2
Colon ca. * (SW480 met)SW620	2.4	Prostate	2.0
Colon ca. HT29	0.8	Prostate ca. * (bone met)PC-3	0.0
Colon ca. HCT-116	0.0	Testis	6.6
Colon ca. CaCo-2	9.3	Melanoma Hs688(A).T	0.0
83219 CC Well to Mod Diff (ODO3866)	3.2	Melanoma* (met) Hs688(B).T	0.0
Colon ca. HCC-2998	0.9	Melanoma UACC-62	0.0
Gastric ca. * (liver met) NCI-N87	0.0	Melanoma M14	0.0
Bladder	2.9	Melanoma LOX IMVI	0.0
Trachea	5.3	Melanoma* (met) SK-MEL-5	0.0
Kidney	0.0	Adipose	0.0

Table 28. Panel 2D

Tissue Name	Relative Expression(%)	Relative Expression(%)
	2Dtm2328f_ ag1388	2dtm4516f_ ag2455
Normal Colon GENPAK 061003	5.9	17.6
83219 CC Well to Mod Diff (ODO3866)	10.1	9.0
83220 CC NAT (ODO3866)	3.2	18.8
83221 CC Gr.2 rectosigmoid (ODO3868)	4.2	4.2
83222 CC NAT (ODO3868)	10.9	2.7
83235 CC Mod Diff (ODO3920)	0.0	4.0
83236 CC NAT (ODO3920)	5.0	3.0
83237 CC Gr.2 ascend colon (ODO3921)	9.9	7.2
83238 CC NAT (ODO3921)	2.4	17.0
83241 CC from Partial Hepatectomy (ODO4309)	5.2	0.0
83242 Liver NAT (ODO4309)	0.0	0.0
87472 Colon mets to lung (OD04451-01)	11.0	17.1
87473 Lung NAT (OD04451-02)	23.8	20.2
Normal Prostate Clontech A+ 6546-1	6.3	4.7
84140 Prostate Cancer (OD04410)	11.2	12.6
84141 Prostate NAT (OD04410)	0.0	11.9
87073 Prostate Cancer (OD04720-01)	0.0	4.4
87074 Prostate NAT (OD04720-02)	3.5	7.2
Normal Lung GENPAK 061010	25.0	23.8
83239 Lung Met to Muscle (ODO4286)	0.0	4.3
83240 Muscle NAT (ODO4286)	8.5	0.0
84136 Lung Malignant Cancer (OD03126)	8.5	11.1
84137 Lung NAT (OD03126)	0.0	15.3
84871 Lung Cancer (OD04404)	6.8	0.0
84872 Lung NAT (OD04404)	15.0	18.2
84875 Lung Cancer (OD04565)	2.8	14.8
84876 Lung NAT (OD04565)	5.0	13.8

85950 Lung Cancer (OD04237-01)	2.4	0.0
85970 Lung NAT (OD04237-02)	6.4	0.0
83255 Ocular Mel Met to Liver (ODO4310)	0.0	0.0
83256 Liver NAT (ODO4310)	4.8	0.0
84139 Melanoma Mets to Lung (OD04321)	2.7	0.0
84138 Lung NAT (OD04321)	13.5	31.4
Normal Kidney GENPAK 061008	0.5	4.7
83786 Kidney Ca, Nuclear grade 2 (OD04338)	9.8	7.5
83787 Kidney NAT (OD04338)	1.6	2.1
83788 Kidney Ca Nuclear grade 1/2 (OD04339)	2.3	10.2
83789 Kidney NAT (OD04339)	0.0	0.0
83790 Kidney Ca, Clear cell type (OD04340)	12.0	10.4
83791 Kidney NAT (OD04340)	2.9	10.0
83792 Kidney Ca, Nuclear grade 3 (OD04348)	5.6	2.5
83793 Kidney NAT (OD04348)	5.5	1.4
87474 Kidney Cancer (OD04622-01)	33.0	21.9
87475 Kidney NAT (OD04622-03)	5.0	5.5
85973 Kidney Cancer (OD04450-01)	0.0	0.0
85974 Kidney NAT (OD04450-03)	0.0	0.0
Kidney Cancer Clontech 8120607	0.0	9.1
Kidney NAT Clontech 8120608	5.3	2.6
Kidney Cancer Clontech 8120613	0.0	0.0
Kidney NAT Clontech 8120614	0.0	0.0
Kidney Cancer Clontech 9010320	24.7	32.5
Kidney NAT Clontech 9010321	8.4	0.0
Normal Uterus GENPAK 061018	3.7	2.0
Uterus Cancer GENPAK 064011	5.7	2.3
Normal Thyroid Clontech A+ 6570-1	3.2	4.4
Thyroid Cancer GENPAK 064010	3.1	2.4
Thyroid Cancer INVITROGEN A302152	4.4	9.3
Thyroid NAT INVITROGEN A302153	0.0	11.0
Normal Breast GENPAK 061019	34.9	23.3
84877 Breast Cancer (OD04566)	0.9	11.1
85975 Breast Cancer (OD04590-01)	33.9	39.0
85976 Breast Cancer Mets (OD04590-03)	92.0	76.8
87070 Breast Cancer Metastasis (OD04655-05)	100.0	100.0
GENPAK Breast Cancer 064006	0.0	12.2
Breast Cancer Res. Gen. 1024	5.5	13.7
Breast Cancer Clontech 9100266	0.9	2.6
Breast NAT Clontech 9100265	0.0	5.2
Breast Cancer INVITROGEN A209073	6.0	4.2
Breast NAT INVITROGEN A2090734	4.6	12.6
Normal Liver GENPAK 061009	2.7	0.0
Liver Cancer GENPAK 064003	3.3	1.3
Liver Cancer Research Genetics RNA 1025	9.0	2.3

Liver Cancer Research Genetics RNA 1026	5.6	1.6
Paired Liver Cancer Tissue Research Genetics RNA 6004-T	6.0	3.6
Paired Liver Tissue Research Genetics RNA 6004-N	0.0	2.6
Paired Liver Cancer Tissue Research Genetics RNA 6005-T	3.2	2.1
Paired Liver Tissue Research Genetics RNA 6005-N	8.1	0.0
Normal Bladder GENPAK 061001	11.8	17.9
Bladder Cancer Research Genetics RNA 1023	7.2	1.9
Bladder Cancer INVITROGEN A302173	6.0	2.7
87071 Bladder Cancer (OD04718-01)	1.5	2.6
87072 Bladder Normal Adjacent (OD04718-03)	11.3	1.9
Normal Ovary Res. Gen.	0.3	2.1
Ovarian Cancer GENPAK 064008	8.4	1.6
87492 Ovary Cancer (OD04768-07)	0.0	2.7
87493 Ovary NAT (OD04768-08)	0.0	0.0
Normal Stomach GENPAK 061017	6.6	13.2
Gastric Cancer Clontech 9060358	2.1	4.8
NAT Stomach Clontech 9060359	6.0	7.1
Gastric Cancer Clontech 9060395	11.0	7.5
NAT Stomach Clontech 9060394	3.6	9.9
Gastric Cancer Clontech 9060397	3.1	0.0
NAT Stomach Clontech 9060396	0.0	4.3
Gastric Cancer GENPAK 064005	0.0	6.8

Table 29. Panels 4D/4R

Tissue Name	Relative Expression(%)		Relative Expression(%)
	4Dtm1781f_ag1388	4rtm1790f_ag1388	4Dx4tm4260f_ag2455_a1
93768 Secondary Th1 anti-CD28/anti-CD3	2.6	2.9	5.3
93769 Secondary Th2 anti-CD28/anti-CD3	4.9	3.7	6.5
93770 Secondary Tr1 anti-CD28/anti-CD3	9.9	3.4	5.1
93573 Secondary Th1 resting day 4-6 in IL-2	12.0	12.2	6.8
93572 Secondary Th2 resting day 4-6 in IL-2	12.1	16.4	14.9
93571 Secondary Tr1 resting day 4-6 in IL-2	11.5	16.2	25.2
93568 primary Th1 anti-CD28/anti-CD3	5.0	6.2	1.8
93569 primary Th2 anti-CD28/anti-CD3	4.6	5.5	1.0
93570 primary Tr1 anti-CD28/anti-CD3	5.8	4.0	1.4
93565 primary Th1 resting dy 4-6 in IL-2	31.2	100.0	23.4
93566 primary Th2 resting dy 4-6 in IL-2	36.1	55.1	27.2
93567 primary Tr1 resting dy 4-6 in IL-2	22.1	4.9	28.0
93351_CD45RA CD4 lymphocyte anti-CD28/anti-CD3	0.0	0.9	2.4
93352_CD45RO CD4 lymphocyte anti-CD28/anti-CD3	3.6	4.0	2.2
93251_CD8 Lymphocytes anti-CD28/anti-CD3	3.6	2.4	2.5
93353_chronic CD8 Lymphocytes 2ry_resting dy 4-6 in IL-2	3.7	3.0	0.0

93574_chronic CD8 Lymphocytes 2ry_activated CD3/CD28	3.7	3.6	3.4
93354 CD4 none	7.3	11.6	17.4
93252 Secondary Th1/Th2/Tr1 anti-CD95 CH11	39.2	43.2	18.5
93103 LAK cells resting	6.4	4.5	5.1
93788 LAK cells IL-2	9.4	8.2	5.3
93787 LAK cells IL-2+IL-12	2.5	7.5	2.7
93789 LAK cells IL-2+IFN gamma	3.9	13.7	3.7
93790 LAK cells IL-2+ IL-18	1.5	1.3	3.2
93104 LAK cells PMA/ionomycin and IL-18	0.0	0.4	1.0
93578 NK Cells IL-2 resting	10.0	9.2	10.6
93109_Mixed Lymphocyte Reaction_Two Way MLR	3.1	6.9	8.8
93110_Mixed Lymphocyte Reaction_Two Way MLR	0.0	1.4	4.0
93111_Mixed Lymphocyte Reaction_Two Way MLR	6.7	6.0	6.5
93112 Mononuclear Cells (PBMCs) resting	9.7	12.5	5.9
93113 Mononuclear Cells (PBMCs) PWM	5.0	12.2	2.7
93114 Mononuclear Cells (PBMCs) PHA-L	5.6	5.1	4.7
93249 Ramos (B cell) none	6.8	5.7	4.7
93250 Ramos (B cell) ionomycin	4.1	48.3	9.4
93349 B lymphocytes PWM	7.1	17.7	10.3
93350 B lymphocytes CD40L and IL-4	21.8	2.7	36.9
92665 EOL-1 (Eosinophil) dbcAMP differentiated	100.0	65.1	100.0
93248 EOL-1 (Eosinophil) dbcAMP/PMAionomycin	17.6	35.4	37.9
93356 Dendritic Cells none	1.4	2.0	0.0
93355 Dendritic Cells LPS 100 ng/ml	0.0	0.0	2.5
93775 Dendritic Cells anti-CD40	0.0	0.7	0.7
93774 Monocytes resting	10.5	23.2	18.7
93776 Monocytes LPS 50 ng/ml	2.6	6.2	3.0
93581 Macrophages resting	2.8	5.1	5.5
93582 Macrophages LPS 100 ng/ml	0.0	1.1	1.6
93098 HUVEC (Endothelial) none	0.0	0.1	0.0
93099 HUVEC (Endothelial) starved	0.0	0.0	0.0
93100 HUVEC (Endothelial) IL-1b	0.0	0.2	0.0
93779 HUVEC (Endothelial) IFN gamma	0.0	0.0	0.0
93102 HUVEC (Endothelial) TNF alpha + IFN gamma	0.0	0.0	0.0
93101 HUVEC (Endothelial) TNF alpha + IL4	0.0	0.1	0.0
93781 HUVEC (Endothelial) IL-11	0.0	0.0	0.0
93583 Lung Microvascular Endothelial Cells none	0.0	0.0	0.0
93584 Lung Microvascular Endothelial Cells TNFa (4 ng/ml) and IL1b (1 ng/ml)	0.0	0.4	0.0
92662 Microvascular Dermal endothelium none	0.0	0.4	0.0
92663 Microvascular Dermal endothelium TNFa (4 ng/ml) and IL1b (1 ng/ml)	0.0	0.3	0.0
93773 Bronchial epithelium TNFa (4 ng/ml) and	1.5	0.0	0.0

IL1b (1 ng/ml) **			
93347 Small Airway Epithelium none	0.0	0.0	0.0
93348 Small Airway Epithelium_TNFa (4 ng/ml) and IL1b (1 ng/ml)	0.0	0.2	0.7
92668 Coronary Artery SMC resting	1.3	0.0	0.0
92669 Coronary Artery SMC_TNFa (4 ng/ml) and IL1b (1 ng/ml)	0.0	0.0	0.0
93107 astrocytes resting	0.0	0.5	0.0
93108 astrocytes_TNFa (4 ng/ml) and IL1b (1 ng/ml)	0.0	0.0	0.0
92666 KU-812 (Basophil) resting	1.9	5.6	3.5
92667 KU-812 (Basophil) PMA/ionoycin	2.4	6.7	3.9
93579 CCD1106 (Keratinocytes) none	0.0	0.0	0.0
93580 CCD1106 (Keratinocytes)_TNFa and IFNg **	0.0	0.4	0.0
93791 Liver Cirrhosis	10.7	1.8	7.3
93792 Lupus Kidney	2.5	2.6	1.5
93577 NCI-H292	0.0	4.5	3.8
93358 NCI-H292 IL-4	0.0	2.3	0.0
93360 NCI-H292 IL-9	1.3	0.4	0.5
93359 NCI-H292 IL-13	0.0	0.4	0.0
93357 NCI-H292 IFN gamma	0.0	0.5	0.0
93777 HPAEC -	0.0	0.0	0.0
93778 HPAEC IL-1 beta/TNA alpha	0.0	0.1	0.4
93254 Normal Human Lung Fibroblast none	0.0	0.8	0.0
93253 Normal Human Lung Fibroblast_TNFa (4 ng/ml) and IL-1b (1 ng/ml)	0.0	0.6	0.0
93257 Normal Human Lung Fibroblast IL-4	0.0	0.0	0.0
93256 Normal Human Lung Fibroblast IL-9	0.0	0.0	0.0
93255 Normal Human Lung Fibroblast IL-13	0.0	0.0	0.0
93258 Normal Human Lung Fibroblast IFN gamma	0.0	0.0	0.0
93106 Dermal Fibroblasts CCD1070 resting	0.0	0.2	0.0
93361 Dermal Fibroblasts CCD1070_TNF alpha 4 ng/ml	8.9	19.2	9.4
93105 Dermal Fibroblasts CCD1070_IL-1 beta 1 ng/ml	0.0	0.0	0.5
93772 dermal fibroblast IFN gamma	0.0	0.0	0.0
93771 dermal fibroblast IL-4	0.0	0.0	0.0
93259 IBD Colitis 1**	2.9	0.2	0.9
93260 IBD Colitis 2	1.5	1.1	2.4
93261 IBD Crohns	1.4	0.5	0.0
735010 Colon normal	34.9	5.5	31.0
735019 Lung none	11.8	2.7	11.6
64028-1 Thymus none	1.5	0.4	0.9
64030-1 Kidney none	4.5	6.7	11.8

Table 30. Panel CNSD.01



Tissue Name	Relative Expression(%)	Tissue Name	Relative Expression(%)
	cns1x4tm6186f_ ag2455 a2		cns1x4tm6186f_ ag2455 a2
102633 BA4 Control	9.1	102605 BA17 PSP	1.3
102641 BA4 Control2	59.7	102612 BA17 PSP2	8.6
102625 BA4 Alzheimer's2	14.7	102637 Sub Nigra Control	31.8
102649 BA4 Parkinson's	20.1	102645 Sub Nigra Control2	35.7
102656 BA4 Parkinson's2	51.0	102629 Sub Nigra Alzheimer's2	15.7
102664 BA4 Huntington's	5.6	102660 Sub Nigra Parkinson's2	29.9
102671 BA4 Huntington's2	29.6	102667 Sub Nigra Huntington's	50.1
102603 BA4 PSP	9.6	102674 Sub Nigra Huntington's2	9.8
102610 BA4 PSP2	22.2	102614 Sub Nigra PSP2	2.0
102588 BA4 Depression	0.9	102592 Sub Nigra Depression	0.0
102596 BA4 Depression2	8.8	102599 Sub Nigra Depression2	0.0
102634 BA7 Control	13.6	102636 Glob Palladus Control	43.8
102642 BA7 Control2	31.4	102644 Glob Palladus Control2	100.0
102626 BA7 Alzheimer's2	0.0	102620 Glob Palladus Alzheimer's	18.3
102650 BA7 Parkinson's	23.4	102628 Glob Palladus Alzheimer's2	15.2
102657 BA7 Parkinson's2	27.4	102652 Glob Palladus Parkinson's	24.9
102665 BA7 Huntington's	21.7	102659 Glob Palladus Parkinson's2	66.9
102672 BA7 Huntington's2	36.8	102606 Glob Palladus PSP	45.4
102604 BA7 PSP	7.7	102613 Glob Palladus PSP2	43.1
102611 BA7 PSP2	0.0	102591 Glob Palladus Depression	12.9
102589 BA7 Depression	9.0	102638 Temp Pole Control	23.1
102632 BA9 Control	3.7	102646 Temp Pole Control2	67.9
102640 BA9 Control2	30.4	102622 Temp Pole Alzheimer's	2.5
102617 BA9 Alzheimer's	0.0	102630 Temp Pole Alzheimer's2	6.7
102624 BA9 Alzheimer's2	1.7	102653 Temp Pole Parkinson's	39.7
102648 BA9 Parkinson's	6.8	102661 Temp Pole Parkinson's2	12.8
102655 BA9 Parkinson's2	15.7	102668 Temp Pole Huntington's	26.1
102663 BA9 Huntington's	21.7	102607 Temp Pole PSP	0.0
102670 BA9 Huntington's2	1.1	102615 Temp Pole PSP2	0.0
102602 BA9 PSP	3.6	102600 Temp Pole Depression2	4.8
102609 BA9 PSP2	6.2	102639 Cing Gyr Control	36.1
102587 BA9 Depression	8.5	102647 Cing Gyr Control2	28.9
102595 BA9 Depression2	0.0	102623 Cing Gyr Alzheimer's	7.0
102635 BA17 Control	12.7	102631 Cing Gyr Alzheimer's2	0.0
102643 BA17 Control2	36.0	102654 Cing Gyr Parkinson's	17.7
102627 BA17 Alzheimer's2	5.3	102662 Cing Gyr Parkinson's2	14.1
102651 BA17 Parkinson's	23.5	102669 Cing Gyr Huntington's	52.1
102658 BA17 Parkinson's2	18.3	102676 Cing Gyr Huntington's2	8.5
102666 BA17 Huntington's	24.9	102608 Cing Gyr PSP	0.0
102673 BA17 Huntington's2	6.8	102616 Cing Gyr PSP2	0.6
102590 BA17 Depression	3.7	102594 Cing Gyr Depression	5.0

102597 BA17 Depression2	6.6	102601 Cing Gyr Depression2	3.4
-------------------------	-----	-----------------------------	-----

**Panel 1.2 Summary:** Ag1388 Expression of the NOV3 gene in the samples on this panel seems to be restricted, in large part, to normal tissues. The NOV3 gene is most highly expressed in a sample derived from cerebellum (CT = 26). Expression of this gene is also prominent in stomach. Based upon this pattern of expression, the expression of this gene might be of use as a marker of cerebellar or stomach tissue.

Among CNS samples, the NOV3 gene is expressed in cerebellum, amygdala, hippocampus, thalamus, cerebral cortex and spinal cord. This result is consistent with what is observed in Panel 1.3D; please see below for summary of potential implications of the expression of this gene in the central nervous system.

The NOV3 gene encodes a type 1 membrane protein with several leucine-rich-repeat domains, indicating that this gene product may be involved in extracellular signalling and/or interactions with the extracellular matrix. Among metabolically relevant tissues, this gene is expressed at low but significant levels in the adrenal gland, thyroid, heart and liver. As a potential extracellular signalling molecule, the NOV3 gene product may serve as an antibody target for diseases involving any or all of these tissues.

**Panel 1.3D Summary:** Ag2455 Expression of the NOV3 gene in this panel is largely restricted to normal brain and normal lymphoid tissues. Highest expression of this gene is detected in spleen (CT = 30), with lower but significant expression in lymph node, bone marrow and thymus. Thus, the expression of this gene might be useful as a marker of lymphoid tissue.

Moderate and roughly equivalent expression is also detected in several regions of the CNS including amygdala, cerebellum, substantia nigra, hippocampus, thalamus, cerebral cortex and spinal cord. In *Drosophila*, the LRR region of axon guidance proteins has been shown to be critical for function (especially in axon repulsion) (ref. 1). Since the NOV3 gene encodes a leucine-rich-repeat protein that is expressed across all brain regions, it is an excellent candidate neuronal guidance protein for axons, dendrites and/or growth cones in general. Therefore, therapeutic modulation of the levels of this protein, or possible signaling via this protein, may be of utility in enhancing/directing compensatory synaptogenesis and fiber growth in the CNS in response to neuronal death (stroke, head trauma), axon lesion (spinal cord injury), or neurodegeneration (Alzheimer's, Parkinson's, Huntington's, vascular dementia or any neurodegenerative disease).

**Panel 2D Summary:** Ag1388/Ag2455 Results from two experiments using different probe/primer sets are in good agreement. Strikingly, expression of the NOV3 gene is highest

in two metastatic breast cancer samples (CT = 31-32), and is also detectable in several other breast cancer samples. In addition, there appears to be a moderate association with overexpression of the NOV3 gene in kidney cancers when compared to their normal adjacent tissues, as 6 of 9 pairs show this pattern of expression. Thus, expression of this gene could be used as a marker for the detection of breast or kidney cancer. In addition, therapeutic down modulation of the NOV3 gene product, through the use of antibodies or small molecule drugs, may be useful for the treatment of breast or kidney cancer.

**Panel 4D/4R Summary:** Ag1388/Ag2455 Significant expression of the NOV3 gene is detected in bone marrow, spleen, and lymph node, as well as in the thymus in one experiment. These results are consistent with what is observed in Panel 1.3D. In addition, differential NOV3 gene expression is observed in the eosinophil cell line EOL-1 under resting conditions over that in EOL-1 cells stimulated by phorbol ester and ionomycin. Furthermore, unstimulated T lymphocytes (Th1, Th2, and Tr1) expressed this gene at higher levels than anti-CD28 + anti-CD3-stimulated T cells. Thus, the NOV3 gene may be involved in both eosinophil and T lymphocyte function. Antibodies raised against the NOV3 protein that stimulate its activity may be useful in reduction of eosinophil activation and may therefore be useful therapeutic antibodies for asthma and allergy, and also as anti-inflammatory therapeutics for T cell-mediated autoimmune and inflammatory diseases. Furthermore, the isolated extracellular domain of the NOV3 protein may likewise function as a protein therapeutic in the treatment of asthma, emphysema, and allergy, as well as in other autoimmune and inflammatory diseases such as rheumatoid arthritis, inflammatory bowel disease, and psoriasis.

**Panel CNSD.01 Summary:** Ag2455 Among the samples on this panel, the NOV3 gene is most highly expressed in the globus palladus, a region of the basal ganglia involved in the control of movement; various inputs to the globus palladus are lost in Parkinson's disease and Huntington's disease. Since there is evidence that leucine-rich repeat proteins are critical in axonal guidance, the protein encoded by the NOV3 gene may be important in the treatment of Parkinson's and/or Huntington's disease by stimulating neuroregeneration and/or stem cell implantation for the establishment of connectivity. Likewise modulation of the activity of this protein may serve to slow or stop neurodegeneration in these diseases. (Battye et al., Repellent signaling by Slit requires the leucine-rich repeats. J. Neurosci. 21: 4290-4298, 2001.)

#### **NOV4: Cathepsin-L Precursor-like**

Expression of the NOV4 gene (GMba39917\_A) was assessed using the primer-probe sets Ag2453 described in Table 31.

Table 31. Probe Name Ag2453

Primers	Sequences	TM	Length	Start Position	SEQ ID NO:
Forward	5'-CTCTGGAAGGGCAGATGTTT-3'	59.3	20	473	161
Probe	FAM-5'- TGGAAAACAGGCAAACTTATCTCACTGA- 3'-TAMRA	66.9	28	493	162
Reverse	5'-CCAGAGCAGTCTACCAGATTGA-3'	59.5	22	527	163

Expression of this gene in panels 1.3D, 2D, 4D, and Cns\_Neurodegeneration\_V1.0  
 5 was low/undetectable (Ct values >35) in all samples (data not shown).

#### NOV5: Fatty Acid-Binding Protein-like

Expression of the NOV5 gene (GMba38118\_A) was assessed using the primer-probe  
 set Ag2456, described in Table 32. Results of the RTQ-PCR runs are shown in Tables 33, 34,  
 35, 36, and 37.

10

Table 32. Probe Name Ag2456

Primers	Sequences	TM	Length	Start Position	SEQ ID NO:
Forward	5'-AGTGGTGGAGTGTGTCATGAA-3'	59	21	404	164
Probe	TET-5'- CAATGTCACCTGTACTCGGATCTATGA-3'- TAMRA	64.5	27	425	165
Reverse	5'-CTGTCCAAAGTGATGATGGAA-3'	58.6	21	468	166

Table 33. Panel 1.3D

Tissue Name	Relative Expression(%) 1.3dtm3778t_ ag2456	Tissue Name	Relative Expression(%) 1.3dtm3778t_ ag2456
Liver adenocarcinoma	2.7	Kidney (fetal)	3.0
Pancreas	4.2	Renal ca. 786-0	3.6
Pancreatic ca. CAPAN 2	1.0	Renal ca. A498	20.6
Adrenal gland	2.3	Renal ca. RXF 393	2.0
Thyroid	4.0	Renal ca. ACHN	0.8
Salivary gland	2.3	Renal ca. UO-31	12.4
Pituitary gland	3.3	Renal ca. TK-10	1.3
Brain (fetal)	15.6	Liver	0.9
Brain (whole)	5.4	Liver (fetal)	6.1
Brain (amygdala)	14.6	Liver ca. (hepatoblast) HepG2	2.9
Brain (cerebellum)	4.6	Lung	28.9
Brain (hippocampus)	71.2	Lung (fetal)	7.8
Brain (substantia nigra)	7.9	Lung ca. (small cell) LX-1	4.2
Brain (thalamus)	11.7	Lung ca. (small cell) NCI-H69	14.3

Cerebral Cortex	12.4	Lung ca. (s.cell var.) SHP-77	20.9
Spinal cord	13.7	Lung ca. (large cell) NCI-H460	3.1
CNS ca. (glio/astro) U87-MG	3.6	Lung ca. (non-sm. cell) A549	3.3
CNS ca. (glio/astro) U-118-MG	1.7	Lung ca. (non-s.cell) NCI-H23	7.7
CNS ca. (astro) SW1783	0.7	Lung ca (non-s.cell) HOP-62	1.9
CNS ca.* (neuro; met) SK-N-AS	25.3	Lung ca. (non-s.cl) NCI-H522	0.4
CNS ca. (astro) SF-539	1.4	Lung ca. (squam.) SW 900	0.5
CNS ca. (astro) SNB-75	1.2	Lung ca. (squam.) NCI-H596	9.7
CNS ca. (glio) SNB-19	0.7	Mammary gland	15.9
CNS ca. (glio) U251	0.4	Breast ca.* (pl. effusion) MCF-7	1.2
CNS ca. (glio) SF-295	0.4	Breast ca.* (pl.ef) MDA-MB-231	20.9
Heart (fetal)	7.9	Breast ca.* (pl. effusion) T47D	0.5
Heart	12.5	Breast ca. BT-549	32.3
Fetal Skeletal	14.3	Breast ca. MDA-N	1.3
Skeletal muscle	4.3	Ovary	1.2
Bone marrow	6.9	Ovarian ca. OVCAR-3	2.1
Thymus	4.2	Ovarian ca. OVCAR-4	0.1
Spleen	17.1	Ovarian ca. OVCAR-5	4.1
Lymph node	6.6	Ovarian ca. OVCAR-8	4.7
Colorectal	7.7	Ovarian ca. IGROV-1	2.5
Stomach	16.0	Ovarian ca.* (ascites) SK-OV-3	9.5
Small intestine	23.0	Uterus	3.4
Colon ca. SW480	14.6	Placenta	21.8
Colon ca.* (SW480 met)SW620	10.3	Prostate	2.6
Colon ca. HT29	6.0	Prostate ca.* (bone met)PC-3	6.7
Colon ca. HCT-116	23.2	Testis	7.4
Colon ca. CaCo-2	13.1	Melanoma Hs688(A).T	0.7
83219 CC Well to Mod Diff (ODO3866)	16.5	Melanoma* (met) Hs688(B).T	0.6
Colon ca. HCC-2998	25.3	Melanoma UACC-62	2.5
Gastric ca.* (liver met) NCI-N87	17.0	Melanoma M14	2.5
Bladder	3.7	Melanoma LOX IMVI	16.8
Trachea	20.0	Melanoma* (met) SK-MEL-5	100.0
Kidney	0.8	Adipose	13.4

Table 34. Panel 2D

Tissue Name	Relative Expression(%)	Tissue Name	Relative Expression(%)
	2dtm3779t_ ag2456		2dtm3779t_ ag2456
Normal Colon GENPAK 061003	13.9	Kidney NAT Clontech 8120608	0.1
83219 CC Well to Mod Diff (ODO3866)	3.3	Kidney Cancer Clontech 8120613	0.2
83220 CC NAT (ODO3866)	2.7	Kidney NAT Clontech 8120614	0.0
83221 CC Gr.2 rectosigmoid (ODO3868)	1.7	Kidney Cancer Clontech 9010320	1.8
83222 CC NAT (ODO3868)	0.6	Kidney NAT Clontech 9010321	0.2

83235 CC Mod Diff (ODO3920)	4.2	Normal Uterus GENPAK 061018	0.5
83236 CC NAT (ODO3920)	1.7	Uterus Cancer GENPAK 064011	1.6
83237 CC Gr.2 ascend colon (ODO3921)	10.2	Normal Thyroid Clontech A+ 6570-1	1.0
83238 CC NAT (ODO3921)	3.1	Thyroid Cancer GENPAK 064010	0.6
83241 CC from Partial Hepatectomy (ODO4309)	2.6	Thyroid Cancer INVITROGEN A302152	0.6
83242 Liver NAT (ODO4309)	0.3	Thyroid NAT INVITROGEN A302153	1.4
87472 Colon mets to lung (OD04451-01)	1.4	Normal Breast GENPAK 061019	2.1
87473 Lung NAT (OD04451-02)	2.5	84877 Breast Cancer (OD04566)	0.7
Normal Prostate Clontech A+ 6546-1	0.5	85975 Breast Cancer (OD04590-01)	2.0
84140 Prostate Cancer (OD04410)	2.0	85976 Breast Cancer Mets (OD04590-03)	3.1
84141 Prostate NAT (OD04410)	4.0	87070 Breast Cancer Metastasis (OD04655-05)	1.1
87073 Prostate Cancer (OD04720-01)	1.1	GENPAK Breast Cancer 064006	1.8
87074 Prostate NAT (OD04720-02)	1.5	Breast Cancer Res. Gen. 1024	1.0
Normal Lung GENPAK 061010	11.3	Breast Cancer Clontech 9100266	0.8
83239 Lung Met to Muscle (ODO4286)	1.4	Breast NAT Clontech 9100265	0.6
83240 Muscle NAT (ODO4286)	1.2	Breast Cancer INVITROGEN A209073	1.5
84136 Lung Malignant Cancer (OD03126)	5.8	Breast NAT INVITROGEN A2090734	0.7
84137 Lung NAT (OD03126)	20.7	Normal Liver GENPAK 061009	0.0
84871 Lung Cancer (OD04404)	100.0	Liver Cancer GENPAK 064003	0.2
84872 Lung NAT (OD04404)	3.3	Liver Cancer Research Genetics RNA 1025	0.1
84875 Lung Cancer (OD04565)	36.1	Liver Cancer Research Genetics RNA 1026	0.2
84876 Lung NAT (OD04565)	2.9	Paired Liver Cancer Tissue Research Genetics RNA 6004-T	0.2
85950 Lung Cancer (OD04237-01)	5.7	Paired Liver Tissue Research Genetics RNA 6004-N	0.6
85970 Lung NAT (OD04237-02)	4.2	Paired Liver Cancer Tissue Research Genetics RNA 6005-T	0.2
83255 Ocular Mel Met to Liver (ODO4310)	1.3	Paired Liver Tissue Research Genetics RNA 6005-N	0.0
83256 Liver NAT (ODO4310)	0.4	Normal Bladder GENPAK 061001	2.6
84139 Melanoma Mets to Lung (OD04321)	3.2	Bladder Cancer Research Genetics RNA 1023	0.5
84138 Lung NAT (OD04321)	8.7	Bladder Cancer INVITROGEN A302173	12.9
Normal Kidney GENPAK 061008	1.0	87071 Bladder Cancer (OD04718-01)	4.0
83786 Kidney Ca, Nuclear grade 2 (OD04338)	1.2	87072 Bladder Normal Adjacent (OD04718-03)	1.5
83787 Kidney NAT (OD04338)	0.7	Normal Ovary Res. Gen.	0.2
83788 Kidney Ca Nuclear grade 1/2 (OD04339)	1.3	Ovarian Cancer GENPAK 064008	5.8
83789 Kidney NAT (OD04339)	1.0	87492 Ovary Cancer (OD04768-	3.1

		07)	
83790 Kidney Ca, Clear cell type (OD04340)	1.7	87493 Ovary NAT (OD04768-08)	1.1
83791 Kidney NAT (OD04340)	0.6	Normal Stomach GENPAK 061017	1.5
83792 Kidney Ca, Nuclear grade 3 (OD04348)	2.5	Gastric Cancer Clontech 9060358	0.7
83793 Kidney NAT (OD04348)	0.4	NAT Stomach Clontech 9060359	2.4
87474 Kidney Cancer (OD04622-01)	3.0	Gastric Cancer Clontech 9060395	4.2
87475 Kidney NAT (OD04622-03)	0.1	NAT Stomach Clontech 9060394	1.6
85973 Kidney Cancer (OD04450-01)	0.6	Gastric Cancer Clontech 9060397	4.6
85974 Kidney NAT (OD04450-03)	0.3	NAT Stomach Clontech 9060396	0.8
Kidney Cancer Clontech 8120607	0.0	Gastric Cancer GENPAK 064005	3.2

Table 35. Panel 3D

Tissue Name	Relative Expression(%)	Tissue Name	Relative Expression(%)
	3dx4tm6021t_a g2456_b2		3dx4tm6021t_a g2456_b2
94905_Daoy_Medulloblastoma/Cerebellum sscDNA	2.0	94954_Ca Ski_Cervical epidermoid carcinoma (metastasis) sscDNA	25.0
94906_TE671_Medulloblastoma/Cerebellum sscDNA	0.1	94955_ES-2_Ovarian clear cell carcinoma sscDNA	24.1
94907_D283_Med_Medulloblastoma/Cerebellum sscDNA	7.1	94957_Ramos/6h stim_ Stimulated with PMA/ionomycin 6h sscDNA	25.3
94908_PFSK-1_Primitive Neuroectodermal/Cerebellum sscDNA	3.8	94958_Ramos/14h stim_ Stimulated with PMA/ionomycin 14h sscDNA	28.7
94909_XF-498_CNS sscDNA	0.0	94962_MEG-01_Chronic myelogenous leukemia (megakaryoblast) sscDNA	48.4
94910_SNB-78_CNS/glioma sscDNA	0.7	94963_Raji_Burkitt's lymphoma sscDNA	13.1
94911_SF-268_CNS/glioblastoma sscDNA	2.2	94964_Daudi_Burkitt's lymphoma sscDNA	46.1
94912_T98G_Glioblastoma sscDNA	0.3	94965_U266_B-cell plasmacytoma/myeloma sscDNA	1.9
96776_SK-N-SH_Neuroblastoma (metastasis) sscDNA	7.4	94968_CA46_Burkitt's lymphoma sscDNA	22.0
94913_SF-295_CNS/glioblastoma sscDNA	0.7	94970_RL_non-Hodgkin's B-cell lymphoma sscDNA	10.9
94914_Cerebellum sscDNA	7.1	94972_JM1_pre-B-cell lymphoma/leukemia sscDNA	23.6
96777_Cerebellum sscDNA	2.8	94973_Jurkat_T cell leukemia sscDNA	23.4
94916_NCI-H292_Mucoepidermoid lung carcinoma sscDNA	28.3	94974_TF-1_Erythroleukemia sscDNA	19.1
94917_DMS-114_Small cell lung cancer sscDNA	8.7	94975_HUT 78_T-cell lymphoma sscDNA	21.3
94918_DMS-79_Small cell lung cancer/neuroendocrine sscDNA	62.6	94977_U937_Histiocytic lymphoma sscDNA	40.0

94919_NCI-H146_Small cell lung cancer/neuroendocrine sscDNA	63.7	94980_KU-812_Myelogenous leukemia sscDNA	25.7
94920_NCI-H526_Small cell lung cancer/neuroendocrine sscDNA	90.5	94981_769-P_Clear cell renal carcinoma sscDNA	5.5
94921_NCI-N417_Small cell lung cancer/neuroendocrine sscDNA	0.3	94983_Caki-2_Clear cell renal carcinoma sscDNA	26.3
94923_NCI-H82_Small cell lung cancer/neuroendocrine sscDNA	1.7	94984_SW 839_Clear cell renal carcinoma sscDNA	0.2
94924_NCI-H157_Squamous cell lung cancer (metastasis) sscDNA	21.5	94986_G401_Wilms' tumor sscDNA	4.2
94925_NCI-H1155_Large cell lung cancer/neuroendocrine sscDNA	0.6	94987_Hs766T_Pancreatic carcinoma (LN metastasis) sscDNA	2.7
94926_NCI-H1299_Large cell lung cancer/neuroendocrine sscDNA	63.0	94988_CAPAN-1_Pancreatic adenocarcinoma (liver metastasis) sscDNA	4.3
94927_NCI-H727_Lung carcinoid sscDNA	100.0	94989_SU86.86_Pancreatic carcinoma (liver metastasis) sscDNA	20.2
94928_NCI-UMC-11_Lung carcinoid sscDNA	1.4	94990_BxPC-3_Pancreatic adenocarcinoma sscDNA	6.8
94929_LX-1_Small cell lung cancer sscDNA	17.7	94991_HPAC_Pancreatic adenocarcinoma sscDNA	11.5
94930_Colo-205_Colon cancer sscDNA	14.5	94992_MIA PaCa-2_Pancreatic carcinoma sscDNA	1.7
94931_KM12_Colon cancer sscDNA	51.3	94993_CFPAC-1_Pancreatic ductal adenocarcinoma sscDNA	17.5
94932_KM20L2_Colon cancer sscDNA	5.2	94994_PANC-1_Pancreatic epithelioid ductal carcinoma sscDNA	7.0
94933_NCI-H716_Colon cancer sscDNA	63.6	94996_T24_Bladder carcinoma (transitional cell) sscDNA	16.7
94935_SW-48_Colon adenocarcinoma sscDNA	4.1	94997_5637_Bladder carcinoma sscDNA	19.6
94936_SW1116_Colon adenocarcinoma sscDNA	5.6	94998_HT-1197_Bladder carcinoma sscDNA	13.2
94937_LS 174T_Colon adenocarcinoma sscDNA	12.8	94999_UM-UC-3_Bladder carcinoma (transitional cell) sscDNA	5.7
94938_SW-948_Colon adenocarcinoma sscDNA	2.1	95000_A204_Rhabdomyosarcoma sscDNA	1.6
94939_SW-480_Colon adenocarcinoma sscDNA	7.0	95001_HT-1080_Fibrosarcoma sscDNA	3.3
94940_NCI-SNU-5_Gastric carcinoma sscDNA	6.8	95002_MG-63_Osteosarcoma (bone) sscDNA	3.0
94941_KATO III_Gastric carcinoma sscDNA	15.8	95003_SK-LMS-1_Leiomyosarcoma (vulva) sscDNA	1.3
94943_NCI-SNU-16_Gastric carcinoma sscDNA	16.8	95004_SJRH30_Rhabdomyosarcoma (met to bone marrow) sscDNA	0.2
94944_NCI-SNU-1_Gastric carcinoma sscDNA	81.9	95005_A431_Epidermoid carcinoma sscDNA	13.0
94946_RF-1_Gastric adenocarcinoma sscDNA	17.6	95007_WM266-4_Melanoma sscDNA	0.7
94947_RF-48_Gastric adenocarcinoma sscDNA	27.2	95010_DU 145_Prostate carcinoma (brain metastasis) sscDNA	0.3
96778_MKN-45_Gastric carcinoma sscDNA	6.7	95012_MDA-MB-468_Breast adenocarcinoma sscDNA	0.7



94949_NCI-N87_Gastric carcinoma_sscDNA	18.3	95013_SCC-4_Squamous cell carcinoma of tongue_sscDNA	0.9
94951_OVCAR-5_Ovarian carcinoma_sscDNA	3.9	95014_SCC-9_Squamous cell carcinoma of tongue_sscDNA	0.6
94952_RL95-2_Uterine carcinoma_sscDNA	0.1	95015_SCC-15_Squamous cell carcinoma of tongue_sscDNA	0.5
94953_HelaS3_Cervical adenocarcinoma_sscDNA	2.5	95017_CAL 27_Squamous cell carcinoma of tongue_sscDNA	9.9

Table 36. Panel 4D

Tissue Name	Relative Expression(%)	Tissue Name	Relative Expression(%)
	4dtm3780t_ag2456		4dtm3780t_ag2456
93768_Secondary Th1_anti-CD28/anti-CD3	19.5	93100_HUVEC (Endothelial)_IL-1b	6.0
93769_Secondary Th2_anti-CD28/anti-CD3	11.1	93779_HUVEC (Endothelial)_IFN gamma	11.1
93770_Secondary Tr1_anti-CD28/anti-CD3	15.9	93102_HUVEC (Endothelial)_TNF alpha + IFN gamma	5.8
93573_Secondary Th1_resting day 4-6 in IL-2	0.5	93101_HUVEC (Endothelial)_TNF alpha + IL4	33.0
93572_Secondary Th2_resting day 4-6 in IL-2	0.8	93781_HUVEC (Endothelial)_IL-11	4.2
93571_Secondary Tr1_resting day 4-6 in IL-2	0.9	93583_Lung Microvascular Endothelial Cells none	15.2
93568_primary Th1_anti-CD28/anti-CD3	17.0	93584_Lung Microvascular Endothelial Cells TNFa (4 ng/ml) and IL1b (1 ng/ml)	20.0
93569_primary Th2_anti-CD28/anti-CD3	14.5	92662_Microvascular Dermal endothelium none	22.5
93570_primary Tr1_anti-CD28/anti-CD3	29.1	92663_Microvascular Dermal endothelium TNFa (4 ng/ml) and IL1b (1 ng/ml)	9.5
93565_primary Th1_resting dy 4-6 in IL-2	4.0	93773_Bronchial epithelium TNFa (4 ng/ml) and IL1b (1 ng/ml) **	1.8
93566_primary Th2_resting dy 4-6 in IL-2	2.9	93347_Small Airway Epithelium none	3.4
93567_primary Tr1_resting dy 4-6 in IL-2	1.5	93348_Small Airway Epithelium TNFa (4 ng/ml) and IL1b (1 ng/ml)	16.5
93351_CD45RA CD4 lymphocyte_anti-CD28/anti-CD3	8.0	92668_Coronary Artery SMC resting	3.0
93352_CD45RO CD4 lymphocyte_anti-CD28/anti-CD3	12.1	92669_Coronary Artery SMC TNFa (4 ng/ml) and IL1b (1 ng/ml)	1.6
93251_CD8 Lymphocytes_anti-CD28/anti-CD3	14.5	93107_astrocytes_resting	3.7
93353_chronic CD8 Lymphocytes 2ry_resting dy 4-6 in IL-2	8.8	93108_astrocytes TNFa (4 ng/ml) and IL1b (1 ng/ml)	1.1
93574_chronic CD8 Lymphocytes 2ry_activated CD3/CD28	7.9	92666_KU-812 (Basophil)_resting	10.0
93354_CD4_none	0.4	92667_KU-812 (Basophil)_PMA/ionoycin	18.9
93252_Secondary	1.7	93579_CCD1106	4.8

Th1/Th2/Tr1_anti-CD95 CH11		(Keratinocytes)_none	
		93580_CCD1106	
93103_LAK cells resting	9.5	(Keratinocytes)_TNFa and IFN $\gamma$ **	0.7
93788_LAK cells IL-2	11.3	93791_Liver Cirrhosis	0.4
93787_LAK cells IL-2+IL-12	6.7	93792_Lupus Kidney	0.3
93789_LAK cells_IL-2+IFN gamma	9.3	93577_NCI-H292	1.8
93790_LAK cells IL-2+ IL-18	11.3	93358_NCI-H292 IL-4	4.2
93104_LAK cells_PMA/ionomycin and IL-18	9.4	93360_NCI-H292 IL-9	6.7
93578_NK Cells IL-2 resting	3.3	93359_NCI-H292 IL-13	2.0
93109_Mixed Lymphocyte Reaction Two Way MLR	4.8	93357_NCI-H292 IFN gamma	3.0
93110_Mixed Lymphocyte Reaction Two Way MLR	6.5	93777_HPAEC -	9.7
93111_Mixed Lymphocyte Reaction Two Way MLR	4.4	93778_HPAEC_IL-1 beta/TNA alpha	9.0
93112_Mononuclear Cells (PBMCs) resting	0.3	93254_Normal Human Lung Fibroblast_none	1.1
93113_Mononuclear Cells (PBMCs) PWM	30.1	93253_Normal Human Lung Fibroblast_TNFa (4 ng/ml) and IL- 1b (1 ng/ml)	0.5
93114_Mononuclear Cells (PBMCs) PHA-L	12.9	93257_Normal Human Lung Fibroblast IL-4	5.6
93249_Ramos (B cell)_none	22.4	93256_Normal Human Lung Fibroblast_IL-9	3.7
93250_Ramos (B cell) ionomycin	73.2	93255_Normal Human Lung Fibroblast IL-13	3.4
93349_B lymphocytes PWM	100.0	93258_Normal Human Lung Fibroblast IFN gamma	3.9
93350_B lymphocytes_CD40L and IL-4	6.7	93106_Dermal Fibroblasts CCD1070 resting	6.2
92665_EOL-1 (Eosinophil)_dbcAMP differentiated	5.5	93361_Dermal Fibroblasts CCD1070 TNF alpha 4 ng/ml	10.7
93248_EOL-1 (Eosinophil)_dbcAMP/PMAionom ycin	3.6	93105_Dermal Fibroblasts CCD1070_IL-1 beta 1 ng/ml	2.4
93356_Dendritic Cells_none	17.3	93772_dermal fibroblast_IFN gamma	1.6
93355_Dendritic Cells_LPS 100 ng/ml	16.8	93771_dermal fibroblast_IL-4	3.0
93775_Dendritic Cells anti-CD40	21.9	93260_IBD Colitis 2	0.4
93774_Monocytes resting	0.5	93261_IBD Crohns	0.4
93776_Monocytes LPS 50 ng/ml	1.1	735010_Colon normal	2.9
93581_Macrophages resting	39.2	735019_Lung none	6.7
93582_Macrophages_LPS 100 ng/ml	3.7	64028-1_Thymus_none	1.7
93098_HUVEC (Endothelial)_none	11.7	64030-1_Kidney none	6.4
93099_HUVEC (Endothelial)_starved	18.8		

Table 37. Panel CNS\_neurodegeneration\_v1.0

Tissue Name	Relative Expression (%)	Tissue Name	Relative Expression (%)
	tm7017t_ag2456 b2 s1		tm7017t_ag2456 b2 s1
AD 1 Hippo	0.0	Control (Path) 3 Temporal Ctx	0.0
AD 2 Hippo	0.0	Control (Path) 4 Temporal Ctx	0.1
AD 3 Hippo	0.0	AD 1 Occipital Ctx	0.0
AD 4 Hippo	0.0	AD 2 Occipital Ctx (Missing)	0.0
AD 5 Hippo	100.0	AD 3 Occipital Ctx	0.0
AD 6 Hippo	0.5	AD 4 Occipital Ctx	0.0
Control 2 Hippo	0.0	AD 5 Occipital Ctx	99.2
Control 4 Hippo	0.0	AD 6 Occipital Ctx	2.4
Control (Path) 3 Hippo	0.2	Control 1 Occipital Ctx	0.0
AD 1 Temporal Ctx	0.0	Control 2 Occipital Ctx	0.0
AD 2 Temporal Ctx	0.0	Control 3 Occipital Ctx	0.0
AD 3 Temporal Ctx	0.0	Control 4 Occipital Ctx	0.0
AD 4 Temporal Ctx	0	Control (Path) 1 Occipital Ctx	0.1
AD 5 Inf Temporal Ctx	46.2	Control (Path) 2 Occipital Ctx	0.0
AD 5 Sup Temporal Ctx	99.2	Control (Path) 3 Occipital Ctx	0.0
AD 6 Inf Temporal Ctx	0.5	Control (Path) 4 Occipital Ctx	0.0
AD 6 Sup Temporal Ctx	0.4	Control 1 Parietal	0.0
Control 1 Temporal Ctx	0.0	Control 2 Parietal	0.1
Control 2 Temporal Ctx	0.0	Control 3 Parietal	0.0
Control 3 Temporal Ctx	0.0	Control (Path) 1 Parietal	0.1
Control 3 Temporal Ctx	0.0	Control (Path) 2 Parietal	0.0
Control (Path) 1 Temporal Ctx	0.0	Control (Path) 3 Parietal	0.0
Control (Path) 2 Temporal Ctx	0.0	Control (Path) 4 Parietal	0.1

**Panel 1.3D Summary:** Ag2456 Expression of the NOV5 gene is highest in melanoma (CT = 26.4) and is expressed at moderate to high levels across all melanoma cancer cell lines present in this panel. This expression profile strongly suggests that the NOV5 gene could be used to distinguish melanoma cell lines from other tissue samples.

Panel 1.3D also shows that the NOV5 gene is expressed at high to moderate levels in the brain. Among CNS samples, this gene is expressed at highest levels (CT = 26.9) in the hippocampus region of the brain. Expression is also detected in the cerebral cortex, cerebellum, substantia nigra, thalamus, amygdala, and spinal cord. The NOV5 gene encodes a protein with homology to fatty acid binding proteins. Fatty acids are ubiquitous in central nervous system associated membranes such as myelin, synaptic vesicles, pre- and post-synaptic membranes, and synaptosomal cytosol, where they play a critical role in membrane composition and fluidity. Therefore, the fatty acid binding proteins that transport the hydrophobic fatty acids into the cell play an important role both during development and

during dendritic outgrowth repair, axonal extension, and compensatory synaptogenesis. Fatty acid transport proteins are upregulated during the response to injury, and the decrease in levels in aged mammals may be partially responsible for their decreased ability to respond to and repair CNS injury. Thus, the Gmba38818\_A protein product may play a role in some or all of these central nervous system related processes and therapeutic modulation of the gene product could be important in treating these same disease processes.

This gene is also widely expressed at moderate levels in most metabolic tissues, including adipose, adrenal gland, adult and fetal heart, adult and fetal liver, adult and skeletal muscle, pancreas (CT=31), pituitary and thyroid. Therefore, therapeutic targeting of the fatty acid binding protein encoded by the NOV5 gene may be useful for the treatment of metabolic diseases, such as obesity and diabetes.

**Panel 2D Summary Ag2456** Expression of the NOV5 gene is highest in lung cancer (CT = 23.1). Overexpression of the NOV5 gene is seen in 3/5 lung cancer samples when compared to their normal adjacent tissue counterparts. Thus, based on this expression profile, the expression of the NOV5 gene could be used to distinguish lung cancer samples from normal lung. In addition, therapeutic modulation of the NOV5 gene product, through the use of small molecule drugs or antibodies, could be beneficial in the treatment of lung cancer.

**Panel 3D Summary Ag2456** Expression of the NOV5 gene is highest in samples derived from colon cancer (CT=29), and lung cancer (CT=28.3) cell lines. Overexpression of this gene in lung cancers is consistent with the results in panel 2D. Thus, based on this expression pattern, the NOV5 gene could be used to distinguish lung cancer cell lines from other cell lines. In addition, therapeutic modulation of this gene product, through the use of small molecule drugs or antibodies, could potentially be effective in the treatment of lung cancer.

**Panel 4D Summary Ag2456** Expression of the NOV5 gene is highest in primary B cells activated by PWM (CT = 24.4), and in an activated B cell line, Ramos (CT = 24.9). The expression of the Gmba38818\_A gene in PBMC treated with the B cell mitogen, PWM, (CT = 26.2) is consistent with this data. This gene probably encodes for a fatty acid binding protein that might be involved in B cell trafficking. Thus, drug targeting of the fatty acid binding protein encoded by the NOV5 gene may be valuable for treatment of immune disease processes, particularly autoimmune diseases such as lupus, rheumatoid arthritis, and diseases associated with hyperglobulinemia.

**Panel CNS\_neurodegeneration\_v1.0 Summary Ag2456** Expression of the NOV5 gene is highest in tissue samples derived from different brain regions of a patient with

Alzheimer's disease. These regions include the hippocampus (CT = 19.4), the superior temporal cortex (CT = 19.5), the inferior temporal cortex (CT = 20.6), and the occipital cortex (CT = 19.5). Thus, this gene may be involved in the pathology of at least one form of Alzheimer's disease. Upregulation of the NOV5 gene or its protein product may be of use in enhancing compensatory synatogenesis and axon or dendritic outgrowth in response to spinal cord injury, neuronal death resulting from stroke or head trauma, or neurodegeneration present in Alzheimer's, Parkinson's, Huntington's, spinocerebellar ataxia, progressive supranuclear palsy. (Glatz et al., J Mol Neurosci 16:23-32, 2001; Pu et al., Mol Cell Biochem 198:69-78, 1999; Liu et al., J Neurosci Res 48:551-62, 1997.)

#### 10 NOV6a: Neurolysin Precursor-like

Expression of the NOV6a gene (SC133790496\_A) was assessed using the primer-probe set Ag2458, described in Table 38. Results of the RTQ-PCR runs are shown in Tables 39, 40, 41, 42, 43, 44, and 45.

15 Table 38. Probe Name Ag2458

Primers	Sequences	TM	Length	Start Position	SEQ ID NO:
Forward	5'-GTTGGTGGTTCCAGGATTTT-3'	58.7	20	58	167
Probe	TET-5'-TGATGTCTCCTCTTCAGGCAATGTCT-3'-TAMRA	66.6	26	104	168
Reverse	5'-CTGCCAGCCACAGTATAGGA-3'	58.9	20	130	169

Table 39. Panel 1.3D

Tissue Name	Relative Expression(%)	
	1.3dtm4270t_ag2458	1.3dx4tm5407t_ag2458_a2
Liver adenocarcinoma	33.9	41.4
Pancreas	1.3	0.8
Pancreatic ca. CAPAN 2	6.9	44.3
Adrenal gland	0.7	1.1
Thyroid	2.8	3.3
Salivary gland	0.6	2
Pituitary gland	1.6	0.4
Brain (fetal)	9.2	19.7
Brain (whole)	5.4	17.7
Brain (amygdala)	6.7	9.0
Brain (cerebellum)	2.7	10.2
Brain (hippocampus)	23	13.1
Brain (substantia nigra)	1.6	7.2
Brain (thalamus)	4.9	16.6
Cerebral Cortex	26.2	8.2

Spinal cord	2.4	9.8
CNS ca. (glio/astro) U87-MG	11.0	19.7
CNS ca. (glio/astro) U-118-MG	45.1	82.4
CNS ca. (astro) SW1783	21.9	46.0
CNS ca.* (neuro; met) SK-N-AS	73.7	40.2
CNS ca. (astro) SF-539	9.9	12.0
CNS ca. (astro) SNB-75	22.5	71.5
CNS ca. (glio) SNB-19	6.2	18.1
CNS ca. (glio) U251	5.9	45.0
CNS ca. (glio) SF-295	13.0	26.4
Heart (fetal)	1.7	0.0
Heart	1.2	4.4
Fetal Skeletal	11.4	1.2
Skeletal muscle	3.8	41.7
Bone marrow	1.5	2.2
Thymus	0.8	0.4
Spleen	0.9	0.8
Lymph node	1.3	10.4
Colorectal	4.8	3.1
Stomach	0.0	3.1
Small intestine	1.1	2.3
Colon ca. SW480	19.5	18.9
Colon ca.* (SW480 met)SW620	29.9	29.8
Colon ca. HT29	17.7	9.7
Colon ca. HCT-116	22.1	43.8
Colon ca. CaCo-2	13.5	18.4
83219 CC Well to Mod Diff (ODO3866)	10.6	7.0
Colon ca. HCC-2998	45.7	21.1
Gastric ca.* (liver met) NCI-N87	38.4	69.5
Bladder	7.4	13.6
Trachea	2.9	3.0
Kidney	1.3	3.5
Kidney (fetal)	3.6	3.9
Renal ca. 786-0	10.0	19.0
Renal ca. A498	29.7	28.6
Renal ca. RXF 393	5.6	53.0
Renal ca. ACHN	5.5	13.3
Renal ca. UO-31	21.6	45.5
Renal ca. TK-10	20.4	27.0
Liver	2.9	2.4
Liver (fetal)	3.8	5.0
Liver ca. (hepatoblast) HepG2	17.3	28.2
Lung	1.9	2.5
Lung (fetal)	1.4	5.6
Lung ca. (small cell) LX-1	11.8	40.6

Lung ca. (small cell) NCI-H69	31.4	44.0
Lung ca. (s.cell var.) SHP-77	69.3	90.5
Lung ca. (large cell) NCI-H460	9.9	63.6
Lung ca. (non-sm. cell) A549	20.9	25.9
Lung ca. (non-s.cell) NCI-H23	11.3	10.7
Lung ca (non-s.cell) HOP-62	4.1	9.1
Lung ca. (non-s.cl) NCI-H522	29.1	30.0
Lung ca. (squam.) SW 900	9.7	20.1
Lung ca. (squam.) NCI-H596	9.5	43.2
Mammary gland	5.3	9.0
Breast ca.* (pl. effusion) MCF-7	14.3	30.8
Breast ca.* (pl.ef) MDA-MB-231	42.3	41.1
Breast ca.* (pl. effusion) T47D	9.6	13.8
Breast ca. BT-549	100.0	100.0
Breast ca. MDA-N	17.2	8.8
Ovary	4.8	0.9
Ovarian ca. OVCAR-3	11.3	20.9
Ovarian ca. OVCAR-4	2.5	10.6
Ovarian ca. OVCAR-5	20.0	26.3
Ovarian ca. OVCAR-8	18.6	16.5
Ovarian ca. IGROV-1	6.9	6.8
Ovarian ca.* (ascites) SK-OV-3	32.3	64.3
Uterus	1.8	4.3
Placenta	2.2	1.1
Prostate	2.0	2.4
Prostate ca.* (bone met) PC-3	3.1	3.2
Testis	2.0	1.5
Melanoma Hs688(A).T	4.6	5.4
Melanoma* (met) Hs688(B).T	2.4	6.9
Melanoma UACC-62	1.3	12.6
Melanoma M14	5.9	56.2
Melanoma LOX IMVI	14.7	8.1
Melanoma* (met) SK-MEL-5	16.2	24.7
Adipose	4.4	3.4

Table 40. Panel 2D

Tissue Name	Relative Expression(%)	Tissue Name	Relative Expression(%)
	2dtm4271t_ ag2458		2dtm4271t_ ag2458
Normal Colon GENPAK 061003	62.4	Kidney NAT Clontech 8120608	7.3
83219 CC Well to Mod Diff (ODO3866)	16.8	Kidney Cancer Clontech 8120613	14.4
83220 CC NAT (ODO3866)	11.7	Kidney NAT Clontech 8120614	8.8
83221 CC Gr.2 rectosigmoid (ODO3868)	18.6	Kidney Cancer Clontech 9010320	12.2

83222 CC NAT (ODO3868)	8.4	Kidney NAT Clontech 9010321	22.1
83235 CC Mod Diff (ODO3920)	34.2	Normal Uterus GENPAK 061018	8.3
83236 CC NAT (ODO3920)	11.3	Uterus Cancer GENPAK 064011	15.3
83237 CC Gr.2 ascend colon (ODO3921)	74.7	Normal Thyroid Clontech A+ 6570-1	15.1
83238 CC NAT (ODO3921)	9.6	Thyroid Cancer GENPAK 064010	33.0
83241 CC from Partial Hepatectomy (ODO4309)	35.6	Thyroid Cancer INVITROGEN A302152	21.6
83242 Liver NAT (ODO4309)	32.3	Thyroid NAT INVITROGEN A302153	14.4
87472 Colon mets to lung (OD04451-01)	29.7	Normal Breast GENPAK 061019	33.2
87473 Lung NAT (OD04451-02)	6.4	84877 Breast Cancer (OD04566)	44.8
Normal Prostate Clontech A+ 6546-1	8.8	85975 Breast Cancer (OD04590-01)	95.9
84140 Prostate Cancer (OD04410)	25.9	85976 Breast Cancer Mets (OD04590-03)	61.1
84141 Prostate NAT (OD04410)	27.9	87070 Breast Cancer Metastasis (OD04655-05)	38.4
87073 Prostate Cancer (OD04720-01)	15.8	GENPAK Breast Cancer 064006	33.2
87074 Prostate NAT (OD04720-02)	28.1	Breast Cancer Res. Gen. 1024	23.0
Normal Lung GENPAK 061010	24.8	Breast Cancer Clontech 9100266	33.4
83239 Lung Met to Muscle (ODO4286)	100.0	Breast NAT Clontech 9100265	19.5
83240 Muscle NAT (ODO4286)	31.9	Breast Cancer INVITROGEN A209073	47.0
84136 Lung Malignant Cancer (OD03126)	29.5	Breast NAT INVITROGEN A2090734	37.6
84137 Lung NAT (OD03126)	27.9	Normal Liver GENPAK 061009	15.5
84871 Lung Cancer (OD04404)	71.7	Liver Cancer GENPAK 064003	14.0
84872 Lung NAT (OD04404)	15.1	Liver Cancer Research Genetics RNA 1025	20.4
84875 Lung Cancer (OD04565)	28.5	Liver Cancer Research Genetics RNA 1026	7.1
84876 Lung NAT (OD04565)	13.1	Paired Liver Cancer Tissue Research Genetics RNA 6004-T	24.8
85950 Lung Cancer (OD04237-01)	90.1	Paired Liver Tissue Research Genetics RNA 6004-N	18.0
85970 Lung NAT (OD04237-02)	16.8	Paired Liver Cancer Tissue Research Genetics RNA 6005-T	13.4
83255 Ocular Mel Met to Liver (ODO4310)	76.3	Paired Liver Tissue Research Genetics RNA 6005-N	7.3
83256 Liver NAT (ODO4310)	26.8	Normal Bladder GENPAK 061001	59.9
84139 Melanoma Mets to Lung (OD04321)	36.3	Bladder Cancer Research Genetics RNA 1023	5.2
84138 Lung NAT (OD04321)	22.5	Bladder Cancer INVITROGEN A302173	30.1
Normal Kidney GENPAK 061008	33.7	87071 Bladder Cancer (OD04718-01)	65.5
83786 Kidney Ca, Nuclear grade 2 (OD04338)	68.8	87072 Bladder Normal Adjacent (OD04718-03)	18.4
83787 Kidney NAT (OD04338)	33.4	Normal Ovary Res. Gen.	5.1
83788 Kidney Ca Nuclear grade 1/2 (OD04339)	30.6	Ovarian Cancer GENPAK 064008	29.1



83789 Kidney NAT (OD04339)	27.2	87492 Ovary Cancer (OD04768-07)	66.0
83790 Kidney Ca, Clear cell type (OD04340)	49.3	87493 Ovary NAT (OD04768-08)	7.7
83791 Kidney NAT (OD04340)	32.1	Normal Stomach GENPAK 061017	16.4
83792 Kidney Ca, Nuclear grade 3 (OD04348)	16.0	Gastric Cancer Clontech 9060358	3.5
83793 Kidney NAT (OD04348)	35.4	NAT Stomach Clontech 9060359	10.5
87474 Kidney Cancer (OD04622-01)	13.2	Gastric Cancer Clontech 9060395	29.9
87475 Kidney NAT (OD04622-03)	4.0	NAT Stomach Clontech 9060394	12.9
85973 Kidney Cancer (OD04450-01)	48.6	Gastric Cancer Clontech 9060397	42.3
85974 Kidney NAT (OD04450-03)	30.4	NAT Stomach Clontech 9060396	6.2
Kidney Cancer Clontech 8120607	20.4	Gastric Cancer GENPAK 064005	31.0

Table 41. Panel 3D

Tissue Name	Relative Expression(%)	Tissue Name	Relative Expression(%)
	3dx4tm5121t_ag2458_b2		3dx4tm5121t_ag2458_b2
94905_Daoy_Medulloblastoma/Cerebellum_sscDNA	13.6	94954_Ca Ski_Cervical epidermoid carcinoma (metastasis) sscDNA	24.3
94906_TE671_Medulloblastom/Cerebellum sscDNA	7.4	94955_ES-2_Ovarian clear cell carcinoma sscDNA	16.1
94907_D283 Med_Medulloblastoma/Cerebellum sscDNA	53.0	94957_Ramos/6h stim_ Stimulated with PMA/ionomycin 6h sscDNA	8.7
94908_PFSK-1_Primitive Neuroectodermal/Cerebellum_sscDNA	6.5	94958_Ramos/14h stim_ Stimulated with PMA/ionomycin 14h sscDNA	8.3
94909_XF-498_CNS_sscDNA	6.8	94962_MEG-01_Chronic myelogenous leukemia (megokaryoblast) sscDNA	22.1
94910_SNB-78_CNS/glioma sscDNA	9.8	94963_Raji_Burkitt's lymphoma sscDNA	8.3
94911_SF-268_CNS/glioblastoma sscDNA	10.2	94964_Daudi_Burkitt's lymphoma sscDNA	19.8
94912_T98G_Glioblastoma_sscDNA	15.7	94965_U266_B-cell plasmacytoma/myeloma sscDNA	6.4
96776_SK-N-SH_Neuroblastoma (metastasis) sscDNA	16.5	94968_CA46_Burkitt's lymphoma sscDNA	6.5
94913_SF-295_CNS/glioblastoma sscDNA	7.4	94970_RL_non-Hodgkin's B-cell lymphoma sscDNA	9.0
94914_Cerebellum sscDNA	3.9	94972_JM1_pre-B-cell lymphoma/leukemia sscDNA	4.1
96777_Cerebellum sscDNA	0.8	94973_Jurkat_T cell leukemia sscDNA	9.8
94916_NCI-H292_Mucoepidermoid lung carcinoma sscDNA	46.9	94974_TF-1 Erythroleukemia sscDNA	31.5

94917_DMS-114_Small cell lung cancer sscDNA	10.9	94975_HUT 78 T-cell lymphoma sscDNA	15.7
94918_DMS-79_Small cell lung cancer/neuroendocrine sscDNA	100.0	94977_U937_Histiocytic lymphoma sscDNA	30.5
94919_NCI-H146_Small cell lung cancer/neuroendocrine sscDNA	33.4	94980_KU-812_Myelogenous leukemia sscDNA	21.7
94920_NCI-H526_Small cell lung cancer/neuroendocrine sscDNA	30.2	94981_769-P_Clear cell renal carcinoma sscDNA	16.6
94921_NCI-N417_Small cell lung cancer/neuroendocrine sscDNA	26.1	94983_Caki-2_Clear cell renal carcinoma sscDNA	16.8
94923_NCI-H82_Small cell lung cancer/neuroendocrine sscDNA	28.4	94984_SW 839_Clear cell renal carcinoma sscDNA	11.8
94924_NCI-H157_Squamous cell lung cancer (metastasis) sscDNA	88.0	94986_G401_Wilms' tumor sscDNA	16.5
94925_NCI-H1155_Large cell lung cancer/neuroendocrine sscDNA	31.3	94987_Hs766T_Pancreatic carcinoma (LN metastasis) sscDNA	12.9
94926_NCI-H1299_Large cell lung cancer/neuroendocrine sscDNA	32.4	94988_CAPAN-1_Pancreatic adenocarcinoma (liver metastasis) sscDNA	12.0
94927_NCI-H727_Lung carcinoid sscDNA	23.0	94989_SU86.86_Pancreatic carcinoma (liver metastasis) sscDNA	32.6
94928_NCI-UMC-11_Lung carcinoid sscDNA	75.0	94990_BxPC-3_Pancreatic adenocarcinoma sscDNA	4.0
94929_LX-1_Small cell lung cancer sscDNA	17.0	94991_HPAC_Pancreatic adenocarcinoma sscDNA	26.4
94930_Colo-205_Colon cancer sscDNA	11.1	94992_MIA PaCa-2_Pancreatic carcinoma sscDNA	8.2
94931_KM12_Colon cancer sscDNA	37.3	94993_CFPAC-1_Pancreatic ductal adenocarcinoma sscDNA	30.3
94932_KM20L2_Colon cancer sscDNA	7.8	94994_PANC-1_Pancreatic epithelioid ductal carcinoma sscDNA	26.7
94933_NCI-H716_Colon cancer sscDNA	32.3	94996_T24_Bladder carcinoma (transitional cell) sscDNA	8.2
94935_SW-48_Colon adenocarcinoma sscDNA	7.8	94997_5637_Bladder carcinoma sscDNA	20.5
94936_SW1116_Colon adenocarcinoma sscDNA	10.9	94998_HT-1197_Bladder carcinoma sscDNA	18.0
94937_LS 174T_Colon adenocarcinoma sscDNA	29.3	94999_UM-UC-3_Bladder carcinoma (transitional cell) sscDNA	4.6
94938_SW-948_Colon adenocarcinoma sscDNA	1.9	95000_A204_Rhabdomyosarcoma sscDNA	20.0
94939_SW-480_Colon adenocarcinoma sscDNA	4.9	95001_HT-1080_Fibrosarcoma sscDNA	15.4
94940_NCI-SNU-5_Gastric carcinoma sscDNA	8.3	95002_MG-63_Osteosarcoma (bone) sscDNA	16.2
94941_KATO III_Gastric carcinoma sscDNA	53.1	95003_SK-LMS-1_Leiomyosarcoma (vulva) sscDNA	27.5
94943_NCI-SNU-16_Gastric carcinoma sscDNA	7.3	95004_SJRH30_Rhabdomyosarcoma (met to bone marrow) sscDNA	12.5
94944_NCI-SNU-1_Gastric	64.4	95005_A431_Epidermoid	6.9

carcinoma_sscDNA		carcinoma_sscDNA	
94946_RF-1_Gastric adenocarcinoma_sscDNA	11.4	95007_WM266-4_Melanoma_sscDNA	7.5
94947_RF-48_Gastric adenocarcinoma_sscDNA	15.4	95010_DU145_Prostate carcinoma (brain metastasis)_sscDNA	0.1
96778_MKN-45_Gastric carcinoma_sscDNA	28.8	95012_MDA-MB-468_Breast adenocarcinoma_sscDNA	13.5
94949_NCI-N87_Gastric carcinoma_sscDNA	19.5	95013_SCC-4_Squamous cell carcinoma of tongue_sscDNA	1.3
94951_OVCAR-5_Ovarian carcinoma_sscDNA	11.7	95014_SCC-9_Squamous cell carcinoma of tongue_sscDNA	0.3
94952_RL95-2_Uterine carcinoma_sscDNA	4.5	95015_SCC-15_Squamous cell carcinoma of tongue_sscDNA	0.3
94953_HelaS3_Cervical adenocarcinoma_sscDNA	11.3	95017_CAL27_Squamous cell carcinoma of tongue_sscDNA	24.5

Table 42. Panel 4D

Tissue Name	Relative Expression(%)	Tissue Name	Relative Expression(%)
	4dtm4272t_ag2458		4dtm4272t_ag2458
93768_Secondary Th1_anti-CD28/anti-CD3	14.5	93100_HUVEC (Endothelial)_IL-1b	16.5
93769_Secondary Th2_anti-CD28/anti-CD3	7.4	93779_HUVEC (Endothelial)_IFN gamma	26.1
93770_Secondary Tr1_anti-CD28/anti-CD3	9.5	93102_HUVEC (Endothelial)_TNF alpha + IFN gamma	16.0
93573_Secondary Th1_resting day 4-6 in IL-2	0.2	93101_HUVEC (Endothelial)_TNF alpha + IL4	23.2
93572_Secondary Th2_resting day 4-6 in IL-2	0.6	93781_HUVEC (Endothelial)_IL-11	13.6
93571_Secondary Tr1_resting day 4-6 in IL-2	0.8	93583_Lung Microvascular Endothelial Cells_none	21.0
93568_primary Th1_anti-CD28/anti-CD3	19.8	93584_Lung Microvascular Endothelial Cells_TNFa (4 ng/ml) and IL1b (1 ng/ml)	18.3
93569_primary Th2_anti-CD28/anti-CD3	13.0	92662_Microvascular Dermal endothelium_none	35.4
93570_primary Tr1_anti-CD28/anti-CD3	19.2	92663_Microvascular Dermal endothelium_TNFa (4 ng/ml) and IL1b (1 ng/ml)	20.0
93565_primary Th1_resting dy 4-6 in IL-2	8.8	93773_Bronchial epithelium_TNFa (4 ng/ml) and IL1b (1 ng/ml) **	14.9
93566_primary Th2_resting dy 4-6 in IL-2	2.2	93347_Small Airway Epithelium_none	7.2
93567_primary Tr1_resting dy 4-6 in IL-2	3.6	93348_Small Airway Epithelium_TNFa (4 ng/ml) and IL1b (1 ng/ml)	45.4
93351_CD45RA CD4 lymphocyte_anti-CD28/anti-CD3	19.5	92668_Coronary Artery SMC_resting	17.7
93352_CD45RO CD4 lymphocyte_anti-CD28/anti-CD3	17.7	92669_Coronary Artery SMC_TNFa (4 ng/ml) and IL1b (1 ng/ml)	10.8

93251_CD8 Lymphocytes_anti-CD28/anti-CD3	9.3	93107_astrocytes resting	11.1
93353_chronic CD8 Lymphocytes 2ry_resting dy 4-6 in IL-2	11.0	93108_astrocytes_TNFa (4 ng/ml) and IL1b (1 ng/ml)	10.5
93574_chronic CD8 Lymphocytes 2ry_activated CD3/CD28	5.5	92666_KU-812 (Basophil)_resting	18.8
93354_CD4 none	0.7	92667_KU-812 (Basophil)_PMA/ionoycin	27.9
93252_Secondary Th1/Th2/Tr1_anti-CD95 CH11	0.9	93579_CCD1106 (Keratinocytes)_none	20.9
93103_LAK cells_resting	15.8	93580_CCD1106 (Keratinocytes)_TNFa and IFNg **	7.4
93788_LAK cells_IL-2	6.1	93791_Liver Cirrhosis	3.7
93787_LAK cells_IL-2+IL-12	8.8	93792_Lupus Kidney	1.9
93789_LAK cells_IL-2+IFN gamma	11.7	93577_NCI-H292	18.6
93790_LAK cells_IL-2+ IL-18	13.2	93358_NCI-H292_IL-4	33.7
93104_LAK cells_PMA/ionomycin and IL-18	8.5	93360_NCI-H292_IL-9	36.9
93578_NK Cells_IL-2_resting	2.5	93359_NCI-H292_IL-13	20.0
93109_Mixed Lymphocyte Reaction_Two Way MLR	17.0	93357_NCI-H292_IFN gamma	20.4
93110_Mixed Lymphocyte Reaction_Two Way MLR	10.2	93777_HPAEC_-	18.8
93111_Mixed Lymphocyte Reaction_Two Way MLR	7.4	93778_HPAEC_IL-1 beta/TNA alpha	18.9
93112_Mononuclear Cells (PBMCs)_resting	2.4	93254_Normal Human Lung Fibroblast_none	9.5
93113_Mononuclear Cells (PBMCs)_PWM	23.7	93253_Normal Human Lung Fibroblast_TNFa (4 ng/ml) and IL-1b (1 ng/ml)	3.7
93114_Mononuclear Cells (PBMCs)_PHA-L	9.6	93257_Normal Human Lung Fibroblast_IL-4	24.7
93249_Ramos (B cell)_none	30.4	93256_Normal Human Lung Fibroblast_IL-9	19.2
93250_Ramos (B cell)_ionomycin	100.0	93255_Normal Human Lung Fibroblast_IL-13	14.3
93349_B lymphocytes_PWM	70.2	93258_Normal Human Lung Fibroblast_IFN gamma	23.2
93350_B lymphocytes_CD40L and IL-4	5.5	93106_Dermal Fibroblasts CCD1070_resting	47.0
92665_EOL-1 (Eosinophil)_dbcAMP differentiated	11.7	93361_Dermal Fibroblasts CCD1070_TNF alpha 4 ng/ml	42.3
93248_EOL-1 (Eosinophil)_dbcAMP/PMAionomycin	6.3	93105_Dermal Fibroblasts CCD1070_IL-1 beta 1 ng/ml	20.2
93356_Dendritic Cells_none	12.4	93772_dermal fibroblast_IFN gamma	9.2
93355_Dendritic Cells_LPS 100 ng/ml	9.0	93771_dermal fibroblast_IL-4	22.1
93775_Dendritic Cells_anti-CD40	12.5	93260_IBD Colitis 2	1.1
93774_Monocytes_resting	15.2	93261_IBD Crohns	1.0

93776_Monocytes_LPS 50 ng/ml	11.7	735010_Colon_normal	4.1
93581_Macrophages_resting	41.8	735019_Lung_none	8.9
93582_Macrophages_LPS 100 ng/ml	6.8	64028-1_Thymus_none	10.5
93098_HUVEC (Endothelial)_none	35.8	64030-1_Kidney_none	3.6
93099_HUVEC (Endothelial)_starved	58.2		

Table 43. Panel CNS\_1

Tissue Name	Relative Expression(%)	
	cns1x4tm6185t_ ag2458 b2	cns1tm6569t_ ag2458
102633_BA4 Control	47.4	40.3
102641_BA4 Control2	74.3	47.3
102625_BA4 Alzheimer's2	16.6	5.6
102649_BA4 Parkinson's	40.9	42.6
102656_BA4 Parkinson's2	100.0	74.7
102664_BA4 Huntington's	41.3	33.2
102671_BA4 Huntington's2	18.3	6.2
102603_BA4 PSP	8.4	13.1
102610_BA4 PSP2	35.5	40.9
102588_BA4 Depression	26.1	21.6
102596_BA4 Depression2	6.0	3.0
102634_BA7 Control	75.7	32.8
102642_BA7 Control2	75.9	46.0
102626_BA7 Alzheimer's2	6.1	2.2
102650_BA7 Parkinson's	27.3	14.1
102657_BA7 Parkinson's2	30.2	40.3
102665_BA7 Huntington's	43.5	37.4
102672_BA7 Huntington's2	44.5	27.9
102604_BA7 PSP	47.9	55.9
102611_BA7 PSP2	23.5	20.0
102589_BA7 Depression	20.7	18.7
102632_BA9 Control	33.5	25.7
102640_BA9 Control2	81.2	72.2
102617_BA9 Alzheimer's	5.1	13.9
102624_BA9 Alzheimer's2	29.0	15.6
102648_BA9 Parkinson's	46.8	33.0
102655_BA9 Parkinson's2	61.1	95.9
102663_BA9 Huntington's	67.5	100.0
102670_BA9 Huntington's2	20.5	12.9
102602_BA9 PSP	9.5	18.6
102609_BA9 PSP2	3.6	12.5
102587_BA9 Depression	10.4	10.2
102595_BA9 Depression2	5.4	11.3

102635 BA17 Control	30.3	34.9
102643 BA17 Control2	45.0	30.8
102627 BA17 Alzheimer's2	12.9	4.3
102651 BA17 Parkinson's	52.9	27.2
102658 BA17 Parkinson's2	55.5	37.4
102666 BA17 Huntington's	34.0	24.3
102673 BA17 Huntington's2	13.7	8.2
102590 BA17 Depression	17.3	20.9
102597 BA17 Depression2	38.8	13.5
102605 BA17 PSP	38.0	38.7
102612 BA17 PSP2	12.4	13.3
102637 Sub Nigra Control	42.0	24.3
102645 Sub Nigra Control2	41.1	97.3
102629 Sub Nigra Alzheimer's2	19.4	7.6
102660 Sub Nigra Parkinson's2	85.7	28.7
102667 Sub Nigra Huntington's	53.9	28.9
102674 Sub Nigra Huntington's2	41.8	25.2
102614 Sub Nigra PSP2	9.8	6.3
102592 Sub Nigra Depression	11.7	6.9
102599 Sub Nigra Depression2	5.8	10.6
102636 Glob Palladus Control	17.5	19.1
102644 Glob Palladus Control2	16.3	8.5
102620 Glob Palladus Alzheimer's	11.9	12.4
102628 Glob Palladus Alzheimer's2	7.3	10.8
102652 Glob Palladus Parkinson's	84.3	59.0
102659 Glob Palladus Parkinson's2	22.3	11.3
102606 Glob Palladus PSP	10.6	7.1
102613 Glob Palladus PSP2	15.7	9.2
102591 Glob Palladus Depression	9.2	3.7
102638 Temp Pole Control	22.1	17.8
102646 Temp Pole Control2	45.1	51.0
102622 Temp Pole Alzheimer's	11.4	14.1
102630 Temp Pole Alzheimer's2	7.2	14.1
102653 Temp Pole Parkinson's	25.9	22.4
102661 Temp Pole Parkinson's2	25.4	39.8
102668 Temp Pole Huntington's	39.1	37.4
102607 Temp Pole PSP	13.7	6.8
102615 Temp Pole PSP2	17.0	7.9
102600 Temp Pole Depression2	3.1	15.5
102639 Cing Gyr Control	58.5	53.6
102647 Cing Gyr Control2	38.5	47.0
102623 Cing Gyr Alzheimer's	17.0	48.6
102631 Cing Gyr Alzheimer's2	11.7	8.3
102654 Cing Gyr Parkinson's	31.0	43.2
102662 Cing Gyr Parkinson's2	41.7	48.0

102669 Cing Gyr Huntington's	84.9	77.9
102676 Cing Gyr Huntington's2	22.1	7.2
102608 Cing Gyr PSP	26.1	19.6
102616 Cing Gyr PSP2	8.9	11.3
102594 Cing Gyr Depression	12.7	11.5
102601 Cing Gyr Depression2	8.5	10.8

Table 44. Panel CNS\_1.1

Tissue Name	Relative Expression(%)	
	cns_1.1tm673 3t ag2458 b2	cns_1.1tm673 4t ag2458 b2
102601 Cing Gyr Depression2	8.4	9.7
102594 Cing Gyr Depression	11.0	18.8
102616 Cing Gyr PSP2	7.7	7.4
102608 Cing Gyr PSP	22.2	23.2
102676 Cing Gyr Huntington's2	9.1	14.5
102669 Cing Gyr Huntington's	44.5	71.0
102662 Cing Gyr Parkinson's2	32.6	39.6
102654 Cing Gyr Parkinson's	36.9	49.2
102631 Cing Gyr Alzheimer's2	14.1	18.0
102623 Cing Gyr Alzheimer's	30.0	11.7
102647 Cing Gyr Control2	26.2	39.0
102639 Cing Gyr Control	47.8	75.4
102600 Temp Pole Depression2	8.3	7.6
102615 Temp Pole PSP2	4.5	4.4
102607 Temp Pole PSP	5.3	5.9
102668 Temp Pole Huntington's	34.4	46.0
102661 Temp Pole Parkinson's2	18.2	49.8
102653 Temp Pole Parkinson's	37.9	37.0
102630 Temp Pole Alzheimer's2	7.4	6.2
102622 Temp Pole Alzheimer's	3.1	7.1
102646 Temp Pole Control2	32.7	47.8
102638 Temp Pole Control	13.2	13.4
102591 Glob Palladus Depression	8.6	7.3
102613 Glob Palladus PSP2	12.8	7.7
102606 Glob Palladus PSP	17.2	2.1
102659 Glob Palladus Parkinson's2	24.3	34.4
102652 Glob Palladus Parkinson's	64.2	87.9
102628 Glob Palladus Alzheimer's2	9.5	6.3
102620 Glob Palladus Alzheimer's	17.8	14.1
102644 Glob Palladus Control2	16.2	14.2
102636 Glob Palladus Control	8.3	23.7
102599 Sub Nigra Depression2	3.9	6.5
102592 Sub Nigra Depression	33.4	0.0
102614 Sub Nigra PSP2	13.1	11.0

102674 Sub Nigra Huntington's2	48.1	46.0
102667 Sub Nigra Huntington's	42.8	59.7
102660 Sub Nigra Parkinson's2	55.9	78.3
102629 Sub Nigra Alzheimer's2	14.1	18.1
102645 Sub Nigra Control2	18.8	14.3
102637 Sub Nigra Control	32.0	39.4
102597 BA17 Depression2	29.8	33.3
102590 BA17 Depression	16.9	22.2
102612 BA17 PSP2	10.6	5.7
102605 BA17 PSP	34.9	40.3
102673 BA17 Huntington's2	10.4	19.3
102666 BA17 Huntington's	51.2	63.3
102658 BA17 Parkinson's2	62.4	92.4
102651 BA17 Parkinson's	40.2	51.9
102627 BA17 Alzheimer's2	3.3	9.4
102643 BA17 Control2	71.2	69.4
102635 BA17 Control	42.0	43.4
102595 BA9 Depression2	7.6	16.4
102587 BA9 Depression	8.1	19.9
102609 BA9 PSP2	2.7	11.7
102602 BA9 PSP	14.2	21.9
102670 BA9 Huntington's2	16.1	21.8
102663 BA9 Huntington's	59.1	37.4
102655 BA9 Parkinson's2	56.5	76.5
102648 BA9 Parkinson's	34.0	48.2
102624 BA9 Alzheimer's2	30.7	20.4
102617 BA9 Alzheimer's	12.8	2.1
102640 BA9 Control2	67.2	100.0
102632 BA9 Control	24.3	44.1
102589 BA7 Depression	19.9	26.2
102611 BA7 PSP2	38.5	36.8
102604 BA7 PSP	49.7	56.2
102672 BA7 Huntington's2	29.3	49.0
102665 BA7 Huntington's	34.6	45.8
102657 BA7 Parkinson's2	25.4	43.4
102650 BA7 Parkinson's	28.9	23.1
102626 BA7 Alzheimer's2	11.1	9.2
102642 BA7 Control2	41.8	38.8
102634 BA7 Control	55.4	45.2
102596 BA4 Depression2	6.4	19.6
102588 BA4 Depression	0.0	23.8
102610 BA4 PSP2	45.8	23.0
102603 BA4 PSP	13.0	23.9
102671 BA4 Huntington's2	6.0	10.7
102664 BA4 Huntington's	31.2	23.6



102656 BA4 Parkinson's2	100.0	93.1
102649 BA4 Parkinson's	58.9	55.2
102625 BA4 Alzheimer's2	8.2	2.2
102641 BA4 Control2	39.1	0.0
102633 BA4 Control	43.8	51.1

Table 45. Panel CNS\_Neurodegeneration\_v1.0

Tissue Name	Relative Expression(%) tm7017t_ ag2458 b2 s2	Tissue Name	Relative Expression(%) tm7017t_ ag2458 b2 s2
AD 1 Hippo	2.8	Control (Path) 3 Temporal Ctx	1.5
AD 2 Hippo	6.2	Control (Path) 4 Temporal Ctx	11.6
AD 3 Hippo	1.1	AD 1 Occipital Ctx	3.4
AD 4 Hippo	1.6	AD 2 Occipital Ctx (Missing)	0.0
AD 5 hippo	59.9	AD 3 Occipital Ctx	1.1
AD 6 Hippo	12.9	AD 4 Occipital Ctx	6.3
Control 2 Hippo	7.2	AD 5 Occipital Ctx	17.5
Control 4 Hippo	2.2	AD 6 Occipital Ctx	38.1
Control (Path) 3 Hippo	1.0	Control 1 Occipital Ctx	0.8
AD 1 Temporal Ctx	2.4	Control 2 Occipital Ctx	16.6
AD 2 Temporal Ctx	9.8	Control 3 Occipital Ctx	4.2
AD 3 Temporal Ctx	1.1	Control 4 Occipital Ctx	1.5
AD 4 Temporal Ctx	5.5	Control (Path) 1 Occipital Ctx	22.9
AD 5 Inf Temporal Ctx	100.0	Control (Path) 2 Occipital Ctx	3.5
AD 5 Sup Temporal Ctx	46.5	Control (Path) 3 Occipital Ctx	0.3
AD 6 Inf Temporal Ctx	14.2	Control (Path) 4 Occipital Ctx	3.6
AD 6 Sup Temporal Ctx	17.9	Control 1 Parietal	1.9
Control 1 Temporal Ctx	1.9	Control 2 Parietal	27.9
Control 2 Temporal Ctx	13.6	Control 3 Parietal	7.8
Control 3 Temporal Ctx	5.7	Control (Path) 1 Parietal	24.8
Control 4 Temporal Ctx	2.3	Control (Path) 2 Parietal	8.9
Control (Path) 1 Temporal Ctx	16.7	Control (Path) 3 Parietal	1.2
Control (Path) 2 Temporal Ctx	9.4	Control (Path) 4 Parietal	16.1

**Panel 1.3D Summary:** Ag2458 Results from two experiments using the same probe and primer sets are in very good agreement. Highest expression is seen in breast cancer in both runs (CT = 28-30). The NOV6A gene is expressed at moderate levels across a wide variety of cancerous cell lines as opposed to normal tissues. Thus, the expression of this gene could be used to distinguish cell line derived samples from normal tissue derived samples. In addition, since the cell lines are derived from cancerous tissue, expression of the NOV6A gene potentially could be used to distinguish cancerous material from normal material and specifically, as a marker for breast cancer. Finally, since the expression of this gene is largely

associated with cancerous cells, therapeutic modulation of this gene product, through the use of small molecule drugs or antibodies, might be beneficial in the treatment of breast or other cancers.

**Panel 2D Summary:** Ag2458 In this experiment, expression of the NOV6A gene is most pronounced in lung cancer with a CT of 28.4. Other tissues also demonstrating significant expression are ocular melanoma (CT = 28.8), bladder cancer (CT = 29.0), ovarian cancer and gastric cancers. The NOV6A gene appears to show a stronger association with malignant tissue as compared to normal adjacent tissue. For instance, there is at least a 2 to 3 fold difference in expression level between malignant tissue and normal adjacent tissue samples derived from gastric, ovary, lung and colon cancers. Thus, the NOV6A gene could be used to distinguish between malignant and normal tissues of the stomach, ovary, lung and colon. In addition, therapeutic modulation of this gene product, through the use of small molecule drugs or antibodies might be of benefit in the treatment of the associated cancers.

**Panel 3D Summary:** Ag2458 The NOV6A gene is highly expressed in lung cancer (CT=27.4) and expressed at moderate/low level among all the tissue samples in the panel. Please see panel 2D for a discussion of potential utility for this expression profile.

**Panel 4D Summary:** Ag2458 The NOV6A gene is highly expressed in an activated B cell line, Ramos (26.8) and in primary B cells activated by PWM(27.3). The gene is also expressed at moderate/low levels among most of the tissues in the sample regardless of treatment.

Since the NOV6A gene most probably encodes a neurolysin like molecule with potential enzymatic activity, it may be important in maintaining normal cellular functions in a number of tissues. Therapies designed with the protein encoded by the NOV6A gene could be important in regulating cellular viability or function.

**Panel CNS\_1 Summary:** Ag2458 Results from two experiments using the same probe/primer set are in good agreement. Highest expression of the NOV6A gene occurs at moderate levels (CT = 30.7) in Brodman's Area 4 from a Parkinson's patient and Brodman's Area 9 from a Huntington's patient (CT = 30.2). This gene is expressed at moderate/low levels across most of the tissues (healthy and diseased) in the sample. Please see panel CNS\_neurodegeneration\_v1.0 for potential utility of this gene in diseases of the CNS.

**Panel CNS\_1.1 Summary:** Ag2458 Results from two experiments using the same probe/primer set are in very good agreement. Highest expression of the NOV6A gene occurs in Brodman's Area 4 in a Parkinson's patient (CT=31.6) and Brodman's Area 9 in a control

patient (CT=32.2). Please see panel CNS\_neurodegeneration\_V1.0 for a discussion of potential utility of this gene in diseases of the CNS.

**Panel CNS\_Neurodegeneration\_v1.0 Summary Ag2458** The NOV6A gene is highly expressed in the a tissue sample from the inferior temporal cortex from an Alzheimer's patient (CT = 27.6) and expressed at moderate levels in samples from the occipital cortex (CT = 29), superior temporal cortex (CT = 28.7), and the hippocampus (CT = 28.4) of an Alzheimer's patient. Significant expression is also detected in tissue samples derived from a control patient originating in the parietal region (CT = 29.6), and occipital cortex (CT = 29.7) regions of the brain. Expression of this gene is detectable at moderate/low levels in most of the tissues in this sample. The wide expression of the gene across many tissues involved in the central nervous system indicates that the NOV6A gene, which encodes a neurolysin-like molecule with enzymatic activity, has specific function and utility to CNS processes. Aminopeptidases are increased in Huntington's disease, and mediate neurotoxic processing of A-beta in Alzheimer's disease brains, indicating that agents that inhibit the activity of these enzymes may be useful in treating neurodegenerative disorders, including Alzheimer's disease and Huntington's disease. Metallopeptidases have been implicated in the normal and disease-state processing of peptides involved in neurological, endocrine and cardiovascular functions. In this context, specific inhibitors of these enzymes could selectively modulate peptide levels and thus have considerable therapeutic potential for the treatment of stroke, epilepsy, schizophrenia and depression. Thus, therapeutic modulation of the protein encoded by the NOV6A gene, may have considerable efficacy in treating these central nervous system disorders. (Shrimpton and Smith, J Pept Sci 6:251-63, 2000; Saido, Neurobiol Aging 19:S69-75, 1998; Kaneko et al., Neuroscience 104:1003-11, 2001; Mantle et al., J Neurol Sci. 131:65-70, 1995.)

#### NOV7a: gamma-aminobutyric acid (GABA) transporter-like

Expression of the NOV7a gene (ba122o1) was assessed using the primer-probe sets Ag1481 and Ag2307 described in Tables 46 and 47. Results of the RTQ-PCR runs are shown in Tables 48, 49, 50, 51, 52, 53, and 54.

Table 46. Probe Name Ag1481

Primers	Sequences	TM	Length	Start Position	SEQ ID NO:
Forward	5'-TGGGAGAAGGTCAAGTTCTACA-3'	58.8	22	1020	170
Probe	FAM-5'-ATCTCCATTGGCATCATCGTGTTCAG-3'-TAMRA	69.2	26	1062	171
Reverse	5'-GCAGGAAGATCTGAGACGTGTA-3'	59.5	22	1089	172

Table 47. Probe Name Ag2307

Primers	Sequences	TM	Length	Start Position	SEQ ID NO:
Forward	5'-GGAACCTCTTGACGTCGATGTA-3'	59.2	22	705	173
Probe	TET-5'-AACTTGACCTTCTCCCAGGCCAGT-3'-TAMRA	70	25	728	174
Reverse	5'-TCGTCATCAATATCCTGGTCAT-3'	59.3	22	779	175

Table 48. Panel 1.3D

Tissue Name	Relative Expression(%)		Relative Expression(%)
	1.3dtm4170f_ag1481	1.3dx4tm5350f_ag1481 a2	1.3dtm4557t_ag2307
Liver adenocarcinoma	0.0	0.0	0.0
Pancreas	0.0	0.0	0.0
Pancreatic ca. CAPAN 2	0.0	0.0	0.0
Adrenal gland	0.0	2.1	0.0
Thyroid	0.0	0.0	0.0
Salivary gland	0.0	0.0	0.0
Pituitary gland	13.8	17.8	4.5
Brain (fetal)	9.0	23.8	3.0
Brain (whole)	24.7	100.0	22.7
Brain (amygdala)	25.9	48.7	23.5
Brain (cerebellum)	12.2	60.6	15.6
Brain (hippocampus)	100.0	67.2	27.2
Brain (substantia nigra)	4.5	23.0	3.8
Brain (thalamus)	24.8	63.6	21.6
Cerebral Cortex	52.8	70.9	100.0
Spinal cord	1.8	10.1	4.3
CNS ca. (glio/astro) U87-MG	0.0	0.0	0.0
CNS ca. (glio/astro) U-118-MG	0.0	0.0	0.0
CNS ca. (astro) SW1783	0.0	0.0	0.0
CNS ca.* (neuro; met ) SK-N-AS	0.1	0.0	0.0
CNS ca. (astro) SF-539	0.0	0.0	0.0
CNS ca. (astro) SNB-75	0.0	0.0	0.0
CNS ca. (glio) SNB-19	0.0	0.0	0.0
CNS ca. (glio) U251	0.0	0.3	0.0
CNS ca. (glio) SF-295	0.0	0.0	0.0
Heart (fetal)	0.0	0.5	0.0
Heart	0.0	0.0	0.0
Fetal Skeletal	0.2	4.1	0.3
Skeletal muscle	0.0	0.0	0.0
Bone marrow	0.0	0.0	0.0
Thymus	0.0	0.0	0.1
Spleen	0.0	1.0	0.0
Lymph node	0.1	0.0	0.0
Colorectal	0.4	0.0	0.0

Stomach	0.0	0.0	0.0
Small intestine	0.0	0.5	0.0
Colon ca. SW480	0.0	0.0	0.0
Colon ca.* (SW480 met)SW620	0.0	0.0	0.0
Colon ca. HT29	0.0	0.0	0.0
Colon ca. HCT-116	0.0	1.0	0.0
Colon ca. CaCo-2	0.0	0.0	0.0
83219 CC Well to Mod Diff (ODO3866)	0.0	0.0	0.0
Colon ca. HCC-2998	0.0	0.0	0.0
Gastric ca.* (liver met) NCI-N87	0.0	0.0	0.0
Bladder	0.0	0.0	0.0
Trachea	0.0	0.0	0.1
Kidney	0.0	0.0	0.0
Kidney (fetal)	0.8	3.5	0.2
Renal ca. 786-0	0.0	0.0	0.0
Renal ca. A498	0.0	0.0	0.0
Renal ca. RXF 393	0.0	0.0	0.0
Renal ca. ACHN	0.0	0.0	0.0
Renal ca. UO-31	0.0	0.0	0.0
Renal ca. TK-10	0.0	0.0	0.0
Liver	0.0	0.0	0.0
Liver (fetal)	0.0	0.0	0.0
Liver ca. (hepatoblast) HepG2	0.0	0.0	0.0
Lung	0.0	0.0	0.0
Lung (fetal)	0.0	0.2	0.0
Lung ca. (small cell) LX-1	0.0	0.0	0.0
Lung ca. (small cell) NCI-H69	0.0	0.0	0.0
Lung ca. (s.cell var.) SHP-77	0.0	0.0	0.0
Lung ca. (large cell)NCI-H460	0.0	1.7	0.0
Lung ca. (non-sm. cell) A549	0.0	0.0	0.0
Lung ca. (non-s.cell) NCI-H23	0.0	0.0	0.0
Lung ca (non-s.cell) HOP-62	0.0	0.0	0.0
Lung ca. (non-s.cl) NCI-H522	9.4	14.4	8.4
Lung ca. (squam.) SW 900	0.0	0.0	0.0
Lung ca. (squam.) NCI-H596	0.0	0.0	0.0
Mammary gland	0.0	1.6	0.0
Breast ca.* (pl. effusion) MCF-7	0.0	0.0	0.0
Breast ca.* (pl.ef) MDA-MB-231	0.0	0.0	0.0
Breast ca.* (pl. effusion) T47D	0.0	0.0	0.0
Breast ca. BT-549	0.0	0.0	0.0
Breast ca. MDA-N	0.0	0.0	0.3
Ovary	0.4	0.0	0.2
Ovarian ca. OVCAR-3	0.0	0.0	0.0
Ovarian ca. OVCAR-4	0.0	0.0	0.0
Ovarian ca. OVCAR-5	0.0	0.0	0.0

Ovarian ca. OVCAR-8	0.0	0.0	0.0
Ovarian ca. IGROV-1	0.1	0.0	0.0
Ovarian ca.* (ascites) SK-OV-3	0.0	0.0	0.0
Uterus	0.0	0.0	0.0
Placenta	0.0	0.4	0.0
Prostate	0.0	0.0	0.0
Prostate ca.* (bone met)PC-3	0.0	0.0	0.0
Testis	1.8	2.2	0.9
Melanoma Hs688(A).T	0.0	0.0	0.0
Melanoma* (met) Hs688(B).T	0.0	0.0	0.0
Melanoma UACC-62	0.3	0.0	0.0
Melanoma M14	0.0	0.0	0.0
Melanoma LOX IMVI	0.0	0.0	0.0
Melanoma* (met) SK-MEL-5	0.0	0.0	0.0
Adipose	0.0	0.0	0.1

Table 49. Panel General\_screening\_panel\_v1.4

Tissue Name	Relative Expression(%)	
	General_screeni ng_panel_v1.4 (384)tm6981f_a g1481 b2	tm7150f_ag1481 _b1
D6005-01_Human adipose	0.0	0.1
112193 Metastatic melanoma	0.0	0.0
112192 Metastatic melanoma	0.0	0.0
95280_Epidermis (metastatic melanoma)	0.0	0.0
95279_Epidermis (metastatic melanoma)	0.0	0.0
Melanoma (met) SK-MEL-5	0.3	0.0
112196 Tongue (oncology)	0.0	0.0
113461 Testis Pool	1.6	0.2
Prostate ca.(bone met) PC-3	0.0	0.0
113455 Prostate Pool	0.0	0.0
103396 Placenta	0.0	0.0
113463 Uterus Pool	0.0	0.0
Ovarian carcinoma OVCAR-3	0.0	0.2
Ovarian carcinoma(ascites) SK-OV-3	0.0	0.1
95297 Adenocarcinoma (ovary)	0.0	0.0
Ovarian carcinoma OVCAR-5	0.0	0.2
Ovarian carcinoma IGROV-1	0.0	0.0
Ovarian carcinoma OVCAR-8	0.0	0.0
103368 Ovary	0.0	0.0
MCF7 breast carcinoma(pleural effusion)	0.0	0.0
Breast ca. (pleural effusion) MDA-MB-231	0.1	0.0
112189 ductal cell carcinoma(breast)	0.0	0.0
Breast ca. (pleural effusion) T47D	0.2	0.0
Breast carcinoma MDA-N	0.0	0.0

113452 Breast Pool	0.0	0.0
103398 Trachea	0.4	0.0
112354 lung	0.0	0.0
103374 Fetal Lung	0.6	0.0
94921 Small cell carcinoma of the lung	0.3	1.1
Lung ca.(small cell) LX-1	0.0	0.0
94919 Small cell carcinoma of the lung	0.2	0.3
Lung ca.(s.cell var.) SHP-77	0.0	0.0
95268 Lung (Large cell carcinoma)	0.0	0.0
94920 Small cell carcinoma of the lung	0.0	0.0
Lung ca.(non-s.cell) NCI-H23	0.0	0.5
Lung ca.(large cell) NCI-H460	0.0	0.0
Lung ca.(non-s.cell) HOP-62	0.0	0.0
Lung ca.(non-s.cl) NCI-H522	62.3	43.4
103392 Liver	0.0	0.0
103393 Fetal Liver	0.0	0.0
Liver ca.(hepatoblast) HepG2	0.0	0.0
113465 Kidney Pool	0.2	0.0
103373 Fetal Kidney	2.7	1.6
Renal ca. 786-0	0.0	0.0
112188 renal cell carcinoma	0.0	0.0
Renal ca. ACHN	0.0	0.1
112190 Renal cell carcinoma	0.0	0.0
Renal ca. TK-10	0.0	0.1
Bladder	0.0	0.0
Gastric ca.(liver met) NCI-N87	0.0	0.2
112197 Stomach	0.0	0.1
94938 Colon Adenocarcinoma	0.0	0.0
Colon ca. SW480	0.0	0.0
Colon ca.(SW480 met) SW620	0.0	0.0
Colon ca. HT29	0.0	0.0
Colon ca. HCT-116	0.3	0.4
Colon ca. CaCo-2	0.0	0.0
83219 CC Well to Mod Diff (ODO3866)	0.0	0.0
94936 Colon Adenocarcinoma	0.0	0.0
94930 Colon	0.0	0.0
94935 Colon Adenocarcinoma	0.0	0.0
113468 Colon Pool	0.2	0.0
113457 Small Intestine Pool	0.2	0.0
113460 Stomach Pool	0.0	0.0
113467 Bone Marrow Pool	0.0	0.0
103371 Fetal Heart	0.0	0.0
113451 Heart Pool	0.1	0.0
113466 Lymph Node Pool	0.2	0.0
103372 Fetal Skeletal Muscle	0.0	0.0

113456 Skeletal Muscle Pool	0.0	0.0
113459 Spleen Pool	0.0	0.0
113462 Thymus Pool	0.3	0.0
CNS ca. (glio/astro) U87-MG	0.0	0.0
CNS ca. (glio/astro) U-118-MG	0.0	0.0
CNS ca. (neuro;met) SK-N-AS	0.2	0.0
95264 Brain astrocytoma	0.0	0.0
CNS ca. (astro) SNB-75	0.0	0.0
CNS ca. (glio) SNB-19	0.0	0.0
CNS ca. (glio) SF-295	0.0	0.0
113447 Brain (Amygdala) Pool	22.9	28.2
103382 Brain (cerebellum)	100.0	100.0
64019-1 brain(fetal)	28.7	35.7
113448 Brain (Hippocampus) Pool	35.9	28.7
113464 Cerebral Cortex Pool	28.5	33.0
113449 Brain (Substantia nigra) Pool	25.6	53.9
113450 Brain (Thalamus) Pool	14.1	30.2
103384 Brain (whole)	11.7	47.2
113458 Spinal Cord Pool	6.4	10.6
103375 Adrenal Gland	0.0	0.0
113454 Pituitary gland Pool	9.9	8.0
103397 Salivary Gland	0.0	0.0
103369 Thyroid (female)	0.0	0.0
Pancreatic ca. CAPAN2	0.0	0.0
113453 Pancreas Pool	0.0	0.0

## Panel 50. Panel 2D

Tissue Name	Relative Expression(%)	
	2dtm4171f_ag1481	2dx4tm4724f_ag1481_a1
Normal Colon GENPAK 061003	0.0	0.0
83219 CC Well to Mod Diff (ODO3866)	0.0	30.2
83220 CC NAT (ODO3866)	0.0	0.0
83221 CC Gr.2 rectosigmoid (ODO3868)	0.0	0.0
83222 CC NAT (ODO3868)	0.0	0.0
83235 CC Mod Diff (ODO3920)	0.0	0.0
83236 CC NAT (ODO3920)	0.0	0.0
83237 CC Gr.2 ascend colon (ODO3921)	50.7	50.0
83238 CC NAT (ODO3921)	100.0	8.1
83241 CC from Partial Hepatectomy (ODO4309)	0.0	0.0
83242 Liver NAT (ODO4309)	0.0	0.0
87472 Colon mets to lung (OD04451-01)	0.0	0.0
87473 Lung NAT (OD04451-02)	0.0	5.3
Normal Prostate Clontech A+ 6546-1	0.0	0.0
84140 Prostate Cancer (OD04410)	0.0	0.0



84141 Prostate NAT (OD04410)	0.0	0.0
87073 Prostate Cancer (OD04720-01)	0.0	0.0
87074 Prostate NAT (OD04720-02)	0.0	0.0
Normal Lung GENPAK 061010	0.0	0.0
83239 Lung Met to Muscle (ODO4286)	60.3	0.0
83240 Muscle NAT (ODO4286)	0.0	0.0
84136 Lung Malignant Cancer (OD03126)	0.0	0.0
84137 Lung NAT (OD03126)	0.0	0.0
84871 Lung Cancer (OD04404)	0.0	23.5
84872 Lung NAT (OD04404)	0.0	100.0
84875 Lung Cancer (OD04565)	0.0	0.0
84876 Lung NAT (OD04565)	0.0	0.0
85950 Lung Cancer (OD04237-01)	0.0	0.0
85970 Lung NAT (OD04237-02)	0.0	0.0
83255 Ocular Mel Met to Liver (ODO4310)	0.0	0.0
83256 Liver NAT (ODO4310)	0.0	0.0
84139 Melanoma Mets to Lung (OD04321)	0.0	0.0
84138 Lung NAT (OD04321)	0.0	0.0
Normal Kidney GENPAK 061008	0.0	0.0
83786 Kidney Ca, Nuclear grade 2 (OD04338)	0.0	0.0
83787 Kidney NAT (OD04338)	0.0	0.0
83788 Kidney Ca Nuclear grade 1/2 (OD04339)	0.0	0.0
83789 Kidney NAT (OD04339)	0.0	0.0
83790 Kidney Ca, Clear cell type (OD04340)	0.0	0.0
83791 Kidney NAT (OD04340)	0.0	0.0
83792 Kidney Ca, Nuclear grade 3 (OD04348)	22.5	0.0
83793 Kidney NAT (OD04348)	0.0	0.0
87474 Kidney Cancer (OD04622-01)	39.8	0.0
87475 Kidney NAT (OD04622-03)	0.0	0.0
85973 Kidney Cancer (OD04450-01)	0.0	0.0
85974 Kidney NAT (OD04450-03)	26.4	0.0
Kidney Cancer Clontech 8120607	0.0	0.0
Kidney NAT Clontech 8120608	0.0	0.0
Kidney Cancer Clontech 8120613	0.0	0.0
Kidney NAT Clontech 8120614	0.0	0.0
Kidney Cancer Clontech 9010320	0.0	8.3
Kidney NAT Clontech 9010321	43.5	0.0
Normal Uterus GENPAK 061018	0.0	10.2
Uterus Cancer GENPAK 064011	0.0	0.0
Normal Thyroid Clontech A+ 6570-1	0.0	0.0
Thyroid Cancer GENPAK 064010	0.0	0.0
Thyroid Cancer INVITROGEN A302152	0.0	0.0
Thyroid NAT INVITROGEN A302153	0.0	0.0
Normal Breast GENPAK 061019	0.0	0.0
84877 Breast Cancer (OD04566)	0.0	0.0

85975 Breast Cancer (OD04590-01)	0.0	31.2
85976 Breast Cancer Mets (OD04590-03)	0.0	0.0
87070 Breast Cancer Metastasis (OD04655-05)	0.0	55.3
GENPAK Breast Cancer 064006	15.3	0.0
Breast Cancer Res. Gen. 1024	0.0	0.0
Breast Cancer Clontech 9100266	0.0	0.0
Breast NAT Clontech 9100265	0.0	0.0
Breast Cancer INVITROGEN A209073	0.0	0.0
Breast NAT INVITROGEN A2090734	0.0	0.0
Normal Liver GENPAK 061009	0.0	0.0
Liver Cancer GENPAK 064003	0.0	20.1
Liver Cancer Research Genetics RNA 1025	0.0	0.0
Liver Cancer Research Genetics RNA 1026	0.0	0.0
Paired Liver Cancer Tissue Research Genetics RNA 6004-T	0.0	0.0
Paired Liver Tissue Research Genetics RNA 6004-N	0.0	13.9
Paired Liver Cancer Tissue Research Genetics RNA 6005-T	0.0	0.0
Paired Liver Tissue Research Genetics RNA 6005-N	0.0	0.0
Normal Bladder GENPAK 061001	0.0	0.0
Bladder Cancer Research Genetics RNA 1023	52.8	17.6
Bladder Cancer INVITROGEN A302173	50.3	0.0
87071 Bladder Cancer (OD04718-01)	17.0	0.0
87072 Bladder Normal Adjacent (OD04718-03)	0.0	0.0
Normal Ovary Res. Gen.	42.9	24.6
Ovarian Cancer GENPAK 064008	0.0	0.0
87492 Ovary Cancer (OD04768-07)	0.0	0.0
87493 Ovary NAT (OD04768-08)	0.0	0.0
Normal Stomach GENPAK 061017	0.0	0.0
Gastric Cancer Clontech 9060358	0.0	0.0
NAT Stomach Clontech 9060359	0.0	0.0
Gastric Cancer Clontech 9060395	0.0	0.0
NAT Stomach Clontech 9060394	0.0	0.0
Gastric Cancer Clontech 9060397	0.0	0.0
NAT Stomach Clontech 9060396	0.0	0.0
Gastric Cancer GENPAK 064005	0.0	0.0

Panel 51. Panel 3D

Tissue Name	Relative Expression(%)	Tissue Name	Relative Expression(%)
	3dtm4953f_ ag1481		3dtm4953f_ ag1481
94905_Daoy_Medulloblastoma/ Cerebellum sscDNA	0.0	94954_Ca Ski_Cervical epidermoid carcinoma (metastasis) sscDNA	0.0
94906_TE671_Medulloblastom/ Cerebellum sscDNA	0.0	94955_ES-2_Ovarian clear cell carcinoma sscDNA	0.0
94907_D283 Med_Medulloblastoma/Cerebell	0.0	94957_Ramos/6h stim_Stimulated with PMA/ionomycin 6h sscDNA	0.0

um_sscDNA			
94908_PFSK-1_Primitive Neuroectodermal/Cerebellum_sscDNA	0.0	94958_Ramos/14h_stim_ Stimulated with PMA/ionomycin 14h_sscDNA	0.0
94909_XF-498_CNS_sscDNA	0.0	94962_MEG-01_Chronic myelogenous leukemia (megokaryoblast)_sscDNA	0.0
94910_SNB- 78_CNS/glioma_sscDNA	0.0	94963_Raji_Burkitt's lymphoma_sscDNA	0.0
94911_SF- 268_CNS/glioblastoma_sscDNA	0.0	94964_Daudi_Burkitt's lymphoma_sscDNA	0.0
94912_T98G_Glioblastoma_sscDNA	0.0	94965_U266_B-cell plasmacytoma/myeloma_sscDNA	0.0
96776_SK-N- SH_Neuroblastoma (metastasis)_sscDNA	0.0	94968_CA46_Burkitt's lymphoma_sscDNA	0.0
94913_SF- 295_CNS/glioblastoma_sscDNA	0.0	94970_RL_non-Hodgkin's B-cell lymphoma_sscDNA	0.0
94914_Cerebellum_sscDNA	0.0	94972_JM1_pre-B-cell lymphoma/leukemia_sscDNA	0.0
96777_Cerebellum_sscDNA	0.0	94973_Jurkat_T cell leukemia_sscDNA	0.0
94916_NCI- H292_Mucoepidermoid lung carcinoma_sscDNA	0.0	94974_TF- 1_Erythroleukemia_sscDNA	0.0
94917_DMS-114_Small cell lung cancer_sscDNA	0.0	94975_HUT 78_T-cell lymphoma_sscDNA	0.0
94918_DMS-79_Small cell lung cancer/neuroendocrine_sscDNA	0.0	94977_U937_Histiocytic lymphoma_sscDNA	0.0
94919_NCI-H146_Small cell lung cancer/neuroendocrine_sscDNA	0.0	94980_KU-812_Myelogenous leukemia_sscDNA	0.0
94920_NCI-H526_Small cell lung cancer/neuroendocrine_sscDNA	0.0	94981_769-P_Clear cell renal carcinoma_sscDNA	0.0
94921_NCI-N417_Small cell lung cancer/neuroendocrine_sscDNA	0.0	94983_Caki-2_Clear cell renal carcinoma_sscDNA	0.0
94923_NCI-H82_Small cell lung cancer/neuroendocrine_sscDNA	0.0	94984_SW 839_Clear cell renal carcinoma_sscDNA	0.0
94924_NCI-H157_Squamous cell lung cancer (metastasis)_sscDNA	0.0	94986_G401_Wilms' tumor_sscDNA	0.0
94925_NCI-H1155_Large cell lung cancer/neuroendocrine_sscDNA	0.0	94987_Hs766T_Pancreatic carcinoma (LN metastasis)_sscDNA	0.0
94926_NCI-H1299_Large cell lung cancer/neuroendocrine_sscDNA	0.0	94988_CAPAN-1_Pancreatic adenocarcinoma (liver metastasis)_sscDNA	0.0
94927_NCI-H727_Lung carcinoid_sscDNA	0.0	94989_SU86.86_Pancreatic carcinoma (liver metastasis)_sscDNA	0.0
94928_NCI-UMC-11_Lung carcinoid_sscDNA	0.0	94990_BxPC-3_Pancreatic adenocarcinoma_sscDNA	0.0
94929_LX-1_Small cell lung cancer_sscDNA	0.0	94991_HPAC_Pancreatic adenocarcinoma_sscDNA	0.0
94930_Colo-205_Colon cancer_sscDNA	0.0	94992_MIA PaCa-2_Pancreatic carcinoma_sscDNA	0.0
94931_KM12_Colon	0.0	94993_CFPAC-1_Pancreatic	0.0

cancer_sscDNA		ductal adenocarcinoma_sscDNA	
94932_KM20L2_Colon cancer_sscDNA	0.0	94994_PANC-1_Pancreatic epithelioid ductal carcinoma_sscDNA	0.0
94933_NCI-H716_Colon cancer_sscDNA	0.0	94996_T24_Bladder carcinoma (transitional cell)_sscDNA	0.0
94935_SW-48_Colon adenocarcinoma_sscDNA	0.0	94997_5637_Bladder carcinoma_sscDNA	0.0
94936_SW1116_Colon adenocarcinoma_sscDNA	0.0	94998_HT-1197_Bladder carcinoma_sscDNA	0.0
94937_LS 174T_Colon adenocarcinoma_sscDNA	0.0	94999_UM-UC-3_Bladder carcinoma (transitional cell)_sscDNA	0.0
94938_SW-948_Colon adenocarcinoma_sscDNA	0.0	95000_A204_Rhabdomyosarcoma sscDNA	0.0
94939_SW-480_Colon adenocarcinoma_sscDNA	0.0	95001_HT- 1080_Fibrosarcoma_sscDNA	0.0
94940_NCI-SNU-5_Gastric carcinoma_sscDNA	0.0	95002_MG-63_Osteosarcoma (bone)_sscDNA	0.0
94941_KATO III_Gastric carcinoma_sscDNA	0.0	95003_SK-LMS- 1_Leiomyosarcoma (vulva)_sscDNA	0.0
94943_NCI-SNU-16_Gastric carcinoma_sscDNA	0.0	95004_SJRH30_Rhabdomyosarco ma (met to bone marrow)_sscDNA	100.0
94944_NCI-SNU-1_Gastric carcinoma_sscDNA	0.0	95005_A431_Epidermoid carcinoma_sscDNA	0.0
94946_RF-1_Gastric adenocarcinoma_sscDNA	0.0	95007_WM266- 4_Melanoma_sscDNA	0.0
94947_RF-48_Gastric adenocarcinoma_sscDNA	0.0	95010_DU 145 Prostate carcinoma (brain metastasis)_sscDNA	0.0
96778_MKN-45_Gastric carcinoma_sscDNA	0.0	95012_MDA-MB-468_Breast adenocarcinoma_sscDNA	0.0
94949_NCI-N87_Gastric carcinoma_sscDNA	0.0	95013_SCC-4_Squamous cell carcinoma of tongue_sscDNA	0.0
94951_OVCAR-5_Ovarian carcinoma_sscDNA	0.0	95014_SCC-9_Squamous cell carcinoma of tongue_sscDNA	0.0
94952_RL95-2_Uterine carcinoma_sscDNA	0.0	95015_SCC-15_Squamous cell carcinoma of tongue_sscDNA	0.0
94953_HelaS3_Cervical adenocarcinoma_sscDNA	0.0	95017_CAL 27_Squamous cell carcinoma of tongue_sscDNA	0.0

Table 52. Panel 4D

Tissue Name	Relative Expression(%)	Relative Expression(%)	
	4dx4tm4512t_ ag2307_a2	4dtm2475f_ag1481	4dtm4172f_ ag1481
93768_Secondary Th1_anti-CD28/anti- CD3	10.4	0.0	10.7
93769_Secondary Th2_anti-CD28/anti- CD3	0.0	0.0	0.0
93770_Secondary Tr1_anti-CD28/anti- CD3	0.0	0.0	0.0
93573_Secondary Th1_resting day 4-6 in IL-2	2.6	0.0	12.9
93572_Secondary Th2_resting day 4-6 in IL-2	0.0	0.0	0.0

93571_Secondary Tr1_resting day 4-6 in IL-2	0.0	0.0	0.0
93568_primary Th1_anti-CD28/anti-CD3	2.8	0.0	0.0
93569_primary Th2_anti-CD28/anti-CD3	2.9	0.0	0.0
93570_primary Tr1_anti-CD28/anti-CD3	3.7	4.5	0.0
93565_primary Th1_resting dy 4-6 in IL-2	0.0	2.9	0.0
93566_primary Th2_resting dy 4-6 in IL-2	0.0	0.0	0.0
93567_primary Tr1_resting dy 4-6 in IL-2	2.2	0.0	0.0
93351_CD45RA CD4 lymphocyte anti-CD28/anti-CD3	14.7	21.0	10.3
93352_CD45RO CD4 lymphocyte anti-CD28/anti-CD3	0.0	7.6	0.0
93251_CD8 Lymphocytes_anti-CD28/anti-CD3	0.0	9.7	0.0
93353_chronic CD8 Lymphocytes 2ry resting dy 4-6 in IL-2	0.0	0.0	0.0
93574_chronic CD8 Lymphocytes 2ry activated CD3/CD28	0.0	0.0	0.0
93354_CD4 none	14.8	0.0	0.0
93252_Secondary Th1/Th2/Tr1_anti-CD95 CH11	0.0	0.0	0.0
93103_LAK cells resting	0.6	0.0	0.0
93788_LAK cells IL-2	0.0	0.0	0.0
93787_LAK cells IL-2+IL-12	23.4	33.0	0.0
93789_LAK cells IL-2+IFN gamma	2.4	39.0	28.1
93790_LAK cells IL-2+ IL-18	43.6	30.1	18.9
93104_LAK cells_PMA/ionomycin and IL-18	0.7	0.0	0.0
93578_NK Cells IL-2 resting	0.0	0.0	0.0
93109_Mixed Lymphocyte Reaction Two Way MLR	9.5	19.5	28.3
93110_Mixed Lymphocyte Reaction Two Way MLR	0.0	20.6	0.0
93111_Mixed Lymphocyte Reaction Two Way MLR	6.0	0.0	0.0
93112_Mononuclear Cells (PBMCs) resting	1.0	7.0	0.0
93113_Mononuclear Cells (PBMCs) PWM	8.6	0.0	0.0
93114_Mononuclear Cells (PBMCs) PHA-L	0.0	0.0	0.0
93249_Ramos (B cell) none	0.0	0.0	0.0
93250_Ramos (B cell) ionomycin	0.0	0.0	0.0
93349_B lymphocytes PWM	41.6	70.7	44.8
93350_B lymphocytes CD40L and IL-4	7.6	23.3	9.7
92665_EOL-1 (Eosinophil)_dbcAMP differentiated	0.0	0.0	0.0
93248_EOL-1 (Eosinophil)_dbcAMP/PMAionomycin	0.0	19.3	0.0

93356_Dendritic Cells_none	0.0	0.0	0.0
93355_Dendritic Cells_LPS 100 ng/ml	0.0	0.0	0.0
93775_Dendritic Cells_anti-CD40	0.0	0.0	0.0
93774_Monocytes_resting	0.0	0.0	0.0
93776_Monocytes_LPS 50 ng/ml	0.0	0.0	0.0
93581_Macrophages_resting	0.0	23.5	0.0
93582_Macrophages_LPS 100 ng/ml	0.0	0.0	0.0
93098_HUVEC (Endothelial)_none	0.0	0.0	0.0
93099_HUVEC (Endothelial)_starved	5.4	0.0	0.0
93100_HUVEC (Endothelial)_IL-1b	0.0	8.4	0.0
93779_HUVEC (Endothelial)_IFN gamma	0.0	6.1	0.0
93102_HUVEC (Endothelial)_TNF alpha + IFN gamma	0.0	0.0	0.0
93101_HUVEC (Endothelial)_TNF alpha + IL4	0.0	0.0	0.0
93781_HUVEC (Endothelial)_IL-11	0.0	0.0	0.0
93583_Lung Microvascular Endothelial Cells_none	14.8	0.0	0.0
93584_Lung Microvascular Endothelial Cells_TNFa (4 ng/ml) and IL1b (1 ng/ml)	0.0	0.0	0.0
92662_Microvascular Dermal endothelium_none	0.0	0.0	0.0
92663_Microvascular Dermal endothelium_TNFa (4 ng/ml) and IL1b (1 ng/ml)	0.0	0.0	11.0
93773_Bronchial epithelium_TNFa (4 ng/ml) and IL1b (1 ng/ml) **	0.0	0.0	0.0
93347_Small Airway Epithelium_none	6.5	0.0	0.0
93348_Small Airway Epithelium_TNFa (4 ng/ml) and IL1b (1 ng/ml)	7.4	0.0	0.0
92668_Coronary Artery SMC_resting	0.0	0.0	0.0
92669_Coronary Artery SMC_TNFa (4 ng/ml) and IL1b (1 ng/ml)	0.0	1.2	0.0
93107_astrocytes_resting	6.9	0.0	0.0
93108_astrocytes_TNFa (4 ng/ml) and IL1b (1 ng/ml)	0.0	0.0	0.0
92666_KU-812 (Basophil)_resting	0.0	0.0	0.0
92667_KU-812 (Basophil)_PMA/ionoycin	0.9	0.0	0.0
93579_CCD1106 (Keratinocytes)_none	0.0	0.0	0.0
93580_CCD1106 (Keratinocytes)_TNFa and IFNg **	0.0	0.0	0.0
93791_Liver Cirrhosis	45.1	72.7	25.2
93792_Lupus Kidney	9.9	0.0	0.0
93577_NCI-H292	0.0	0.0	0.0
93358_NCI-H292_IL-4	0.0	0.0	0.0
93360_NCI-H292_IL-9	0.0	0.0	0.0
93359_NCI-H292_IL-13	0.0	0.0	0.0
93357_NCI-H292_IFN gamma	0.0	0.0	0.0
93777_HPAEC -	0.0	0.0	0.0

93778 HPAEC IL-1 beta/TNA alpha	0.0	0.0	0.0
93254 Normal Human Lung Fibroblast none	0.0	0.0	0.0
93253 Normal Human Lung Fibroblast TNFa (4 ng/ml) and IL-1b (1 ng/ml)	0.0	0.0	0.0
93257 Normal Human Lung Fibroblast IL-4	0.0	0.0	0.0
93256 Normal Human Lung Fibroblast IL-9	0.0	0.0	0.0
93255 Normal Human Lung Fibroblast IL-13	7.6	0.0	0.0
93258 Normal Human Lung Fibroblast IFN gamma	0.0	0.0	0.0
93106 Dermal Fibroblasts CCD1070 resting	0.0	0.0	0.0
93361 Dermal Fibroblasts CCD1070 TNF alpha 4 ng/ml	0.0	0.0	0.0
93105 Dermal Fibroblasts CCD1070 IL-1 beta 1 ng/ml	3.2	0.0	0.0
93772 dermal fibroblast IFN gamma	3.1	0.0	0.0
93771 dermal fibroblast IL-4	0.0	0.0	0.0
93260 IBD Colitis 2	0.0	1.5	0.0
93261 IBD Crohns	0.0	0.0	0.0
735010 Colon normal	100.0	100.0	100.0
735019 Lung none	60.8	33.2	47.6
64028-1 Thymus none	10.6	0.0	8.0
64030-1 Kidney none	0.0	1.0	11.0

Table 53. Panel CNS\_1

Tissue Name	Relative Expression(%)	Tissue Name	Relative Expression(%)
	cns1x4tm6179 f ag1481 a1		cns1x4tm6179 f ag1481 a1
102633 BA4 Control	1.1	102605 BA17 PSP	1.2
102641 BA4 Control2	4.2	102612 BA17 PSP2	0.4
102625 BA4 Alzheimer's2	0.4	102637 Sub Nigra Control	0.7
102649 BA4 Parkinson's	2.7	102645 Sub Nigra Control2	2.6
102656 BA4 Parkinson's2	4.3	102629 Sub Nigra Alzheimer's2	0.7
102664 BA4 Huntington's	2.3	102660 Sub Nigra Parkinson's2	3.8
102671 BA4 Huntington's2	0.3	102667 Sub Nigra Huntington's	3.0
102603 BA4 PSP	0.3	102674 Sub Nigra Huntington's2	1.2
102610 BA4 PSP2	1.1	102614 Sub Nigra PSP2	0.6
102588 BA4 Depression	0.2	102592 Sub Nigra Depression	0.0
102596 BA4 Depression2	0.3	102599 Sub Nigra Depression2	0.3
102634 BA7 Control	1.4	102636 Glob Palladus Control	1.8
102642 BA7 Control2	2.1	102644 Glob Palladus Control2	2.4
102626 BA7 Alzheimer's2	0.3	102620 Glob Palladus Alzheimer's	1.0
102650 BA7 Parkinson's	0.4	102628 Glob Palladus Alzheimer's2	0.7

102657 BA7 Parkinson's2	1.5	102652 Glob Palladus Parkinson's	9.2
102665 BA7 Huntington's	2.6	102659 Glob Palladus Parkinson's2	2.0
102672 BA7 Huntington's2	0.6	102606 Glob Palladus PSP	1.5
102604 BA7 PSP	1.8	102613 Glob Palladus PSP2	1.5
102611 BA7 PSP2	1.0	102591 Glob Palladus Depression	0.2
102589 BA7 Depression	0.2	102638 Temp Pole Control	1.4
102632 BA9 Control	1.2	102646 Temp Pole Control2	2.8
102640 BA9 Control2	6.1	102622 Temp Pole Alzheimer's	100.0
102617 BA9 Alzheimer's	0.6	102630 Temp Pole Alzheimer's2	0.0
102624 BA9 Alzheimer's2	0.5	102653 Temp Pole Parkinson's	0.9
102648 BA9 Parkinson's	1.4	102661 Temp Pole Parkinson's2	0.9
102655 BA9 Parkinson's2	2.6	102668 Temp Pole Huntington's	1.1
102663 BA9 Huntington's	2.7	102607 Temp Pole PSP	0.2
102670 BA9 Huntington's2	0.5	102615 Temp Pole PSP2	0.3
102602 BA9 PSP	0.8	102600 Temp Pole Depression2	0.1
102609 BA9 PSP2	0.3	102639 Cing Gyr Control	2.4
102587 BA9 Depression	0.2	102647 Cing Gyr Control2	2.8
102595 BA9 Depression2	0.1	102623 Cing Gyr Alzheimer's	0.6
102635 BA17 Control	1.3	102631 Cing Gyr Alzheimer's2	0.2
102643 BA17 Control2	3.8	102654 Cing Gyr Parkinson's	0.7
102627 BA17 Alzheimer's2	0.3	102662 Cing Gyr Parkinson's2	1.6
102651 BA17 Parkinson's	0.7	102669 Cing Gyr Huntington's	2.6
102658 BA17 Parkinson's2	1.7	102676 Cing Gyr Huntington's2	0.5
102666 BA17 Huntington's	2.4	102608 Cing Gyr PSP	0.4
102673 BA17 Huntington's2	0.3	102616 Cing Gyr PSP2	0.3
102590 BA17 Depression	0.2	102594 Cing Gyr Depression	0.1
102597 BA17 Depression2	1.3	102601 Cing Gyr Depression2	0.3

Table 54. Panel CNS\_Neurodegeneration\_v1.0

Tissue Name	Relative Expression(%)	Tissue Name	Relative Expression(%)
	tm6958f_ag1481_a1s1		tm6958f_ag1481_a1s1
AD 1 Hippo	3.2	Control (Path) 3 Temporal Ctx	2.1
AD 2 Hippo	15.9	Control (Path) 4 Temporal Ctx	21.1
AD 3 Hippo	1.1	AD 1 Occipital Ctx	6.2
AD 4 Hippo	4.1	AD 2 Occipital Ctx (Missing)	0.0
AD 5 Hippo	92.1	AD 3 Occipital Ctx	1.5
AD 6 Hippo	20.4	AD 4 Occipital Ctx	12.4
Control 2 Hippo	28.9	AD 5 Occipital Ctx	61.1
Control 4 Hippo	1.7	AD 6 Occipital Ctx	12.2
Control (Path) 3 Hippo	0.7	Control 1 Occipital Ctx	0.8
AD 1 Temporal Ctx	5.0	Control 2 Occipital Ctx	89.8
AD 2 Temporal Ctx	18.6	Control 3 Occipital Ctx	10.6
AD 3 Temporal Ctx	1.7	Control 4 Occipital Ctx	0.2



AD 4 Temporal Ctx	9.9	Control (Path) 1 Occipital Ctx	69.1
AD 5 Inf Temporal Ctx	88.6	Control (Path) 2 Occipital Ctx	5.1
AD 5 Sup Temporal Ctx	16.9	Control (Path) 3 Occipital Ctx	0.4
AD 6 Inf Temporal Ctx	17.1	Control (Path) 4 Occipital Ctx	12.0
AD 6 Sup Temporal Ctx	23.4	Control 1 Parietal	2.1
Control 1 Temporal Ctx	1.8	Control 2 Parietal	17.7
Control 2 Temporal Ctx	62.9	Control 3 Parietal	15.4
Control 3 Temporal Ctx	8.3	Control (Path) 1 Parietal	100.0
Control 3 Temporal Ctx	3.3	Control (Path) 2 Parietal	15.3
Control (Path) 1 Temporal Ctx	51.6	Control (Path) 3 Parietal	1.2
Control (Path) 2 Temporal Ctx	25.7	Control (Path) 4 Parietal	32.8

**Panel 1.3D Summary Ag1481/Ag2307** Results from experiments using different probe and prime sets are in very good agreement. The NOV7a gene is expressed at high to moderate levels in all the tissue samples originating from the central nervous system, including the pituitary gland, amygdala, cerebellum, hippocampus, substantia nigra, thalamus, cerebral cortex and spinal cord. Highest expression is detected in the hippocampus region (CT=27-30). These high expression levels of the NOV7a gene suggest that the NOV7a protein product may be essential for normal central nervous system function. Thus, expression of the NOV7a gene could potentially be used to distinguish brain tissues from other tissues and may also be an excellent target in the treatment of neuropsychiatric disease.

Moderate expression of the NOV7a gene also occurs in lung cancer cell lines (CT=30.4, 31.3). Therefore, in addition to its CNS utility, expression of the NOV7a gene could potentially be used to distinguish between lung cancer cell lines and other tissues or cell lines.

**Panel General\_screening\_panel\_v1.4 Summary Ag1481** Results from two experiments using the same probe and primer set are in excellent agreement. Highest expression of the NOV7a gene is seen in the cerebellum (CT = 25) with significant expression detected in all the tissues samples originating from regions of the brain including the amygdala, hippocampus, cerebral cortex, substantia nigra, thalamus, and spinal cord. In addition, high expression of the NOV7a gene is present in lung cancer cell lines (CT = 26) The results from this panel are in excellent agreement with the expression profile detected in panel 1.3D. Therefore, these results suggest that expression of the NOV7a gene could be used to distinguish normal brain tissue from other tissues. The NOV7a gene could also possibly serve as a marker of lung cancer cell lines from other cell lines and tissues.

The metabolic expression of the NOV7a gene is limited to the pituitary gland with CT values ranging from 29-32. Therefore, the NOV7a protein product may be a small molecule target for the treatment of diseases involving the pituitary gland.

5      **Panel 2D Summary Ag1481** Among the tissues samples in this panel, expression of the NOV7a gene is low but significant in normal colon tissue adjacent to a colon tumor (CT = 34) as well as in a lung cancer metastasis to muscle (CT = 34.8). Two replicates of this experiment follow similar trends with both showing no expression in most tissue samples. Thus, this expression profile suggests that expression of the NOV7a gene could potentially be used to distinguish between colon cancer and normal tissue.

10      **Panel 2.2 Summary Ag 2307** Expression of this gene in panel 2.2 is low/undetectable (Ct values >35) in all samples (data not shown).

15      **Panel 3D Summary Ag1481** High expression of the NOV7a gene is detected in a metastatic rhabdomyosarcoma cell line with a CT value of 18.2. Moderate expression is also detected in two lung cancer samples (small cell CT =33.1; large cell CT = 32.8) and cerebellum (CT = 28.2). Thus, this gene could be used to distinguish these samples from other cell line samples.

20      **Panel 4D Summary Ag1481/Ag2307** Results from two experiments using two different probe/primer sets are in excellent agreement. Expression of the NOV7a gene is greatest in tissue derived from normal colon (CT = 32) and is also observed at moderate levels in lung tissue (CT = 33), mitogen stimulated B cells (CT = 32-33), LAK cells stimulated with IL-2 and gamma interferon (CT = 33-34), and LAK cells treated with IL-2 and IL-18 (CT = 34). The NOV7a gene encodes a protein with homology to vesicular GABA transporters that may be active in regulating secretion within the colon and perhaps the lung. The function of this type of transporter in leukocytes has not been described. Therapeutic regulation of the protein encoded by NOV7a could be important in the treatment of colitis as well as diseases involving the lung, including asthma and emphysema.

25      **Panel CNS\_1 Summary Ag1481** The NOV7a gene is widely expressed at low to moderate levels in most of the tissue samples in this panel. Expression of the gene is highest (CT = 25) in the temporal pole from an Alzheimer's patient. Panel CNS.01 also shows the NOV7a gene to be downregulated in the parietal, prefrontal, and cingulated cortex of depressed patients. It could therefore make an excellent drug target for schizophrenia. Multiple laboratories have shown a GABAergic deficit in schizophrenia and bipolar diaorder, usually a decrease in the number of interneurons producing GABA. Thus, therapeutic modulation or potentiation of this protein to increase the amount of GABA transported to the

synaptic vesicles could be of benefit in schizophrenia and/or bipolar disorder. Furthermore, the gene for this protein is located on chromosome 20 (specifically at 20q12), a locus that has been linked to schizophrenia. This information, when coupled with the fact that at least 4 amino acid changing SNPs exist in the coding region of this gene, make the NOV7a gene an excellent candidate for screening for risk of psychiatric disease.

**Panel CNS\_Neurodegeneration\_v1.0 Summary Ag1481** The NOV7a gene shows expression at moderate to low levels in most of the tissues in this sample. Highest expression is detected in the parietal cortex of a control patient (CT = 28.5). Other tissue samples showing moderate levels of expression of the NOV7a gene include the occipital cortex (CT = 29), and temporal cortex (CT = 29.5) region of a control patient and the occipital cortex (CT = 29.2), inferior temporal cortex (CT = 29.7) and hippocampus regions of an Alzheimer's patient (CT = 28.6). Based on this expression profile, this gene does not appear to be differentially regulated in Alzheimer's disease, although this panel does confirm that this gene is expressed at moderate to high levels in the CNS.

This protein appears to be the human homologue of the rat vesicular GABA transporter (VGAT). GABA, the primary inhibitory neurotransmitter in the mammalian brain, is synthesized from glutamate in the cytoplasm by two isoforms of glutamic acid decarboxylase (GAD65 and GAD67). As with the monoamine neurotransmitters, a vesicular transporter is then necessary to transport the transmitter into the synaptic vesicle. This protein is thus critical for normal CNS function and would make an excellent drug target in neuropsychiatric disease. A large number of antiepileptics have been shown to work by either potentiating GABA transmission, or by increasing GABA production in interneurons. Therefore, therapeutic induction of the NOV7a gene or its activity may be of benefit in the control of seizures. (Gurling et al., Am J Hum Genet 68:661-73, 2001; Reynolds and Beasley, J Chem Neuroanat 22:95-100, 2001; Moshe, Neurology 55:S32-40; discussion S54-8, 2000; Timmermans and Scheuermann, Eur J Morphol 36:133-42, 1998.)

#### **NOV10: UNC5 Receptor-like**

Expression of the NOV10 gene (SC121209524\_A) was assessed using the primer-probe sets Ag1522, Ag1848, Ag2263, and Ag2422 described in Tables 55, 56, 57, and 58. Results of the RTQ-PCR runs are shown in Tables 59, 60, 61, 62, 63, 64, and 65.

**Table 55.** Probe Name Ag1522

Primers	Sequences	TM	Length	Start Position	SEQ ID NO:
Forward	5'-TGACTTCGACACAGACATCACT-3'	58.4	22	1275	176
Probe	TET-5'-ACTCATCTGCTGCCCTGACTGGTG-	69.2	24	1298	177

	3'-TAMRA				
Reverse	5'-CCTTGCCGTCTTAAAGTTGAC-3'	58.9	21	1333	178

Table 56. Probe Name Ag1848

Primers	Sequences	TM	Length	Start Position	SEQ ID NO:
Forward	5'-TGACTTCGACACAGACATCACT-3'	58.4	22	1242	179
Probe	TET-5'-ACTCATCTGCTGCCCTGACTGGTG-3'-TAMRA	69.2	24	1265	180
Reverse	5'-CCTTGCCGTCTTAAAGTTGAC-3'	58.9	21	1300	181

Table 57. Probe Name Ag2263

Primers	Sequences	TM	Length	Start Position	SEQ ID NO:
Forward	5'-TGACTTCGACACAGACATCACT-3'	58.4	22	1234	182
Probe	TET-5'-ACTCATCTGCTGCCCTGACTGGTG-3'-TAMRA	69.2	24	1257	183
Reverse	5'-CCTTGCCGTCTTAAAGTTGAC-3'	58.9	21	1292	184

5

Table 58. Probe Name Ag2422

Primers	Sequences	TM	Length	Start Position	SEQ ID NO:
Forward	5'-GGCTCCCTGGACACTCTCT-3'	59.4	19	2617	185
Probe	FAM-5'-CTGTCAACACCCAGCTGGGACCTTAT-3'-TAMRA	71	26	2654	186
Reverse	5'-TGGACAGTGGGATCTTGAAG-3'	58.6	20	2682	187

Table 59. Panel 1.2

Tissue Name	Relative Expression(%)	Tissue Name	Relative Expression(%)
	1.2tm2156t_ag1522		1.2tm2156t_ag1522
Endothelial cells	1.2	Renal ca. 786-0	0.0
Heart (fetal)	17.9	Renal ca. A498	0.3
Pancreas	0.7	Renal ca. RXF 393	0.2
Pancreatic ca. CAPAN 2	4.9	Renal ca. ACHN	0.0
Adrenal Gland (new lot*)	7.9	Renal ca. UO-31	0.5
Thyroid	0.0	Renal ca. TK-10	0.3
Salivary gland	2.5	Liver	2.4
Pituitary gland	0.1	Liver (fetal)	0.5
Brain (fetal)	0.2	Liver ca. (hepatoblast) HepG2	0.3
Brain (whole)	3.2	Lung	0.3
Brain (amygdala)	4.4	Lung (fetal)	0.4
Brain (cerebellum)	9.0	Lung ca. (small cell) LX-1	25.3
Brain (hippocampus)	18.9	Lung ca. (small cell) NCI-H69	43.8
Brain (thalamus)	15.7	Lung ca. (s.cell var.) SHP-77	0.3
Cerebral Cortex	35.4	Lung ca. (large cell) NCI-H460	54.7
Spinal cord	1.6	Lung ca. (non-sm. cell) A549	0.3

CNS ca. (glio/astro) U87-MG	72.2	Lung ca. (non-s.cell) NCI-H23	2.4
CNS ca. (glio/astro) U-118-MG	3.1	Lung ca (non-s.cell) HOP-62	1.7
CNS ca. (astro) SW1783	0.3	Lung ca. (non-s.cl) NCI-H522	9.3
CNS ca.* (neuro; met) SK-N-AS	36.3	Lung ca. (squam.) SW 900	1.5
CNS ca. (astro) SF-539	5.8	Lung ca. (squam.) NCI-H596	22.4
CNS ca. (astro) SNB-75	1.7	Mammary gland	1.4
CNS ca. (glio) SNB-19	23.8	Breast ca.* (pl. effusion) MCF-7	0.8
CNS ca. (glio) U251	2.9	Breast ca.* (pl.ef) MDA-MB-231	0.0
CNS ca. (glio) SF-295	100.0	Breast ca.* (pl. effusion) T47D	18.4
Heart	31.6	Breast ca. BT-549	0.0
Skeletal Muscle (new lot*)	3.4	Breast ca. MDA-N	0.0
Bone marrow	0.2	Ovary	6.9
Thymus	0.2	Ovarian ca. OVCAR-3	1.7
Spleen	2.1	Ovarian ca. OVCAR-4	12.9
Lymph node	0.5	Ovarian ca. OVCAR-5	5.7
Colorectal	1.4	Ovarian ca. OVCAR-8	5.3
Stomach	1.3	Ovarian ca. IGROV-1	0.8
Small intestine	3.3	Ovarian ca.* (ascites) SK-OV-3	5.4
Colon ca. SW480	0.8	Uterus	0.9
Colon ca.* (SW480 met)SW620	2.2	Placenta	0.9
Colon ca. HT29	0.1	Prostate	10.0
Colon ca. HCT-116	7.5	Prostate ca.* (bone met)PC-3	0.0
Colon ca. CaCo-2	6.3	Testis	0.3
83219 CC Well to Mod Diff (ODO3866)	3.0	Melanoma Hs688(A).T	21.2
Colon ca. HCC-2998	1.2	Melanoma* (met) Hs688(B).T	28.5
Gastric ca.* (liver met) NCI-N87	24.7	Melanoma UACC-62	2.4
Bladder	12.8	Melanoma M14	0.0
Trachea	0.3	Melanoma LOX IMVI	0.0
Kidney	19.2	Melanoma* (met) SK-MEL-5	1.2
Kidney (fetal)	6.6		

Table 60. Panel 1.3D

Tissue Name	Relative Expression(%)	Relative Expression(%)	Relative Expression(%)	Relative Expression(%)
	1.3dtm4258t_ag1522	1.3dtm4351t_ag1848	1.3dx4tm5633t_ag2263_b1	1.3dtm4220_ag2422
Liver adenocarcinoma	15.8	12.3	31.5	18.3
Pancreas	1.7	1.4	2.8	2.9
Pancreatic ca. CAPAN 2	6.7	4.6	21.7	5.5
Adrenal gland	3.9	2.0	3.5	3.0
Thyroid	1.7	1.5	0.0	2.5
Salivary gland	0.6	0.2	2.3	0.3
Pituitary gland	2.1	1.4	2.9	4.3
Brain (fetal)	1.4	1.1	3.5	1.1

Brain (whole)	28.7	13.5	43.1	10.4
Brain (amygdala)	16.8	13.0	31.3	18.6
Brain (cerebellum)	8.2	6.5	42.3	9.2
Brain (hippocampus)	60.7	47.6	16.8	51.8
Brain (substantia nigra)	8.9	5.2	32.3	6.8
Brain (thalamus)	40.1	22.2	62.0	19.8
Cerebral Cortex	25.9	18.4	36.6	14.3
Spinal cord	10.2	5.4	38.0	7.9
CNS ca. (glio/astro) U87-MG	43.2	34.6	100.0	48.6
CNS ca. (glio/astro) U-118-MG	10.2	8.0	6.4	7.5
CNS ca. (astro) SW1783	0.9	0.8	2.8	1.1
CNS ca.* (neuro; met) SK-N-AS	100.0	100.0	59.1	100.0
CNS ca. (astro) SF-539	9.7	8.3	17.6	9.0
CNS ca. (astro) SNB-75	12.9	12.1	8.4	12.1
CNS ca. (glio) SNB-19	19.5	17.6	46.2	17.2
CNS ca. (glio) U251	13.4	10.6	24.5	10.9
CNS ca. (glio) SF-295	66.9	62.4	64.1	62.0
Heart (fetal)	15.6	12.5	20.0	18.7
Heart	2.2	1.1	3.4	3.3
Fetal Skeletal	22.2	14.0	6.7	19.3
Skeletal muscle	0.3	0.2	1.4	0.7
Bone marrow	0.7	0.3	0.4	0.8
Thymus	2.0	1.6	3.6	3.4
Spleen	7.9	5.6	4.5	5.9
Lymph node	2.6	1.9	2.7	2.1
Colorectal	4.7	9.2	12.8	10.3
Stomach	6.1	2.4	3.6	4.5
Small intestine	2.9	2.9	4.5	4.9
Colon ca. SW480	2.0	1.0	1.9	1.5
Colon ca.* (SW480 met)SW620	1.0	1.2	2.0	2.1
Colon ca. HT29	0.0	0.1	0.0	0.0
Colon ca. HCT-116	4.2	2.9	4.7	5.6
Colon ca. CaCo-2	5.3	3.9	12.5	7.2
83219 CC Well to Mod Diff (ODO3866)	14.8	17.3	19.8	23.5
Colon ca. HCC-2998	0.7	1.6	0.0	0.5
Gastric ca.* (liver met) NCI-N87	21.9	22.8	19.1	25.7
Bladder	2.1	1.7	3.4	1.5
Trachea	12.2	6.8	1.6	13.8
Kidney	1.4	0.6	3.9	3.0
Kidney (fetal)	5.3	5.8	5.2	6.3
Renal ca. 786-0	0.0	0.0	0.0	0.0
Renal ca. A498	7.7	7.9	6.8	9.7

Renal ca. RXF 393	0.1	3.6	0.8	0.0
Renal ca. ACHN	0.0	0.0	0.0	0.0
Renal ca. UO-31	0.2	0.3	0.5	0.3
Renal ca. TK-10	0.0	0.0	0.0	0.0
Liver	0.3	0.0	0.0	0.6
Liver (fetal)	1.1	1.0	0.4	1.2
Liver ca. (hepatoblast) HepG2	0.2	0.0	0.8	0.3
Lung	8.2	9.4	4.1	10.3
Lung (fetal)	4.3	4.2	7.3	4.5
Lung ca. (small cell) LX-1	8.4	6.9	31.8	9.9
Lung ca. (small cell) NCI- H69	44.4	48.6	90.7	54.3
Lung ca. (s.cell var.) SHP- 77	0.7	0.8	0.5	1.1
Lung ca. (large cell) NCI- H460	16.2	11.9	22.4	12.1
Lung ca. (non-sm. cell) A549	0.4	0.3	0.2	0.4
Lung ca. (non-s.cell) NCI- H23	2.0	0.9	3.3	1.2
Lung ca (non-s.cell) HOP- 62	0.4	0.9	1.6	0.7
Lung ca. (non-s.cl) NCI- H522	1.7	0.8	1.7	1.1
Lung ca. (squam.) SW 900	0.5	0.3	1.9	0.2
Lung ca. (squam.) NCI- H596	4.0	4.1	26.4	2.4
Mammary gland	6.3	4.4	3.0	2.8
Breast ca.* (pl. effusion) MCF-7	1.1	0.4	1.5	0.9
Breast ca.* (pl.ef) MDA- MB-231	0.8	1.2	0.7	1.4
Breast ca.* (pl. effusion) T47D	9.6	5.7	14.0	4.4
Breast ca. BT-549	0.2	0.3	0.2	0.3
Breast ca. MDA-N	0.0	0.0	0.0	0.0
Ovary	6.4	4.9	6.2	9.5
Ovarian ca. OVCAR-3	1.1	0.6	1.1	0.8
Ovarian ca. OVCAR-4	1.0	1.4	11.4	1.5
Ovarian ca. OVCAR-5	2.4	2.6	5.7	3.3
Ovarian ca. OVCAR-8	3.6	1.6	2.6	5.4
Ovarian ca. IGROV-1	0.6	0.2	0.7	0.2
Ovarian ca.* (ascites) SK- OV-3	2.0	2.6	2.1	1.1
Uterus	2.7	1.3	3.9	4.2
Placenta	2.0	2.0	5.8	4.8
Prostate	4.4	2.5	3.4	5.4
Prostate ca.* (bone met)PC- 3	0.1	0.0	0.2	0.0
Testis	8.1	5.5	3.5	6.4
Melanoma Hs688(A).T	31.6	25.0	59.7	27.4

Melanoma* (met) Hs688(B).T	46.0	17.1	87.3	28.5
Melanoma UACC-62	0.1	0.2	2.0	0.5
Melanoma M14	0.0	0.0	0.0	0.0
Melanoma LOX IMVI	0.1	0.2	0.0	0.0
Melanoma* (met) SK-MEL-5	0.9	0.9	1.7	0.6
Adipose	3.6	2.3	5.1	2.9

Table 61. Panel 2D

Tissue Name	Relative Expression(%)	Relative Expression(%)	Relative Expression(%)		Relative Expression(%)
	2dtm4352t_ ag1848	2dtm5513t_ ag2263	2Dtm2353 t ag1522	2dtm2417t_ ag1522	2dtm4221f_ ag2422
Normal Colon GENPAK 061003	35.1	59.0	20.2	46.0	36.9
83219 CC Well to Mod Diff (ODO3866)	22.5	21.8	15.3	45.1	21.3
83220 CC NAT (ODO3866)	7.4	7.7	6.1	15.2	5.5
83221 CC Gr.2 rectosigmoid (ODO3868)	5.8	5.9	7.0	8.2	13.2
83222 CC NAT (ODO3868)	0.5	9.3	0.3	0.5	0.8
83235 CC Mod Diff (ODO3920)	2.5	5.6	1.2	4.0	5.8
83236 CC NAT (ODO3920)	4.1	5.4	3.0	4.7	7.2
83237 CC Gr.2 ascend colon (ODO3921)	24.1	19.9	10.7	22.5	25.5
83238 CC NAT (ODO3921)	7.3	5.6	3.6	4.3	5.8
83241 CC from Partial Hepatectomy (ODO4309)	20.7	19.3	12.1	19.9	27.0
83242 Liver NAT (ODO4309)	2.4	2.6	0.4	3.6	3.3
87472 Colon mets to lung (OD04451-01)	6.1	8.5	5.8	11.9	10.7
87473 Lung NAT (OD04451-02)	7.7	10.0	9.3	17.7	15.4
Normal Prostate Clontech A+ 6546-1	7.3	21.6	10.5	51.0	7.0
84140 Prostate Cancer (OD04410)	14.9	9.0	12.2	14.9	17.4
84141 Prostate NAT (OD04410)	25.3	19.2	14.6	13.8	29.7
87073 Prostate Cancer (OD04720-01)	22.7	31.6	12.2	18.0	30.6
87074 Prostate NAT (OD04720-02)	17.7	16.7	11.8	11.8	25.0
Normal Lung GENPAK 061010	17.6	12.8	7.3	17.8	22.4
83239 Lung Met to Muscle (ODO4286)	25.0	31.0	12.7	27.4	22.1
83240 Muscle NAT (ODO4286)	6.2	7.3	7.4	8.7	9.5
84136 Lung Malignant Cancer (OD03126)	26.1	28.3	22.7	27.4	20.4



84137 Lung NAT (OD03126)	21.9	13.9	12.7	21.9	31.9
84871 Lung Cancer (OD04404)	41.5	30.4	17.9	41.5	48.0
84872 Lung NAT (OD04404)	10.0	11.8	16.4	28.7	12.4
84875 Lung Cancer (OD04565)	28.5	27.9	22.5	38.2	40.6
84876 Lung NAT (OD04565)	8.5	8.6	8.1	11.7	16.3
85950 Lung Cancer (OD04237-01)	10.9	8.8	9.8	7.1	9.6
85970 Lung NAT (OD04237-02)	14.3	14.0	12.9	23.0	16.0
83255 Ocular Mel Met to Liver (ODO4310)	0.7	0.5	0.6	0.5	1.1
83256 Liver NAT (ODO4310)	1.8	3.3	3.5	2.6	3.0
84139 Melanoma Mets to Lung (OD04321)	3.6	4.3	1.4	2.0	2.9
84138 Lung NAT (OD04321)	25.2	24.0	20.4	14.4	18.6
Normal Kidney GENPAK 061008	18.0	17.4	20.2	19.9	26.1
83786 Kidney Ca, Nuclear grade 2 (OD04338)	2.9	2.7	1.7	4.2	4.9
83787 Kidney NAT (OD04338)	17.2	11.3	6.2	11.7	22.8
83788 Kidney Ca Nuclear grade 1/2 (OD04339)	3.7	4.6	3.6	10.0	6.6
83789 Kidney NAT (OD04339)	11.4	12.1	11.7	12.2	11.0
83790 Kidney Ca, Clear cell type (OD04340)	66.0	65.1	46.7	50.7	70.7
83791 Kidney NAT (OD04340)	14.8	12.9	15.3	19.1	16.8
83792 Kidney Ca, Nuclear grade 3 (OD04348)	16.3	16.8	21.0	9.5	17.0
83793 Kidney NAT (OD04348)	8.8	11.5	8.2	5.8	9.3
87474 Kidney Cancer (OD04622-01)	27.7	24.8	24.0	25.3	41.5
87475 Kidney NAT (OD04622-03)	3.4	3.1	2.1	4.6	5.9
85973 Kidney Cancer (OD04450-01)	0.2	0.5	0.2	0.0	0.5
85974 Kidney NAT (OD04450-03)	9.3	9.9	5.9	6.3	12.9
Kidney Cancer Clontech 8120607	11.9	12.8	7.3	9.1	13.4
Kidney NAT Clontech 8120608	7.9	5.6	12.2	6.2	8.0
Kidney Cancer Clontech 8120613	5.2	8.8	3.6	8.0	10.1
Kidney NAT Clontech 8120614	8.9	7.5	6.2	6.7	9.3
Kidney Cancer Clontech 9010320	25.0	21.9	18.7	61.1	22.1

Kidney NAT Clontech 9010321	16.4	12.9	14.0	20.3	17.9
Normal Uterus GENPAK 061018	3.3	8.4	4.1	5.6	6.0
Uterus Cancer GENPAK 064011	17.1	11.7	9.6	10.7	15.6
Normal Thyroid Clontech A+ 6570-1	2.6	1.5	2.6	9.2	3.6
Thyroid Cancer GENPAK 064010	100.0	82.9	100.0	72.7	100.0
Thyroid Cancer INVITROGEN A302152	12.5	8.0	7.6	4.5	11.7
Thyroid NAT INVITROGEN A302153	2.8	3.2	3.0	2.4	6.0
Normal Breast GENPAK 061019	9.9	12.9	10.3	5.7	7.2
84877 Breast Cancer (OD04566)	12.8	12.9	11.7	15.9	12.8
85975 Breast Cancer (OD04590-01)	27.2	16.5	17.9	39.0	25.3
85976 Breast Cancer Mets (OD04590-03)	35.4	42.0	26.1	66.0	27.9
87070 Breast Cancer Metastasis (OD04655-05)	6.0	5.2	4.5	5.4	3.5
GENPAK Breast Cancer 064006	28.1	21.6	30.8	32.1	36.3
Breast Cancer Res. Gen. 1024	19.8	16.7	20.7	46.7	14.8
Breast Cancer Clontech 9100266	13.9	11.0	13.1	15.9	22.1
Breast NAT Clontech 9100265	15.6	16.4	10.4	14.4	20.9
Breast Cancer INVITROGEN A209073	34.2	25.5	22.2	26.8	50.0
Breast NAT INVITROGEN A2090734	7.1	4.3	6.7	9.7	11.3
Normal Liver GENPAK 061009	1.6	1.7	1.4	4.2	2.3
Liver Cancer GENPAK 064003	1.7	1.3	1.0	2.8	1.3
Liver Cancer Research Genetics RNA 1025	3.3	2.3	1.4	1.1	3.2
Liver Cancer Research Genetics RNA 1026	4.9	6.4	7.8	6.5	10.7
Paired Liver Cancer Tissue Research Genetics RNA 6004-T	4.2	3.0	5.0	9.9	5.2
Paired Liver Tissue Research Genetics RNA 6004-N	3.5	4.2	4.7	7.9	3.7
Paired Liver Cancer Tissue Research Genetics RNA 6005-T	8.2	10.3	7.9	11.5	6.7
Paired Liver Tissue Research Genetics RNA 6005-N	2.7	1.6	2.0	3.2	2.3
Normal Bladder GENPAK 061001	13.6	11.5	6.8	17.9	15.2

Bladder Cancer Research Genetics RNA 1023	14.5	14.2	10.7	22.8	14.2
Bladder Cancer INVITROGEN A302173	22.7	17.7	18.0	29.3	23.5
87071 Bladder Cancer (OD04718-01)	26.1	21.0	14.5	29.3	28.3
87072 Bladder Normal Adjacent (OD04718-03)	3.1	3.2	2.9	5.0	4.2
Normal Ovary Res. Gen.	3.6	4.6	1.4	4.7	5.4
Ovarian Cancer GENPAK 064008	89.5	100.0	40.9	100.0	76.3
87492 Ovary Cancer (OD04768-07)	16.7	15.6	9.7	43.2	19.5
87493 Ovary NAT (OD04768-08)	10.8	6.7	6.5	7.9	8.3
Normal Stomach GENPAK 061017	14.7	14.8	11.8	39.5	13.1
Gastric Cancer Clontech 9060358	2.9	2.8	1.4	6.0	2.9
NAT Stomach Clontech 9060359	7.4	10.8	6.4	19.9	8.7
Gastric Cancer Clontech 9060395	21.6	21.2	11.1	58.6	32.3
NAT Stomach Clontech 9060394	23.7	13.8	6.8	34.6	22.2
Gastric Cancer Clontech 9060397	24.8	25.2	15.4	78.5	31.9
NAT Stomach Clontech 9060396	6.1	7.5	3.9	14.5	7.9
Gastric Cancer GENPAK 064005	7.0	7.3	2.5	14.8	13.0

Table 62. Panel 3D

Tissue Name	Relative Expression(%)	Tissue Name	Relative Expression(%)
	3dx4tm6021t_ag2263_b1		3dx4tm6021t_ag2263_b1
94905_Daoy_Medulloblastoma/Cerebellum_sscDNA	19.1	94954_Ca Ski_Cervical epidermoid carcinoma (metastasis) sscDNA	0.4
94906_TE671_Medulloblastom/Cerebellum_sscDNA	8.4	94955_ES-2_Ovarian clear cell carcinoma sscDNA	0.0
94907_D283 Med_Medulloblastoma/Cerebellum sscDNA	39.3	94957_Ramos/6h stim_ Stimulated with PMA/ionomycin 6h sscDNA	0.0
94908_PFSK-1_Primitive Neuroectodermal/Cerebellum_sscDNA	59.5	94958_Ramos/14h stim_ Stimulated with PMA/ionomycin 14h sscDNA	0.0
94909_XF-498_CNS_sscDNA	0.9	94962_MEG-01_Chronic myelogenous leukemia (megokaryoblast) sscDNA	3.9
94910_SNB-78_CNS/glioma_sscDNA	35.4	94963_Raji_Burkitt's lymphoma sscDNA	0.0
94911_SF-268_CNS/glioblastoma_sscDNA	0.0	94964_Daudi_Burkitt's lymphoma sscDNA	0.0
94912_T98G_Glioblastoma_sscDNA	1.2	94965_U266_B-cell plasmacytoma/myeloma sscDN	0.0

		A	
96776_SK-N-SH_Neuroblastoma (metastasis) sscDNA	94.4	94968_CA46_Burkitt's lymphoma sscDNA	0.0
94913_SF-295_CNS/glioblastoma sscDNA	0.3	94970_RL_non-Hodgkin's B-cell lymphoma sscDNA	0.0
94914_Cerebellum sscDNA	37.4	94972_JM1_pre-B-cell lymphoma/leukemia sscDNA	0.0
96777_Cerebellum sscDNA	35.1	94973_Jurkat T cell leukemia sscDNA	0.5
94916_NCI-H292_Mucoepidermoid lung carcinoma sscDNA	4.3	94974_TF-1 Erythroleukemia sscDNA	73.1
94917_DMS-114_Small cell lung cancer sscDNA	6.6	94975_HUT 78 T-cell lymphoma sscDNA	0.0
94918_DMS-79_Small cell lung cancer/neuroendocrine sscDNA	100.0	94977_U937_Histiocytic lymphoma sscDNA	0.0
94919_NCI-H146_Small cell lung cancer/neuroendocrine sscDNA	37.3	94980_KU-812_Myelogenous leukemia sscDNA	0.6
94920_NCI-H526_Small cell lung cancer/neuroendocrine sscDNA	17.2	94981_769-P_Clear cell renal carcinoma sscDNA	0.0
94921_NCI-N417_Small cell lung cancer/neuroendocrine sscDNA	88.8	94983_Caki-2_Clear cell renal carcinoma sscDNA	0.0
94923_NCI-H82_Small cell lung cancer/neuroendocrine sscDNA	95.3	94984_SW 839_Clear cell renal carcinoma sscDNA	0.0
94924_NCI-H157_Squamous cell lung cancer (metastasis) sscDNA	0.8	94986_G401_Wilms' tumor sscDNA	2.8
94925_NCI-H1155_Large cell lung cancer/neuroendocrine sscDNA	55.7	94987_Hs766T_Pancreatic carcinoma (LN metastasis) sscDNA	0.6
94926_NCI-H1299_Large cell lung cancer/neuroendocrine sscDNA	0.0	94988_CAPAN-1_Pancreatic adenocarcinoma (liver metastasis) sscDNA	3.1
94927_NCI-H727_Lung carcinoid sscDNA	0.7	94989_SU86.86_Pancreatic carcinoma (liver metastasis) sscDNA	0.4
94928_NCI-UMC-11_Lung carcinoid sscDNA	7.9	94990_BxPC-3_Pancreatic adenocarcinoma sscDNA	22.9
94929_LX-1_Small cell lung cancer sscDNA	1.8	94991_HPAC_Pancreatic adenocarcinoma sscDNA	35.7
94930_Colo-205_Colon cancer sscDNA	0.3	94992_MIA PaCa-2_Pancreatic carcinoma sscDNA	0.6
94931_KM12_Colon cancer sscDNA	0.1	94993_CFPAC-1_Pancreatic ductal adenocarcinoma sscDNA	1.1
94932_KM20L2_Colon cancer sscDNA	0.6	94994_PANC-1_Pancreatic epithelioid ductal carcinoma sscDNA	0.3
94933_NCI-H716_Colon cancer sscDNA	70.2	94996_T24_Bladder carcinoma (transitional cell) sscDNA	0.0
94935_SW-48_Colon adenocarcinoma sscDNA	0.0	94997_5637_Bladder carcinoma sscDNA	2.2
94936_SW1116_Colon adenocarcinoma sscDNA	16.6	94998_HT-1197_Bladder carcinoma sscDNA	0.4
94937_LS 174T_Colon adenocarcinoma sscDNA	4.2	94999_UM-UC-3_Bladder carcinoma (transitional	0.2

		cell)_sscDNA	
94938_SW-948_Colon adenocarcinoma sscDNA	0.4	95000_A204_Rhabdomyosarcoma sscDNA	0.0
94939_SW-480_Colon adenocarcinoma sscDNA	0.0	95001_HT-1080_Fibrosarcoma sscDNA	7.9
94940_NCI-SNU-5_Gastric carcinoma sscDNA	1.8	95002_MG-63_Osteosarcoma (bone) sscDNA	16.3
94941_KATO III_Gastric carcinoma sscDNA	17.5	95003_SK-LMS-1_Leiomyosarcoma (vulva) sscDNA	0.0
94943_NCI-SNU-16_Gastric carcinoma sscDNA	0.7	95004_SJRH30_Rhabdomyosarcoma (met to bone marrow) sscDNA	3.9
94944_NCI-SNU-1_Gastric carcinoma sscDNA	23.0	95005_A431_Epidermoid carcinoma sscDNA	34.9
94946_RF-1_Gastric adenocarcinoma sscDNA	0.0	95007_WM266-4_Melanoma sscDNA	0.0
94947_RF-48_Gastric adenocarcinoma sscDNA	0.0	95010_DU 145_Prostate carcinoma (brain metastasis) sscDNA	0.0
96778_MKN-45_Gastric carcinoma sscDNA	11.5	95012_MDA-MB-468_Breast adenocarcinoma sscDNA	16.3
94949_NCI-N87_Gastric carcinoma sscDNA	24.1	95013_SCC-4_Squamous cell carcinoma of tongue sscDNA	0.0
94951_OVCAR-5_Ovarian carcinoma sscDNA	3.7	95014_SCC-9_Squamous cell carcinoma of tongue sscDNA	0.0
94952_RL95-2_Uterine carcinoma sscDNA	4.6	95015_SCC-15_Squamous cell carcinoma of tongue sscDNA	0.0
94953_HelaS3_Cervical adenocarcinoma sscDNA	5.9	95017_CAL 27_Squamous cell carcinoma of tongue sscDNA	7.1

Table 63. Panel 4D

Tissue Name	Relative Expression(%)	Relative Expression(%)	Relative Expression(%)	Relative Expression(%)
	4dtm2473t_ag1522	4dtm3214t_ag2263	4dtm4353t_ag1848	4dtm4222_ag2422
93768_Secondary Th1_anti-CD28/anti-CD3	0.0	0.0	0.1	0.2
93769_Secondary Th2_anti-CD28/anti-CD3	0.0	0.0	0.0	0.0
93770_Secondary Tr1_anti-CD28/anti-CD3	0.0	0.0	0.0	4.6
93573_Secondary Th1_resting day 4-6 in IL-2	0.1	0.1	0.0	0.0
93572_Secondary Th2_resting day 4-6 in IL-2	0.0	0.0	0.0	0.0
93571_Secondary Tr1_resting day 4-6 in IL-2	0.0	0.0	0.0	0.2
93568_primary Th1_anti-CD28/anti-CD3	0.1	0.2	0.2	1.0
93569_primary Th2_anti-CD28/anti-CD3	0.1	0.1	0.2	0.3
93570_primary Tr1_anti-CD28/anti-CD3	0.2	0.0	0.5	0.6
93565_primary Th1_resting dy 4-6 in IL-2	0.0	0.0	0.0	0.0
93566_primary Th2_resting	0.0	0.0	0.0	0.0

dy 4-6 in IL-2				
93567_primary Tr1_resting dy 4-6 in IL-2	0.0	0.0	0.0	0.0
93351_CD45RA CD4 lymphocyte_anti-CD28/anti- CD3	4.9	8.5	6.3	10.6
93352_CD45RO CD4 lymphocyte_anti-CD28/anti- CD3	0.0	0.0	0.0	0.0
93251_CD8 Lymphocytes_anti- CD28/anti-CD3	0.0	0.0	0.0	0.0
93353_chronic CD8 Lymphocytes 2ry_resting dy 4-6 in IL-2	0.0	0.0	0.0	0.0
93574_chronic CD8 Lymphocytes 2ry_activated CD3/CD28	0.0	0.0	0.0	0.0
93354_CD4_none	0.0	0.0	0.0	0.0
93252_Secondary Th1/Th2/Tr1_anti-CD95 CH11	0.0	0.0	0.0	0.0
93103_LAK cells_resting	1.8	2.0	2.7	5.8
93788_LAK cells_IL-2	0.0	0.0	0.0	0.0
93787_LAK cells_IL-2+IL- 12	0.0	0.0	0.0	0.2
93789_LAK cells_IL-2+IFN gamma	0.0	0.0	0.0	0.2
93790_LAK cells_IL-2+ IL- 18	0.0	0.0	0.4	0.1
93104_LAK cells_PMA/ionomycin and IL-18	1.1	1.7	1.0	2.5
93578_NK Cells IL- 2_resting	0.0	0.0	0.1	0.0
93109_Mixed Lymphocyte Reaction_Two Way MLR	0.0	0.2	0.0	0.2
93110_Mixed Lymphocyte Reaction_Two Way MLR	0.2	0.8	0.3	0.6
93111_Mixed Lymphocyte Reaction_Two Way MLR	0.5	0.1	0.2	0.3
93112_Mononuclear Cells (PBMCs)_resting	0.0	0.1	0.0	0.0
93113_Mononuclear Cells (PBMCs)_PWM	0.0	0.0	0.1	0.0
93114_Mononuclear Cells (PBMCs)_PHA-L	0.0	0.0	0.0	0.0
93249_Ramos (B cell)_none	0.0	0.0	0.0	0.0
93250_Ramos (B cell)_ionomycin	0.0	0.0	0.0	0.0
93349_B lymphocytes_PWM	0.2	0.0	0.0	0.0
93350_B lymphocytes_CD40L and IL- 4	0.0	0.1	0.0	0.3
92665_EOL-1 (Eosinophil)_dbcAMP differentiated	0.2	0.4	0.2	0.0

93248_EOL-1 (Eosinophil)_dbcAMP/PMA ionomycin	0.0	0.2	0.4	0.6
93356_Dendritic Cells_none	1.4	1.0	1.1	2.8
93355_Dendritic Cells_LPS 100 ng/ml	0.3	0.3	0.4	0.4
93775_Dendritic Cells_anti- CD40	2.4	3.5	3.0	6.7
93774_Monocytes_resting	0.8	0.6	0.8	1.3
93776_Monocytes_LPS 50 ng/ml	0.0	0.3	0.0	0.0
93581_Macrophages_resting	1.3	0.0	1.0	2.0
93582_Macrophages_LPS 100 ng/ml	0.0	0.1	0.2	0.4
93098_HUVEC (Endothelial)_none	1.1	0.6	1.4	2.5
93099_HUVEC (Endothelial)_starved	4.4	2.9	4.7	6.0
93100_HUVEC (Endothelial)_IL-1b	1.7	1.0	2.8	2.3
93779_HUVEC (Endothelial)_IFN gamma	1.6	2.5	1.4	1.9
93102_HUVEC (Endothelial)_TNF alpha + IFN gamma	0.3	0.5	0.3	0.5
93101_HUVEC (Endothelial)_TNF alpha + IL4	0.2	0.3	0.3	1.3
93781_HUVEC (Endothelial)_IL-11	0.9	2.2	1.2	0.5
93583_Lung Microvascular Endothelial Cells_none	2.2	2.8	6.5	6.7
93584_Lung Microvascular Endothelial Cells_TNFa (4 ng/ml) and IL1b (1 ng/ml)	12.7	8.5	11.9	15.5
92662_Microvascular Dermal endothelium_none	32.1	22.4	30.8	22.4
92663_Microvascular Dermal endothelium_TNFa (4 ng/ml) and IL1b (1 ng/ml)	16.3	8.8	16.2	14.4
93773_Bronchial epithelium_TNFa (4 ng/ml) and IL1b (1 ng/ml) **	24.0	15.1	31.2	50.7
93347_Small Airway Epithelium_none	8.8	6.7	5.9	12.8
93348_Small Airway Epithelium_TNFa (4 ng/ml) and IL1b (1 ng/ml)	31.9	21.0	43.5	44.8
92668_Coronary Artery SMC_resting	27.4	8.5	28.7	35.8
92669_Coronary Artery SMC_TNFa (4 ng/ml) and IL1b (1 ng/ml)	12.9	27.4	21.6	17.8
93107_astrocytes_resting	17.1	23.8	14.9	24.3
93108_astrocytes_TNFa (4 ng/ml) and IL1b (1 ng/ml)	32.8	28.1	29.5	35.1
92666_KU-812	1.0	1.3	1.8	0.7

(Basophil)_resting				
92667_KU-812 (Basophil) PMA/ionoycin	1.4	2.0	3.3	3.7
93579_CCD1106 (Keratinocytes) none	1.4	0.7	0.2	2.7
93580_CCD1106 (Keratinocytes)_TNFa and IFNg **	0.9	0.8	0.3	1.3
93791_Liver Cirrhosis	2.9	2.4	3.0	4.8
93792_Lupus Kidney	3.0	0.9	2.9	4.4
93577_NCI-H292	10.4	5.6	13.7	18.8
93358_NCI-H292_IL-4	14.2	6.8	14.9	17.1
93360_NCI-H292_IL-9	13.2	9.3	16.7	12.8
93359_NCI-H292_IL-13	9.4	15.9	8.6	9.0
93357_NCI-H292_IFN gamma	3.8	4.7	4.7	5.3
93777_HPAEC -	1.2	1.6	1.0	2.8
93778_HPAEC_IL-1 beta/TNA alpha	5.8	4.7	2.6	6.0
93254_Normal Human Lung Fibroblast none	100.0	100.0	100.0	100.0
93253_Normal Human Lung Fibroblast_TNFa (4 ng/ml) and IL-1b (1 ng/ml)	8.5	15.9	12.2	15.2
93257_Normal Human Lung Fibroblast_IL-4	74.2	45.7	79.6	97.3
93256_Normal Human Lung Fibroblast_IL-9	27.7	30.6	48.6	50.3
93255_Normal Human Lung Fibroblast_IL-13	48.0	27.4	39.5	55.9
93258_Normal Human Lung Fibroblast_IFN gamma	76.3	42.6	82.9	98.6
93106_Dermal Fibroblasts CCD1070_resting	52.8	27.2	56.3	65.5
93361_Dermal Fibroblasts CCD1070_TNF alpha 4 ng/ml	33.9	19.8	42.6	46.7
93105_Dermal Fibroblasts CCD1070_IL-1 beta 1 ng/ml	29.1	70.2	27.9	28.9
93772_dermal fibroblast_IFN gamma	6.1	8.9	3.6	7.9
93771_dermal fibroblast_IL-4	14.5	17.3	16.2	18.9
93260_IBD Colitis 2	0.1	0.2	0.1	0.5
93261_IBD Crohns	0.6	0.0	0.4	0.8
735010_Colon_normal	7.6	8.0	6.4	11.3
735019_Lung_none	59.5	47.6	75.8	74.7
64028-1_Thymus_none	16.5	10.2	17.3	19.6
64030-1_Kidney_none	6.8	3.0	9.0	6.5

Table 64. Panel CNS\_1

Tissue Name	Relative Expression(%)	Tissue Name	Relative Expression(%)
-------------	---------------------------	-------------	---------------------------



	CNS1tm6191t_ ag2263 a2		CNS1tm6191t_a g2263 a2
102633 BA4 Control	22.8	102605 BA17 PSP	11.2
102641 BA4 Control2	38.1	102612 BA17 PSP2	7.1
102625 BA4 Alzheimer's2	3.7	102637 Sub Nigra Control	100.0
102649 BA4 Parkinson's	45.6	102645 Sub Nigra Control2	51.6
102656 BA4 Parkinson's2	31.1	102629 Sub Nigra Alzheimer's2	30.7
102664 BA4 Huntington's	12.3	102660 Sub Nigra Parkinson's2	89.0
102671 BA4 Huntington's2	12.2	102667 Sub Nigra Huntington's	58.9
102603 BA4 PSP	13.6	102674 Sub Nigra Huntington's2	16.0
102610 BA4 PSP2	42.5	102614 Sub Nigra PSP2	22.4
102588 BA4 Depression	27.8	102592 Sub Nigra Depression	40.4
102596 BA4 Depression2	10.8	102599 Sub Nigra Depression2	12.7
102634 BA7 Control	28.3	102636 Glob Palladus Control	36.0
102642 BA7 Control2	27.2	102644 Glob Palladus Control2	21.2
102626 BA7 Alzheimer's2	5.5	102620 Glob Palladus Alzheimer's	26.0
102650 BA7 Parkinson's	13.2	102628 Glob Palladus Alzheimer's2	11.1
102657 BA7 Parkinson's2	12.7	102652 Glob Palladus Parkinson's	73.0
102665 BA7 Huntington's	14.7	102659 Glob Palladus Parkinson's2	15.6
102672 BA7 Huntington's2	22.2	102606 Glob Palladus PSP	14.9
102604 BA7 PSP	28.9	102613 Glob Palladus PSP2	10.4
102611 BA7 PSP2	8.9	102591 Glob Palladus Depression	28.3
102589 BA7 Depression	5.4	102638 Temp Pole Control	5.4
102632 BA9 Control	14.2	102646 Temp Pole Control2	25.0
102640 BA9 Control2	56.8	102622 Temp Pole Alzheimer's	10.0
102617 BA9 Alzheimer's	5.5	102630 Temp Pole Alzheimer's2	2.5
102624 BA9 Alzheimer's2	13.7	102653 Temp Pole Parkinson's	15.5
102648 BA9 Parkinson's	16.1	102661 Temp Pole Parkinson's2	27.9
102655 BA9 Parkinson's2	21.0	102668 Temp Pole Huntington's	22.2
102663 BA9 Huntington's	21.3	102607 Temp Pole PSP	1.3
102670 BA9 Huntington's2	11.9	102615 Temp Pole PSP2	6.3
102602 BA9 PSP	27.7	102600 Temp Pole Depression2	12.3
102609 BA9 PSP2	5.9	102639 Cing Gyr Control	48.1
102587 BA9 Depression	11.0	102647 Cing Gyr Control2	28.0
102595 BA9 Depression2	9.5	102623 Cing Gyr Alzheimer's	27.1
102635 BA17 Control	24.8	102631 Cing Gyr Alzheimer's2	13.1
102643 BA17 Control2	45.4	102654 Cing Gyr Parkinson's	29.5
102627 BA17 Alzheimer's2	6.4	102662 Cing Gyr Parkinson's2	37.2
102651 BA17 Parkinson's	35.2	102669 Cing Gyr Huntington's	70.3
102658 BA17 Parkinson's2	15.2	102676 Cing Gyr Huntington's2	32.0
102666 BA17 Huntington's	15.5	102608 Cing Gyr PSP	42.6
102673 BA17 Huntington's2	8.1	102616 Cing Gyr PSP2	8.3
102590 BA17 Depression	26.1	102594 Cing Gyr Depression	20.5
102597 BA17 Depression2	59.7	102601 Cing Gyr Depression2	36.1

Table 65 Panel CNS\_Neurodegeneration\_v1.0

Tissue Name	Relative Expression(%)	Relative Expression(%)
	tm6993t_ ag1848 b2	tm6900f_ ag2422 b2s2
AD 1 Hippo	28.3	21.2
AD 2 Hippo	38.0	38.5
AD 3 Hippo	12.0	14.8
AD 4 Hippo	17.7	13.3
AD 5 hippo	45.4	57.7
AD 6 Hippo	66.9	95.3
Control 2 Hippo	43.3	46.0
Control 4 Hippo	34.1	30.2
Control (Path) 3 Hippo	3.9	12.6
AD 1 Temporal Ctx	47.1	40.4
AD 2 Temporal Ctx	49.2	39.6
AD 3 Temporal Ctx	14.5	15.6
AD 4 Temporal Ctx	41.4	36.2
AD 5 Inf Temporal Ctx	78.1	88.4
AD 5 Sup Temporal Ctx	40.9	56.7
AD 6 Inf Temporal Ctx	83.9	74.1
AD 6 Sup Temporal Ctx	58.2	71.5
Control 1 Temporal Ctx	17.9	11.3
Control 2 Temporal Ctx	45.7	44.7
Control 3 Temporal Ctx	14.6	15.6
Control 4 Temporal Ctx	23.2	19.0
Control (Path) 1 Temporal Ctx	45.9	40.1
Control (Path) 2 Temporal Ctx	24.7	21.7
Control (Path) 3 Temporal Ctx	6.0	7.7
Control (Path) 4 Temporal Ctx	32.0	23.9
AD 1 Occipital Ctx	24.2	26.4
AD 2 Occipital Ctx (Missing)	0.0	0.0
AD 3 Occipital Ctx	19.2	18.1
AD 4 Occipital Ctx	30.1	23.2
AD 5 Occipital Ctx	6.0	26.7
AD 6 Occipital Ctx	43.3	50.2
Control 1 Occipital Ctx	14.5	12.7
Control 2 Occipital Ctx	66.7	76.0
Control 3 Occipital Ctx	17.8	17.4
Control 4 Occipital Ctx	23.3	15.7
Control (Path) 1 Occipital Ctx	100.0	100.0
Control (Path) 2 Occipital Ctx	18.7	12.3
Control (Path) 3 Occipital Ctx	7.9	7.1
Control (Path) 4 Occipital Ctx	24.4	13.9
Control 1 Parietal	23.2	22.2
Control 2 Parietal	46.0	64.3

Control 3 Parietal	26.1	17.2
Control (Path) 1 Parietal	51.1	54.1
Control (Path) 2 Parietal	36.4	27.8
Control (Path) 3 Parietal	6.1	5.1
Control (Path) 4 Parietal	46.0	36.4

**Panel 1.2 Summary:** Ag1522 Expression of the NOV10 gene is highest in CNS cancer cell lines (CT=26.1). Of nine tissue samples derived from CNS cancer cell lines, expression of the NOV10 gene occurs in all samples, with expression high (CT=26.1, 26.6, 27.6) in three samples, moderate in five samples and low in one sample. High expression is also detectable in melanoma cell lines (CT=27.9). Significant expression of the NOV10 gene is seen in gastric cancer (28.1) and all ten samples of lung cancer cell lines in this sample. Thus, expression of the NOV10 gene could be used to distinguish those cancer cell lines from normal tissues. In addition, therapeutic modulation of the expression, or activity of the NOV10 gene product, might be of use in the treatment of melanoma, gastric cancer, lung cancer and brain cancer.

**Panel 1.3D Summary** Ag1522/Ag1848/Ag2263/Ag2422 Four experiments using different probe/primer sets on the same tissue panel produce results that are in excellent agreement. In all four experiments, highest expression of the NOV10 gene is detected in CNS cancer cell lines. Expression is also significant in lung cancer and melanoma cell lines and in healthy brain tissue from the hippocampus and thalamus regions. Thus, the expression of the NOV10 gene could be used to distinguish these tissue samples from other samples. Moreover, therapeutic modulation of the expression, or function, of the NOV10 gene, through the use of small molecule drugs or antibodies, might be beneficial in the treatment of melanoma, lung cancer and brain cancer.

Among metabolic tissues, there is high expression of the NOV10 gene in adult heart tissue (CT=27.8) and moderate expression in fetal heart, adult and fetal liver, pancreas, adrenal gland, thyroid and pituitary. The NOV10 gene appears to be differentially expressed in fetal (CT value = 31) and adult skeletal muscle (CT value = 37) using the probe and primer set Ag1848 and may be useful for the differentiation of the adult from the fetal phenotype in this tissue.

**Panel 2D Summary** Ag1522/Ag1848/Ag2263/Ag2422 Results from multiple experiments with four different probe and primer sets are in very good agreement. In all four experiments, highest expression of the NOV10 gene is detected in thyroid and ovarian cancers (CTs = 27-30), with lower expression also seen in most of the other tissues on this panel. Thus, the expression of the NOV10 gene could be used to distinguish ovarian and thyroid

cancer cell lines from other tissues. Moreover, therapeutic modulation of the expression this gene, or its function, through the use of small molecule drugs or antibodies, might be of benefit in the treatment of ovarian and thyroid cancer. In addition, experiments with Ag2263 show differential expression between samples derived from lung cancer and their adjacent normal tissues. Thus, expression of the NOV10 gene could be used to distinguish cancerous lung tissue from normal lung tissue. Moreover, therapeutic modulation of the expression or function of this gene or its protein product, through the use of antibodies or small molecule drugs, might be of benefit in the treatment of lung cancer

**Panel 3D Summary Ag2263** Expression of the NOV10 gene occurs at moderate levels across all the tissues in this panel. Highest expression is detected in a small cell lung cancer (CT = 30.6) and neuroblastoma (CT = 30.7). In addition, significant expression is detected in a cluster of small cell lung cancer lines. Thus, this gene could be used to distinguish lung cancer cell lines from other samples. Moreover, therapeutic modulation of the NOV10 gene or its protein product, through the use of small molecule drugs or antibodies might be of benefit in the treatment of small cell lung cancer.

**Panel 4D Summary Ag1522/Ag1848/Ag2263/Ag2422** Experiments using each of the four probe and primer sets that correspond to the NOV10 gene produce results that are in excellent agreement. In all the experiments, expression of the NOV10 gene occurs at moderate to low levels in many of the tissues in the sample. Highest expression in each experiment occurs in lung fibroblasts (CT = 29). Moderate expression in lung fibroblasts treated with IL-4 is also consistent among all four experiments (CT = 30). Lower expression is also detected in a variety of fibroblasts, endothelial and smooth muscle cells. The expression of the NOV10 gene produces a complex profile; it is upregulated by TNF-alpha in small airway epithelium, but clearly downregulated by the same stimulus in lung fibroblasts. The gene most probably encodes a netrin receptor that may be important in understanding cell migration. Regulation of the protein encoded for by the NOV10 gene could potentially control the progression of keloid formation, emphysema and other conditions in which TNF-alpha and IL-1 beta are present and tissue remodeling may occur.

**Panel CNS\_1 Summary Ag2263** Expression of the NOV10 gene is moderate to low across many of the tissues in this panel. Highest expression is detected in the substantia nigra (CT = 31.4). Although no disease-specific expression is seen in this panel, the expression profile confirms the expression of this gene in the central nervous system. Please see panel\_CNS\_neurodegeneration for potential utility of the NOV10 gene regarding the CNS.

**Panel CNS\_Neurodegeneration\_v1.0 Summary Ag1848/Ag2422** Two experiments using different probe/primer sets produce results that are in good agreement. Highest expression of the NOV10 gene is detected in the occipital cortex of a control patient. Significant levels of expression are also detected in the hippocampus, inferior temporal cortex, and the superior temporal cortex of brain tissue from an Alzheimer's patient.

Based on its homology, the NOV10 gene product is most similar to an UNC5H receptor, which as a class are known to act both in axon guidance and neuronal migration during development, as well as inducers of apoptosis (except when stimulated by the ligand netrin-1). Panel CNS\_Neurodegeneration\_V1.0 shows a moderate increase (1.5 to 2-fold) in the temporal cortex of the Alzheimer's disease brain when compared to non-demented elderly showing a high amyloid plaque load. Thus the NOV10 gene represents a protein that differentiates demented and non-demented elderly who have a severe amyloid plaque load, making it an excellent drug target in Alzheimer's disease. The modulation and/or selective stimulation of this receptor may be of use in enhancing or directing compensatory synatogenesis and axon/dendritic outgrowth in response to neuronal death (stroke, head trauma) neurodegeneration (Alzheimer's, Parkinson's, Huntington's, spinocerebellar ataxia, progressive supranuclear palsy) or spinal cord injury. Furthermore, antagonism of this receptor may decrease apoptosis in Alzheimer's disease. (Ellezam et al., Exp Neurol. 168:105-15, 2001; Braisted et al., J Neurosci. 20:5792-801, 2000; Montell, Development 126:3035-46, 1999.)

#### **NOV11a: Hepatocyte Growth Factor-like**

Expression of the NOV11a gene (GMba446g13\_A) was assessed using the primer-probe sets Ag3086 and Ag3797, described in Tables 66 and 67. Results from RTQ-PCR runs are shown in Tables 68, 69, 70, 71, 72 and 73.

**Table 66. Probe Name Ag3086**

Primers	Sequences	TM	Length	Start Position	SEQ ID NO:
Forward	5'-GGACCCCATTCGACTACTGT-3'	20	20	1309	188
Probe	FAM-5'- CTGATGACCAGCCGCCATCAATC-3'- TAMRA	23	23	1345	189
Reverse	5'-TTCTCAAACCTGCACCTGGTC-3'	20	20	1399	190

**Table 67. Probe Name Ag3797**

Primers	Sequences	TM	Length	Start Position	SEQ ID NO:
Forward	5'-TCTGGACGACAACTATTGCC-3'	58.7	20	627	191
Probe	FAM-5'-	69.2	25	672	192

	ATGGTGCTACACTACGGATCCGAG-3'- TAMRA				
Reverse	5'-GTCACAGAATTCTCGCTCGA-3'	59.1	20	698	193

Table 68. Panel 1.3D

Tissue Name	Relative Expression(%)	Tissue Name	Relative Expression(%)
	1.3dx4tm5430 f_ag3086_a1		1.3dx4tm5430 f_ag3086_a1
Liver adenocarcinoma	0.7	Kidney (fetal)	31.1
Pancreas	17.9	Renal ca. 786-0	0.2
Pancreatic ca. CAPAN 2	0.6	Renal ca. A498	0.5
Adrenal gland	2.7	Renal ca. RXF 393	0.7
Thyroid	3.3	Renal ca. ACHN	0.8
Salivary gland	1.2	Renal ca. UO-31	0.4
Pituitary gland	3.6	Renal ca. TK-10	0.2
Brain (fetal)	3.2	Liver	94.2
Brain (whole)	3.4	Liver (fetal)	100.0
Brain (amygdala)	2.1	Liver ca. (hepatoblast) HepG2	58.4
Brain (cerebellum)	1.5	Lung	2.8
Brain (hippocampus)	3.0	Lung (fetal)	12.9
Brain (substantia nigra)	1.7	Lung ca. (small cell) LX-1	1.3
Brain (thalamus)	3.0	Lung ca. (small cell) NCI-H69	0.2
Cerebral Cortex	0.9	Lung ca. (s.cell var.) SHP-77	1.2
Spinal cord	2.9	Lung ca. (large cell) NCI-H460	1.4
CNS ca. (glio/astro) U87-MG	0.7	Lung ca. (non-sm. cell) A549	0.2
CNS ca. (glio/astro) U-118-MG	0.9	Lung ca. (non-s.cell) NCI-H23	0.9
CNS ca. (astro) SW1783	0.4	Lung ca. (non-s.cell) HOP-62	0.5
CNS ca.* (neuro; met ) SK-N-AS	0.7	Lung ca. (non-s.cl) NCI-H522	0.6
CNS ca. (astro) SF-539	0.5	Lung ca. (squam.) SW 900	0.4
CNS ca. (astro) SNB-75	1.2	Lung ca. (squam.) NCI-H596	0.5
CNS ca. (glio) SNB-19	1.6	Mammary gland	3.1
CNS ca. (glio) U251	2.4	Breast ca.* (pl. effusion) MCF-7	0.7
CNS ca. (glio) SF-295	0.7	Breast ca.* (pl.ef) MDA-MB-231	0.7
Heart (fetal)	0.6	Breast ca.* (pl. effusion) T47D	2.7
Heart	0.5	Breast ca. BT-549	0.7
Fetal Skeletal	0.2	Breast ca. MDA-N	0.0
Skeletal muscle	1.4	Ovary	0.4
Bone marrow	2.0	Ovarian ca. OVCAR-3	0.6
Thymus	1.2	Ovarian ca. OVCAR-4	0.4
Spleen	4.0	Ovarian ca. OVCAR-5	0.4
Lymph node	3.1	Ovarian ca. OVCAR-8	0.7
Colorectal	1.6	Ovarian ca. IGROV-1	0.7
Stomach	10.3	Ovarian ca.* (ascites) SK-OV-3	0.0
Small intestine	29.6	Uterus	3.2
Colon ca. SW480	0.7	Placenta	4.6

Colon ca.* (SW480 met)SW620	0.2	Prostate	2.1
Colon ca. HT29	0.2	Prostate ca.* (bone met)PC-3	0.9
Colon ca. HCT-116	1.2	Testis	12.4
Colon ca. CaCo-2	2.4	Melanoma Hs688(A).T	0.1
83219 CC Well to Mod Diff (ODO3866)	2.1	Melanoma* (met) Hs688(B).T	0.2
Colon ca. HCC-2998	1.4	Melanoma UACC-62	0.4
Gastric ca.* (liver met) NCI-N87	1.8	Melanoma M14	0.8
Bladder	4.5	Melanoma LOX IMVI	0.0
Trachea	2.6	Melanoma* (met) SK-MEL-5	0.4
Kidney	26.1	Adipose	2.2

Table 69. General Screening Panel \_v1.4

Tissue Name	Relative Expression(%)	Tissue Name	Relative Expression(%)
	1.4x4tm7355f_a g3797_a1		1.4x4tm7355f_a g3797_a1
D6005-01 Human adipose	1.4	Renal ca. TK-10	28.9
112193_Metastatic melanoma	0.4	Bladder	8.4
112192_Metastatic melanoma	0.5	Gastric ca.(liver met) NCI-N87	2.7
95280_Epidermis (metastatic melanoma)	0.3	112197_Stomach	1.4
95279_Epidermis (metastatic melanoma)	0.3	94938 Colon Adenocarcinoma	1.0
Melanoma (met) SK-MEL-5	0.5	Colon ca. SW480	3.9
112196_Tongue (oncology)	0.8	Colon ca.(SW480 met) SW620	1.2
113461 Testis Pool	2.0	Colon ca. HT29	0.2
Prostate ca.(bone met) PC-3	1.5	Colon ca. HCT-116	4.3
113455 Prostate Pool	1.8	Colon ca. CaCo-2	11.5
103396 Placenta	1.7	83219 CC Well to Mod Diff (ODO3866)	2.8
113463 Uterus Pool	0.5	94936 Colon Adenocarcinoma	2.9
Ovarian carcinoma OVCAR-3	1.0	94930 Colon	0.5
Ovarian carcinoma(ascites)_SK-OV-3	0.8	94935 Colon Adenocarcinoma	0.2
95297 Adenocarcinoma (ovary)	0.3	113468 Colon Pool	1.6
Ovarian carcinoma OVCAR-5	6.4	113457 Small Intestine Pool	2.0
Ovarian carcinoma IGROV-1	4.6	113460 Stomach Pool	1.9
Ovarian carcinoma OVCAR-8	2.9	113467 Bone Marrow Pool	0.4
103368 Ovary	1.9	103371 Fetal Heart	0.8
MCF7_breast carcinoma(pleural effusion)	2.3	113451 Heart Pool	0.7
Breast ca. (pleural effusion) MDA-MB-231	2.2	113466 Lymph Node Pool	1.7
112189_ductal cell carcinoma(breast)	3.0	103372 Fetal Skeletal Muscle	0.7
Breast ca. (pleural effusion) T47D	18.5	113456 Skeletal Muscle Pool	1.1
Breast carcinoma MDA-N	0.7	113459 Spleen Pool	2.5
113452_Breast Pool	1.5	113462 Thymus Pool	2.4

103398 Trachea	1.2	CNS ca. (glio/astro) U87-MG	2.7
112354 lung	0.4	CNS ca. (glio/astro) U-118-MG	3.0
103374 Fetal Lung	2.3	CNS ca. (neuro;met) SK-N-AS	2.1
94921_Small cell carcinoma of the lung	0.2	95264 Brain astrocytoma	0.6
Lung ca.(small cell) LX-1	3.3	CNS ca. (astro) SNB-75	1.8
94919_Small cell carcinoma of the lung	0.5	CNS ca. (glio) SNB-19	4.1
Lung ca.(s.cell var.) SHP-77	2.4	CNS ca. (glio) SF-295	2.1
95268 Lung (Large cell carcinoma)	0.6	113447 Brain (Amygdala) Pool	0.9
94920_Small cell carcinoma of the lung	0.6	103382 Brain (cerebellum)	1.9
Lung ca.(non-s.cell) NCI-H23	3.7	64019-1 brain(fetal)	2.8
Lung ca.(large cell) NCI-H460	0.9	113448_Brain (Hippocampus) Pool	1.0
Lung ca.(non-s.cell) HOP-62	1.2	113464 Cerebral Cortex Pool	0.7
Lung ca.(non-s.cl) NCI-H522	1.7	113449_Brain (Substantia nigra) Pool	0.9
103392 Liver	26.6	113450 Brain (Thalamus) Pool	1.0
103393 Fetal Liver	45.5	103384 Brain (whole)	1.6
Liver ca.(hepatoblast) HepG2	100.0	113458 Spinal Cord Pool	1.7
113465 Kidney Pool	1.7	103375 Adrenal Gland	3.1
103373 Fetal Kidney	11.1	113454 Pituitary gland Pool	1.7
Renal ca. 786-0	1.0	103397 Salivary Gland	1.0
112188 renal cell carcinoma	0.3	103369 Thyroid (female)	2.8
Renal ca. ACHN	1.4	Pancreatic ca. CAPAN2	0.8
112190 Renal cell carcinoma	1.8	113453 Pancreas Pool	7.5

Table 70. Panel 2.2

Tissue Name	Relative Expression(%)	Tissue Name	Relative Expression(%)
	2.2x4tm6408f_a g3086_a1		2.2x4tm6408f_a g3086_a1
Normal Colon GENPAK 061003	1.4	83793 Kidney NAT (OD04348)	40.9
97759 Colon cancer (OD06064)	0.1	98938 Kidney malignant cancer (OD06204B)	0.4
97760 Colon cancer NAT (OD06064)	0.0	98939 Kidney normal adjacent tissue (OD06204E)	5.1
97778 Colon cancer (OD06159)	0.0	85973 Kidney Cancer (OD04450-01)	5.7
97779 Colon cancer NAT (OD06159)	1.4	85974 Kidney NAT (OD04450-03)	15.0
98861 Colon cancer (OD06297-04)	0.0	Kidney Cancer Clontech 8120613	0.2
98862 Colon cancer NAT (OD06297-015)	1.1	Kidney NAT Clontech 8120614	5.9
83237 CC Gr.2 ascend colon (ODO3921)	0.4	Kidney Cancer Clontech 9010320	0.4
83238 CC NAT (ODO3921)	0.2	Kidney NAT Clontech 9010321	1.5
97766 Colon cancer metastasis (OD06104)	0.0	Kidney Cancer Clontech 8120607	0.1



97767 Lung NAT (OD06104)	0.6	Kidney NAT Clontech 8120608	3.5
87472 Colon mets to lung (OD04451-01)	1.3	Normal Uterus GENPAK 061018	0.2
87473 Lung NAT (OD04451-02)	0.4	Uterus Cancer GENPAK 064011	0.1
Normal Prostate Clontech A+ 6546-1 (8090438)	0.6	Normal Thyroid Clontech A+ 6570-1 (7080817)	0.5
84140 Prostate Cancer (OD04410)	0.2	Thyroid Cancer GENPAK 064010	0.3
84141 Prostate NAT (OD04410)	0.5	Thyroid Cancer INVITROGEN A302152	2.1
Normal Ovary Res. Gen.	0.4	Thyroid NAT INVITROGEN A302153	0.4
98863 Ovarian cancer (OD06283-03)	0.2	Normal Breast GENPAK 061019	0.7
98865 Ovarian cancer NAT/fallopian tube (OD06283-07)	1.2	84877 Breast Cancer (OD04566)	2.3
Ovarian Cancer GENPAK 064008	1.5	Breast Cancer Res. Gen. 1024	1.9
97773 Ovarian cancer (OD06145)	0.9	85975 Breast Cancer (OD04590-01)	5.1
97775 Ovarian cancer NAT (OD06145)	1.8	85976 Breast Cancer Mets (OD04590-03)	1.3
98853 Ovarian cancer (OD06455-03)	0.6	87070 Breast Cancer Metastasis (OD04655-05)	0.7
98854 Ovarian NAT (OD06455-07) Fallopian tube	0.2	GENPAK Breast Cancer 064006	0.5
Normal Lung GENPAK 061010	0.8	Breast Cancer Clontech 9100266	0.2
92337 Invasive poor diff. lung adeno (ODO4945-01)	0.3	Breast NAT Clontech 9100265	0.5
92338 Lung NAT (ODO4945-03)	1.1	Breast Cancer INVITROGEN A209073	0.2
84136 Lung Malignant Cancer (OD03126)	1.6	Breast NAT INVITROGEN A2090734	1.4
84137 Lung NAT (OD03126)	0.3	97763 Breast cancer (OD06083)	0.7
90372 Lung Cancer (OD05014A)	0.5	97764 Breast cancer node metastasis (OD06083)	0.2
90373 Lung NAT (OD05014B)	0.6	Normal Liver GENPAK 061009	28.7
97761 Lung cancer (OD06081)	0.5	Liver Cancer Research Genetics RNA 1026	7.5
97762 Lung cancer NAT (OD06081)	1.2	Liver Cancer Research Genetics RNA 1025	45.0
85950 Lung Cancer (OD04237-01)	0.3	Paired Liver Cancer Tissue Research Genetics RNA 6004-T	35.7
85970 Lung NAT (OD04237-02)	1.1	Paired Liver Tissue Research Genetics RNA 6004-N	5.1
83255 Ocular Mel Met to Liver (ODO4310)	0.2	Paired Liver Cancer Tissue Research Genetics RNA 6005-T	14.7
83256 Liver NAT (ODO4310)	21.6	Paired Liver Tissue Research Genetics RNA 6005-N	65.0
84139 Melanoma Mets to Lung (OD04321)	0.2	Liver Cancer GENPAK 064003	100.0
84138 Lung NAT (OD04321)	0.2	Normal Bladder GENPAK 061001	2.8
Normal Kidney GENPAK 061008	5.5	Bladder Cancer Research Genetics RNA 1023	0.2
83786 Kidney Ca, Nuclear grade.2 (OD04338)	20.6	Bladder Cancer INVITROGEN A302173	0.7
83787 Kidney NAT (OD04338)	4.5	Normal Stomach GENPAK 061017	2.5

83788 Kidney Ca Nuclear grade 1/2 (OD04339)	6.5	Gastric Cancer Clontech 9060397	0.0
83789 Kidney NAT (OD04339)	6.0	NAT Stomach Clontech 9060396	0.1
83790 Kidney Ca, Clear cell type (OD04340)	0.4	Gastric Cancer Clontech 9060395	0.0
83791 Kidney NAT (OD04340)	8.7	NAT Stomach Clontech 9060394	0.3
83792 Kidney Ca, Nuclear grade 3 (OD04348)	0.3	Gastric Cancer GENPAK 064005	2.8

Table 71. Panel 4D

Tissue Name	Relative Expression(%)	Tissue Name	Relative Expression(%)
	4dx4tm5510f_a g3086_a2		4dx4tm5510f_a g3086_a2
93768_Secondary Th1_anti-CD28/anti-CD3	0.7	93100_HUVEC (Endothelial)_IL-1b	0.4
93769_Secondary Th2_anti-CD28/anti-CD3	0.9	93779_HUVEC (Endothelial)_IFN gamma	1.2
93770_Secondary Tr1_anti-CD28/anti-CD3	1.1	93102_HUVEC (Endothelial)_TNF alpha + IFN gamma	0.3
93573_Secondary Th1_resting day 4-6 in IL-2	2.8	93101_HUVEC (Endothelial)_TNF alpha + IL4	0.2
93572_Secondary Th2_resting day 4-6 in IL-2	1.4	93781_HUVEC (Endothelial)_IL-11	0.8
93571_Secondary Tr1_resting day 4-6 in IL-2	1.3	93583_Lung Microvascular Endothelial Cells_none	1.0
93568_primary Th1_anti-CD28/anti-CD3	0.7	93584_Lung Microvascular Endothelial Cells_TNFa (4 ng/ml) and IL1b (1 ng/ml)	0.9
93569_primary Th2_anti-CD28/anti-CD3	0.9	92662_Microvascular Dermal endothelium_none	1.6
93570_primary Tr1_anti-CD28/anti-CD3	1.1	92663_Microvascular Dermal endothelium_TNFa (4 ng/ml) and IL1b (1 ng/ml)	0.8
93565_primary Th1_resting dy 4-6 in IL-2	6.4	93773_Bronchial epithelium_TNFa (4 ng/ml) and IL1b (1 ng/ml) **	3.2
93566_primary Th2_resting dy 4-6 in IL-2	3.1	93347_Small Airway Epithelium_none	1.8
93567_primary Tr1_resting dy 4-6 in IL-2	2.0	93348_Small Airway Epithelium_TNFa (4 ng/ml) and IL1b (1 ng/ml)	3.3
93351_CD45RA CD4 lymphocyte_anti-CD28/anti-CD3	0.4	92668_Coronary Artery SMC_resting	1.0
93352_CD45RO CD4 lymphocyte_anti-CD28/anti-CD3	1.4	92669_Coronary Artery SMC_TNFa (4 ng/ml) and IL1b (1 ng/ml)	0.6
93251_CD8 Lymphocytes_anti-CD28/anti-CD3	1.4	93107_astrocytes_resting	3.2
93353_chronic CD8 Lymphocytes 2ry_resting dy 4-6 in IL-2	1.7	93108_astrocytes_TNFa (4 ng/ml) and IL1b (1 ng/ml)	2.7
93574_chronic CD8 Lymphocytes 2ry_activated CD3/CD28	0.6	92666_KU-812 (Basophil)_resting	1.5
93354_CD4_none	2.1	92667_KU-812 (Basophil)_PMA/ionoycin	1.2
93252_Secondary	4.2	93579_CCD1106	1.0

Th1/Th2/Tr1_anti-CD95 CH11		(Keratinocytes)_none	
93103_LAK cells_resting	1.2	93580_CCD1106 (Keratinocytes)_TNFa and IFNg **	3.6
93788_LAK cells_IL-2	3.7	93791_Liver Cirrhosis	84.6
93787_LAK cells_IL-2+IL-12	2.2	93792_Lupus Kidney	33.9
93789_LAK cells_IL-2+IFN gamma	3.0	93577_NCI-H292	8.6
93790_LAK cells_IL-2+ IL-18	2.6	93358_NCI-H292_IL-4	7.1
93104_LAK cells_PMA/ionomycin and IL-18	1.0	93360_NCI-H292_IL-9	6.5
93578_NK Cells_IL-2_resting	1.5	93359_NCI-H292_IL-13	2.8
93109_Mixed Lymphocyte Reaction_Two Way MLR	2.2	93357_NCI-H292_IFN gamma	3.1
93110_Mixed Lymphocyte Reaction_Two Way MLR	1.2	93777_HPAEC_-	1.7
93111_Mixed Lymphocyte Reaction_Two Way MLR	1.3	93778_HPAEC_IL-1 beta/TNA alpha	1.4
93112_Mononuclear Cells (PBMCs)_resting	0.7	93254_Normal Human Lung Fibroblast_none	4.3
93113_Mononuclear Cells (PBMCs)_PWM	0.8	93253_Normal Human Lung Fibroblast_TNFa (4 ng/ml) and IL- 1b (1 ng/ml)	4.9
93114_Mononuclear Cells (PBMCs)_PHA-L	0.6	93257_Normal Human Lung Fibroblast_IL-4	2.2
93249_Ramos (B cell)_none	1.9	93256_Normal Human Lung Fibroblast_IL-9	1.2
93250_Ramos (B cell)_ionomycin	1.4	93255_Normal Human Lung Fibroblast_IL-13	1.6
93349_B lymphocytes_PWM	1.2	93258_Normal Human Lung Fibroblast_IFN gamma	1.9
93350_B lymphocytes_CD40L and IL-4	2.2	93106_Dermal Fibroblasts CCD1070_resting	3.3
92665_EOL-1 (Eosinophil)_dbcAMP differentiated	2.4	93361_Dermal Fibroblasts CCD1070_TNF alpha 4 ng/ml	4.7
93248_EOL-1 (Eosinophil)_dbcAMP/PMAionom ycin	2.6	93105_Dermal Fibroblasts CCD1070_IL-1 beta 1 ng/ml	0.7
93356_Dendritic Cells_none	2.2	93772_dermal fibroblast_IFN gamma	0.8
93355_Dendritic Cells_LPS 100 ng/ml	2.1	93771_dermal fibroblast_IL-4	2.4
93775_Dendritic Cells_anti-CD40	1.8	93260_IBD Colitis 2	11.6
93774_Monocytes_resting	1.5	93261_IBD Crohns	14.2
93776_Monocytes_LPS 50 ng/ml	0.6	735010_Colon_normal	61.0
93581_Macrophages_resting	1.7	735019_Lung_none	3.6
93582_Macrophages_LPS 100 ng/ml	1.1	64028-1_Thymus_none	100.0
93098_HUVEC (Endothelial)_none	1.3	64030-1_Kidney_none	5.7
93099_HUVEC (Endothelial)_starved	1.2		

Table 72. Panel 4.1D

Tissue Name	Relative Expression(%)	
	4.1dx4tm5986 f ag3797 a1	4.1dtm6034f_ ag3797
93768 Secondary Th1 anti-CD28/anti-CD3	8.9	1.3
93769 Secondary Th2 anti-CD28/anti-CD3	2.6	1.3
93770 Secondary Tr1 anti-CD28/anti-CD3	3.1	0.9
93573 Secondary Th1 resting day 4-6 in IL-2	1.5	1.6
93572 Secondary Th2 resting day 4-6 in IL-2	3.4	0.7
93571 Secondary Tr1 resting day 4-6 in IL-2	3.4	0.9
93568 primary Th1 anti-CD28/anti-CD3	3.2	0.3
93569 primary Th2 anti-CD28/anti-CD3	2.0	1.1
93570 primary Tr1 anti-CD28/anti-CD3	2.7	1.0
93565 primary Th1 resting dy 4-6 in IL-2	3.2	0.4
93566 primary Th2 resting dy 4-6 in IL-2	4.5	0.0
93567 primary Tr1 resting dy 4-6 in IL-2	2.3	0.7
93351 CD45RA CD4 lymphocyte anti-CD28/anti-CD3	2.0	0.7
93352 CD45RO CD4 lymphocyte anti-CD28/anti-CD3	1.8	2.0
93251 CD8 Lymphocytes anti-CD28/anti-CD3	5.6	0.9
93353 chronic CD8 Lymphocytes 2ry resting dy 4-6 in IL-2	4.6	1.1
93574 chronic CD8 Lymphocytes 2ry activated CD3/CD28	1.8	0.2
93354 CD4 none	7.2	1.3
93252 Secondary Th1/Th2/Tr1 anti-CD95 CH11	6.6	1.1
93103 LAK cells resting	7.6	0.4
93788 LAK cells IL-2	4.8	0.3
93787 LAK cells IL-2+IL-12	5.7	0.8
93789 LAK cells IL-2+IFN gamma	5.5	0.2
93790 LAK cells IL-2+ IL-18	1.6	0.4
93104 LAK cells PMA/ionomycin and IL-18	2.7	1.3
93578 NK Cells IL-2 resting	5.6	2.0
93109 Mixed Lymphocyte Reaction Two Way MLR	4.9	2.0
93110 Mixed Lymphocyte Reaction Two Way MLR	0.5	0.8
93111 Mixed Lymphocyte Reaction Two Way MLR	6.0	0.2
93112 Mononuclear Cells (PBMCs) resting	1.3	0.4
93113 Mononuclear Cells (PBMCs) PWM	7.9	0.5
93114 Mononuclear Cells (PBMCs) PHA-L	5.1	0.5
93249 Ramos (B cell) none	5.7	0.6
93250 Ramos (B cell) ionomycin	4.4	0.3
93349 B lymphocytes PWM	1.1	0.2
93350 B lymphocytes CD40L and IL-4	4.3	0.6
92665 EOL-1 (Eosinophil) dbcAMP differentiated	8.4	3.5
93248 EOL-1 (Eosinophil) dbcAMP/PMAionomycin	7.2	5.1
93356 Dendritic Cells none	3.4	1.0
93355 Dendritic Cells LPS 100 ng/ml	5.5	0.5
93775 Dendritic Cells anti-CD40	2.6	0.3
93774 Monocytes resting	1.1	0.9
93776 Monocytes LPS 50 ng/ml	2.6	0.3

93581 Macrophages resting	5.2	0.2
93582 Macrophages LPS 100 ng/ml	1.4	0.3
93098 HUVEC (Endothelial) none	1.2	0.2
93099 HUVEC (Endothelial) starved	3.4	0.2
93100 HUVEC (Endothelial) IL-1b	2.4	0.1
93779 HUVEC (Endothelial) IFN gamma	2.6	1.2
93102 HUVEC (Endothelial) TNF alpha + IFN gamma	0.0	0.3
93101 HUVEC (Endothelial) TNF alpha + IL4	1.6	0.4
93781 HUVEC (Endothelial) IL-11	2.2	0.4
93583 Lung Microvascular Endothelial Cells none	1.8	0.9
93584 Lung Microvascular Endothelial Cells TNFa (4 ng/ml) and IL1b (1 ng/ml)	2.2	0.3
92662 Microvascular Dermal endothelium none	1.4	0.5
92663 Microvascular Dermal endothelium TNFa (4 ng/ml) and IL1b (1 ng/ml)	2.2	0.3
93773 Bronchial epithelium TNFa (4 ng/ml) and IL1b (1 ng/ml) **	17.8	0.5
93347 Small Airway Epithelium none	1.5	0.2
93348 Small Airway Epithelium TNFa (4 ng/ml) and IL1b (1 ng/ml)	3.0	0.6
92668 Coronary Artery SMC resting	1.1	0.6
92669 Coronary Artery SMC TNFa (4 ng/ml) and IL1b (1 ng/ml)	1.9	0.8
93107 astrocytes resting	2.5	1.5
93108 astrocytes TNFa (4 ng/ml) and IL1b (1 ng/ml)	0.5	1.2
92666 KU-812 (Basophil) resting	4.3	0.8
92667 KU-812 (Basophil) PMA/ionoycin	3.0	0.6
93579 CCD1106 (Keratinocytes) none	1.6	0.9
93580 CCD1106 (Keratinocytes) TNFa and IFNg **	2.4	0.0
93791 Liver Cirrhosis	76.6	9.8
93577 NCI-H292	5.4	4.1
93358 NCI-H292 IL-4	10.3	0.6
93360 NCI-H292 IL-9	16.5	1.3
93359 NCI-H292 IL-13	8.5	3.6
93357 NCI-H292 IFN gamma	5.8	3.4
93777 HPAEC -	1.2	1.0
93778 HPAEC IL-1 beta/TNA alpha	1.5	0.3
93254 Normal Human Lung Fibroblast none	2.5	0.8
93253 Normal Human Lung Fibroblast TNFa (4 ng/ml) and IL-1b (1 ng/ml)	5.7	0.9
93257 Normal Human Lung Fibroblast IL-4	2.9	0.4
93256 Normal Human Lung Fibroblast IL-9	2.5	0.4
93255 Normal Human Lung Fibroblast IL-13	2.7	1.9
93258 Normal Human Lung Fibroblast IFN gamma	0.0	2.2
93106 Dermal Fibroblasts CCD1070 resting	6.1	3.4
93361 Dermal Fibroblasts CCD1070 TNF alpha 4 ng/ml	2.1	3.8
93105 Dermal Fibroblasts CCD1070 IL-1 beta 1 ng/ml	4.0	1.5
93772 dermal fibroblast IFN gamma	1.6	0.9
93771 dermal fibroblast IL-4	1.4	1.3
93892 Dermal fibroblasts none	2.3	1.5

99202 Neutrophils TNFa+LPS	0.0	1.7
99203 Neutrophils none	0.8	0.6
735010 Colon normal	21.7	6.7
735019 Lung none	3.7	10.6
64028-1 Thymus none	11.7	27.0
64030-1 Kidney none	100.0	100.0

Table 73. Panel CNS\_Neurodegeneration\_v1.0

Tissue Name	Relative Expression(%) tm7142f_ ag3797 b2	Tissue Name	Relative Expression(%) tm7142f_ ag3797 b2
AD 1 Hippo	53.6	Control (Path) 3 Temporal Ctx	12.5
AD 2 Hippo	69.7	Control (Path) 4 Temporal Ctx	62.2
AD 3 Hippo	25.6	AD 1 Occipital Ctx	48.0
AD 4 Hippo	33.9	AD 2 Occipital Ctx (Missing)	0.0
AD 5 Hippo	91.6	AD 3 Occipital Ctx	13.0
AD 6 Hippo	39.7	AD 4 Occipital Ctx	40.7
Control 2 Hippo	38.4	AD 5 Occipital Ctx	51.9
Control 4 Hippo	59.4	AD 6 Occipital Ctx	28.4
Control (Path) 3 Hippo	7.8	Control 1 Occipital Ctx	2.6
AD 1 Temporal Ctx	41.0	Control 2 Occipital Ctx	100.0
AD 2 Temporal Ctx	70.4	Control 3 Occipital Ctx	33.1
AD 3 Temporal Ctx	21.3	Control 4 Occipital Ctx	18.6
AD 4 Temporal Ctx	46.7	Control (Path) 1 Occipital Ctx	82.7
AD 5 Inf Temporal Ctx	92.1	Control (Path) 2 Occipital Ctx	18.7
AD 5 Sup Temporal Ctx	74.8	Control (Path) 3 Occipital Ctx	3.4
AD 6 Inf Temporal Ctx	44.5	Control (Path) 4 Occipital Ctx	49.0
AD 6 Sup Temporal Ctx	57.9	Control 1 Parietal	19.8
Control 1 Temporal Ctx	22.8	Control 2 Parietal	60.6
Control 2 Temporal Ctx	45.7	Control 3 Parietal	31.0
Control 3 Temporal Ctx	13.8	Control (Path) 1 Parietal	57.3
Control 3 Temporal Ctx	51.4	Control (Path) 2 Parietal	31.0
Control (Path) 1 Temporal Ctx	62.8	Control (Path) 3 Parietal	5.7
Control (Path) 2 Temporal Ctx	41.4	Control (Path) 4 Parietal	52.1

5 **Panel 1.3D Summary Ag3086** The NOV11a gene is highly expressed in both fetal and adult liver tissue (CTs = 26) and liver cancer cell lines (CT = 27). The gene is also expressed at moderate to low levels in most of the other tissues in the panel. Thus, since the NOV11a gene appears to be highly expressed in liver tissue, it could therefore be used to distinguish liver derived tissue from other tissues. The NOV11a gene product may also be a potential therapeutic treatment of disease in any of these tissues.

In tissues involved in the central nervous system, the NOV11a gene is moderately expressed in the fetal and adult brain, including the adult thalamus, substantia nigra, hippocampus, amygdala and is also expressed at low but significant levels in the cerebellum and cerebral cortex. This expression profile suggests that the NOV11a gene has functional significance in the CNS. The close homologue to the NOV11a gene product, hepatocyte growth factor, has numerous therapeutic applications in the CNS, including prevention of neuronal death in animal models of stroke and ischemia. Hepatocyte growth factor has mitogenic activity, crossing the blood brain barrier when disrupted, and thus has potential application as a protein therapeutic to treat brain pathologies when administered directly to the cortico spinal fluid or systemically when the blood brain barrier is disrupted. Hepatocyte growth factor-like protein is a neurotrophic factor useful in the prevention of motoneuron atrophy upon axotomy. Therefore, the protein encoded by the NOV11a gene may be useful as a therapeutic agent in treating stroke and neurodegenerative diseases including Alzheimer's disease, Parkinson's disease, and Huntington's disease. The potential role of the NOV11a gene or its protein product in brain plasticity and regeneration affords utility in treating brain damage and aging related disorders, such as memory impairment that has hippocampal dysfunction as its primary focus.

**General\_Screening\_Panel\_1.4 Ag3797** The expression of the NOV11a gene in panel 1.4 appears to be highest in a sample derived from a liver cancer cell line (HepG2) (CT = 25.3). In addition there is substantial expression of this gene associated with other liver derived material (adult liver CT=27.2; fetal liver CT=26.5). Thus, the expression of the NOV11a gene could be used to distinguish liver derived specimens from other samples. In addition, therapeutic modulation of this gene might be of benefit in the treatment of liver related disorders.

**Panel 2.2 Summary Ag3086** The expression of the NOV11a gene appears to be highest in a sample derived from a liver cancer specimen (CT=26) and is also significant in a number of samples derived from liver tissue. This result is consistent with what is seen in Panels 1.4 and 2D. In addition there appears to be substantial expression of this gene associated with normal kidney tissue (CT=27.2) when compared to adjacent kidney cancer specimens. Thus, this gene could be used to distinguish liver tissue from non-liver tissue as well as distinguish normal kidney tissue when compared to adjacent kidney cancer. Moreover, therapeutic modulation of the expression of the NOV11a gene or function of its product might be of benefit in the treatment of kidney cancer.

**Panel 4D Summary Ag3086** The NOV11a gene is highly expressed in the thymus (CT = 24), colon (CT = 28.4), and IBD Colitis 2 (CT = 27.2) and is expressed at lower levels in mature T cells. The NOV11a gene encodes a putative hepatocyte like growth factor homologue. There are reports that hepatocyte growth factor (HGF) is expressed in the thymus and colon. In the thymus, HGF may promote T cell production and in the colon, overexpression of HGF has been shown to leads to IBD like disease in mice. Therapies designed with the protein encoded for by the NOV11a gene could be important in the regulation of T cell development and immune function and be useful in organ transplantation. In addition, blocking the function of the NOV11a gene product could help in the treatment of IBD colitis.

**Panel 4.1D Summary Ag3797** Results from two experiments using the same probe and primer set are in very good agreement. In both experiments, highest expression of the NOV11a gene is detected in kidney (CT=29, 27.4). Moderate expression is also detected in liver cirrhosis (CT=29.4, 30.7). Moderate to low expression of the gene is detected in many of the tissues in this panel. Thus, expression of the NOV11a gene could be used to distinguish those tissues from other tissues.

**Panel CNS\_Neurodegeneration\_v1.0 Summary Ag3797** Highest expression of the NOV11a gene is detected in the occipital cortex of a control patient (CT=31.3). Moderate to low expression is detected throughout the tissue samples in this panel. Please see panel 1.3 for a discussion of potential utility of this gene with regards to the CNS. (Korhonen et al., Eur J Neurosci. 12:3453-61, 2000; Powell et al., Neuron 30:79-89, 2001; Stella et al., Mol Biol Cell 12:1341-52, 2001; Kern et al., Cytokine 14:170-6, 2001; Hayashi et al., Gene Ther 8:1167-73, 2001; Tamura et al., Scand J Immunol. 47:296-301, 1998; Takayama et al., Lab Invest. 81:297-305, 2001.)

**NOV12: 26S protease regulatory subunit-like**

Expression of the NOV12 gene (GMAC023940\_A) was assessed using the primer-probe set Ag1505 described in Table 74. Results from RTQ-PCR runs are shown in Tables 75, 76, 77, and 78.

**Table 74. Probe Name Ag1505**

Primers	Sequences	TM	Length	Start Position	SEQ ID NO:
Forward	5'-GAAGAAGCCCATCTTTCAGATT-3'	58.8	22	1140	194
Probe	TET-5'-TGATGTAACCCTGCACGACTTGATCA-3'-TAMRA	68.7	26	1188	195
Reverse	5'-AGCACCAGAGAGGTCATCTTTA-3'	58.1	22	1218	196



Table 75. Panel 1.2

Tissue Name	Relative Expression(%)	Tissue Name	Relative Expression(%)
	1.2tm2128t_ag1505		1.2tm2128t_ag1505
Endothelial cells	0.5	Renal ca. 786-0	0.0
Heart (fetal)	0.3	Renal ca. A498	0.0
Pancreas	0.0	Renal ca. RXF 393	0.0
Pancreatic ca. CAPAN 2	0.0	Renal ca. ACHN	0.0
Adrenal Gland (new lot*)	0.0	Renal ca. UO-31	0.0
Thyroid	0.0	Renal ca. TK-10	0.0
Salivary gland	26.6	Liver	24.1
Pituitary gland	0.0	Liver (fetal)	19.6
Brain (fetal)	3.4	Liver ca. (hepatoblast) HepG2	0.0
Brain (whole)	0.0	Lung	0.0
Brain (amygdala)	2.6	Lung (fetal)	0.0
Brain (cerebellum)	2.8	Lung ca. (small cell) LX-1	0.0
Brain (hippocampus)	13.2	Lung ca. (small cell) NCI-H69	0.4
Brain (thalamus)	0.2	Lung ca. (s.cell var.) SHP-77	0.0
Cerebral Cortex	0.6	Lung ca. (large cell) NCI-H460	0.0
Spinal cord	0.0	Lung ca. (non-sm. cell) A549	1.1
CNS ca. (glio/astro) U87-MG	0.0	Lung ca. (non-s.cell) NCI-H23	0.0
CNS ca. (glio/astro) U-118-MG	0.3	Lung ca (non-s.cell) HOP-62	0.0
CNS ca. (astro) SW1783	0.0	Lung ca. (non-s.cl) NCI-H522	0.0
CNS ca.* (neuro; met) SK-N-AS	5.8	Lung ca. (squam.) SW 900	0.0
CNS ca. (astro) SF-539	0.0	Lung ca. (squam.) NCI-H596	0.0
CNS ca. (astro) SNB-75	0.0	Mammary gland	21.0
CNS ca. (glio) SNB-19	0.6	Breast ca.* (pl. effusion) MCF-7	0.0
CNS ca. (glio) U251	14.1	Breast ca.* (pl.ef) MDA-MB-231	1.8
CNS ca. (glio) SF-295	0.0	Breast ca.* (pl. effusion) T47D	0.2
Heart	0.2	Breast ca. BT-549	0.0
Skeletal Muscle (new lot*)	0.2	Breast ca. MDA-N	0.0
Bone marrow	0.5	Ovary	0.0
Thymus	0.0	Ovarian ca. OVCAR-3	0.0
Spleen	0.0	Ovarian ca. OVCAR-4	0.0
Lymph node	0.0	Ovarian ca. OVCAR-5	0.0
Colorectal	2.0	Ovarian ca. OVCAR-8	0.0
Stomach	11.7	Ovarian ca. IGROV-1	0.0
Small intestine	0.3	Ovarian ca.* (ascites) SK-OV-3	0.0
Colon ca. SW480	0.0	Uterus	0.0
Colon ca.* (SW480 met)SW620	0.0	Placenta	0.0
Colon ca. HT29	0.0	Prostate	0.0
Colon ca. HCT-116	0.0	Prostate ca.* (bone met)PC-3	0.0
Colon ca. CaCo-2	0.0	Testis	0.5
83219 CC Well to Mod Diff (ODO3866)	1.5	Melanoma Hs688(A).T	0.0

Colon ca. HCC-2998	0.0	Melanoma* (met) Hs688(B).T	0.2
Gastric ca.* (liver met) NCI-N87	100.0	Melanoma UACC-62	0.0
Bladder	45.4	Melanoma M14	5.1
Trachea	0.0	Melanoma LOX IMVI	0.8
Kidney	73.7	Melanoma* (met) SK-MEL-5	0.0
Kidney (fetal)	8.4		

Table 76. Panel 1.3D

Tissue Name	Relative Expression(%)	Tissue Name	Relative Expression(%)
	1.3dx4tm5367t_ag1505_b2		1.3dx4tm5367t_ag1505_b2
Liver adenocarcinoma	0.0	Kidney (fetal)	10.1
Pancreas	0.0	Renal ca. 786-0	0.0
Pancreatic ca. CAPAN 2	0.0	Renal ca. A498	0.0
Adrenal gland	6.0	Renal ca. RXF 393	0.0
Thyroid	0.0	Renal ca. ACHN	0.0
Salivary gland	0.0	Renal ca. UO-31	0.0
Pituitary gland	0.0	Renal ca. TK-10	0.0
Brain (fetal)	0.0	Liver	18.3
Brain (whole)	0.0	Liver (fetal)	4.2
Brain (amygdala)	0.0	Liver ca. (hepatoblast) HepG2	0.0
Brain (cerebellum)	0.0	Lung	0.0
Brain (hippocampus)	0.0	Lung (fetal)	0.0
Brain (substantia nigra)	0.0	Lung ca. (small cell) LX-1	0.0
Brain (thalamus)	0.0	Lung ca. (small cell) NCI-H69	0.0
Cerebral Cortex	0.0	Lung ca. (s.cell var.) SHP-77	0.0
Spinal cord	0.0	Lung ca. (large cell) NCI-H460	0.0
CNS ca. (glio/astro) U87-MG	0.0	Lung ca. (non-sm. cell) A549	12.0
CNS ca. (glio/astro) U-118-MG	0.0	Lung ca. (non-s.cell) NCI-H23	0.0
CNS ca. (astro) SW1783	0.0	Lung ca. (non-s.cell) HOP-62	0.0
CNS ca.* (neuro; met) SK-N-AS	5.4	Lung ca. (non-s.cl) NCI-H522	0.0
CNS ca. (astro) SF-539	0.0	Lung ca. (squam.) SW 900	0.0
CNS ca. (astro) SNB-75	0.0	Lung ca. (squam.) NCI-H596	0.0
CNS ca. (glio) SNB-19	0.0	Mammary gland	7.4
CNS ca. (glio) U251	100.0	Breast ca.* (pl. effusion) MCF-7	0.0
CNS ca. (glio) SF-295	0.0	Breast ca.* (pl.ef) MDA-MB-231	0.0
Heart (fetal)	0.0	Breast ca.* (pl. effusion) T47D	0.0
Heart	0.0	Breast ca. BT-549	0.0
Fetal Skeletal	13.0	Breast ca. MDA-N	0.0
Skeletal muscle	0.0	Ovary	0.0
Bone marrow	0.0	Ovarian ca. OVCAR-3	0.0
Thymus	0.0	Ovarian ca. OVCAR-4	0.0
Spleen	0.0	Ovarian ca. OVCAR-5	0.0
Lymph node	0.0	Ovarian ca. OVCAR-8	0.0

Colorectal	0.0	Ovarian ca. IGROV-1	0.0
Stomach	19.8	Ovarian ca.* (ascites) SK-OV-3	0.0
Small intestine	2.2	Uterus	0.0
Colon ca. SW480	0.0	Placenta	0.0
Colon ca.* (SW480 met)SW620	0.0	Prostate	0.0
Colon ca. HT29	0.0	Prostate ca.* (bone met)PC-3	0.0
Colon ca. HCT-116	0.0	Testis	5.7
Colon ca. CaCo-2	0.0	Melanoma Hs688(A).T	0.0
83219 CC Well to Mod Diff (ODO3866)	0.0	Melanoma* (met) Hs688(B).T	0.0
Colon ca. HCC-2998	0.0	Melanoma UACC-62	0.0
Gastric ca.* (liver met) NCI-N87	21.4	Melanoma M14	0.0
Bladder	0.0	Melanoma LOX IMVI	3.6
Trachea	0.0	Melanoma* (met) SK-MEL-5	0.0
Kidney	0.0	Adipose	2.8

Table 77. Panel 2.2

Tissue Name	Relative Expression(%)	Tissue Name	Relative Expression(%)
	2.2x4tm6351t_a g1505_a2		2.2x4tm6351t ag1505_a2
Normal Colon GENPAK 061003	0.0	83793 Kidney NAT (OD04348)	12.9
97759 Colon cancer (OD06064)	0.0	98938 Kidney malignant cancer (OD06204B)	4.1
97760 Colon cancer NAT (OD06064)	0.0	98939 Kidney normal adjacent tissue (OD06204E)	7.6
97778 Colon cancer (OD06159)	0.0	85973 Kidney Cancer (OD04450- 01)	0.0
97779 Colon cancer NAT (OD06159)	1.7	85974 Kidney NAT (OD04450-03)	2.5
98861 Colon cancer (OD06297-04)	0.0	Kidney Cancer Clontech 8120613	0.0
98862 Colon cancer NAT (OD06297-015)	0.0	Kidney NAT Clontech 8120614	11.9
83237 CC Gr.2 ascend colon (ODO3921)	0.0	Kidney Cancer Clontech 9010320	0.0
83238 CC NAT (ODO3921)	0.0	Kidney NAT Clontech 9010321	0.0
97766 Colon cancer metastasis (OD06104)	0.0	Kidney Cancer Clontech 8120607	0.0
97767 Lung NAT (OD06104)	0.0	Kidney NAT Clontech 8120608	0.0
87472 Colon mets to lung (OD04451-01)	0.0	Normal Uterus GENPAK 061018	0.0
87473 Lung NAT (OD04451-02)	0.0	Uterus Cancer GENPAK 064011	0.0
Normal Prostate Clontech A+ 6546-1 (8090438)	0.0	Normal Thyroid Clontech A+ 6570-1 (7080817)	0.0
84140 Prostate Cancer (OD04410)	0.0	Thyroid Cancer GENPAK 064010	0.0
84141 Prostate NAT (OD04410)	0.0	Thyroid Cancer INVITROGEN A302152	0.0
Normal Ovary Res. Gen.	2.2	Thyroid NAT INVITROGEN A302153	0.0
98863 Ovarian cancer (OD06283- 03)	0.0	Normal Breast GENPAK 061019	100.0

98865 Ovarian cancer NAT/fallopian tube (OD06283-07)	0.0	84877 Breast Cancer (OD04566)	0.0
Ovarian Cancer GENPAK 064008	0.0	Breast Cancer Res. Gen. 1024	4.9
97773 Ovarian cancer (OD06145)	3.5	85975 Breast Cancer (OD04590-01)	0.0
97775 Ovarian cancer NAT (OD06145)	0.0	85976 Breast Cancer Mets (OD04590-03)	0.0
98853 Ovarian cancer (OD06455-03)	0.0	87070 Breast Cancer Metastasis (OD04655-05)	0.0
98854 Ovarian NAT (OD06455-07) Fallopian tube	0.0	GENPAK Breast Cancer 064006	0.0
Normal Lung GENPAK 061010	0.0	Breast Cancer Clontech 9100266	0.0
92337 Invasive poor diff. lung adeno (ODO4945-01)	0.0	Breast NAT Clontech 9100265	0.0
92338 Lung NAT (ODO4945-03)	4.0	Breast Cancer INVITROGEN A209073	5.9
84136 Lung Malignant Cancer (OD03126)	0.0	Breast NAT INVITROGEN A2090734	48.3
84137 Lung NAT (OD03126)	0.0	97763 Breast cancer (OD06083)	14.2
90372 Lung Cancer (OD05014A)	2.7	97764 Breast cancer node metastasis (OD06083)	0.0
90373 Lung NAT (OD05014B)	0.0	Normal Liver GENPAK 061009	47.4
97761 Lung cancer (OD06081)	0.0	Liver Cancer Research Genetics RNA 1026	0.0
97762 Lung cancer NAT (OD06081)	0.0	Liver Cancer Research Genetics RNA 1025	0.0
85950 Lung Cancer (OD04237-01)	0.0	Paired Liver Cancer Tissue Research Genetics RNA 6004-T	0.0
85970 Lung NAT (OD04237-02)	0.0	Paired Liver Tissue Research Genetics RNA 6004-N	5.5
83255 Ocular Mel Met to Liver (ODO4310)	0.0	Paired Liver Cancer Tissue Research Genetics RNA 6005-T	0.0
83256 Liver NAT (ODO4310)	4.5	Paired Liver Tissue Research Genetics RNA 6005-N	0.0
84139 Melanoma Mets to Lung (OD04321)	0.0	Liver Cancer GENPAK 064003	1.5
84138 Lung NAT (OD04321)	0.0	Normal Bladder GENPAK 061001	0.0
Normal Kidney GENPAK 061008	2.7	Bladder Cancer Research Genetics RNA 1023	0.0
83786 Kidney Ca, Nuclear grade 2 (OD04338)	27.4	Bladder Cancer INVITROGEN A302173	0.0
83787 Kidney NAT (OD04338)	0.0	Normal Stomach GENPAK 061017	67.3
83788 Kidney Ca Nuclear grade 1/2 (OD04339)	0.0	Gastric Cancer Clontech 9060397	0.0
83789 Kidney NAT (OD04339)	3.5	NAT Stomach Clontech 9060396	4.1
83790 Kidney Ca, Clear cell type (OD04340)	0.0	Gastric Cancer Clontech 9060395	0.0
83791 Kidney NAT (OD04340)	14.8	NAT Stomach Clontech 9060394	7.7
83792 Kidney Ca, Nuclear grade 3 (OD04348)	0.0	Gastric Cancer GENPAK 064005	0.0

Table 78. Panel 3D

Tissue Name	Relative Expression(%)	Tissue Name	Relative Expression(%)
	3dtm4935t_ag1 505		3dtm4935t_ag 1505
94905_Daoy_Medulloblastoma/Cerebellum sscDNA	0.9	94954_Ca Ski_Cervical epidermoid carcinoma (metastasis) sscDNA	0.0
94906_TE671_Medulloblastom/Cerebellum sscDNA	0.5	94955_ES-2_Ovarian clear cell carcinoma sscDNA	0.7
94907_D283_Med_Medulloblastoma/Cerebellum sscDNA	9.3	94957_Ramos/6h stim_Stimulated with PMA/ionomycin 6h sscDNA	0.0
94908_PFSK-1_Primitive Neuroectodermal/Cerebellum sscDNA	3.3	94958_Ramos/14h stim_Stimulated with PMA/ionomycin 14h sscDNA	0.0
94909_XF-498_CNS sscDNA	0.8	94962_MEG-01_Chronic myelogenous leukemia (megakaryoblast) sscDNA	0.0
94910_SNB-78_CNS/glioma sscDNA	1.4	94963_Raji_Burkitt's lymphoma sscDNA	0.0
94911_SF-268_CNS/glioblastoma sscDNA	3.2	94964_Daudi_Burkitt's lymphoma sscDNA	0.0
94912_T98G_Glioblastoma sscDNA	0.7	94965_U266_B-cell plasmacytoma/myeloma sscDNA	0.0
96776_SK-N-SH_Neuroblastoma (metastasis) sscDNA	0.7	94968_CA46_Burkitt's lymphoma sscDNA	0.0
94913_SF-295_CNS/glioblastoma sscDNA	0.0	94970_RL_non-Hodgkin's B-cell lymphoma sscDNA	0.0
94914_Cerebellum sscDNA	0.0	94972_JM1_pre-B-cell lymphoma/leukemia sscDNA	0.0
96777_Cerebellum sscDNA	0.0	94973_Jurkat_T cell leukemia sscDNA	0.0
94916_NCI-H292_Mucoepidermoid lung carcinoma sscDNA	0.3	94974_TF-1 Erythroleukemia sscDNA	0.0
94917_DMS-114_Small cell lung cancer sscDNA	0.0	94975_HUT 78_T-cell lymphoma sscDNA	0.0
94918_DMS-79_Small cell lung cancer/neuroendocrine sscDNA	100.0	94977_U937_Histiocytic lymphoma sscDNA	0.0
94919_NCI-H146_Small cell lung cancer/neuroendocrine sscDNA	1.9	94980_KU-812_Myelogenous leukemia sscDNA	0.0
94920_NCI-H526_Small cell lung cancer/neuroendocrine sscDNA	0.1	94981_769-P_Clear cell renal carcinoma sscDNA	0.0
94921_NCI-N417_Small cell lung cancer/neuroendocrine sscDNA	1.5	94983_Caki-2_Clear cell renal carcinoma sscDNA	0.0
94923_NCI-H82_Small cell lung cancer/neuroendocrine sscDNA	0.0	94984_SW 839_Clear cell renal carcinoma sscDNA	0.0
94924_NCI-H157_Squamous cell lung cancer (metastasis) sscDNA	0.0	94986_G401_Wilms' tumor sscDNA	0.0
94925_NCI-H1155_Large cell lung cancer/neuroendocrine sscDNA	0.0	94987_Hs766T_Pancreatic carcinoma (LN metastasis) sscDNA	1.4
94926_NCI-H1299_Large cell lung cancer/neuroendocrine sscDNA	0.0	94988_CAPAN-1_Pancreatic adenocarcinoma (liver metastasis) sscDNA	0.0
94927_NCI-H727_Lung carcinoid sscDNA	0.0	94989_SU86.86_Pancreatic carcinoma (liver metastasis) sscDNA	0.7

94928_NCI-UMC-11_Lung carcinoid sscDNA	16.3	94990_BxPC-3_Pancreatic adenocarcinoma sscDNA	0.5
94929_LX-1_Small cell lung cancer sscDNA	0.4	94991_HPAC_Pancreatic adenocarcinoma sscDNA	2.2
94930_Colo-205_Colon cancer sscDNA	0.0	94992_MIA PaCa-2_Pancreatic carcinoma sscDNA	0.0
94931_KM12_Colon cancer sscDNA	0.0	94993_CFPAC-1_Pancreatic ductal adenocarcinoma sscDNA	0.0
94932_KM20L2_Colon cancer sscDNA	0.0	94994_PANC-1_Pancreatic epithelioid ductal carcinoma sscDNA	0.0
94933_NCI-H716_Colon cancer sscDNA	0.0	94996_T24_Bladder carcinoma (transitional cell) sscDNA	0.0
94935_SW-48_Colon adenocarcinoma sscDNA	0.0	94997_5637_Bladder carcinoma sscDNA	0.0
94936_SW1116_Colon adenocarcinoma sscDNA	0.0	94998_HT-1197_Bladder carcinoma sscDNA	1.7
94937_LS 174T_Colon adenocarcinoma sscDNA	0.0	94999_UM-UC-3_Bladder carcinoma (transitional cell) sscDNA	0.2
94938_SW-948_Colon adenocarcinoma sscDNA	0.0	95000_A204_Rhabdomyosarcoma sscDNA	0.1
94939_SW-480_Colon adenocarcinoma sscDNA	0.0	95001_HT-1080_Fibrosarcoma sscDNA	0.1
94940_NCI-SNU-5_Gastric carcinoma sscDNA	0.0	95002_MG-63_Osteosarcoma (bone) sscDNA	0.0
94941_KATO III_Gastric carcinoma sscDNA	0.0	95003_SK-LMS-1 Leiomyosarcoma (vulva) sscDNA	8.8
94943_NCI-SNU-16_Gastric carcinoma sscDNA	5.8	95004_SJRH30_Rhabdomyosarcoma (met to bone marrow) sscDNA	0.0
94944_NCI-SNU-1_Gastric carcinoma sscDNA	0.0	95005_A431_Epidermoid carcinoma sscDNA	0.0
94946_RF-1_Gastric adenocarcinoma sscDNA	0.0	95007_WM266-4_Melanoma sscDNA	0.0
94947_RF-48_Gastric adenocarcinoma sscDNA	0.0	95010_DU 145_Prostate carcinoma (brain metastasis) sscDNA	0.0
96778_MKN-45_Gastric carcinoma sscDNA	0.0	95012_MDA-MB-468_Breast adenocarcinoma sscDNA	0.0
94949_NCI-N87_Gastric carcinoma sscDNA	1.0	95013_SCC-4_Squamous cell carcinoma of tongue sscDNA	0.0
94951_OVCAR-5_Ovarian carcinoma sscDNA	0.0	95014_SCC-9_Squamous cell carcinoma of tongue sscDNA	0.0
94952_RL95-2_Uterine carcinoma sscDNA	0.0	95015_SCC-15_Squamous cell carcinoma of tongue sscDNA	0.1
94953_HelaS3_Cervical adenocarcinoma sscDNA	0.0	95017_CAL 27_Squamous cell carcinoma of tongue sscDNA	10.7

**Panel 1.2 Summary Ag1505** The expression of this gene in panel 1.2 appears to be highest in a sample derived from a gastric cancer cell line (NCI-N87) (CT = 30.4).

Interestingly, this gene is more highly expressed in adult kidney tissue (CT = 30.6) than in fetal kidney. Expression of the NOV12 gene is also detected in the hippocampus (CT = 33.3) and in two CNS cancer cell lines (CTs = 33.2, 34.5). Thus, the expression of the NOV12 gene could

be used to distinguish gastric cancer from other tissues or to distinguish adult kidney tissue from fetal kidney tissue. Moreover, therapeutic modulation of the expression or activity of the NOV12 gene product, through the use of small molecule drugs or antibodies, might be of benefit in the treatment of gastric cancer.

5        Among tissues involved in metabolic processes, the NOV12 gene is expressed at significant levels in both adult and fetal liver (adult CT = 32.5, fetal CT = 32.8) and may play a role as a small molecule target in the treatment of any or all diseases of the liver.

For tissues involved in the central nervous system, the NOV12 gene is homologous to human S4 protein, a proteasome complex subunit, which interacts with hepatitis B virus (HBV) X-protein (HBX). A peptide derived from the S4 protein may be used to  
10        interfere with HBV infection, and is thus useful in therapy of hepatitis B. Such peptides are also useful as antigens to generate polyclonal or monoclonal antibodies for diagnostic applications. DNA probes and primers derived from the NOV12 gene may also be used to detect HBV infection. The proteasome mediates the degradation of ubiquitinated intracellular  
15        proteins. Numerous neurodegenerative diseases have been associated with improper ubiquitination and targeting of proteins to the proteasome. For example, alpha synuclein, which mediates Parkinson's disease, associates with a subunit of the regulatory complex of the proteasome, suggesting that the mutated alpha synuclein changes proteasomal activity and results in the disease. Parkin has ubiquitin ligase activity disrupted by mutations that induce  
20        early onset Parkinson's disease. Alzheimer's disease is also associated with improper ubiquitination and subsequent degradation of proteins by the proteasome. Phosphorylation of the S4 protein in response to gamma interferon decreases the level of the protein and thus regulates its function. Thus, agents that affect the phosphorylation and level of the NOV12 gene product may be useful in influencing proteasome activity and consequently aberrant  
25        neurodegenerative protein degradation involved in Parkinson's disease, Alzheimer's disease, and other neurodegenerative disorders. Such agents would be useful in treatment of these diseases.

**Panel 1.3D Summary Ag1505** Low levels of NOV12 gene expression are detected in a CNS cancer cell line (CT=34).

30        **Panel 2.2 Summary Ag1505** Expression of the NOV12 gene in this panel is detected only in normal tissues. In all three tissue types where the gene is detected, the NOV12 gene is overexpressed in normal tissue when compared to corresponding cancerous tissue. The NOV12 gene is expressed in normal breast (CT = 33.4), normal liver (CT = 34.5) and stomach

(CT = 34), and undetected in the corresponding cancerous tissues. Thus, the expression of this gene could be used to distinguish normal breast, stomach and liver tissues from other tissues.

**Panel 3D Summary Ag1505** High expression of the NOV12 gene is detected in a small cell lung cancer line (CT = 28.6). Moderate levels of expression are detected in carcinoma of the tongue (CT = 31.9) and low levels of gene expression are detected in bladder, gastric, pancreatic cancers and leiomyosarcoma. Thus, the expression of the NOV12 gene could be used to distinguish these tissues from other samples. In addition, therapeutic modulation of the expression or activity of the NOV12 gene or its protein product, through the use of small molecule drugs or antibodies, might be of benefit in the treatment of small cell lung cancer. (Layfield et al., Neuropathol Appl Neurobiol. 27:171-9, 2001; Ghee et al., J Neurochem. 75: 2221-4, 2000; Rivett et al., Biochimie 83:363-6, 2001.)



### OTHER EMBODIMENTS

Although particular embodiments have been disclosed herein in detail, this has been done by way of example for purposes of illustration only, and is not intended to be limiting with respect to the scope of the appended claims, which follow. In particular, it is contemplated by the inventors that various substitutions, alterations, and modifications may be made to the invention without departing from the spirit and scope of the invention as defined by the claims. The choice of nucleic acid starting material, clone of interest, or library type is believed to be a matter of routine for a person of ordinary skill in the art with knowledge of the embodiments described herein. Other aspects, advantages, and modifications considered to be within the scope of the following claims.

**WHAT IS CLAIMED IS:**

1. An isolated polypeptide comprising an amino acid sequence selected from the group consisting of:
  - (a) a mature form of an amino acid sequence selected from the group consisting of SEQ ID NOS:2, 4, 6, 8, 10, 12, 14, 16, 18, 20, 22, 24, 26, 28, 30, 32, 34, 36, 38, 40, 42, 44, 46, 48, 50, 52, 54, 56, 58, 60, 62 and/or 64;
  - (b) a variant of a mature form of an amino acid sequence selected from the group consisting of SEQ ID NOS:2, 4, 6, 8, 10, 12, 14, 16, 18, 20, 22, 24, 26, 28, 30, 32, 34, 36, 38, 40, 42, 44, 46, 48, 50, 52, 54, 56, 58, 60, 62 and/or 64, wherein one or more amino acid residues in said variant differs from the amino acid sequence of said mature form, provided that said variant differs in no more than 15% of the amino acid residues from the amino acid sequence of said mature form;
  - (c) an amino acid sequence selected from the group consisting of SEQ ID NOS:2, 4, 6, 8, 10, 12, 14, 16, 18, 20, 22, 24, 26, 28, 30, 32, 34, 36, 38, 40, 42, 44, 46, 48, 50, 52, 54, 56, 58, 60, 62 and/or 64; and
  - (d) a variant of an amino acid sequence selected from the group consisting of SEQ ID NOS:2, 4, 6, 8, 10, 12, 14, 16, 18, 20, 22, 24, 26, 28, 30, 32, 34, 36, 38, 40, 42, 44, 46, 48, 50, 52, 54, 56, 58, 60, 62 and/or 64 wherein one or more amino acid residues in said variant differs from the amino acid sequence of said mature form, provided that said variant differs in no more than 15% of amino acid residues from said amino acid sequence.
2. The polypeptide of claim 1, wherein said polypeptide comprises the amino acid sequence of a naturally-occurring allelic variant of an amino acid sequence selected from the group consisting of SEQ ID NOS:2, 4, 6, 8, 10, 12, 14, 16, 18, 20, 22, 24, 26, 28, 30, 32, 34, 36, 38, 40, 42, 44, 46, 48, 50, 52, 54, 56, 58, 60, 62 and/or 64.

3. The polypeptide of claim 2, wherein said allelic variant comprises an amino acid sequence that is the translation of a nucleic acid sequence differing by a single nucleotide from a nucleic acid sequence selected from the group consisting of SEQ ID NOS:1, 3, 5, 7, 9, 11, 13, 15, 17, 19, 21, 23, 25, 27, 29, 31, 33, 35, 37, 39, 41, 43, 45, 47, 49, 51, 53, 55, 57, 59, 61 and/or 63.
4. The polypeptide of claim 1, wherein the amino acid sequence of said variant comprises a conservative amino acid substitution.
5. An isolated nucleic acid molecule comprising a nucleic acid sequence encoding a polypeptide comprising an amino acid sequence selected from the group consisting of:
  - (a) a mature form of an amino acid sequence selected from the group consisting of SEQ ID NOS:2, 4, 6, 8, 10, 12, 14, 16, 18, 20, 22, 24, 26, 28, 30, 32, 34, 36, 38, 40, 42, 44, 46, 48, 50, 52, 54, 56, 58, 60, 62 and/or 64;
  - (b) a variant of a mature form of an amino acid sequence selected from the group consisting of SEQ ID NOS:2, 4, 6, 8, 10, 12, 14, 16, 18, 20, 22, 24, 26, 28, 30, 32, 34, 36, 38, 40, 42, 44, 46, 48, 50, 52, 54, 56, 58, 60, 62 and/or 64, wherein one or more amino acid residues in said variant differs from the amino acid sequence of said mature form, provided that said variant differs in no more than 15% of the amino acid residues from the amino acid sequence of said mature form;
  - (c) an amino acid sequence selected from the group consisting of SEQ ID NOS:2, 4, 6, 8, 10, 12, 14, 16, 18, 20, 22, 24, 26, 28, 30, 32, 34, 36, 38, 40, 42, 44, 46, 48, 50, 52, 54, 56, 58, 60, 62 and/or 64;
  - (d) a variant of an amino acid sequence selected from the group consisting of SEQ ID NOS:2, 4, 6, 8, 10, 12, 14, 16, 18, 20, 22, 24, 26, 28, 30, 32, 34, 36, 38, 40, 42, 44, 46, 48, 50, 52, 54, 56, 58, 60, 62 and/or 64, wherein one or more amino acid residues in said variant differs from the amino acid sequence of said mature form, provided that said variant differs in no more than 15% of amino acid residues from said amino acid sequence;

- (e) a nucleic acid fragment encoding at least a portion of a polypeptide comprising an amino acid sequence chosen from the group consisting of SEQ ID NOS:2, 4, 6, 8, 10, 12, 14, 16, 18, 20, 22, 24, 26, 28, 30, 32, 34, 36, 38, 40, 42, 44, 46, 48, 50, 52, 54, 56, 58, 60, 62 and/or 64, or a variant of said polypeptide, wherein one or more amino acid residues in said variant differs from the amino acid sequence of said mature form, provided that said variant differs in no more than 15% of amino acid residues from said amino acid sequence; and
  - (f) a nucleic acid molecule comprising the complement of (a), (b), (c), (d) or (e).
- 6. The nucleic acid molecule of claim 5, wherein the nucleic acid molecule comprises the nucleotide sequence of a naturally-occurring allelic nucleic acid variant.
- 7. The nucleic acid molecule of claim 5, wherein the nucleic acid molecule encodes a polypeptide comprising the amino acid sequence of a naturally-occurring polypeptide variant.
- 8. The nucleic acid molecule of claim 5, wherein the nucleic acid molecule differs by a single nucleotide from a nucleic acid sequence selected from the group consisting of SEQ ID NOS:1, 3, 5, 7, 9, 11, 13, 15, 17, 19, 21, 23, 25, 27, 29, 31, 33, 35, 37, 39, 41, 43, 45, 47, 49, 51, 53, 55, 57, 59, 61 and/or 63.
- 9. The nucleic acid molecule of claim 5, wherein said nucleic acid molecule comprises a nucleotide sequence selected from the group consisting of
  - (a) a nucleotide sequence selected from the group consisting of SEQ ID NOS:1, 3, 5, 7, 9, 11, 13, 15, 17, 19, 21, 23, 25, 27, 29, 31, 33, 35, 37, 39, 41, 43, 45, 47, 49, 51, 53, 55, 57, 59, 61 and/or 63;
  - (b) a nucleotide sequence differing by one or more nucleotides from a nucleotide sequence selected from the group consisting of SEQ ID NOS:1, 3, 5, 7, 9, 11, 13, 15, 17, 19, 21, 23, 25, 27, 29, 31, 33, 35, 37, 39, 41, 43, 45, 47, 49, 51, 53, 55, 57, 59, 61 and/or 63, provided that no more than 20% of the nucleotides differ from said nucleotide sequence;

- (c) a nucleic acid fragment of (a); and
  - (d) a nucleic acid fragment of (b).
10. The nucleic acid molecule of claim 5, wherein said nucleic acid molecule hybridizes under stringent conditions to a nucleotide sequence chosen from the group consisting of SEQ ID NOS:1, 3, 5, 7, 9, 11, 13, 15, 17, 19, 21, 23, 25, 27, 29, 31, 33, 35, 37, 39, 41, 43, 45, 47, 49, 51, 53, 55, 57, 59, 61 and/or 63, or a complement of said nucleotide sequence.
11. The nucleic acid molecule of claim 5, wherein the nucleic acid molecule comprises a nucleotide sequence selected from the group consisting of
- (a) a first nucleotide sequence comprising a coding sequence differing by one or more nucleotide sequences from a coding sequence encoding said amino acid sequence, provided that no more than 20% of the nucleotides in the coding sequence in said first nucleotide sequence differ from said coding sequence;
  - (b) an isolated second polynucleotide that is a complement of the first polynucleotide; and
  - (c) a nucleic acid fragment of (a) or (b).
12. A vector comprising the nucleic acid molecule of claim 11.
13. The vector of claim 12, further comprising a promoter operably-linked to said nucleic acid molecule.
14. A cell comprising the vector of claim 12.
15. An antibody that immunospecifically-binds to the polypeptide of claim 1.
16. The antibody of claim 15, wherein said antibody is a monoclonal antibody.
17. The antibody of claim 15, wherein the antibody is a humanized antibody.
18. A method for determining the presence or amount of the polypeptide of claim 1 in a sample, the method comprising:

- (a) providing the sample;
  - (b) contacting the sample with an antibody that binds immunospecifically to the polypeptide; and
  - (c) determining the presence or amount of antibody bound to said polypeptide,
- thereby determining the presence or amount of polypeptide in said sample.
19. A method for determining the presence or amount of the nucleic acid molecule of claim 5 in a sample, the method comprising:
- (a) providing the sample;
  - (b) contacting the sample with a probe that binds to said nucleic acid molecule; and
  - (c) determining the presence or amount of the probe bound to said nucleic acid molecule,
- thereby determining the presence or amount of the nucleic acid molecule in said sample.
20. A method of identifying an agent that binds to a polypeptide of claim 1, the method comprising:
- (a) contacting said polypeptide with said agent; and
  - (b) determining whether said agent binds to said polypeptide.
21. A method for identifying an agent that modulates the expression or activity of the polypeptide of claim 1, the method comprising:
- (a) providing a cell expressing said polypeptide;
  - (b) contacting the cell with said agent; and
  - (c) determining whether the agent modulates expression or activity of said polypeptide,
- whereby an alteration in expression or activity of said peptide indicates said agent modulates expression or activity of said polypeptide.
22. A method for modulating the activity of the polypeptide of claim 1, the method comprising contacting a cell sample expressing the polypeptide of said claim with a

compound that binds to said polypeptide in an amount sufficient to modulate the activity of the polypeptide.

23. A method of treating or preventing a NOVX-associated disorder, said method comprising administering to a subject in which such treatment or prevention is desired the polypeptide of claim 1 in an amount sufficient to treat or prevent said NOVX-associated disorder in said subject.
24. The method of claim 23, wherein said subject is a human.
25. A method of treating or preventing a NOVX-associated disorder, said method comprising administering to a subject in which such treatment or prevention is desired the nucleic acid of claim 5 in an amount sufficient to treat or prevent said NOVX-associated disorder in said subject.
26. The method of claim 25, wherein said subject is a human.
27. A method of treating or preventing a NOVX-associated disorder, said method comprising administering to a subject in which such treatment or prevention is desired the antibody of claim 15 in an amount sufficient to treat or prevent said NOVX-associated disorder in said subject.
28. The method of claim 27, wherein the subject is a human.
29. A pharmaceutical composition comprising the polypeptide of claim 1 and a pharmaceutically-acceptable carrier.
30. A pharmaceutical composition comprising the nucleic acid molecule of claim 5 and a pharmaceutically-acceptable carrier.
31. A pharmaceutical composition comprising the antibody of claim 15 and a pharmaceutically-acceptable carrier.
32. A kit comprising in one or more containers, the pharmaceutical composition of claim 29.

33. A kit comprising in one or more containers, the pharmaceutical composition of claim 30.
34. A kit comprising in one or more containers, the pharmaceutical composition of claim 31.
35. The use of a therapeutic in the manufacture of a medicament for treating a syndrome associated with a human disease, the disease selected from a NOVX-associated disorder, wherein said therapeutic is selected from the group consisting of a NOVX polypeptide, a NOVX nucleic acid, and a NOVX antibody.
36. A method for screening for a modulator of activity or of latency or predisposition to a NOVX-associated disorder, said method comprising:
  - (a) administering a test compound to a test animal at increased risk for a NOVX-associated disorder, wherein said test animal recombinantly expresses the polypeptide of claim 1;
  - (b) measuring the activity of said polypeptide in said test animal after administering the compound of step (a);
  - (c) comparing the activity of said protein in said test animal with the activity of said polypeptide in a control animal not administered said polypeptide, wherein a change in the activity of said polypeptide in said test animal relative to said control animal indicates the test compound is a modulator of latency or predisposition to a NOVX-associated disorder.
37. The method of claim 36, wherein said test animal is a recombinant test animal that expresses a test protein transgene or expresses said transgene under the control of a promoter at an increased level relative to a wild-type test animal, and wherein said promoter is not the native gene promoter of said transgene.



38. A method for determining the presence of or predisposition to a disease associated with altered levels of the polypeptide of claim 1 in a first mammalian subject, the method comprising:
- (a) measuring the level of expression of the polypeptide in a sample from the first mammalian subject; and
  - (b) comparing the amount of said polypeptide in the sample of step (a) to the amount of the polypeptide present in a control sample from a second mammalian subject known not to have, or not to be predisposed to, said disease,
- wherein an alteration in the expression level of the polypeptide in the first subject as compared to the control sample indicates the presence of or predisposition to said disease.
39. A method for determining the presence of or predisposition to a disease associated with altered levels of the nucleic acid molecule of claim 5 in a first mammalian subject, the method comprising:
- (a) measuring the amount of the nucleic acid in a sample from the first mammalian subject; and
  - (b) comparing the amount of said nucleic acid in the sample of step (a) to the amount of the nucleic acid present in a control sample from a second mammalian subject known not to have or not be predisposed to, the disease;
- wherein an alteration in the level of the nucleic acid in the first subject as compared to the control sample indicates the presence of or predisposition to the disease.
40. A method of treating a pathological state in a mammal, the method comprising administering to the mammal a polypeptide in an amount that is sufficient to alleviate the pathological state, wherein the polypeptide is a polypeptide having an amino acid sequence at least 95% identical to a polypeptide comprising an amino acid sequence of at least one of SEQ ID NOS:2, 4, 6, 8, 10, 12, 14, 16, 18, 20, 22, 24, 26, 28, 30, 32, 34, 36, 38, 40, 42, 44, 46, 48, 50, 52, 54, 56, 58, 60, 62 and/or 64, or a biologically active fragment thereof.

41. A method of treating a pathological state in a mammal, the method comprising administering to the mammal the antibody of claim 15 in an amount sufficient to alleviate the pathological state.

(19) World Intellectual Property Organization  
International Bureau(43) International Publication Date  
11 April 2002 (11.04.2002)

PCT

(10) International Publication Number  
WO 02/029058 A3

- (51) International Patent Classification<sup>7</sup>: C12N 15/12,  
C07K 14/47, 14/475, 14/705, C12N 15/63, 1/21, 5/10,  
C12Q 1/68, G01N 33/68
- (21) International Application Number: PCT/US01/31248
- (22) International Filing Date: 5 October 2001 (05.10.2001)
- (25) Filing Language: English
- (26) Publication Language: English
- (30) Priority Data:
- |            |                             |    |
|------------|-----------------------------|----|
| 60/238,323 | 5 October 2000 (05.10.2000) | US |
| 60/238,325 | 5 October 2000 (05.10.2000) | US |
| 60/238,372 | 6 October 2000 (06.10.2000) | US |
| 60/238,373 | 6 October 2000 (06.10.2000) | US |
| 60/238,379 | 6 October 2000 (06.10.2000) | US |
| 60/238,382 | 6 October 2000 (06.10.2000) | US |
| 60/238,383 | 6 October 2000 (06.10.2000) | US |
| 60/238,384 | 6 October 2000 (06.10.2000) | US |
| 60/238,397 | 6 October 2000 (06.10.2000) | US |
| 60/238,400 | 6 October 2000 (06.10.2000) | US |
| 60/238,401 | 6 October 2000 (06.10.2000) | US |
| 60/238,402 | 6 October 2000 (06.10.2000) | US |
| 60/275,892 | 14 March 2001 (14.03.2001)  | US |
| 60/296,860 | 8 June 2001 (08.06.2001)    | US |
- (63) Related by continuation (CON) or continuation-in-part (CIP) to earlier applications:
- |          |                             |
|----------|-----------------------------|
| US       | 60/238,323 (CIP)            |
| Filed on | 5 October 2000 (05.10.2000) |
| US       | 60/238,325 (CIP)            |
| Filed on | 5 October 2000 (05.10.2000) |
| US       | 60/238,372 (CIP)            |
| Filed on | 6 October 2000 (06.10.2000) |
| US       | 60/238,373 (CIP)            |
| Filed on | 6 October 2000 (06.10.2000) |
| US       | 60/238,379 (CIP)            |
| Filed on | 6 October 2000 (06.10.2000) |
| US       | 60/238,382 (CIP)            |
| Filed on | 6 October 2000 (06.10.2000) |
| US       | 60/238,383 (CIP)            |
| Filed on | 6 October 2000 (06.10.2000) |
| US       | 60/238,384 (CIP)            |
| Filed on | 6 October 2000 (06.10.2000) |
- (71) Applicant (for all designated States except US): CURAGEN CORPORATION [US/US]; 555 Long Wharf Drive, 11th floor, New Haven, CT 06511 (US).
- (72) Inventors; and
- (75) Inventors/Applicants (for US only): SHIMKETS, Richard, A. [US/US]; 191 Lecte Street, West Haven, CT 06516 (US). TAUPIER, Raymond, J., Jr. [US/US]; 34 Pardee Place Extension, West Haven, CT 06512 (US). BURGESS, Catherine, E. [US/US]; 90 Carriage Hill Drive, Wethersfield, CT 06109 (US). ZERHUSEN, Bryan, D. [US/US]; 337 Monticello Drive, Branford, CT 06405 (US). MEZES, Peter, S. [US/US]; 7 Clark's Lane, Old Lyme, CT 06371 (US). RASTELLI, Luca [IT/US]; 52 Pepperbush Lane, Guilford, CT 06437 (US). MALYANKAR, Uriel, M. [IN/US]; 35 Averill Place, Branford, CT 06405 (US). GROSSE, William, M. [US/US]; 15 Rice Terrace Road, Branford, CT 06405 (US). ALSOBROOK, John, P., II [US/US]; 60 Lake Drive, Madison, CT 06443 (US). LEPLEY, Denise, M. [US/US]; 51 Church Street, Branford, CT 06405 (US). SPYTEK, Kimberly, Ann [US/US]; 28 Court Street #1, New Haven, CT 06511 (US). LI, Li [CN/US]; 487 Oak Avenue #67, Cheshire, CT 06410 (US). EDINGER, Shlomit [US/US]; 555 Long Wharf Drive, New Haven, CT 06511 (US). GERLACH, Valerie [US/US]; 18 Rock Pasture Road, Branford, CT 06405 (US). ELLERMAN, Karen [US/US]; 87 Montoya Drive, Branford, CT 06405 (US). MACDOUGALL, John [CA/US]; 117 Russell Street, Hamden, CT 06517 (US). GUNTHER, Erik [US/US]; 555 Long Wharf Drive, New Haven, CT 06511 (US). MILLET, Isabelle [US/US]; 555 Long Wharf Drive, New Haven, CT 06511 (US). STONE, David [US/US]; 223 Whitehorn Drive, Guilford, CT 06437 (US). SMITHSON,

[Continued on next page]

(54) Title: HUMAN PROTEINS, POLYNUCLEOTIDES ENCODING THEM AND METHODS OF USING THE SAME

(57) Abstract: Disclosed herein are nucleic acid sequences that encode novel polypeptides. Also disclosed are polypeptides encoded by these nucleic acid sequences, and antibodies, which immunospecifically bind to the polypeptide, as well as derivatives, variants, mutants, or fragments of the aforementioned polypeptide, polynucleotide, or antibody. The invention further discloses therapeutic, diagnostic and research methods for diagnosis, treatment, and prevention of disorders involving any one of these novel human nucleic acids and proteins.

WO 02/029058 A3



Glenda [US/US]; 81 Main Street #32A, Branford, CT 06405 (US). **SZEKERES, Edward, S., Jr.** [US/US]; 130 Montoya Drive, Branford, CT 06405 (US).

- (74) Agent: **ELRIFI, Ivor, R.**; Mintz, Levin, Cohn, Ferris, Glovsky, and Popeo, P.C., One Financial Center, Boston, MA 02111 (US).

- (81) Designated States (*national*): AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW.

- (84) Designated States (*regional*): ARIPO patent (GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).

**Published:**

— with international search report

- (88) Date of publication of the international search report:  
19 June 2003

*For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.*

## INTERNATIONAL SEARCH REPORT

International Application No.

PCT/US 01/31248

## A. CLASSIFICATION OF SUBJECT MATTER

IPC 7 C12N15/12 C07K14/47 C07K14/475 C07K14/705 C12N15/63  
C12N1/21 C12N5/10 C12Q1/68 G01N33/68

According to International Patent Classification (IPC) or to both national classification and IPC

## B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

IPC 7 C07K

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practical, search terms used)

EMBL, SEQUENCE SEARCH, EPO-Internal, WPI Data

## C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	DATABASE EMBL18 April 1997 (1997-04-18) ADAMS MD ET AL.: "EST 187885 HCC cell line (metastasis to liver in mouse) II Homo sapiens cDNA, 5' end similar to alpha-1-microglobulin" Database accession no. AA316097 XP002220565 the whole document -- -/--	5,9-14



Further documents are listed in the continuation of box C.



Patent family members are listed in annex.

## \* Special categories of cited documents:

- \*A\* document defining the general state of the art which is not considered to be of particular relevance  
 \*E\* earlier document but published on or after the international filing date  
 \*L\* document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)  
 \*O\* document referring to an oral disclosure, use, exhibition or other means  
 \*P\* document published prior to the international filing date but later than the priority date claimed

- \*T\* later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention  
 \*X\* document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone  
 \*Y\* document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art.  
 \*&\* document member of the same patent family

Date of the actual completion of the international search

13 November 2002

Date of mailing of the international search report

13.03.03

Name and mailing address of the ISA

European Patent Office, P.B. 5818 Patentlaan 2  
 NL - 2280 HV Rijswijk  
 Tel (+31-70) 340-2040, Tx. 31 651 epo nl,  
 Fax (+31-70) 340-3016

Authorized officer

van Heusden, M

## INTERNATIONAL SEARCH REPORT

International Publication No.  
PCT/US 01/31248

C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT		
Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
T	DATABASE EMBL15 October 2001 (2001-10-15) GODBOLE SD ET AL.: "A human alpha-2 macroglobulin-like polypeptide" Database accession no. AAG63548, AAH74532 XP002220566 the whole document	1,2,4-7, 9-21, 23-35, 38-41
P,X	-& WO 01 57266 A (HYSEC INC) 9 August 2001 (2001-08-09)  SEQ ID NO: 4 claims 1-25,29,30; example 3 ---	1,2,4-7, 9-21, 23-35, 38-41
T	DATABASE EMBL10 January 2002 (2002-01-10) ROSEN CA ET AL.: "Human cDNA SEQ ID NO: 583" Database accession no. ABB10275 XP002220567 the whole document	1,2,4-7, 9-21, 23-35, 38-41
P,X	-& WO 01 54474 A (HUMAN GENOME SCIENCES INC) 2 August 2001 (2001-08-02)  SEQ ID NO: 583 ---	1,2,4-7, 9-21, 23-35, 38-41
T	DATABASE EMBL 18 February 2002 (2002-02-18) DRMANAC RT ET AL.: "Novel human diagnostic protein #21215" Database accession no. ABG21224, AAS85411 XP002220568 the whole document	1,2,4-7, 9-21, 23-35, 38-41
E	-& WO 01 75067 A (HYSEQ INC) 11 October 2001 (2001-10-11)  SEQ ID NO: 21215 claims 1-20,27,28 ---	1,2,4-7, 9-21, 23-35, 38-41
E	WO 02 33087 A (BURGESS CATHERINE E ;MACDOUGALL JOHN R (US); MALYANKAR URIEL M (US) 25 April 2002 (2002-04-25) SEQ ID NO: 9 claims 1-49 -----	1-21, 23-41

# INTERNATIONAL SEARCH REPORT

International application No.  
PCT/US 01/31248

## Box I Observations where certain claims were found unsearchable (Continuation of Item 1 of first sheet)

This International Search Report has not been established in respect of certain claims under Article 17(2)(a) for the following reasons:

1. ☒ Claims Nos.:  
because they relate to subject matter not required to be searched by this Authority, namely:  
see FURTHER INFORMATION sheet PCT/ISA/210
2. ☒ Claims Nos.: 22  
because they relate to parts of the International Application that do not comply with the prescribed requirements to such an extent that no meaningful International Search can be carried out, specifically:  
see FURTHER INFORMATION sheet PCT/ISA/210
3. ☐ Claims Nos.:  
because they are dependent claims and are not drafted in accordance with the second and third sentences of Rule 6.4(a).

## Box II Observations where unity of invention is lacking (Continuation of item 2 of first sheet)

This International Searching Authority found multiple inventions in this International application, as follows:

see additional sheet

1. ☐ As all required additional search fees were timely paid by the applicant, this International Search Report covers all searchable claims.
2. ☐ As all searchable claims could be searched without effort justifying an additional fee, this Authority did not invite payment of any additional fee.
3. ☐ As only some of the required additional search fees were timely paid by the applicant, this International Search Report covers only those claims for which fees were paid, specifically claims Nos.:
4. ☒ No required additional search fees were timely paid by the applicant. Consequently, this International Search Report is restricted to the invention first mentioned in the claims; it is covered by claims Nos.:

1-41 partially

Remark on Protest

- ☐ The additional search fees were accompanied by the applicant's protest.
- ☐ No protest accompanied the payment of additional search fees.

FURTHER INFORMATION CONTINUED FROM PCT/ISA/ 210

This International Searching Authority found multiple (groups of) inventions in this international application, as follows:

1. Claims: 1-41 (partially)

A polypeptide comprising the sequence represented by SEQ ID NO: 2 or a variant thereof that differs in no more than 15% of the amino acid residues; a nucleic acid molecule encoding said polypeptide or a portion thereof, the complement thereof, the nucleic acid represented by SEQ ID NO: 1 or a nucleic acid hybridizing thereto; a vector comprising said nucleic acid; a cell comprising said vector; an antibody specific for said polypeptide; a method of determining the presence or amount of said polypeptide or nucleic acid in a sample; a method of identifying a binding or modulating agent; pharmaceutical compositions and kits comprising said polypeptide, nucleic acid or antibody; methods of treatment or diagnostic methods, based on said polypeptide, nucleic acid or antibody.

2. Claims: 1-41 (partially)

As for subject 1 but relating to SEQ ID NO: 3 and 4

3. Claims: 1-41 (partially)

As for subject 1 but relating to SEQ ID NO: 5 and 6

4. Claims: 1-41 (partially)

As for subject 1 but relating to SEQ ID NO: 7 and 8

5. Claims: 1-41 (partially)

As for subject 1 but relating to SEQ ID NO: 9 and 10

6. Claims: 1-41 (partially)

As for subject 1 but relating to SEQ ID NO: 11 to 28

7. Claims: 1-41 (partially)

As for subject 1 but relating to SEQ ID NO: 29 to 40

8. Claims: 1-41 (partially)

As for subject 1 but relating to SEQ ID NO: 41 to 44



FURTHER INFORMATION CONTINUED FROM PCT/ISA/ 210

9. Claims: 1-41 (partially)

As for subject 1 but relating to SEQ ID NO: 45 to 54

10. Claims: 1-41 (partially)

As for subject 1 but relating to SEQ ID NO: 55 and 56

11. Claims: 1-41 (partially)

As for subject 1 but relating to SEQ ID NO: 57 to 62

12. Claims: 1-41 (partially)

As for subject 1 but relating to SEQ ID NO: 63 and 64

## FURTHER INFORMATION CONTINUED FROM PCT/SA/ 210

## Continuation of Box I.1

Although claims 36-39 are directed to a diagnostic method practised on the human/animal body, the search has been carried out and based on the alleged effects of the compound/composition.

Although claims 23-28 and 40-41 are directed to a method of treatment of the human/animal body, the search has been carried out and based on the alleged effects of the compound/composition.

## Continuation of Box I.2

Claims Nos.: 22

Present claim 22 relates to a compound defined by reference to a desirable characteristic, namely "binding to the polypeptide in an amount sufficient to modulate the activity of the polypeptide".

The claim any compound having this characteristic, whereas the application provides no support within the meaning of Article 6 PCT and/or disclosure within the meaning of Article 5 PCT for such a compound. In the present case, the claim so lacks support, and the application so lacks disclosure, that a meaningful search is impossible. Independent of the above reasoning, the claim also lacks clarity (Article 6 PCT). An attempt is made to define the compound by reference to a result to be achieved. Again, this lack of clarity in the present case is such as to render a meaningful search impossible.

The applicant's attention is drawn to the fact that claims, or parts of claims, relating to inventions in respect of which no international search report has been established need not be the subject of an international preliminary examination (Rule 66.1(e) PCT). The applicant is advised that the EPO policy when acting as an International Preliminary Examining Authority is normally not to carry out a preliminary examination on matter which has not been searched. This is the case irrespective of whether or not the claims are amended following receipt of the search report or during any Chapter II procedure.

## INTERNATIONAL SEARCH REPORT

Information on patent family members

International application No

PCT/US 01/31248

Patent document cited in search report	Publication date	Patent family member(s)	Publication date
WO 0157266	A	09-08-2001	AU 2591801 A 31-07-2001
			AU 3128801 A 14-08-2001
			AU 3297101 A 07-08-2001
			AU 3300301 A 07-08-2001
			AU 3329301 A 14-08-2001
			AU 3484701 A 14-08-2001
			AU 3484801 A 14-08-2001
			AU 3486501 A 14-08-2001
			AU 3494401 A 14-08-2001
			AU 3665801 A 14-08-2001
			AU 3666001 A 14-08-2001
			AU 3666301 A 14-08-2001
			AU 3672101 A 14-08-2001
			AU 4314201 A 14-08-2001
			EP 1261735 A2 04-12-2002
			EP 1254265 A1 06-11-2002
			EP 1254266 A1 06-11-2002
			EP 1254268 A1 06-11-2002
			EP 1254269 A1 06-11-2002
			EP 1254270 A1 06-11-2002
			WO 0153326 A1 26-07-2001
			WO 0155334 A2 02-08-2001
			WO 0155335 A2 02-08-2001
			WO 0157255 A1 09-08-2001
			WO 0157260 A1 09-08-2001
			WO 0157175 A2 09-08-2001
			WO 0157261 A1 09-08-2001
			WO 0157262 A1 09-08-2001
			WO 0157187 A2 09-08-2001
			WO 0157265 A1 09-08-2001
			WO 0157188 A2 09-08-2001
			WO 0157266 A1 09-08-2001
			WO 0157267 A1 09-08-2001
			WO 0157190 A2 09-08-2001
			US 2002128187 A1 12-09-2002
			US 2002137044 A1 26-09-2002
			US 2002127199 A1 12-09-2002
			AU 3995501 A 12-09-2001
			AU 4925101 A 15-10-2001
			AU 4972801 A 15-10-2001
			AU 5119401 A 15-10-2001
			AU 5521401 A 15-10-2001
			EP 1268762 A1 02-01-2003
			EP 1268510 A2 02-01-2003
			WO 0164839 A2 07-09-2001
			WO 0175067 A2 11-10-2001
			WO 0175064 A2 11-10-2001
			WO 0174836 A1 11-10-2001
			WO 0175093 A1 11-10-2001
			US 6436703 B1 20-08-2002
WO 0154474	A	02-08-2001	AU 2950801 A 07-08-2001
			AU 3095801 A 07-08-2001
			AU 3645901 A 07-08-2001
			AU 3646001 A 07-08-2001
			AU 3646101 A 07-08-2001
			AU 3646201 A 07-08-2001
			AU 3646301 A 07-08-2001

## INTERNATIONAL SEARCH REPORT

information on patent family members

International Application No

PCT/US 01/31248

Patent document cited in search report		Publication date	Patent family member(s)	Publication date
WO 0154474	A		AU 3646401 A	07-08-2001
			AU 3646501 A	07-08-2001
			AU 3646601 A	07-08-2001
			AU 3794301 A	07-08-2001
			AU 3794401 A	07-08-2001
			AU 3794701 A	07-08-2001
			AU 3794901 A	07-08-2001
			AU 3795001 A	07-08-2001
			AU 3795101 A	07-08-2001
			AU 3795201 A	07-08-2001
			AU 3795301 A	07-08-2001
			AU 3795401 A	07-08-2001
			AU 3795501 A	07-08-2001
			AU 3795701 A	07-08-2001
			AU 3795801 A	07-08-2001
			AU 3972601 A	07-08-2001
			AU 3972701 A	07-08-2001
			AU 3972801 A	07-08-2001
			AU 4140201 A	07-08-2001
			AU 4140301 A	07-08-2001
			AU 4140401 A	07-08-2001
			AU 4140501 A	07-08-2001
			AU 4140601 A	07-08-2001
			AU 4140701 A	07-08-2001
			AU 4140801 A	07-08-2001
			AU 4140901 A	07-08-2001
			AU 4141001 A	07-08-2001
			AU 4141101 A	20-08-2001
			AU 4141201 A	07-08-2001
			AU 4141301 A	07-08-2001
			AU 4141401 A	07-08-2001
			AU 4141501 A	07-08-2001
			AU 4141601 A	07-08-2001
			AU 4141701 A	07-08-2001
			AU 4141801 A	07-08-2001
			AU 4141901 A	07-08-2001
			AU 4313401 A	07-08-2001
			AU 4313501 A	07-08-2001
			AU 4313601 A	07-08-2001
			AU 4313701 A	14-08-2001
			AU 4526201 A	07-08-2001
			AU 4719001 A	07-08-2001
			AU 4719101 A	07-08-2001
WO 0175067	A	11-10-2001	AU 3486501 A	14-08-2001
			AU 3995501 A	12-09-2001
			AU 4925101 A	15-10-2001
			AU 4972801 A	15-10-2001
			AU 5119401 A	15-10-2001
			AU 5521401 A	15-10-2001
			EP 1254266 A1	06-11-2002
			EP 1268762 A1	02-01-2003
			EP 1268510 A2	02-01-2003
			WO 0157266 A1	09-08-2001
			WO 0164839 A2	07-09-2001
			WO 0175067 A2	11-10-2001
			WO 0175064 A2	11-10-2001
			WO 0174836 A1	11-10-2001

# INTERNATIONAL SEARCH REPORT

Information on patent family members

International application No  
PCT/US 01/31248

Patent document cited in search report	Publication date	Patent family member(s)	Publication date
WO 0175067 A		WO 0175093 A1	11-10-2001
		US 6436703 B1	20-08-2002
		US 2002061567 A1	23-05-2002
		US 2002146757 A1	10-10-2002
WO 0233087 A	25-04-2002	AU 1663702 A	29-04-2002
		WO 0233087 A2	25-04-2002

**This Page is Inserted by IFW Indexing and Scanning  
Operations and is not part of the Official Record**

**BEST AVAILABLE IMAGES**

Defective images within this document are accurate representations of the original documents submitted by the applicant.

Defects in the images include but are not limited to the items checked:

- ☐ BLACK BORDERS
- ☐ IMAGE CUT OFF AT TOP, BOTTOM OR SIDES
- ☐ FADED TEXT OR DRAWING
- ☐ BLURRED OR ILLEGIBLE TEXT OR DRAWING
- ☐ SKEWED/SLANTED IMAGES
- ☒ ~~COLOR~~ OR BLACK AND WHITE PHOTOGRAPHS
- ☐ GRAY SCALE DOCUMENTS
- ☒ ~~LINES~~ OR MARKS ON ORIGINAL DOCUMENT
- ☐ REFERENCE(S) OR EXHIBIT(S) SUBMITTED ARE POOR QUALITY
- ☐ OTHER: \_\_\_\_\_

**IMAGES ARE BEST AVAILABLE COPY.**

**As rescanning these documents will not correct the image problems checked, please do not report these problems to the IFW Image Problem Mailbox.**